ASI,ASSSUBCELFR,Descri,TISI,VAI,Ti,ASSCTY,RELAT,CONFISC,CUB,SRI,SASI,CHI,CI,BAFO
7524,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL618647,,BAO_0000218
7525,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL618648,,BAO_0000218
7526,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL618649,,BAO_0000218
7527,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL618650,,BAO_0000218
7528,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL618651,,BAO_0000218
7529,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL876497,,BAO_0000218
7530,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL618652,,BAO_0000218
7531,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL618653,,BAO_0000218
7532,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL618654,,BAO_0000218
7533,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL618655,,BAO_0000218
7534,,Compound was tested for solubility in water,,,50597,,N,1,Intermediate,1,,CHEMBL618656,,BAO_0000218
7535,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,,22229,,U,0,Intermediate,1,,CHEMBL618657,,BAO_0000100
7536,,Solubility was determined,,,50597,,N,1,Intermediate,1,,CHEMBL618658,,BAO_0000218
7537,,solubility in water (ug/mL) at 37 degree C.,,,50597,,N,1,Intermediate,1,,CHEMBL618659,,BAO_0000218
7538,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,,50597,,N,1,Intermediate,1,,CHEMBL618660,,BAO_0000218
7539,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,,50597,,N,1,Intermediate,1,,CHEMBL618661,,BAO_0000218
7540,,Half life in rats,,,50597,,N,1,Intermediate,1,,CHEMBL873807,,BAO_0000218
7541,,Half life in Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL618662,,BAO_0000218
7542,,Half life period after 3 mg/kg iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL618663,,BAO_0000218
7543,,Half life period after 3 mg/kg iv administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618664,,BAO_0000218
7544,,Half life period after 3 mg/kg iv administration in the rat,,,50597,,N,1,Intermediate,1,,CHEMBL618665,,BAO_0000218
7545,,Half life period in female Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL876498,,BAO_0000218
7546,,Half life period in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618666,,BAO_0000218
7547,,Half-life in rats was determined,,,50597,,N,1,Intermediate,1,,CHEMBL620440,,BAO_0000218
7548,,Half-life in rats with metabolic oxidation,,,50597,,N,1,Intermediate,1,,CHEMBL620441,,BAO_0000218
7549,,Half-life in rats,,,50597,,N,1,Intermediate,1,,CHEMBL620442,,BAO_0000218
7550,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL620443,,BAO_0000218
7551,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL620444,,BAO_0000218
7552,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL620445,,BAO_0000218
7553,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL620446,,BAO_0000218
7554,,Biological half-life measured in plasma of rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL620447,,BAO_0000218
7555,,Biological half-life measured in plasma of rat; 22-25,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621129,,BAO_0000218
7556,,Biological half-life measured in plasma of rat; 9-16,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621130,,BAO_0000218
7557,,Compound was evaluated for its half life when administered intravenously in rat,,,50597,,N,1,Intermediate,1,,CHEMBL873808,,BAO_0000218
7558,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,,50597,,N,1,Intermediate,1,,CHEMBL876598,,BAO_0000218
7559,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621131,,BAO_0000218
7560,,Half life (T1/2) after oral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621132,,BAO_0000218
7561,,Half life of compound after iv administration of 20 mg/kg dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621133,,BAO_0000218
7562,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,,N,1,Expert,1,,CHEMBL621312,,BAO_0000218
7563,,Half life of compound was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621313,,BAO_0000218
7564,,Half life of compound was determined in rat blood,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621314,,BAO_0000218
7565,,Half life at 1 mg/kg was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621315,,BAO_0000218
7566,,Half life at 10 mg/kg was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621316,,BAO_0000218
7567,,Half life in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621317,,BAO_0000218
7568,,Half life in rats in hours,,,50597,,N,1,Intermediate,1,,CHEMBL621318,,BAO_0000218
7569,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621319,,BAO_0000218
7570,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621377,,BAO_0000218
7571,,Half life was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621378,,BAO_0000218
7572,,Half life after i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL876599,,BAO_0000218
7573,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621379,,BAO_0000218
7574,,Half life in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621380,,BAO_0000218
7575,,Half life in rat plasma; Not detected,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621381,,BAO_0000218
7576,,Half life in rats,,,50597,,N,1,Intermediate,1,,CHEMBL618515,,BAO_0000218
7577,,Half life period of compound was determined after peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL618516,,BAO_0000218
7578,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL618517,,BAO_0000218
7579,,Half life period in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618518,,BAO_0000218
7580,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL618519,,BAO_0000218
7581,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,,50597,,N,1,Intermediate,1,,CHEMBL618698,,BAO_0000218
7582,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,,50597,,N,1,Intermediate,1,,CHEMBL618862,,BAO_0000218
7583,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL618863,,BAO_0000218
7584,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,,50597,,N,1,Intermediate,1,,CHEMBL618864,,BAO_0000218
7585,,Half life time in rat the dose of 2 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL618865,,BAO_0000218
7586,,Half-life 24 hr after 10 mg/kg iv administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL618866,,BAO_0000218
7587,,Half-life 24 hr after 2 mg/kg iv administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL618867,,BAO_0000218
7588,,Half-life consistent with the observed metabolic steady state in rats,,,50597,,N,1,Intermediate,1,,CHEMBL875828,,BAO_0000218
7589,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,,50597,,N,1,Intermediate,1,,CHEMBL618868,,BAO_0000218
7590,,Half-life for oxidative metabolic stability was determined using male human,,,50597,,N,1,Intermediate,1,,CHEMBL618869,,BAO_0000218
7591,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,,50597,,N,1,Intermediate,1,,CHEMBL618870,,BAO_0000218
7592,,Half-life in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL618871,,BAO_0000218
7593,,Half-life in rat plasma was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL618872,,BAO_0000218
7594,,Half-life in rats was determined,,,50597,,N,1,Intermediate,1,,CHEMBL873816,,BAO_0000218
7595,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,,22224,,U,0,Autocuration,1,,CHEMBL618873,,BAO_0000218
7596,,Area under curve after oral dose of 0.1 mg//kg,,,22224,,U,0,Autocuration,1,,CHEMBL621602,,BAO_0000019
7597,,Area under curve after oral dose of 0.3 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL621603,,BAO_0000218
7598,,Area under curve after oral dose of 1 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL621604,,BAO_0000218
7599,,Area under curve after oral dose of 10 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL621605,,BAO_0000218
7600,,Area under curve after oral dose of 23.4 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL621606,,BAO_0000218
7601,,Area under curve after oral dose of 3 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL621607,,BAO_0000218
7602,,Area under curve after oral dose of 3.87 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL621608,,BAO_0000218
7603,,Area under curve was determined,,,22224,,U,0,Autocuration,1,,CHEMBL621609,,BAO_0000019
7604,,Area under curve at a dose of 10 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL621610,,BAO_0000218
7605,,Area under curve was determined; ND=No data,,,50597,,N,1,Intermediate,1,,CHEMBL621611,,BAO_0000218
7606,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,,50597,,N,1,Intermediate,1,,CHEMBL621612,,BAO_0000218
7607,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,,50597,,N,1,Intermediate,1,,CHEMBL622308,,BAO_0000218
7608,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,,50597,,N,1,Intermediate,1,,CHEMBL622309,,BAO_0000218
7609,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,,50597,,N,1,Intermediate,1,,CHEMBL622310,,BAO_0000218
7610,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,,50597,,N,1,Intermediate,1,,CHEMBL622311,,BAO_0000218
7611,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,,50597,,N,1,Intermediate,1,,CHEMBL622312,,BAO_0000218
7612,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,,50597,,N,1,Intermediate,1,,CHEMBL622931,,BAO_0000218
7613,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,,50597,,N,1,Intermediate,1,,CHEMBL622932,,BAO_0000218
7614,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622736,,BAO_0000218
7615,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622737,,BAO_0000218
7616,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622738,,BAO_0000218
7617,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622739,,BAO_0000218
7618,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622740,,BAO_0000218
7619,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622741,,BAO_0000218
7620,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622742,,BAO_0000218
7621,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622743,,BAO_0000218
7622,,AUC in mice,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL622744,,BAO_0000218
7623,,Area under curve was measured from the graph obtained from concentration Vs time,,,22224,,U,0,Autocuration,1,,CHEMBL624134,,BAO_0000019
7624,,Area under curve value of compound per hour after oral administration,,,22224,,U,0,Autocuration,1,,CHEMBL624135,,BAO_0000019
7625,,Area under curve was determined after oral administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624136,,BAO_0000218
7626,,Area under curve was determined after oral administration in rats; No data,,,50597,,N,1,Intermediate,1,,CHEMBL624137,,BAO_0000218
7627,,Area under curve was determined after oral administration in rats;No data,,,50597,,N,1,Intermediate,1,,CHEMBL624320,,BAO_0000218
7628,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,,50588,,N,1,Intermediate,1,,CHEMBL624321,,BAO_0000218
7629,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624322,,BAO_0000218
7630,,Area under curve was determined for the compound after iv dose of 5.06 in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624323,,BAO_0000218
7631,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624324,,BAO_0000218
7632,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624325,,BAO_0000218
7633,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624326,,BAO_0000218
7634,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624327,,BAO_0000218
7635,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624328,,BAO_0000218
7636,,Area under curve was determined in Dogs after peroral administration,,,50588,,N,1,Intermediate,1,,CHEMBL627848,,BAO_0000218
7637,,Area under curve was determined in Rats after peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL627849,,BAO_0000218
7638,,Area under curve was determined in carotid blood of rat when administered intradermally,,,50597,,N,1,Intermediate,1,,CHEMBL627850,,BAO_0000218
7639,,Area under curve was determined in portal blood of rat when administered intradermally,,,50597,,N,1,Intermediate,1,,CHEMBL627851,,BAO_0000218
7640,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,50594,,N,1,Intermediate,1,,CHEMBL627852,,BAO_0000218
7641,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,,50594,,N,1,Intermediate,1,,CHEMBL627853,,BAO_0000218
7642,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,,50594,,N,1,Intermediate,1,,CHEMBL627854,,BAO_0000218
7643,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,50594,,N,1,Intermediate,1,,CHEMBL627855,,BAO_0000218
7644,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,,50594,,N,1,Intermediate,1,,CHEMBL627856,,BAO_0000218
7645,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,,50594,,N,1,Intermediate,1,,CHEMBL875339,,BAO_0000218
7646,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,,50594,,N,1,Intermediate,1,,CHEMBL627857,,BAO_0000218
7647,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL627858,,BAO_0000218
7648,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627859,,BAO_0000218
7649,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,955.0,,50597,,N,1,Intermediate,1,,CHEMBL627860,,BAO_0000218
7650,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,948.0,,50597,,N,1,Intermediate,1,,CHEMBL627019,,BAO_0000218
7651,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627020,,BAO_0000218
7652,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627021,,BAO_0000218
7653,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627022,,BAO_0000218
7654,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,,50597,,N,1,Intermediate,1,,CHEMBL627023,,BAO_0000218
7655,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL627024,,BAO_0000218
7656,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL627025,,BAO_0000218
7657,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627026,,BAO_0000218
7658,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627027,,BAO_0000218
7659,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,955.0,,50597,,N,1,Intermediate,1,,CHEMBL627028,,BAO_0000218
7660,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,948.0,,50597,,N,1,Intermediate,1,,CHEMBL627029,,BAO_0000218
7661,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627030,,BAO_0000218
7662,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627031,,BAO_0000218
7663,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627032,,BAO_0000218
7664,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627033,,BAO_0000218
7665,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,,50597,,N,1,Intermediate,1,,CHEMBL627034,,BAO_0000218
7666,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL627035,,BAO_0000218
7667,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL627036,,BAO_0000218
7668,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,178.0,,50597,,N,1,Intermediate,1,,CHEMBL875340,,BAO_0000218
7669,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,948.0,,50597,,N,1,Intermediate,1,,CHEMBL627037,,BAO_0000218
7670,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627038,,BAO_0000218
7671,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627039,,BAO_0000218
7672,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627040,,BAO_0000218
7673,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL624663,,BAO_0000218
7674,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL625963,,BAO_0000218
7675,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,955.0,,50597,,N,1,Intermediate,1,,CHEMBL876799,,BAO_0000218
7676,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626133,,BAO_0000218
7677,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,,50597,,N,1,Intermediate,1,,CHEMBL626134,,BAO_0000218
7678,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626135,,BAO_0000218
7679,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626136,,BAO_0000218
7680,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,,50597,,N,1,Intermediate,1,,CHEMBL626137,,BAO_0000218
7681,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626138,,BAO_0000218
7682,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626139,,BAO_0000218
7683,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL626140,,BAO_0000218
7684,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL626141,,BAO_0000218
7685,,C24h in rat p.o. at 20 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL626142,,BAO_0000218
7686,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627930,,BAO_0000218
7687,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627931,,BAO_0000218
7688,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627932,,BAO_0000218
7689,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL627933,,BAO_0000218
7690,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL627934,,BAO_0000218
7691,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL627935,,BAO_0000218
7692,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627936,,BAO_0000218
7693,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627937,,BAO_0000218
7694,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627938,,BAO_0000218
7695,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627939,,BAO_0000218
7696,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627940,,BAO_0000218
7697,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627941,,BAO_0000218
7698,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,178.0,,50597,,N,1,Intermediate,1,,CHEMBL876800,,BAO_0000218
7699,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627942,,BAO_0000218
7700,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627943,,BAO_0000218
7701,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627944,,BAO_0000218
7702,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627945,,BAO_0000218
7703,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628584,,BAO_0000218
7704,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628585,,BAO_0000218
7705,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628586,,BAO_0000218
7706,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628587,,BAO_0000218
7707,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628588,,BAO_0000218
7708,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628589,,BAO_0000218
7709,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625304,,BAO_0000218
7710,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625305,,BAO_0000218
7711,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625306,,BAO_0000218
7712,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625307,,BAO_0000218
7713,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625308,,BAO_0000218
7714,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627740,,BAO_0000218
7715,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627741,,BAO_0000218
7716,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627742,,BAO_0000218
7717,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627743,,BAO_0000218
7718,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627744,,BAO_0000218
7719,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL627745,,BAO_0000218
7720,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL627746,,BAO_0000218
7721,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL627747,,BAO_0000218
7722,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL876810,,BAO_0000218
7723,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL627748,,BAO_0000218
7724,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL627749,,BAO_0000218
7725,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL627750,,BAO_0000218
7726,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618728,,BAO_0000218
7727,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618729,,BAO_0000218
7728,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618730,,BAO_0000218
7729,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618731,,BAO_0000218
7730,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618732,,BAO_0000218
7731,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618733,,BAO_0000218
7732,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618734,,BAO_0000218
7733,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618735,,BAO_0000218
7734,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL876602,,BAO_0000218
7735,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618736,,BAO_0000218
7736,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618737,,BAO_0000218
7737,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618738,,BAO_0000218
7738,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618739,,BAO_0000218
7739,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618740,,BAO_0000218
7740,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618741,,BAO_0000218
7741,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618742,,BAO_0000218
7742,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL618743,,BAO_0000218
7743,,Half-life from rat plasma at a single oral dose of 25 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL618744,,BAO_0000218
7744,,Half-life in male rat,,,50597,,N,1,Intermediate,1,,CHEMBL618745,,BAO_0000218
7745,,Half-life in rat after peroral administration at 10 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL620479,,BAO_0000218
7746,,Half-life in rat after peroral administration at 5 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL620480,,BAO_0000218
7747,,Half-life in rat at a dose of 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620481,,BAO_0000218
7748,,Half-life was evaluated in rats,,,50597,,N,1,Intermediate,1,,CHEMBL620482,,BAO_0000218
7749,,Half-life was measured in rat,,,50597,,N,1,Intermediate,1,,CHEMBL876603,,BAO_0000218
7750,,Half-life period for the compound was determined in rats at 50 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL620483,,BAO_0000218
7751,,Half-life period in rats after intravenous administration at 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620484,,BAO_0000218
7752,,Half-life period in rat at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620485,,BAO_0000218
7753,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL620486,,BAO_0000218
7754,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,,50597,,N,1,Intermediate,1,,CHEMBL620487,,BAO_0000218
7755,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,,50597,,N,1,Intermediate,1,,CHEMBL620488,,BAO_0000218
7756,,Half-life time in rat the dose of 2 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620489,,BAO_0000218
7757,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,,50597,,N,1,Intermediate,1,,CHEMBL620490,,BAO_0000218
7758,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620491,,BAO_0000218
7759,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL876604,,BAO_0000218
7760,,Oral half life was determined,,,50597,,N,1,Intermediate,1,,CHEMBL620492,,BAO_0000218
7761,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,,50597,,N,1,Intermediate,1,,CHEMBL620493,,BAO_0000218
7762,,Pharmacokinetic property (t1/2) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620494,,BAO_0000218
7763,,Plasma elimination half-life was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL620495,,BAO_0000218
7764,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL620496,,BAO_0000218
7765,,Plasma half life was observed after intravenous administration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL620497,,BAO_0000218
7766,,Plasma half-life was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL620498,,BAO_0000218
7767,,Plasma half-life following oral administration in Fisher rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL620499,,BAO_0000218
7768,,Plasma half-life in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL620500,,BAO_0000218
7769,,Plasmatic Half-life after intravenous administration to rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL873809,,BAO_0000218
7770,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,,50597,,N,1,Intermediate,1,,CHEMBL620501,,BAO_0000218
7771,,Terminal half life after intravenous administration (1 mg/kg) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620502,,BAO_0000218
7772,,Terminal half life in Rat at a oral dose of 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620503,,BAO_0000218
7773,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,,50597,,N,1,Intermediate,1,,CHEMBL620504,,BAO_0000218
7774,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL876605,,BAO_0000218
7775,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620505,,BAO_0000218
7776,,plasma half life was observed after intravenous administration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL873811,,BAO_0000218
7777,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,,N,1,Expert,1,,CHEMBL624016,,BAO_0000218
7778,,Half life of compound determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624017,,BAO_0000218
7779,,Mean residence time determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624018,,BAO_0000218
7780,,Plasma half life determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624019,,BAO_0000218
7781,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,955.0,,50597,,N,1,Intermediate,1,,CHEMBL624020,,BAO_0000218
7782,,Compound was evaluated for pharmacokinetic parameter maximum time period,,,50597,,N,1,Intermediate,1,,CHEMBL624201,,BAO_0000218
7783,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL872528,,BAO_0000218
7784,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL624202,,BAO_0000218
7785,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL624203,,BAO_0000218
7786,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL624350,,BAO_0000218
7787,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL621320,,BAO_0000218
7788,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621321,,BAO_0000218
7789,,Maximum time (Tmax) required to reach Cmax in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621322,,BAO_0000218
7790,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL621323,,BAO_0000218
7791,,Maximum time of clearance of compound in rats after peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL621324,,BAO_0000218
7792,,Maximum time at the dose of 2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621325,,BAO_0000218
7793,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL875837,,BAO_0000218
7794,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621326,,BAO_0000218
7795,,Tmax in Guinea pig (PO dose),,,50597,,N,1,Intermediate,1,,CHEMBL621327,,BAO_0000218
7796,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,,50597,,N,1,Intermediate,1,,CHEMBL621328,,BAO_0000218
7797,,Pharmacokinetic parameter (Tmax) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621329,,BAO_0000218
7798,,Pharmacokinetic parameter (Tmax) was estimated,,,50597,,N,1,Intermediate,1,,CHEMBL621330,,BAO_0000218
7799,,Pharmacokinetic property (Tmax) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621331,,BAO_0000218
7800,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,,50597,,N,1,Intermediate,1,,CHEMBL621332,,BAO_0000218
7801,,T max in Rat at a oral dose of 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621333,,BAO_0000218
7802,,T max was determined at 10 mg/kg po dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621334,,BAO_0000218
7803,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,,50594,,N,1,Intermediate,1,,CHEMBL621335,,BAO_0000218
7804,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,,50588,,N,1,Intermediate,1,,CHEMBL621336,,BAO_0000218
7805,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621337,,BAO_0000218
7806,,Area under curve was measured after i.v. administration into Beagle dog.,,,50588,,N,1,Intermediate,1,,CHEMBL621338,,BAO_0000218
7807,,Area under curve was measured after iv administration into Beagle dog,,,50588,,N,1,Intermediate,1,,CHEMBL875838,,BAO_0000218
7808,,Area under curve was measured after po administration into Beagle dog,,,50588,,N,1,Intermediate,1,,CHEMBL621339,,BAO_0000218
7809,,Area under curve was measured after po administration into Beagle dog.,,,50588,,N,1,Intermediate,1,,CHEMBL621340,,BAO_0000218
7810,,Area under curve was measured at peroral dose of 3 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL621341,,BAO_0000218
7811,,Area under curve was measured by using concentration Vs time,,,22224,,U,0,Autocuration,1,,CHEMBL621342,,BAO_0000019
7812,,Area under curve was measured by using concentration Vs time; not tested,,,22224,,U,0,Autocuration,1,,CHEMBL621343,,BAO_0000019
7813,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,,50594,,N,1,Intermediate,1,,CHEMBL621344,,BAO_0000218
7814,,Area under curve(AUC) was measured in mice after oral administration.,,,50594,,N,1,Intermediate,1,,CHEMBL621345,,BAO_0000218
7815,,Area under curve(AUC) value of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL621346,,BAO_0000019
7816,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,,22224,,U,0,Autocuration,1,,CHEMBL621347,,BAO_0000218
7817,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,,50588,,N,1,Intermediate,1,,CHEMBL621348,,BAO_0000218
7818,,Area under curve(carotid artery) was determined by the availability in blood,178.0,,22224,,U,0,Autocuration,1,,CHEMBL621349,,BAO_0000019
7819,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,178.0,,22224,,U,0,Autocuration,1,,CHEMBL621350,,BAO_0000019
7820,,Area under curve(carotid artery) was determined by the availability in blood; No data,178.0,,22224,,U,0,Autocuration,1,,CHEMBL875839,,BAO_0000019
7821,,Area under curve(portal vein) was determined by the availability in blood,178.0,,22224,,U,0,Autocuration,1,,CHEMBL620211,,BAO_0000019
7822,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,178.0,,22224,,U,0,Autocuration,1,,CHEMBL620212,,BAO_0000019
7823,,Area under curve(portal vein) was determined by the availability in blood; No data,178.0,,22224,,U,0,Autocuration,1,,CHEMBL620213,,BAO_0000019
7824,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1969.0,,50797,,N,1,Intermediate,1,,CHEMBL620214,,BAO_0000218
7825,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1969.0,,50797,,N,1,Intermediate,1,,CHEMBL620215,,BAO_0000218
7826,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,1969.0,,50797,,N,1,Intermediate,1,,CHEMBL620216,,BAO_0000218
7827,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",1969.0,,50588,,N,1,Intermediate,1,,CHEMBL620888,,BAO_0000218
7828,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",1969.0,,50588,,N,1,Intermediate,1,,CHEMBL620889,,BAO_0000218
7829,,Area under plasma concentration vs time curve observed in rats for 0-3 h,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL620890,,BAO_0000019
7830,,Area under plasma time curve determined in male rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL620891,,BAO_0000218
7831,,Area under the MAP curve measured over 5 min.,,,22224,,U,0,Autocuration,1,,CHEMBL620892,,BAO_0000019
7832,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,,50594,,N,1,Intermediate,1,,CHEMBL621079,,BAO_0000218
7833,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,,50594,,N,1,Intermediate,1,,CHEMBL621080,,BAO_0000218
7834,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,,50588,,N,1,Intermediate,1,,CHEMBL621081,,BAO_0000218
7835,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,,100712,,N,1,Intermediate,1,,CHEMBL621082,,BAO_0000218
7836,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,,50597,,N,1,Intermediate,1,,CHEMBL621083,,BAO_0000218
7837,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,,50588,,N,1,Intermediate,1,,CHEMBL621084,,BAO_0000218
7838,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,,50588,,N,1,Intermediate,1,,CHEMBL621085,,BAO_0000218
7839,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,,50588,,N,1,Intermediate,1,,CHEMBL621086,,BAO_0000218
7840,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,50588,,N,1,Intermediate,1,,CHEMBL621087,,BAO_0000218
7841,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,,50588,,N,1,Intermediate,1,,CHEMBL622607,,BAO_0000218
7842,,Serum AUC in marmosets (IV dose),,,50588,,N,1,Intermediate,1,,CHEMBL622608,,BAO_0000218
7843,,Area under the curve after intravenous administration at a dose of 10 umol/kg,,,22224,,U,0,Autocuration,1,,CHEMBL624481,,BAO_0000019
7844,,Area under the curve after intravenous administration at a dose of 2 umol/kg,,,22224,,U,0,Autocuration,1,,CHEMBL624482,,BAO_0000019
7845,,Area under the curve after intravenous administration at a dose of 4 umol/kg,,,22224,,U,0,Autocuration,1,,CHEMBL624483,,BAO_0000019
7846,,Area under the curve after intravenous administration at a dose of 40 umol/kg,,,22224,,U,0,Autocuration,1,,CHEMBL624484,,BAO_0000019
7847,,Area under the curve after intravenous administration at a dose of 5 umol/kg,,,22224,,U,0,Autocuration,1,,CHEMBL624485,,BAO_0000019
7848,,Area under the curve for fumarate salt was evaluated in F344 Rats.,,,50597,,N,1,Intermediate,1,,CHEMBL624486,,BAO_0000218
7849,,Area under the curve for the compound was calculated.,,,22224,,U,0,Autocuration,1,,CHEMBL624487,,BAO_0000019
7850,,Area under the curve in concentration/ time,,,22224,,U,0,Autocuration,1,,CHEMBL624488,,BAO_0000019
7851,,Area under the curve administered intraintestinal in rats.,,,50597,,N,1,Intermediate,1,,CHEMBL624489,,BAO_0000218
7852,,Area under the curve administered intravenously in rats.,,,50597,,N,1,Intermediate,1,,CHEMBL625184,,BAO_0000218
7853,,Area under the curve during intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL625185,,BAO_0000019
7854,,Area under the curve during intravenous administration; Not determined,,,22224,,U,0,Autocuration,1,,CHEMBL875954,,BAO_0000019
7855,,Area under the curve during systemic administration,,,22224,,U,0,Autocuration,1,,CHEMBL625186,,BAO_0000019
7856,,Area under the curve during systemic administration; Not determined,,,22224,,U,0,Autocuration,1,,CHEMBL625187,,BAO_0000019
7857,,Area under the curve was calculated for the compound.,,,22224,,U,0,Autocuration,1,,CHEMBL625188,,BAO_0000019
7858,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,,50588,,N,1,Intermediate,1,,CHEMBL625189,,BAO_0000218
7859,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,,50588,,N,1,Intermediate,1,,CHEMBL625190,,BAO_0000218
7860,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL621733,,BAO_0000218
7861,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL621734,,BAO_0000218
7862,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,,50597,,N,1,Intermediate,1,,CHEMBL621735,,BAO_0000218
7863,,Clearance of the drug was measured in the plasma of rat; No data,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621736,,BAO_0000218
7864,,The pharmacokinetic parameter plasma clearance in vivo in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621737,,BAO_0000218
7865,,Plasma clearance at the dose of 2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621738,,BAO_0000218
7866,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL622806,,BAO_0000218
7867,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL623519,,BAO_0000218
7868,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL623520,,BAO_0000218
7869,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,50597,,N,1,Intermediate,1,,CHEMBL623521,,BAO_0000218
7870,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL623522,,BAO_0000218
7871,,Clearance rate in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623523,,BAO_0000218
7872,,Clearance rate in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623690,,BAO_0000218
7873,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL623691,,BAO_0000218
7874,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL623692,,BAO_0000218
7875,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL623693,,BAO_0000218
7876,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL623694,,BAO_0000218
7877,,Clearance of compound after iv administration of 20 mg/kg dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623695,,BAO_0000218
7878,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL623696,,BAO_0000218
7879,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL623697,,BAO_0000218
7880,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1969.0,,22224,,U,0,Intermediate,1,,CHEMBL623698,,BAO_0000218
7881,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,1969.0,,22224,,U,0,Intermediate,1,,CHEMBL623699,,BAO_0000218
7882,,Mean (%CV) PK parameters for CL(mL/min/kg).,,,50597,,N,1,Intermediate,1,,CHEMBL623700,,BAO_0000218
7883,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623701,,BAO_0000218
7884,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623702,,BAO_0000218
7885,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623703,,BAO_0000218
7886,,Plasma clearance in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL623704,,BAO_0000218
7887,,Plasma clearance in rat after administration of 2 mg/kg iv,,,50597,,N,1,Intermediate,1,,CHEMBL623705,,BAO_0000218
7888,,Plasma clearance in rat after administration of 2 mg/kg iv,,,50597,,N,1,Intermediate,1,,CHEMBL623706,,BAO_0000218
7889,,Plasma clearance was determined,,,50597,,N,1,Intermediate,1,,CHEMBL623707,,BAO_0000218
7890,,Plasma clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623708,,BAO_0000218
7891,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL623709,,BAO_0000218
7892,,Plasma clearance in rat by iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL623710,,BAO_0000218
7893,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL623711,,BAO_0000218
7894,,Plasma clearance in rat p.o.,,,50597,,N,1,Intermediate,1,,CHEMBL623712,,BAO_0000218
7895,,Plasma clearance in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623713,,BAO_0000218
7896,,Plasma clearance was determined; ND denotes no data,,,50597,,N,1,Intermediate,1,,CHEMBL623714,,BAO_0000218
7897,,Plasma clearance was determined; ND denotes not determined,,,50597,,N,1,Intermediate,1,,CHEMBL623715,,BAO_0000218
7898,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL623716,,BAO_0000218
7899,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,,50597,,N,1,Intermediate,1,,CHEMBL622980,,BAO_0000218
7900,,Plasma administration to rats,,,50597,,N,1,Intermediate,1,,CHEMBL622981,,BAO_0000218
7901,,Plasma clearance of the compound in female Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL622982,,BAO_0000218
7902,,Plasma clearance was observed after intravenous administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622983,,BAO_0000218
7903,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622984,,BAO_0000218
7904,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622985,,BAO_0000218
7905,,plasma clearance was observed after intravenous administration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623631,,BAO_0000218
7906,,In vivo CL/F determined,,,50597,,N,1,Intermediate,1,,CHEMBL623632,,BAO_0000218
7907,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623633,,BAO_0000218
7908,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623634,,BAO_0000218
7909,,Compound was tested for the lower blood clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623635,,BAO_0000218
7910,,Evaluated for the low clearance in rat (in vivo),,,50597,,N,1,Intermediate,1,,CHEMBL621195,,BAO_0000218
7911,,Pharmacokinetic property (CLb)of the compound was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621196,,BAO_0000218
7912,,Rapid clearance after intravenous administration in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL875287,,BAO_0000218
7913,,Clearance measured in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621197,,BAO_0000218
7914,,Compound was evaluated for plasma clearance in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621198,,BAO_0000218
7915,,Low plasma clearance was calculated in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621199,,BAO_0000218
7916,,Pharmacokinetic property (Clp) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621200,,BAO_0000218
7917,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621201,,BAO_0000218
7918,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621202,,BAO_0000218
7919,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621203,,BAO_0000218
7920,,Plasma clearance after IV dosing at 1 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621204,,BAO_0000218
7921,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621205,,BAO_0000218
7922,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621206,,BAO_0000218
7923,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621207,,BAO_0000218
7924,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621208,,BAO_0000218
7925,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621209,,BAO_0000218
7926,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,948.0,,50597,,N,1,Intermediate,1,,CHEMBL876484,,BAO_0000218
7927,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621210,,BAO_0000218
7928,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621211,,BAO_0000218
7929,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621212,,BAO_0000218
7930,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621213,,BAO_0000218
7931,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621214,,BAO_0000218
7932,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621215,,BAO_0000218
7933,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621216,,BAO_0000218
7934,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621217,,BAO_0000218
7935,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621218,,BAO_0000218
7936,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621219,,BAO_0000218
7937,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621220,,BAO_0000218
7938,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621221,,BAO_0000218
7939,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621222,,BAO_0000218
7940,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621223,,BAO_0000218
7941,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL876485,,BAO_0000218
7942,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621224,,BAO_0000218
7943,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621225,,BAO_0000218
7944,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621226,,BAO_0000218
7945,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621227,,BAO_0000218
7946,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621228,,BAO_0000218
7947,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621229,,BAO_0000218
7948,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621230,,BAO_0000218
7949,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621231,,BAO_0000218
7950,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621232,,BAO_0000218
7951,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621233,,BAO_0000218
7952,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621234,,BAO_0000218
7953,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621235,,BAO_0000218
7954,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621236,,BAO_0000218
7955,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621237,,BAO_0000218
7956,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL876486,,BAO_0000218
7957,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,160.0,,50597,,N,1,Intermediate,1,,CHEMBL622436,,BAO_0000218
7958,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,160.0,,50597,,N,1,Intermediate,1,,CHEMBL622437,,BAO_0000218
7959,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,160.0,,50597,,N,1,Intermediate,1,,CHEMBL622438,,BAO_0000218
7960,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622439,,BAO_0000218
7961,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622440,,BAO_0000218
7962,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622441,,BAO_0000218
7963,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622442,,BAO_0000218
7964,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622443,,BAO_0000218
7965,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622444,,BAO_0000218
7966,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622445,,BAO_0000218
7967,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622446,,BAO_0000218
7968,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622447,,BAO_0000218
7969,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622448,,BAO_0000218
7970,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622449,,BAO_0000218
7971,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622450,,BAO_0000218
7972,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622451,,BAO_0000218
7973,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622452,,BAO_0000218
7974,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622453,,BAO_0000218
7975,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622454,,BAO_0000218
7976,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622455,,BAO_0000218
7977,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL876024,,BAO_0000218
7978,,T max was determined at 3 mg/kg po dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622456,,BAO_0000218
7979,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL622457,,BAO_0000218
7980,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL622458,,BAO_0000218
7981,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622459,,BAO_0000218
7982,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL873343,,BAO_0000218
7983,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622460,,BAO_0000218
7984,,Time for maximum plasma concentration determined in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622461,,BAO_0000218
7985,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622462,,BAO_0000218
7986,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,,50597,,N,1,Intermediate,1,,CHEMBL622463,,BAO_0000218
7987,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,,50597,,N,1,Intermediate,1,,CHEMBL622464,,BAO_0000218
7988,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622465,,BAO_0000218
7989,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,,50597,,N,1,Intermediate,1,,CHEMBL622466,,BAO_0000218
7990,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622467,,BAO_0000218
7991,,Time of maximum plasma concentration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622468,,BAO_0000218
7992,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL876025,,BAO_0000218
7993,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622469,,BAO_0000218
7994,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622470,,BAO_0000218
7995,,Time required to reach maximum concentration (Cmax) after oral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622471,,BAO_0000218
7996,,Time required to reach maximum concentration in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622472,,BAO_0000218
7997,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622473,,BAO_0000218
7998,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624282,,BAO_0000218
7999,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624283,,BAO_0000218
8000,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624284,,BAO_0000218
8001,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624285,,BAO_0000218
8002,,Time to reach Cmax after oral administration to rats,,,50597,,N,1,Intermediate,1,,CHEMBL624286,,BAO_0000218
8003,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,,50597,,N,1,Intermediate,1,,CHEMBL624287,,BAO_0000218
8004,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,,50597,,N,1,Intermediate,1,,CHEMBL624288,,BAO_0000218
8005,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624289,,BAO_0000218
8006,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL873344,,BAO_0000218
8007,,Tmax after peroral administration (10 mg/kg) was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL619623,,BAO_0000218
8008,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,,N,1,Expert,1,,CHEMBL621399,,BAO_0000218
8009,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621400,,BAO_0000218
8010,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,,50597,,N,1,Intermediate,1,,CHEMBL621401,,BAO_0000218
8011,,Tmax was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621402,,BAO_0000218
8012,,Tmax was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621403,,BAO_0000218
8013,,Tmax after oral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621121,,BAO_0000218
8014,,Tmax after peroral administration in rats at 2.4 uM/kg,,,50597,,N,1,Intermediate,1,,CHEMBL872525,,BAO_0000218
8015,,Tmax in male rat,,,50597,,N,1,Intermediate,1,,CHEMBL621122,,BAO_0000218
8016,,Tmax in rat at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621123,,BAO_0000218
8017,,Tmax in rat by po administration at a dose of 40 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621124,,BAO_0000218
8018,,Tmax in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621125,,BAO_0000218
8019,,Tmax was measured in rats after peroral administration at 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621126,,BAO_0000218
8020,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,,50597,,N,1,Intermediate,1,,CHEMBL621127,,BAO_0000218
8021,,Tmax value after administration of 20 mg/Kg oral dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621128,,BAO_0000218
8022,,Tmax value at a dose of 10 mg/kg in male SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL618263,,BAO_0000218
8023,,Tmax value at a dose of 100 mg/kg in male SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL618264,,BAO_0000218
8024,,Tmax value at a dose of 50 mg/kg in male SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL618265,,BAO_0000218
8025,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL618266,,BAO_0000218
8026,,time required to reach maximum concentration (Cmax) after oral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618267,,BAO_0000218
8027,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),1088.0,,50597,,N,1,Intermediate,1,,CHEMBL618450,,BAO_0000218
8028,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),1088.0,,50597,,N,1,Intermediate,1,,CHEMBL618451,,BAO_0000218
8029,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL618452,,BAO_0000218
8030,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL618453,,BAO_0000218
8031,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL618454,,BAO_0000218
8032,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL618455,,BAO_0000218
8033,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,,50597,,N,1,Intermediate,1,,CHEMBL618456,,BAO_0000218
8034,,Compound distribution in rat tissues was determined,,,50597,,N,1,Intermediate,1,,CHEMBL618457,,BAO_0000218
8035,,Volume of distribution was evaluated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618458,,BAO_0000218
8036,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL618459,,BAO_0000218
8037,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL876733,,BAO_0000218
8038,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,,50588,,N,1,Intermediate,1,,CHEMBL618460,,BAO_0000218
8039,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL618461,,BAO_0000218
8040,,Area under the curve was determined after oral administration (300 uM/Kg),,,22224,,U,0,Autocuration,1,,CHEMBL618462,,BAO_0000019
8041,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL618463,,BAO_0000218
8042,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL618464,,BAO_0000218
8043,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL618465,,BAO_0000218
8044,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL618466,,BAO_0000218
8045,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL618467,,BAO_0000218
8046,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL618468,,BAO_0000218
8047,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL618469,,BAO_0000218
8048,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL618470,,BAO_0000218
8049,,Plasma drug AUC in rat (PO dose),,,22224,,U,0,Autocuration,1,,CHEMBL618471,,BAO_0000218
8050,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,,50594,,N,1,Intermediate,1,,CHEMBL618472,,BAO_0000218
8051,,Area under was determined at a dose of 30 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL618473,,BAO_0000218
8052,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,,50506,,N,1,Intermediate,1,,CHEMBL621699,,BAO_0000218
8053,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,,50597,,N,1,Intermediate,1,,CHEMBL621700,,BAO_0000218
8054,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,,50597,,N,1,Intermediate,1,,CHEMBL621701,,BAO_0000218
8055,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,,50506,,N,1,Intermediate,1,,CHEMBL621702,,BAO_0000218
8056,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,,50588,,N,1,Intermediate,1,,CHEMBL621703,,BAO_0000218
8057,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,,50588,,N,1,Intermediate,1,,CHEMBL621704,,BAO_0000218
8058,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,,50597,,N,1,Intermediate,1,,CHEMBL624259,,BAO_0000218
8059,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,,50597,,N,1,Intermediate,1,,CHEMBL624260,,BAO_0000218
8060,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,,50597,,N,1,Intermediate,1,,CHEMBL624430,,BAO_0000218
8061,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,,50597,,N,1,Intermediate,1,,CHEMBL624431,,BAO_0000218
8062,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,,50597,,N,1,Intermediate,1,,CHEMBL624432,,BAO_0000218
8063,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,,50597,,N,1,Intermediate,1,,CHEMBL624433,,BAO_0000218
8064,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,,50597,,N,1,Intermediate,1,,CHEMBL624434,,BAO_0000218
8065,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,,50597,,N,1,Intermediate,1,,CHEMBL624435,,BAO_0000218
8066,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,,50594,,N,1,Intermediate,1,,CHEMBL618570,,BAO_0000218
8067,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,50594,,N,1,Intermediate,1,,CHEMBL618571,,BAO_0000218
8068,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,,50594,,N,1,Intermediate,1,,CHEMBL618572,,BAO_0000218
8069,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,50594,,N,1,Intermediate,1,,CHEMBL618573,,BAO_0000218
8070,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,,50594,,N,1,Intermediate,1,,CHEMBL619267,,BAO_0000218
8071,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,50594,,N,1,Intermediate,1,,CHEMBL619431,,BAO_0000218
8072,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,,50594,,N,1,Intermediate,1,,CHEMBL619432,,BAO_0000218
8073,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,50594,,N,1,Intermediate,1,,CHEMBL619433,,BAO_0000218
8074,,AUC in mice after oral dose (50 mg/kg),1969.0,,22224,,U,0,Autocuration,1,,CHEMBL619434,,BAO_0000218
8075,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,1977.0,,50594,,N,1,Intermediate,1,,CHEMBL619435,,BAO_0000218
8076,,AUC (0-4 hr) ug/ml/h,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL619436,,BAO_0000019
8077,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,,50597,,N,1,Intermediate,1,,CHEMBL619437,,BAO_0000218
8078,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,,22224,,U,0,Autocuration,1,,CHEMBL619438,,BAO_0000218
8079,,Compound was evaluated for Area under curve in mice,,,50594,,N,1,Intermediate,1,,CHEMBL619439,,BAO_0000218
8080,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,50597,,N,1,Intermediate,1,,CHEMBL619440,,BAO_0000218
8081,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,22224,,U,0,Autocuration,1,,CHEMBL619441,,BAO_0000218
8082,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,,50597,,N,1,Intermediate,1,,CHEMBL619442,,BAO_0000218
8083,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,,22224,,U,0,Autocuration,1,,CHEMBL875156,,BAO_0000019
8084,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,,22224,,U,0,Autocuration,1,,CHEMBL619443,,BAO_0000019
8085,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,,22224,,U,0,Autocuration,1,,CHEMBL619444,,BAO_0000019
8086,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,,22224,,U,0,Autocuration,1,,CHEMBL623464,,BAO_0000019
8087,,Compound was evaluated for area under curve when administered through oral route in mouse,,,50594,,N,1,Intermediate,1,,CHEMBL623465,,BAO_0000218
8088,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,,50597,,N,1,Intermediate,1,,CHEMBL623466,,BAO_0000218
8089,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,,50597,,N,1,Intermediate,1,,CHEMBL623467,,BAO_0000218
8090,,Plasma clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623468,,BAO_0000218
8091,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,,50597,,N,1,Intermediate,1,,CHEMBL622660,,BAO_0000218
8092,,Plasma clearance rate in Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL622661,,BAO_0000218
8093,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL622662,,BAO_0000218
8094,,Pharmacokinetic property (total body clearance) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622663,,BAO_0000218
8095,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL622664,,BAO_0000218
8096,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622665,,BAO_0000218
8097,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622666,,BAO_0000218
8098,,Cl in rat i.v. at 2 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL621615,,BAO_0000218
8099,,Clearance of compound after intravenous administration in rats at 24 uM/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621616,,BAO_0000218
8100,,Clearance was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621617,,BAO_0000218
8101,,Clearance by intravenous administration of 3.4 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621618,,BAO_0000218
8102,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621619,,BAO_0000218
8103,,Clearance rate after i.v. administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621620,,BAO_0000218
8104,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL621786,,BAO_0000218
8105,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL621787,,BAO_0000218
8106,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,,50597,,N,1,Intermediate,1,,CHEMBL621788,,BAO_0000218
8107,,Clearance (Cl) after oral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621789,,BAO_0000218
8108,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621790,,BAO_0000218
8109,,Compound was tested for plasma clearance in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621791,,BAO_0000218
8110,Microsomes,In vitro microsome metabolism clearance in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621792,,BAO_0000218
8111,Microsomes,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,,50597,,N,1,Intermediate,1,,CHEMBL621793,,BAO_0000218
8112,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL621794,,BAO_0000218
8113,,In vivo plasma clearance was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621795,,BAO_0000218
8114,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621796,,BAO_0000218
8115,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,2107.0,,50597,Hepatocyte,N,1,Intermediate,1,,CHEMBL621797,401.0,BAO_0000218
8116,,Pharmacokinetic property (Plasma clearance) was measured in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621798,,BAO_0000218
8117,,Pharmacokinetic property (clearance) in rat i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL621799,,BAO_0000218
8118,,"Plasma Clearance was evaluated in rats, iv",,,50597,,N,1,Intermediate,1,,CHEMBL621800,,BAO_0000218
8119,,Plasma clearance (in vivo) in rats was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621801,,BAO_0000218
8120,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621802,,BAO_0000218
8121,,Plasma clearance was determined,,,50597,,N,1,Intermediate,1,,CHEMBL618596,,BAO_0000218
8122,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL618597,,BAO_0000218
8123,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL618598,,BAO_0000218
8124,,Plasma clearance in rats,,,50597,,N,1,Intermediate,1,,CHEMBL618599,,BAO_0000218
8125,,Plasma clearance rate determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618600,,BAO_0000218
8126,,Plasma clearance was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618601,,BAO_0000218
8127,,Plasma clearance was determined,,,50597,,N,1,Intermediate,1,,CHEMBL618602,,BAO_0000218
8128,,Plasma clearance value in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618603,,BAO_0000218
8129,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL618604,,BAO_0000218
8130,,Clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618605,,BAO_0000218
8131,,Total body clearance in rat i.v. at 2 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL618606,,BAO_0000218
8132,,Clearance of compound in rats after intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL618607,,BAO_0000218
8133,,Clearance after iv administration to rats,,,50597,,N,1,Intermediate,1,,CHEMBL618608,,BAO_0000218
8134,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL618609,,BAO_0000218
8135,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL618610,,BAO_0000218
8136,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL618611,,BAO_0000218
8137,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL618612,,BAO_0000218
8138,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL618613,,BAO_0000218
8139,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL621076,,BAO_0000218
8140,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL621077,,BAO_0000218
8141,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,,50597,,N,1,Intermediate,1,,CHEMBL621078,,BAO_0000218
8142,,Clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621251,,BAO_0000218
8143,,Clearance in rat after oral administration at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621252,,BAO_0000218
8144,,Clearance in rat.,,,50597,,N,1,Intermediate,1,,CHEMBL621253,,BAO_0000218
8145,,Clearance rate following an oral dose of 20 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621254,,BAO_0000218
8146,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,,50597,,N,1,Intermediate,1,,CHEMBL621255,,BAO_0000218
8147,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621256,,BAO_0000218
8148,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621257,,BAO_0000218
8149,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621258,,BAO_0000218
8150,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621259,,BAO_0000218
8151,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621260,,BAO_0000218
8152,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL876494,,BAO_0000218
8153,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621261,,BAO_0000218
8154,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621262,,BAO_0000218
8155,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621263,,BAO_0000218
8156,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621264,,BAO_0000218
8157,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621265,,BAO_0000218
8158,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621266,,BAO_0000218
8159,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621267,,BAO_0000218
8160,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621268,,BAO_0000218
8161,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621269,,BAO_0000218
8162,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621270,,BAO_0000218
8163,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621271,,BAO_0000218
8164,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621272,,BAO_0000218
8165,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621273,,BAO_0000218
8166,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621274,,BAO_0000218
8167,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL876495,,BAO_0000218
8168,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621275,,BAO_0000218
8169,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621276,,BAO_0000218
8170,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621277,,BAO_0000218
8171,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,160.0,,50597,,N,1,Intermediate,1,,CHEMBL621278,,BAO_0000218
8172,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,160.0,,50597,,N,1,Intermediate,1,,CHEMBL621279,,BAO_0000218
8173,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),160.0,,50597,,N,1,Intermediate,1,,CHEMBL621280,,BAO_0000218
8174,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621281,,BAO_0000218
8175,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621282,,BAO_0000218
8176,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621283,,BAO_0000218
8177,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621284,,BAO_0000218
8178,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621285,,BAO_0000218
8179,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621286,,BAO_0000218
8180,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL623220,,BAO_0000218
8181,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL623221,,BAO_0000218
8182,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL876029,,BAO_0000218
8183,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,945.0,,50597,,N,1,Intermediate,1,,CHEMBL623222,,BAO_0000218
8184,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,945.0,,50597,,N,1,Intermediate,1,,CHEMBL623223,,BAO_0000218
8185,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,945.0,,50597,,N,1,Intermediate,1,,CHEMBL621445,,BAO_0000218
8186,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621446,,BAO_0000218
8187,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621447,,BAO_0000218
8188,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,178.0,,50597,,N,1,Intermediate,1,,CHEMBL619681,,BAO_0000218
8189,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,178.0,,50597,,N,1,Intermediate,1,,CHEMBL619682,,BAO_0000218
8190,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,178.0,,50597,,N,1,Intermediate,1,,CHEMBL619683,,BAO_0000218
8191,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,955.0,,50597,,N,1,Intermediate,1,,CHEMBL619684,,BAO_0000218
8192,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,955.0,,50597,,N,1,Intermediate,1,,CHEMBL619685,,BAO_0000218
8193,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,955.0,,50597,,N,1,Intermediate,1,,CHEMBL619686,,BAO_0000218
8194,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,955.0,,50597,,N,1,Intermediate,1,,CHEMBL619687,,BAO_0000218
8195,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,955.0,,50597,,N,1,Intermediate,1,,CHEMBL619688,,BAO_0000218
8196,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,948.0,,50597,,N,1,Intermediate,1,,CHEMBL619689,,BAO_0000218
8197,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,948.0,,50597,,N,1,Intermediate,1,,CHEMBL619690,,BAO_0000218
8198,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,948.0,,50597,,N,1,Intermediate,1,,CHEMBL619691,,BAO_0000218
8199,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL619692,,BAO_0000218
8200,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,,N,1,Expert,1,,CHEMBL619693,,BAO_0000218
8201,,Vc value after IV dose at a dose of 5 mg/kg in rats.,,,50597,,N,1,Intermediate,1,,CHEMBL619694,,BAO_0000218
8202,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL619695,,BAO_0000218
8203,,Compound was evaluated for pharmacokinetic parameter volume of distribution,,,50597,,N,1,Intermediate,1,,CHEMBL619696,,BAO_0000218
8204,,Compound was evaluated for volume of distribution in rat,,,50597,,N,1,Intermediate,1,,CHEMBL619697,,BAO_0000218
8205,,Steady state volume distribution was determined; steady state(ss),,,50597,,N,1,Intermediate,1,,CHEMBL619698,,BAO_0000218
8206,,Steady state volume of distribution after iv administration to rats,,,50597,,N,1,Intermediate,1,,CHEMBL619699,,BAO_0000218
8207,,Steady state volume of distribution dosing at 3 mg/kg iv,,,50597,,N,1,Intermediate,1,,CHEMBL619700,,BAO_0000218
8208,,The compound was evaluated for volume of distribution in rat,,,50597,,N,1,Intermediate,1,,CHEMBL619701,,BAO_0000218
8209,,The compound was tested for volume of distribution in rat,,,50597,,N,1,Intermediate,1,,CHEMBL619702,,BAO_0000218
8210,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,,50597,,N,1,Intermediate,1,,CHEMBL620335,,BAO_0000218
8211,,Volume distribution (VD) after oral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620336,,BAO_0000218
8212,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620337,,BAO_0000218
8213,,Volume distribution in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620520,,BAO_0000218
8214,,Volume distribution in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620521,,BAO_0000218
8215,,Volume distribution in rat after peroral administration at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL875825,,BAO_0000218
8216,,Volume distribution in rat after peroral administration at 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620522,,BAO_0000218
8217,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620523,,BAO_0000218
8218,,Volume of distribution in rat.,,,50597,,N,1,Intermediate,1,,CHEMBL620524,,BAO_0000218
8219,,Volume of distribution in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620525,,BAO_0000218
8220,,Volume of distribution in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620526,,BAO_0000218
8221,,Volume of distribution in rat by iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL620527,,BAO_0000218
8222,,Volume of distribution in rats,,,50597,,N,1,Intermediate,1,,CHEMBL620528,,BAO_0000218
8223,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,,50597,,N,1,Intermediate,1,,CHEMBL620529,,BAO_0000218
8224,,Volume distribution at the dose of 2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620530,,BAO_0000218
8225,,Steady state volume of distribution was determined,,,50597,,N,1,Intermediate,1,,CHEMBL620531,,BAO_0000218
8226,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,22224,,U,0,Intermediate,1,,CHEMBL620532,,BAO_0000218
8227,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,,22224,,U,0,Intermediate,1,,CHEMBL620533,,BAO_0000218
8228,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,,22224,,U,0,Intermediate,1,,CHEMBL620534,,BAO_0000218
8229,,Mean (%CV) PK parameters for Vdss(mL/kg).,,,50597,,N,1,Intermediate,1,,CHEMBL620535,,BAO_0000218
8230,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL875826,,BAO_0000218
8231,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL620536,,BAO_0000218
8232,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL620537,,BAO_0000218
8233,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL618526,,BAO_0000218
8234,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,,50597,,N,1,Intermediate,1,,CHEMBL618527,,BAO_0000218
8235,,Pharmacokinetic property (Vdss) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618528,,BAO_0000218
8236,,Pharmacokinetic property (vdss) was measured in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618529,,BAO_0000218
8237,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618530,,BAO_0000218
8238,,Volume of distribution in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618531,,BAO_0000218
8239,,The pharmacokinetic parameter volume of distribution in vivo in rats,,,50597,,N,1,Intermediate,1,,CHEMBL618532,,BAO_0000218
8240,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL618533,,BAO_0000218
8241,,Vdss in rat i.v. at 2 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL618534,,BAO_0000218
8242,,Volume distribution after intravenous administration (1 mg/kg) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618535,,BAO_0000218
8243,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL618536,,BAO_0000218
8244,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL618537,,BAO_0000218
8245,,Volume distribution at a dose of 10 uM/kg in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL618538,,BAO_0000218
8246,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL618539,,BAO_0000218
8247,,Volume distribution was calculated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618540,,BAO_0000218
8248,,Volume distribution was determined,,,50597,,N,1,Intermediate,1,,CHEMBL618541,,BAO_0000218
8249,,Volume of distribution after intravenous administration was evaluated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618542,,BAO_0000218
8250,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50597,,N,1,Intermediate,1,,CHEMBL622544,,BAO_0000218
8251,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,,50597,,N,1,Intermediate,1,,CHEMBL622545,,BAO_0000218
8252,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,,50597,,N,1,Intermediate,1,,CHEMBL622546,,BAO_0000218
8253,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,,50597,,N,1,Intermediate,1,,CHEMBL622547,,BAO_0000218
8254,,Volume of distribution in steady state was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622548,,BAO_0000218
8255,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL622549,,BAO_0000218
8256,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,,50597,,N,1,Intermediate,1,,CHEMBL622550,,BAO_0000218
8257,,Compound was evaluated for area under curve when administered through oral route to mouse,,,50594,,N,1,Intermediate,1,,CHEMBL622551,,BAO_0000218
8258,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,50597,,N,1,Intermediate,1,,CHEMBL622552,,BAO_0000218
8259,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,,50597,,N,1,Intermediate,1,,CHEMBL622553,,BAO_0000218
8260,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,,22224,,U,0,Autocuration,1,,CHEMBL622554,,BAO_0000218
8261,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,,50588,,N,1,Intermediate,1,,CHEMBL622555,,BAO_0000218
8262,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,50594,,N,1,Intermediate,1,,CHEMBL622556,,BAO_0000218
8263,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,50594,,N,1,Intermediate,1,,CHEMBL622557,,BAO_0000218
8264,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,178.0,,50594,,N,1,Intermediate,1,,CHEMBL622558,,BAO_0000218
8265,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,178.0,,50594,,N,1,Intermediate,1,,CHEMBL622559,,BAO_0000218
8266,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,,50588,,N,1,Intermediate,1,,CHEMBL622560,,BAO_0000218
8267,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,,50597,,N,1,Intermediate,1,,CHEMBL622561,,BAO_0000218
8268,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,,50597,,N,1,Intermediate,1,,CHEMBL622562,,BAO_0000218
8269,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,,50597,,N,1,Intermediate,1,,CHEMBL622563,,BAO_0000218
8270,,Concentration of compound in Central nervous system,,,22224,,U,0,Autocuration,1,,CHEMBL622564,,BAO_0000019
8271,,Concentration of compound in Central nervous system; Not detectable,,,22224,,U,0,Autocuration,1,,CHEMBL622565,,BAO_0000019
8272,,"Concentration of diester in the blood, following oral administration in mice",,,50594,,N,1,Intermediate,1,,CHEMBL622566,,BAO_0000218
8273,,"Concentration of monoester in the blood, following oral administration in mice",,,50594,,N,1,Intermediate,1,,CHEMBL624515,,BAO_0000218
8274,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,,50594,,N,1,Intermediate,1,,CHEMBL624516,,BAO_0000218
8275,,Evaluated for Pharmacokinetic property: Area under the curve,,,22224,,U,0,Autocuration,1,,CHEMBL624517,,BAO_0000019
8276,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,,50594,,N,1,Intermediate,1,,CHEMBL624518,,BAO_0000218
8277,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,,100710,,N,1,Intermediate,1,,CHEMBL624519,,BAO_0000218
8278,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,,100710,,N,1,Intermediate,1,,CHEMBL624520,,BAO_0000218
8279,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,,100710,,N,1,Intermediate,1,,CHEMBL624521,,BAO_0000218
8280,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,,100710,,N,1,Intermediate,1,,CHEMBL624522,,BAO_0000218
8281,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,,100710,,N,1,Intermediate,1,,CHEMBL624523,,BAO_0000218
8282,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,100710,,N,1,Intermediate,1,,CHEMBL624409,,BAO_0000218
8283,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,,100710,,N,1,Intermediate,1,,CHEMBL624410,,BAO_0000218
8284,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,100710,,N,1,Intermediate,1,,CHEMBL624411,,BAO_0000218
8285,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,,100710,,N,1,Intermediate,1,,CHEMBL623531,,BAO_0000218
8286,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,,100710,,N,1,Intermediate,1,,CHEMBL623532,,BAO_0000218
8287,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,,100710,,N,1,Intermediate,1,,CHEMBL623533,,BAO_0000218
8288,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,100710,,N,1,Intermediate,1,,CHEMBL623534,,BAO_0000218
8289,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,,50594,,N,1,Intermediate,1,,CHEMBL623535,,BAO_0000218
8290,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,,50594,,N,1,Intermediate,1,,CHEMBL623536,,BAO_0000218
8291,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,,50594,,N,1,Intermediate,1,,CHEMBL623537,,BAO_0000218
8292,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,,50594,,N,1,Intermediate,1,,CHEMBL623538,,BAO_0000218
8293,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,,50594,,N,1,Intermediate,1,,CHEMBL623539,,BAO_0000218
8294,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,,50594,,N,1,Intermediate,1,,CHEMBL623540,,BAO_0000218
8295,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,,50594,,N,1,Intermediate,1,,CHEMBL623541,,BAO_0000218
8296,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,,50594,,N,1,Intermediate,1,,CHEMBL623542,,BAO_0000218
8297,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,,50594,,N,1,Intermediate,1,,CHEMBL623543,,BAO_0000218
8298,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,,50594,,N,1,Intermediate,1,,CHEMBL623544,,BAO_0000218
8299,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,,50594,,N,1,Intermediate,1,,CHEMBL623545,,BAO_0000218
8300,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,,50594,,N,1,Intermediate,1,,CHEMBL623546,,BAO_0000218
8301,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623547,,BAO_0000218
8302,,High i.v. clearance in Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL623548,,BAO_0000218
8303,Microsomes,In vitro clearance in rat liver microsomes,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL623549,,BAO_0000218
8304,Microsomes,Intrinsic clearance in rat liver microsomes was determined,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL623550,,BAO_0000218
8305,,Intrinsic clearance in rat hepatocytes was determined,2107.0,,50597,Hepatocyte,N,1,Intermediate,1,,CHEMBL875276,401.0,BAO_0000218
8306,,Plasma Clearance was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621872,,BAO_0000218
8307,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621873,,BAO_0000218
8308,,Plasma clearance in rat.,,,50597,,N,1,Intermediate,1,,CHEMBL621874,,BAO_0000218
8309,,Plasma clearance in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621875,,BAO_0000218
8310,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621876,,BAO_0000218
8311,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,,50597,,N,1,Intermediate,1,,CHEMBL621877,,BAO_0000218
8312,,Plasma clearance was measured in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621878,,BAO_0000218
8313,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621879,,BAO_0000218
8314,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621880,,BAO_0000218
8315,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621881,,BAO_0000218
8316,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621882,,BAO_0000218
8317,,Total clearance at 1 mg/kg was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL875283,,BAO_0000218
8318,,Total clearance at 10 mg/kg was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621883,,BAO_0000218
8319,,Clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621884,,BAO_0000218
8320,,Plasma clearance rate determined in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621885,,BAO_0000218
8321,,Clearance of compound in rat was evaluated,,,50597,,N,1,Intermediate,1,,CHEMBL621886,,BAO_0000218
8322,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621887,,BAO_0000218
8323,,Pharmacokinetic property (blood clearance) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621888,,BAO_0000218
8324,,Plasma clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621889,,BAO_0000218
8325,,Plasma clearance in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621890,,BAO_0000218
8326,Microsomes,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621891,,BAO_0000218
8327,,Clearance in Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL621892,,BAO_0000218
8328,,Clearance rat,,,50597,,N,1,Intermediate,1,,CHEMBL621893,,BAO_0000218
8329,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,,50597,,N,1,Intermediate,1,,CHEMBL621894,,BAO_0000218
8330,,Clearance rat; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL621895,,BAO_0000218
8331,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL875284,,BAO_0000218
8332,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,,50597,,N,1,Intermediate,1,,CHEMBL618699,,BAO_0000218
8333,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,,50597,,N,1,Intermediate,1,,CHEMBL618700,,BAO_0000218
8334,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL618701,,BAO_0000218
8335,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL876600,,BAO_0000218
8336,,Clearance of compound in rat after 1 mg/kg i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL618702,,BAO_0000218
8337,,Compound was evaluated for Hepatic clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618703,,BAO_0000218
8338,,In vivo clearance after 5 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL618704,,BAO_0000218
8339,,Compound was tested for plasma clearance in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL618705,,BAO_0000218
8340,,Hepatic clearance after intravenous administration was evaluated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618706,,BAO_0000218
8341,,Lower clearance in rat (i.v.) at 0.5 mpk,,,50597,,N,1,Intermediate,1,,CHEMBL618707,,BAO_0000218
8342,,Pharmacokinetic parameter expressed as plasma clearance in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL618708,,BAO_0000218
8343,,Pharmacokinetic property (Clp) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618709,,BAO_0000218
8344,,Plasma clearance in Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL618710,,BAO_0000218
8345,,Plasma clearance (Clp) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618711,,BAO_0000218
8346,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL618712,,BAO_0000218
8347,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL618713,,BAO_0000218
8348,,Plasma clearance after intravenous administration of 1 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618714,,BAO_0000218
8349,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL618715,,BAO_0000218
8350,,Plasma clearance in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL618716,,BAO_0000218
8351,,Plasma clearance measured in rat,,,50597,,N,1,Intermediate,1,,CHEMBL876601,,BAO_0000218
8352,,Plasma clearance was calculated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618717,,BAO_0000218
8353,,Plasma clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618718,,BAO_0000218
8354,,Plasma clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618719,,BAO_0000218
8355,,Plasma clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618720,,BAO_0000218
8356,,Plasma clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618721,,BAO_0000218
8357,,Plasma clearance in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621477,,BAO_0000218
8358,,Plasma clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621478,,BAO_0000218
8359,,Plasma clearance was evaluated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621479,,BAO_0000218
8360,,Plasma clearance was evaluated in rat; Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL621480,,BAO_0000218
8361,,Plasma clearance rate was determined for the compound in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621481,,BAO_0000218
8362,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,,50597,,N,1,Intermediate,1,,CHEMBL621482,,BAO_0000218
8363,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,,50597,,N,1,Intermediate,1,,CHEMBL621483,,BAO_0000218
8364,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,,50597,,N,1,Intermediate,1,,CHEMBL621484,,BAO_0000218
8365,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621485,,BAO_0000218
8366,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,948.0,,50597,,N,1,Intermediate,1,,CHEMBL621486,,BAO_0000218
8367,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,160.0,,50597,,N,1,Intermediate,1,,CHEMBL621487,,BAO_0000218
8368,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,160.0,,50597,,N,1,Intermediate,1,,CHEMBL621488,,BAO_0000218
8369,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,160.0,,50597,,N,1,Intermediate,1,,CHEMBL621489,,BAO_0000218
8370,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,160.0,,50597,,N,1,Intermediate,1,,CHEMBL621490,,BAO_0000218
8371,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,160.0,,50597,,N,1,Intermediate,1,,CHEMBL621491,,BAO_0000218
8372,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621492,,BAO_0000218
8373,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621493,,BAO_0000218
8374,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621494,,BAO_0000218
8375,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621495,,BAO_0000218
8376,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621496,,BAO_0000218
8377,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621497,,BAO_0000218
8378,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621498,,BAO_0000218
8379,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621499,,BAO_0000218
8380,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL618634,,BAO_0000218
8381,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL618635,,BAO_0000218
8382,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL618636,,BAO_0000218
8383,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL619737,,BAO_0000218
8384,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL619738,,BAO_0000218
8385,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624329,,BAO_0000218
8386,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624330,,BAO_0000218
8387,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624331,,BAO_0000218
8388,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624332,,BAO_0000218
8389,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624333,,BAO_0000218
8390,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624334,,BAO_0000218
8391,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624335,,BAO_0000218
8392,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL620016,,BAO_0000218
8393,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL620169,,BAO_0000218
8394,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL620170,,BAO_0000218
8395,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL620171,,BAO_0000218
8396,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL620172,,BAO_0000218
8397,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,945.0,,50597,,N,1,Intermediate,1,,CHEMBL620173,,BAO_0000218
8398,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,945.0,,50597,,N,1,Intermediate,1,,CHEMBL620174,,BAO_0000218
8399,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,945.0,,50597,,N,1,Intermediate,1,,CHEMBL620175,,BAO_0000218
8400,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,945.0,,50597,,N,1,Intermediate,1,,CHEMBL620176,,BAO_0000218
8401,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,945.0,,50597,,N,1,Intermediate,1,,CHEMBL620177,,BAO_0000218
8402,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL620178,,BAO_0000218
8403,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL620179,,BAO_0000218
8404,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,50597,,N,1,Intermediate,1,,CHEMBL620180,,BAO_0000218
8405,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL620181,,BAO_0000218
8406,,Volume of distribution of compound in rats after intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL620182,,BAO_0000218
8407,,Volume of distribution in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620183,,BAO_0000218
8408,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL620184,,BAO_0000218
8409,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,,50597,,N,1,Intermediate,1,,CHEMBL620185,,BAO_0000218
8410,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,,50597,,N,1,Intermediate,1,,CHEMBL620186,,BAO_0000218
8411,,Volume of distribution was determined in Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL620187,,BAO_0000218
8412,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL620188,,BAO_0000218
8413,,Volume of distribution was reported in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL620189,,BAO_0000218
8414,,Volumes of distribution in rat after peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL620190,,BAO_0000218
8415,,Volumes of distribution in rat after po administration,,,50597,,N,1,Intermediate,1,,CHEMBL620191,,BAO_0000218
8416,,Volumes of distribution in rat after po administration; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL620192,,BAO_0000218
8417,,Pharmacokinetic property (Volume) in rat i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL620193,,BAO_0000218
8418,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,,50597,,N,1,Intermediate,1,,CHEMBL620194,,BAO_0000218
8419,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,,50597,,N,1,Intermediate,1,,CHEMBL876730,,BAO_0000218
8420,,Volume distribution in rat after oral administration at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620195,,BAO_0000218
8421,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL620196,,BAO_0000218
8422,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620197,,BAO_0000218
8423,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,,50597,,N,1,Intermediate,1,,CHEMBL620198,,BAO_0000218
8424,,Volume of distribution in rats,,,50597,,N,1,Intermediate,1,,CHEMBL620199,,BAO_0000218
8425,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL620200,,BAO_0000218
8426,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL620201,,BAO_0000218
8427,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL620202,,BAO_0000218
8428,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL620203,,BAO_0000218
8429,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,,50597,,N,1,Intermediate,1,,CHEMBL620204,,BAO_0000218
8430,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL620205,,BAO_0000218
8431,,Pharmacokinetic parameter (Vss) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624664,,BAO_0000218
8432,,Pharmacokinetic property (Volume) in rat i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL624665,,BAO_0000218
8433,,Pharmacokinetic property (Vss) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624666,,BAO_0000218
8434,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,,50597,,N,1,Intermediate,1,,CHEMBL624667,,BAO_0000218
8435,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL624668,,BAO_0000218
8436,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL624669,,BAO_0000218
8437,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL624670,,BAO_0000218
8438,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL624671,,BAO_0000218
8439,,Steady state volume distribution in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624672,,BAO_0000218
8440,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624673,,BAO_0000218
8441,,Steady state volume of distribution determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624674,,BAO_0000218
8442,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624675,,BAO_0000218
8443,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621728,,BAO_0000218
8444,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621729,,BAO_0000218
8445,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,,50597,,N,1,Intermediate,1,,CHEMBL621730,,BAO_0000218
8446,,Volume distribution in rat after administration of 2 mg/kg iv,,,50597,,N,1,Intermediate,1,,CHEMBL621731,,BAO_0000218
8447,,Volume distribution in rat after administration of 2 mg/kg iv,,,50597,,N,1,Intermediate,1,,CHEMBL621732,,BAO_0000218
8448,,Volume in steady state distribution value was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621908,,BAO_0000218
8449,,Volume in steady state distribution value was determined; ND denotes no data,,,50597,,N,1,Intermediate,1,,CHEMBL875347,,BAO_0000218
8450,,Volume in steady state distribution value was determined; ND denotes not determined,,,50597,,N,1,Intermediate,1,,CHEMBL621909,,BAO_0000218
8451,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,50597,,N,1,Intermediate,1,,CHEMBL621910,,BAO_0000218
8452,,Volume of distribution at steady state was evaluated in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621911,,BAO_0000218
8453,,Volume of distribution at steady state was observed after intravenous administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621912,,BAO_0000218
8454,,Volume of distribution in steady state was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621913,,BAO_0000218
8455,,Volume of distribution in steady state was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621914,,BAO_0000218
8456,,Volume of distribution after i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL621915,,BAO_0000218
8457,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL621916,,BAO_0000218
8458,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",2107.0,,50594,,N,1,Intermediate,1,,CHEMBL621917,,BAO_0000218
8459,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2107.0,,50594,,N,1,Intermediate,1,,CHEMBL621918,,BAO_0000218
8460,,Biodistribution of compound (oxidized form) in spleen tissue,2106.0,,50594,,N,1,Intermediate,1,,CHEMBL621919,,BAO_0000218
8461,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",2106.0,,50594,,N,1,Intermediate,1,,CHEMBL621920,,BAO_0000218
8462,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",2106.0,,50594,,N,1,Intermediate,1,,CHEMBL621921,,BAO_0000218
8463,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2106.0,,50594,,N,1,Intermediate,1,,CHEMBL622401,,BAO_0000218
8464,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2106.0,,50594,,N,1,Intermediate,1,,CHEMBL875348,,BAO_0000218
8465,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",2106.0,,50594,,N,1,Intermediate,1,,CHEMBL622402,,BAO_0000218
8466,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,178.0,,50594,,N,1,Intermediate,1,,CHEMBL622403,,BAO_0000218
8467,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",178.0,,50594,,N,1,Intermediate,1,,CHEMBL622404,,BAO_0000218
8468,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,955.0,,50594,,N,1,Intermediate,1,,CHEMBL622405,,BAO_0000218
8469,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",955.0,,50594,,N,1,Intermediate,1,,CHEMBL622406,,BAO_0000218
8470,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",955.0,,50594,,N,1,Intermediate,1,,CHEMBL622407,,BAO_0000218
8471,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,948.0,,50594,,N,1,Intermediate,1,,CHEMBL622408,,BAO_0000218
8472,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",948.0,,50594,,N,1,Intermediate,1,,CHEMBL622409,,BAO_0000218
8473,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",948.0,,50594,,N,1,Intermediate,1,,CHEMBL622410,,BAO_0000218
8474,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,2113.0,,50594,,N,1,Intermediate,1,,CHEMBL622411,,BAO_0000218
8475,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",2113.0,,50594,,N,1,Intermediate,1,,CHEMBL627864,,BAO_0000218
8476,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2113.0,,50594,,N,1,Intermediate,1,,CHEMBL627865,,BAO_0000218
8477,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,2107.0,,50594,,N,1,Intermediate,1,,CHEMBL627866,,BAO_0000218
8478,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2107.0,,50594,,N,1,Intermediate,1,,CHEMBL627751,,BAO_0000218
8479,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,2106.0,,50594,,N,1,Intermediate,1,,CHEMBL627752,,BAO_0000218
8480,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",2106.0,,50594,,N,1,Intermediate,1,,CHEMBL627753,,BAO_0000218
8481,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2106.0,,50594,,N,1,Intermediate,1,,CHEMBL627754,,BAO_0000218
8482,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,,50594,,N,1,Intermediate,1,,CHEMBL627755,,BAO_0000218
8483,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),955.0,,50594,,N,1,Intermediate,1,,CHEMBL627756,,BAO_0000218
8484,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),955.0,,50594,,N,1,Intermediate,1,,CHEMBL627757,,BAO_0000218
8485,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),955.0,,50594,,N,1,Intermediate,1,,CHEMBL627758,,BAO_0000218
8486,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),955.0,,50594,,N,1,Intermediate,1,,CHEMBL627759,,BAO_0000218
8487,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),955.0,,50594,,N,1,Intermediate,1,,CHEMBL627760,,BAO_0000218
8488,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),955.0,,50594,,N,1,Intermediate,1,,CHEMBL627761,,BAO_0000218
8489,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),948.0,,50594,,N,1,Intermediate,1,,CHEMBL876811,,BAO_0000218
8490,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),948.0,,50594,,N,1,Intermediate,1,,CHEMBL627762,,BAO_0000218
8491,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),948.0,,50594,,N,1,Intermediate,1,,CHEMBL627763,,BAO_0000218
8492,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),948.0,,50594,,N,1,Intermediate,1,,CHEMBL627764,,BAO_0000218
8493,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),948.0,,50594,,N,1,Intermediate,1,,CHEMBL627765,,BAO_0000218
8494,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),948.0,,50594,,N,1,Intermediate,1,,CHEMBL627766,,BAO_0000218
8495,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),2113.0,,50594,,N,1,Intermediate,1,,CHEMBL627767,,BAO_0000218
8496,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),2113.0,,50594,,N,1,Intermediate,1,,CHEMBL627768,,BAO_0000218
8497,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),2113.0,,50594,,N,1,Intermediate,1,,CHEMBL628422,,BAO_0000218
8498,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),2113.0,,50594,,N,1,Intermediate,1,,CHEMBL628423,,BAO_0000218
8499,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL628424,,BAO_0000218
8500,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL628425,,BAO_0000218
8501,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,,50597,,N,1,Intermediate,1,,CHEMBL628426,,BAO_0000218
8502,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50597,,N,1,Intermediate,1,,CHEMBL628427,,BAO_0000218
8503,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL626938,,BAO_0000218
8504,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL626939,,BAO_0000218
8505,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL626940,,BAO_0000218
8506,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL626941,,BAO_0000218
8507,,Plasma clearance was reported in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL626942,,BAO_0000218
8508,,Plasma clearance after intravenous administration (1 mg/kg) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL876812,,BAO_0000218
8509,,Plasma clearance of compound in rats was evaluated,,,50597,,N,1,Intermediate,1,,CHEMBL626943,,BAO_0000218
8510,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,,50597,,N,1,Intermediate,1,,CHEMBL626944,,BAO_0000218
8511,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL626945,,BAO_0000218
8512,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,,50597,,N,1,Intermediate,1,,CHEMBL626946,,BAO_0000218
8513,,Plasma clearance rate in Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL626856,,BAO_0000218
8514,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL626857,,BAO_0000218
8515,,The compound was evaluated for plasma clearance in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626858,,BAO_0000218
8516,,Total plasma clearance in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627018,,BAO_0000218
8517,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625331,,BAO_0000218
8518,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625332,,BAO_0000218
8519,,C max was determined at 10 mg/kg po dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL877590,,BAO_0000218
8520,,C max was determined at 3 mg/kg po dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625333,,BAO_0000218
8521,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625334,,BAO_0000218
8522,,Cmax after single intravenous bolus of 1 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625335,,BAO_0000218
8523,,Cmax of compound at 5 mg/kg after po administration was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625336,,BAO_0000218
8524,,Cmax 24 hr after 10 mg/kg oral administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625337,,BAO_0000218
8525,,Cmax 24 hr after 2 mg/kg oral administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625338,,BAO_0000218
8526,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625339,,BAO_0000218
8527,,Cmax in rat after administration of 2 mg/kg iv,,,50597,,N,1,Intermediate,1,,CHEMBL625340,,BAO_0000218
8528,,Cmax in rat after administration of 2 mg/kg iv,,,50597,,N,1,Intermediate,1,,CHEMBL625341,,BAO_0000218
8529,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622687,,BAO_0000218
8530,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622688,,BAO_0000218
8531,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,178.0,,50597,,N,1,Intermediate,1,,CHEMBL622689,,BAO_0000218
8532,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,178.0,,50597,,N,1,Intermediate,1,,CHEMBL620295,,BAO_0000218
8533,,Cmax after 10 mg/kg oral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620296,,BAO_0000218
8534,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,,50597,,N,1,Intermediate,1,,CHEMBL620297,,BAO_0000218
8535,,Cmax after IV dosing at 1 mg/kg in rat; no data,,,50597,,N,1,Intermediate,1,,CHEMBL620298,,BAO_0000218
8536,,Cmax after oral administration at 20 mpk in rats,,,50597,,N,1,Intermediate,1,,CHEMBL620299,,BAO_0000218
8537,,Cmax after oral administration at 20 mpk in rats; Not performed.,,,50597,,N,1,Intermediate,1,,CHEMBL620300,,BAO_0000218
8538,,Cmax after oral administration at 20 mpk in rats d; Not performed.,,,50597,,N,1,Intermediate,1,,CHEMBL620301,,BAO_0000218
8539,,Cmax after oral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620302,,BAO_0000218
8540,,Cmax after oral administration at a dose of 2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620303,,BAO_0000218
8541,,Cmax after oral administration at a dose of 4 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620304,,BAO_0000218
8542,,Cmax in rats after 20 mg/kg oral dose,,,50597,,N,1,Intermediate,1,,CHEMBL620305,,BAO_0000218
8543,,Cmax after peroral administration in rats at 2.4 uM/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620306,,BAO_0000218
8544,,Cmax at the dose of 2 mg/Kg administered perorally in rats,,,50597,,N,1,Intermediate,1,,CHEMBL620307,,BAO_0000218
8545,,Cmax at the dose of 5 mg/Kg administered perorally in rats,,,50597,,N,1,Intermediate,1,,CHEMBL620308,,BAO_0000218
8546,,Cmax by administering at 20 mg/kg p.o. in rats,,,50597,,N,1,Intermediate,1,,CHEMBL620309,,BAO_0000218
8547,,Cmax in male rat,,,50597,,N,1,Intermediate,1,,CHEMBL620310,,BAO_0000218
8548,,Cmax in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620311,,BAO_0000218
8549,,Cmax in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620312,,BAO_0000218
8550,,Cmax in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620313,,BAO_0000218
8551,,Cmax in rat at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620314,,BAO_0000218
8552,,Cmax in rat at the dose of 1 mg/kg i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL620315,,BAO_0000218
8553,,Cmax in rat by po administration at a dose of 40 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620316,,BAO_0000218
8554,,Cmax in rat p.o. at 20 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL620317,,BAO_0000218
8555,,Cmax in rats,,,50597,,N,1,Intermediate,1,,CHEMBL620318,,BAO_0000218
8556,,Cmax in rats,,,50597,,N,1,Intermediate,1,,CHEMBL620319,,BAO_0000218
8557,,Cmax was evaluated after 20 uM/kg of peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL620320,,BAO_0000218
8558,,Cmax was measured in rats after peroral administration at 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620321,,BAO_0000218
8559,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,,50597,,N,1,Intermediate,1,,CHEMBL620322,,BAO_0000218
8560,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,50597,,N,1,Intermediate,1,,CHEMBL620323,,BAO_0000218
8561,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1870.0,,50597,,N,1,Intermediate,1,,CHEMBL620324,,BAO_0000218
8562,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1870.0,,50597,,N,1,Intermediate,1,,CHEMBL620325,,BAO_0000218
8563,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL620326,,BAO_0000218
8564,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL620327,,BAO_0000218
8565,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,50597,,N,1,Intermediate,1,,CHEMBL620328,,BAO_0000218
8566,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,50597,,N,1,Intermediate,1,,CHEMBL620329,,BAO_0000218
8567,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,1891.0,,50597,,N,1,Intermediate,1,,CHEMBL620330,,BAO_0000218
8568,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,1891.0,,50597,,N,1,Intermediate,1,,CHEMBL875286,,BAO_0000218
8569,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,50597,,N,1,Intermediate,1,,CHEMBL620331,,BAO_0000218
8570,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,50597,,N,1,Intermediate,1,,CHEMBL620332,,BAO_0000218
8571,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL620333,,BAO_0000218
8572,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL620334,,BAO_0000218
8573,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621015,,BAO_0000218
8574,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621016,,BAO_0000218
8575,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621191,,BAO_0000218
8576,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621192,,BAO_0000218
8577,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621193,,BAO_0000218
8578,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621194,,BAO_0000218
8579,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624204,,BAO_0000218
8580,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624205,,BAO_0000218
8581,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624206,,BAO_0000218
8582,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624207,,BAO_0000218
8583,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624208,,BAO_0000218
8584,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624209,,BAO_0000218
8585,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624210,,BAO_0000218
8586,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624211,,BAO_0000218
8587,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624212,,BAO_0000218
8588,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624213,,BAO_0000218
8589,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL876611,,BAO_0000218
8590,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624214,,BAO_0000218
8591,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624215,,BAO_0000218
8592,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624216,,BAO_0000218
8593,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624217,,BAO_0000218
8594,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624218,,BAO_0000218
8595,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624219,,BAO_0000218
8596,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624220,,BAO_0000218
8597,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624221,,BAO_0000218
8598,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL624222,,BAO_0000218
8599,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL624223,,BAO_0000218
8600,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL624224,,BAO_0000218
8601,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL624225,,BAO_0000218
8602,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622420,,BAO_0000218
8603,,Volume of steady state distribution after i.v. administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622421,,BAO_0000218
8604,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622422,,BAO_0000218
8605,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622423,,BAO_0000218
8606,,Vss was determined,,,50597,,N,1,Intermediate,1,,CHEMBL622424,,BAO_0000218
8607,,Vss in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622425,,BAO_0000218
8608,,Vss was evaluated after 10 uM/kg of intra arterial administration,,,50597,,N,1,Intermediate,1,,CHEMBL876612,,BAO_0000218
8609,,volume of distribution at steady state was observed after intravenous administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622426,,BAO_0000218
8610,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622427,,BAO_0000218
8611,,Pharmacokinetic (PK) parameter Vz in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622428,,BAO_0000218
8612,,Volume distribution in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622429,,BAO_0000218
8613,,Volume of distribution in rat; No data,,,50597,,N,1,Intermediate,1,,CHEMBL622430,,BAO_0000218
8614,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL622431,,BAO_0000218
8615,,% absorption predicted from in vitro rat ileum transport studies,2116.0,,50597,,N,1,Intermediate,1,,CHEMBL622432,,BAO_0000218
8616,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL622433,,BAO_0000218
8617,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL622434,,BAO_0000218
8618,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL622435,,BAO_0000218
8619,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL618748,,BAO_0000218
8620,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL618749,,BAO_0000218
8621,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL618750,,BAO_0000218
8622,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL618751,,BAO_0000218
8623,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL618752,,BAO_0000218
8624,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618753,,BAO_0000218
8625,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL618754,,BAO_0000218
8626,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618755,,BAO_0000218
8627,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618756,,BAO_0000218
8628,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618757,,BAO_0000218
8629,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618758,,BAO_0000218
8630,,Oral bioavailability in rat (dose 30 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL621088,,BAO_0000218
8631,,Pharmacokinetic property (cLogP) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621089,,BAO_0000218
8632,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621090,,BAO_0000218
8633,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621091,,BAO_0000218
8634,,Clearance in rat.,,,50597,,N,1,Intermediate,1,,CHEMBL876731,,BAO_0000218
8635,,Compound was evaluated for its clearance when administered intravenously in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621092,,BAO_0000218
8636,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621093,,BAO_0000218
8637,,Blood: Brain distribution ratio is determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621094,,BAO_0000218
8638,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,,50597,,N,1,Intermediate,1,,CHEMBL621095,,BAO_0000218
8639,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,,50597,,N,1,Intermediate,1,,CHEMBL621096,,BAO_0000218
8640,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621097,,BAO_0000218
8641,,Percent dose excreted in 0-48 hours administered ip to male rat,,,50597,,N,1,Intermediate,1,,CHEMBL621098,,BAO_0000218
8642,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),2037.0,,50597,,N,1,Intermediate,1,,CHEMBL621099,,BAO_0000218
8643,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),2037.0,,50597,,N,1,Intermediate,1,,CHEMBL621100,,BAO_0000218
8644,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),2037.0,,50597,,N,1,Intermediate,1,,CHEMBL621101,,BAO_0000218
8645,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),2037.0,,50597,,N,1,Intermediate,1,,CHEMBL621102,,BAO_0000218
8646,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),2037.0,,50597,,N,1,Intermediate,1,,CHEMBL876732,,BAO_0000218
8647,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,,N,1,Intermediate,1,,CHEMBL621103,,BAO_0000218
8648,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,,N,1,Intermediate,1,,CHEMBL621104,,BAO_0000218
8649,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,,N,1,Intermediate,1,,CHEMBL621105,,BAO_0000218
8650,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,,N,1,Intermediate,1,,CHEMBL621106,,BAO_0000218
8651,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,,N,1,Intermediate,1,,CHEMBL621107,,BAO_0000218
8652,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,,N,1,Intermediate,1,,CHEMBL621108,,BAO_0000218
8653,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,,N,1,Intermediate,1,,CHEMBL621109,,BAO_0000218
8654,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),2113.0,,50594,,N,1,Intermediate,1,,CHEMBL621110,,BAO_0000218
8655,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),2113.0,,50594,,N,1,Intermediate,1,,CHEMBL621111,,BAO_0000218
8656,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),2107.0,,50594,,N,1,Intermediate,1,,CHEMBL622541,,BAO_0000218
8657,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),2107.0,,50594,,N,1,Intermediate,1,,CHEMBL622542,,BAO_0000218
8658,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),2107.0,,50594,,N,1,Intermediate,1,,CHEMBL622543,,BAO_0000218
8659,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),2107.0,,50594,,N,1,Intermediate,1,,CHEMBL624412,,BAO_0000218
8660,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),2107.0,,50594,,N,1,Intermediate,1,,CHEMBL624413,,BAO_0000218
8661,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),2107.0,,50594,,N,1,Intermediate,1,,CHEMBL624414,,BAO_0000218
8662,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),2048.0,,50594,,N,1,Intermediate,1,,CHEMBL624415,,BAO_0000218
8663,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),2048.0,,50594,,N,1,Intermediate,1,,CHEMBL624416,,BAO_0000218
8664,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),2048.0,,50594,,N,1,Intermediate,1,,CHEMBL624417,,BAO_0000218
8665,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),2048.0,,50594,,N,1,Intermediate,1,,CHEMBL624418,,BAO_0000218
8666,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),2048.0,,50594,,N,1,Intermediate,1,,CHEMBL624419,,BAO_0000218
8667,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),2048.0,,50594,,N,1,Intermediate,1,,CHEMBL624420,,BAO_0000218
8668,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),2385.0,,50594,,N,1,Intermediate,1,,CHEMBL624421,,BAO_0000218
8669,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),2385.0,,50594,,N,1,Intermediate,1,,CHEMBL624422,,BAO_0000218
8670,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),2385.0,,50594,,N,1,Intermediate,1,,CHEMBL624423,,BAO_0000218
8671,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),2385.0,,50594,,N,1,Intermediate,1,,CHEMBL625123,,BAO_0000218
8672,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),2385.0,,50594,,N,1,Intermediate,1,,CHEMBL625124,,BAO_0000218
8673,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),2385.0,,50594,,N,1,Intermediate,1,,CHEMBL625125,,BAO_0000218
8674,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),14.0,,50594,,N,1,Intermediate,1,,CHEMBL625126,,BAO_0000218
8675,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),14.0,,50594,,N,1,Intermediate,1,,CHEMBL626947,,BAO_0000218
8676,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),14.0,,50594,,N,1,Intermediate,1,,CHEMBL626948,,BAO_0000218
8677,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),14.0,,50594,,N,1,Intermediate,1,,CHEMBL626949,,BAO_0000218
8678,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),14.0,,50594,,N,1,Intermediate,1,,CHEMBL626950,,BAO_0000218
8679,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),14.0,,50594,,N,1,Intermediate,1,,CHEMBL626951,,BAO_0000218
8680,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),2106.0,,50594,,N,1,Intermediate,1,,CHEMBL626952,,BAO_0000218
8681,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),2106.0,,50594,,N,1,Intermediate,1,,CHEMBL626953,,BAO_0000218
8682,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),2106.0,,50594,,N,1,Intermediate,1,,CHEMBL626954,,BAO_0000218
8683,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),2106.0,,50594,,N,1,Intermediate,1,,CHEMBL626955,,BAO_0000218
8684,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),2106.0,,50594,,N,1,Intermediate,1,,CHEMBL626956,,BAO_0000218
8685,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),2106.0,,50594,,N,1,Intermediate,1,,CHEMBL626957,,BAO_0000218
8686,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),178.0,,50594,,N,1,Intermediate,1,,CHEMBL626958,,BAO_0000218
8687,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),178.0,,50594,,N,1,Intermediate,1,,CHEMBL626959,,BAO_0000218
8688,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),178.0,,50594,,N,1,Intermediate,1,,CHEMBL626960,,BAO_0000218
8689,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),178.0,,50594,,N,1,Intermediate,1,,CHEMBL626961,,BAO_0000218
8690,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),178.0,,50594,,N,1,Intermediate,1,,CHEMBL627589,,BAO_0000218
8691,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),178.0,,50594,,N,1,Intermediate,1,,CHEMBL627590,,BAO_0000218
8692,,Time taken for EC90 was determined when tested in mouse,,,50594,,N,1,Intermediate,1,,CHEMBL627591,,BAO_0000218
8693,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,,50594,,N,1,Intermediate,1,,CHEMBL627592,,BAO_0000218
8694,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,,50594,,N,1,Intermediate,1,,CHEMBL627593,,BAO_0000218
8695,,Half life in mice,,,50594,,N,1,Intermediate,1,,CHEMBL627594,,BAO_0000218
8696,,Half life period in mouse after 10 mg/Kg dose,,,50594,,N,1,Intermediate,1,,CHEMBL876813,,BAO_0000218
8697,,Half life period in mouse after 10 mg/kg dose,,,50594,,N,1,Intermediate,1,,CHEMBL627595,,BAO_0000218
8698,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594,,N,1,Intermediate,1,,CHEMBL627596,,BAO_0000218
8699,,Cmax value at 5 mg/kg po was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627597,,BAO_0000218
8700,,Cmax value evaluated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627598,,BAO_0000218
8701,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,955.0,,50597,,N,1,Intermediate,1,,CHEMBL627599,,BAO_0000218
8702,,Cmax value after administration of 20 mg/Kg oral dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627600,,BAO_0000218
8703,,Cmax value at 1 mg/kg po in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627601,,BAO_0000218
8704,,Cmax value at 5 mg/kg po in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627776,,BAO_0000218
8705,,Cmax value at a dose of 10 mg/kg in male SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL627777,,BAO_0000218
8706,,Cmax value at a dose of 100 mg/kg in male SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL627778,,BAO_0000218
8707,,Cmax value at a dose of 50 mg/kg in male SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL627779,,BAO_0000218
8708,,Cmax value in rats at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL876814,,BAO_0000218
8709,,Cmax value was evaluated in rats at a dose of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627780,,BAO_0000218
8710,,Cmax value was determined after peroral administration of 20 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627781,,BAO_0000218
8711,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,,50597,,N,1,Intermediate,1,,CHEMBL627782,,BAO_0000218
8712,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627783,,BAO_0000218
8713,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627784,,BAO_0000218
8714,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL627785,,BAO_0000218
8715,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL627786,,BAO_0000218
8716,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627787,,BAO_0000218
8717,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627788,,BAO_0000218
8718,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626579,,BAO_0000218
8719,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626580,,BAO_0000218
8720,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL876815,,BAO_0000218
8721,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626581,,BAO_0000218
8722,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626582,,BAO_0000218
8723,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626583,,BAO_0000218
8724,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL626205,,BAO_0000218
8725,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL626206,,BAO_0000218
8726,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL626207,,BAO_0000218
8727,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL623882,,BAO_0000218
8728,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,,50597,,N,1,Intermediate,1,,CHEMBL623883,,BAO_0000218
8729,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,,50597,,N,1,Intermediate,1,,CHEMBL623884,,BAO_0000218
8730,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623885,,BAO_0000218
8731,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623886,,BAO_0000218
8732,,Maximal concentration in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL623887,,BAO_0000218
8733,,Maximal concentration after i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL623888,,BAO_0000218
8734,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623889,,BAO_0000218
8735,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623890,,BAO_0000218
8736,,Cmax in rat plasma after oral dose (50 mg/Kg),1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623891,,BAO_0000218
8737,,Maximal plasma concentration was determined.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623892,,BAO_0000218
8738,,Maximal plasma drug concentration was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623893,,BAO_0000218
8739,,Maximal concentration in rats after peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL877616,,BAO_0000218
8740,,Maximum concentration in rat after 2 mg/kg peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL623894,,BAO_0000218
8741,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623895,,BAO_0000218
8742,,Maximum concentration of compound in rat was evaluated.,,,50597,,N,1,Intermediate,1,,CHEMBL623896,,BAO_0000218
8743,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623897,,BAO_0000218
8744,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623898,,BAO_0000218
8745,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623899,,BAO_0000218
8746,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623900,,BAO_0000218
8747,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL623901,,BAO_0000218
8748,,Maximum concentration was evaluated in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623902,,BAO_0000218
8749,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,1359.0,,50597,,N,1,Intermediate,1,,CHEMBL623903,,BAO_0000218
8750,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623904,,BAO_0000218
8751,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL877617,,BAO_0000218
8752,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623905,,BAO_0000218
8753,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623906,,BAO_0000218
8754,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623907,,BAO_0000218
8755,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL623908,,BAO_0000218
8756,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL623909,,BAO_0000218
8757,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL623910,,BAO_0000218
8758,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL623911,,BAO_0000218
8759,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL623912,,BAO_0000218
8760,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL624616,,BAO_0000218
8761,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL624617,,BAO_0000218
8762,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL624618,,BAO_0000218
8763,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL624619,,BAO_0000218
8764,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL624794,,BAO_0000218
8765,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL624795,,BAO_0000218
8766,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL623921,,BAO_0000218
8767,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL623922,,BAO_0000218
8768,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL623923,,BAO_0000218
8769,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL623924,,BAO_0000218
8770,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL623925,,BAO_0000218
8771,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL623926,,BAO_0000218
8772,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL623927,,BAO_0000218
8773,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL623928,,BAO_0000218
8774,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL623929,,BAO_0000218
8775,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL623930,,BAO_0000218
8776,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL623931,,BAO_0000218
8777,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622165,,BAO_0000218
8778,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621249,,BAO_0000218
8779,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621250,,BAO_0000218
8780,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621448,,BAO_0000218
8781,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621449,,BAO_0000218
8782,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621450,,BAO_0000218
8783,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621451,,BAO_0000218
8784,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621452,,BAO_0000218
8785,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621453,,BAO_0000218
8786,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621454,,BAO_0000218
8787,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621455,,BAO_0000218
8788,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621456,,BAO_0000218
8789,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625145,,BAO_0000218
8790,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL875847,,BAO_0000218
8791,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625146,,BAO_0000218
8792,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625147,,BAO_0000218
8793,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625148,,BAO_0000218
8794,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625149,,BAO_0000218
8795,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625150,,BAO_0000218
8796,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625151,,BAO_0000218
8797,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625152,,BAO_0000218
8798,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625153,,BAO_0000218
8799,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625154,,BAO_0000218
8800,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625155,,BAO_0000218
8801,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,,N,1,Intermediate,1,,CHEMBL625156,,BAO_0000218
8802,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,,N,1,Intermediate,1,,CHEMBL624354,,BAO_0000218
8803,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL624355,,BAO_0000218
8804,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL624356,,BAO_0000218
8805,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL624357,,BAO_0000218
8806,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL624358,,BAO_0000218
8807,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),2435.0,,50597,,N,1,Intermediate,1,,CHEMBL624359,,BAO_0000218
8808,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),2435.0,,50597,,N,1,Intermediate,1,,CHEMBL624360,,BAO_0000218
8809,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),2435.0,,50597,,N,1,Intermediate,1,,CHEMBL624361,,BAO_0000218
8810,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),2435.0,,50597,,N,1,Intermediate,1,,CHEMBL624362,,BAO_0000218
8811,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),2435.0,,50597,,N,1,Intermediate,1,,CHEMBL624363,,BAO_0000218
8812,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),178.0,,50597,,N,1,Intermediate,1,,CHEMBL624364,,BAO_0000218
8813,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),178.0,,50597,,N,1,Intermediate,1,,CHEMBL624365,,BAO_0000218
8814,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),178.0,,50597,,N,1,Intermediate,1,,CHEMBL624366,,BAO_0000218
8815,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),178.0,,50597,,N,1,Intermediate,1,,CHEMBL624367,,BAO_0000218
8816,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),955.0,,50597,,N,1,Intermediate,1,,CHEMBL624368,,BAO_0000218
8817,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),955.0,,50597,,N,1,Intermediate,1,,CHEMBL624369,,BAO_0000218
8818,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),955.0,,50597,,N,1,Intermediate,1,,CHEMBL624370,,BAO_0000218
8819,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),955.0,,50597,,N,1,Intermediate,1,,CHEMBL625069,,BAO_0000218
8820,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),955.0,,50597,,N,1,Intermediate,1,,CHEMBL625070,,BAO_0000218
8821,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),948.0,,50597,,N,1,Intermediate,1,,CHEMBL626051,,BAO_0000218
8822,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),948.0,,50597,,N,1,Intermediate,1,,CHEMBL626052,,BAO_0000218
8823,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),948.0,,50597,,N,1,Intermediate,1,,CHEMBL626053,,BAO_0000218
8824,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),948.0,,50597,,N,1,Intermediate,1,,CHEMBL626054,,BAO_0000218
8825,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),948.0,,50597,,N,1,Intermediate,1,,CHEMBL626055,,BAO_0000218
8826,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626056,,BAO_0000218
8827,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626057,,BAO_0000218
8828,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625193,,BAO_0000218
8829,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625194,,BAO_0000218
8830,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625195,,BAO_0000218
8831,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625196,,BAO_0000218
8832,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625197,,BAO_0000218
8833,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625198,,BAO_0000218
8834,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627929,,BAO_0000218
8835,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627074,,BAO_0000218
8836,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627075,,BAO_0000218
8837,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627076,,BAO_0000218
8838,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627077,,BAO_0000218
8839,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627078,,BAO_0000218
8840,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627079,,BAO_0000218
8841,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,50594,,N,1,Intermediate,1,,CHEMBL873824,,BAO_0000218
8842,,Half life in mouse plasma was determined at dose 25 mg/kg,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL627080,,BAO_0000218
8843,,Half life was determined,,,50594,,N,1,Intermediate,1,,CHEMBL627081,,BAO_0000218
8844,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,,50594,,N,1,Intermediate,1,,CHEMBL627082,,BAO_0000218
8845,,Half-life in male mice after 1 mg/kg intravenous dose,,,50594,,N,1,Intermediate,1,,CHEMBL627083,,BAO_0000218
8847,,Half life in mice plasma,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL627085,,BAO_0000218
8848,,Half life in mouse,,,50594,,N,1,Intermediate,1,,CHEMBL627086,,BAO_0000218
8849,,Half life in mouse plasma at dose 25 mg/kg,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL627087,,BAO_0000218
8850,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,,50594,,N,1,Intermediate,1,,CHEMBL627088,,BAO_0000218
8851,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,,50594,,N,1,Intermediate,1,,CHEMBL627089,,BAO_0000218
8852,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,,50594,,N,1,Intermediate,1,,CHEMBL627090,,BAO_0000218
8853,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,50594,,N,1,Intermediate,1,,CHEMBL627091,,BAO_0000218
8854,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,,50594,,N,1,Intermediate,1,,CHEMBL627092,,BAO_0000218
8855,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,,50594,,N,1,Intermediate,1,,CHEMBL876785,,BAO_0000218
8856,,Half-life by iv administration in mouse,,,50594,,N,1,Intermediate,1,,CHEMBL627093,,BAO_0000218
8857,,Half-life by oral administration in mouse,,,50594,,N,1,Intermediate,1,,CHEMBL627094,,BAO_0000218
8858,,Half-life in mice,,,50594,,N,1,Intermediate,1,,CHEMBL627095,,BAO_0000218
8859,,Half-life using mouse brain homogenate,955.0,,50594,,N,1,Intermediate,1,,CHEMBL627096,,BAO_0000218
8860,,Half-life was measured in mice,,,50594,,N,1,Intermediate,1,,CHEMBL627097,,BAO_0000218
8861,,Half-life was measured in mouse after an iv dose of 1 mg/kg,,,50594,,N,1,Intermediate,1,,CHEMBL627098,,BAO_0000218
8862,,Half-life period was determined in mouse blood,178.0,,50594,,N,1,Intermediate,1,,CHEMBL627099,,BAO_0000218
8863,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",955.0,,50594,,N,1,Intermediate,1,,CHEMBL627100,,BAO_0000218
8864,,Plasma half life in mouse,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL627101,,BAO_0000218
8865,,Stability of the peptide in the presence of mouse serum,,,50594,,N,1,Intermediate,1,,CHEMBL627102,,BAO_0000218
8866,,Terminal half life of compound was determined in mouse,,,50594,,N,1,Intermediate,1,,CHEMBL627103,,BAO_0000218
8867,,Terminal half life was evaluated in mice after intravenous administration,,,50594,,N,1,Intermediate,1,,CHEMBL627104,,BAO_0000218
8868,,Terminal half life was evaluated in mice after oral administration,,,50594,,N,1,Intermediate,1,,CHEMBL627105,,BAO_0000218
8869,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,,50594,,N,1,Intermediate,1,,CHEMBL876786,,BAO_0000218
8870,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,,50594,,N,1,Intermediate,1,,CHEMBL873825,,BAO_0000218
8871,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,,50594,,N,1,Intermediate,1,,CHEMBL627106,,BAO_0000218
8872,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,,50594,,N,1,Intermediate,1,,CHEMBL626336,,BAO_0000218
8873,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,,50594,,N,1,Intermediate,1,,CHEMBL877462,,BAO_0000218
8874,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,,50594,,N,1,Intermediate,1,,CHEMBL626337,,BAO_0000218
8875,,Half life after intraperitoneal administration of 100 mg/kg in mice,,,50594,,N,1,Intermediate,1,,CHEMBL626338,,BAO_0000218
8876,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,,50594,,N,1,Intermediate,1,,CHEMBL626339,,BAO_0000218
8877,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,,50594,,N,1,Intermediate,1,,CHEMBL626340,,BAO_0000218
8878,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,,50594,,N,1,Intermediate,1,,CHEMBL625377,,BAO_0000218
8879,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,,50594,,N,1,Intermediate,1,,CHEMBL625378,,BAO_0000218
8880,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,,50594,,N,1,Intermediate,1,,CHEMBL625379,,BAO_0000218
8881,Microsomes,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,,22224,,U,0,Autocuration,1,,CHEMBL625380,,BAO_0000251
8882,Microsomes,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,,22224,,U,0,Autocuration,1,,CHEMBL625381,,BAO_0000251
8883,,Stability to porcine renal DHP-I,,,22224,,U,0,Autocuration,1,,CHEMBL625382,,BAO_0000019
8884,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,,22224,,U,0,Autocuration,1,,CHEMBL873828,,BAO_0000218
8885,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,,22224,,U,0,Autocuration,1,,CHEMBL625383,,BAO_0000218
8886,,Half-life of the parent prodrug in porcine esterase solution,,,22224,,U,0,Autocuration,1,,CHEMBL625384,,BAO_0000019
8887,,"First order rate constant, k was determined in in pig liver Esterase",,,22224,,U,0,Autocuration,1,,CHEMBL625385,,BAO_0000019
8888,,Half life of the in pig liver Esterase,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL625386,,BAO_0000221
8889,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL623571,,BAO_0000221
8890,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL623572,,BAO_0000221
8891,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL623573,,BAO_0000221
8892,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL623574,,BAO_0000221
8893,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL623575,,BAO_0000221
8894,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL623749,,BAO_0000221
8895,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL623750,,BAO_0000221
8896,,Half-life in vitro in pig liver,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL623751,,BAO_0000221
8897,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL623752,,BAO_0000221
8898,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623753,,BAO_0000218
8899,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623754,,BAO_0000218
8900,,Maximum concentration in rat plasma was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623755,,BAO_0000218
8901,,Maximum concentration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623756,,BAO_0000218
8902,,Maximum concentration in rats at 1-2 hours,,,50597,,N,1,Intermediate,1,,CHEMBL623757,,BAO_0000218
8903,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,,50597,,N,1,Intermediate,1,,CHEMBL623758,,BAO_0000218
8904,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,955.0,,50597,,N,1,Intermediate,1,,CHEMBL623759,,BAO_0000218
8905,,Maximum concentration at the dose of 2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623760,,BAO_0000218
8906,,Maximum concentration was evaluated in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623761,,BAO_0000218
8907,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623762,,BAO_0000218
8908,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL877594,,BAO_0000218
8909,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623763,,BAO_0000218
8910,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623764,,BAO_0000218
8911,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623765,,BAO_0000218
8912,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL623766,,BAO_0000218
8913,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL623767,,BAO_0000218
8914,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL623768,,BAO_0000218
8915,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623769,,BAO_0000218
8916,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623770,,BAO_0000218
8917,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623771,,BAO_0000218
8918,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623772,,BAO_0000218
8919,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623773,,BAO_0000218
8920,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623774,,BAO_0000218
8921,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623775,,BAO_0000218
8922,,Cmax in rat (PO dose),,,50597,,N,1,Intermediate,1,,CHEMBL623776,,BAO_0000218
8923,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622191,,BAO_0000218
8924,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622192,,BAO_0000218
8925,,Maximum plasma concentration determined in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622193,,BAO_0000218
8926,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622194,,BAO_0000218
8927,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622195,,BAO_0000218
8928,,Maximum plasma concentration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622196,,BAO_0000218
8929,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622197,,BAO_0000218
8930,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622198,,BAO_0000218
8931,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622199,,BAO_0000218
8932,,Maximum plasma concentration of compound was measured in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622200,,BAO_0000218
8933,,Maximum plasma concentration after 20 mg/kg oral administration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622201,,BAO_0000218
8934,,Maximum plasma concentration after oral administration to rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623990,,BAO_0000218
8935,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623991,,BAO_0000218
8936,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623992,,BAO_0000218
8937,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623993,,BAO_0000218
8938,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623994,,BAO_0000218
8939,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623995,,BAO_0000218
8940,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623996,,BAO_0000218
8941,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623997,,BAO_0000218
8942,,Maximum plasma concentration dosed orally in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623998,,BAO_0000218
8943,,Maximum plasma concentration dosed orally in rats after 6 hours,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623999,,BAO_0000218
8944,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624000,,BAO_0000218
8945,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624001,,BAO_0000218
8946,,Maximum plasma concentration in rat after po administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624002,,BAO_0000218
8947,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624003,,BAO_0000218
8948,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624004,,BAO_0000218
8949,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624005,,BAO_0000218
8950,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624006,,BAO_0000218
8951,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624007,,BAO_0000218
8952,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624008,,BAO_0000218
8953,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624009,,BAO_0000218
8954,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL874387,,BAO_0000218
8955,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624010,,BAO_0000218
8956,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624011,,BAO_0000218
8957,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624012,,BAO_0000218
8958,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624013,,BAO_0000218
8959,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624736,,BAO_0000218
8960,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624737,,BAO_0000218
8961,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624738,,BAO_0000218
8962,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624739,,BAO_0000218
8963,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624740,,BAO_0000218
8964,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624896,,BAO_0000218
8965,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624897,,BAO_0000218
8966,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624108,,BAO_0000218
8967,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624109,,BAO_0000218
8968,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624110,,BAO_0000218
8969,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624111,,BAO_0000218
8970,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624112,,BAO_0000218
8971,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624113,,BAO_0000218
8972,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL619709,,BAO_0000218
8973,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL619710,,BAO_0000218
8974,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619711,,BAO_0000218
8975,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619712,,BAO_0000218
8976,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619713,,BAO_0000218
8977,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619714,,BAO_0000218
8978,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619715,,BAO_0000218
8979,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619716,,BAO_0000218
8980,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619717,,BAO_0000218
8981,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619718,,BAO_0000218
8982,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619719,,BAO_0000218
8983,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL875329,,BAO_0000218
8984,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619720,,BAO_0000218
8985,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619721,,BAO_0000218
8986,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619722,,BAO_0000218
8987,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619723,,BAO_0000218
8988,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619724,,BAO_0000218
8989,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619725,,BAO_0000218
8990,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619726,,BAO_0000218
8991,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619727,,BAO_0000218
8992,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619728,,BAO_0000218
8993,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL619729,,BAO_0000218
8994,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2385.0,,50597,,N,1,Intermediate,1,,CHEMBL619730,,BAO_0000218
8995,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2385.0,,50597,,N,1,Intermediate,1,,CHEMBL619731,,BAO_0000218
8996,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2385.0,,50597,,N,1,Intermediate,1,,CHEMBL619732,,BAO_0000218
8997,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2385.0,,50597,,N,1,Intermediate,1,,CHEMBL619733,,BAO_0000218
8998,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2385.0,,50597,,N,1,Intermediate,1,,CHEMBL619734,,BAO_0000218
8999,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),14.0,,50597,,N,1,Intermediate,1,,CHEMBL619735,,BAO_0000218
9000,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),14.0,,50597,,N,1,Intermediate,1,,CHEMBL875330,,BAO_0000218
9001,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),14.0,,50597,,N,1,Intermediate,1,,CHEMBL628465,,BAO_0000218
9002,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),14.0,,50597,,N,1,Intermediate,1,,CHEMBL628466,,BAO_0000218
9003,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),14.0,,50597,,N,1,Intermediate,1,,CHEMBL628467,,BAO_0000218
9004,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2106.0,,50597,,N,1,Intermediate,1,,CHEMBL628468,,BAO_0000218
9005,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2106.0,,50597,,N,1,Intermediate,1,,CHEMBL628469,,BAO_0000218
9006,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2106.0,,50597,,N,1,Intermediate,1,,CHEMBL628470,,BAO_0000218
9007,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2106.0,,50597,,N,1,Intermediate,1,,CHEMBL628471,,BAO_0000218
9008,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2106.0,,50597,,N,1,Intermediate,1,,CHEMBL628472,,BAO_0000218
9009,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2046.0,,50597,,N,1,Intermediate,1,,CHEMBL625191,,BAO_0000218
9010,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2046.0,,50597,,N,1,Intermediate,1,,CHEMBL625192,,BAO_0000218
9011,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2046.0,,50597,,N,1,Intermediate,1,,CHEMBL875337,,BAO_0000218
9012,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626341,,BAO_0000218
9013,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626342,,BAO_0000218
9014,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621943,,BAO_0000218
9015,,Half life in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621944,,BAO_0000218
9016,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,,50597,,N,1,Intermediate,1,,CHEMBL621945,,BAO_0000218
9017,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,,50597,,N,1,Intermediate,1,,CHEMBL621946,,BAO_0000218
9018,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL621947,,BAO_0000218
9019,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,,50597,,N,1,Intermediate,1,,CHEMBL621948,,BAO_0000218
9020,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL621949,,BAO_0000218
9021,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,,50597,,N,1,Intermediate,1,,CHEMBL621950,,BAO_0000218
9022,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,,50597,,N,1,Intermediate,1,,CHEMBL621951,,BAO_0000218
9023,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621952,,BAO_0000218
9024,,Stability (%) in rat liver microsomes,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621953,,BAO_0000218
9025,,Area under curve was calculated after intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL621954,,BAO_0000218
9026,,Area under the curve was calculated after iv administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621955,,BAO_0000218
9027,,Area under the curve was calculated in rat after peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL621956,,BAO_0000218
9028,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL621957,,BAO_0000218
9029,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL621958,,BAO_0000218
9030,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL621959,,BAO_0000218
9031,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,,50597,,N,1,Intermediate,1,,CHEMBL621960,,BAO_0000218
9032,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,,50597,,N,1,Intermediate,1,,CHEMBL621961,,BAO_0000218
9033,,p value of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL621962,,BAO_0000218
9034,,p value of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL876787,,BAO_0000218
9035,,p value of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL621963,,BAO_0000218
9036,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,,50597,,N,1,Intermediate,1,,CHEMBL622637,,BAO_0000218
9037,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,,50597,,N,1,Intermediate,1,,CHEMBL622638,,BAO_0000218
9038,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,,50597,,N,1,Intermediate,1,,CHEMBL626561,,BAO_0000218
9039,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,,22224,,U,0,Autocuration,1,,CHEMBL626562,,BAO_0000019
9040,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,,22224,,U,0,Autocuration,1,,CHEMBL626563,,BAO_0000218
9041,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,,22224,,U,0,Autocuration,1,,CHEMBL626564,,BAO_0000218
9042,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,,22224,,U,0,Autocuration,1,,CHEMBL626565,,BAO_0000218
9043,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,,22224,,U,0,Autocuration,1,,CHEMBL626566,,BAO_0000218
9044,,Clearance rate in rabbits,,,22224,,U,0,Autocuration,1,,CHEMBL626567,,BAO_0000218
9045,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,,22224,,U,0,Autocuration,1,,CHEMBL626568,,BAO_0000218
9046,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626569,,BAO_0000218
9047,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626570,,BAO_0000218
9048,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626571,,BAO_0000218
9049,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626572,,BAO_0000218
9050,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626573,,BAO_0000218
9051,Microsomes,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL626574,,BAO_0000251
9052,Microsomes,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL626575,,BAO_0000251
9053,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,,22224,,U,0,Autocuration,1,,CHEMBL626576,,BAO_0000218
9054,,Dose at which bioavailability of perorally administered compound was tested in rabbit,,,22224,,U,0,Autocuration,1,,CHEMBL626577,,BAO_0000218
9055,,The compound was tested for its bioavailability in rabbit (by oral dosage).,,,22224,,U,0,Autocuration,1,,CHEMBL626578,,BAO_0000218
9056,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL625263,,BAO_0000218
9057,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL625264,,BAO_0000218
9058,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL625265,,BAO_0000218
9059,Microsomes,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,,22224,,U,0,Autocuration,1,,CHEMBL625266,,BAO_0000251
9060,Microsomes,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,,22224,,U,0,Autocuration,1,,CHEMBL876796,,BAO_0000251
9061,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL625267,,BAO_0000218
9062,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL625268,,BAO_0000218
9063,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL625269,,BAO_0000218
9064,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL624689,,BAO_0000218
9065,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL624690,,BAO_0000218
9066,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),1088.0,,22224,,U,0,Autocuration,1,,CHEMBL624691,,BAO_0000218
9067,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),1088.0,,22224,,U,0,Autocuration,1,,CHEMBL624692,,BAO_0000218
9068,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,,22224,,U,0,Autocuration,1,,CHEMBL624693,,BAO_0000218
9069,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,,22224,,U,0,Autocuration,1,,CHEMBL624694,,BAO_0000218
9070,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,,22224,,U,0,Autocuration,1,,CHEMBL877596,,BAO_0000221
9071,,Time within which only 10% of the drug was degraded,,,22224,,U,0,Autocuration,1,,CHEMBL624695,,BAO_0000019
9072,,Half life period in rabbit liver homogenate,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL624696,,BAO_0000221
9073,,Half life value in rabbits,,,22224,,U,0,Autocuration,1,,CHEMBL624697,,BAO_0000019
9074,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,178.0,,22224,,U,0,Autocuration,1,,CHEMBL624698,,BAO_0000218
9075,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,178.0,,22224,,U,0,Autocuration,1,,CHEMBL624699,,BAO_0000218
9076,,Half-life period in rabbits following intravenous administration at 2 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL624700,,BAO_0000218
9077,,AUC 0-8 hr value in rats at 10 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622903,,BAO_0000218
9078,,AUC after administration at 2000 mg/kg/day in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622904,,BAO_0000218
9079,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622905,,BAO_0000218
9080,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622906,,BAO_0000218
9081,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622907,,BAO_0000218
9082,,AUC in rat after oral administration at 10.5 mg/kg dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622908,,BAO_0000218
9083,,AUC in rat after oral administration at 11.2 mg/kg dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622909,,BAO_0000218
9084,,AUC in rat after oral administration at 9.7 mg/kg dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622910,,BAO_0000218
9085,,AUC in rat brain after oral administration at 10 mg/kg,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622911,,BAO_0000218
9086,,AUC in rat p.o.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622912,,BAO_0000218
9087,,AUC in rat p.o. at 20 mg/kg concentration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622913,,BAO_0000218
9088,,AUC in rat plasma after oral administration at 10 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622914,,BAO_0000218
9089,,AUC in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622915,,BAO_0000218
9090,,AUC value after IV dose at a dose of 5 mg/kg in rats.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622916,,BAO_0000218
9091,,AUC value after oral dose at a dose of 10 mg/kg in rats.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622917,,BAO_0000218
9092,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622918,,BAO_0000218
9093,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622919,,BAO_0000218
9094,,Maximum plasma concentration was evaluated in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622920,,BAO_0000218
9095,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622921,,BAO_0000218
9096,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622922,,BAO_0000218
9097,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622923,,BAO_0000218
9098,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL877604,,BAO_0000218
9099,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622924,,BAO_0000218
9100,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622925,,BAO_0000218
9101,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622926,,BAO_0000218
9102,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623625,,BAO_0000218
9103,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,1969.0,,50597,,N,1,Expert,1,,CHEMBL623626,,BAO_0000218
9104,,Maximum plasma drug concentration was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623627,,BAO_0000218
9105,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623628,,BAO_0000218
9106,,Mean peak plasma concentration was observed after intravenous administration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623629,,BAO_0000218
9107,,Mean peak plasma concentration was observed after oral administration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623630,,BAO_0000218
9108,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623804,,BAO_0000218
9109,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623805,,BAO_0000218
9110,,Peak oral plasma concentration was determined in rats by oral administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623806,,BAO_0000218
9111,,Peak plasma concentration (Cmax) was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623807,,BAO_0000218
9112,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623808,,BAO_0000218
9113,,Peak plasma concentration (Cmax) in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623809,,BAO_0000218
9114,,Peak plasma concentration at 1 mg/kg peroral administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623810,,BAO_0000218
9115,,Peak plasma concentration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623811,,BAO_0000218
9116,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623812,,BAO_0000218
9117,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL877605,,BAO_0000218
9118,,Pharmacokinetic property (Cmax) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623813,,BAO_0000218
9119,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,,50597,,N,1,Intermediate,1,,CHEMBL623814,,BAO_0000218
9120,,Cmax in rat after 3mg/kg oral dose,,,50597,,N,1,Intermediate,1,,CHEMBL623815,,BAO_0000218
9121,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,,50597,,N,1,Intermediate,1,,CHEMBL623816,,BAO_0000218
9122,,Cmax in rats after 20 mg/kg oral dose,,,50597,,N,1,Intermediate,1,,CHEMBL623145,,BAO_0000218
9123,,Cmax in rat plasma after 30mg/kg oral dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623146,,BAO_0000218
9124,,Plasma concentration after oral administration of 100 mg/kg to rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623147,,BAO_0000218
9125,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,955.0,,50597,,N,1,Intermediate,1,,CHEMBL623042,,BAO_0000218
9126,,Tested for the Cmax in rat at 10 mg/kg per orally,,,50597,,N,1,Intermediate,1,,CHEMBL623043,,BAO_0000218
9127,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL623044,,BAO_0000218
9128,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL623045,,BAO_0000218
9129,,Bioavailability as oral Cmax in rats at 30 mins,,,50597,,N,1,Intermediate,1,,CHEMBL623046,,BAO_0000218
9130,,Bioavailability as oral Cmax in rats at 6hr,,,50597,,N,1,Intermediate,1,,CHEMBL623226,,BAO_0000218
9131,,The maximum concentration of compound was measured at the dose of 100 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL623227,,BAO_0000218
9132,,The maximum concentration of compound was measured at the dose of 300 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL623228,,BAO_0000218
9133,,The maximum concentration of compound was measured at the dose of 30 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL623229,,BAO_0000218
9134,,The maximum plasma levels for the compounds were determined by LC-MS.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623230,,BAO_0000218
9135,,mean peak plasma concentration was observed after intravenous administration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623231,,BAO_0000218
9136,,mean peak plasma concentration was observed after oral administration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623232,,BAO_0000218
9137,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623233,,BAO_0000218
9138,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,,50597,,N,1,Intermediate,1,,CHEMBL623234,,BAO_0000218
9139,,Concentration in plasma (portal) following oral dose in rats at 1 hr,,,50597,,N,1,Intermediate,1,,CHEMBL623235,,BAO_0000218
9140,,Concentration in plasma (portal) following oral dose in rats at 2 hr,,,50597,,N,1,Intermediate,1,,CHEMBL623236,,BAO_0000218
9141,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,,50597,,N,1,Intermediate,1,,CHEMBL623237,,BAO_0000218
9142,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,,50597,,N,1,Intermediate,1,,CHEMBL623238,,BAO_0000218
9143,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,,50597,,N,1,Intermediate,1,,CHEMBL623239,,BAO_0000218
9144,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,1969.0,,22224,,U,0,Intermediate,1,,CHEMBL623240,,BAO_0000218
9145,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",1898.0,,50597,,N,1,Intermediate,1,,CHEMBL623241,,BAO_0000218
9146,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",1898.0,,50597,,N,1,Intermediate,1,,CHEMBL623242,,BAO_0000218
9147,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,,50597,,N,1,Intermediate,1,,CHEMBL874394,,BAO_0000218
9148,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,,50597,,N,1,Intermediate,1,,CHEMBL623243,,BAO_0000218
9149,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL623244,,BAO_0000218
9150,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL623245,,BAO_0000218
9151,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL623246,,BAO_0000218
9152,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL623247,,BAO_0000218
9153,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL623248,,BAO_0000218
9154,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL623249,,BAO_0000218
9155,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625072,,BAO_0000218
9156,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625073,,BAO_0000218
9157,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625074,,BAO_0000218
9158,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625075,,BAO_0000218
9159,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625076,,BAO_0000218
9160,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625077,,BAO_0000218
9161,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625078,,BAO_0000218
9162,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL874395,,BAO_0000218
9163,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625079,,BAO_0000218
9164,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625080,,BAO_0000218
9165,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625081,,BAO_0000218
9166,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625082,,BAO_0000218
9167,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625083,,BAO_0000218
9168,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625084,,BAO_0000218
9169,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625085,,BAO_0000218
9170,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625086,,BAO_0000218
9171,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625087,,BAO_0000218
9172,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625088,,BAO_0000218
9173,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622205,,BAO_0000218
9174,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622206,,BAO_0000218
9175,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622207,,BAO_0000218
9176,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622366,,BAO_0000218
9177,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622367,,BAO_0000218
9178,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL875331,,BAO_0000218
9179,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622368,,BAO_0000218
9180,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622369,,BAO_0000218
9181,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622370,,BAO_0000218
9182,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622371,,BAO_0000218
9183,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622372,,BAO_0000218
9184,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622373,,BAO_0000218
9185,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622374,,BAO_0000218
9186,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622375,,BAO_0000218
9187,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622376,,BAO_0000218
9188,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622377,,BAO_0000218
9189,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622378,,BAO_0000218
9190,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622379,,BAO_0000218
9191,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622380,,BAO_0000218
9192,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622381,,BAO_0000218
9193,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622382,,BAO_0000218
9194,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622383,,BAO_0000218
9195,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,,50597,,N,1,Intermediate,1,,CHEMBL875332,,BAO_0000218
9196,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,,50597,,N,1,Intermediate,1,,CHEMBL622384,,BAO_0000218
9197,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,,50597,,N,1,Intermediate,1,,CHEMBL622385,,BAO_0000218
9198,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,,50597,,N,1,Intermediate,1,,CHEMBL622386,,BAO_0000218
9199,,The compound was tested for the plasma binding in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622387,,BAO_0000218
9200,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,,50597,,N,1,Intermediate,1,,CHEMBL622388,,BAO_0000218
9201,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,,50597,,N,1,Intermediate,1,,CHEMBL622389,,BAO_0000218
9202,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,,50597,,N,1,Intermediate,1,,CHEMBL622390,,BAO_0000218
9203,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL622391,,BAO_0000218
9204,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL622392,,BAO_0000218
9205,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL622393,,BAO_0000218
9206,,Plasma level at 2 hr after administration of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL622394,,BAO_0000218
9207,,plasma level at 2 hr after administration of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL622395,,BAO_0000218
9208,,Stability in rat serum measured as % recovery at 1 min,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL622396,,BAO_0000218
9209,,Stability in rat serum measured as % recovery at 10 min,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL624894,,BAO_0000218
9210,,Stability in rat serum measured as % recovery at 10 mins,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL624895,,BAO_0000218
9211,,Stability in rat serum measured as % recovery at 2 hr,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL624058,,BAO_0000218
9212,,Stability in rat serum measured as % recovery at 3 min,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL624059,,BAO_0000218
9213,,Stability in rat serum measured as % recovery at 3 mins,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL624060,,BAO_0000218
9214,,Stability in rat serum measured as % recovery at 5 min,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL624061,,BAO_0000218
9215,,Stability in rat serum measured as % recovery at 5 mins,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL624062,,BAO_0000218
9216,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624063,,BAO_0000218
9217,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624064,,BAO_0000218
9218,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624065,,BAO_0000218
9219,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624066,,BAO_0000218
9220,,Half life tested in mature male rat at a dose of 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL877490,,BAO_0000218
9221,,Half life after intravenous administration of 1 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL874442,,BAO_0000218
9222,,Half life period after administration (30 mg/kg) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626890,,BAO_0000218
9223,,Half life period in rat after 5 mg/Kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL626891,,BAO_0000218
9224,,Half life period in rat after 5 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL626892,,BAO_0000218
9225,,Half life period was determined,,,50597,,N,1,Intermediate,1,,CHEMBL626893,,BAO_0000218
9226,,Half life period was evaluated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626894,,BAO_0000218
9227,,Half life period was evaluated in rat; 0.5-1.0,,,50597,,N,1,Intermediate,1,,CHEMBL626895,,BAO_0000218
9228,,Half life period was evaluated in rat; 5.9-7.5,,,50597,,N,1,Intermediate,1,,CHEMBL626896,,BAO_0000218
9229,,Half-life in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626897,,BAO_0000218
9230,,Half-life time in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL626898,,BAO_0000218
9231,,Terminal half-life after iv administration to rats,,,50597,,N,1,Intermediate,1,,CHEMBL626899,,BAO_0000218
9232,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL626900,,BAO_0000218
9233,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626901,,BAO_0000218
9234,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,,50597,,N,1,Intermediate,1,,CHEMBL626902,,BAO_0000218
9235,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,,50597,,N,1,Intermediate,1,,CHEMBL626903,,BAO_0000218
9236,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL874443,,BAO_0000218
9237,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626904,,BAO_0000218
9238,,Half life in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626905,,BAO_0000218
9239,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL873830,,BAO_0000218
9240,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626906,,BAO_0000218
9241,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631076,,BAO_0000218
9242,,Biological half-life was measured in plasma of rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631077,,BAO_0000218
9243,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,50597,,N,1,Intermediate,1,,CHEMBL631078,,BAO_0000218
9244,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,,50597,,N,1,Intermediate,1,,CHEMBL631079,,BAO_0000218
9245,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL631080,,BAO_0000218
9246,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL631081,,BAO_0000218
9247,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL631239,,BAO_0000218
9248,,Compound was evaluated for plasma half life in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631240,,BAO_0000218
9249,,AUC value at a dose of 5 mg/kg (p.o.) in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631241,,BAO_0000218
9250,,AUC value after administration of 20 mg/Kg oral dose in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631242,,BAO_0000218
9251,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631243,,BAO_0000218
9252,,AUC0-96 after administration at 50 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL874444,,BAO_0000218
9253,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631244,,BAO_0000218
9254,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,,50597,,N,1,Intermediate,1,,CHEMBL631245,,BAO_0000218
9255,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL627162,,BAO_0000218
9256,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL627163,,BAO_0000218
9257,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL627164,,BAO_0000218
9258,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627165,,BAO_0000218
9259,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,,50597,,N,1,Intermediate,1,,CHEMBL627166,,BAO_0000218
9260,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,,50597,,N,1,Intermediate,1,,CHEMBL627167,,BAO_0000218
9261,,Area under curve (AUC) at a dose of 30 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL627822,,BAO_0000218
9262,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL627823,,BAO_0000218
9263,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL627824,,BAO_0000218
9264,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL627825,,BAO_0000218
9265,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627826,,BAO_0000218
9266,,Area under curve (Pharmacokinetic property) was determined,,,50597,,N,1,Intermediate,1,,CHEMBL627827,,BAO_0000218
9267,,Area under curve (Pharmacokinetic property) of the compound; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL627828,,BAO_0000218
9268,,Area under curve after intravenous administration (1 mg/kg) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627829,,BAO_0000218
9269,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL627830,,BAO_0000218
9270,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL627831,,BAO_0000218
9271,,Area under curve in male SD rats was observed after oral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627832,,BAO_0000218
9272,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627833,,BAO_0000218
9273,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,,N,1,Expert,1,,CHEMBL627834,,BAO_0000218
9274,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,,50597,,N,1,Expert,1,,CHEMBL628004,,BAO_0000218
9275,,Area under curve at 5 mg/kg po was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL628005,,BAO_0000218
9276,,Area under curve in Rat at a oral dose of 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL628006,,BAO_0000218
9277,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,50597,,N,1,Intermediate,1,,CHEMBL628007,,BAO_0000218
9278,,Area under curve was determined,,,50597,,N,1,Intermediate,1,,CHEMBL625676,,BAO_0000218
9279,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,,50597,,N,1,Intermediate,1,,CHEMBL631309,,BAO_0000218
9280,,Area under curve after intravenous administration at 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL631310,,BAO_0000218
9281,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,,50597,,N,1,Intermediate,1,,CHEMBL631311,,BAO_0000218
9282,,Area under curve at 4 hr in rat,,,50597,,N,1,Intermediate,1,,CHEMBL631312,,BAO_0000218
9283,,Area under curve at a dose of 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL631313,,BAO_0000218
9284,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,,50597,,N,1,Intermediate,1,,CHEMBL631314,,BAO_0000218
9285,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,,50597,,N,1,Intermediate,1,,CHEMBL631315,,BAO_0000218
9286,,Area under curve for a 2-mpk po dose in SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL631316,,BAO_0000218
9287,,Area under curve in SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL631317,,BAO_0000218
9288,,Area under curve in rat after oral administration at 13 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL874471,,BAO_0000218
9289,,Area under curve in rat by po administration at 0-24 hr,,,50597,,N,1,Intermediate,1,,CHEMBL631318,,BAO_0000218
9290,,Area under curve in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631319,,BAO_0000218
9291,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL631320,,BAO_0000218
9292,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL631321,,BAO_0000218
9293,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,,50597,,N,1,Intermediate,1,,CHEMBL631322,,BAO_0000218
9294,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,,50597,,N,1,Intermediate,1,,CHEMBL631323,,BAO_0000218
9295,,Area under curve value in rat at a dose of 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL631324,,BAO_0000218
9296,,Area under curve was determined after oral administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL631325,,BAO_0000218
9297,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL631326,,BAO_0000218
9298,,Area under curve was determined after peroral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL631327,,BAO_0000218
9299,,Area under curve was determined at a dose 30 mpk administered orally.,,,50597,,N,1,Intermediate,1,,CHEMBL631328,,BAO_0000218
9300,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,,50597,,N,1,Intermediate,1,,CHEMBL631329,,BAO_0000218
9301,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627217,,BAO_0000218
9302,,Area under curve was determined in male rat,,,50597,,N,1,Intermediate,1,,CHEMBL626352,,BAO_0000218
9303,,Area under curve was determined in rat after PO administration,,,50597,,N,1,Intermediate,1,,CHEMBL626353,,BAO_0000218
9304,,Area under curve was determined in rat after a 3 mg/kg of oral dose,,,50597,,N,1,Intermediate,1,,CHEMBL626354,,BAO_0000218
9305,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626355,,BAO_0000218
9306,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626356,,BAO_0000218
9307,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,,50597,,N,1,Intermediate,1,,CHEMBL626357,,BAO_0000218
9308,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626358,,BAO_0000218
9309,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626359,,BAO_0000218
9310,,Peak plasma concentration in rat at a dose of 3 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626360,,BAO_0000218
9311,,Plasma concentration at 2 hr in rats was evaluated.,,,50597,,N,1,Intermediate,1,,CHEMBL626361,,BAO_0000218
9312,,Plasma concentration at 2 hr in rats was evaluated; Not available,,,50597,,N,1,Intermediate,1,,CHEMBL626362,,BAO_0000218
9313,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626363,,BAO_0000218
9314,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,,N,1,Intermediate,1,,CHEMBL626970,,BAO_0000218
9315,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,,N,1,Intermediate,1,,CHEMBL626971,,BAO_0000218
9316,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626972,,BAO_0000218
9317,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626973,,BAO_0000218
9318,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626974,,BAO_0000218
9319,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL874592,,BAO_0000218
9320,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,,50597,,N,1,Intermediate,1,,CHEMBL626975,,BAO_0000218
9321,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,,50597,,N,1,Intermediate,1,,CHEMBL626976,,BAO_0000218
9322,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL626977,,BAO_0000218
9323,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL626978,,BAO_0000218
9324,,PK study was carried to determine the relative absorption ranking in rat.,,,50597,,N,1,Intermediate,1,,CHEMBL626979,,BAO_0000218
9325,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626980,,BAO_0000218
9326,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626981,,BAO_0000218
9327,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626982,,BAO_0000218
9328,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626983,,BAO_0000218
9329,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL622522,,BAO_0000218
9330,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL622523,,BAO_0000218
9331,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL622524,,BAO_0000218
9332,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL622525,,BAO_0000218
9333,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL622526,,BAO_0000218
9334,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL619849,,BAO_0000218
9335,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL619850,,BAO_0000218
9336,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL623864,,BAO_0000218
9337,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL623865,,BAO_0000218
9338,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL623866,,BAO_0000218
9339,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL623867,,BAO_0000218
9340,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL877615,,BAO_0000218
9341,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL623868,,BAO_0000218
9342,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL623869,,BAO_0000218
9343,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL623870,,BAO_0000218
9344,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL623871,,BAO_0000218
9345,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL623872,,BAO_0000218
9346,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622129,,BAO_0000218
9347,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622130,,BAO_0000218
9348,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622131,,BAO_0000218
9349,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622132,,BAO_0000218
9350,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622133,,BAO_0000218
9351,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622134,,BAO_0000218
9352,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622135,,BAO_0000218
9353,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622136,,BAO_0000218
9354,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL622137,,BAO_0000218
9355,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL622138,,BAO_0000218
9356,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623017,,BAO_0000218
9357,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623018,,BAO_0000218
9358,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623019,,BAO_0000218
9359,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623020,,BAO_0000218
9360,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623021,,BAO_0000218
9361,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623022,,BAO_0000218
9362,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623023,,BAO_0000218
9363,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623024,,BAO_0000218
9364,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623025,,BAO_0000218
9365,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620545,,BAO_0000218
9366,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620546,,BAO_0000218
9367,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620547,,BAO_0000218
9368,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620548,,BAO_0000218
9369,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620549,,BAO_0000218
9370,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620550,,BAO_0000218
9371,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620551,,BAO_0000218
9372,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620552,,BAO_0000218
9373,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620553,,BAO_0000218
9374,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620554,,BAO_0000218
9375,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL875845,,BAO_0000218
9376,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620555,,BAO_0000218
9377,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620556,,BAO_0000218
9378,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620557,,BAO_0000218
9379,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL620558,,BAO_0000218
9380,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL620559,,BAO_0000218
9381,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622939,,BAO_0000218
9382,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622940,,BAO_0000218
9383,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622941,,BAO_0000218
9384,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622942,,BAO_0000218
9385,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622943,,BAO_0000218
9386,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622944,,BAO_0000218
9387,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622945,,BAO_0000218
9388,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622946,,BAO_0000218
9389,,Compound was evaluated for terminal half life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622947,,BAO_0000218
9390,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622948,,BAO_0000218
9391,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622949,,BAO_0000218
9392,,Compound was tested for its half life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622950,,BAO_0000218
9393,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,1969.0,,22224,,U,0,Intermediate,1,,CHEMBL622951,,BAO_0000218
9394,,Compound was tested for its plasma half life in Sprague Dawley rats,1969.0,,22224,,U,0,Intermediate,1,,CHEMBL622952,,BAO_0000366
9395,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,1969.0,,22224,,U,0,Intermediate,1,,CHEMBL622953,,BAO_0000366
9396,,Compound was tested for plasma half-life period in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL873818,,BAO_0000218
9397,,Elimination half life after i.v. administration of compound in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622954,,BAO_0000218
9398,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622955,,BAO_0000218
9399,,Elimination half-life after IV dosing at 1 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL875229,,BAO_0000218
9400,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622956,,BAO_0000218
9401,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622957,,BAO_0000218
9402,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622958,,BAO_0000218
9403,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622959,,BAO_0000218
9404,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622960,,BAO_0000218
9405,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622961,,BAO_0000218
9406,,Evaluated for the half life in rat (in vivo),,,50597,,N,1,Intermediate,1,,CHEMBL622962,,BAO_0000218
9407,,Hafl life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622963,,BAO_0000218
9408,,Hafl life rat,,,50597,,N,1,Intermediate,1,,CHEMBL622964,,BAO_0000218
9409,,Hafl life rat,,,50597,,N,1,Intermediate,1,,CHEMBL622965,,BAO_0000218
9410,,Hafl life rat; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL622966,,BAO_0000218
9411,,Hafl life rat; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL622967,,BAO_0000218
9412,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622968,,BAO_0000218
9413,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622969,,BAO_0000218
9414,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL875327,,BAO_0000218
9415,,Half life in rat after 1 mg/kg i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL628638,,BAO_0000218
9416,,Half life in rat after 2 mg/kg peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL628639,,BAO_0000218
9417,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625840,,BAO_0000218
9418,,Half life of 10 mg/kg oral dose determined in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625841,,BAO_0000218
9419,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL625842,,BAO_0000218
9420,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL625843,,BAO_0000218
9421,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL625844,,BAO_0000218
9422,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL873822,,BAO_0000218
9423,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL625845,,BAO_0000218
9424,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL627059,,BAO_0000218
9425,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL627060,,BAO_0000218
9426,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL627061,,BAO_0000218
9427,,Half life of compound at 5 mg/kg after po administration was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627709,,BAO_0000218
9428,,Half life of compound determined after intravenous administration to rat,,,50597,,N,1,Intermediate,1,,CHEMBL627710,,BAO_0000218
9429,,Half life of compound was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627711,,BAO_0000218
9430,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627712,,BAO_0000218
9431,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,50597,,N,1,Intermediate,1,,CHEMBL627713,,BAO_0000218
9432,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,50597,,N,1,Intermediate,1,,CHEMBL627714,,BAO_0000218
9433,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,,22224,,U,0,Intermediate,1,,CHEMBL627889,,BAO_0000218
9434,,Half life determined in rat by intravenous administration,,,22224,,U,0,Intermediate,1,,CHEMBL627890,,BAO_0000218
9435,,Half life determined in rats after iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL627891,,BAO_0000218
9436,,Half life in rat plasma after administration of 2 mg/kg iv,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627892,,BAO_0000218
9437,,Half life in rat plasma after administration of 2 mg/kg iv,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627893,,BAO_0000218
9438,,Half life in rat plasma was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627894,,BAO_0000218
9439,,Half life in rat plasma was determined; NA means not applicable,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627895,,BAO_0000218
9440,,Half life in rat was tested,,,50597,,N,1,Intermediate,1,,CHEMBL627896,,BAO_0000218
9441,,Half life measured in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627897,,BAO_0000218
9442,,Half life recorded in rats,,,50597,,N,1,Intermediate,1,,CHEMBL627898,,BAO_0000218
9443,,Half life was calculated,,,50597,,N,1,Intermediate,1,,CHEMBL627899,,BAO_0000218
9444,,Half life was calculated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL873823,,BAO_0000218
9445,,Half life was determined,,,50597,,N,1,Intermediate,1,,CHEMBL627900,,BAO_0000218
9446,,Half life after 10 mg/kg oral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627901,,BAO_0000218
9447,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,,50597,,N,1,Intermediate,1,,CHEMBL627902,,BAO_0000218
9448,,Half life after administering orally a dose of 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627903,,BAO_0000218
9449,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL627904,,BAO_0000218
9450,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,,50597,,N,1,Intermediate,1,,CHEMBL627905,,BAO_0000218
9451,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627906,,BAO_0000218
9452,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627907,,BAO_0000218
9453,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL876783,,BAO_0000218
9454,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,,50597,,N,1,Intermediate,1,,CHEMBL627908,,BAO_0000218
9455,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,50597,,N,1,Intermediate,1,,CHEMBL627909,,BAO_0000218
9456,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,,50597,,N,1,Intermediate,1,,CHEMBL627910,,BAO_0000218
9457,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,,50597,,N,1,Intermediate,1,,CHEMBL627911,,BAO_0000218
9458,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,,50597,,N,1,Intermediate,1,,CHEMBL627912,,BAO_0000218
9459,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,,50597,,N,1,Intermediate,1,,CHEMBL627913,,BAO_0000218
9460,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,,50597,,N,1,Intermediate,1,,CHEMBL627914,,BAO_0000218
9461,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,,50597,,N,1,Intermediate,1,,CHEMBL627915,,BAO_0000218
9462,,Area under the curve was evaluated after 20 uM/kg of peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL627916,,BAO_0000218
9463,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627917,,BAO_0000218
9464,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627918,,BAO_0000218
9465,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL627919,,BAO_0000218
9466,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627920,,BAO_0000218
9467,,Area under the curve was evaluated at an oral dose of 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627921,,BAO_0000218
9468,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,50597,,N,1,Intermediate,1,,CHEMBL627922,,BAO_0000218
9469,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,50597,,N,1,Intermediate,1,,CHEMBL876784,,BAO_0000218
9470,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,50597,,N,1,Intermediate,1,,CHEMBL627923,,BAO_0000218
9471,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,50597,,N,1,Intermediate,1,,CHEMBL626208,,BAO_0000218
9472,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,50597,,N,1,Intermediate,1,,CHEMBL626209,,BAO_0000218
9473,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,50597,,N,1,Intermediate,1,,CHEMBL626210,,BAO_0000218
9474,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627994,,BAO_0000218
9475,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627995,,BAO_0000218
9476,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,,50597,,N,1,Intermediate,1,,CHEMBL627996,,BAO_0000218
9477,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,,50597,,N,1,Intermediate,1,,CHEMBL627997,,BAO_0000218
9478,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL627998,,BAO_0000218
9479,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL628640,,BAO_0000218
9480,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL628641,,BAO_0000218
9481,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL628642,,BAO_0000218
9482,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,50597,,N,1,Intermediate,1,,CHEMBL628643,,BAO_0000218
9483,,Compound was tested for area under curve in rat,,,50597,,N,1,Intermediate,1,,CHEMBL628644,,BAO_0000218
9484,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,,50597,,N,1,Intermediate,1,,CHEMBL628645,,BAO_0000218
9485,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL628646,,BAO_0000218
9486,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL628647,,BAO_0000218
9487,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,,50597,,N,1,Intermediate,1,,CHEMBL628648,,BAO_0000218
9488,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,,50597,,N,1,Intermediate,1,,CHEMBL625358,,BAO_0000218
9489,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,,50597,,N,1,Intermediate,1,,CHEMBL625359,,BAO_0000218
9490,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,,50597,,N,1,Intermediate,1,,CHEMBL625360,,BAO_0000218
9491,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL625361,,BAO_0000218
9492,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL625362,,BAO_0000218
9493,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625363,,BAO_0000218
9494,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,,50597,,N,1,Intermediate,1,,CHEMBL625364,,BAO_0000218
9495,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL625365,,BAO_0000218
9496,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL625366,,BAO_0000218
9497,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL625367,,BAO_0000218
9498,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625368,,BAO_0000218
9499,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625369,,BAO_0000218
9500,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625370,,BAO_0000218
9501,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625371,,BAO_0000218
9502,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625372,,BAO_0000218
9503,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625373,,BAO_0000218
9504,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625374,,BAO_0000218
9505,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL877593,,BAO_0000218
9506,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625375,,BAO_0000218
9507,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625376,,BAO_0000218
9508,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621973,,BAO_0000218
9509,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621974,,BAO_0000218
9510,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL621975,,BAO_0000218
9511,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622166,,BAO_0000218
9512,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622167,,BAO_0000218
9513,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622168,,BAO_0000218
9514,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622169,,BAO_0000218
9515,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622170,,BAO_0000218
9516,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622171,,BAO_0000218
9517,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622172,,BAO_0000218
9518,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622173,,BAO_0000218
9519,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622174,,BAO_0000218
9520,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622175,,BAO_0000218
9521,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622176,,BAO_0000218
9522,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622177,,BAO_0000218
9523,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622178,,BAO_0000218
9524,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622179,,BAO_0000218
9525,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622180,,BAO_0000218
9526,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622181,,BAO_0000218
9527,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622182,,BAO_0000218
9528,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622183,,BAO_0000218
9529,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622184,,BAO_0000218
9530,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622185,,BAO_0000218
9531,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622186,,BAO_0000218
9532,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL622187,,BAO_0000218
9533,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL625002,,BAO_0000218
9534,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL622090,,BAO_0000218
9535,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL622091,,BAO_0000218
9536,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL622092,,BAO_0000218
9537,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL622093,,BAO_0000218
9538,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL622094,,BAO_0000218
9539,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL622095,,BAO_0000218
9540,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL622264,,BAO_0000218
9541,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622265,,BAO_0000218
9542,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622266,,BAO_0000218
9543,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622267,,BAO_0000218
9544,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622268,,BAO_0000218
9545,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622269,,BAO_0000218
9546,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625071,,BAO_0000218
9547,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621621,,BAO_0000218
9548,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621622,,BAO_0000218
9549,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621623,,BAO_0000218
9550,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621624,,BAO_0000218
9551,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621625,,BAO_0000218
9552,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621626,,BAO_0000218
9553,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621627,,BAO_0000218
9554,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621628,,BAO_0000218
9555,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL875328,,BAO_0000218
9556,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621629,,BAO_0000218
9557,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621630,,BAO_0000218
9558,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621631,,BAO_0000218
9559,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621632,,BAO_0000218
9560,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621633,,BAO_0000218
9561,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621634,,BAO_0000218
9562,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621635,,BAO_0000218
9563,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621636,,BAO_0000218
9564,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621637,,BAO_0000218
9565,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL621638,,BAO_0000218
9566,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL618883,,BAO_0000218
9567,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL618884,,BAO_0000218
9568,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL628627,,BAO_0000218
9569,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL628628,,BAO_0000218
9570,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL628629,,BAO_0000218
9571,,Half life after administering orally a dose of 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL628630,,BAO_0000218
9572,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,,50597,,N,1,Intermediate,1,,CHEMBL628631,,BAO_0000218
9573,,Half life after administering intravenously a dose of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL628632,,BAO_0000218
9574,,Half life after oral dosing in rats,,,50597,,N,1,Intermediate,1,,CHEMBL628633,,BAO_0000218
9575,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,,50597,,N,1,Intermediate,1,,CHEMBL628634,,BAO_0000218
9576,,Half life by intravenous administration of 3.4 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627789,,BAO_0000218
9577,,Half life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627790,,BAO_0000218
9578,,Half life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627791,,BAO_0000218
9579,,Half life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627792,,BAO_0000218
9580,,Half life in rat after intravenous administration of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL627793,,BAO_0000218
9581,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627794,,BAO_0000218
9582,,Half life in rat after po administration of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL627795,,BAO_0000218
9583,,Half life in rat after po administration of the compound; ND means Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL627796,,BAO_0000218
9584,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL875335,,BAO_0000218
9585,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627797,,BAO_0000218
9586,,Half life in rat i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL627798,,BAO_0000218
9587,,Half life in rat i.v. at 2 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL627799,,BAO_0000218
9588,,Half life in rats,,,50597,,N,1,Intermediate,1,,CHEMBL627800,,BAO_0000218
9589,,Half life in rats after intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL627801,,BAO_0000218
9590,,Half life in rats at the dose of 1.0 mpk by i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL627802,,BAO_0000218
9591,,Half life in rat,,,50597,,N,1,Expert,1,,CHEMBL627803,,BAO_0000218
9592,,Half life was evaluated after intravenous administration to rats,,,50597,,N,1,Intermediate,1,,CHEMBL873820,,BAO_0000218
9593,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,,50597,,N,1,Intermediate,1,,CHEMBL627804,,BAO_0000218
9594,,Half life was evaluated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627805,,BAO_0000218
9595,,Half life was evaluated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627806,,BAO_0000218
9596,,Half life was evaluated in rat; Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL627107,,BAO_0000218
9597,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,,50597,,N,1,Intermediate,1,,CHEMBL627108,,BAO_0000218
9598,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,,50597,,N,1,Intermediate,1,,CHEMBL627109,,BAO_0000218
9599,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627110,,BAO_0000218
9600,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,,22224,,U,0,Intermediate,1,,CHEMBL627111,,BAO_0000218
9601,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,,22224,,U,0,Intermediate,1,,CHEMBL627112,,BAO_0000218
9602,,Half life was measured in rat at dose of 30 mg/kg by iv administration,,,22224,,U,0,Intermediate,1,,CHEMBL627113,,BAO_0000218
9603,,Half life was measured in rat at dose of 30 mg/kg by po administration,,,22224,,U,0,Intermediate,1,,CHEMBL627114,,BAO_0000218
9604,,Half life (t1/2) was determined,,,50597,,N,1,Intermediate,1,,CHEMBL627115,,BAO_0000218
9605,,Half life period at a dose of 10 uM/kg in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL627116,,BAO_0000218
9606,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,,50597,,N,1,Intermediate,1,,CHEMBL627117,,BAO_0000218
9607,,Half life period was determined,,,50597,,N,1,Intermediate,1,,CHEMBL627118,,BAO_0000218
9608,,Half life period after intravenous administration at 20 mpk in rats,,,50597,,N,1,Intermediate,1,,CHEMBL627119,,BAO_0000218
9609,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,,50597,,N,1,Intermediate,1,,CHEMBL627120,,BAO_0000218
9610,,Half life period after intravenous administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626922,,BAO_0000218
9611,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL626923,,BAO_0000218
9612,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL626924,,BAO_0000218
9613,,Half life period in 80% rat plasma at 37 degree Centigrade,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626925,,BAO_0000218
9614,,Half life period in SD rats,,,50597,,N,1,Intermediate,1,,CHEMBL626926,,BAO_0000218
9615,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626927,,BAO_0000218
9616,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626928,,BAO_0000218
9617,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626929,,BAO_0000218
9618,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626930,,BAO_0000218
9619,,Half life period in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626931,,BAO_0000218
9620,,Half life period in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626932,,BAO_0000218
9621,,Half life period in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626933,,BAO_0000218
9622,,Half life period in rat after oral administration at 10.5 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL873826,,BAO_0000218
9623,,Half life period in rat after oral administration at 11.2 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL626934,,BAO_0000218
9624,,Half life period in rat after oral administration at 13 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL626935,,BAO_0000218
9625,,Half life period in rat after oral administration at 9.7 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL626936,,BAO_0000218
9626,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL626937,,BAO_0000218
9627,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625906,,BAO_0000218
9628,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625907,,BAO_0000218
9629,,PK study was carried to determine AUC (area under curve) value in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625908,,BAO_0000218
9630,,Pharmacokinetic parameter AUC after intravenous administration to rats,,,50597,,N,1,Intermediate,1,,CHEMBL625909,,BAO_0000218
9631,,Pharmacokinetic parameter AUC after oral administration to rats,,,50597,,N,1,Intermediate,1,,CHEMBL625910,,BAO_0000218
9632,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625911,,BAO_0000218
9633,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,,50597,,N,1,Intermediate,1,,CHEMBL625912,,BAO_0000218
9634,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,,50597,,N,1,Intermediate,1,,CHEMBL626538,,BAO_0000218
9635,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,,50597,,N,1,Intermediate,1,,CHEMBL876794,,BAO_0000218
9636,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,,50597,,N,1,Intermediate,1,,CHEMBL626539,,BAO_0000218
9637,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,,50597,,N,1,Intermediate,1,,CHEMBL626540,,BAO_0000218
9638,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626541,,BAO_0000218
9639,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626542,,BAO_0000218
9640,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626543,,BAO_0000218
9641,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626544,,BAO_0000218
9642,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626545,,BAO_0000218
9643,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626546,,BAO_0000218
9644,,Pharmacokinetic parameter area under curve was reported,,,50597,,N,1,Intermediate,1,,CHEMBL626547,,BAO_0000218
9645,,Pharmacokinetic property (AUC) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626548,,BAO_0000218
9646,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,,50597,,N,1,Intermediate,1,,CHEMBL626549,,BAO_0000218
9647,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,,50597,,N,1,Intermediate,1,,CHEMBL626550,,BAO_0000218
9648,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL626551,,BAO_0000218
9649,,Pharmacokinetic property was determined,,,50597,,N,1,Intermediate,1,,CHEMBL623777,,BAO_0000218
9650,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL623778,,BAO_0000218
9651,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL623779,,BAO_0000218
9652,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623780,,BAO_0000218
9653,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622015,,BAO_0000218
9654,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622016,,BAO_0000218
9655,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,,50597,,N,1,Intermediate,1,,CHEMBL622017,,BAO_0000218
9656,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,,50597,,N,1,Intermediate,1,,CHEMBL622018,,BAO_0000218
9657,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,,50597,,N,1,Intermediate,1,,CHEMBL622019,,BAO_0000218
9658,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,,50597,,N,1,Intermediate,1,,CHEMBL622020,,BAO_0000218
9659,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,,50597,,N,1,Intermediate,1,,CHEMBL622021,,BAO_0000218
9660,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,,50597,,N,1,Intermediate,1,,CHEMBL622022,,BAO_0000218
9661,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622023,,BAO_0000218
9662,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL622024,,BAO_0000218
9663,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,,50597,,N,1,Intermediate,1,,CHEMBL622693,,BAO_0000218
9664,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,,50597,,N,1,Intermediate,1,,CHEMBL622694,,BAO_0000218
9665,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL622695,,BAO_0000218
9666,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,,50597,,N,1,Intermediate,1,,CHEMBL622696,,BAO_0000218
9667,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,,50597,,N,1,Intermediate,1,,CHEMBL622697,,BAO_0000218
9668,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,,50597,,N,1,Intermediate,1,,CHEMBL622874,,BAO_0000218
9669,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,,50597,,N,1,Intermediate,1,,CHEMBL622875,,BAO_0000218
9670,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,,50597,,N,1,Intermediate,1,,CHEMBL622876,,BAO_0000218
9671,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,,50597,,N,1,Intermediate,1,,CHEMBL622877,,BAO_0000218
9672,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,,50597,,N,1,Intermediate,1,,CHEMBL622878,,BAO_0000218
9673,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622879,,BAO_0000218
9674,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,,50597,,N,1,Intermediate,1,,CHEMBL877602,,BAO_0000218
9675,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL622880,,BAO_0000218
9676,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL622881,,BAO_0000218
9677,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL622882,,BAO_0000218
9678,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL622883,,BAO_0000218
9679,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622884,,BAO_0000218
9680,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622885,,BAO_0000218
9681,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,50597,,N,1,Intermediate,1,,CHEMBL622886,,BAO_0000218
9682,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL622887,,BAO_0000218
9683,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622888,,BAO_0000218
9684,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",178.0,,50597,,N,1,Intermediate,1,,CHEMBL622889,,BAO_0000218
9685,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",178.0,,50597,,N,1,Intermediate,1,,CHEMBL622890,,BAO_0000218
9686,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",178.0,,50597,,N,1,Intermediate,1,,CHEMBL622891,,BAO_0000218
9687,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",178.0,,50597,,N,1,Intermediate,1,,CHEMBL877603,,BAO_0000218
9688,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",955.0,,50597,,N,1,Intermediate,1,,CHEMBL622892,,BAO_0000218
9689,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",955.0,,50597,,N,1,Intermediate,1,,CHEMBL622893,,BAO_0000218
9690,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",955.0,,50597,,N,1,Intermediate,1,,CHEMBL622894,,BAO_0000218
9691,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",955.0,,50597,,N,1,Intermediate,1,,CHEMBL622895,,BAO_0000218
9692,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622896,,BAO_0000218
9693,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",948.0,,50597,,N,1,Intermediate,1,,CHEMBL622897,,BAO_0000218
9694,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",948.0,,50597,,N,1,Intermediate,1,,CHEMBL622898,,BAO_0000218
9695,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",948.0,,50597,,N,1,Intermediate,1,,CHEMBL622899,,BAO_0000218
9696,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622900,,BAO_0000218
9697,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624114,,BAO_0000218
9698,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624115,,BAO_0000218
9699,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624116,,BAO_0000218
9700,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624117,,BAO_0000218
9701,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624118,,BAO_0000218
9702,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624119,,BAO_0000218
9703,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624120,,BAO_0000218
9704,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624121,,BAO_0000218
9705,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624122,,BAO_0000218
9706,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624123,,BAO_0000218
9707,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624124,,BAO_0000218
9708,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624125,,BAO_0000218
9709,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624126,,BAO_0000218
9710,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624127,,BAO_0000218
9711,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624128,,BAO_0000218
9712,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",14.0,,50597,,N,1,Intermediate,1,,CHEMBL624129,,BAO_0000218
9713,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",14.0,,50597,,N,1,Intermediate,1,,CHEMBL624130,,BAO_0000218
9714,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",14.0,,50597,,N,1,Intermediate,1,,CHEMBL622340,,BAO_0000218
9715,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",14.0,,50597,,N,1,Intermediate,1,,CHEMBL622341,,BAO_0000218
9716,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",160.0,,50597,,N,1,Intermediate,1,,CHEMBL622342,,BAO_0000218
9717,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",160.0,,50597,,N,1,Intermediate,1,,CHEMBL622343,,BAO_0000218
9718,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",160.0,,50597,,N,1,Intermediate,1,,CHEMBL622344,,BAO_0000218
9719,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",160.0,,50597,,N,1,Intermediate,1,,CHEMBL622345,,BAO_0000218
9720,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622346,,BAO_0000218
9721,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622347,,BAO_0000218
9722,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622348,,BAO_0000218
9723,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622349,,BAO_0000218
9724,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622350,,BAO_0000218
9725,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622351,,BAO_0000218
9726,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622352,,BAO_0000218
9727,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622353,,BAO_0000218
9728,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622354,,BAO_0000218
9729,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622355,,BAO_0000218
9730,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622356,,BAO_0000218
9731,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622357,,BAO_0000218
9732,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622358,,BAO_0000218
9733,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL622359,,BAO_0000218
9734,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL874393,,BAO_0000218
9735,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL622872,,BAO_0000218
9736,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL622873,,BAO_0000218
9737,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL623047,,BAO_0000218
9738,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL623048,,BAO_0000218
9739,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL623049,,BAO_0000218
9740,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL623050,,BAO_0000218
9741,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL623051,,BAO_0000218
9742,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL623052,,BAO_0000218
9743,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL626343,,BAO_0000218
9744,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,,N,1,Intermediate,1,,CHEMBL626344,,BAO_0000218
9745,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,,N,1,Intermediate,1,,CHEMBL626345,,BAO_0000218
9746,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,,N,1,Intermediate,1,,CHEMBL626346,,BAO_0000218
9747,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL626347,,BAO_0000218
9748,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL626348,,BAO_0000218
9749,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL626349,,BAO_0000218
9750,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL626350,,BAO_0000218
9751,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL626351,,BAO_0000218
9752,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL627650,,BAO_0000218
9753,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,,N,1,Intermediate,1,,CHEMBL627651,,BAO_0000218
9754,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,,N,1,Intermediate,1,,CHEMBL627652,,BAO_0000218
9755,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL627653,,BAO_0000218
9756,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627654,,BAO_0000218
9757,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627835,,BAO_0000218
9758,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627836,,BAO_0000218
9759,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627837,,BAO_0000218
9760,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627838,,BAO_0000218
9761,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,,50597,,N,1,Intermediate,1,,CHEMBL875338,,BAO_0000218
9762,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627839,,BAO_0000218
9763,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627840,,BAO_0000218
9764,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627841,,BAO_0000218
9765,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627842,,BAO_0000218
9766,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627843,,BAO_0000218
9767,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627844,,BAO_0000218
9768,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,,50597,,N,1,Intermediate,1,,CHEMBL627845,,BAO_0000218
9769,,Half life period in rat by iv administration at a dose of 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627846,,BAO_0000218
9770,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627847,,BAO_0000218
9771,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),1969.0,,50597,,N,1,Intermediate,1,,CHEMBL873821,,BAO_0000218
9772,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626079,,BAO_0000218
9773,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626080,,BAO_0000218
9774,,Half life period was evaluated in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626081,,BAO_0000218
9775,,Half life period was evaluated in rat plasma; Not tested,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL875344,,BAO_0000218
9776,,Half life period was evaluated in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626082,,BAO_0000218
9777,,"Half life period was evaluated in rats, iv",,,50597,,N,1,Intermediate,1,,CHEMBL626250,,BAO_0000218
9778,,Half life period after intravenous administration at 5 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626251,,BAO_0000218
9779,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL626252,,BAO_0000218
9780,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626253,,BAO_0000218
9781,,Half life stability of compound was evaluated in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626254,,BAO_0000218
9782,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626255,,BAO_0000218
9783,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL626256,,BAO_0000218
9784,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL626257,,BAO_0000218
9785,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,,50597,,N,1,Intermediate,1,,CHEMBL626258,,BAO_0000218
9786,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL626259,,BAO_0000218
9787,,Half in rat i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL626260,,BAO_0000218
9788,,Half period in rat after intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL875345,,BAO_0000218
9789,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626261,,BAO_0000218
9790,,Half-life measured in in vitro Cathepsin B assay in rat liver,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626262,,BAO_0000218
9791,,Half-life of compound was determined in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626263,,BAO_0000218
9792,,Half-life at 10 mg/kg in rat upon intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL625270,,BAO_0000218
9793,,Half-life determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625271,,BAO_0000218
9794,,Half-life determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625272,,BAO_0000218
9795,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625273,,BAO_0000218
9796,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625274,,BAO_0000218
9797,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625275,,BAO_0000218
9798,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625276,,BAO_0000218
9799,,Half-life in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625277,,BAO_0000218
9800,,Half-life in rat plasma was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625278,,BAO_0000218
9801,,Half-life in rat plasma; Not tested,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625279,,BAO_0000218
9802,,Half-life in rat serum,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL625280,,BAO_0000218
9803,,Half-life in rat serum; na is not available,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL876797,,BAO_0000218
9804,,Half-life was calculated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625281,,BAO_0000218
9805,,Half-life was calculated in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL873827,,BAO_0000218
9806,,Half-life was determined,,,50597,,N,1,Intermediate,1,,CHEMBL625282,,BAO_0000218
9807,,Half-life was determined,,,50597,,N,1,Intermediate,1,,CHEMBL625283,,BAO_0000218
9808,,Half-life after administration of 20 mg/Kg oral dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625284,,BAO_0000218
9809,,Half-life after administration of 3.2 mg/kg intravenously in male rat,,,50597,,N,1,Intermediate,1,,CHEMBL625285,,BAO_0000218
9810,,Half-life after intravenous administration in female rat,,,50597,,N,1,Intermediate,1,,CHEMBL625286,,BAO_0000218
9811,,Half-life after intravenous administration in male rat,,,50597,,N,1,Intermediate,1,,CHEMBL625287,,BAO_0000218
9812,,Half-life after intravenous dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625288,,BAO_0000218
9813,,Half-life in a rat liver homogenate preparation,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625289,,BAO_0000218
9814,,Half-life in plasma of rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625290,,BAO_0000218
9815,,Half-life in plasma of rat at dose of 3-10 mgkg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL876798,,BAO_0000218
9816,,Half-life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625291,,BAO_0000218
9817,,Half-life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625292,,BAO_0000218
9818,,Half-life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625293,,BAO_0000218
9819,,Half-life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622832,,BAO_0000218
9820,,Half-life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622833,,BAO_0000218
9821,,Half-life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622834,,BAO_0000218
9822,,Half-life in rat after oral administration at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622835,,BAO_0000218
9823,,Half-life in rat after po administration at a dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622836,,BAO_0000218
9824,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,,50597,,N,1,Intermediate,1,,CHEMBL622837,,BAO_0000218
9825,,Half-life in rat at 3 mg/kg dose administered intravenously,,,50597,,N,1,Intermediate,1,,CHEMBL622838,,BAO_0000218
9826,,Half-life in rat brain homogenate,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622839,,BAO_0000218
9827,,Half-life in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622840,,BAO_0000218
9828,,Half-life in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622841,,BAO_0000218
9829,,Half-life in Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL622842,,BAO_0000218
9830,,Half-life in vitro in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622843,,BAO_0000218
9831,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622844,,BAO_0000218
9832,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,,50597,,N,1,Intermediate,1,,CHEMBL622845,,BAO_0000218
9833,,The area under the curve of compound was measured at the dose of 100 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622846,,BAO_0000218
9834,,The area under the curve of compound was measured at the dose of 300 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622847,,BAO_0000218
9835,,The area under the curve of compound was measured at the dose of 30 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622848,,BAO_0000218
9836,,Bioavailability as oral AUC in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622849,,BAO_0000218
9837,,The plasma concentration versus time curve (AUC) was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622850,,BAO_0000218
9838,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL876807,,BAO_0000218
9839,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622851,,BAO_0000218
9840,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622852,,BAO_0000218
9841,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,,50597,,N,1,Intermediate,1,,CHEMBL622853,,BAO_0000218
9842,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,,50597,,N,1,Intermediate,1,,CHEMBL622854,,BAO_0000218
9843,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622855,,BAO_0000218
9844,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622856,,BAO_0000218
9845,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622857,,BAO_0000218
9846,,AUC in rat after po administration at a dose of 10 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622858,,BAO_0000218
9847,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622859,,BAO_0000218
9848,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622860,,BAO_0000218
9849,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622861,,BAO_0000218
9850,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622862,,BAO_0000218
9851,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622863,,BAO_0000218
9852,,Area under curve value 6 hr after po administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623817,,BAO_0000218
9853,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,50597,,N,1,Intermediate,1,,CHEMBL623818,,BAO_0000218
9854,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,,50597,,N,1,Intermediate,1,,CHEMBL623819,,BAO_0000218
9855,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,50597,,N,1,Intermediate,1,,CHEMBL623820,,BAO_0000218
9856,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,,50597,,N,1,Intermediate,1,,CHEMBL623821,,BAO_0000218
9857,,AUC normalized for dose (AUCN) in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623822,,BAO_0000218
9858,,Area under curve in rat after p.o. administration,,,50597,,N,1,Intermediate,1,,CHEMBL623823,,BAO_0000218
9859,,Area under curve in rat after p.o. administration,,,50597,,N,1,Intermediate,1,,CHEMBL623824,,BAO_0000218
9860,,Area under curve in rat after p.o. administration; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL623825,,BAO_0000218
9861,,Area under curve in rat after peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL622070,,BAO_0000218
9862,,Area under curve (carotid artery) value of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL622071,,BAO_0000218
9863,,Bioavailability expressed as the area under curve of rat carotid artery,,,50597,,N,1,Intermediate,1,,CHEMBL622072,,BAO_0000218
9864,,Area under curve in male SD rats was observed after intravenous administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622073,,BAO_0000218
9865,,Area under curve of the compound was determined,,,50597,,N,1,Intermediate,1,,CHEMBL622074,,BAO_0000218
9866,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,,50597,,N,1,Intermediate,1,,CHEMBL622075,,BAO_0000218
9867,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622076,,BAO_0000218
9868,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622077,,BAO_0000218
9869,,Area under curve (portal vein) value of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL622078,,BAO_0000218
9870,,Bioavailability expressed as the area under curve of rat portal vein,,,50597,,N,1,Intermediate,1,,CHEMBL622079,,BAO_0000218
9871,,Area Under plasma concentration time curve in rat upon peroral administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622080,,BAO_0000218
9872,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL877612,,BAO_0000218
9873,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622081,,BAO_0000218
9874,,Compound was evaluated for oral bioavailability in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622082,,BAO_0000218
9875,,Compound was evaluated for oral bioavailability in rats after iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL622083,,BAO_0000218
9876,,Compound was evaluated for oral bioavailability in rats; 30-80,,,50597,,N,1,Intermediate,1,,CHEMBL622084,,BAO_0000218
9877,,Compound was evaluated for oral bioavailability in rats; 50-60,,,50597,,N,1,Intermediate,1,,CHEMBL622085,,BAO_0000218
9878,,Compound was evaluated for oral bioavailability in rats; no data,,,50597,,N,1,Intermediate,1,,CHEMBL622086,,BAO_0000218
9879,,Compound was evaluated for oral bioavailability in rats; peptide,,,50597,,N,1,Intermediate,1,,CHEMBL622087,,BAO_0000218
9880,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",178.0,,50597,,N,1,Intermediate,1,,CHEMBL622088,,BAO_0000218
9881,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",178.0,,50597,,N,1,Intermediate,1,,CHEMBL622089,,BAO_0000218
9882,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",178.0,,50597,,N,1,Intermediate,1,,CHEMBL623685,,BAO_0000218
9883,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",178.0,,50597,,N,1,Intermediate,1,,CHEMBL623686,,BAO_0000218
9884,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",945.0,,50597,,N,1,Intermediate,1,,CHEMBL623687,,BAO_0000218
9885,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",945.0,,50597,,N,1,Intermediate,1,,CHEMBL623688,,BAO_0000218
9886,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",945.0,,50597,,N,1,Intermediate,1,,CHEMBL623689,,BAO_0000218
9887,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",945.0,,50597,,N,1,Intermediate,1,,CHEMBL622485,,BAO_0000218
9888,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622486,,BAO_0000218
9889,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL877613,,BAO_0000218
9890,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622487,,BAO_0000218
9891,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622488,,BAO_0000218
9892,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",948.0,,50597,,N,1,Intermediate,1,,CHEMBL622489,,BAO_0000218
9893,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622490,,BAO_0000218
9894,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622491,,BAO_0000218
9895,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622492,,BAO_0000218
9896,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622493,,BAO_0000218
9897,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622494,,BAO_0000218
9898,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL622495,,BAO_0000218
9899,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,,50597,,N,1,Intermediate,1,,CHEMBL622496,,BAO_0000218
9900,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622497,,BAO_0000218
9901,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,,50597,,N,1,Intermediate,1,,CHEMBL622498,,BAO_0000218
9902,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624918,,BAO_0000218
9903,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624919,,BAO_0000218
9904,,Biodistribution of compound in rat blood after 5 min of administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624920,,BAO_0000218
9905,,Biodistribution of compound in rat blood after 5 min of administration.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624921,,BAO_0000218
9906,,Biodistribution of compound in rat brain after 5 min of administration,955.0,,50597,,N,1,Intermediate,1,,CHEMBL624922,,BAO_0000218
9907,,Biodistribution of compound in rat heart after 5 min of administration,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624923,,BAO_0000218
9908,,Biodistribution of compound in rat heart after 5 min of administration.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624924,,BAO_0000218
9909,,Biodistribution of compound in rat kidney after 5 min of administration,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624925,,BAO_0000218
9910,,Biodistribution of compound in rat kidney after 5 min of administration.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624926,,BAO_0000218
9911,,Biodistribution of compound in rat liver after 5 min of administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624927,,BAO_0000218
9912,,Biodistribution of compound in rat liver after 5 min of administration.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL874402,,BAO_0000218
9913,,Biodistribution of compound in rat lung after 5 min of administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624928,,BAO_0000218
9914,,Biodistribution of compound in rat lung after 5 min of administration.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624929,,BAO_0000218
9915,,Biodistribution of compound in rat muscle after 5 min of administration,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624930,,BAO_0000218
9916,,Biodistribution of compound in rat muscle after 5 min of administration.,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624931,,BAO_0000218
9917,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624932,,BAO_0000218
9918,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624933,,BAO_0000218
9919,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624934,,BAO_0000218
9920,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624935,,BAO_0000218
9921,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,,N,1,Intermediate,1,,CHEMBL624936,,BAO_0000218
9922,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,,N,1,Intermediate,1,,CHEMBL624937,,BAO_0000218
9923,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL624938,,BAO_0000218
9924,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL624939,,BAO_0000218
9925,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,,N,1,Intermediate,1,,CHEMBL624940,,BAO_0000218
9926,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,,N,1,Intermediate,1,,CHEMBL874403,,BAO_0000218
9927,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,,50597,,N,1,Intermediate,1,,CHEMBL624941,,BAO_0000218
9928,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624942,,BAO_0000218
9929,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624943,,BAO_0000218
9930,,% Bioavailability after 1 day of the drug administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624944,,BAO_0000218
9931,,% Bioavailability after 4 day of the drug administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624945,,BAO_0000218
9932,,Absolute bioavailability was evaluated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624946,,BAO_0000218
9933,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,,50597,,N,1,Intermediate,1,,CHEMBL624947,,BAO_0000218
9934,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL624948,,BAO_0000218
9935,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL624949,,BAO_0000218
9936,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622025,,BAO_0000218
9937,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622026,,BAO_0000218
9938,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622027,,BAO_0000218
9939,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622028,,BAO_0000218
9940,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622029,,BAO_0000218
9941,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622208,,BAO_0000218
9942,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622209,,BAO_0000218
9943,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622210,,BAO_0000218
9944,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,,50597,,N,1,Intermediate,1,,CHEMBL622211,,BAO_0000218
9945,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,,50597,,N,1,Intermediate,1,,CHEMBL622212,,BAO_0000218
9946,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL622213,,BAO_0000218
9947,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL874404,,BAO_0000218
9948,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620452,,BAO_0000218
9949,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620453,,BAO_0000218
9950,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL620454,,BAO_0000218
9951,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624067,,BAO_0000218
9952,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,,50597,,N,1,Intermediate,1,,CHEMBL624068,,BAO_0000218
9953,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,992.0,,50597,,N,1,Intermediate,1,,CHEMBL624069,,BAO_0000218
9954,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,992.0,,50597,,N,1,Intermediate,1,,CHEMBL624070,,BAO_0000218
9955,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,992.0,,50597,,N,1,Intermediate,1,,CHEMBL624071,,BAO_0000218
9956,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,995.0,,50597,,N,1,Intermediate,1,,CHEMBL624072,,BAO_0000218
9957,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,995.0,,50597,,N,1,Intermediate,1,,CHEMBL624073,,BAO_0000218
9958,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,995.0,,50597,,N,1,Intermediate,1,,CHEMBL624788,,BAO_0000218
9959,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,995.0,,50597,,N,1,Intermediate,1,,CHEMBL624789,,BAO_0000218
9960,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,,50597,,N,1,Intermediate,1,,CHEMBL624790,,BAO_0000218
9961,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,,50597,,N,1,Intermediate,1,,CHEMBL624791,,BAO_0000218
9962,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL624792,,BAO_0000218
9963,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,,50597,,N,1,Intermediate,1,,CHEMBL624793,,BAO_0000218
9964,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL877491,,BAO_0000218
9965,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624957,,BAO_0000218
9966,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624958,,BAO_0000218
9967,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624959,,BAO_0000218
9968,,Dissociation constant was determined,,,50597,,N,1,Intermediate,1,,CHEMBL624960,,BAO_0000218
9969,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,,50597,,N,1,Intermediate,1,,CHEMBL624961,,BAO_0000218
9970,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL624962,,BAO_0000218
9971,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL624963,,BAO_0000218
9972,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,,50597,,N,1,Intermediate,1,,CHEMBL624964,,BAO_0000218
9973,,LogP value was evaluated in the in situ rat gut perfusion assay,,,50597,,N,1,Intermediate,1,,CHEMBL624965,,BAO_0000218
9974,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624966,,BAO_0000218
9975,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624967,,BAO_0000218
9976,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624968,,BAO_0000218
9977,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL624969,,BAO_0000218
9978,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,,50597,,N,1,Expert,1,,CHEMBL624970,,BAO_0000218
9979,,Half-life was evaluated after 10 uM/kg of intra arterial administration,,,50597,,N,1,Intermediate,1,,CHEMBL624971,,BAO_0000218
9980,,Half-life was evaluated after 20 uM/kg of peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL624972,,BAO_0000218
9981,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624973,,BAO_0000218
9982,,Half-life was evaluated in plasma of rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL624974,,BAO_0000218
9983,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624975,,BAO_0000218
9984,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL877492,,BAO_0000218
9985,,Half-life was measured in rat after an iv dose of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624976,,BAO_0000218
9986,,Half-life period of compound in rats after peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL624977,,BAO_0000218
9987,,Half-life period of compound was measured in rat plasma.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626848,,BAO_0000218
9988,,Half-life period of compound was measured in rat plasma; ND is not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626849,,BAO_0000218
9989,,Half-life period of compound was measured in rat plasma; not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626850,,BAO_0000218
9990,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL626851,,BAO_0000218
9991,,Half-life period in rat by iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL626852,,BAO_0000218
9992,,Half-life period in rats following intravenous administration at 2 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626853,,BAO_0000218
9993,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50597,,N,1,Intermediate,1,,CHEMBL626854,,BAO_0000218
9994,,Half-life period was determined for the compound in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627486,,BAO_0000218
9995,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,,50597,,N,1,Intermediate,1,,CHEMBL627487,,BAO_0000218
9996,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,,50597,,N,1,Intermediate,1,,CHEMBL627488,,BAO_0000218
9997,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,,50597,,N,1,Intermediate,1,,CHEMBL627489,,BAO_0000218
9998,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL627490,,BAO_0000218
9999,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL873829,,BAO_0000218
10000,,Half-life was determined in rat at a dose of 1 mpk i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL627655,,BAO_0000218
10001,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,,50597,,N,1,Intermediate,1,,CHEMBL625994,,BAO_0000218
10002,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,,50597,,N,1,Intermediate,1,,CHEMBL625995,,BAO_0000218
10003,,Half-life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625996,,BAO_0000218
10004,,In vitro half life in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625850,,BAO_0000218
10005,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625851,,BAO_0000218
10006,,In vitro half life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625852,,BAO_0000218
10007,,In vivo half life period after intravenous administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625853,,BAO_0000218
10008,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625854,,BAO_0000218
10009,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,,50597,,N,1,Intermediate,1,,CHEMBL874450,,BAO_0000218
10010,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL625855,,BAO_0000218
10011,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL625856,,BAO_0000218
10012,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL625857,,BAO_0000218
10013,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL873831,,BAO_0000218
10014,,Longer half-life in rat (i.v.) at 0.5 mpk,,,50597,,N,1,Intermediate,1,,CHEMBL625858,,BAO_0000218
10015,,Longer half-life in rat (p.o.) at 2.0 mpk,,,50597,,N,1,Intermediate,1,,CHEMBL625859,,BAO_0000218
10016,,Pharmacokinetic property (half life) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625860,,BAO_0000218
10017,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625861,,BAO_0000218
10018,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625862,,BAO_0000218
10019,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625863,,BAO_0000218
10020,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625864,,BAO_0000218
10021,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625865,,BAO_0000218
10022,,Pharmacokinetic half time was determined intravenously in rats.,,,50597,,N,1,Intermediate,1,,CHEMBL625866,,BAO_0000218
10023,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625867,,BAO_0000218
10024,,Plasma half life of hydrolysis of the compound,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625868,,BAO_0000218
10025,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625869,,BAO_0000218
10026,,Plasma half life period was calculated in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL874451,,BAO_0000218
10027,,Plasma half-life in Sprague-Dawley rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625870,,BAO_0000218
10028,,Plasma half-life in Sprague-Dawley rats; Not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625871,,BAO_0000218
10029,,Plasma half-life in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625872,,BAO_0000218
10030,,Plasma half-life in rats; <MQL,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625873,,BAO_0000218
10031,,Plasma half-life period (0-8 h) was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625874,,BAO_0000218
10032,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625875,,BAO_0000218
10033,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625876,,BAO_0000218
10034,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631258,,BAO_0000218
10035,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631259,,BAO_0000218
10036,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631260,,BAO_0000218
10037,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",178.0,,50597,,N,1,Intermediate,1,,CHEMBL631261,,BAO_0000218
10038,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",178.0,,50597,,N,1,Intermediate,1,,CHEMBL631262,,BAO_0000218
10039,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",178.0,,50597,,N,1,Intermediate,1,,CHEMBL631263,,BAO_0000218
10040,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,,50597,,N,1,Intermediate,1,,CHEMBL631264,,BAO_0000218
10041,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,,50597,,N,1,Intermediate,1,,CHEMBL631265,,BAO_0000218
10042,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,,50597,,N,1,Intermediate,1,,CHEMBL631266,,BAO_0000218
10043,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,,50597,,N,1,Intermediate,1,,CHEMBL631267,,BAO_0000218
10044,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,,50597,,N,1,Intermediate,1,,CHEMBL631268,,BAO_0000218
10045,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,,50597,,N,1,Intermediate,1,,CHEMBL631269,,BAO_0000218
10046,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,,50597,,N,1,Intermediate,1,,CHEMBL631270,,BAO_0000218
10047,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",948.0,,50597,,N,1,Intermediate,1,,CHEMBL631271,,BAO_0000218
10048,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",948.0,,50597,,N,1,Intermediate,1,,CHEMBL631272,,BAO_0000218
10049,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",948.0,,50597,,N,1,Intermediate,1,,CHEMBL631273,,BAO_0000218
10050,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",948.0,,50597,,N,1,Intermediate,1,,CHEMBL631274,,BAO_0000218
10051,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",948.0,,50597,,N,1,Intermediate,1,,CHEMBL631275,,BAO_0000218
10052,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",948.0,,50597,,N,1,Intermediate,1,,CHEMBL626984,,BAO_0000218
10053,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",948.0,,50597,,N,1,Intermediate,1,,CHEMBL626985,,BAO_0000218
10054,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626986,,BAO_0000218
10055,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626987,,BAO_0000218
10056,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626988,,BAO_0000218
10057,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626989,,BAO_0000218
10058,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626990,,BAO_0000218
10059,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626991,,BAO_0000218
10060,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626992,,BAO_0000218
10061,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626993,,BAO_0000218
10062,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL874593,,BAO_0000218
10063,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626994,,BAO_0000218
10064,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626995,,BAO_0000218
10065,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626190,,BAO_0000218
10066,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626191,,BAO_0000218
10067,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626364,,BAO_0000218
10068,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626365,,BAO_0000218
10069,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626366,,BAO_0000218
10070,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626367,,BAO_0000218
10071,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626368,,BAO_0000218
10072,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626369,,BAO_0000218
10073,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626370,,BAO_0000218
10074,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,,50597,,N,1,Intermediate,1,,CHEMBL626371,,BAO_0000218
10075,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,,50597,,N,1,Intermediate,1,,CHEMBL626372,,BAO_0000218
10076,,Bioavailability after a dose of 10 mg/kg p.o.,,,50597,,N,1,Intermediate,1,,CHEMBL626373,,BAO_0000218
10077,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626374,,BAO_0000218
10078,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,,50597,,N,1,Intermediate,1,,CHEMBL626375,,BAO_0000218
10079,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL626376,,BAO_0000218
10080,,Bioavailability in rat po was determined,,,50597,,N,1,Intermediate,1,,CHEMBL626377,,BAO_0000218
10081,,Bioavailability of compound at 10 mg/kg in rat after oral administration,,,50597,,N,1,Intermediate,1,,CHEMBL626378,,BAO_0000218
10082,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL626379,,BAO_0000218
10083,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL626380,,BAO_0000218
10084,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL626381,,BAO_0000218
10085,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626382,,BAO_0000218
10086,,Bioavailability in rat (Sprague-Dawley) (female),,,50597,,N,1,Intermediate,1,,CHEMBL626383,,BAO_0000218
10087,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL874652,,BAO_0000218
10088,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL626384,,BAO_0000218
10089,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,,50597,,N,1,Intermediate,1,,CHEMBL626385,,BAO_0000218
10090,,Bioavailability in rat at an oral dose of 2 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626386,,BAO_0000218
10091,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626387,,BAO_0000218
10092,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626388,,BAO_0000218
10093,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626389,,BAO_0000218
10094,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626390,,BAO_0000218
10095,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,,50597,,N,1,Intermediate,1,,CHEMBL626391,,BAO_0000218
10096,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626392,,BAO_0000218
10097,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626393,,BAO_0000218
10098,,Bioavailability was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623026,,BAO_0000218
10099,,Bioavailability,,,50597,,N,1,Intermediate,1,,CHEMBL623027,,BAO_0000218
10100,,Bioavailability,,,50597,,N,1,Intermediate,1,,CHEMBL623028,,BAO_0000218
10101,,Bioavailability in rat after 1 day dosing,,,50597,,N,1,Intermediate,1,,CHEMBL623029,,BAO_0000218
10102,,Bioavailability in rat after 4 day dosing,,,50597,,N,1,Intermediate,1,,CHEMBL623030,,BAO_0000218
10103,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,,50597,,N,1,Intermediate,1,,CHEMBL623031,,BAO_0000218
10104,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,,50597,,N,1,Intermediate,1,,CHEMBL623032,,BAO_0000218
10105,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623033,,BAO_0000218
10106,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623034,,BAO_0000218
10107,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623035,,BAO_0000218
10108,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL623036,,BAO_0000218
10109,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL623037,,BAO_0000218
10110,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623038,,BAO_0000218
10111,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL874385,,BAO_0000218
10112,,Bioavailability in rat (Fisher) (fasted),,,50597,,N,1,Intermediate,1,,CHEMBL623039,,BAO_0000218
10113,,Bioavailability in monkey after po administration of 10 mg/kg dose,,,22224,,U,0,Intermediate,1,,CHEMBL623040,,BAO_0000218
10114,,Oral bioavailability in monkey (dose 10 mg/kg),,,22224,,U,0,Intermediate,1,,CHEMBL623041,,BAO_0000218
10115,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623741,,BAO_0000218
10116,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623742,,BAO_0000218
10117,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623743,,BAO_0000218
10118,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623744,,BAO_0000218
10119,,Bioavailability in rat (dose 2.0 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL623745,,BAO_0000218
10120,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,,50597,,N,1,Intermediate,1,,CHEMBL623746,,BAO_0000218
10121,,Oral bioavailability in rat (dose 5 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL623747,,BAO_0000218
10122,,Bioavailability in rat after po administration of 30 mg/kg dose,,,22224,,U,0,Intermediate,1,,CHEMBL623748,,BAO_0000218
10123,,Bioavailability in rat after po administration of 30 mg/kg dose,,,22224,,U,0,Intermediate,1,,CHEMBL623916,,BAO_0000218
10124,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL623917,,BAO_0000218
10125,,Bioavailability in rat (dose 2 mg/kg i.v.),,,50597,,N,1,Intermediate,1,,CHEMBL623918,,BAO_0000218
10126,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL874386,,BAO_0000218
10127,,Bioavailability in rat; Only traces detected in rat plasma,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623919,,BAO_0000218
10128,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623920,,BAO_0000218
10129,,Bioavailability upon oral administration of compound,,,50597,,N,1,Intermediate,1,,CHEMBL623148,,BAO_0000218
10130,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL623149,,BAO_0000218
10131,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623150,,BAO_0000218
10132,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,,50597,,N,1,Intermediate,1,,CHEMBL623151,,BAO_0000218
10133,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,,50597,,N,1,Intermediate,1,,CHEMBL623152,,BAO_0000218
10134,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,,50597,,N,1,Expert,1,,CHEMBL623153,,BAO_0000218
10135,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,,50597,,N,1,Expert,1,,CHEMBL623154,,BAO_0000218
10136,,In vitro and metabolic stability was determined,,,50597,,N,1,Intermediate,1,,CHEMBL623155,,BAO_0000218
10137,,In vitro metabolic stability in rat hepatocytes,,,50597,,N,1,Intermediate,1,,CHEMBL623156,,BAO_0000218
10138,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,,50597,,N,1,Intermediate,1,,CHEMBL623157,,BAO_0000218
10139,,Metabolic rate for compound was observed in rat hepatocytes,2107.0,,50597,Hepatocyte,N,1,Intermediate,1,,CHEMBL623158,401.0,BAO_0000218
10140,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,,50597,,N,1,Intermediate,1,,CHEMBL623159,,BAO_0000218
10141,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,,50597,,N,1,Intermediate,1,,CHEMBL874390,,BAO_0000218
10142,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,,50597,,N,1,Intermediate,1,,CHEMBL623160,,BAO_0000218
10143,,Metabolism of compound in rat S9 microsomes; Trace,,,50597,,N,1,Intermediate,1,,CHEMBL623161,,BAO_0000218
10144,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,,50597,,N,1,Intermediate,1,,CHEMBL623162,,BAO_0000218
10145,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,,50597,,N,1,Intermediate,1,,CHEMBL623163,,BAO_0000218
10146,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,,50597,,N,1,Intermediate,1,,CHEMBL623164,,BAO_0000218
10147,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,,50597,,N,1,Intermediate,1,,CHEMBL623165,,BAO_0000218
10148,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,,50597,,N,1,Intermediate,1,,CHEMBL623166,,BAO_0000218
10149,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,,50597,,N,1,Intermediate,1,,CHEMBL624983,,BAO_0000218
10150,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,,50597,,N,1,Intermediate,1,,CHEMBL624984,,BAO_0000218
10151,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,,50597,,N,1,Intermediate,1,,CHEMBL624985,,BAO_0000218
10152,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,,50597,,N,1,Intermediate,1,,CHEMBL622970,,BAO_0000218
10153,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL622971,,BAO_0000218
10154,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,,50597,,N,1,Intermediate,1,,CHEMBL622972,,BAO_0000218
10155,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL622973,,BAO_0000218
10156,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,,50597,,N,1,Intermediate,1,,CHEMBL622974,,BAO_0000218
10157,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL622975,,BAO_0000218
10158,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,,50597,,N,1,Intermediate,1,,CHEMBL622976,,BAO_0000218
10159,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,,50597,,N,1,Intermediate,1,,CHEMBL622977,,BAO_0000218
10160,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,,50597,,N,1,Intermediate,1,,CHEMBL624351,,BAO_0000218
10161,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,,50597,,N,1,Intermediate,1,,CHEMBL624352,,BAO_0000218
10162,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,,50597,,N,1,Intermediate,1,,CHEMBL624353,,BAO_0000218
10163,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,,50597,,N,1,Intermediate,1,,CHEMBL622397,,BAO_0000218
10164,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,,50597,,N,1,Intermediate,1,,CHEMBL622398,,BAO_0000218
10165,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,,50597,,N,1,Intermediate,1,,CHEMBL622399,,BAO_0000218
10166,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,,50597,,N,1,Intermediate,1,,CHEMBL622400,,BAO_0000218
10167,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,,50597,,N,1,Intermediate,1,,CHEMBL628428,,BAO_0000218
10168,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,,50597,,N,1,Intermediate,1,,CHEMBL628590,,BAO_0000218
10169,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL628591,,BAO_0000218
10170,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,,50597,,N,1,Intermediate,1,,CHEMBL628592,,BAO_0000218
10171,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL628593,,BAO_0000218
10172,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,,50597,,N,1,Intermediate,1,,CHEMBL875333,,BAO_0000218
10173,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL628594,,BAO_0000218
10174,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628595,,BAO_0000218
10175,,Stability in rat plasma was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628596,,BAO_0000218
10176,,Stability in rat plasma was determined; ND= no data,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628597,,BAO_0000218
10177,,Tested for plasma half life period in rat (0-8 hr),1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628598,,BAO_0000218
10178,,Tested for plasma half life period in rat (0-8 hr); Not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628599,,BAO_0000218
10179,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL628600,,BAO_0000218
10180,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL628601,,BAO_0000218
10181,,Tested for the half life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL628602,,BAO_0000218
10182,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,,50597,,N,1,Intermediate,1,,CHEMBL628603,,BAO_0000218
10183,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL628604,,BAO_0000218
10184,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,,50597,,N,1,Intermediate,1,,CHEMBL628605,,BAO_0000218
10185,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL628606,,BAO_0000218
10186,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,,50597,,N,1,Intermediate,1,,CHEMBL628607,,BAO_0000218
10187,,The biological half life the compound was measured at the dose of 100 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL628608,,BAO_0000218
10188,,The biological half life the compound was measured at the dose of 30 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL628609,,BAO_0000218
10189,,The compound was evaluated for plasma half life period in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628610,,BAO_0000218
10190,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL873819,,BAO_0000218
10191,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL628611,,BAO_0000218
10192,,The pharmacokinetic parameter half-life period in vivo in rats,,,50597,,N,1,Intermediate,1,,CHEMBL628612,,BAO_0000218
10193,,"The pharmacokinetic property, Half-life was determined",,,50597,,N,1,Intermediate,1,,CHEMBL628613,,BAO_0000218
10194,,"The pharmacokinetic property, Half-life in rat in vivo",,,50597,,N,1,Intermediate,1,,CHEMBL628614,,BAO_0000218
10195,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,,50597,,N,1,Intermediate,1,,CHEMBL628615,,BAO_0000218
10196,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,,50597,,N,1,Intermediate,1,,CHEMBL628616,,BAO_0000218
10197,,The plasma half life period in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627924,,BAO_0000218
10198,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627925,,BAO_0000218
10199,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,,50597,,N,1,Intermediate,1,,CHEMBL627926,,BAO_0000218
10200,,t1/2 (apparent elimination)of the compound was determined,,,50597,,N,1,Intermediate,1,,CHEMBL627927,,BAO_0000218
10201,,t1/2 value in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627928,,BAO_0000218
10202,,Half life in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627539,,BAO_0000218
10203,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL876790,,BAO_0000218
10204,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,,50597,,N,1,Intermediate,1,,CHEMBL858186,,BAO_0000218
10205,,Half-life period in fasted rats,,,50597,,N,1,Intermediate,1,,CHEMBL627540,,BAO_0000218
10206,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL627541,,BAO_0000218
10207,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL627715,,BAO_0000218
10208,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627716,,BAO_0000218
10209,,Maximum time required to achieve Cmax was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627717,,BAO_0000218
10210,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,50597,,N,1,Intermediate,1,,CHEMBL627718,,BAO_0000218
10211,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,50597,,N,1,Intermediate,1,,CHEMBL627719,,BAO_0000218
10212,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,,50597,,N,1,Intermediate,1,,CHEMBL627720,,BAO_0000218
10213,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL627721,,BAO_0000218
10214,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,,50597,,N,1,Intermediate,1,,CHEMBL627722,,BAO_0000218
10215,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL627723,,BAO_0000218
10216,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL626058,,BAO_0000218
10217,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL626059,,BAO_0000218
10218,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL626060,,BAO_0000218
10219,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626061,,BAO_0000218
10220,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,50597,,N,1,Intermediate,1,,CHEMBL876791,,BAO_0000218
10221,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,50597,,N,1,Intermediate,1,,CHEMBL626062,,BAO_0000218
10222,,Tmax at the dose of 2 mg/Kg administered perorally in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626063,,BAO_0000218
10223,,Tmax at the dose of 5 mg/Kg administered perorally in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626064,,BAO_0000218
10224,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626065,,BAO_0000218
10225,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626066,,BAO_0000218
10226,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626067,,BAO_0000218
10227,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,,50597,,N,1,Intermediate,1,,CHEMBL626068,,BAO_0000218
10228,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,,50597,,N,1,Intermediate,1,,CHEMBL626069,,BAO_0000218
10229,,Percent total excretion of 3-methoxyacetaminophen glucuronide,,,50597,,N,1,Intermediate,1,,CHEMBL626070,,BAO_0000218
10230,,Percent total excretion of N-methoxyacetaminophen glucuronide,,,50597,,N,1,Intermediate,1,,CHEMBL626071,,BAO_0000218
10231,,Percent total excretion of N-methoxyacetaminophen sulfate,,,50597,,N,1,Intermediate,1,,CHEMBL626072,,BAO_0000218
10232,,Percent total excretion of acetaminophen,,,50597,,N,1,Intermediate,1,,CHEMBL626073,,BAO_0000218
10233,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626741,,BAO_0000218
10234,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,,50597,,N,1,Intermediate,1,,CHEMBL626742,,BAO_0000218
10235,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626743,,BAO_0000218
10236,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,50597,,N,1,Intermediate,1,,CHEMBL876792,,BAO_0000218
10237,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,,50597,,N,1,Intermediate,1,,CHEMBL626744,,BAO_0000218
10238,,Compound was tested for antidiuretic activity in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626745,,BAO_0000218
10239,,AUC in rat after 3mg/kg oral dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626746,,BAO_0000218
10240,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626747,,BAO_0000218
10241,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626748,,BAO_0000218
10242,,Bioavailability administered orally at a dose of 10 mg/kg to rats,,,50597,,N,1,Intermediate,1,,CHEMBL626749,,BAO_0000218
10243,,Oral Bioavailability was determined,,,50597,,N,1,Intermediate,1,,CHEMBL626750,,BAO_0000218
10244,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626751,,BAO_0000218
10245,,Oral bioavailability in rat; Not performed.,,,50597,,N,1,Intermediate,1,,CHEMBL626913,,BAO_0000218
10246,,Bioavailability,,,50597,,N,1,Intermediate,1,,CHEMBL626914,,BAO_0000218
10247,,Bioavailability was determined; ND denotes no data,,,50597,,N,1,Intermediate,1,,CHEMBL626915,,BAO_0000218
10248,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626916,,BAO_0000218
10249,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626917,,BAO_0000218
10250,,Binding towards rat plasma protein at 10 uM,,,50597,,N,1,Intermediate,1,,CHEMBL626918,,BAO_0000218
10251,,Binding towards rat plasma protein at 100 uM,,,50597,,N,1,Intermediate,1,,CHEMBL626919,,BAO_0000218
10252,,Bioavailability in rat (dose 20 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL626920,,BAO_0000218
10253,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,,50597,,N,1,Intermediate,1,,CHEMBL621976,,BAO_0000218
10254,,Bioavailability in rat after 5 mg/kg oral gavage,,,50597,,N,1,Intermediate,1,,CHEMBL877599,,BAO_0000218
10255,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621977,,BAO_0000218
10256,,Bioavailability in rat (dose 1 mg/kg i.v.),,,50597,,N,1,Intermediate,1,,CHEMBL621978,,BAO_0000218
10257,,Bioavailability in rat (dose 3 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL621979,,BAO_0000218
10258,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621980,,BAO_0000218
10259,,Bioavailability of the compound in rats after administration of 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL621981,,BAO_0000218
10260,,Bioavailability after administration of 10 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL621982,,BAO_0000218
10261,,Bioavailability after administration of 2 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL882953,,BAO_0000218
10262,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL621983,,BAO_0000218
10263,,Bioavailability in dogs was determined; high,,,50597,,N,1,Intermediate,1,,CHEMBL621984,,BAO_0000218
10264,,Bioavailability in monkey after intravenous administration at 1 mpk,,,50597,,N,1,Intermediate,1,,CHEMBL621985,,BAO_0000218
10265,,Bioavailability in monkey after peroral administration at 10 mpk,,,50597,,N,1,Intermediate,1,,CHEMBL621986,,BAO_0000218
10266,,Bioavailability in rat after intravenous administration at 1 mpk,,,50597,,N,1,Intermediate,1,,CHEMBL621987,,BAO_0000218
10267,,Bioavailability in rat after intravenous administration at 2 mpk,,,50597,,N,1,Intermediate,1,,CHEMBL877600,,BAO_0000218
10268,,Bioavailability in rat after peroral administration at 30 mpk,,,50597,,N,1,Intermediate,1,,CHEMBL621988,,BAO_0000218
10269,,Bioavailability in rat after peroral administration at at 100 mpk,,,50597,,N,1,Intermediate,1,,CHEMBL621989,,BAO_0000218
10270,,Bioavailability in rats was evaluated,,,50597,,N,1,Intermediate,1,,CHEMBL621990,,BAO_0000218
10271,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,,50597,,N,1,Intermediate,1,,CHEMBL621991,,BAO_0000218
10272,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,,50597,,N,1,Intermediate,1,,CHEMBL621992,,BAO_0000218
10273,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,,50597,,N,1,Intermediate,1,,CHEMBL621993,,BAO_0000218
10274,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,,50597,,N,1,Intermediate,1,,CHEMBL621994,,BAO_0000218
10275,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621995,,BAO_0000218
10276,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621996,,BAO_0000218
10277,,Oral bioavailability in rat (dose 10 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL621997,,BAO_0000218
10278,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,,50597,,N,1,Intermediate,1,,CHEMBL621998,,BAO_0000218
10279,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621999,,BAO_0000218
10280,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622000,,BAO_0000218
10281,,Bioavailability was measured in rat after oral administration; 2-4,,,50597,,N,1,Intermediate,1,,CHEMBL622001,,BAO_0000218
10282,,Bioavailability was measured in rat after oral administration; 3-7,,,50597,,N,1,Intermediate,1,,CHEMBL622002,,BAO_0000218
10283,,Bioavailability in rat (intraduodenal administration),,,50597,,N,1,Intermediate,1,,CHEMBL622003,,BAO_0000218
10284,,Bioavailability in rat (intraduodenal administration),,,50597,,N,1,Intermediate,1,,CHEMBL877601,,BAO_0000218
10285,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624871,,BAO_0000218
10286,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622004,,BAO_0000218
10287,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL882954,,BAO_0000218
10288,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,,50597,,N,1,Intermediate,1,,CHEMBL622005,,BAO_0000218
10289,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,,50597,,N,1,Intermediate,1,,CHEMBL622006,,BAO_0000218
10290,,Bioavailability was measured in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622007,,BAO_0000218
10291,,Bioavailability was reported,,,50597,,N,1,Intermediate,1,,CHEMBL622008,,BAO_0000218
10292,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,50597,,N,1,Intermediate,1,,CHEMBL622009,,BAO_0000218
10293,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL622010,,BAO_0000218
10294,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622011,,BAO_0000218
10295,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL622012,,BAO_0000218
10296,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,,50597,,N,1,Intermediate,1,,CHEMBL622013,,BAO_0000218
10297,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL622014,,BAO_0000218
10298,,Bioavailability was determined at 3 mg/kg po dose in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624749,,BAO_0000218
10299,,Oral bioavailability in rat (dose 2 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL624750,,BAO_0000218
10300,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL624751,,BAO_0000218
10301,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,,50597,,N,1,Intermediate,1,,CHEMBL624752,,BAO_0000218
10302,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,,50597,,N,1,Intermediate,1,,CHEMBL624753,,BAO_0000218
10303,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624754,,BAO_0000218
10304,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,,50597,,N,1,Intermediate,1,,CHEMBL624755,,BAO_0000218
10305,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624756,,BAO_0000218
10306,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624757,,BAO_0000218
10307,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,,50597,,N,1,Intermediate,1,,CHEMBL624758,,BAO_0000218
10308,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622270,,BAO_0000218
10309,,Bioavailability in rat (Sprague-Dawley),,,50597,,N,1,Intermediate,1,,CHEMBL622271,,BAO_0000218
10310,,Bioavailability in rat at the dose of 2 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622272,,BAO_0000218
10311,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622273,,BAO_0000218
10312,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL622274,,BAO_0000218
10313,,Bioavailability value of compound in rats was determined after peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL622275,,BAO_0000218
10314,,Oral bioavailability in rat (dose 20 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL622276,,BAO_0000218
10315,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622277,,BAO_0000218
10316,,Oral bioavailability in rat (dose 5 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL622278,,BAO_0000218
10317,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622279,,BAO_0000218
10318,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622280,,BAO_0000218
10319,,Compound was evaluated for oral bioavailability in rats; 15-27 %,,,50597,,N,1,Intermediate,1,,CHEMBL624083,,BAO_0000218
10320,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,,50597,,N,1,Intermediate,1,,CHEMBL624084,,BAO_0000218
10321,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,,50597,,N,1,Intermediate,1,,CHEMBL624085,,BAO_0000218
10322,,Compound was tested for bioavailability in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624086,,BAO_0000218
10323,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624087,,BAO_0000218
10324,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624088,,BAO_0000218
10325,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,,22224,,U,0,Intermediate,1,,CHEMBL624089,,BAO_0000218
10326,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,22224,,U,0,Intermediate,1,,CHEMBL624090,,BAO_0000218
10327,,Evaluated for the bioavailability in rat (in vivo),,,50597,,N,1,Intermediate,1,,CHEMBL624091,,BAO_0000218
10328,,F value of compound in rats was determined after peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL624092,,BAO_0000218
10329,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL624093,,BAO_0000218
10330,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL624094,,BAO_0000218
10331,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL624095,,BAO_0000218
10332,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL624096,,BAO_0000218
10333,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,,50597,,N,1,Intermediate,1,,CHEMBL624097,,BAO_0000218
10334,,Maximum fall in carotid flow in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624098,,BAO_0000218
10335,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL874392,,BAO_0000218
10336,,Oral bioavailability in rat (dose 5 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL624099,,BAO_0000218
10337,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL624100,,BAO_0000218
10338,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL624101,,BAO_0000218
10339,,Oral bioavailability in rat (male Wistar),,,50597,,N,1,Intermediate,1,,CHEMBL624102,,BAO_0000218
10340,,Oral bioavailability after administration (30 mg/kg) in rat; good,,,50597,,N,1,Intermediate,1,,CHEMBL624103,,BAO_0000218
10341,,Oral bioavailability at the dose of 2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624104,,BAO_0000218
10342,,Oral bioavailability determined in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624105,,BAO_0000218
10343,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL624106,,BAO_0000218
10344,,Oral bioavailability in rat (dose single 10 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL624107,,BAO_0000218
10345,,Oral bioavailability in rat (dose single 10 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL623943,,BAO_0000218
10346,,Oral bioavailability in rat (dose 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL623944,,BAO_0000218
10347,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,,50597,,N,1,Intermediate,1,,CHEMBL623945,,BAO_0000218
10348,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,,50597,,N,1,Intermediate,1,,CHEMBL623946,,BAO_0000218
10349,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,,50597,,N,1,Intermediate,1,,CHEMBL623947,,BAO_0000218
10350,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,,50597,,N,1,Intermediate,1,,CHEMBL623948,,BAO_0000218
10351,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,,50597,,N,1,Intermediate,1,,CHEMBL623949,,BAO_0000218
10352,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,,50597,,N,1,Intermediate,1,,CHEMBL623950,,BAO_0000218
10353,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,,50597,,N,1,Intermediate,1,,CHEMBL874398,,BAO_0000218
10354,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,,50597,,N,1,Intermediate,1,,CHEMBL623951,,BAO_0000218
10355,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,,50597,,N,1,Intermediate,1,,CHEMBL623952,,BAO_0000218
10356,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,,50597,,N,1,Intermediate,1,,CHEMBL623953,,BAO_0000218
10357,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL623954,,BAO_0000218
10358,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,,50597,,N,1,Intermediate,1,,CHEMBL623955,,BAO_0000218
10359,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL623956,,BAO_0000218
10360,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,,50597,,N,1,Intermediate,1,,CHEMBL627807,,BAO_0000218
10361,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL627808,,BAO_0000218
10362,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,,50597,,N,1,Intermediate,1,,CHEMBL627809,,BAO_0000218
10363,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,,50597,,N,1,Intermediate,1,,CHEMBL627810,,BAO_0000218
10364,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,,50597,,N,1,Intermediate,1,,CHEMBL627811,,BAO_0000218
10365,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,,50597,,N,1,Intermediate,1,,CHEMBL627812,,BAO_0000218
10366,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,,50597,,N,1,Intermediate,1,,CHEMBL627813,,BAO_0000218
10367,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,,50597,,N,1,Intermediate,1,,CHEMBL627814,,BAO_0000218
10368,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,,50597,,N,1,Intermediate,1,,CHEMBL875336,,BAO_0000218
10369,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,,50597,,N,1,Intermediate,1,,CHEMBL627815,,BAO_0000218
10370,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,,50597,,N,1,Intermediate,1,,CHEMBL627816,,BAO_0000218
10371,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,,50597,,N,1,Intermediate,1,,CHEMBL627817,,BAO_0000218
10372,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,,50597,,N,1,Intermediate,1,,CHEMBL627818,,BAO_0000218
10373,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,,50597,,N,1,Intermediate,1,,CHEMBL627819,,BAO_0000218
10374,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,,50597,,N,1,Intermediate,1,,CHEMBL627820,,BAO_0000218
10375,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,,50597,,N,1,Intermediate,1,,CHEMBL627821,,BAO_0000218
10376,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,,50597,,N,1,Intermediate,1,,CHEMBL628464,,BAO_0000218
10377,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,,50597,,N,1,Intermediate,1,,CHEMBL626239,,BAO_0000218
10378,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,,50597,,N,1,Intermediate,1,,CHEMBL626240,,BAO_0000218
10379,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,,50597,,N,1,Intermediate,1,,CHEMBL626241,,BAO_0000218
10380,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,,50597,,N,1,Intermediate,1,,CHEMBL626242,,BAO_0000218
10381,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,,50597,,N,1,Intermediate,1,,CHEMBL626243,,BAO_0000218
10382,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,,50597,,N,1,Intermediate,1,,CHEMBL626244,,BAO_0000218
10383,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL626907,,BAO_0000218
10384,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL626908,,BAO_0000218
10385,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL626909,,BAO_0000218
10386,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,,50597,,N,1,Intermediate,1,,CHEMBL626910,,BAO_0000218
10387,,Percent total excretion of acetaminophen cysteine conjugate,,,50597,,N,1,Intermediate,1,,CHEMBL875342,,BAO_0000218
10388,,Percent total excretion of acetaminophen glucuronide,,,50597,,N,1,Intermediate,1,,CHEMBL626911,,BAO_0000218
10389,,Percent total excretion of acetaminophen sulfate,,,50597,,N,1,Intermediate,1,,CHEMBL626912,,BAO_0000218
10390,,Percent total excretion of acetaminophen-mercapturic acid,,,50597,,N,1,Intermediate,1,,CHEMBL627065,,BAO_0000218
10391,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627066,,BAO_0000218
10392,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627067,,BAO_0000218
10393,,Biodistribution of compound in rat muscle after 5 min of administration,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL627068,,BAO_0000218
10394,,Biodistribution of compound in rat muscle after 5 min of administration.,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL627069,,BAO_0000218
10395,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,,22224,,U,0,Autocuration,1,,CHEMBL627070,,BAO_0000218
10396,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,,22224,,U,0,Autocuration,1,,CHEMBL627071,,BAO_0000218
10397,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,,22224,,U,0,Autocuration,1,,CHEMBL627072,,BAO_0000218
10398,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,,22224,,U,0,Autocuration,1,,CHEMBL627073,,BAO_0000218
10399,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,,22224,,U,0,Autocuration,1,,CHEMBL625387,,BAO_0000218
10400,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,,22224,,U,0,Autocuration,1,,CHEMBL625388,,BAO_0000218
10401,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1969.0,,22224,,U,0,Autocuration,1,,CHEMBL625389,,BAO_0000218
10402,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1969.0,,22224,,U,0,Autocuration,1,,CHEMBL875343,,BAO_0000218
10403,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,,50497,,N,1,Intermediate,1,,CHEMBL876795,,BAO_0000218
10404,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,,50497,,N,1,Intermediate,1,,CHEMBL626552,,BAO_0000218
10405,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,,50497,,N,1,Intermediate,1,,CHEMBL626553,,BAO_0000218
10406,,The human biological plasma half life of the compound,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626554,,BAO_0000366
10407,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626555,,BAO_0000218
10408,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,,50597,,N,1,Intermediate,1,,CHEMBL626556,,BAO_0000218
10409,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,,50597,,N,1,Intermediate,1,,CHEMBL626557,,BAO_0000218
10410,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,,50597,,N,1,Intermediate,1,,CHEMBL626558,,BAO_0000218
10411,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,,50597,,N,1,Intermediate,1,,CHEMBL626559,,BAO_0000218
10412,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,,50597,,N,1,Intermediate,1,,CHEMBL626560,,BAO_0000218
10413,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,,50597,,N,1,Intermediate,1,,CHEMBL876803,,BAO_0000218
10414,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,,50597,,N,1,Intermediate,1,,CHEMBL627964,,BAO_0000218
10415,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,,50597,,N,1,Intermediate,1,,CHEMBL627965,,BAO_0000218
10416,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,,50597,,N,1,Intermediate,1,,CHEMBL627966,,BAO_0000218
10417,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,,50597,,N,1,Intermediate,1,,CHEMBL627967,,BAO_0000218
10418,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,,50597,,N,1,Intermediate,1,,CHEMBL627968,,BAO_0000218
10419,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,,50597,,N,1,Intermediate,1,,CHEMBL627969,,BAO_0000218
10420,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,,50597,,N,1,Intermediate,1,,CHEMBL627970,,BAO_0000218
10421,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627971,,BAO_0000218
10422,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627972,,BAO_0000218
10423,,Dissociation constant against binding to human cyclophilin A,,,180,,D,9,Expert,1,,CHEMBL856029,,BAO_0000357
10424,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,,11591,,H,8,Expert,1,,CHEMBL627973,,BAO_0000019
10425,,-Log C was determined by performing the electroshock minimum test,,,22224,,U,0,Autocuration,1,,CHEMBL627974,,BAO_0000019
10426,,-Log C was determined by performing the foot shock test,,,22224,,U,0,Autocuration,1,,CHEMBL627975,,BAO_0000019
10427,,-Log C was determined by performing the incl screen test,,,22224,,U,0,Autocuration,1,,CHEMBL627976,,BAO_0000019
10428,,-Log C was determined by performing the maximum electroshock test,,,22224,,U,0,Autocuration,1,,CHEMBL627977,,BAO_0000019
10429,,-Log C was determined by performing the pentylenetetrazole test,,,22224,,U,0,Autocuration,1,,CHEMBL627978,,BAO_0000019
10430,,Tested for experimental arotinoid inhibitory dose,,,22224,,U,0,Autocuration,1,,CHEMBL627979,,BAO_0000019
10431,,Negative log transformed activity,,,22224,,U,0,Autocuration,1,,CHEMBL876804,,BAO_0000019
10432,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,,22224,,U,0,Autocuration,1,,CHEMBL627980,,BAO_0000019
10433,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,,50512,,N,1,Intermediate,1,,CHEMBL627981,,BAO_0000218
10434,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,,50512,,N,1,Intermediate,1,,CHEMBL627982,,BAO_0000218
10435,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,,50512,,N,1,Intermediate,1,,CHEMBL627983,,BAO_0000218
10436,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,2116.0,,50512,,N,1,Intermediate,1,,CHEMBL627984,,BAO_0000218
10437,,Solubility in water was determined; values expressed as -log,,,22229,,U,0,Autocuration,1,,CHEMBL627985,,BAO_0000100
10438,,Ratio of Kcat to that of Km was determined,,,22224,,U,0,Autocuration,1,,CHEMBL627986,,BAO_0000019
10439,,Observed first order rate constant,,,22224,,U,0,Autocuration,1,,CHEMBL627987,,BAO_0000019
10440,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,,22224,,U,0,Autocuration,1,,CHEMBL627988,,BAO_0000019
10441,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL627989,,BAO_0000218
10442,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL627990,,BAO_0000218
10443,,Oral Bioavailability after administration of 10 mg/kg in male rat,,,50597,,N,1,Intermediate,1,,CHEMBL876805,,BAO_0000218
10444,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL627991,,BAO_0000218
10445,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627992,,BAO_0000218
10446,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,,50597,,N,1,Intermediate,1,,CHEMBL627993,,BAO_0000218
10447,,Oral bioavailability at 1 mg/kg was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622817,,BAO_0000218
10448,,Oral bioavailability at 10 mg/kg was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622818,,BAO_0000218
10449,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,,50597,,N,1,Intermediate,1,,CHEMBL622819,,BAO_0000218
10450,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL872267,,BAO_0000218
10451,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622820,,BAO_0000218
10452,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622821,,BAO_0000218
10453,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622822,,BAO_0000218
10454,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622823,,BAO_0000218
10455,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622824,,BAO_0000218
10456,,Oral bioavailability in rat at a dose of 3 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622825,,BAO_0000218
10457,,Oral bioavailability in rat after oral administration at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622901,,BAO_0000218
10458,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622902,,BAO_0000218
10459,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL621844,,BAO_0000218
10460,,Oral bioavailability in Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL621845,,BAO_0000218
10461,,Oral bioavailability,,,50597,,N,1,Intermediate,1,,CHEMBL621846,,BAO_0000218
10462,,Oral bioavailability in rat (dose 30 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL621847,,BAO_0000218
10463,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,,50597,,N,1,Intermediate,1,,CHEMBL877609,,BAO_0000218
10464,,Bioavailability in rat (dose 3 mg/kg i.v.),,,50597,,N,1,Intermediate,1,,CHEMBL621848,,BAO_0000218
10465,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,,50597,,N,1,Intermediate,1,,CHEMBL621849,,BAO_0000218
10466,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL622030,,BAO_0000218
10467,,Percent oral bioavailability determined in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622031,,BAO_0000218
10468,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622032,,BAO_0000218
10469,,The compound was evaluated for bioavailability in rats; 32-51,,,50597,,N,1,Intermediate,1,,CHEMBL622033,,BAO_0000218
10470,,Bioavailability in rat (dose 20 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL622034,,BAO_0000218
10471,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622035,,BAO_0000218
10472,,Bioavailability percent in rat at the dose of 2 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL882966,,BAO_0000218
10473,,Bioavailability was evaluated after 20 uM/kg of peroral administration,,,50597,,N,1,Intermediate,1,,CHEMBL622036,,BAO_0000218
10474,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622037,,BAO_0000218
10475,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622038,,BAO_0000218
10476,,Bioavailability in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622039,,BAO_0000218
10477,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,178.0,,50597,,N,1,Intermediate,1,,CHEMBL622040,,BAO_0000218
10478,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,178.0,,50597,,N,1,Intermediate,1,,CHEMBL622041,,BAO_0000218
10479,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,178.0,,50597,,N,1,Intermediate,1,,CHEMBL622042,,BAO_0000218
10480,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,178.0,,50597,,N,1,Intermediate,1,,CHEMBL622043,,BAO_0000218
10481,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,178.0,,50597,,N,1,Intermediate,1,,CHEMBL622044,,BAO_0000218
10482,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL622045,,BAO_0000218
10483,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL622046,,BAO_0000218
10484,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL622047,,BAO_0000218
10485,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL877610,,BAO_0000218
10486,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622048,,BAO_0000218
10487,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622049,,BAO_0000218
10488,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622050,,BAO_0000218
10489,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622051,,BAO_0000218
10490,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,,50597,,N,1,Intermediate,1,,CHEMBL622052,,BAO_0000218
10491,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,,50597,,N,1,Intermediate,1,,CHEMBL622053,,BAO_0000218
10492,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,,50597,,N,1,Intermediate,1,,CHEMBL622054,,BAO_0000218
10493,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,,50597,,N,1,Intermediate,1,,CHEMBL622055,,BAO_0000218
10494,,Oral bioavailability in rats was determined; High,,,50597,,N,1,Intermediate,1,,CHEMBL622056,,BAO_0000218
10495,,Oral bioavailability in the rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL622057,,BAO_0000218
10496,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,,50597,,N,1,Intermediate,1,,CHEMBL628008,,BAO_0000218
10497,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,,50597,,N,1,Intermediate,1,,CHEMBL622058,,BAO_0000218
10498,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL622059,,BAO_0000218
10499,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL622060,,BAO_0000218
10500,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL622061,,BAO_0000218
10501,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,,N,1,Intermediate,1,,CHEMBL622062,,BAO_0000218
10502,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622063,,BAO_0000218
10503,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,,N,1,Expert,1,,CHEMBL877611,,BAO_0000218
10504,,Oral bioavailability of compound in Sprague Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL622064,,BAO_0000218
10505,,Oral bioavailability of compound in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622065,,BAO_0000218
10506,,Oral bioavailability in rat (dose 2 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL622066,,BAO_0000218
10507,,Oral bioavailability of compound in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL622067,,BAO_0000218
10508,,Oral bioavailability of compound in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622068,,BAO_0000218
10509,,Oral bioavailability of compound was determined in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622069,,BAO_0000218
10510,,Oral bioavailability at a dose of 30 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624796,,BAO_0000218
10511,,Oral bioavailability in rat (dose 10 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL624797,,BAO_0000218
10512,,Oral bioavailability in rat (dose 10 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL623053,,BAO_0000218
10513,,Oral bioavailability evaluated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623054,,BAO_0000218
10514,,Oral bioavailability in fasted rat,,,50597,,N,1,Intermediate,1,,CHEMBL623055,,BAO_0000218
10515,,Oral bioavailability in fed rat,,,50597,,N,1,Intermediate,1,,CHEMBL623056,,BAO_0000218
10516,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL623057,,BAO_0000218
10517,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623058,,BAO_0000218
10518,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL623059,,BAO_0000218
10519,,Oral bioavailability in rat after administration of 10 mg/kg po,,,50597,,N,1,Intermediate,1,,CHEMBL623060,,BAO_0000218
10520,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623061,,BAO_0000218
10521,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623062,,BAO_0000218
10522,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623063,,BAO_0000218
10523,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623064,,BAO_0000218
10524,,Oral bioavailability in ratrs,,,50597,,N,1,Intermediate,1,,CHEMBL623065,,BAO_0000218
10525,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623066,,BAO_0000218
10526,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623067,,BAO_0000218
10527,,Oral bioavailability in rats was determined; High,,,50597,,N,1,Intermediate,1,,CHEMBL623068,,BAO_0000218
10528,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623069,,BAO_0000218
10529,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623070,,BAO_0000218
10530,,Oral bioavailability was calculated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623071,,BAO_0000218
10531,,Oral bioavailability,,,50597,,N,1,Intermediate,1,,CHEMBL623072,,BAO_0000218
10532,,Oral bioavailability,,,50597,,N,1,Intermediate,1,,CHEMBL623073,,BAO_0000218
10533,,Oral bioavailability,,,50597,,N,1,Intermediate,1,,CHEMBL623074,,BAO_0000218
10534,,Oral bioavailability,,,50597,,N,1,Intermediate,1,,CHEMBL623075,,BAO_0000218
10535,,Oral bioavailability after i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL623076,,BAO_0000218
10536,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,50597,,N,1,Intermediate,1,,CHEMBL623077,,BAO_0000218
10537,,Oral bioavailability in rat (Sprague-Dawley),,,50597,,N,1,Intermediate,1,,CHEMBL623078,,BAO_0000218
10538,,Oral bioavailability in Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL623079,,BAO_0000218
10539,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,50597,,N,1,Intermediate,1,,CHEMBL623080,,BAO_0000218
10540,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL623081,,BAO_0000218
10541,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,,50597,,N,1,Intermediate,1,,CHEMBL623082,,BAO_0000218
10542,,Oral bioavailability in fasted rat,,,50597,,N,1,Intermediate,1,,CHEMBL874400,,BAO_0000218
10543,,Oral bioavailability in fed rat,,,50597,,N,1,Intermediate,1,,CHEMBL623083,,BAO_0000218
10544,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623084,,BAO_0000218
10545,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623085,,BAO_0000218
10546,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623086,,BAO_0000218
10547,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623087,,BAO_0000218
10548,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623088,,BAO_0000218
10549,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623089,,BAO_0000218
10550,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623090,,BAO_0000218
10551,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623091,,BAO_0000218
10552,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623092,,BAO_0000218
10553,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623093,,BAO_0000218
10554,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL874401,,BAO_0000218
10555,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623094,,BAO_0000218
10556,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623095,,BAO_0000218
10557,,Oral bioavailability in rat after peroral administration at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL623096,,BAO_0000218
10558,,Oral bioavailability in rat after peroral administration at 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624913,,BAO_0000218
10559,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL624914,,BAO_0000218
10560,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624915,,BAO_0000218
10561,,Oral bioavailability in rat; Not measured,,,50597,,N,1,Intermediate,1,,CHEMBL624916,,BAO_0000218
10562,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624917,,BAO_0000218
10563,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,,50597,,N,1,Intermediate,1,,CHEMBL625157,,BAO_0000218
10564,,In vitro metabolic potential in rat liver microsomes,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625158,,BAO_0000218
10565,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,,50597,,N,1,Intermediate,1,,CHEMBL625159,,BAO_0000218
10566,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,,50597,,N,1,Intermediate,1,,CHEMBL625160,,BAO_0000218
10567,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625161,,BAO_0000218
10568,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625162,,BAO_0000218
10569,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625163,,BAO_0000218
10570,,Oral bioavailability in rats at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625164,,BAO_0000218
10571,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50597,,N,1,Intermediate,1,,CHEMBL625165,,BAO_0000218
10572,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625166,,BAO_0000218
10573,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,,50597,,N,1,Intermediate,1,,CHEMBL625167,,BAO_0000218
10574,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,,50597,,N,1,Intermediate,1,,CHEMBL625168,,BAO_0000218
10575,,Plasma clearance of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL625169,,BAO_0000218
10576,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,,50597,,N,1,Intermediate,1,,CHEMBL626264,,BAO_0000218
10577,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626265,,BAO_0000218
10578,,The compound was tested for plasma clearance in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626266,,BAO_0000218
10579,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626267,,BAO_0000218
10580,,Plasma concentration upon oral administration of 1 mg/Kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626268,,BAO_0000218
10581,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,,50597,,N,1,Intermediate,1,,CHEMBL626269,,BAO_0000218
10582,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,,50597,,N,1,Intermediate,1,,CHEMBL626270,,BAO_0000218
10583,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626271,,BAO_0000218
10584,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,,50597,,N,1,Intermediate,1,,CHEMBL626272,,BAO_0000218
10585,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,,50597,,N,1,Intermediate,1,,CHEMBL626273,,BAO_0000218
10586,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,,50597,,N,1,Intermediate,1,,CHEMBL875346,,BAO_0000218
10587,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,,50597,,N,1,Intermediate,1,,CHEMBL626274,,BAO_0000218
10588,,Compound was tested for protein binding in rat plasma,,,50597,,N,1,Intermediate,1,,CHEMBL626275,,BAO_0000218
10589,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,,50597,,N,1,Intermediate,1,,CHEMBL624646,,BAO_0000218
10590,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,,50597,,N,1,Intermediate,1,,CHEMBL624647,,BAO_0000218
10591,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624648,,BAO_0000218
10592,,Area under curve ratio was determined (po/iv) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624649,,BAO_0000218
10593,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL624650,,BAO_0000218
10594,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL624651,,BAO_0000218
10595,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,,50597,,N,1,Intermediate,1,,CHEMBL624652,,BAO_0000218
10596,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624653,,BAO_0000218
10597,,Ratio of AUCbrain to AUCplasma,,,50597,,N,1,Intermediate,1,,CHEMBL624654,,BAO_0000218
10598,,Ratio of brain to plasma,,,50597,,N,1,Intermediate,1,,CHEMBL624655,,BAO_0000218
10599,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,,50597,,N,1,Intermediate,1,,CHEMBL624656,,BAO_0000218
10600,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,,50597,,N,1,Intermediate,1,,CHEMBL624657,,BAO_0000218
10601,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,,50597,,N,1,Intermediate,1,,CHEMBL624658,,BAO_0000218
10602,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,,50597,,N,1,Intermediate,1,,CHEMBL624659,,BAO_0000218
10603,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,,50597,,N,1,Intermediate,1,,CHEMBL624660,,BAO_0000218
10604,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,,50597,,N,1,Intermediate,1,,CHEMBL624661,,BAO_0000218
10605,,Steady state brain :blood ratio was determined,,,50597,,N,1,Intermediate,1,,CHEMBL624662,,BAO_0000218
10606,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,,N,1,Intermediate,1,,CHEMBL625199,,BAO_0000218
10607,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,,50597,,N,1,Intermediate,1,,CHEMBL625200,,BAO_0000218
10608,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,,N,1,Intermediate,1,,CHEMBL625201,,BAO_0000218
10609,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,,50597,,N,1,Intermediate,1,,CHEMBL625202,,BAO_0000218
10610,,Percentage recovery after 3h incubation with rat hapatocytes was determined,,,50597,,N,1,Intermediate,1,,CHEMBL625203,,BAO_0000218
10611,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,,50597,,N,1,Intermediate,1,,CHEMBL625204,,BAO_0000218
10612,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,,50597,,N,1,Intermediate,1,,CHEMBL625205,,BAO_0000218
10613,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625206,,BAO_0000218
10614,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,,22224,,U,0,Autocuration,1,,CHEMBL625207,,BAO_0000019
10615,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,,22224,,U,0,Autocuration,1,,CHEMBL625208,,BAO_0000019
10616,,In vivo absorption in Caco-2 cell line monolayers was determined,,,50587,Caco-2,N,1,Intermediate,1,,CHEMBL625209,495.0,BAO_0000218
10617,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625210,,BAO_0000100
10618,,Area under curve was determine after peroral administration at 10 mpk in Rat,,,50597,,N,1,Intermediate,1,,CHEMBL625211,,BAO_0000218
10619,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,50797,,N,1,Intermediate,1,,CHEMBL625212,,BAO_0000218
10620,,Area under curve was determine after peroral administration at 160 mpk in Rat,,,50597,,N,1,Intermediate,1,,CHEMBL625213,,BAO_0000218
10621,,Area under curve was determine after peroral administration at 20 mpk in Rat,,,50597,,N,1,Intermediate,1,,CHEMBL625214,,BAO_0000218
10622,,Area under curve was determine after peroral administration at 50 mpk in Rat,,,50597,,N,1,Intermediate,1,,CHEMBL874542,,BAO_0000218
10623,,Calculated partition coefficient (clogP) (AlogP),,,22229,,U,0,Autocuration,1,,CHEMBL625215,,BAO_0000100
10624,,Activated partial thromboplastin time measured,,,22224,,U,0,Autocuration,1,,CHEMBL625216,,BAO_0000019
10625,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,,22224,,U,0,Autocuration,1,,CHEMBL625217,,BAO_0000100
10626,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,,22224,,U,0,Autocuration,1,,CHEMBL625218,,BAO_0000100
10627,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL622864,,BAO_0000218
10628,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622865,,BAO_0000218
10629,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622866,,BAO_0000218
10630,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL622867,,BAO_0000218
10631,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,1969.0,,50512,,N,1,Intermediate,1,,CHEMBL876808,,BAO_0000218
10632,,AUC in brain,955.0,,22224,,U,0,Autocuration,1,,CHEMBL627725,,BAO_0000019
10633,,AUC in serum,1977.0,,22224,,U,0,Autocuration,1,,CHEMBL627726,,BAO_0000019
10634,,AUC was determined,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL627727,,BAO_0000019
10635,,AUC of the compound.,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL627728,,BAO_0000019
10636,,AUC value (0-4 hr),1969.0,,22224,,U,0,Autocuration,1,,CHEMBL627729,,BAO_0000019
10637,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",1969.0,,22224,,U,0,Autocuration,1,,CHEMBL627730,,BAO_0000019
10638,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL627731,,BAO_0000019
10639,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",1969.0,,22224,,U,0,Autocuration,1,,CHEMBL627732,,BAO_0000019
10640,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",1969.0,,22224,,U,0,Autocuration,1,,CHEMBL627733,,BAO_0000019
10641,,AUC(area under curve) was determined after intravenous administration in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627734,,BAO_0000218
10642,,AUC(area under curve) was determined after oral administration in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627735,,BAO_0000218
10643,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,1969.0,,50512,,N,1,Intermediate,1,,CHEMBL627736,,BAO_0000218
10644,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL876809,,BAO_0000218
10645,,Area Under Curve after oral dosing of 100 uM/Kg,,,22224,,U,0,Autocuration,1,,CHEMBL627737,,BAO_0000019
10646,,Area Under Curve after oral dosing of 30 uM/Kg,,,22224,,U,0,Autocuration,1,,CHEMBL627738,,BAO_0000019
10647,,Area Under Curve was measured by ploting the graph between concentration verses time,,,22224,,U,0,Autocuration,1,,CHEMBL627739,,BAO_0000019
10648,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,,50588,,N,1,Intermediate,1,,CHEMBL626143,,BAO_0000218
10649,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,,22224,,U,0,Autocuration,1,,CHEMBL626144,,BAO_0000218
10650,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,,50592,,N,1,Intermediate,1,,CHEMBL626145,,BAO_0000218
10651,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,,50597,,N,1,Intermediate,1,,CHEMBL626146,,BAO_0000218
10652,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,178.0,,50597,,N,1,Intermediate,1,,CHEMBL626147,,BAO_0000218
10653,,Area under curve (AUC) was determined,,,22224,,U,0,Autocuration,1,,CHEMBL626148,,BAO_0000019
10654,,Area under curve (AUC) following ip administration at 1 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626149,,BAO_0000218
10655,,Area under curve (AUC) was determined; ND is Not determined,,,22224,,U,0,Autocuration,1,,CHEMBL626150,,BAO_0000019
10656,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,,50588,,N,1,Intermediate,1,,CHEMBL626151,,BAO_0000218
10657,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,,50588,,N,1,Intermediate,1,,CHEMBL626152,,BAO_0000218
10658,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,,50588,,N,1,Intermediate,1,,CHEMBL626153,,BAO_0000218
10659,,Area under curve (AUR) was determined,,,22224,,U,0,Autocuration,1,,CHEMBL626154,,BAO_0000019
10660,,Area under curve at 1 uM/dg administered intravenously,,,22224,,U,0,Autocuration,1,,CHEMBL626155,,BAO_0000019
10661,,Area under curve at 10 uM/dg administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626156,,BAO_0000019
10662,,Area under curve at 2 uM/dg administered intravenously,,,22224,,U,0,Autocuration,1,,CHEMBL626157,,BAO_0000019
10663,,Area under curve at 20 uM/dg administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626158,,BAO_0000019
10664,,Area under curve at a peroral dose of 3 mg/kg in dog,,,50588,,N,1,Intermediate,1,,CHEMBL626159,,BAO_0000218
10665,,Area under curve at a peroral dose of 3 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626160,,BAO_0000218
10666,,Area under curve at an iv dose of 1 mg/kg in dog,,,50588,,N,1,Intermediate,1,,CHEMBL626161,,BAO_0000218
10667,,Area under curve at an iv dose of 1 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626162,,BAO_0000218
10668,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,,22224,,U,0,Autocuration,1,,CHEMBL626163,,BAO_0000019
10669,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,,22224,,U,0,Autocuration,1,,CHEMBL626164,,BAO_0000019
10670,,Area under curve measured as conc vs time after intravenous administration to mice.,,,50594,,N,1,Intermediate,1,,CHEMBL626165,,BAO_0000218
10671,,Area under curve measured as conc vs time after peroral administration to mice.,,,50594,,N,1,Intermediate,1,,CHEMBL626166,,BAO_0000218
10672,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,,50588,,N,1,Intermediate,1,,CHEMBL626167,,BAO_0000218
10673,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,,50588,,N,1,Intermediate,1,,CHEMBL626168,,BAO_0000218
10674,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,,50588,,N,1,Intermediate,1,,CHEMBL877463,,BAO_0000218
10675,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,,50588,,N,1,Intermediate,1,,CHEMBL626169,,BAO_0000218
10676,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,948.0,,50597,,N,1,Intermediate,1,,CHEMBL626170,,BAO_0000218
10677,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,948.0,,50597,,N,1,Intermediate,1,,CHEMBL626171,,BAO_0000218
10678,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,948.0,,50597,,N,1,Intermediate,1,,CHEMBL626172,,BAO_0000218
10679,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,948.0,,50597,,N,1,Intermediate,1,,CHEMBL626173,,BAO_0000218
10680,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626174,,BAO_0000218
10681,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626175,,BAO_0000218
10682,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626176,,BAO_0000218
10683,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626177,,BAO_0000218
10684,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622499,,BAO_0000218
10685,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622500,,BAO_0000218
10686,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622501,,BAO_0000218
10687,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622502,,BAO_0000218
10688,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622503,,BAO_0000218
10689,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL877614,,BAO_0000218
10690,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624839,,BAO_0000218
10691,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624840,,BAO_0000218
10692,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624841,,BAO_0000218
10693,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624842,,BAO_0000218
10694,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624843,,BAO_0000218
10695,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624844,,BAO_0000218
10696,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624845,,BAO_0000218
10697,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL621904,,BAO_0000218
10698,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621905,,BAO_0000218
10699,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL874382,,BAO_0000218
10700,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL621906,,BAO_0000218
10701,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,955.0,,50597,,N,1,Intermediate,1,,CHEMBL621907,,BAO_0000218
10702,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622096,,BAO_0000218
10703,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622097,,BAO_0000218
10704,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,948.0,,50597,,N,1,Intermediate,1,,CHEMBL622098,,BAO_0000218
10705,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,948.0,,50597,,N,1,Intermediate,1,,CHEMBL622099,,BAO_0000218
10706,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,948.0,,50597,,N,1,Intermediate,1,,CHEMBL622100,,BAO_0000218
10707,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622101,,BAO_0000218
10708,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622102,,BAO_0000218
10709,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622103,,BAO_0000218
10710,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622104,,BAO_0000218
10711,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622105,,BAO_0000218
10712,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622106,,BAO_0000218
10713,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622107,,BAO_0000218
10714,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622108,,BAO_0000218
10715,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622109,,BAO_0000218
10716,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL622110,,BAO_0000218
10717,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL622111,,BAO_0000218
10718,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL874383,,BAO_0000218
10719,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,14.0,,50597,,N,1,Intermediate,1,,CHEMBL622112,,BAO_0000218
10720,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,14.0,,50597,,N,1,Intermediate,1,,CHEMBL622113,,BAO_0000218
10721,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,14.0,,50597,,N,1,Intermediate,1,,CHEMBL622114,,BAO_0000218
10722,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622115,,BAO_0000218
10723,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622116,,BAO_0000218
10724,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622117,,BAO_0000218
10725,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622118,,BAO_0000218
10726,,Oral bioavailability in rats at 6 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622119,,BAO_0000218
10727,,Oral bioavailability in rat (dose 6 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL622120,,BAO_0000218
10728,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL622121,,BAO_0000218
10729,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622122,,BAO_0000218
10730,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622123,,BAO_0000218
10731,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622124,,BAO_0000218
10732,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622125,,BAO_0000218
10733,,Oral bioavailability,,,50597,,N,1,Intermediate,1,,CHEMBL622126,,BAO_0000218
10734,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL620455,,BAO_0000218
10735,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620456,,BAO_0000218
10736,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620457,,BAO_0000218
10737,,Oral bioavailability was evaluated; Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL620458,,BAO_0000218
10738,,Oral bioavailability,,,50597,,N,1,Intermediate,1,,CHEMBL620459,,BAO_0000218
10739,,Oral bioavailability in rat by oral dosing,,,50597,,N,1,Intermediate,1,,CHEMBL620460,,BAO_0000218
10740,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL620461,,BAO_0000218
10741,,Oral bioavailability in rat (Sprague-Dawley),,,50597,,N,1,Intermediate,1,,CHEMBL620462,,BAO_0000218
10742,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,50597,,N,1,Intermediate,1,,CHEMBL620463,,BAO_0000218
10743,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,50597,,N,1,Intermediate,1,,CHEMBL620464,,BAO_0000218
10744,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL620465,,BAO_0000218
10745,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL620466,,BAO_0000218
10746,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620467,,BAO_0000218
10747,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL620468,,BAO_0000218
10748,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,,50597,,N,1,Intermediate,1,,CHEMBL620469,,BAO_0000218
10749,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,,50597,,N,1,Intermediate,1,,CHEMBL620470,,BAO_0000218
10750,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620471,,BAO_0000218
10751,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620472,,BAO_0000218
10752,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620473,,BAO_0000218
10753,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620474,,BAO_0000218
10754,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL620475,,BAO_0000218
10755,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620476,,BAO_0000218
10756,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL620477,,BAO_0000218
10757,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL620478,,BAO_0000218
10758,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL618768,,BAO_0000218
10759,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL618769,,BAO_0000218
10760,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL618770,,BAO_0000218
10761,,Oral bioavailability (dose 20 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL618771,,BAO_0000218
10762,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL618772,,BAO_0000218
10763,,Oral bioavailability in rat at 10 mg/kg of the compound,,,50597,,N,1,Intermediate,1,,CHEMBL618773,,BAO_0000218
10764,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,,50597,,N,1,Intermediate,1,,CHEMBL875842,,BAO_0000218
10765,,Bioavailability in rat (dose 3 mg/kg i.v.),,,50597,,N,1,Intermediate,1,,CHEMBL618774,,BAO_0000218
10766,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,,50597,,N,1,Intermediate,1,,CHEMBL618775,,BAO_0000218
10767,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL618776,,BAO_0000218
10768,,Percent bioavailability (F) in rats after iv administration,,,50597,,N,1,Intermediate,1,,CHEMBL618777,,BAO_0000218
10769,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL618778,,BAO_0000218
10770,,Bioavailability in rat (dose 5 uM/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL618779,,BAO_0000218
10771,,Oral bioavailability,,,50597,,N,1,Intermediate,1,,CHEMBL618780,,BAO_0000218
10772,,Bioavailability in rat (dose 2 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL618781,,BAO_0000218
10773,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,,50597,,N,1,Intermediate,1,,CHEMBL618782,,BAO_0000218
10774,,Oral bioavailability in rat (dose 20 mg/kg),,,50597,,N,1,Intermediate,1,,CHEMBL618783,,BAO_0000218
10775,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618784,,BAO_0000218
10776,,Percent oral bioavailability evaluated in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618785,,BAO_0000218
10777,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618786,,BAO_0000218
10778,,Percent oral bioavailability in rat; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL618787,,BAO_0000218
10779,,Oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618788,,BAO_0000218
10780,,Bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL618789,,BAO_0000218
10781,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,,50597,,N,1,Intermediate,1,,CHEMBL618790,,BAO_0000218
10782,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,,50597,,N,1,Intermediate,1,,CHEMBL618791,,BAO_0000218
10783,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL875843,,BAO_0000218
10784,,Oral bioavailability in rat (dose 20 mg/kg p.o.),,,50597,,N,1,Intermediate,1,,CHEMBL618792,,BAO_0000218
10785,,Cmax at a dose of 30 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623395,,BAO_0000218
10786,,Cmax in monkeys at a dose of 1 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL623396,,BAO_0000218
10787,,Cmax in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623397,,BAO_0000218
10788,,Cmax in rats at a dose of 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL623398,,BAO_0000218
10789,,Cmax was measured in mice after an oral dose of 50 mg/kg.,,,50594,,N,1,Intermediate,1,,CHEMBL623399,,BAO_0000218
10790,,"Cmax value at a dose of 12.7 uM/kg, po",,,22224,,U,0,Autocuration,1,,CHEMBL623400,,BAO_0000218
10791,,"Cmax value at a dose of 6.3 uM/kg, iv",,,22224,,U,0,Autocuration,1,,CHEMBL623401,,BAO_0000218
10792,,"Cmax value at a dose of 7.1 uM/kg, iv",,,22224,,U,0,Autocuration,1,,CHEMBL623402,,BAO_0000218
10793,,Cmax value of compound was determined after 1 hr,,,22224,,U,0,Autocuration,1,,CHEMBL623403,,BAO_0000218
10794,,Cmax value of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL623404,,BAO_0000218
10795,,Cmax value administered intraintestinal in rats.,,,50597,,N,1,Intermediate,1,,CHEMBL625997,,BAO_0000218
10796,,Cmax value administered perorally was determined in rat; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL625998,,BAO_0000218
10797,,Cmax value at the dose of 2.3 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL625999,,BAO_0000218
10798,,Cmax value at the dose of 5 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626000,,BAO_0000218
10799,,Cmax value in the period of 8 hr after dosing. ,,,22224,,U,0,Autocuration,1,,CHEMBL626001,,BAO_0000218
10800,,Cmax value at a oral dose of 20 mg/kg; Not tested,,,22224,,U,0,Autocuration,1,,CHEMBL626002,,BAO_0000218
10801,,Cmax value at a oral dose of 20 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626003,,BAO_0000218
10802,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,,50597,,N,1,Intermediate,1,,CHEMBL626004,,BAO_0000218
10803,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,,50512,,N,1,Intermediate,1,,CHEMBL626005,,BAO_0000218
10804,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,,50597,,N,1,Intermediate,1,,CHEMBL626006,,BAO_0000218
10805,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626007,,BAO_0000218
10806,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL626008,,BAO_0000218
10807,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,2107.0,,50588,,N,1,Intermediate,1,,CHEMBL626009,,BAO_0000218
10808,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,,50588,,N,1,Intermediate,1,,CHEMBL626010,,BAO_0000218
10809,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,178.0,,50594,,N,1,Intermediate,1,,CHEMBL626011,,BAO_0000218
10810,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,178.0,,50594,,N,1,Intermediate,1,,CHEMBL626012,,BAO_0000218
10811,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,178.0,,50594,,N,1,Intermediate,1,,CHEMBL626013,,BAO_0000218
10812,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,178.0,,50594,,N,1,Intermediate,1,,CHEMBL626014,,BAO_0000218
10813,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,178.0,,50594,,N,1,Intermediate,1,,CHEMBL877496,,BAO_0000218
10814,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,,50588,,N,1,Intermediate,1,,CHEMBL626015,,BAO_0000218
10815,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,,50588,,N,1,Intermediate,1,,CHEMBL626016,,BAO_0000218
10816,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,,50588,,N,1,Intermediate,1,,CHEMBL626017,,BAO_0000218
10817,,Bioavailability as maximal plasma concentration in dogs,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626018,,BAO_0000218
10818,,Bioavailability as maximal plasma concentration in dogs,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626692,,BAO_0000218
10819,,Bioavailability as maximal plasma concentration in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626693,,BAO_0000218
10820,,Bioavailability as maximal plasma concentration in rats,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626694,,BAO_0000218
10821,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,,50588,,N,1,Intermediate,1,,CHEMBL626695,,BAO_0000218
10822,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,,50588,,N,1,Intermediate,1,,CHEMBL626696,,BAO_0000218
10823,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,,50588,,N,1,Intermediate,1,,CHEMBL626697,,BAO_0000218
10824,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,178.0,,50588,,N,1,Intermediate,1,,CHEMBL626859,,BAO_0000218
10825,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,,50588,,N,1,Intermediate,1,,CHEMBL626860,,BAO_0000218
10826,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,,50588,,N,1,Intermediate,1,,CHEMBL626861,,BAO_0000218
10827,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,,50597,,N,1,Intermediate,1,,CHEMBL626296,,BAO_0000218
10828,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626297,,BAO_0000218
10829,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626298,,BAO_0000218
10830,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626299,,BAO_0000218
10831,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626300,,BAO_0000218
10832,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626301,,BAO_0000218
10833,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626962,,BAO_0000218
10834,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626963,,BAO_0000218
10835,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626964,,BAO_0000218
10836,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,1969.0,,100710,,N,1,Intermediate,1,,CHEMBL626965,,BAO_0000218
10837,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL626966,,BAO_0000218
10838,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL626967,,BAO_0000218
10839,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,1969.0,,100710,,N,1,Intermediate,1,,CHEMBL626968,,BAO_0000218
10840,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,948.0,,50597,,N,1,Intermediate,1,,CHEMBL626969,,BAO_0000218
10841,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,948.0,,50597,,N,1,Intermediate,1,,CHEMBL627126,,BAO_0000218
10842,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,948.0,,50597,,N,1,Intermediate,1,,CHEMBL631276,,BAO_0000218
10843,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,948.0,,50597,,N,1,Intermediate,1,,CHEMBL631277,,BAO_0000218
10844,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,948.0,,50597,,N,1,Intermediate,1,,CHEMBL631278,,BAO_0000218
10845,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,948.0,,50597,,N,1,Intermediate,1,,CHEMBL874457,,BAO_0000218
10846,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,948.0,,50597,,N,1,Intermediate,1,,CHEMBL631279,,BAO_0000218
10847,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,948.0,,50597,,N,1,Intermediate,1,,CHEMBL631280,,BAO_0000218
10848,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,948.0,,50597,,N,1,Intermediate,1,,CHEMBL631281,,BAO_0000218
10849,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,948.0,,50597,,N,1,Intermediate,1,,CHEMBL631968,,BAO_0000218
10850,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,948.0,,50597,,N,1,Intermediate,1,,CHEMBL631969,,BAO_0000218
10851,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,948.0,,50597,,N,1,Intermediate,1,,CHEMBL631970,,BAO_0000218
10852,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,948.0,,50597,,N,1,Intermediate,1,,CHEMBL631971,,BAO_0000218
10853,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,948.0,,50597,,N,1,Intermediate,1,,CHEMBL631972,,BAO_0000218
10854,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,948.0,,50597,,N,1,Intermediate,1,,CHEMBL630435,,BAO_0000218
10855,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,948.0,,50597,,N,1,Intermediate,1,,CHEMBL630436,,BAO_0000218
10856,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,948.0,,50597,,N,1,Intermediate,1,,CHEMBL630437,,BAO_0000218
10857,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,948.0,,50597,,N,1,Intermediate,1,,CHEMBL630438,,BAO_0000218
10858,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,948.0,,50597,,N,1,Intermediate,1,,CHEMBL630439,,BAO_0000218
10859,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL630440,,BAO_0000218
10860,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL630441,,BAO_0000218
10861,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL630442,,BAO_0000218
10862,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625234,,BAO_0000218
10863,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625235,,BAO_0000218
10864,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625236,,BAO_0000218
10865,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625237,,BAO_0000218
10866,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626125,,BAO_0000218
10867,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626126,,BAO_0000218
10868,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626127,,BAO_0000218
10869,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626128,,BAO_0000218
10870,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626129,,BAO_0000218
10871,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626130,,BAO_0000218
10872,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626131,,BAO_0000218
10873,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626132,,BAO_0000218
10874,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626752,,BAO_0000218
10875,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626753,,BAO_0000218
10876,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626754,,BAO_0000218
10877,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626755,,BAO_0000218
10878,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626756,,BAO_0000218
10879,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626757,,BAO_0000218
10880,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626758,,BAO_0000218
10881,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626759,,BAO_0000218
10882,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626760,,BAO_0000218
10883,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL626394,,BAO_0000218
10884,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL626395,,BAO_0000218
10885,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL626396,,BAO_0000218
10886,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL626397,,BAO_0000218
10887,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,50588,,N,1,Intermediate,1,,CHEMBL626398,,BAO_0000218
10888,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL626399,,BAO_0000218
10889,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL874653,,BAO_0000218
10890,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL626400,,BAO_0000218
10891,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL626401,,BAO_0000218
10892,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL626402,,BAO_0000218
10893,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL626403,,BAO_0000218
10894,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL626404,,BAO_0000218
10895,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL626405,,BAO_0000218
10896,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625529,,BAO_0000218
10897,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625530,,BAO_0000218
10898,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625531,,BAO_0000218
10899,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL625532,,BAO_0000218
10900,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625533,,BAO_0000218
10901,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL875474,,BAO_0000218
10902,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625534,,BAO_0000218
10903,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625535,,BAO_0000218
10904,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625536,,BAO_0000218
10905,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL625537,,BAO_0000218
10906,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625538,,BAO_0000218
10907,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL625539,,BAO_0000218
10908,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625540,,BAO_0000218
10909,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625541,,BAO_0000218
10910,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625542,,BAO_0000218
10911,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL625543,,BAO_0000218
10912,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL625544,,BAO_0000218
10913,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL625545,,BAO_0000218
10914,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL625546,,BAO_0000218
10915,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL625547,,BAO_0000218
10916,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL625548,,BAO_0000218
10917,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL625549,,BAO_0000218
10918,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL625550,,BAO_0000218
10919,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL625551,,BAO_0000218
10920,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL875475,,BAO_0000218
10921,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL625552,,BAO_0000218
10922,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL625553,,BAO_0000218
10923,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL625554,,BAO_0000218
10924,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,50588,,N,1,Intermediate,1,,CHEMBL625555,,BAO_0000218
10925,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL625556,,BAO_0000218
10926,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL624986,,BAO_0000218
10927,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624987,,BAO_0000218
10928,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624988,,BAO_0000218
10929,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624989,,BAO_0000218
10930,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624990,,BAO_0000218
10931,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL874391,,BAO_0000218
10932,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624991,,BAO_0000218
10933,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624992,,BAO_0000218
10934,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624993,,BAO_0000218
10935,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624994,,BAO_0000218
10936,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624995,,BAO_0000218
10937,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624996,,BAO_0000218
10938,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624997,,BAO_0000218
10939,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624998,,BAO_0000218
10940,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624999,,BAO_0000218
10941,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL882955,,BAO_0000218
10942,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL625000,,BAO_0000218
10943,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL625001,,BAO_0000218
10944,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL625089,,BAO_0000218
10945,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL625090,,BAO_0000218
10946,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL625091,,BAO_0000218
10947,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL625092,,BAO_0000218
10948,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL625093,,BAO_0000218
10949,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL625094,,BAO_0000218
10950,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL625095,,BAO_0000218
10951,,Compound was evaluated for its bioavailability in the dogs,,,50588,,N,1,Intermediate,1,,CHEMBL625096,,BAO_0000218
10952,,Compound was evaluated for its bioavailability in the rats,,,50597,,N,1,Intermediate,1,,CHEMBL625097,,BAO_0000218
10953,,Compound was evaluated for oral bioavailability,,,22224,,U,0,Autocuration,1,,CHEMBL882956,,BAO_0000218
10954,,Compound was evaluated for percentage of Oral bioavailability in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625098,,BAO_0000218
10955,,Bioavailability in guinea pig,,,22224,,U,0,Autocuration,1,,CHEMBL625099,,BAO_0000218
10956,,Compound was evaluated for the oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625100,,BAO_0000218
10957,,Compound was evaluated for the oral bioavailability in dog,,,50588,,N,1,Intermediate,1,,CHEMBL625101,,BAO_0000218
10958,,Compound was evaluated for the oral bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL874396,,BAO_0000218
10959,,Bioavailability in dog (dosed i.v.),,,22224,,U,0,Autocuration,1,,CHEMBL625102,,BAO_0000218
10960,,Compound was tested for in vivo bioavailability in dog,,,50588,,N,1,Intermediate,1,,CHEMBL625103,,BAO_0000218
10961,,Compound was tested for in vivo bioavailability in hamsters,,,100712,,N,1,Intermediate,1,,CHEMBL625104,,BAO_0000218
10962,,Compound was tested for in vivo bioavailability in monkey,,,22224,,U,0,Autocuration,1,,CHEMBL625105,,BAO_0000218
10963,,Compound was tested for in vivo bioavailability in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625106,,BAO_0000218
10964,,Oral bioavailability in mouse,,,22224,,U,0,Autocuration,1,,CHEMBL625107,,BAO_0000218
10965,,Compound was tested for percent of oral bioavailability in mice; 56-74,,,50594,,N,1,Intermediate,1,,CHEMBL625108,,BAO_0000218
10966,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,,22224,,U,0,Autocuration,1,,CHEMBL625109,,BAO_0000218
10967,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,,22224,,U,0,Autocuration,1,,CHEMBL625110,,BAO_0000218
10968,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,,22224,,U,0,Autocuration,1,,CHEMBL625111,,BAO_0000218
10969,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,,50594,,N,1,Intermediate,1,,CHEMBL625112,,BAO_0000218
10970,,Oral bioavailability in nude mice,,,50594,,N,1,Intermediate,1,,CHEMBL875334,,BAO_0000218
10971,,Bioavailability in monkey (i.d. dosing),,,22224,,U,0,Autocuration,1,,CHEMBL628617,,BAO_0000218
10972,,Bioavailability in rat,,,22224,,U,0,Autocuration,1,,CHEMBL628618,,BAO_0000218
10973,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,,22224,,U,0,Autocuration,1,,CHEMBL628619,,BAO_0000218
10974,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,,22224,,U,0,Autocuration,1,,CHEMBL628620,,BAO_0000218
10975,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,,100710,,N,1,Intermediate,1,,CHEMBL628621,,BAO_0000218
10976,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,,100710,,N,1,Intermediate,1,,CHEMBL628622,,BAO_0000218
10977,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,,100710,,N,1,Intermediate,1,,CHEMBL628623,,BAO_0000218
10978,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,1969.0,,100710,,N,1,Intermediate,1,,CHEMBL628624,,BAO_0000218
10979,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL628625,,BAO_0000218
10980,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,1969.0,,100710,,N,1,Intermediate,1,,CHEMBL628626,,BAO_0000218
10981,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL627041,,BAO_0000218
10982,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL627042,,BAO_0000218
10983,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL627043,,BAO_0000218
10984,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL627044,,BAO_0000218
10985,,Cmax in mouse plasma,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL627045,,BAO_0000218
10986,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL627046,,BAO_0000218
10987,,Maximal plasma concentration in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627047,,BAO_0000218
10988,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627048,,BAO_0000218
10989,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627049,,BAO_0000218
10990,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627050,,BAO_0000218
10991,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627051,,BAO_0000218
10992,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627052,,BAO_0000218
10993,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627053,,BAO_0000218
10994,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627054,,BAO_0000218
10995,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,50594,,N,1,Intermediate,1,,CHEMBL627055,,BAO_0000218
10996,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,,50594,,N,1,Intermediate,1,,CHEMBL627056,,BAO_0000218
10997,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,,50594,,N,1,Intermediate,1,,CHEMBL627057,,BAO_0000218
10998,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,50594,,N,1,Intermediate,1,,CHEMBL627058,,BAO_0000218
10999,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,,50594,,N,1,Intermediate,1,,CHEMBL626211,,BAO_0000218
11000,,Maximum Concentration of the compound.,,,22224,,U,0,Autocuration,1,,CHEMBL626212,,BAO_0000218
11001,,Maximum Concentration was measured after iv administration into Beagle dog,,,50588,,N,1,Intermediate,1,,CHEMBL626213,,BAO_0000218
11002,,Maximum Concentration was measured after iv administration into Beagle dog.,,,50588,,N,1,Intermediate,1,,CHEMBL626214,,BAO_0000218
11003,,Maximum Concentration was measured after po administration into Beagle dog,,,50588,,N,1,Intermediate,1,,CHEMBL626215,,BAO_0000218
11004,,Maximum Concentration was measured after po administration into Beagle dog.,,,50588,,N,1,Intermediate,1,,CHEMBL626216,,BAO_0000218
11005,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,178.0,,22224,,U,0,Autocuration,1,,CHEMBL626217,,BAO_0000218
11006,,Maximum blood level reached after an iv dose of 12.2 uM/kg,178.0,,22224,,U,0,Autocuration,1,,CHEMBL626218,,BAO_0000218
11007,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,178.0,,22224,,U,0,Autocuration,1,,CHEMBL626219,,BAO_0000218
11008,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,178.0,,22224,,U,0,Autocuration,1,,CHEMBL626220,,BAO_0000218
11009,,Maximum blood level reached after an oral dose of 5.0 mg/kg,178.0,,22224,,U,0,Autocuration,1,,CHEMBL626221,,BAO_0000218
11010,,Maximum blood level reached at dose of 10.6 uM/kg orally,178.0,,22224,,U,0,Autocuration,1,,CHEMBL626222,,BAO_0000218
11011,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,,50512,,N,1,Intermediate,1,,CHEMBL626223,,BAO_0000218
11012,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,,50512,,N,1,Intermediate,1,,CHEMBL626224,,BAO_0000218
11013,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,955.0,,50597,,N,1,Intermediate,1,,CHEMBL626225,,BAO_0000218
11014,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,955.0,,50597,,N,1,Intermediate,1,,CHEMBL626226,,BAO_0000218
11015,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,955.0,,50597,,N,1,Intermediate,1,,CHEMBL626227,,BAO_0000218
11016,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,955.0,,50597,,N,1,Intermediate,1,,CHEMBL626228,,BAO_0000218
11017,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626229,,BAO_0000218
11018,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626921,,BAO_0000218
11019,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL876793,,BAO_0000218
11020,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625309,,BAO_0000218
11021,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,50278,,N,1,Intermediate,1,,CHEMBL625310,,BAO_0000218
11022,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL625311,,BAO_0000218
11023,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625312,,BAO_0000218
11024,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,,22224,,U,0,Autocuration,1,,CHEMBL625313,,BAO_0000218
11025,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,,50594,,N,1,Intermediate,1,,CHEMBL625314,,BAO_0000218
11026,,Maximum concentration in male rats after iv administration of 20 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625315,,BAO_0000218
11027,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625316,,BAO_0000218
11028,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625317,,BAO_0000218
11029,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625318,,BAO_0000218
11030,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625319,,BAO_0000218
11031,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625320,,BAO_0000218
11032,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625321,,BAO_0000218
11033,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625322,,BAO_0000218
11034,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL876801,,BAO_0000218
11035,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625323,,BAO_0000218
11036,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625324,,BAO_0000218
11037,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625325,,BAO_0000218
11038,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625326,,BAO_0000218
11039,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625327,,BAO_0000218
11040,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625328,,BAO_0000218
11041,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625329,,BAO_0000218
11042,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625330,,BAO_0000218
11043,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627774,,BAO_0000218
11044,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627775,,BAO_0000218
11045,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627949,,BAO_0000218
11046,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627950,,BAO_0000218
11047,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627951,,BAO_0000218
11048,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627952,,BAO_0000218
11049,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627953,,BAO_0000218
11050,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627954,,BAO_0000218
11051,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627955,,BAO_0000218
11052,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627956,,BAO_0000218
11053,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL876802,,BAO_0000218
11054,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627957,,BAO_0000218
11055,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627958,,BAO_0000218
11056,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627959,,BAO_0000218
11057,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627960,,BAO_0000218
11058,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627961,,BAO_0000218
11059,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627962,,BAO_0000218
11060,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,50597,,N,1,Intermediate,1,,CHEMBL627963,,BAO_0000218
11061,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,,N,1,Intermediate,1,,CHEMBL624759,,BAO_0000218
11062,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,50597,,N,1,Intermediate,1,,CHEMBL624760,,BAO_0000218
11063,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,,N,1,Intermediate,1,,CHEMBL624761,,BAO_0000218
11064,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,,N,1,Intermediate,1,,CHEMBL877607,,BAO_0000218
11065,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624762,,BAO_0000218
11066,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624763,,BAO_0000218
11067,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624764,,BAO_0000218
11068,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624765,,BAO_0000218
11069,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624766,,BAO_0000218
11070,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624767,,BAO_0000218
11071,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL624768,,BAO_0000218
11072,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624769,,BAO_0000218
11073,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624770,,BAO_0000218
11074,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,50588,,N,1,Intermediate,1,,CHEMBL624771,,BAO_0000218
11075,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624772,,BAO_0000218
11076,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL624773,,BAO_0000218
11077,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL624774,,BAO_0000218
11078,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL624775,,BAO_0000218
11079,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL624776,,BAO_0000218
11080,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL624777,,BAO_0000218
11081,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL624778,,BAO_0000218
11082,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL624779,,BAO_0000218
11083,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL624780,,BAO_0000218
11084,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL624781,,BAO_0000218
11085,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL877608,,BAO_0000218
11086,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL624782,,BAO_0000218
11087,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL624783,,BAO_0000218
11088,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL624784,,BAO_0000218
11089,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL624785,,BAO_0000218
11090,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL624786,,BAO_0000218
11091,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL624787,,BAO_0000218
11092,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL628676,,BAO_0000218
11093,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL621842,,BAO_0000218
11094,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL621843,,BAO_0000218
11095,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL623873,,BAO_0000218
11096,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL623874,,BAO_0000218
11097,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL623875,,BAO_0000218
11098,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL623876,,BAO_0000218
11099,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL623877,,BAO_0000218
11100,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL623878,,BAO_0000218
11101,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL623879,,BAO_0000218
11102,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL623880,,BAO_0000218
11103,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL623881,,BAO_0000218
11104,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL623957,,BAO_0000218
11105,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL623958,,BAO_0000218
11106,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL623959,,BAO_0000218
11107,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL623960,,BAO_0000218
11108,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL623961,,BAO_0000218
11109,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL623962,,BAO_0000218
11110,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,50588,,N,1,Intermediate,1,,CHEMBL624676,,BAO_0000218
11111,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624677,,BAO_0000218
11112,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL624678,,BAO_0000218
11113,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624679,,BAO_0000218
11114,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624680,,BAO_0000218
11115,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,,22224,,U,0,Autocuration,1,,CHEMBL624849,,BAO_0000218
11116,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,,22224,,U,0,Autocuration,1,,CHEMBL624850,,BAO_0000218
11117,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,,22224,,U,0,Autocuration,1,,CHEMBL874399,,BAO_0000218
11118,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,,22224,,U,0,Autocuration,1,,CHEMBL624851,,BAO_0000218
11119,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,,22224,,U,0,Autocuration,1,,CHEMBL624852,,BAO_0000218
11120,,Oral bioavailability in rat (dose 10 mg/kg),,,22224,,U,0,Autocuration,1,,CHEMBL624853,,BAO_0000218
11121,,Oral bioavailability in rat (Sprague-Dawley),,,22224,,U,0,Autocuration,1,,CHEMBL624854,,BAO_0000218
11122,,Oral bioavailability in rat,,,22224,,U,0,Autocuration,1,,CHEMBL624855,,BAO_0000218
11123,,Oral bioavailability in rats was determined in vivo,,,22224,,U,0,Autocuration,1,,CHEMBL624856,,BAO_0000218
11124,,Oral bioavailability in dog,,,22224,,U,0,Autocuration,1,,CHEMBL882957,,BAO_0000218
11125,,Oral bioavailability of compound in monkey,,,22224,,U,0,Autocuration,1,,CHEMBL624857,,BAO_0000218
11126,,Oral bioavailability of compound in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622202,,BAO_0000218
11127,,Bioavailability in rat of PMEA prodrug,,,22224,,U,0,Autocuration,1,,CHEMBL622203,,BAO_0000218
11128,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,,50597,,N,1,Intermediate,1,,CHEMBL625522,,BAO_0000218
11129,,Serum conc at 3 hours following 25 mg/kg dose,,,22224,,U,0,Autocuration,1,,CHEMBL622868,,BAO_0000218
11130,,Urine conc 0-5 hours following 25 mg/kg dose,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL622869,,BAO_0000218
11131,,Urine conc 0-24 hours following 25 mg/kg dose,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL622870,,BAO_0000218
11132,,Oral bioavailability in African green monkeys; 20-25,,,22224,,U,0,Autocuration,1,,CHEMBL622871,,BAO_0000218
11133,,Oral bioavailability in cynomolgus monkey.,,,100710,,N,1,Intermediate,1,,CHEMBL620560,,BAO_0000218
11134,,Oral bioavailability in dog,,,22224,,U,0,Autocuration,1,,CHEMBL620561,,BAO_0000218
11135,,Oral bioavailability in dog at 10 mg/kg oral dose,,,50588,,N,1,Intermediate,1,,CHEMBL620562,,BAO_0000218
11136,,Oral bioavailability in hamster at 10 mg/kg oral dose,,,100712,,N,1,Intermediate,1,,CHEMBL620563,,BAO_0000218
11137,,Oral bioavailability in rat at 10 mg/kg oral dose,,,50597,,N,1,Intermediate,1,,CHEMBL620564,,BAO_0000218
11138,,Oral bioavailability in rat,,,22224,,U,0,Autocuration,1,,CHEMBL872265,,BAO_0000218
11139,,Oral bioavailability in rat,,,22224,,U,0,Autocuration,1,,CHEMBL620565,,BAO_0000218
11140,,Oral bioavailability,,,22224,,U,0,Autocuration,1,,CHEMBL620566,,BAO_0000218
11141,,Oral bioavailability was determined; range 49-102%,,,22224,,U,0,Autocuration,1,,CHEMBL620567,,BAO_0000218
11142,,Oral bioavailability was determined in dogs,,,50588,,N,1,Intermediate,1,,CHEMBL620568,,BAO_0000218
11143,,Oral bioavailability in rat,,,22224,,U,0,Autocuration,1,,CHEMBL620569,,BAO_0000218
11144,,Oral bioavailability,,,22224,,U,0,Autocuration,1,,CHEMBL620570,,BAO_0000218
11145,,Oral bioavailability was determined; Not orally available,,,22224,,U,0,Autocuration,1,,CHEMBL620571,,BAO_0000218
11146,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,,50594,,N,1,Intermediate,1,,CHEMBL620572,,BAO_0000218
11147,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,,22224,,U,0,Autocuration,1,,CHEMBL620573,,BAO_0000218
11148,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL620574,,BAO_0000218
11149,,Oral bioavailability in Rhesus monkey,,,22224,,U,0,Autocuration,1,,CHEMBL620575,,BAO_0000218
11150,,Oral bioavailability in dog (female mongrel),,,22224,,U,0,Autocuration,1,,CHEMBL620576,,BAO_0000218
11151,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,,22224,,U,0,Autocuration,1,,CHEMBL875846,,BAO_0000218
11152,,Oral bioavailability in dog,,,22224,,U,0,Autocuration,1,,CHEMBL620577,,BAO_0000218
11153,,Percentage Bioavailability was evaluated.,,,22224,,U,0,Autocuration,1,,CHEMBL620578,,BAO_0000218
11154,,Bioavailability in rat administered i.d.,,,22224,,U,0,Autocuration,1,,CHEMBL620579,,BAO_0000218
11155,,Bioavailability,,,22224,,U,0,Autocuration,1,,CHEMBL621248,,BAO_0000218
11156,,Bioavailability in dog (male Beagle) i.v. administration,,,22224,,U,0,Autocuration,1,,CHEMBL625390,,BAO_0000218
11157,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,,22224,,U,0,Autocuration,1,,CHEMBL625391,,BAO_0000218
11158,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,,22224,,U,0,Autocuration,1,,CHEMBL872266,,BAO_0000218
11159,,Oral bioavailability in rat (Sprague-Dawley) (male),,,22224,,U,0,Autocuration,1,,CHEMBL625392,,BAO_0000218
11160,,The oral bioavailability was measured on rats after oral administration,,,50597,,N,1,Intermediate,1,,CHEMBL625393,,BAO_0000218
11161,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625394,,BAO_0000218
11162,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,,50797,,N,1,Intermediate,1,,CHEMBL625395,,BAO_0000218
11163,,Bioavailability in rat (dose 10 mg/kg i.d.),,,22224,,U,0,Autocuration,1,,CHEMBL625396,,BAO_0000218
11164,,Bioavailability in dog (male Beagle) i.v. administration,,,22224,,U,0,Autocuration,1,,CHEMBL625397,,BAO_0000218
11165,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL625398,,BAO_0000218
11166,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,,50594,,N,1,Intermediate,1,,CHEMBL625399,,BAO_0000218
11167,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,,50594,,N,1,Intermediate,1,,CHEMBL626074,,BAO_0000218
11168,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL626075,,BAO_0000218
11169,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626076,,BAO_0000218
11170,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1969.0,,50797,,N,1,Intermediate,1,,CHEMBL626077,,BAO_0000218
11171,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),178.0,,50597,,N,1,Intermediate,1,,CHEMBL626078,,BAO_0000218
11172,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),178.0,,22224,,U,0,Autocuration,1,,CHEMBL625846,,BAO_0000218
11173,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),178.0,,22224,,U,0,Autocuration,1,,CHEMBL625847,,BAO_0000218
11174,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,,50597,,N,1,Expert,1,,CHEMBL625848,,BAO_0000218
11175,,Maximum concentration of compound in plasma administered orally to rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625849,,BAO_0000218
11176,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626023,,BAO_0000218
11177,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626024,,BAO_0000218
11178,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626025,,BAO_0000218
11179,,Maximum concentration after 10 mg/kg by oral administration,,,22224,,U,0,Autocuration,1,,CHEMBL626026,,BAO_0000218
11180,,Maximum concentration at a dose of 1.5 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626027,,BAO_0000218
11181,,Maximum concentration at a dose of 2.0 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626028,,BAO_0000218
11182,,Maximum concentration in dog plasma,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626029,,BAO_0000218
11183,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626030,,BAO_0000218
11184,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626031,,BAO_0000218
11185,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626032,,BAO_0000218
11186,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626033,,BAO_0000218
11187,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626034,,BAO_0000218
11188,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626035,,BAO_0000218
11189,,Maximum concentration in plasma at Tmax,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626036,,BAO_0000218
11190,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,1969.0,,50588,,N,1,Expert,1,,CHEMBL626037,,BAO_0000218
11191,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,1969.0,,100712,,N,1,Intermediate,1,,CHEMBL626038,,BAO_0000218
11192,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626039,,BAO_0000218
11193,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626040,,BAO_0000218
11194,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,1969.0,,50592,,N,1,Intermediate,1,,CHEMBL626041,,BAO_0000218
11195,,Maximum concentration was calculated,,,22224,,U,0,Autocuration,1,,CHEMBL626042,,BAO_0000218
11196,,Maximum concentration was calculated.,,,22224,,U,0,Autocuration,1,,CHEMBL626043,,BAO_0000218
11197,,Maximum concentration at a peroral dose of 10 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626044,,BAO_0000218
11198,,Maximum concentration of the drug at 10 uM/dg administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626045,,BAO_0000218
11199,,Maximum concentration of the drug at 2 uM/dg administered intravenously,,,22224,,U,0,Autocuration,1,,CHEMBL626046,,BAO_0000218
11200,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626047,,BAO_0000218
11201,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",1969.0,,100712,,N,1,Intermediate,1,,CHEMBL626048,,BAO_0000218
11202,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626049,,BAO_0000218
11203,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626050,,BAO_0000218
11204,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL874541,,BAO_0000218
11205,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,1969.0,,100712,,N,1,Intermediate,1,,CHEMBL622826,,BAO_0000218
11206,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,1969.0,,100712,,N,1,Intermediate,1,,CHEMBL622827,,BAO_0000218
11207,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622828,,BAO_0000218
11208,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622829,,BAO_0000218
11209,,Maximum concentration reached following intravenous administration in male rat,,,50597,,N,1,Intermediate,1,,CHEMBL876806,,BAO_0000218
11210,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,,50588,,N,1,Intermediate,1,,CHEMBL622830,,BAO_0000218
11211,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622831,,BAO_0000218
11212,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,,50588,,N,1,Intermediate,1,,CHEMBL626794,,BAO_0000218
11213,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL626795,,BAO_0000218
11214,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL626796,,BAO_0000218
11215,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL626797,,BAO_0000218
11216,,Maximum drug concentration is determined after oral dosing in rats.,,,50597,,N,1,Intermediate,1,,CHEMBL626798,,BAO_0000218
11217,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,,50588,,N,1,Intermediate,1,,CHEMBL626799,,BAO_0000218
11218,,Maximum observed concentration in oral (5 mg/kg) fed dogs,,,50588,,N,1,Intermediate,1,,CHEMBL626800,,BAO_0000218
11219,,Maximum plasma concentration,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626801,,BAO_0000218
11220,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL876816,,BAO_0000218
11221,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626802,,BAO_0000218
11222,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626803,,BAO_0000218
11223,,Maximum plasma concentration following oral administration of 30 umol/kg,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626804,,BAO_0000218
11224,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626805,,BAO_0000218
11225,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626309,,BAO_0000218
11226,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626310,,BAO_0000218
11227,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626311,,BAO_0000218
11228,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626312,,BAO_0000218
11229,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,995.0,,50597,,N,1,Intermediate,1,,CHEMBL626313,,BAO_0000218
11230,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,995.0,,50597,,N,1,Intermediate,1,,CHEMBL626314,,BAO_0000218
11231,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,995.0,,50597,,N,1,Intermediate,1,,CHEMBL626315,,BAO_0000218
11232,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,995.0,,50597,,N,1,Intermediate,1,,CHEMBL626316,,BAO_0000218
11233,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,995.0,,50597,,N,1,Intermediate,1,,CHEMBL626317,,BAO_0000218
11234,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,,N,1,Intermediate,1,,CHEMBL626318,,BAO_0000218
11235,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,,N,1,Intermediate,1,,CHEMBL626319,,BAO_0000218
11236,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,,N,1,Intermediate,1,,CHEMBL626320,,BAO_0000218
11237,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,,N,1,Intermediate,1,,CHEMBL875053,,BAO_0000218
11238,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,,N,1,Intermediate,1,,CHEMBL626321,,BAO_0000218
11239,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,,N,1,Intermediate,1,,CHEMBL626322,,BAO_0000218
11240,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,,N,1,Intermediate,1,,CHEMBL626323,,BAO_0000218
11241,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,,N,1,Intermediate,1,,CHEMBL626324,,BAO_0000218
11242,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,,N,1,Intermediate,1,,CHEMBL626325,,BAO_0000218
11243,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,,N,1,Intermediate,1,,CHEMBL626326,,BAO_0000218
11244,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,,N,1,Intermediate,1,,CHEMBL626327,,BAO_0000218
11245,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,,N,1,Intermediate,1,,CHEMBL626328,,BAO_0000218
11246,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626329,,BAO_0000218
11247,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626330,,BAO_0000218
11248,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626331,,BAO_0000218
11249,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626332,,BAO_0000218
11250,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626333,,BAO_0000218
11251,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626334,,BAO_0000218
11252,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626335,,BAO_0000218
11253,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",178.0,,50597,,N,1,Intermediate,1,,CHEMBL624798,,BAO_0000218
11254,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",955.0,,50597,,N,1,Intermediate,1,,CHEMBL624799,,BAO_0000218
11255,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",955.0,,50597,,N,1,Intermediate,1,,CHEMBL624800,,BAO_0000218
11256,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",955.0,,50597,,N,1,Intermediate,1,,CHEMBL624801,,BAO_0000218
11257,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",955.0,,50597,,N,1,Intermediate,1,,CHEMBL624802,,BAO_0000218
11258,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",955.0,,50597,,N,1,Intermediate,1,,CHEMBL624803,,BAO_0000218
11259,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",955.0,,50597,,N,1,Intermediate,1,,CHEMBL624804,,BAO_0000218
11260,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",955.0,,50597,,N,1,Intermediate,1,,CHEMBL624805,,BAO_0000218
11261,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",955.0,,50597,,N,1,Intermediate,1,,CHEMBL624806,,BAO_0000218
11262,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624807,,BAO_0000218
11263,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624808,,BAO_0000218
11264,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624809,,BAO_0000218
11265,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624810,,BAO_0000218
11266,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL877618,,BAO_0000218
11267,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624811,,BAO_0000218
11268,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624812,,BAO_0000218
11269,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624813,,BAO_0000218
11270,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624814,,BAO_0000218
11271,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624815,,BAO_0000218
11272,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624816,,BAO_0000218
11273,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624817,,BAO_0000218
11274,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624818,,BAO_0000218
11275,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL624819,,BAO_0000218
11276,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624820,,BAO_0000218
11277,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624821,,BAO_0000218
11278,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,50588,,N,1,Intermediate,1,,CHEMBL624822,,BAO_0000218
11279,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL624823,,BAO_0000218
11280,,Observed diffusion coefficient in organic solvent for Escherichia coli,,,50212,,N,1,Intermediate,1,,CHEMBL624824,,BAO_0000218
11281,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",178.0,,50597,,N,1,Intermediate,1,,CHEMBL624825,,BAO_0000218
11282,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL624826,,BAO_0000218
11283,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2081.0,,50597,,N,1,Intermediate,1,,CHEMBL876817,,BAO_0000218
11284,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2081.0,,50597,,N,1,Intermediate,1,,CHEMBL624827,,BAO_0000218
11285,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,50597,,N,1,Intermediate,1,,CHEMBL624828,,BAO_0000218
11286,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL624829,,BAO_0000218
11287,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624830,,BAO_0000218
11288,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624831,,BAO_0000218
11289,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2081.0,,50597,,N,1,Intermediate,1,,CHEMBL624832,,BAO_0000218
11290,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2081.0,,50597,,N,1,Intermediate,1,,CHEMBL624833,,BAO_0000218
11291,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL624834,,BAO_0000218
11292,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,50597,,N,1,Intermediate,1,,CHEMBL624835,,BAO_0000218
11293,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL624836,,BAO_0000218
11294,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL624837,,BAO_0000218
11295,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624838,,BAO_0000218
11296,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL622188,,BAO_0000218
11297,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,948.0,,50597,,N,1,Intermediate,1,,CHEMBL622189,,BAO_0000218
11298,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,948.0,,50597,,N,1,Intermediate,1,,CHEMBL622190,,BAO_0000218
11299,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625170,,BAO_0000218
11300,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625171,,BAO_0000218
11301,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625172,,BAO_0000218
11302,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625173,,BAO_0000218
11303,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625174,,BAO_0000218
11304,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625175,,BAO_0000218
11305,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625176,,BAO_0000218
11306,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625177,,BAO_0000218
11307,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625178,,BAO_0000218
11308,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625179,,BAO_0000218
11309,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625180,,BAO_0000218
11310,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,,22224,,U,0,Autocuration,1,,CHEMBL625181,,BAO_0000218
11311,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL625182,,BAO_0000218
11312,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL625183,,BAO_0000218
11313,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,,50597,,N,1,Intermediate,1,,CHEMBL875848,,BAO_0000218
11314,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL622260,,BAO_0000218
11315,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,,50597,,N,1,Intermediate,1,,CHEMBL622261,,BAO_0000218
11316,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL622262,,BAO_0000218
11317,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622263,,BAO_0000218
11318,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622418,,BAO_0000218
11319,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622419,,BAO_0000218
11320,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL623388,,BAO_0000218
11321,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,,50594,,N,1,Intermediate,1,,CHEMBL623389,,BAO_0000218
11322,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL623390,,BAO_0000218
11323,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL623391,,BAO_0000218
11324,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,,50594,,N,1,Intermediate,1,,CHEMBL623392,,BAO_0000218
11325,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,,50594,,N,1,Intermediate,1,,CHEMBL623393,,BAO_0000218
11326,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL623394,,BAO_0000218
11327,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL618885,,BAO_0000218
11328,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,,50594,,N,1,Intermediate,1,,CHEMBL618886,,BAO_0000218
11329,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL618887,,BAO_0000218
11330,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL619535,,BAO_0000218
11331,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,,50594,,N,1,Intermediate,1,,CHEMBL619536,,BAO_0000218
11332,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,,50594,,N,1,Intermediate,1,,CHEMBL619537,,BAO_0000218
11333,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL619705,,BAO_0000218
11334,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL619706,,BAO_0000218
11335,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,,50594,,N,1,Intermediate,1,,CHEMBL619707,,BAO_0000218
11336,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL619708,,BAO_0000218
11337,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL625219,,BAO_0000218
11338,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,,50594,,N,1,Intermediate,1,,CHEMBL625220,,BAO_0000218
11339,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,,50594,,N,1,Intermediate,1,,CHEMBL625221,,BAO_0000218
11340,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL625222,,BAO_0000218
11341,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL625223,,BAO_0000218
11342,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,,50594,,N,1,Intermediate,1,,CHEMBL625224,,BAO_0000218
11343,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,,N,1,Intermediate,1,,CHEMBL625225,,BAO_0000218
11344,,Biodistribution in Rat blood after 24 hours of iv administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625226,,BAO_0000218
11345,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625227,,BAO_0000218
11346,,Biodistribution in Rat blood after 30 minutes of iv administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625228,,BAO_0000218
11347,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,178.0,,50597,,N,1,Intermediate,1,,CHEMBL875354,,BAO_0000218
11348,,Biodistribution in Rat blood after 5 minutes of iv administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625229,,BAO_0000218
11349,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625230,,BAO_0000218
11350,,Biodistribution in Rat heart after 24 hours of iv administration,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625231,,BAO_0000218
11351,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625900,,BAO_0000218
11352,,Biodistribution in Rat heart after 30 minutes of iv administration,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625901,,BAO_0000218
11353,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625902,,BAO_0000218
11354,,Biodistribution in Rat heart after 5 minutes of iv administration,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625903,,BAO_0000218
11355,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625904,,BAO_0000218
11356,,Biodistribution in Rat liver after 24 hours of iv administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625905,,BAO_0000218
11357,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627861,,BAO_0000218
11358,,Biodistribution in Rat liver after 30 minutes of iv administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627862,,BAO_0000218
11359,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627863,,BAO_0000218
11360,,Biodistribution in Rat liver after 30 minutes of iv administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627769,,BAO_0000218
11361,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL627770,,BAO_0000218
11362,,Cmax in cynomolgus monkey (PO dose),,,100710,,N,1,Intermediate,1,,CHEMBL627771,,BAO_0000218
11363,,Cmax in rat (PO dose),,,50597,,N,1,Intermediate,1,,CHEMBL627772,,BAO_0000218
11364,,Cmax in rat (PO dose),,,50597,,N,1,Intermediate,1,,CHEMBL627773,,BAO_0000218
11365,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621922,,BAO_0000218
11366,,Cmax in rat plasma after oral dose (10 mg/kg),1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621923,,BAO_0000218
11367,,Cmax in plasma after oral dose (10 mg/kg),1969.0,,22224,,U,0,Autocuration,1,,CHEMBL621924,,BAO_0000218
11368,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL621925,,BAO_0000218
11369,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL621926,,BAO_0000218
11370,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,1969.0,,50592,,N,1,Intermediate,1,,CHEMBL621927,,BAO_0000218
11371,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621928,,BAO_0000218
11372,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621929,,BAO_0000218
11373,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL621930,,BAO_0000218
11374,,Maximum plasma concentration after oral dosing in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621931,,BAO_0000218
11375,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL621932,,BAO_0000218
11376,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL621933,,BAO_0000218
11377,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL621934,,BAO_0000218
11378,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL621935,,BAO_0000218
11379,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL621936,,BAO_0000218
11380,,Maximum plasma concentration was determined,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL621937,,BAO_0000218
11381,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL621938,,BAO_0000218
11382,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL621939,,BAO_0000218
11383,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL621940,,BAO_0000218
11384,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL621941,,BAO_0000218
11385,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL621942,,BAO_0000218
11386,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626178,,BAO_0000218
11387,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626179,,BAO_0000218
11388,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626180,,BAO_0000218
11389,,Plasma Cmax in rat (PO dose),1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626181,,BAO_0000218
11390,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626182,,BAO_0000218
11391,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626183,,BAO_0000218
11392,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626184,,BAO_0000218
11393,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,,50597,,N,1,Intermediate,1,,CHEMBL626185,,BAO_0000218
11394,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626186,,BAO_0000218
11395,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL877589,,BAO_0000218
11396,,Maximum concentration of the drug at 1 uM/dg administered intravenously,,,22224,,U,0,Autocuration,1,,CHEMBL626187,,BAO_0000218
11397,,Maximum concentration of the drug at 20 uM/dg administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626188,,BAO_0000218
11398,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626189,,BAO_0000218
11399,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,,22224,,U,0,Autocuration,1,,CHEMBL626855,,BAO_0000218
11400,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,178.0,,22224,,U,0,Autocuration,1,,CHEMBL623781,,BAO_0000218
11401,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,,22224,,U,0,Autocuration,1,,CHEMBL623782,,BAO_0000218
11402,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623783,,BAO_0000218
11403,,Cmax in dog plasma after 1mg/kg oral dose,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL623784,,BAO_0000218
11404,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL623785,,BAO_0000218
11405,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623786,,BAO_0000218
11406,,Oral maximum concentration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623787,,BAO_0000218
11407,,Oral maximum concentration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623788,,BAO_0000218
11408,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL623789,,BAO_0000218
11409,,Peak concentration in blood after intravenous administration to mice,178.0,,50594,,N,1,Intermediate,1,,CHEMBL623790,,BAO_0000218
11410,,Peak concentration in blood after peroral administration to mice,178.0,,50594,,N,1,Intermediate,1,,CHEMBL623791,,BAO_0000218
11411,,Peak concentration in rat plasma was determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623792,,BAO_0000218
11412,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL623793,,BAO_0000218
11413,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL623794,,BAO_0000218
11414,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623795,,BAO_0000218
11415,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623796,,BAO_0000218
11416,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623797,,BAO_0000218
11417,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623798,,BAO_0000218
11418,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623799,,BAO_0000218
11419,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",160.0,,50597,,N,1,Intermediate,1,,CHEMBL624490,,BAO_0000218
11420,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",160.0,,50597,,N,1,Intermediate,1,,CHEMBL624491,,BAO_0000218
11421,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",160.0,,50597,,N,1,Intermediate,1,,CHEMBL624492,,BAO_0000218
11422,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",160.0,,50597,,N,1,Intermediate,1,,CHEMBL624493,,BAO_0000218
11423,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",160.0,,50597,,N,1,Intermediate,1,,CHEMBL877595,,BAO_0000218
11424,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",160.0,,50597,,N,1,Intermediate,1,,CHEMBL624494,,BAO_0000218
11425,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",160.0,,50597,,N,1,Intermediate,1,,CHEMBL624495,,BAO_0000218
11426,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",160.0,,50597,,N,1,Intermediate,1,,CHEMBL624681,,BAO_0000218
11427,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624682,,BAO_0000218
11428,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624683,,BAO_0000218
11429,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624684,,BAO_0000218
11430,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624685,,BAO_0000218
11431,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624686,,BAO_0000218
11432,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624687,,BAO_0000218
11433,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624688,,BAO_0000218
11434,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL627161,,BAO_0000218
11435,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL622127,,BAO_0000218
11436,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL622128,,BAO_0000218
11437,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL874384,,BAO_0000218
11438,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624898,,BAO_0000218
11439,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624899,,BAO_0000218
11440,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624900,,BAO_0000218
11441,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624901,,BAO_0000218
11442,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624902,,BAO_0000218
11443,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624903,,BAO_0000218
11444,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624904,,BAO_0000218
11445,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624905,,BAO_0000218
11446,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624906,,BAO_0000218
11447,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624907,,BAO_0000218
11448,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624908,,BAO_0000218
11449,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624909,,BAO_0000218
11450,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL624910,,BAO_0000218
11451,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624911,,BAO_0000218
11452,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL874388,,BAO_0000218
11453,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL624912,,BAO_0000218
11454,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL622930,,BAO_0000218
11455,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623121,,BAO_0000218
11456,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623122,,BAO_0000218
11457,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623123,,BAO_0000218
11458,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623124,,BAO_0000218
11459,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623125,,BAO_0000218
11460,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623126,,BAO_0000218
11461,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623127,,BAO_0000218
11462,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623128,,BAO_0000218
11463,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623129,,BAO_0000218
11464,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623130,,BAO_0000218
11465,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623131,,BAO_0000218
11466,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL623132,,BAO_0000218
11467,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL623133,,BAO_0000218
11468,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL623134,,BAO_0000218
11469,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL874389,,BAO_0000218
11470,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,,50597,,N,1,Intermediate,1,,CHEMBL623135,,BAO_0000218
11471,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL623136,,BAO_0000218
11472,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,,50597,,N,1,Intermediate,1,,CHEMBL623137,,BAO_0000218
11473,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL623138,,BAO_0000218
11474,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL623139,,BAO_0000218
11475,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL623140,,BAO_0000218
11476,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL623141,,BAO_0000218
11477,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL623142,,BAO_0000218
11478,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL623143,,BAO_0000218
11479,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL623144,,BAO_0000218
11480,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623405,,BAO_0000218
11481,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL624074,,BAO_0000218
11482,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,,50597,,N,1,Intermediate,1,,CHEMBL624075,,BAO_0000218
11483,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL624076,,BAO_0000218
11484,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,,50597,,N,1,Intermediate,1,,CHEMBL624077,,BAO_0000218
11485,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL624078,,BAO_0000218
11486,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624079,,BAO_0000218
11487,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624261,,BAO_0000218
11488,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,,50597,,N,1,Intermediate,1,,CHEMBL624262,,BAO_0000218
11489,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL624263,,BAO_0000218
11490,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL624264,,BAO_0000218
11491,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL624265,,BAO_0000218
11492,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,,50597,,N,1,Intermediate,1,,CHEMBL624266,,BAO_0000218
11493,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL624267,,BAO_0000218
11494,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,,50597,,N,1,Intermediate,1,,CHEMBL624268,,BAO_0000218
11495,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL875227,,BAO_0000218
11496,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624269,,BAO_0000218
11497,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624270,,BAO_0000218
11498,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,,50597,,N,1,Intermediate,1,,CHEMBL624271,,BAO_0000218
11499,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL624272,,BAO_0000218
11500,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,50597,,N,1,Intermediate,1,,CHEMBL624273,,BAO_0000218
11501,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624274,,BAO_0000218
11502,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624275,,BAO_0000218
11503,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624276,,BAO_0000218
11504,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624277,,BAO_0000218
11505,,% dose converted to 2-amino-5-chlorophenyl sulfate,,,22224,,U,0,Autocuration,1,,CHEMBL624278,,BAO_0000019
11506,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,,22224,,U,0,Autocuration,1,,CHEMBL624279,,BAO_0000019
11507,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1988.0,,50597,,N,1,Intermediate,1,,CHEMBL624280,,BAO_0000218
11508,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1988.0,,50597,,N,1,Intermediate,1,,CHEMBL624281,,BAO_0000218
11509,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1988.0,,50597,,N,1,Intermediate,1,,CHEMBL622933,,BAO_0000218
11510,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1988.0,,50597,,N,1,Intermediate,1,,CHEMBL622934,,BAO_0000218
11511,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622935,,BAO_0000218
11512,,Biodistribution in Rat liver after 5 minutes of iv administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622936,,BAO_0000218
11513,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL875228,,BAO_0000218
11514,,Biodistribution in Rat lung after 24 hours of iv administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622937,,BAO_0000218
11515,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622938,,BAO_0000218
11516,,Biodistribution in Rat lung after 30 minutes of iv administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL619736,,BAO_0000218
11517,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625117,,BAO_0000218
11518,,Biodistribution in Rat lung after 5 minutes of iv administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625118,,BAO_0000218
11519,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625119,,BAO_0000218
11520,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",2037.0,,50597,,N,1,Intermediate,1,,CHEMBL625120,,BAO_0000218
11521,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,,50597,,N,1,Intermediate,1,,CHEMBL625121,,BAO_0000218
11522,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",10000006.0,,50597,,N,1,Intermediate,1,,CHEMBL625122,,BAO_0000218
11523,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL622204,,BAO_0000218
11524,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL877503,,BAO_0000218
11525,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627127,,BAO_0000218
11526,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,10000000.0,,22224,,U,0,Autocuration,1,,CHEMBL627128,,BAO_0000218
11527,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,10000000.0,,22224,,U,0,Autocuration,1,,CHEMBL627129,,BAO_0000218
11528,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,10000000.0,,22224,,U,0,Autocuration,1,,CHEMBL627130,,BAO_0000218
11529,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL627131,,BAO_0000218
11530,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL627132,,BAO_0000218
11531,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,955.0,,50597,,N,1,Intermediate,1,,CHEMBL627133,,BAO_0000218
11532,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL627134,,BAO_0000218
11533,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL627135,,BAO_0000218
11534,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL627136,,BAO_0000218
11535,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,,N,1,Intermediate,1,,CHEMBL628435,,BAO_0000218
11536,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,,N,1,Intermediate,1,,CHEMBL628436,,BAO_0000218
11537,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,,N,1,Intermediate,1,,CHEMBL628437,,BAO_0000218
11538,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL628438,,BAO_0000218
11539,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL628439,,BAO_0000218
11540,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,948.0,,50597,,N,1,Intermediate,1,,CHEMBL628440,,BAO_0000218
11541,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL628441,,BAO_0000218
11542,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL628442,,BAO_0000218
11543,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL628443,,BAO_0000218
11544,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL628444,,BAO_0000218
11545,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL628445,,BAO_0000218
11546,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL877504,,BAO_0000218
11547,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628446,,BAO_0000218
11548,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626874,,BAO_0000218
11549,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626875,,BAO_0000218
11550,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626876,,BAO_0000218
11551,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626877,,BAO_0000218
11552,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626878,,BAO_0000218
11553,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL626879,,BAO_0000218
11554,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626880,,BAO_0000218
11555,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL626881,,BAO_0000218
11556,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626882,,BAO_0000218
11557,,Peak plasma concentration was measured in dogs,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626883,,BAO_0000218
11558,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL626884,,BAO_0000218
11559,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626885,,BAO_0000218
11560,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626886,,BAO_0000218
11561,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626887,,BAO_0000218
11562,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL626888,,BAO_0000218
11563,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,,50588,,N,1,Intermediate,1,,CHEMBL626889,,BAO_0000218
11564,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,,22224,,U,0,Autocuration,1,,CHEMBL626761,,BAO_0000218
11565,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,,50588,,N,1,Intermediate,1,,CHEMBL626762,,BAO_0000218
11566,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,,50588,,N,1,Intermediate,1,,CHEMBL626763,,BAO_0000218
11567,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,,50597,,N,1,Intermediate,1,,CHEMBL626764,,BAO_0000218
11568,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,,50597,,N,1,Intermediate,1,,CHEMBL626765,,BAO_0000218
11569,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,,50588,,N,1,Intermediate,1,,CHEMBL626766,,BAO_0000218
11570,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,,50597,,N,1,Intermediate,1,,CHEMBL626767,,BAO_0000218
11571,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,,50597,,N,1,Intermediate,1,,CHEMBL626768,,BAO_0000218
11572,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,,50588,,N,1,Intermediate,1,,CHEMBL626769,,BAO_0000218
11573,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,,50588,,N,1,Intermediate,1,,CHEMBL874463,,BAO_0000218
11574,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,,22224,,U,0,Autocuration,1,,CHEMBL626770,,BAO_0000218
11575,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,,22224,,U,0,Autocuration,1,,CHEMBL626771,,BAO_0000218
11576,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,,50597,,N,1,Intermediate,1,,CHEMBL626772,,BAO_0000218
11577,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,,100710,,N,1,Intermediate,1,,CHEMBL626773,,BAO_0000218
11578,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,,50594,,N,1,Intermediate,1,,CHEMBL626774,,BAO_0000218
11579,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,,50588,,N,1,Intermediate,1,,CHEMBL626775,,BAO_0000218
11580,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,,50588,,N,1,Intermediate,1,,CHEMBL626776,,BAO_0000218
11581,,Maximum concentration (Cmax) in rat when administered orally,,,50597,,N,1,Intermediate,1,,CHEMBL626777,,BAO_0000218
11582,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626778,,BAO_0000218
11583,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,,22224,,U,0,Autocuration,1,,CHEMBL626779,,BAO_0000218
11584,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,,22224,,U,0,Autocuration,1,,CHEMBL626780,,BAO_0000218
11585,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626781,,BAO_0000218
11586,,Pharmacokinetic profile Cmax was evaluated in rats,,,50597,,N,1,Intermediate,1,,CHEMBL632164,,BAO_0000218
11587,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,,50588,,N,1,Intermediate,1,,CHEMBL632165,,BAO_0000218
11588,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,,50594,,N,1,Intermediate,1,,CHEMBL632166,,BAO_0000218
11589,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,,50588,,N,1,Intermediate,1,,CHEMBL632167,,BAO_0000218
11590,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,,50594,,N,1,Intermediate,1,,CHEMBL632168,,BAO_0000218
11591,,Cmax in rat plasma,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL632169,,BAO_0000218
11592,,Cmax in dog plasma after 30mg/kg oral dose,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL632170,,BAO_0000218
11593,,Cmax in rat plasma after 30mg/kg oral dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL632171,,BAO_0000218
11594,,Plasma level in rats at 30 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL632172,,BAO_0000218
11595,,Tested for maximum plasma concentration in mice,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL632173,,BAO_0000218
11596,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL632174,,BAO_0000218
11597,,The Cmax values in female wistar rats.,,,50597,,N,1,Intermediate,1,,CHEMBL632175,,BAO_0000218
11598,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL632176,,BAO_0000218
11599,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL632177,,BAO_0000218
11600,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL632178,,BAO_0000218
11601,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,,50597,,N,1,Intermediate,1,,CHEMBL632179,,BAO_0000218
11602,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL632180,,BAO_0000218
11603,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL632181,,BAO_0000218
11604,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL632182,,BAO_0000218
11605,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,178.0,,22224,,U,0,Autocuration,1,,CHEMBL632183,,BAO_0000218
11606,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,,50588,,N,1,Intermediate,1,,CHEMBL632184,,BAO_0000218
11607,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,,50597,,N,1,Intermediate,1,,CHEMBL874470,,BAO_0000218
11608,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL631302,,BAO_0000218
11609,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL631303,,BAO_0000218
11610,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL631304,,BAO_0000218
11611,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL631305,,BAO_0000218
11612,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL631306,,BAO_0000218
11613,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL631307,,BAO_0000218
11614,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL631308,,BAO_0000218
11615,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,,50597,,N,1,Intermediate,1,,CHEMBL625557,,BAO_0000218
11616,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625558,,BAO_0000218
11617,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625559,,BAO_0000218
11618,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625560,,BAO_0000218
11619,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625561,,BAO_0000218
11620,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625562,,BAO_0000218
11621,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL875320,,BAO_0000218
11622,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625563,,BAO_0000218
11623,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625564,,BAO_0000218
11624,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",995.0,,50597,,N,1,Intermediate,1,,CHEMBL625565,,BAO_0000218
11625,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",995.0,,50597,,N,1,Intermediate,1,,CHEMBL625566,,BAO_0000218
11626,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",995.0,,50597,,N,1,Intermediate,1,,CHEMBL625567,,BAO_0000218
11627,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",995.0,,50597,,N,1,Intermediate,1,,CHEMBL625568,,BAO_0000218
11628,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",995.0,,50597,,N,1,Intermediate,1,,CHEMBL628217,,BAO_0000218
11629,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",995.0,,50597,,N,1,Intermediate,1,,CHEMBL628218,,BAO_0000218
11630,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",995.0,,50597,,N,1,Intermediate,1,,CHEMBL628219,,BAO_0000218
11631,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",995.0,,50597,,N,1,Intermediate,1,,CHEMBL628220,,BAO_0000218
11632,,Distribution in the blood after 120 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628221,,BAO_0000019
11633,,Distribution in the blood after 15 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628222,,BAO_0000019
11634,,Distribution in the blood after 30 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628223,,BAO_0000019
11635,,Distribution in the blood after 5 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628224,,BAO_0000019
11636,,Distribution in the blood after 60 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628225,,BAO_0000019
11637,,Distribution in the blood after 90 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628226,,BAO_0000019
11638,,Distribution in the bone after 120 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628227,,BAO_0000019
11639,,Distribution in the bone after 15 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL875481,,BAO_0000019
11640,,Distribution in the bone after 30 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628228,,BAO_0000019
11641,,Distribution in the bone after 5 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628229,,BAO_0000019
11642,,Distribution in the bone after 60 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628230,,BAO_0000019
11643,,Distribution in the bone after 90 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628231,,BAO_0000019
11644,,Distribution in the heart after 120 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628232,,BAO_0000019
11645,,Distribution in the heart after 15 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628233,,BAO_0000019
11646,,Distribution in the heart after 30 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628234,,BAO_0000019
11647,,Distribution in the heart after 5 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628235,,BAO_0000019
11648,,Distribution in the heart after 60 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628236,,BAO_0000019
11649,,Distribution in the heart after 90 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628237,,BAO_0000019
11650,,Distribution in the kidneys after 120 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628238,,BAO_0000019
11651,,Distribution in the kidneys after 15 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628239,,BAO_0000019
11652,,Distribution in the kidneys after 30 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628240,,BAO_0000019
11653,,Distribution in the kidneys after 5 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628241,,BAO_0000019
11654,,Distribution in the kidneys after 60 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628242,,BAO_0000019
11655,,Distribution in the kidneys after 90 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL875482,,BAO_0000019
11656,,Distribution in the liver after 120 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628243,,BAO_0000019
11657,,Distribution in the liver after 15 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628244,,BAO_0000019
11658,,Distribution in the liver after 30 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628245,,BAO_0000019
11659,,Distribution in the liver after 5 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628246,,BAO_0000019
11660,,Distribution in the liver after 60 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628247,,BAO_0000019
11661,,Distribution in the liver after 90 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628248,,BAO_0000019
11662,,Distribution in the lung after 120 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628249,,BAO_0000019
11663,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,,50594,,N,1,Intermediate,1,,CHEMBL625452,,BAO_0000218
11664,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,,50594,,N,1,Intermediate,1,,CHEMBL625453,,BAO_0000218
11665,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,,50594,,N,1,Intermediate,1,,CHEMBL625454,,BAO_0000218
11666,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,,50594,,N,1,Intermediate,1,,CHEMBL623844,,BAO_0000218
11667,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623845,,BAO_0000218
11668,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623846,,BAO_0000218
11669,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,,22224,,U,0,Autocuration,1,,CHEMBL623847,,BAO_0000218
11670,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,100710,,N,1,Intermediate,1,,CHEMBL623848,,BAO_0000218
11671,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,100710,,N,1,Intermediate,1,,CHEMBL623849,,BAO_0000218
11672,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,100710,,N,1,Intermediate,1,,CHEMBL623850,,BAO_0000218
11673,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,100710,,N,1,Intermediate,1,,CHEMBL623851,,BAO_0000218
11674,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,,22224,,U,0,Autocuration,1,,CHEMBL623852,,BAO_0000218
11675,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,,50506,,N,1,Intermediate,1,,CHEMBL624551,,BAO_0000218
11676,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,,50506,,N,1,Intermediate,1,,CHEMBL624552,,BAO_0000218
11677,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,,22224,,U,0,Autocuration,1,,CHEMBL624553,,BAO_0000218
11678,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,,22224,,U,0,Autocuration,1,,CHEMBL624554,,BAO_0000218
11679,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624555,,BAO_0000218
11680,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,,50597,,N,1,Intermediate,1,,CHEMBL624741,,BAO_0000218
11681,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,,50588,,N,1,Intermediate,1,,CHEMBL624742,,BAO_0000218
11682,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,,100712,,N,1,Intermediate,1,,CHEMBL624743,,BAO_0000218
11683,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,,50597,,N,1,Intermediate,1,,CHEMBL877606,,BAO_0000218
11684,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL624744,,BAO_0000218
11685,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,,22224,,U,0,Autocuration,1,,CHEMBL624745,,BAO_0000218
11686,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,178.0,,22224,,U,0,Autocuration,1,,CHEMBL624746,,BAO_0000218
11687,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,,22224,,U,0,Autocuration,1,,CHEMBL624747,,BAO_0000218
11688,,Oral absorption expressed as Area under curve was determined,,,22224,,U,0,Autocuration,1,,CHEMBL624748,,BAO_0000019
11689,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,,50588,,N,1,Intermediate,1,,CHEMBL622504,,BAO_0000218
11690,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,,50588,,N,1,Intermediate,1,,CHEMBL622505,,BAO_0000218
11691,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,,100712,,N,1,Intermediate,1,,CHEMBL622506,,BAO_0000218
11692,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,,100712,,N,1,Intermediate,1,,CHEMBL622507,,BAO_0000218
11693,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,,50597,,N,1,Intermediate,1,,CHEMBL622508,,BAO_0000218
11694,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL622509,,BAO_0000019
11695,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL622510,,BAO_0000218
11696,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,,50597,,N,1,Intermediate,1,,CHEMBL622511,,BAO_0000218
11697,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,,100710,,N,1,Intermediate,1,,CHEMBL622512,,BAO_0000218
11698,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,,100710,,N,1,Intermediate,1,,CHEMBL622513,,BAO_0000218
11699,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,,100710,,N,1,Intermediate,1,,CHEMBL622514,,BAO_0000218
11700,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,,50588,,N,1,Intermediate,1,,CHEMBL622515,,BAO_0000218
11701,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,,50588,,N,1,Intermediate,1,,CHEMBL622516,,BAO_0000218
11702,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL622517,,BAO_0000218
11703,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL622518,,BAO_0000218
11704,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL622519,,BAO_0000218
11705,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL622520,,BAO_0000218
11706,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL622521,,BAO_0000218
11707,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,14.0,,50594,,N,1,Intermediate,1,,CHEMBL625113,,BAO_0000218
11708,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,14.0,,50597,,N,1,Intermediate,1,,CHEMBL625114,,BAO_0000218
11709,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,14.0,,50597,,N,1,Intermediate,1,,CHEMBL874397,,BAO_0000218
11710,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625115,,BAO_0000218
11711,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625116,,BAO_0000218
11712,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL623932,,BAO_0000218
11713,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL623933,,BAO_0000218
11714,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL623934,,BAO_0000218
11715,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL623935,,BAO_0000218
11716,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL623936,,BAO_0000218
11717,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL623937,,BAO_0000218
11718,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL623938,,BAO_0000218
11719,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,50594,,N,1,Intermediate,1,,CHEMBL623939,,BAO_0000218
11720,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL623940,,BAO_0000218
11721,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL623941,,BAO_0000218
11722,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL627216,,BAO_0000218
11723,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL623942,,BAO_0000218
11724,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,955.0,,50594,,N,1,Intermediate,1,,CHEMBL618793,,BAO_0000218
11725,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,955.0,,50594,,N,1,Intermediate,1,,CHEMBL618794,,BAO_0000218
11726,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,955.0,,50594,,N,1,Intermediate,1,,CHEMBL618795,,BAO_0000218
11727,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL618796,,BAO_0000218
11728,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL618797,,BAO_0000218
11729,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,2113.0,,50594,,N,1,Intermediate,1,,CHEMBL618798,,BAO_0000218
11730,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2113.0,,50594,,N,1,Intermediate,1,,CHEMBL618799,,BAO_0000218
11731,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,2113.0,,50594,,N,1,Intermediate,1,,CHEMBL618800,,BAO_0000218
11732,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,2113.0,,50594,,N,1,Intermediate,1,,CHEMBL618801,,BAO_0000218
11733,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2113.0,,50594,,N,1,Intermediate,1,,CHEMBL618802,,BAO_0000218
11734,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2113.0,,50594,,N,1,Intermediate,1,,CHEMBL618803,,BAO_0000218
11735,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,2107.0,,50594,,N,1,Intermediate,1,,CHEMBL618804,,BAO_0000218
11736,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2107.0,,50594,,N,1,Intermediate,1,,CHEMBL618805,,BAO_0000218
11737,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,2107.0,,50594,,N,1,Intermediate,1,,CHEMBL618806,,BAO_0000218
11738,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,2107.0,,50594,,N,1,Intermediate,1,,CHEMBL618807,,BAO_0000218
11739,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2107.0,,50594,,N,1,Intermediate,1,,CHEMBL618808,,BAO_0000218
11740,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2107.0,,50594,,N,1,Intermediate,1,,CHEMBL618809,,BAO_0000218
11741,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2385.0,,50594,,N,1,Intermediate,1,,CHEMBL618810,,BAO_0000218
11742,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,2385.0,,50594,,N,1,Intermediate,1,,CHEMBL618811,,BAO_0000218
11743,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,2385.0,,50594,,N,1,Intermediate,1,,CHEMBL875844,,BAO_0000218
11744,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2385.0,,50594,,N,1,Intermediate,1,,CHEMBL618812,,BAO_0000218
11745,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2385.0,,50594,,N,1,Intermediate,1,,CHEMBL618813,,BAO_0000218
11746,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,50594,,N,1,Intermediate,1,,CHEMBL618814,,BAO_0000218
11747,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL618815,,BAO_0000218
11748,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL618816,,BAO_0000218
11749,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL618817,,BAO_0000218
11750,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL620544,,BAO_0000218
11751,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,,50597,,N,1,Intermediate,1,,CHEMBL626230,,BAO_0000218
11752,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,,50597,,N,1,Intermediate,1,,CHEMBL626231,,BAO_0000218
11753,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,,50597,,N,1,Intermediate,1,,CHEMBL626232,,BAO_0000218
11754,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626233,,BAO_0000218
11755,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626234,,BAO_0000218
11756,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL875341,,BAO_0000218
11757,,The maximum plasma concentration (100 mg/kg) administered orally in human,1969.0,,50587,,N,1,Intermediate,1,,CHEMBL626235,,BAO_0000218
11758,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626236,,BAO_0000218
11759,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626237,,BAO_0000218
11760,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626238,,BAO_0000218
11761,,The maximum plasma concentration (200 mg/kg) administered orally in human,1969.0,,50587,,N,1,Intermediate,1,,CHEMBL622412,,BAO_0000218
11762,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623114,,BAO_0000218
11763,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL623115,,BAO_0000218
11764,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL623116,,BAO_0000218
11765,,The maximum plasma concentration (30 mg/kg) administered orally in dog,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL623117,,BAO_0000218
11766,,The maximum plasma concentration (400 mg/kg) administered orally in human,1969.0,,50587,,N,1,Intermediate,1,,CHEMBL623118,,BAO_0000218
11767,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623119,,BAO_0000218
11768,,The maximum plasma concentration (50 mg/kg) administered orally in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623120,,BAO_0000218
11769,,The maximum plasma concentration (800 mg/kg) administered orally in human,1969.0,,50587,,N,1,Intermediate,1,,CHEMBL623286,,BAO_0000218
11770,,The maximum plasma concentration was measured on rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623287,,BAO_0000218
11771,,The maximum plasma concentration was measured on rats after oral administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623288,,BAO_0000218
11772,,Plasma drug Cmax in rat (PO dose),1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623289,,BAO_0000218
11773,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,,22224,,U,0,Autocuration,1,,CHEMBL623290,,BAO_0000218
11774,,maximum Plasma concentration in Dog was determined after Peroral administration,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL623291,,BAO_0000218
11775,,maximum Plasma concentration in Rats was determined after Peroral administration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623292,,BAO_0000218
11776,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL623293,,BAO_0000218
11777,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL623294,,BAO_0000218
11778,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623295,,BAO_0000218
11779,,maximum concentration was measured when administered through oral route in mice,,,50594,,N,1,Intermediate,1,,CHEMBL623296,,BAO_0000218
11780,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,,50594,,N,1,Intermediate,1,,CHEMBL875349,,BAO_0000218
11781,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,,22224,,U,0,Autocuration,1,,CHEMBL623297,,BAO_0000019
11782,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,,22224,,U,0,Autocuration,1,,CHEMBL623298,,BAO_0000019
11783,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,,22224,,U,0,Autocuration,1,,CHEMBL623299,,BAO_0000019
11784,,Pharmacokinetic parameter was evaluated in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623300,,BAO_0000218
11785,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,,50594,,N,1,Intermediate,1,,CHEMBL623301,,BAO_0000218
11786,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,,50594,,N,1,Intermediate,1,,CHEMBL623302,,BAO_0000218
11787,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,,50594,,N,1,Intermediate,1,,CHEMBL623303,,BAO_0000218
11788,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,,50594,,N,1,Intermediate,1,,CHEMBL623304,,BAO_0000218
11789,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,,50594,,N,1,Intermediate,1,,CHEMBL623305,,BAO_0000218
11790,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623306,,BAO_0000218
11791,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623307,,BAO_0000218
11792,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL623308,,BAO_0000218
11793,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL623309,,BAO_0000218
11794,,Plasma Concentration after 120 min of oral administration to mice,,,50594,,N,1,Intermediate,1,,CHEMBL623310,,BAO_0000218
11795,,Plasma Concentration after 30 min of oral administration to mice,,,50594,,N,1,Intermediate,1,,CHEMBL623311,,BAO_0000218
11796,,Plasma Concentration after 60 min of oral administration to mice,,,100710,,N,1,Intermediate,1,,CHEMBL623312,,BAO_0000218
11797,,Plasma Concentration after 60 min of oral administration to mice; Not determined,,,50594,,N,1,Intermediate,1,,CHEMBL875350,,BAO_0000218
11798,,Plasma Concentration after 90 min of oral administration to mice,,,50594,,N,1,Intermediate,1,,CHEMBL628635,,BAO_0000218
11799,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL628636,,BAO_0000218
11800,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL628637,,BAO_0000218
11801,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL628058,,BAO_0000218
11802,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,,50597,,N,1,Intermediate,1,,CHEMBL628059,,BAO_0000218
11803,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,,50597,,N,1,Intermediate,1,,CHEMBL628060,,BAO_0000218
11804,,Distribution in the lung after 15 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628061,,BAO_0000019
11805,,Distribution in the lung after 30 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628062,,BAO_0000019
11806,,Distribution in the lung after 5 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628063,,BAO_0000019
11807,,Distribution in the lung after 60 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628064,,BAO_0000019
11808,,Distribution in the lung after 90 min of intravenous administration,,,22224,,U,0,Autocuration,1,,CHEMBL628065,,BAO_0000019
11809,,Distribution in the muscle after 120 min of intravenous administration,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL628066,,BAO_0000019
11810,,Distribution in the muscle after 15 min of intravenous administration,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL628067,,BAO_0000019
11811,,Distribution in the muscle after 30 min of intravenous administration,2385.0,,50594,,N,1,Intermediate,1,,CHEMBL874646,,BAO_0000218
11812,,Distribution in the muscle after 5 min of intravenous administration,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL628068,,BAO_0000019
11813,,Distribution in the muscle after 60 min of intravenous administration,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL628069,,BAO_0000019
11814,,Distribution in the muscle after 90 min of intravenous administration,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL628070,,BAO_0000019
11815,,Distribution in the spleen after 120 min of intravenous administration,2106.0,,22224,,U,0,Autocuration,1,,CHEMBL628071,,BAO_0000019
11816,,Distribution in the spleen after 15 min of intravenous administration,2106.0,,22224,,U,0,Autocuration,1,,CHEMBL628072,,BAO_0000019
11817,,Distribution in the spleen after 30 min of intravenous administration,2106.0,,22224,,U,0,Autocuration,1,,CHEMBL628073,,BAO_0000019
11818,,Distribution in the spleen after 5 min of intravenous administration,2106.0,,22224,,U,0,Autocuration,1,,CHEMBL628074,,BAO_0000019
11819,,Distribution in the spleen after 60 min of intravenous administration,2106.0,,22224,,U,0,Autocuration,1,,CHEMBL628075,,BAO_0000019
11820,,Distribution in the spleen after 90 min of intravenous administration,2106.0,,22224,,U,0,Autocuration,1,,CHEMBL628076,,BAO_0000019
11821,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,1235.0,,50597,,N,1,Intermediate,1,,CHEMBL628077,,BAO_0000218
11822,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628078,,BAO_0000218
11823,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628079,,BAO_0000218
11824,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,992.0,,50597,,N,1,Intermediate,1,,CHEMBL628080,,BAO_0000218
11825,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL628081,,BAO_0000218
11826,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,1235.0,,50597,,N,1,Intermediate,1,,CHEMBL628082,,BAO_0000218
11827,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,178.0,,50597,,N,1,Intermediate,1,,CHEMBL874647,,BAO_0000218
11828,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626406,,BAO_0000218
11829,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,992.0,,50597,,N,1,Intermediate,1,,CHEMBL626407,,BAO_0000218
11830,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626408,,BAO_0000218
11831,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626409,,BAO_0000218
11832,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626410,,BAO_0000218
11833,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626411,,BAO_0000218
11834,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626412,,BAO_0000218
11835,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626413,,BAO_0000218
11836,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626414,,BAO_0000218
11837,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626415,,BAO_0000218
11838,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",178.0,,50597,,N,1,Intermediate,1,,CHEMBL626416,,BAO_0000218
11839,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",178.0,,50597,,N,1,Intermediate,1,,CHEMBL627062,,BAO_0000218
11840,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",178.0,,50597,,N,1,Intermediate,1,,CHEMBL627063,,BAO_0000218
11841,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",178.0,,50597,,N,1,Intermediate,1,,CHEMBL627064,,BAO_0000218
11842,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",178.0,,50597,,N,1,Intermediate,1,,CHEMBL627227,,BAO_0000218
11843,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",178.0,,50597,,N,1,Intermediate,1,,CHEMBL627228,,BAO_0000218
11844,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",178.0,,50597,,N,1,Intermediate,1,,CHEMBL627229,,BAO_0000218
11845,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",178.0,,50597,,N,1,Intermediate,1,,CHEMBL625792,,BAO_0000218
11846,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",178.0,,50597,,N,1,Intermediate,1,,CHEMBL625793,,BAO_0000218
11847,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",178.0,,50597,,N,1,Intermediate,1,,CHEMBL625794,,BAO_0000218
11848,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",178.0,,50597,,N,1,Intermediate,1,,CHEMBL625795,,BAO_0000218
11849,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,,50594,,N,1,Intermediate,1,,CHEMBL625796,,BAO_0000218
11850,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,,50588,,N,1,Intermediate,1,,CHEMBL625797,,BAO_0000218
11851,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,,50588,,N,1,Intermediate,1,,CHEMBL625798,,BAO_0000218
11852,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,22224,,U,0,Autocuration,1,,CHEMBL875613,,BAO_0000218
11853,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,22224,,U,0,Autocuration,1,,CHEMBL625799,,BAO_0000218
11854,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,,22224,,U,0,Autocuration,1,,CHEMBL625800,,BAO_0000218
11855,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,,22224,,U,0,Autocuration,1,,CHEMBL625801,,BAO_0000218
11856,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,,22224,,U,0,Autocuration,1,,CHEMBL625802,,BAO_0000218
11857,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,22224,,U,0,Autocuration,1,,CHEMBL625803,,BAO_0000218
11858,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,,22224,,U,0,Autocuration,1,,CHEMBL625804,,BAO_0000019
11859,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,,22224,,U,0,Autocuration,1,,CHEMBL622530,,BAO_0000218
11860,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,,50594,,N,1,Intermediate,1,,CHEMBL622531,,BAO_0000218
11861,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL622532,,BAO_0000218
11862,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL623176,,BAO_0000218
11863,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL623177,,BAO_0000218
11864,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL623178,,BAO_0000218
11865,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,,50594,,N,1,Intermediate,1,,CHEMBL623179,,BAO_0000218
11866,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL623180,,BAO_0000218
11867,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL623181,,BAO_0000218
11868,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL624131,,BAO_0000218
11869,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL624132,,BAO_0000218
11870,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL624133,,BAO_0000218
11871,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,,50594,,N,1,Intermediate,1,,CHEMBL624846,,BAO_0000218
11872,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL624847,,BAO_0000218
11873,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL624848,,BAO_0000218
11874,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL625012,,BAO_0000218
11875,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL625013,,BAO_0000218
11876,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,,50594,,N,1,Intermediate,1,,CHEMBL625014,,BAO_0000218
11877,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL625015,,BAO_0000218
11878,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL625016,,BAO_0000218
11879,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,,50594,,N,1,Intermediate,1,,CHEMBL625017,,BAO_0000218
11880,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL625018,,BAO_0000218
11881,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL625019,,BAO_0000218
11882,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL625020,,BAO_0000218
11883,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,,50594,,N,1,Intermediate,1,,CHEMBL625021,,BAO_0000218
11884,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL625022,,BAO_0000218
11885,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,,50594,,N,1,Intermediate,1,,CHEMBL625023,,BAO_0000218
11886,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,,100710,,N,1,Intermediate,1,,CHEMBL625024,,BAO_0000218
11887,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,,100710,,N,1,Intermediate,1,,CHEMBL627626,,BAO_0000218
11888,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,955.0,,22224,,U,0,Autocuration,1,,CHEMBL627627,,BAO_0000218
11889,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,1977.0,,22224,,U,0,Autocuration,1,,CHEMBL627628,,BAO_0000218
11890,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,955.0,,22224,,U,0,Autocuration,1,,CHEMBL627629,,BAO_0000218
11891,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,1977.0,,22224,,U,0,Autocuration,1,,CHEMBL627630,,BAO_0000218
11892,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,,22224,,U,0,Autocuration,1,,CHEMBL627631,,BAO_0000019
11893,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,,22224,,U,0,Autocuration,1,,CHEMBL629515,,BAO_0000218
11894,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2106.0,,50594,,N,1,Intermediate,1,,CHEMBL629516,,BAO_0000218
11895,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2106.0,,50594,,N,1,Intermediate,1,,CHEMBL629517,,BAO_0000218
11896,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2106.0,,50594,,N,1,Intermediate,1,,CHEMBL629518,,BAO_0000218
11897,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,50594,,N,1,Intermediate,1,,CHEMBL877499,,BAO_0000218
11898,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL629519,,BAO_0000218
11899,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL629520,,BAO_0000218
11900,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,,N,1,Intermediate,1,,CHEMBL629521,,BAO_0000218
11901,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,,50594,,N,1,Intermediate,1,,CHEMBL629522,,BAO_0000218
11902,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,,50594,,N,1,Intermediate,1,,CHEMBL629523,,BAO_0000218
11903,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,,50594,,N,1,Intermediate,1,,CHEMBL629524,,BAO_0000218
11904,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,,50594,,N,1,Intermediate,1,,CHEMBL629525,,BAO_0000218
11905,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,,50594,,N,1,Intermediate,1,,CHEMBL629526,,BAO_0000218
11906,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,,50594,,N,1,Intermediate,1,,CHEMBL629527,,BAO_0000218
11907,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,,50594,,N,1,Intermediate,1,,CHEMBL629528,,BAO_0000218
11908,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,,50594,,N,1,Intermediate,1,,CHEMBL629529,,BAO_0000218
11909,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,,50594,,N,1,Intermediate,1,,CHEMBL629530,,BAO_0000218
11910,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,,50594,,N,1,Intermediate,1,,CHEMBL629531,,BAO_0000218
11911,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,,50594,,N,1,Intermediate,1,,CHEMBL628656,,BAO_0000218
11912,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,,50594,,N,1,Intermediate,1,,CHEMBL628657,,BAO_0000218
11913,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL628658,,BAO_0000218
11914,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL628659,,BAO_0000218
11915,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL877500,,BAO_0000218
11916,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL628660,,BAO_0000218
11917,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL628661,,BAO_0000218
11918,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL628662,,BAO_0000218
11919,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL628663,,BAO_0000218
11920,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL628664,,BAO_0000218
11921,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL628665,,BAO_0000218
11922,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL628666,,BAO_0000218
11923,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL628667,,BAO_0000218
11924,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL628668,,BAO_0000218
11925,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL628669,,BAO_0000218
11926,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL628670,,BAO_0000218
11927,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",178.0,,50597,,N,1,Intermediate,1,,CHEMBL628671,,BAO_0000218
11928,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL628672,,BAO_0000218
11929,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL630300,,BAO_0000218
11930,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL629787,,BAO_0000218
11931,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL629788,,BAO_0000218
11932,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL629789,,BAO_0000218
11933,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL629790,,BAO_0000218
11934,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL629791,,BAO_0000218
11935,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL629792,,BAO_0000218
11936,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL629793,,BAO_0000218
11937,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL629794,,BAO_0000218
11938,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,,50597,,N,1,Intermediate,1,,CHEMBL874459,,BAO_0000218
11939,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,,50597,,N,1,Intermediate,1,,CHEMBL629795,,BAO_0000218
11940,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,,50597,,N,1,Intermediate,1,,CHEMBL629796,,BAO_0000218
11941,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,,50597,,N,1,Intermediate,1,,CHEMBL629797,,BAO_0000218
11942,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,,50597,,N,1,Intermediate,1,,CHEMBL629798,,BAO_0000218
11943,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2369.0,,50597,,N,1,Intermediate,1,,CHEMBL629799,,BAO_0000218
11944,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2369.0,,50597,,N,1,Intermediate,1,,CHEMBL629800,,BAO_0000218
11945,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2369.0,,50597,,N,1,Intermediate,1,,CHEMBL629801,,BAO_0000218
11946,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,2369.0,,50597,,N,1,Intermediate,1,,CHEMBL629802,,BAO_0000218
11947,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2369.0,,50597,,N,1,Intermediate,1,,CHEMBL629803,,BAO_0000218
11948,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629804,,BAO_0000218
11949,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629805,,BAO_0000218
11950,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629806,,BAO_0000218
11951,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629807,,BAO_0000218
11952,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629808,,BAO_0000218
11953,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,955.0,,50597,,N,1,Intermediate,1,,CHEMBL629809,,BAO_0000218
11954,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,955.0,,50597,,N,1,Intermediate,1,,CHEMBL629810,,BAO_0000218
11955,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,955.0,,50597,,N,1,Intermediate,1,,CHEMBL629811,,BAO_0000218
11956,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,955.0,,50597,,N,1,Intermediate,1,,CHEMBL629812,,BAO_0000218
11957,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,955.0,,50597,,N,1,Intermediate,1,,CHEMBL629813,,BAO_0000218
11958,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,955.0,,50597,,N,1,Intermediate,1,,CHEMBL874460,,BAO_0000218
11959,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,,N,1,Intermediate,1,,CHEMBL629814,,BAO_0000218
11960,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,,N,1,Intermediate,1,,CHEMBL629815,,BAO_0000218
11961,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,,N,1,Intermediate,1,,CHEMBL629816,,BAO_0000218
11962,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,,N,1,Intermediate,1,,CHEMBL629817,,BAO_0000218
11963,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626643,,BAO_0000218
11964,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626644,,BAO_0000218
11965,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626806,,BAO_0000218
11966,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626807,,BAO_0000218
11967,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627261,,BAO_0000218
11968,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627262,,BAO_0000218
11969,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627263,,BAO_0000218
11970,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627264,,BAO_0000218
11971,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627265,,BAO_0000218
11972,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627266,,BAO_0000218
11973,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627267,,BAO_0000218
11974,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627268,,BAO_0000218
11975,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627269,,BAO_0000218
11976,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627270,,BAO_0000218
11977,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,,50597,,N,1,Intermediate,1,,CHEMBL627271,,BAO_0000218
11978,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,,50597,,N,1,Intermediate,1,,CHEMBL627946,,BAO_0000218
11979,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,,50597,,N,1,Intermediate,1,,CHEMBL875472,,BAO_0000218
11980,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,,50597,,N,1,Intermediate,1,,CHEMBL627947,,BAO_0000218
11981,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,,50597,,N,1,Intermediate,1,,CHEMBL627948,,BAO_0000218
11982,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,,50597,,N,1,Intermediate,1,,CHEMBL628113,,BAO_0000218
11983,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,,50597,,N,1,Intermediate,1,,CHEMBL628114,,BAO_0000218
11984,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,,50597,,N,1,Intermediate,1,,CHEMBL628115,,BAO_0000218
11985,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,,50597,,N,1,Intermediate,1,,CHEMBL628116,,BAO_0000218
11986,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,,50597,,N,1,Intermediate,1,,CHEMBL628117,,BAO_0000218
11987,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,,50597,,N,1,Intermediate,1,,CHEMBL628118,,BAO_0000218
11988,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,,50597,,N,1,Intermediate,1,,CHEMBL628119,,BAO_0000218
11989,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,,50597,,N,1,Intermediate,1,,CHEMBL628120,,BAO_0000218
11990,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,,50597,,N,1,Intermediate,1,,CHEMBL628121,,BAO_0000218
11991,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,,50597,,N,1,Intermediate,1,,CHEMBL628122,,BAO_0000218
11992,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,,50597,,N,1,Intermediate,1,,CHEMBL627297,,BAO_0000218
11993,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,,50597,,N,1,Intermediate,1,,CHEMBL627298,,BAO_0000218
11994,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,,50597,,N,1,Intermediate,1,,CHEMBL627299,,BAO_0000218
11995,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,,50597,,N,1,Intermediate,1,,CHEMBL627300,,BAO_0000218
11996,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,,50597,,N,1,Intermediate,1,,CHEMBL627301,,BAO_0000218
11997,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,,50597,,N,1,Intermediate,1,,CHEMBL627302,,BAO_0000218
11998,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,,50597,,N,1,Intermediate,1,,CHEMBL627303,,BAO_0000218
11999,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,,50597,,N,1,Intermediate,1,,CHEMBL627304,,BAO_0000218
12000,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,,50597,,N,1,Intermediate,1,,CHEMBL627305,,BAO_0000218
12001,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,,50597,,N,1,Intermediate,1,,CHEMBL627306,,BAO_0000218
12002,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,,50597,,N,1,Intermediate,1,,CHEMBL623982,,BAO_0000218
12003,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,,50597,,N,1,Intermediate,1,,CHEMBL623983,,BAO_0000218
12004,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,,50597,,N,1,Intermediate,1,,CHEMBL623984,,BAO_0000218
12005,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,,50597,,N,1,Intermediate,1,,CHEMBL623985,,BAO_0000218
12006,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,,50597,,N,1,Intermediate,1,,CHEMBL623986,,BAO_0000218
12007,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,,50597,,N,1,Intermediate,1,,CHEMBL623987,,BAO_0000218
12008,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,,50597,,N,1,Intermediate,1,,CHEMBL623988,,BAO_0000218
12009,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,,50597,,N,1,Intermediate,1,,CHEMBL623989,,BAO_0000218
12010,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,,50597,,N,1,Intermediate,1,,CHEMBL622215,,BAO_0000218
12011,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,,50597,,N,1,Intermediate,1,,CHEMBL622216,,BAO_0000218
12012,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,,50597,,N,1,Intermediate,1,,CHEMBL877481,,BAO_0000218
12013,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,,22224,,U,0,Autocuration,1,,CHEMBL622217,,BAO_0000218
12014,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,,50594,,N,1,Intermediate,1,,CHEMBL622218,,BAO_0000218
12015,,Pharmacokinetic profile AUC was evaluated in rats,,,50597,,N,1,Intermediate,1,,CHEMBL622219,,BAO_0000218
12016,,Pharmacokinetic property (Area under curve),,,22224,,U,0,Autocuration,1,,CHEMBL622220,,BAO_0000019
12017,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,,50588,,N,1,Intermediate,1,,CHEMBL622221,,BAO_0000218
12018,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,,50594,,N,1,Intermediate,1,,CHEMBL622222,,BAO_0000218
12019,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,,50588,,N,1,Intermediate,1,,CHEMBL622223,,BAO_0000218
12020,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,,50594,,N,1,Intermediate,1,,CHEMBL622224,,BAO_0000218
12021,,Plasma concentration (AUC) was determined,,,22224,,U,0,Autocuration,1,,CHEMBL622225,,BAO_0000019
12022,,Plasma concentration (AUC) was determined; Not detectable,,,22224,,U,0,Autocuration,1,,CHEMBL622226,,BAO_0000019
12023,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,,50512,,N,1,Intermediate,1,,CHEMBL624154,,BAO_0000218
12024,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624155,,BAO_0000218
12025,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,,50597,,N,1,Intermediate,1,,CHEMBL624156,,BAO_0000218
12026,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624157,,BAO_0000218
12027,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL624158,,BAO_0000218
12028,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,,50597,,N,1,Intermediate,1,,CHEMBL624159,,BAO_0000218
12029,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,,50597,,N,1,Intermediate,1,,CHEMBL624160,,BAO_0000218
12030,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,,50597,,N,1,Intermediate,1,,CHEMBL624161,,BAO_0000218
12031,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,,50597,,N,1,Intermediate,1,,CHEMBL624162,,BAO_0000218
12032,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624163,,BAO_0000218
12033,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL624164,,BAO_0000218
12034,,The AUC(0-infinity) values in female wistar rats.,,,50597,,N,1,Intermediate,1,,CHEMBL624165,,BAO_0000218
12035,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL624166,,BAO_0000218
12036,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,,50597,,N,1,Intermediate,1,,CHEMBL624167,,BAO_0000218
12037,,The AUC(0-t)values in female wistar rats.,,,50597,,N,1,Intermediate,1,,CHEMBL624168,,BAO_0000218
12038,,The Area under the concentration time curve of compound was measured on rats,,,50597,,N,1,Intermediate,1,,CHEMBL624169,,BAO_0000218
12039,,The area under curve (100 mg/kg) administered orally in humans,,,50587,,N,1,Intermediate,1,,CHEMBL624170,,BAO_0000218
12040,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,,22224,,U,0,Autocuration,1,,CHEMBL624171,,BAO_0000218
12041,,The area under curve (12.5 mg/kg) administered intravenously in monkey,,,22224,,U,0,Autocuration,1,,CHEMBL624172,,BAO_0000218
12042,,The area under curve (15 mg/kg) administered intravenously in dog,,,50588,,N,1,Intermediate,1,,CHEMBL624173,,BAO_0000218
12043,,The area under curve (200 mg/kg) administered orally in humans,,,50587,,N,1,Intermediate,1,,CHEMBL877488,,BAO_0000218
12044,,The area under curve (25 mg/kg) administered intravenously in rat,,,50597,,N,1,Intermediate,1,,CHEMBL624174,,BAO_0000218
12045,,The area under curve (25 mg/kg) administered orally in marmoset,,,22224,,U,0,Autocuration,1,,CHEMBL624175,,BAO_0000218
12046,,The area under curve (25 mg/kg) administered orally in monkey,,,22224,,U,0,Autocuration,1,,CHEMBL624176,,BAO_0000218
12047,,The area under curve (30 mg/kg) administered orally in dog,,,50588,,N,1,Intermediate,1,,CHEMBL624177,,BAO_0000218
12048,,The area under curve (400 mg/kg) administered orally in humans,,,50587,,N,1,Intermediate,1,,CHEMBL624178,,BAO_0000218
12049,,The area under curve (50 mg/kg) administered orally in fasted rat,,,50597,,N,1,Intermediate,1,,CHEMBL624179,,BAO_0000218
12050,,The area under curve (50 mg/kg) administered orally in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627689,,BAO_0000218
12051,,The area under curve (800 mg/kg) administered orally in humans,,,50587,,N,1,Intermediate,1,,CHEMBL627690,,BAO_0000218
12052,,The compound was evaluated for area under the curve,,,22224,,U,0,Autocuration,1,,CHEMBL627691,,BAO_0000019
12053,,The compound was evaluated for area under the curve in marmosets,,,22224,,U,0,Autocuration,1,,CHEMBL627692,,BAO_0000019
12054,,The compound was evaluated for area under the curve in marmosets,,,22224,,U,0,Autocuration,1,,CHEMBL627693,,BAO_0000019
12055,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,50597,,N,1,Intermediate,1,,CHEMBL627694,,BAO_0000218
12056,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,,50597,,N,1,Intermediate,1,,CHEMBL627695,,BAO_0000218
12057,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,,22224,,U,0,Autocuration,1,,CHEMBL627696,,BAO_0000218
12058,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,50597,,N,1,Intermediate,1,,CHEMBL627697,,BAO_0000218
12059,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,50597,,N,1,Intermediate,1,,CHEMBL627698,,BAO_0000218
12060,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,,50597,,N,1,Intermediate,1,,CHEMBL627699,,BAO_0000218
12061,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627700,,BAO_0000218
12062,,Total drug exposure is determined after oral dosing in rats.,,,50597,,N,1,Intermediate,1,,CHEMBL627701,,BAO_0000218
12063,,Total drug exposure (5 mg/kg) when administered intravenously,,,22224,,U,0,Autocuration,1,,CHEMBL627702,,BAO_0000218
12064,,Total drug exposure (5 mg/kg) when administered orally,,,22224,,U,0,Autocuration,1,,CHEMBL627703,,BAO_0000218
12065,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,,22224,,U,0,Autocuration,1,,CHEMBL626873,,BAO_0000218
12066,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL629583,,BAO_0000218
12067,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,,50588,,N,1,Intermediate,1,,CHEMBL629584,,BAO_0000218
12068,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,,50588,,N,1,Intermediate,1,,CHEMBL629585,,BAO_0000218
12069,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL629586,,BAO_0000218
12070,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",955.0,,50597,,N,1,Intermediate,1,,CHEMBL629587,,BAO_0000218
12071,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL629588,,BAO_0000218
12072,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL629589,,BAO_0000218
12073,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL629590,,BAO_0000218
12074,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL629591,,BAO_0000218
12075,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL629592,,BAO_0000218
12076,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL629593,,BAO_0000218
12077,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL629594,,BAO_0000218
12078,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL629595,,BAO_0000218
12079,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL630290,,BAO_0000218
12080,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL627137,,BAO_0000218
12081,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL627138,,BAO_0000218
12082,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL627139,,BAO_0000218
12083,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL627140,,BAO_0000218
12084,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",948.0,,50597,,N,1,Intermediate,1,,CHEMBL627141,,BAO_0000218
12085,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627142,,BAO_0000218
12086,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627143,,BAO_0000218
12087,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL874449,,BAO_0000218
12088,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627144,,BAO_0000218
12089,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627145,,BAO_0000218
12090,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627146,,BAO_0000218
12091,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627147,,BAO_0000218
12092,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627148,,BAO_0000218
12093,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627149,,BAO_0000218
12094,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL632160,,BAO_0000218
12095,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL632161,,BAO_0000218
12096,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL632162,,BAO_0000218
12097,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL632163,,BAO_0000218
12098,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL874469,,BAO_0000218
12099,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627182,,BAO_0000218
12100,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627183,,BAO_0000218
12101,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627184,,BAO_0000218
12102,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627185,,BAO_0000218
12103,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627186,,BAO_0000218
12104,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627187,,BAO_0000218
12105,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627188,,BAO_0000218
12106,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627189,,BAO_0000218
12107,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,,N,1,Intermediate,1,,CHEMBL627190,,BAO_0000218
12108,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627191,,BAO_0000218
12109,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627192,,BAO_0000218
12110,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627193,,BAO_0000218
12111,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL874590,,BAO_0000218
12112,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627194,,BAO_0000218
12113,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627195,,BAO_0000218
12114,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,992.0,,50597,,N,1,Intermediate,1,,CHEMBL627196,,BAO_0000218
12115,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,992.0,,50597,,N,1,Intermediate,1,,CHEMBL627197,,BAO_0000218
12116,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,992.0,,50597,,N,1,Intermediate,1,,CHEMBL627198,,BAO_0000218
12117,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,992.0,,50597,,N,1,Intermediate,1,,CHEMBL627199,,BAO_0000218
12118,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,992.0,,50597,,N,1,Intermediate,1,,CHEMBL627200,,BAO_0000218
12119,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627201,,BAO_0000218
12120,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627202,,BAO_0000218
12121,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627203,,BAO_0000218
12122,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627204,,BAO_0000218
12123,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL627205,,BAO_0000218
12124,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL627206,,BAO_0000218
12125,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL627207,,BAO_0000218
12126,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL627208,,BAO_0000218
12127,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL627209,,BAO_0000218
12128,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL627210,,BAO_0000218
12129,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL627211,,BAO_0000218
12130,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL627212,,BAO_0000218
12131,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,995.0,,50597,,N,1,Intermediate,1,,CHEMBL627213,,BAO_0000218
12132,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,995.0,,50597,,N,1,Intermediate,1,,CHEMBL626599,,BAO_0000218
12133,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,995.0,,50597,,N,1,Intermediate,1,,CHEMBL626600,,BAO_0000218
12134,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,995.0,,50597,,N,1,Intermediate,1,,CHEMBL626601,,BAO_0000218
12135,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,,22224,,U,0,Autocuration,1,,CHEMBL627484,,BAO_0000019
12136,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),1969.0,,100710,,N,1,Intermediate,1,,CHEMBL627485,,BAO_0000218
12137,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,1969.0,,100710,,N,1,Intermediate,1,,CHEMBL628147,,BAO_0000218
12138,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,1969.0,,100710,,N,1,Intermediate,1,,CHEMBL628148,,BAO_0000218
12139,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),1969.0,,50588,,N,1,Intermediate,1,,CHEMBL628149,,BAO_0000218
12140,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL628150,,BAO_0000218
12141,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL628318,,BAO_0000218
12142,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL628319,,BAO_0000218
12143,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,,50588,,N,1,Intermediate,1,,CHEMBL875609,,BAO_0000218
12144,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,,22224,,U,0,Autocuration,1,,CHEMBL628320,,BAO_0000019
12145,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,,22224,,U,0,Autocuration,1,,CHEMBL628321,,BAO_0000019
12146,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,,22224,,U,0,Autocuration,1,,CHEMBL628322,,BAO_0000019
12147,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,,22224,,U,0,Autocuration,1,,CHEMBL628323,,BAO_0000019
12148,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,,22224,,U,0,Autocuration,1,,CHEMBL628324,,BAO_0000019
12149,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,,22224,,U,0,Autocuration,1,,CHEMBL628325,,BAO_0000019
12150,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,,22224,,U,0,Autocuration,1,,CHEMBL628326,,BAO_0000019
12151,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",1236.0,,50588,,N,1,Intermediate,1,,CHEMBL628327,,BAO_0000218
12152,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",1236.0,,50588,,N,1,Intermediate,1,,CHEMBL628328,,BAO_0000218
12153,,"Concentration of compound in blood of dog 1, after administering intravenously",178.0,,50588,,N,1,Intermediate,1,,CHEMBL628329,,BAO_0000218
12154,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628330,,BAO_0000218
12155,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628331,,BAO_0000218
12156,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628332,,BAO_0000218
12157,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628333,,BAO_0000218
12158,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628334,,BAO_0000218
12159,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628335,,BAO_0000218
12160,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628336,,BAO_0000218
12161,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628337,,BAO_0000218
12162,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628338,,BAO_0000218
12163,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL875610,,BAO_0000218
12164,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628339,,BAO_0000218
12165,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628340,,BAO_0000218
12166,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628341,,BAO_0000218
12167,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622214,,BAO_0000218
12168,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL623167,,BAO_0000218
12169,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL623168,,BAO_0000218
12170,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL623169,,BAO_0000218
12171,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL623170,,BAO_0000218
12172,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627224,,BAO_0000218
12173,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL875634,,BAO_0000218
12174,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627225,,BAO_0000218
12175,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627226,,BAO_0000218
12176,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626083,,BAO_0000218
12177,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626084,,BAO_0000218
12178,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626085,,BAO_0000218
12179,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626086,,BAO_0000218
12180,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626087,,BAO_0000218
12181,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626088,,BAO_0000218
12182,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626089,,BAO_0000218
12183,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626090,,BAO_0000218
12184,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626091,,BAO_0000218
12185,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626092,,BAO_0000218
12186,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626093,,BAO_0000218
12187,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626094,,BAO_0000218
12188,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626095,,BAO_0000218
12189,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",2048.0,,50597,,N,1,Intermediate,1,,CHEMBL626096,,BAO_0000218
12190,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,,22224,,U,0,Autocuration,1,,CHEMBL626097,,BAO_0000218
12191,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626098,,BAO_0000218
12192,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626099,,BAO_0000218
12193,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL626100,,BAO_0000218
12194,,AUC 0-inf in dog,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626101,,BAO_0000218
12195,,AUC 0-inf in guinea pig,1969.0,,50512,,N,1,Intermediate,1,,CHEMBL626102,,BAO_0000218
12196,,AUC 0-t in dog,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626103,,BAO_0000218
12197,,AUC 0-t in guinea pig,1969.0,,50512,,N,1,Intermediate,1,,CHEMBL628391,,BAO_0000218
12198,,The compound was tested for brain to plasma partition in rat,,,50597,,N,1,Intermediate,1,,CHEMBL628392,,BAO_0000218
12199,,The compound was tested for brain to plasma partition in rat.,,,50597,,N,1,Intermediate,1,,CHEMBL628393,,BAO_0000218
12200,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,178.0,,22224,,U,0,Autocuration,1,,CHEMBL628394,,BAO_0000019
12201,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,,50588,,N,1,Intermediate,1,,CHEMBL628395,,BAO_0000218
12202,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,,22224,,U,0,Autocuration,1,,CHEMBL628396,,BAO_0000218
12203,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,,50592,,N,1,Intermediate,1,,CHEMBL628397,,BAO_0000218
12204,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,,50597,,N,1,Intermediate,1,,CHEMBL628398,,BAO_0000218
12205,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,,50797,,N,1,Intermediate,1,,CHEMBL628399,,BAO_0000218
12206,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,,50588,,N,1,Intermediate,1,,CHEMBL628400,,BAO_0000218
12207,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL874907,,BAO_0000218
12208,,Area under curve of the compound was determined,,,22224,,U,0,Autocuration,1,,CHEMBL628401,,BAO_0000019
12209,,AUC in monkeys at a dose of 1 mg/kg,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL628402,,BAO_0000218
12210,,AUC in rats at a dose of 1 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628403,,BAO_0000218
12211,,Compound was evaluated for the overall absorbance loss at pH of 2,,,22224,,U,0,Autocuration,1,,CHEMBL628404,,BAO_0000019
12212,,Compound was evaluated for the overall absorbance loss at pH of 4,,,22224,,U,0,Autocuration,1,,CHEMBL628405,,BAO_0000019
12213,,Compound was evaluated for the overall absorbance loss at pH of 7,,,22224,,U,0,Autocuration,1,,CHEMBL628406,,BAO_0000019
12214,,Compound was evaluated for its absorption in the rats,,,50597,,N,1,Intermediate,1,,CHEMBL628407,,BAO_0000218
12215,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628408,,BAO_0000218
12216,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629171,,BAO_0000218
12217,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629172,,BAO_0000218
12218,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629173,,BAO_0000218
12219,,In vitro percent permeability into rat ileum,,,50597,,N,1,Intermediate,1,,CHEMBL629174,,BAO_0000218
12220,,In vitro percent permeability into rat ileum; Range is 10-17,,,50597,,N,1,Intermediate,1,,CHEMBL629175,,BAO_0000218
12221,,In vitro percent permeability into rat ileum; Range is 10-18,,,50597,,N,1,Intermediate,1,,CHEMBL629176,,BAO_0000218
12222,,In vitro percent permeability into rat ileum; Range is 10-19,,,50597,,N,1,Intermediate,1,,CHEMBL629177,,BAO_0000218
12223,,In vitro percent permeability into rat ileum; Range is 12-15,,,50597,,N,1,Intermediate,1,,CHEMBL629178,,BAO_0000218
12224,,In vitro percent permeability into rat ileum; Range is 13-19,,,50597,,N,1,Intermediate,1,,CHEMBL631869,,BAO_0000218
12225,,In vitro percent permeability into rat ileum; Range is 14-17,,,50597,,N,1,Intermediate,1,,CHEMBL631870,,BAO_0000218
12226,,In vitro percent permeability into rat ileum; Range is 15-18,,,50597,,N,1,Intermediate,1,,CHEMBL631871,,BAO_0000218
12227,,In vitro percent permeability into rat ileum; Range is 2-5,,,50597,,N,1,Intermediate,1,,CHEMBL631872,,BAO_0000218
12228,,In vitro percent permeability into rat ileum; Range is 23-42,2116.0,,22224,,U,0,Autocuration,1,,CHEMBL875775,,BAO_0000221
12229,,In vitro percent permeability into rat ileum; Range is 28-36,,,50597,,N,1,Intermediate,1,,CHEMBL631873,,BAO_0000218
12230,,In vitro percent permeability into rat ileum; Range is 29-35,,,50597,,N,1,Intermediate,1,,CHEMBL631874,,BAO_0000218
12231,,In vitro percent permeability into rat ileum; Range is 46-66,,,50597,,N,1,Intermediate,1,,CHEMBL631875,,BAO_0000218
12232,,In vitro percent permeability into rat ileum; Range is 50-68,,,50597,,N,1,Intermediate,1,,CHEMBL631876,,BAO_0000218
12233,,In vitro percent permeability into rat ileum; Range is 78-81,,,50597,,N,1,Intermediate,1,,CHEMBL631877,,BAO_0000218
12234,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,,50597,,N,1,Intermediate,1,,CHEMBL631878,,BAO_0000218
12235,,In vitro percent permeability into rat ileum; nd indicates not detected,,,50597,,N,1,Intermediate,1,,CHEMBL631879,,BAO_0000218
12236,,In vitro percent permeability into rat ileum; nt indicates not detected,,,50597,,N,1,Intermediate,1,,CHEMBL631880,,BAO_0000218
12237,,In vitro percent permeability into rat ileum; nt indicates not tested,,,50597,,N,1,Intermediate,1,,CHEMBL631881,,BAO_0000218
12238,,Compound was tested for oral absorption in bile-duct cannulated rats,,,50597,,N,1,Intermediate,1,,CHEMBL631882,,BAO_0000218
12239,,Compound was tested for oral absorption in bile-duct cannulated rats.,,,50597,,N,1,Intermediate,1,,CHEMBL630749,,BAO_0000218
12240,,Oral absorption using Caco-2 cell monolayers.,,,50587,,N,1,Intermediate,1,,CHEMBL630750,,BAO_0000218
12241,,Percent of the drug absorbed after administration to humans was determined,,,50587,,N,1,Intermediate,1,,CHEMBL630253,,BAO_0000218
12242,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL630254,,BAO_0000218
12243,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL630255,,BAO_0000218
12244,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL630256,,BAO_0000218
12245,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL875781,,BAO_0000218
12246,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL630257,,BAO_0000218
12247,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",2107.0,,50597,,N,1,Intermediate,1,,CHEMBL630258,,BAO_0000218
12248,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,,50597,,N,1,Intermediate,1,,CHEMBL630259,,BAO_0000218
12249,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",2435.0,,50597,,N,1,Intermediate,1,,CHEMBL630260,,BAO_0000218
12250,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",2435.0,,50597,,N,1,Intermediate,1,,CHEMBL630261,,BAO_0000218
12251,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,,50597,,N,1,Intermediate,1,,CHEMBL630262,,BAO_0000218
12252,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,,50597,,N,1,Intermediate,1,,CHEMBL630263,,BAO_0000218
12253,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,,50597,,N,1,Intermediate,1,,CHEMBL630264,,BAO_0000218
12254,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,,50597,,N,1,Intermediate,1,,CHEMBL630265,,BAO_0000218
12255,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,,50597,,N,1,Intermediate,1,,CHEMBL630266,,BAO_0000218
12256,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL630267,,BAO_0000218
12257,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL630268,,BAO_0000218
12258,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,,50597,,N,1,Intermediate,1,,CHEMBL630269,,BAO_0000218
12259,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,,50597,,N,1,Intermediate,1,,CHEMBL630270,,BAO_0000218
12260,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630141,,BAO_0000218
12261,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630142,,BAO_0000218
12262,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL630143,,BAO_0000218
12263,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL630144,,BAO_0000218
12264,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,2367.0,,50597,,N,1,Intermediate,1,,CHEMBL630145,,BAO_0000218
12265,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,2367.0,,50597,,N,1,Intermediate,1,,CHEMBL630146,,BAO_0000218
12266,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,,50597,,N,1,Intermediate,1,,CHEMBL630147,,BAO_0000218
12267,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,,50597,,N,1,Intermediate,1,,CHEMBL630148,,BAO_0000218
12268,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,,50597,,N,1,Intermediate,1,,CHEMBL630149,,BAO_0000218
12269,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630150,,BAO_0000218
12270,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630151,,BAO_0000218
12271,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL632031,,BAO_0000218
12272,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL632032,,BAO_0000218
12273,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,,50597,,N,1,Intermediate,1,,CHEMBL632033,,BAO_0000218
12274,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,,50597,,N,1,Intermediate,1,,CHEMBL632034,,BAO_0000218
12275,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL632035,,BAO_0000218
12276,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,,50597,,N,1,Intermediate,1,,CHEMBL632036,,BAO_0000218
12277,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL632037,,BAO_0000218
12278,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL632038,,BAO_0000218
12279,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL632039,,BAO_0000218
12280,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL632040,,BAO_0000218
12281,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL632041,,BAO_0000218
12282,,"Concentration of compound in blood of dog 2, after administering intravenously",178.0,,50588,,N,1,Intermediate,1,,CHEMBL632042,,BAO_0000218
12283,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,,50588,,N,1,Intermediate,1,,CHEMBL632043,,BAO_0000218
12284,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,,50588,,N,1,Intermediate,1,,CHEMBL632044,,BAO_0000218
12285,,"Concentration of compound in liver of dog 1, after administering intravenously",2107.0,,50588,,N,1,Intermediate,1,,CHEMBL632045,,BAO_0000218
12286,,"Concentration of compound in liver of dog 2, after administering intravenously",2107.0,,50588,,N,1,Intermediate,1,,CHEMBL632046,,BAO_0000218
12287,,"Concentration of compound in lung of dog 1, after administering intravenously",2048.0,,50588,,N,1,Intermediate,1,,CHEMBL632047,,BAO_0000218
12288,,"Concentration of compound in lung of dog 2, after administering intravenously",2048.0,,50588,,N,1,Intermediate,1,,CHEMBL632048,,BAO_0000218
12289,,"Concentration of compound in muscle of dog 1, after administering intravenously",2385.0,,50588,,N,1,Intermediate,1,,CHEMBL632049,,BAO_0000218
12290,,"Concentration of compound in muscle of dog 2, after administering intravenously",2385.0,,50588,,N,1,Intermediate,1,,CHEMBL876418,,BAO_0000218
12291,,"Concentration of compound in spleen of dog 1,after administering intravenously",2106.0,,50588,,N,1,Intermediate,1,,CHEMBL632050,,BAO_0000218
12292,,"Concentration of compound in spleen of dog 2, after administering intravenously",2106.0,,50588,,N,1,Intermediate,1,,CHEMBL632051,,BAO_0000218
12293,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,,22224,,U,0,Autocuration,1,,CHEMBL632052,,BAO_0000218
12294,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,,22224,,U,0,Autocuration,1,,CHEMBL632053,,BAO_0000218
12295,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,22224,,U,0,Autocuration,1,,CHEMBL632054,,BAO_0000218
12296,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,22224,,U,0,Autocuration,1,,CHEMBL632055,,BAO_0000218
12297,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,,22224,,U,0,Autocuration,1,,CHEMBL631181,,BAO_0000218
12298,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL631182,,BAO_0000218
12299,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL631183,,BAO_0000218
12300,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL631184,,BAO_0000218
12301,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL629774,,BAO_0000218
12302,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL629775,,BAO_0000218
12303,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL876549,,BAO_0000218
12304,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628172,,BAO_0000218
12305,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628173,,BAO_0000218
12306,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628174,,BAO_0000218
12307,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628175,,BAO_0000218
12308,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628176,,BAO_0000218
12309,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628177,,BAO_0000218
12310,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628178,,BAO_0000218
12311,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628179,,BAO_0000218
12312,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,22224,,U,0,Autocuration,1,,CHEMBL628180,,BAO_0000218
12313,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628181,,BAO_0000218
12314,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628182,,BAO_0000218
12315,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628183,,BAO_0000218
12316,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,,22224,,U,0,Autocuration,1,,CHEMBL628184,,BAO_0000218
12317,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628185,,BAO_0000218
12318,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL875617,,BAO_0000218
12319,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,22224,,U,0,Autocuration,1,,CHEMBL628186,,BAO_0000218
12320,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628187,,BAO_0000218
12321,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628188,,BAO_0000218
12322,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628189,,BAO_0000218
12323,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,,22224,,U,0,Autocuration,1,,CHEMBL628190,,BAO_0000218
12324,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628191,,BAO_0000218
12325,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,,22224,,U,0,Autocuration,1,,CHEMBL626513,,BAO_0000218
12326,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626514,,BAO_0000218
12327,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626515,,BAO_0000218
12328,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626516,,BAO_0000218
12329,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626517,,BAO_0000218
12330,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626518,,BAO_0000218
12331,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626519,,BAO_0000218
12332,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626520,,BAO_0000218
12333,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626521,,BAO_0000218
12334,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626522,,BAO_0000218
12335,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626523,,BAO_0000218
12336,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626524,,BAO_0000218
12337,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626688,,BAO_0000218
12338,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626689,,BAO_0000218
12339,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626690,,BAO_0000218
12340,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626691,,BAO_0000218
12341,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL627319,,BAO_0000218
12342,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL624052,,BAO_0000218
12343,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",2046.0,,50597,,N,1,Intermediate,1,,CHEMBL624053,,BAO_0000218
12344,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624054,,BAO_0000218
12345,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624055,,BAO_0000218
12346,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,,N,1,Intermediate,1,,CHEMBL624056,,BAO_0000218
12347,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,,50597,,N,1,Intermediate,1,,CHEMBL624057,,BAO_0000218
12348,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,,50597,,N,1,Intermediate,1,,CHEMBL622281,,BAO_0000218
12349,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,,50597,,N,1,Intermediate,1,,CHEMBL622282,,BAO_0000218
12350,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,,50597,,N,1,Intermediate,1,,CHEMBL622283,,BAO_0000218
12351,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,,50597,,N,1,Intermediate,1,,CHEMBL622284,,BAO_0000218
12352,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,,50597,,N,1,Intermediate,1,,CHEMBL622285,,BAO_0000218
12353,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,,50597,,N,1,Intermediate,1,,CHEMBL622286,,BAO_0000218
12354,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,,22224,,U,0,Autocuration,1,,CHEMBL622287,,BAO_0000100
12355,,Partition coefficient (logD7.4),,,50594,,N,1,Intermediate,1,,CHEMBL622288,,BAO_0000218
12356,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,,50594,,N,1,Intermediate,1,,CHEMBL622289,,BAO_0000218
12357,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",955.0,,50594,,N,1,Intermediate,1,,CHEMBL622290,,BAO_0000218
12358,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,,50594,,N,1,Intermediate,1,,CHEMBL622291,,BAO_0000218
12359,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,955.0,,50594,,N,1,Intermediate,1,,CHEMBL622292,,BAO_0000218
12360,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,,50594,,N,1,Intermediate,1,,CHEMBL622293,,BAO_0000218
12361,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",955.0,,50594,,N,1,Intermediate,1,,CHEMBL622294,,BAO_0000218
12362,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,,50594,,N,1,Intermediate,1,,CHEMBL622295,,BAO_0000218
12363,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,955.0,,50597,,N,1,Intermediate,1,,CHEMBL622296,,BAO_0000218
12364,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL874409,,BAO_0000218
12365,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622297,,BAO_0000218
12366,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622298,,BAO_0000218
12367,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622299,,BAO_0000218
12368,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622300,,BAO_0000218
12369,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622301,,BAO_0000218
12370,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622302,,BAO_0000218
12371,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622303,,BAO_0000218
12372,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622304,,BAO_0000218
12373,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622305,,BAO_0000218
12374,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622306,,BAO_0000218
12375,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626864,,BAO_0000218
12376,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626865,,BAO_0000218
12377,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626866,,BAO_0000218
12378,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626867,,BAO_0000218
12379,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626868,,BAO_0000218
12380,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626869,,BAO_0000218
12381,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626870,,BAO_0000218
12382,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626871,,BAO_0000218
12383,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626872,,BAO_0000218
12384,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL632185,,BAO_0000218
12385,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL632186,,BAO_0000218
12386,,Amount of acetic acid produced by the compound,,,22224,,U,0,Autocuration,1,,CHEMBL629310,,BAO_0000019
12387,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,,22224,,U,0,Autocuration,1,,CHEMBL629311,,BAO_0000019
12388,,Log of (Cbrain/Cblood) in rats,,,50597,,N,1,Intermediate,1,,CHEMBL629312,,BAO_0000218
12389,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629313,,BAO_0000221
12390,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629314,,BAO_0000221
12391,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629315,,BAO_0000221
12392,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629316,,BAO_0000219
12393,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629317,,BAO_0000221
12394,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629318,,BAO_0000019
12395,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL877497,,BAO_0000019
12396,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629319,,BAO_0000019
12397,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629320,,BAO_0000019
12398,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629496,,BAO_0000019
12399,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629497,,BAO_0000019
12400,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629498,,BAO_0000019
12401,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629499,,BAO_0000019
12402,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629500,,BAO_0000019
12403,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629501,,BAO_0000019
12404,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,,22224,,U,0,Autocuration,1,,CHEMBL629502,,BAO_0000019
12405,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,,22224,,U,0,Autocuration,1,,CHEMBL629503,,BAO_0000218
12406,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,,50588,,N,1,Intermediate,1,,CHEMBL629504,,BAO_0000218
12407,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,,22224,,U,0,Autocuration,1,,CHEMBL629505,,BAO_0000019
12408,,Compound was evaluated for total body clearance,,,22224,,U,0,Autocuration,1,,CHEMBL629506,,BAO_0000019
12409,,Compound was evaluated for volume of distribution at steady state,,,22224,,U,0,Autocuration,1,,CHEMBL629507,,BAO_0000019
12410,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,,22224,,U,0,Autocuration,1,,CHEMBL877498,,BAO_0000019
12411,,Percentage of the diamine which is monoprotonated at pH 7.4,,,22224,,U,0,Autocuration,1,,CHEMBL629508,,BAO_0000019
12412,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,,22224,,U,0,Autocuration,1,,CHEMBL629509,,BAO_0000019
12413,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629510,,BAO_0000218
12414,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629511,,BAO_0000218
12415,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629512,,BAO_0000218
12416,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629513,,BAO_0000218
12417,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629514,,BAO_0000218
12418,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628447,,BAO_0000218
12419,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628448,,BAO_0000218
12420,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628449,,BAO_0000218
12421,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631119,,BAO_0000218
12422,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631120,,BAO_0000218
12423,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631121,,BAO_0000218
12424,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,178.0,,50597,,N,1,Intermediate,1,,CHEMBL874458,,BAO_0000218
12425,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631122,,BAO_0000218
12426,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631123,,BAO_0000218
12427,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631124,,BAO_0000218
12428,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631125,,BAO_0000218
12429,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631290,,BAO_0000218
12430,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631291,,BAO_0000218
12431,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631292,,BAO_0000218
12432,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631293,,BAO_0000218
12433,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631294,,BAO_0000218
12434,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631295,,BAO_0000218
12435,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631296,,BAO_0000218
12436,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631297,,BAO_0000218
12437,,Maximum biodistribution (Bmax) was determined.,,,22224,,U,0,Autocuration,1,,CHEMBL631298,,BAO_0000218
12438,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,,50594,,N,1,Intermediate,1,,CHEMBL631299,,BAO_0000218
12439,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,,50594,,N,1,Intermediate,1,,CHEMBL631300,,BAO_0000218
12440,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,,50594,,N,1,Intermediate,1,,CHEMBL631301,,BAO_0000218
12441,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,,50594,,N,1,Intermediate,1,,CHEMBL630291,,BAO_0000218
12442,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,,22224,,U,0,Autocuration,1,,CHEMBL630292,,BAO_0000218
12443,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,,22224,,U,0,Autocuration,1,,CHEMBL630293,,BAO_0000218
12444,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL630294,,BAO_0000218
12445,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,,22224,,U,0,Autocuration,1,,CHEMBL630295,,BAO_0000218
12446,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,,22224,,U,0,Autocuration,1,,CHEMBL630296,,BAO_0000218
12447,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626782,,BAO_0000218
12448,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626783,,BAO_0000218
12449,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,,22224,,U,0,Autocuration,1,,CHEMBL626784,,BAO_0000218
12450,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,,22224,,U,0,Autocuration,1,,CHEMBL626785,,BAO_0000218
12451,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626786,,BAO_0000218
12452,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL626787,,BAO_0000218
12453,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,22224,,U,0,Autocuration,1,,CHEMBL626788,,BAO_0000218
12454,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL625927,,BAO_0000218
12455,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625928,,BAO_0000218
12456,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625929,,BAO_0000218
12457,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625930,,BAO_0000218
12458,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",178.0,,50597,,N,1,Intermediate,1,,CHEMBL625931,,BAO_0000218
12459,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627230,,BAO_0000218
12460,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627231,,BAO_0000218
12461,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627232,,BAO_0000218
12462,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627233,,BAO_0000218
12463,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL875470,,BAO_0000218
12464,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627234,,BAO_0000218
12465,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627235,,BAO_0000218
12466,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627236,,BAO_0000218
12467,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627237,,BAO_0000218
12468,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627238,,BAO_0000218
12469,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627239,,BAO_0000218
12470,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627240,,BAO_0000218
12471,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627241,,BAO_0000218
12472,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627242,,BAO_0000218
12473,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627243,,BAO_0000218
12474,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627244,,BAO_0000218
12475,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627245,,BAO_0000218
12476,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627246,,BAO_0000218
12477,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627247,,BAO_0000218
12478,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627248,,BAO_0000218
12479,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627249,,BAO_0000218
12480,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625569,,BAO_0000218
12481,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625570,,BAO_0000218
12482,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625571,,BAO_0000218
12483,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625572,,BAO_0000218
12484,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625573,,BAO_0000218
12485,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625574,,BAO_0000218
12486,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,,50597,,N,1,Intermediate,1,,CHEMBL626245,,BAO_0000218
12487,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL626246,,BAO_0000218
12488,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL626247,,BAO_0000218
12489,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL626248,,BAO_0000218
12490,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL626249,,BAO_0000218
12491,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL626420,,BAO_0000218
12492,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL626421,,BAO_0000218
12493,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL626422,,BAO_0000218
12494,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL626423,,BAO_0000218
12495,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL626424,,BAO_0000218
12496,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,,50588,,N,1,Intermediate,1,,CHEMBL626425,,BAO_0000218
12497,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,,50597,,N,1,Intermediate,1,,CHEMBL875476,,BAO_0000218
12498,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,,100710,,N,1,Intermediate,1,,CHEMBL626426,,BAO_0000218
12499,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,,22224,,U,0,Autocuration,1,,CHEMBL626427,,BAO_0000100
12500,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,,22224,,U,0,Autocuration,1,,CHEMBL626428,,BAO_0000100
12501,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,,22224,,U,0,Autocuration,1,,CHEMBL626429,,BAO_0000019
12502,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL625025,,BAO_0000019
12503,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625026,,BAO_0000218
12504,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625027,,BAO_0000218
12505,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL874410,,BAO_0000218
12506,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625028,,BAO_0000218
12507,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625029,,BAO_0000218
12508,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625030,,BAO_0000218
12509,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625031,,BAO_0000218
12510,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625032,,BAO_0000218
12511,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625033,,BAO_0000218
12512,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625034,,BAO_0000218
12513,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624872,,BAO_0000218
12514,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624873,,BAO_0000218
12515,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624874,,BAO_0000218
12516,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624875,,BAO_0000218
12517,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624876,,BAO_0000218
12518,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624877,,BAO_0000218
12519,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624878,,BAO_0000218
12520,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624879,,BAO_0000218
12521,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624880,,BAO_0000218
12522,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL624881,,BAO_0000218
12523,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",948.0,,50597,,N,1,Intermediate,1,,CHEMBL624882,,BAO_0000218
12524,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624883,,BAO_0000218
12525,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624884,,BAO_0000218
12526,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624885,,BAO_0000218
12527,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624886,,BAO_0000218
12528,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624887,,BAO_0000218
12529,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624888,,BAO_0000218
12530,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624889,,BAO_0000218
12531,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL624890,,BAO_0000218
12532,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621964,,BAO_0000218
12533,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL621965,,BAO_0000218
12534,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621966,,BAO_0000218
12535,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL621967,,BAO_0000218
12536,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL622164,,BAO_0000218
12537,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,,22224,,U,0,Autocuration,1,,CHEMBL623097,,BAO_0000019
12538,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,,22224,,U,0,Autocuration,1,,CHEMBL623098,,BAO_0000019
12539,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,,22224,,U,0,Autocuration,1,,CHEMBL623099,,BAO_0000019
12540,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,,22224,,U,0,Autocuration,1,,CHEMBL623100,,BAO_0000019
12541,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,,50597,,N,1,Intermediate,1,,CHEMBL628673,,BAO_0000218
12542,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,,50597,,N,1,Intermediate,1,,CHEMBL628674,,BAO_0000218
12543,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,,50597,,N,1,Intermediate,1,,CHEMBL628675,,BAO_0000218
12544,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,,50597,,N,1,Intermediate,1,,CHEMBL627644,,BAO_0000218
12545,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,,50597,,N,1,Intermediate,1,,CHEMBL627645,,BAO_0000218
12546,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,,50597,,N,1,Intermediate,1,,CHEMBL627646,,BAO_0000218
12547,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,,50597,,N,1,Intermediate,1,,CHEMBL627647,,BAO_0000218
12548,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,,50597,,N,1,Intermediate,1,,CHEMBL627648,,BAO_0000218
12549,,Free level in rat plasma,,,50597,,N,1,Intermediate,1,,CHEMBL627649,,BAO_0000218
12550,,Level reaching in blood plasma of rat or human was determined,,,22224,,U,0,Autocuration,1,,CHEMBL628313,,BAO_0000019
12551,,Log (Cbrain/Cblood) in rats,,,50597,,N,1,Intermediate,1,,CHEMBL628314,,BAO_0000218
12552,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,,22224,,U,0,Autocuration,1,,CHEMBL628315,,BAO_0000019
12553,,Mean percentage of compound transport through membrane; expressed as membrane transport,,,22224,,U,0,Autocuration,1,,CHEMBL628316,,BAO_0000019
12554,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL628317,,BAO_0000218
12555,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,,22224,,U,0,Autocuration,1,,CHEMBL628473,,BAO_0000019
12556,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,,22224,,U,0,Autocuration,1,,CHEMBL628474,,BAO_0000019
12557,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,,22224,,U,0,Autocuration,1,,CHEMBL628475,,BAO_0000019
12558,,Net water uptake by a carrier mediated transport (%cm) mechanism,,,22224,,U,0,Autocuration,1,,CHEMBL628476,,BAO_0000019
12559,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,,22224,,U,0,Autocuration,1,,CHEMBL628477,,BAO_0000218
12560,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,,50506,,N,1,Intermediate,1,,CHEMBL628478,,BAO_0000218
12561,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,,50506,,N,1,Intermediate,1,,CHEMBL628479,,BAO_0000218
12562,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,,22224,,U,0,Autocuration,1,,CHEMBL628480,,BAO_0000218
12563,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,,22224,,U,0,Autocuration,1,,CHEMBL628481,,BAO_0000218
12564,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL628482,,BAO_0000218
12565,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,,50597,,N,1,Intermediate,1,,CHEMBL628483,,BAO_0000218
12566,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628484,,BAO_0000218
12567,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628485,,BAO_0000218
12568,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",1969.0,,100710,,N,1,Intermediate,1,,CHEMBL628486,,BAO_0000218
12569,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",1969.0,,50587,,N,1,Intermediate,1,,CHEMBL628487,,BAO_0000218
12570,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628488,,BAO_0000218
12571,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628489,,BAO_0000218
12572,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628490,,BAO_0000218
12573,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,100710,,N,1,Intermediate,1,,CHEMBL628491,,BAO_0000218
12574,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,100710,,N,1,Intermediate,1,,CHEMBL877507,,BAO_0000218
12575,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,22224,,U,0,Autocuration,1,,CHEMBL628492,,BAO_0000218
12576,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,,22224,,U,0,Autocuration,1,,CHEMBL628493,,BAO_0000019
12577,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,,22224,,U,0,Autocuration,1,,CHEMBL628494,,BAO_0000019
12578,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,,22224,,U,0,Autocuration,1,,CHEMBL628495,,BAO_0000019
12579,,Permeability in Caco-2 assay at 10E-6,,,50587,,N,1,Intermediate,1,,CHEMBL628496,,BAO_0000218
12580,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,955.0,,22224,,U,0,Autocuration,1,,CHEMBL628497,,BAO_0000218
12581,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,955.0,,22224,,U,0,Autocuration,1,,CHEMBL628498,,BAO_0000218
12582,,Plasma protein binding was determined,,,22224,,U,0,Autocuration,1,,CHEMBL628499,,BAO_0000019
12583,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL627656,,BAO_0000218
12584,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,,22224,,U,0,Autocuration,1,,CHEMBL627657,,BAO_0000218
12585,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,,22224,,U,0,Autocuration,1,,CHEMBL626808,,BAO_0000218
12586,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626809,,BAO_0000218
12587,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626810,,BAO_0000218
12588,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,,22224,,U,0,Autocuration,1,,CHEMBL626811,,BAO_0000218
12589,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,,22224,,U,0,Autocuration,1,,CHEMBL874465,,BAO_0000218
12590,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626812,,BAO_0000218
12591,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626813,,BAO_0000218
12592,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,,22224,,U,0,Autocuration,1,,CHEMBL626814,,BAO_0000218
12593,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,,22224,,U,0,Autocuration,1,,CHEMBL626815,,BAO_0000019
12594,,Partition coefficient (logP),,,22224,,U,0,Autocuration,1,,CHEMBL628566,,BAO_0000019
12595,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,22229,,U,0,Autocuration,1,,CHEMBL628567,,BAO_0000100
12596,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL628568,,BAO_0000100
12597,,C max in dog,,,50588,,N,1,Intermediate,1,,CHEMBL628569,,BAO_0000218
12598,,C max in guinea pig,,,50512,,N,1,Intermediate,1,,CHEMBL628570,,BAO_0000218
12599,,C max value was evaluated,,,22224,,U,0,Autocuration,1,,CHEMBL628571,,BAO_0000218
12600,,Cmax value after oral dose of 0.1 mg//kg,,,22224,,U,0,Autocuration,1,,CHEMBL628572,,BAO_0000218
12601,,Cmax value after oral dose of 0.3 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL628573,,BAO_0000218
12602,,Cmax value after oral dose of 1 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL628574,,BAO_0000218
12603,,Cmax value after oral dose of 10 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL628575,,BAO_0000218
12604,,Cmax value after oral dose of 23.4 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL628576,,BAO_0000218
12605,,Cmax value after oral dose of 3 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL628577,,BAO_0000218
12606,,Cmax value after oral dose of 3.87 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL628578,,BAO_0000218
12607,,Cmax value in female Beagle dogs,,,50588,,N,1,Intermediate,1,,CHEMBL874466,,BAO_0000218
12608,,Cmax value in male rats,,,50597,,N,1,Intermediate,1,,CHEMBL628579,,BAO_0000218
12609,,Cmax value in rat plasma when administered 20 mg/kg perorally,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628580,,BAO_0000218
12610,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL628581,,BAO_0000218
12611,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL628582,,BAO_0000218
12612,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,,50588,,N,1,Intermediate,1,,CHEMBL628583,,BAO_0000218
12613,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,,22224,,U,0,Autocuration,1,,CHEMBL625782,,BAO_0000218
12614,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,,50592,,N,1,Intermediate,1,,CHEMBL625783,,BAO_0000218
12615,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,,50597,,N,1,Intermediate,1,,CHEMBL625784,,BAO_0000218
12616,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,1969.0,,50797,,N,1,Intermediate,1,,CHEMBL625785,,BAO_0000218
12617,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625786,,BAO_0000218
12618,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,,22224,,U,0,Autocuration,1,,CHEMBL874467,,BAO_0000019
12619,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,,50588,,N,1,Intermediate,1,,CHEMBL625787,,BAO_0000218
12620,,cytotoxicity against HIV protease enzyme.,,,50677,,N,1,Intermediate,1,,CHEMBL625964,,BAO_0000218
12621,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,,50594,,N,1,Intermediate,1,,CHEMBL625965,,BAO_0000218
12622,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,,50594,,N,1,Intermediate,1,,CHEMBL625966,,BAO_0000218
12623,,The plasma clearance in dog.,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL625967,,BAO_0000218
12624,,The plasma clearance in rat.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625968,,BAO_0000218
12625,,Clearance from plasma in male Sprague-Dawley rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625969,,BAO_0000218
12626,,Clearance from plasma in male cynomolgus monkeys,1969.0,,100710,,N,1,Intermediate,1,,CHEMBL625970,,BAO_0000218
12627,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",1969.0,,50588,,N,1,Intermediate,1,,CHEMBL625971,,BAO_0000218
12628,,Clearance of compound in dog plasma,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL625972,,BAO_0000218
12629,,Clearance of compound in human plasma,1969.0,,50587,,N,1,Intermediate,1,,CHEMBL625973,,BAO_0000218
12630,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,,50588,,N,1,Intermediate,1,,CHEMBL625974,,BAO_0000218
12631,,Clearance of compound when administered intravenously as an individual dose to a single dog.,,,50588,,N,1,Intermediate,1,,CHEMBL625975,,BAO_0000218
12632,,"Clearance (10 mg/kg, intravenously) in dog plasma",1969.0,,50588,,N,1,Intermediate,1,,CHEMBL625976,,BAO_0000218
12633,,Clearance value in dog,,,50588,,N,1,Intermediate,1,,CHEMBL625977,,BAO_0000218
12634,,Clearance value in guinea pig,,,50512,,N,1,Intermediate,1,,CHEMBL625978,,BAO_0000218
12635,,Clearance values in rats after iv administration.,,,50597,,N,1,Intermediate,1,,CHEMBL874468,,BAO_0000218
12636,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL625421,,BAO_0000218
12637,,In vivo clearance (5 mg/kg) was determined in rabbits,,,50592,,N,1,Intermediate,1,,CHEMBL625422,,BAO_0000218
12638,,Plasma Clearance rate was determined for the compound in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625423,,BAO_0000218
12639,,Plasma Clearance rate was determined for the compound in squirrel monkeys,,,22224,,U,0,Autocuration,1,,CHEMBL625424,,BAO_0000218
12640,,Plasma clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625425,,BAO_0000218
12641,,Plasma clearance of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL625426,,BAO_0000218
12642,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,,50512,,N,1,Intermediate,1,,CHEMBL625427,,BAO_0000218
12643,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,,50512,,N,1,Intermediate,1,,CHEMBL625428,,BAO_0000218
12644,,Plasma clearance was determined,,,22224,,U,0,Autocuration,1,,CHEMBL625429,,BAO_0000218
12645,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,,50588,,N,1,Intermediate,1,,CHEMBL625430,,BAO_0000218
12646,,Plasma clearance rate was determined for the compound in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625431,,BAO_0000218
12647,,Plasma clearance rate was determined for the compound in squirrel monkeys,,,22224,,U,0,Autocuration,1,,CHEMBL627307,,BAO_0000218
12648,,Slow clearance (CL) was determined,,,22224,,U,0,Autocuration,1,,CHEMBL627308,,BAO_0000218
12649,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL627309,,BAO_0000218
12650,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,22224,,U,0,Autocuration,1,,CHEMBL627310,,BAO_0000218
12651,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL627311,,BAO_0000218
12652,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL627312,,BAO_0000218
12653,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL627313,,BAO_0000218
12654,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL627314,,BAO_0000218
12655,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL627315,,BAO_0000218
12656,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL627316,,BAO_0000218
12657,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL627317,,BAO_0000218
12658,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL627318,,BAO_0000218
12659,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL627999,,BAO_0000218
12660,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628000,,BAO_0000218
12661,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628001,,BAO_0000218
12662,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL628002,,BAO_0000218
12663,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL625610,,BAO_0000218
12664,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL625611,,BAO_0000218
12665,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL625612,,BAO_0000218
12666,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL625613,,BAO_0000218
12667,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL875479,,BAO_0000218
12668,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL625614,,BAO_0000218
12669,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,22224,,U,0,Autocuration,1,,CHEMBL625615,,BAO_0000218
12670,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL626302,,BAO_0000218
12671,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL626303,,BAO_0000218
12672,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627420,,BAO_0000218
12673,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,,50597,,N,1,Intermediate,1,,CHEMBL627421,,BAO_0000218
12674,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,,50597,,N,1,Intermediate,1,,CHEMBL625695,,BAO_0000218
12675,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,,50597,,N,1,Intermediate,1,,CHEMBL625696,,BAO_0000218
12676,,Distribution of compound in mice brain was measured after 1 hr,955.0,,50594,,N,1,Intermediate,1,,CHEMBL875606,,BAO_0000218
12677,,Distribution of compound in mice brain was measured after 24 hr r,955.0,,50594,,N,1,Intermediate,1,,CHEMBL625697,,BAO_0000218
12678,,Distribution of compound in mice brain was measured after 2 hr,955.0,,50594,,N,1,Intermediate,1,,CHEMBL625698,,BAO_0000218
12679,,Distribution of compound in mice brain was measured after 3 hr,955.0,,50594,,N,1,Intermediate,1,,CHEMBL625699,,BAO_0000218
12680,,Distribution of compound in mice brain was measured after 6 hr,955.0,,50594,,N,1,Intermediate,1,,CHEMBL625700,,BAO_0000218
12681,,Distribution of compound in mice liver was measured after 1 hr,,,50594,,N,1,Intermediate,1,,CHEMBL625701,,BAO_0000218
12682,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,,50594,,N,1,Intermediate,1,,CHEMBL625702,,BAO_0000218
12683,,Distribution of compound in mice liver was measured after 2 hr,,,50594,,N,1,Intermediate,1,,CHEMBL625703,,BAO_0000218
12684,,Distribution of compound in mice liver was measured after 3 hr,,,50594,,N,1,Intermediate,1,,CHEMBL625704,,BAO_0000218
12685,,Distribution of compound in mice liver was measured after 6 hr,,,50594,,N,1,Intermediate,1,,CHEMBL625705,,BAO_0000218
12686,,Distribution in dog adrenal medulla 30 min after administration.,1236.0,,50588,,N,1,Intermediate,1,,CHEMBL625706,,BAO_0000218
12687,,Distribution in dog adrenal medulla 72 hours after administration.,1236.0,,50588,,N,1,Intermediate,1,,CHEMBL625707,,BAO_0000218
12688,,Distribution in female dog Ovary 24 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL625708,,BAO_0000218
12689,,Distribution in female dog Ovary 72 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL625709,,BAO_0000218
12690,,Distribution in female dog adipose 24 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624180,,BAO_0000218
12691,,Distribution in female dog adipose 72 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624181,,BAO_0000218
12692,,Distribution in female dog adrenal cortex 72 hours after administration.,1235.0,,50588,,N,1,Intermediate,1,,CHEMBL624182,,BAO_0000218
12693,,Distribution in female dog adrenal cortex 72 hours after administration.,1235.0,,50588,,N,1,Intermediate,1,,CHEMBL624183,,BAO_0000218
12694,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624184,,BAO_0000218
12695,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL877489,,BAO_0000218
12696,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624185,,BAO_0000218
12697,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624186,,BAO_0000218
12698,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624187,,BAO_0000218
12699,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL624188,,BAO_0000218
12700,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624189,,BAO_0000218
12701,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624190,,BAO_0000218
12702,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624191,,BAO_0000218
12703,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624192,,BAO_0000218
12704,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624193,,BAO_0000218
12705,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624194,,BAO_0000218
12706,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624891,,BAO_0000218
12707,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624892,,BAO_0000218
12708,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL624893,,BAO_0000218
12709,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627632,,BAO_0000218
12710,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL627633,,BAO_0000218
12711,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL627634,,BAO_0000218
12712,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,50597,,N,1,Intermediate,1,,CHEMBL627635,,BAO_0000218
12713,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL627636,,BAO_0000218
12714,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,50597,,N,1,Intermediate,1,,CHEMBL626816,,BAO_0000218
12715,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL626817,,BAO_0000218
12716,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,50597,,N,1,Intermediate,1,,CHEMBL626818,,BAO_0000218
12717,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL626819,,BAO_0000218
12718,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,50597,,N,1,Intermediate,1,,CHEMBL626820,,BAO_0000218
12719,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL626821,,BAO_0000218
12720,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626822,,BAO_0000218
12721,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626823,,BAO_0000218
12722,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626824,,BAO_0000218
12723,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626825,,BAO_0000218
12724,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626826,,BAO_0000218
12725,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626827,,BAO_0000218
12726,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626828,,BAO_0000218
12727,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626829,,BAO_0000218
12728,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL626830,,BAO_0000218
12729,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,50597,,N,1,Intermediate,1,,CHEMBL627150,,BAO_0000218
12730,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL627151,,BAO_0000218
12731,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,50597,,N,1,Intermediate,1,,CHEMBL627152,,BAO_0000218
12732,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL627153,,BAO_0000218
12733,,Rate of acetate production by the compound was determined,,,22224,,U,0,Autocuration,1,,CHEMBL627154,,BAO_0000019
12734,,Rate of acetate production by the compound was determined; Not determined,,,22224,,U,0,Autocuration,1,,CHEMBL627155,,BAO_0000019
12735,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,,22224,,U,0,Autocuration,1,,CHEMBL627156,,BAO_0000019
12736,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,,22224,,U,0,Autocuration,1,,CHEMBL627157,,BAO_0000019
12737,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,,50592,,N,1,Intermediate,1,,CHEMBL627158,,BAO_0000218
12738,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,1969.0,,50592,,N,1,Intermediate,1,,CHEMBL627159,,BAO_0000218
12739,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,,50594,,N,1,Intermediate,1,,CHEMBL627160,,BAO_0000218
12740,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,,50597,,N,1,Intermediate,1,,CHEMBL628540,,BAO_0000218
12741,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628541,,BAO_0000218
12742,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628542,,BAO_0000218
12743,,Solubility after at a pH 1.2,,,22229,,U,0,Autocuration,1,,CHEMBL628543,,BAO_0000100
12744,,Solubility after at pH 1.2,,,22229,,U,0,Autocuration,1,,CHEMBL628544,,BAO_0000100
12745,,Solubility after injection of water,,,22229,,U,0,Autocuration,1,,CHEMBL628545,,BAO_0000100
12746,,Statistical significance of IC 50 values; Expressed as R value,,,22224,,U,0,Autocuration,1,,CHEMBL628546,,BAO_0000019
12747,,Systemic availability with respect to methyldopa was determined,,,22224,,U,0,Autocuration,1,,CHEMBL874455,,BAO_0000019
12748,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,,50597,,N,1,Intermediate,1,,CHEMBL628547,,BAO_0000218
12749,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL628548,,BAO_0000218
12750,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL628549,,BAO_0000218
12751,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL628550,,BAO_0000218
12752,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL628551,,BAO_0000218
12753,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL628552,,BAO_0000218
12754,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL628553,,BAO_0000218
12755,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL628554,,BAO_0000218
12756,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL628555,,BAO_0000218
12757,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL628556,,BAO_0000218
12758,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",2113.0,,50592,,N,1,Intermediate,1,,CHEMBL628557,,BAO_0000218
12759,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL628558,,BAO_0000218
12760,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL628559,,BAO_0000218
12761,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL628560,,BAO_0000218
12762,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL874456,,BAO_0000218
12763,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL628561,,BAO_0000218
12764,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL628562,,BAO_0000218
12765,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL628563,,BAO_0000218
12766,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL628564,,BAO_0000218
12767,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL628565,,BAO_0000218
12768,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL631248,,BAO_0000218
12769,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL631249,,BAO_0000218
12770,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",2113.0,,50592,,N,1,Intermediate,1,,CHEMBL627214,,BAO_0000218
12771,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL874591,,BAO_0000218
12772,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL627215,,BAO_0000218
12773,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,1988.0,,50592,,N,1,Intermediate,1,,CHEMBL625471,,BAO_0000218
12774,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,,50592,,N,1,Intermediate,1,,CHEMBL625472,,BAO_0000218
12775,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,,50592,,N,1,Intermediate,1,,CHEMBL625473,,BAO_0000218
12776,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,,50588,,N,1,Intermediate,1,,CHEMBL625474,,BAO_0000218
12777,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,,50588,,N,1,Intermediate,1,,CHEMBL625475,,BAO_0000218
12778,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,,50597,,N,1,Intermediate,1,,CHEMBL625476,,BAO_0000218
12779,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,,50597,,N,1,Intermediate,1,,CHEMBL625477,,BAO_0000218
12780,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,,50597,,N,1,Intermediate,1,,CHEMBL625478,,BAO_0000218
12781,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,,50597,,N,1,Intermediate,1,,CHEMBL625479,,BAO_0000218
12782,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,,50597,,N,1,Intermediate,1,,CHEMBL625480,,BAO_0000218
12783,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625481,,BAO_0000218
12784,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625482,,BAO_0000218
12785,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625483,,BAO_0000218
12786,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625484,,BAO_0000218
12787,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625485,,BAO_0000218
12788,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL625486,,BAO_0000218
12789,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625487,,BAO_0000218
12790,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625488,,BAO_0000218
12791,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625489,,BAO_0000218
12792,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625490,,BAO_0000218
12793,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL625491,,BAO_0000218
12794,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625492,,BAO_0000218
12795,,plasma clearance in human,1969.0,,50587,,N,1,Intermediate,1,,CHEMBL625493,,BAO_0000218
12796,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625494,,BAO_0000218
12797,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625495,,BAO_0000218
12798,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625496,,BAO_0000218
12799,,1-Octanol/water partition coefficient measured at 7.4,,,22229,,U,0,Autocuration,1,,CHEMBL625497,,BAO_0000100
12800,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625498,,BAO_0000100
12801,,Partition coefficient (logP),,,22224,,U,0,Autocuration,1,,CHEMBL625499,,BAO_0000019
12802,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625500,,BAO_0000100
12803,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625501,,BAO_0000100
12804,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625502,,BAO_0000100
12805,,Calculated partition coefficient (clogP) (relative to BAY K 8644),,,22229,,U,0,Autocuration,1,,CHEMBL625503,,BAO_0000100
12806,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625504,,BAO_0000100
12807,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625505,,BAO_0000100
12808,,Calculated partition coefficient of the compound,,,22229,,U,0,Autocuration,1,,CHEMBL625506,,BAO_0000100
12809,,Partition coefficient (logP),,,22224,,U,0,Autocuration,1,,CHEMBL625507,,BAO_0000019
12810,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625508,,BAO_0000100
12811,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625509,,BAO_0000100
12812,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625510,,BAO_0000100
12813,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL883125,,BAO_0000100
12814,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625511,,BAO_0000100
12815,,Partition coefficient of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL874650,,BAO_0000019
12816,,Partition coefficient of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL625512,,BAO_0000019
12817,,Partition coefficient of compound was determined,,,22224,,U,0,Autocuration,1,,CHEMBL625513,,BAO_0000019
12818,,Partition coefficient was determined,,,22224,,U,0,Autocuration,1,,CHEMBL625514,,BAO_0000019
12819,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625515,,BAO_0000100
12820,,partition coefficient of compound was determined,,,22229,,U,0,Autocuration,1,,CHEMBL625516,,BAO_0000100
12821,,The total body administered intravenously in dog,,,50588,,N,1,Intermediate,1,,CHEMBL625517,,BAO_0000218
12822,,The total body administered intravenously in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625518,,BAO_0000218
12823,,Time taken for the administration to female NIH mice weighing 25-30 g.,,,50594,,N,1,Intermediate,1,,CHEMBL625519,,BAO_0000218
12824,,Time taken for the administration,,,22224,,U,0,Autocuration,1,,CHEMBL625520,,BAO_0000019
12825,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,,50588,,N,1,Intermediate,1,,CHEMBL874651,,BAO_0000218
12826,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,,22224,,U,0,Autocuration,1,,CHEMBL625521,,BAO_0000218
12827,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,,50592,,N,1,Intermediate,1,,CHEMBL623171,,BAO_0000218
12828,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,,50597,,N,1,Intermediate,1,,CHEMBL623853,,BAO_0000218
12829,,Plasma clearance for the compound was determined.,,,22224,,U,0,Autocuration,1,,CHEMBL623854,,BAO_0000019
12830,,CLog P value of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL874405,,BAO_0000100
12831,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL623855,,BAO_0000100
12832,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL623856,,BAO_0000100
12833,,ClogP value of the compound; nd ='no data',,,22224,,U,0,Autocuration,1,,CHEMBL623857,,BAO_0000100
12834,,ClogP value of the compound; nd ='not determined',,,22224,,U,0,Autocuration,1,,CHEMBL623858,,BAO_0000100
12835,,CLog P was determined,,,22224,,U,0,Autocuration,1,,CHEMBL623859,,BAO_0000100
12836,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL839829,,BAO_0000100
12837,,CLogP was calculated,,,22224,,U,0,Autocuration,1,,CHEMBL623860,,BAO_0000019
12838,,CLogP value was determined,,,22224,,U,0,Autocuration,1,,CHEMBL623861,,BAO_0000019
12839,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,,22224,,U,0,Autocuration,1,,CHEMBL623862,,BAO_0000019
12840,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL874406,,BAO_0000100
12841,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL623863,,BAO_0000100
12842,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624021,,BAO_0000100
12843,,Distribution in female dog adrenal medulla 24 hours after administration.,1236.0,,50588,,N,1,Intermediate,1,,CHEMBL624022,,BAO_0000218
12844,,Distribution in female dog adrenal medulla 72 hours after administration.,1236.0,,50588,,N,1,Intermediate,1,,CHEMBL624023,,BAO_0000218
12845,,Distribution in female dog bile 24 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624024,,BAO_0000218
12846,,Distribution in female dog bile 72 hr after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624025,,BAO_0000218
12847,,Distribution in female dog blood 24 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624026,,BAO_0000218
12848,,Distribution in female dog blood 72 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624027,,BAO_0000218
12849,,Distribution in female dog heart 24 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624028,,BAO_0000218
12850,,Distribution in female dog heart 72 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624029,,BAO_0000218
12851,,Distribution in female dog kidney 24 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624030,,BAO_0000218
12852,,Distribution in female dog kidney 72 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624031,,BAO_0000218
12853,,Distribution in female dog large intestine 24 hours after administration.,160.0,,50588,,N,1,Intermediate,1,,CHEMBL624032,,BAO_0000218
12854,,Distribution in female dog large intestine 72 hours after administration.,160.0,,50588,,N,1,Intermediate,1,,CHEMBL874407,,BAO_0000218
12855,,Distribution in female dog liver 24 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624033,,BAO_0000218
12856,,Distribution in female dog liver 72 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624034,,BAO_0000218
12857,,Distribution in female dog lung 24 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624035,,BAO_0000218
12858,,Distribution in female dog lung 72 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624036,,BAO_0000218
12859,,Distribution in female dog muscle 24 hours after administration.,2385.0,,50588,,N,1,Intermediate,1,,CHEMBL624037,,BAO_0000218
12860,,Distribution in female dog muscle 72 hours after administration.,2385.0,,50588,,N,1,Intermediate,1,,CHEMBL624038,,BAO_0000218
12861,,Distribution in female dog pancreas 24 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624039,,BAO_0000218
12862,,Distribution in female dog pancreas 72 hours after administration.,,,50588,,N,1,Intermediate,1,,CHEMBL624040,,BAO_0000218
12863,,Distribution in female dog small intestine 24 hours after administration.,160.0,,50588,,N,1,Intermediate,1,,CHEMBL624041,,BAO_0000218
12864,,Distribution in female dog small intestine 72 hours after administration.,160.0,,50588,,N,1,Intermediate,1,,CHEMBL624042,,BAO_0000218
12865,,Distribution in female dog spleen 24 hours after administration.,2106.0,,50588,,N,1,Intermediate,1,,CHEMBL624043,,BAO_0000218
12866,,Distribution in female dog spleen 72 hours after administration.,2106.0,,50588,,N,1,Intermediate,1,,CHEMBL624044,,BAO_0000218
12867,,Distribution in female dog stomach 24 hours after administration.,945.0,,50588,,N,1,Intermediate,1,,CHEMBL624045,,BAO_0000218
12868,,Distribution in female dog stomach 72 hours after administration.,945.0,,50588,,N,1,Intermediate,1,,CHEMBL624046,,BAO_0000218
12869,,Distribution in female dog thyroid 24 hours after administration.,2046.0,,50588,,N,1,Intermediate,1,,CHEMBL624047,,BAO_0000218
12870,,Distribution in female dog thyroid 72 hours after administration.,2046.0,,50588,,N,1,Intermediate,1,,CHEMBL624048,,BAO_0000218
12871,,Distribution in female dog urine 24 hours after administration.,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL874408,,BAO_0000218
12872,,Distribution in female dog urine 72 hr after administration.,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL624049,,BAO_0000218
12873,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL624050,,BAO_0000218
12874,,Plasma concentration at 7 hr after intravenous dosing,,,22224,,U,0,Autocuration,1,,CHEMBL624051,,BAO_0000019
12875,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623278,,BAO_0000218
12876,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623279,,BAO_0000218
12877,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623280,,BAO_0000218
12878,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623963,,BAO_0000218
12879,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623964,,BAO_0000218
12880,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623965,,BAO_0000218
12881,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,,50597,,N,1,Intermediate,1,,CHEMBL623966,,BAO_0000218
12882,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,,50597,,N,1,Intermediate,1,,CHEMBL874415,,BAO_0000218
12883,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,,50597,,N,1,Intermediate,1,,CHEMBL623967,,BAO_0000218
12884,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,,50597,,N,1,Intermediate,1,,CHEMBL623968,,BAO_0000218
12885,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,,50597,,N,1,Intermediate,1,,CHEMBL623969,,BAO_0000218
12886,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,,50597,,N,1,Intermediate,1,,CHEMBL628409,,BAO_0000218
12887,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,,50597,,N,1,Intermediate,1,,CHEMBL628410,,BAO_0000218
12888,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,,50597,,N,1,Intermediate,1,,CHEMBL628411,,BAO_0000218
12889,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,,50597,,N,1,Intermediate,1,,CHEMBL628412,,BAO_0000218
12890,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,,22224,,U,0,Autocuration,1,,CHEMBL628413,,BAO_0000019
12891,,The concentration in plasmat; Not determined,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL628414,,BAO_0000019
12892,,Tissue level at 10 mg/kg/po in wistar rats in blood,,,50597,,N,1,Intermediate,1,,CHEMBL628415,,BAO_0000218
12893,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,,50597,,N,1,Intermediate,1,,CHEMBL628416,,BAO_0000218
12894,,Tissue level at 10 mg/kg/po in wistar rats in heart,,,50597,,N,1,Intermediate,1,,CHEMBL628417,,BAO_0000218
12895,,Tissue level at 10 mg/kg/po in wistar rats in liver,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL874908,,BAO_0000218
12896,,Tissue level at 10 mg/kg/po in wistar rats in plasma,,,50597,,N,1,Intermediate,1,,CHEMBL628418,,BAO_0000218
12897,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL628419,,BAO_0000218
12898,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,,50597,,N,1,Intermediate,1,,CHEMBL628420,,BAO_0000218
12899,,Water solubility at 37 degree C.,,,22224,,U,0,Autocuration,1,,CHEMBL628421,,BAO_0000019
12900,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,22229,,U,0,Autocuration,1,,CHEMBL626726,,BAO_0000100
12901,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,22229,,U,0,Autocuration,1,,CHEMBL626727,,BAO_0000100
12902,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL626728,,BAO_0000218
12903,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL626729,,BAO_0000218
12904,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL626730,,BAO_0000218
12905,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL626731,,BAO_0000218
12906,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,178.0,,50597,,N,1,Intermediate,1,,CHEMBL626732,,BAO_0000218
12907,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL626733,,BAO_0000218
12908,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL626734,,BAO_0000218
12909,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL626735,,BAO_0000218
12910,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL874909,,BAO_0000218
12911,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,948.0,,50597,,N,1,Intermediate,1,,CHEMBL626736,,BAO_0000218
12912,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL626737,,BAO_0000218
12913,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL630999,,BAO_0000218
12914,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL631000,,BAO_0000218
12915,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL631001,,BAO_0000218
12916,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL631002,,BAO_0000218
12917,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631003,,BAO_0000218
12918,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631004,,BAO_0000218
12919,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631005,,BAO_0000218
12920,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631006,,BAO_0000218
12921,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631007,,BAO_0000218
12922,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL631008,,BAO_0000218
12923,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL631009,,BAO_0000218
12924,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL631010,,BAO_0000218
12925,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL631011,,BAO_0000218
12926,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL631012,,BAO_0000218
12927,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL630271,,BAO_0000218
12928,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL630272,,BAO_0000218
12929,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL630273,,BAO_0000218
12930,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL630274,,BAO_0000218
12931,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL630275,,BAO_0000218
12932,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL875782,,BAO_0000218
12933,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL630276,,BAO_0000218
12934,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL630277,,BAO_0000218
12935,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL630278,,BAO_0000218
12936,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,,50597,,N,1,Intermediate,1,,CHEMBL630279,,BAO_0000218
12937,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,,22224,,U,0,Autocuration,1,,CHEMBL630280,,BAO_0000019
12938,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,22224,,U,0,Autocuration,1,,CHEMBL630281,,BAO_0000019
12939,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,,50592,,N,1,Intermediate,1,,CHEMBL630282,,BAO_0000218
12940,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,,50592,,N,1,Intermediate,1,,CHEMBL630283,,BAO_0000218
12941,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,,22224,,U,0,Autocuration,1,,CHEMBL630284,,BAO_0000019
12942,,Alkylating activity was determined,,,22224,,U,0,Autocuration,1,,CHEMBL630285,,BAO_0000019
12943,Microsomes,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,,22224,,U,0,Autocuration,1,,CHEMBL630286,,BAO_0000251
12944,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,,50592,,N,1,Intermediate,1,,CHEMBL630069,,BAO_0000218
12945,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,,50592,,N,1,Intermediate,1,,CHEMBL630070,,BAO_0000218
12946,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,,50592,,N,1,Intermediate,1,,CHEMBL630071,,BAO_0000218
12947,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,,50592,,N,1,Intermediate,1,,CHEMBL630072,,BAO_0000218
12948,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,,50592,,N,1,Intermediate,1,,CHEMBL875110,,BAO_0000218
12949,,Compound was tested for antidiuretic activity in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630073,,BAO_0000218
12950,,Compound was tested for inactivation kinetic values,,,22224,,U,0,Autocuration,1,,CHEMBL630074,,BAO_0000019
12951,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,,22224,,U,0,Autocuration,1,,CHEMBL630075,,BAO_0000218
12952,,Dissociation rate calculated from the first-order equation using the t1/2 value,,,22224,,U,0,Autocuration,1,,CHEMBL630076,,BAO_0000019
12953,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,,22229,,U,0,Autocuration,1,,CHEMBL630077,,BAO_0000100
12954,,Aqueous solubility was measured,,,22229,,U,0,Autocuration,1,,CHEMBL630078,,BAO_0000100
12955,,Aqueous solubility was measured at a pH 4,,,22229,,U,0,Autocuration,1,,CHEMBL630079,,BAO_0000100
12956,,Aqueous solubility (pH 7),,,22229,,U,0,Autocuration,1,,CHEMBL630080,,BAO_0000100
12957,,Aqueous solubility was measured at a pH 9,,,22229,,U,0,Autocuration,1,,CHEMBL630081,,BAO_0000100
12958,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,,22224,,U,0,Autocuration,1,,CHEMBL630082,,BAO_0000019
12959,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,22224,,U,0,Autocuration,1,,CHEMBL630083,,BAO_0000019
12960,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,22224,,U,0,Autocuration,1,,CHEMBL630084,,BAO_0000019
12961,,Aqueous solubility of the compound,,,22229,,U,0,Autocuration,1,,CHEMBL629198,,BAO_0000100
12962,,Aqueous solubility at 37 degree Celsius at pH 7.38,,,22229,,U,0,Autocuration,1,,CHEMBL629199,,BAO_0000100
12963,,Aqueous solubility in pH 7.4 phosphate buffer,,,22229,,U,0,Autocuration,1,,CHEMBL629200,,BAO_0000100
12964,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,,50588,,N,1,Intermediate,1,,CHEMBL629201,,BAO_0000218
12965,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,,50588,,N,1,Intermediate,1,,CHEMBL629202,,BAO_0000218
12966,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,,50587,,N,1,Intermediate,1,,CHEMBL875111,,BAO_0000218
12967,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,,50587,,N,1,Intermediate,1,,CHEMBL629203,,BAO_0000218
12968,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,,50587,,N,1,Intermediate,1,,CHEMBL629204,,BAO_0000218
12969,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,,50587,,N,1,Intermediate,1,,CHEMBL629205,,BAO_0000218
12970,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,,50587,,N,1,Intermediate,1,,CHEMBL629206,,BAO_0000218
12971,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,,22224,,U,0,Autocuration,1,,CHEMBL631185,,BAO_0000019
12972,,Compound was evaluated for the average bile flow rat in rats,,,50597,,N,1,Intermediate,1,,CHEMBL631186,,BAO_0000218
12973,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,,50592,,N,1,Intermediate,1,,CHEMBL631187,,BAO_0000218
12974,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,,50592,,N,1,Intermediate,1,,CHEMBL631188,,BAO_0000218
12975,,Average half life period was determined,,,22224,,U,0,Autocuration,1,,CHEMBL876419,,BAO_0000019
12976,,Average half life period was determined,,,22224,,U,0,Autocuration,1,,CHEMBL631189,,BAO_0000019
12977,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,,50602,,N,1,Intermediate,1,,CHEMBL631190,,BAO_0000218
12978,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,,50602,,N,1,Intermediate,1,,CHEMBL631191,,BAO_0000218
12979,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,,50602,,N,1,Intermediate,1,,CHEMBL631192,,BAO_0000218
12980,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,,50602,,N,1,Intermediate,1,,CHEMBL632400,,BAO_0000218
12981,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,,50602,,N,1,Intermediate,1,,CHEMBL630564,,BAO_0000218
12982,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,,50602,,N,1,Intermediate,1,,CHEMBL630565,,BAO_0000218
12983,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,,50602,,N,1,Intermediate,1,,CHEMBL630566,,BAO_0000218
12984,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,,50602,,N,1,Intermediate,1,,CHEMBL631229,,BAO_0000218
12985,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,,50602,,N,1,Intermediate,1,,CHEMBL631230,,BAO_0000218
12986,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL876428,,BAO_0000100
12987,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL631231,,BAO_0000100
12988,,Calculated partition coefficient (clogP) (MacLogP),,,22229,,U,0,Autocuration,1,,CHEMBL631232,,BAO_0000100
12989,,Hydrophilicity was determined,,,22224,,U,0,Autocuration,1,,CHEMBL631233,,BAO_0000019
12990,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL631234,,BAO_0000100
12991,,Increased absorption was determined,,,22224,,U,0,Autocuration,1,,CHEMBL883126,,BAO_0000019
12992,,Lipophilicity value was evaluated,,,22224,,U,0,Autocuration,1,,CHEMBL631235,,BAO_0000100
12993,,Log P value of the compound.,,,22224,,U,0,Autocuration,1,,CHEMBL631236,,BAO_0000100
12994,,Partition coefficient of compound was determined,,,22224,,U,0,Autocuration,1,,CHEMBL631237,,BAO_0000019
12995,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL631238,,BAO_0000100
12996,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL876429,,BAO_0000100
12997,,Partition coefficient was measured by medchem software; Not calculated,,,22224,,U,0,Autocuration,1,,CHEMBL631414,,BAO_0000019
12998,,Partition coefficient was measured by octanol-water using standard shake-flask method,,,22224,,U,0,Autocuration,1,,CHEMBL631415,,BAO_0000100
12999,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL631416,,BAO_0000100
13000,,Partition coefficient (logP),,,22224,,U,0,Autocuration,1,,CHEMBL631417,,BAO_0000019
13001,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL631418,,BAO_0000100
13002,,The Octanol/Water partition coefficient CLogP,,,22229,,U,0,Autocuration,1,,CHEMBL631419,,BAO_0000100
13003,,The pharmacokinetic parameter C Log p was reported,,,22224,,U,0,Autocuration,1,,CHEMBL631420,,BAO_0000019
13004,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL631421,,BAO_0000100
13005,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL631422,,BAO_0000100
13006,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL631423,,BAO_0000100
13007,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL876430,,BAO_0000218
13008,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL631424,,BAO_0000218
13009,,Compound was administered intravenously in dog to evaluate plasma clearance values,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL631425,,BAO_0000218
13010,,Compound was administered intravenously in monkey to evaluate plasma clearance values,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL631426,,BAO_0000218
13011,,Compound was administered intravenously in mouse to evaluate plasma clearance values,1969.0,,50594,,N,1,Intermediate,1,,CHEMBL631427,,BAO_0000218
13012,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL631428,,BAO_0000218
13013,Microsomes,Intrinsic clearance in Rhesus liver microsome,2107.0,,50797,,N,1,Intermediate,1,,CHEMBL631429,,BAO_0000218
13014,Microsomes,Intrinsic clearance in dog liver microsome,2107.0,,50588,,N,1,Intermediate,1,,CHEMBL631430,,BAO_0000218
13015,Microsomes,Intrinsic clearance in rat liver microsome,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631431,,BAO_0000218
13016,,Low plasma clearance was calculated in rhesus monkey,1969.0,,50797,,N,1,Intermediate,1,,CHEMBL631432,,BAO_0000218
13017,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,50588,,N,1,Intermediate,1,,CHEMBL631433,,BAO_0000218
13018,,Plasma clearance after intravenous dose of 0.3 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL631434,,BAO_0000218
13019,,Plasma clearance after intravenous dose of 1 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL631435,,BAO_0000218
13020,,Plasma clearance after intravenous dose of 3 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL631436,,BAO_0000218
13021,,Plasma clearance after intravenous dose of 3.87 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL631437,,BAO_0000218
13022,,Plasma clearance after peroral administration at 10 mpk in Rat,,,50597,,N,1,Intermediate,1,,CHEMBL631438,,BAO_0000218
13023,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,,50797,,N,1,Intermediate,1,,CHEMBL876431,,BAO_0000218
13024,,Plasma clearance after peroral administration at 10 mpk in dog,,,50588,,N,1,Intermediate,1,,CHEMBL631439,,BAO_0000218
13025,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,,50597,,N,1,Intermediate,1,,CHEMBL631440,,BAO_0000218
13026,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,,22224,,U,0,Autocuration,1,,CHEMBL631441,,BAO_0000019
13027,,Critical Micellar concentration was determined,,,22224,,U,0,Autocuration,1,,CHEMBL631442,,BAO_0000019
13028,,Critical Micellar concentration of the compound. was determined,,,22224,,U,0,Autocuration,1,,CHEMBL626525,,BAO_0000019
13029,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,,22224,,U,0,Autocuration,1,,CHEMBL627168,,BAO_0000019
13030,,Critical micellar concentration was measured in water by the dye solubilization method,,,22224,,U,0,Autocuration,1,,CHEMBL875618,,BAO_0000019
13031,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,,22224,,U,0,Autocuration,1,,CHEMBL626612,,BAO_0000019
13032,,CMR value (relative to BAY K 8644),,,22224,,U,0,Autocuration,1,,CHEMBL626613,,BAO_0000019
13033,,Carbamoylating activity was determined,,,22224,,U,0,Autocuration,1,,CHEMBL626614,,BAO_0000019
13034,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,,22224,,U,0,Autocuration,1,,CHEMBL626615,,BAO_0000218
13035,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,,22224,,U,0,Autocuration,1,,CHEMBL626616,,BAO_0000019
13036,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,,22224,,U,0,Autocuration,1,,CHEMBL626617,,BAO_0000019
13037,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626618,,BAO_0000218
13038,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626619,,BAO_0000218
13039,,"Clearance rate at 0.46 mg/kg, iv, in dogs",,,50588,,N,1,Intermediate,1,,CHEMBL626620,,BAO_0000218
13040,,"Clearance rate at 5.5 mg/kg, iv, in rat",,,50597,,N,1,Intermediate,1,,CHEMBL626621,,BAO_0000218
13041,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,,100710,,N,1,Intermediate,1,,CHEMBL626622,,BAO_0000218
13042,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,,100710,,N,1,Intermediate,1,,CHEMBL626623,,BAO_0000218
13043,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,,50588,,N,1,Intermediate,1,,CHEMBL626624,,BAO_0000218
13044,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL626625,,BAO_0000218
13045,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL626626,,BAO_0000218
13046,,Tested for the total clearance of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL626627,,BAO_0000218
13047,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,,50588,,N,1,Intermediate,1,,CHEMBL626628,,BAO_0000218
13048,,Total body clearance was determined,,,22224,,U,0,Autocuration,1,,CHEMBL626629,,BAO_0000218
13049,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626630,,BAO_0000218
13050,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626631,,BAO_0000218
13051,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,22229,,U,0,Autocuration,1,,CHEMBL626632,,BAO_0000100
13052,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,22229,,U,0,Autocuration,1,,CHEMBL626633,,BAO_0000100
13053,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,,22229,,U,0,Autocuration,1,,CHEMBL626634,,BAO_0000100
13054,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,22229,,U,0,Autocuration,1,,CHEMBL626635,,BAO_0000100
13055,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,22229,,U,0,Autocuration,1,,CHEMBL626636,,BAO_0000100
13056,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,22229,,U,0,Autocuration,1,,CHEMBL626637,,BAO_0000100
13057,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,,50339,,N,1,Intermediate,1,,CHEMBL626638,,BAO_0000218
13058,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,,50339,,N,1,Intermediate,1,,CHEMBL626639,,BAO_0000218
13059,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,,50339,,N,1,Intermediate,1,,CHEMBL626640,,BAO_0000218
13060,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,,50339,,N,1,Intermediate,1,,CHEMBL626641,,BAO_0000218
13061,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,,50339,,N,1,Intermediate,1,,CHEMBL627272,,BAO_0000218
13062,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,,50339,,N,1,Intermediate,1,,CHEMBL627273,,BAO_0000218
13063,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,,50339,,N,1,Intermediate,1,,CHEMBL627441,,BAO_0000218
13064,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,,50339,,N,1,Intermediate,1,,CHEMBL628355,,BAO_0000218
13065,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,,50339,,N,1,Intermediate,1,,CHEMBL628356,,BAO_0000218
13066,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,,50339,,N,1,Intermediate,1,,CHEMBL628357,,BAO_0000218
13067,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,,50339,,N,1,Intermediate,1,,CHEMBL628358,,BAO_0000218
13068,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,,50339,,N,1,Intermediate,1,,CHEMBL622307,,BAO_0000218
13069,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,,22224,,U,0,Autocuration,1,,CHEMBL622527,,BAO_0000019
13070,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,,22224,,U,0,Autocuration,1,,CHEMBL622528,,BAO_0000019
13071,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,,22224,,U,0,Autocuration,1,,CHEMBL622529,,BAO_0000019
13072,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,,22224,,U,0,Autocuration,1,,CHEMBL622992,,BAO_0000019
13073,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,,22224,,U,0,Autocuration,1,,CHEMBL622993,,BAO_0000019
13074,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,,22224,,U,0,Autocuration,1,,CHEMBL622994,,BAO_0000019
13075,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,,50597,,N,1,Intermediate,1,,CHEMBL622995,,BAO_0000218
13076,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,,50597,,N,1,Intermediate,1,,CHEMBL622996,,BAO_0000218
13077,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,,50597,,N,1,Intermediate,1,,CHEMBL622997,,BAO_0000218
13078,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,,50597,,N,1,Intermediate,1,,CHEMBL622998,,BAO_0000218
13079,,Cp max following ip administration at 1 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL622999,,BAO_0000218
13080,,Maximum concentration in plasma was reported at 0.5 hour,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL623000,,BAO_0000218
13081,,Maximum concentration in plasma was reported at 2 hour,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL623001,,BAO_0000218
13082,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,,50594,,N,1,Intermediate,1,,CHEMBL623002,,BAO_0000218
13083,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,,22229,,U,0,Autocuration,1,,CHEMBL623003,,BAO_0000100
13084,,Steady state concentration was evaluated,,,22224,,U,0,Autocuration,1,,CHEMBL623004,,BAO_0000019
13085,,Partition coefficient (logP),,,22224,,U,0,Autocuration,1,,CHEMBL623005,,BAO_0000019
13086,,Partition coefficient (logD7.4),,,22224,,U,0,Autocuration,1,,CHEMBL623006,,BAO_0000019
13087,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL623007,,BAO_0000218
13088,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL623008,,BAO_0000218
13089,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL876654,,BAO_0000218
13090,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL623009,,BAO_0000218
13091,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL623010,,BAO_0000218
13092,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,948.0,,50597,,N,1,Intermediate,1,,CHEMBL623011,,BAO_0000218
13093,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,160.0,,50597,,N,1,Intermediate,1,,CHEMBL623012,,BAO_0000218
13094,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,,22224,,U,0,Autocuration,1,,CHEMBL623013,,BAO_0000019
13095,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,22224,,U,0,Autocuration,1,,CHEMBL623014,,BAO_0000019
13096,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL623015,,BAO_0000019
13097,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL623016,,BAO_0000019
13098,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL624858,,BAO_0000019
13099,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,,50597,,N,1,Intermediate,1,,CHEMBL624859,,BAO_0000218
13100,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL624860,,BAO_0000218
13101,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,50597,,N,1,Intermediate,1,,CHEMBL624861,,BAO_0000218
13102,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,,50597,,N,1,Intermediate,1,,CHEMBL624862,,BAO_0000218
13103,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,,50597,,N,1,Intermediate,1,,CHEMBL624863,,BAO_0000218
13104,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,50597,,N,1,Intermediate,1,,CHEMBL876655,,BAO_0000218
13105,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,,50588,,N,1,Intermediate,1,,CHEMBL624864,,BAO_0000218
13106,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,,50588,,N,1,Intermediate,1,,CHEMBL624865,,BAO_0000218
13107,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,50588,,N,1,Intermediate,1,,CHEMBL624866,,BAO_0000218
13108,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,,50588,,N,1,Expert,1,,CHEMBL624867,,BAO_0000218
13109,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,,50588,,N,1,Intermediate,1,,CHEMBL624868,,BAO_0000218
13110,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,,50588,,N,1,Intermediate,1,,CHEMBL628450,,BAO_0000218
13111,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,,50588,,N,1,Intermediate,1,,CHEMBL628451,,BAO_0000218
13112,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,,50588,,N,1,Intermediate,1,,CHEMBL628452,,BAO_0000218
13113,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,50588,,N,1,Intermediate,1,,CHEMBL628453,,BAO_0000218
13114,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,,50588,,N,1,Intermediate,1,,CHEMBL628454,,BAO_0000218
13115,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,,50588,,N,1,Intermediate,1,,CHEMBL628455,,BAO_0000218
13116,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,,50588,,N,1,Intermediate,1,,CHEMBL628456,,BAO_0000218
13117,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,50588,,N,1,Intermediate,1,,CHEMBL628457,,BAO_0000218
13118,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,,50588,,N,1,Intermediate,1,,CHEMBL877505,,BAO_0000218
13119,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,,50588,,N,1,Intermediate,1,,CHEMBL628458,,BAO_0000218
13120,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,,50588,,N,1,Intermediate,1,,CHEMBL628459,,BAO_0000218
13121,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,,50588,,N,1,Intermediate,1,,CHEMBL628460,,BAO_0000218
13122,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,,50588,,N,1,Intermediate,1,,CHEMBL628461,,BAO_0000218
13123,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,,22224,,U,0,Autocuration,1,,CHEMBL628462,,BAO_0000218
13124,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,50588,,N,1,Intermediate,1,,CHEMBL628463,,BAO_0000218
13125,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,,50597,,N,1,Expert,1,,CHEMBL625666,,BAO_0000218
13126,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,22224,,U,0,Autocuration,1,,CHEMBL625667,,BAO_0000218
13127,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,50597,,N,1,Expert,1,,CHEMBL625668,,BAO_0000218
13128,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,50597,,N,1,Intermediate,1,,CHEMBL625669,,BAO_0000218
13129,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,,22224,,U,0,Autocuration,1,,CHEMBL625670,,BAO_0000019
13130,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625671,,BAO_0000218
13131,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,,50602,,N,1,Intermediate,1,,CHEMBL625672,,BAO_0000218
13132,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,,50602,,N,1,Intermediate,1,,CHEMBL625673,,BAO_0000218
13133,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,,50602,,N,1,Intermediate,1,,CHEMBL625674,,BAO_0000218
13134,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,,50602,,N,1,Intermediate,1,,CHEMBL625675,,BAO_0000218
13135,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,,50602,,N,1,Intermediate,1,,CHEMBL627637,,BAO_0000218
13136,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,,50602,,N,1,Intermediate,1,,CHEMBL627638,,BAO_0000218
13137,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,,50602,,N,1,Intermediate,1,,CHEMBL627639,,BAO_0000218
13138,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,,50602,,N,1,Intermediate,1,,CHEMBL627640,,BAO_0000218
13139,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,,50602,,N,1,Intermediate,1,,CHEMBL627641,,BAO_0000218
13140,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,,50602,,N,1,Intermediate,1,,CHEMBL627642,,BAO_0000218
13141,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,,50602,,N,1,Intermediate,1,,CHEMBL877506,,BAO_0000218
13142,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,,50594,,N,1,Intermediate,1,,CHEMBL627275,,BAO_0000218
13143,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,,50506,,N,1,Intermediate,1,,CHEMBL627643,,BAO_0000218
13144,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,,50506,,N,1,Intermediate,1,,CHEMBL631246,,BAO_0000218
13145,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,,50506,,N,1,Intermediate,1,,CHEMBL631247,,BAO_0000218
13146,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,,50506,,N,1,Intermediate,1,,CHEMBL629532,,BAO_0000218
13147,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,,50506,,N,1,Intermediate,1,,CHEMBL629533,,BAO_0000218
13148,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,,50506,,N,1,Intermediate,1,,CHEMBL629534,,BAO_0000218
13149,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,,50506,,N,1,Intermediate,1,,CHEMBL629535,,BAO_0000218
13150,,Pharmacokinetic parameter :drug bound to plasma was reported,,,22224,,U,0,Autocuration,1,,CHEMBL625932,,BAO_0000019
13151,,compound was evaluated for drug bound in plasma,,,22224,,U,0,Autocuration,1,,CHEMBL625933,,BAO_0000019
13152,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,,50597,,N,1,Intermediate,1,,CHEMBL625934,,BAO_0000218
13153,,Bioavailability,,,22224,,U,0,Autocuration,1,,CHEMBL625935,,BAO_0000218
13154,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,,50597,,N,1,Intermediate,1,,CHEMBL625936,,BAO_0000218
13155,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL625937,,BAO_0000218
13156,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,,50588,,N,1,Intermediate,1,,CHEMBL625938,,BAO_0000218
13157,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,1970.0,,50597,,N,1,Intermediate,1,,CHEMBL625939,,BAO_0000218
13158,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,1970.0,,50597,,N,1,Intermediate,1,,CHEMBL625940,,BAO_0000218
13159,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,1970.0,,50597,,N,1,Intermediate,1,,CHEMBL874464,,BAO_0000218
13160,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,1970.0,,50597,,N,1,Intermediate,1,,CHEMBL625941,,BAO_0000218
13161,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,1970.0,,50597,,N,1,Intermediate,1,,CHEMBL625942,,BAO_0000218
13162,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,1970.0,,50597,,N,1,Intermediate,1,,CHEMBL625943,,BAO_0000218
13163,,In vitro protein binding in human serum at 5 ug/ml,1977.0,,50587,,N,1,Intermediate,1,,CHEMBL625944,,BAO_0000218
13164,,Serum protein binding ability was measured,,,22224,,U,0,Autocuration,1,,CHEMBL625945,,BAO_0000019
13165,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,22224,,U,0,Autocuration,1,,CHEMBL625946,,BAO_0000019
13166,,Oral bioavailability in dog,,,22224,,U,0,Autocuration,1,,CHEMBL625947,,BAO_0000218
13167,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,,50597,,N,1,Intermediate,1,,CHEMBL625948,,BAO_0000218
13168,,Absolute oral bioavailability at an iv dose of 14 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL625949,,BAO_0000218
13169,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL625950,,BAO_0000218
13170,,Oral bioavailability (dose 15 mg/kg i.v.),,,22224,,U,0,Autocuration,1,,CHEMBL625951,,BAO_0000218
13171,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,,22224,,U,0,Autocuration,1,,CHEMBL625952,,BAO_0000218
13172,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,,22224,,U,0,Autocuration,1,,CHEMBL625953,,BAO_0000218
13173,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,,22224,,U,0,Autocuration,1,,CHEMBL625954,,BAO_0000218
13174,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,,22224,,U,0,Autocuration,1,,CHEMBL882959,,BAO_0000218
13175,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,,50588,,N,1,Intermediate,1,,CHEMBL625955,,BAO_0000218
13176,,Bioavailability in ferret,,,22224,,U,0,Autocuration,1,,CHEMBL625956,,BAO_0000218
13177,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,,100710,,N,1,Intermediate,1,,CHEMBL625957,,BAO_0000218
13178,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625958,,BAO_0000218
13179,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625959,,BAO_0000218
13180,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626642,,BAO_0000218
13181,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL631330,,BAO_0000218
13182,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL631331,,BAO_0000218
13183,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL631332,,BAO_0000218
13184,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL631333,,BAO_0000218
13185,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL632018,,BAO_0000218
13186,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL632019,,BAO_0000218
13187,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL632020,,BAO_0000218
13188,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL632021,,BAO_0000218
13189,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL632022,,BAO_0000218
13190,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL632023,,BAO_0000218
13191,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL632024,,BAO_0000218
13192,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL874472,,BAO_0000218
13193,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL632025,,BAO_0000218
13194,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL632026,,BAO_0000218
13195,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL632027,,BAO_0000218
13196,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL632028,,BAO_0000218
13197,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626430,,BAO_0000218
13198,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626431,,BAO_0000218
13199,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626432,,BAO_0000218
13200,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626433,,BAO_0000218
13201,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626434,,BAO_0000218
13202,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627280,,BAO_0000218
13203,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627281,,BAO_0000218
13204,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627282,,BAO_0000218
13205,,Total body clearance was measured at given dose,,,22224,,U,0,Autocuration,1,,CHEMBL627283,,BAO_0000019
13206,,Total body clearance was measured at given dose.,,,22224,,U,0,Autocuration,1,,CHEMBL627284,,BAO_0000218
13207,,Metabolic clearance from the body in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627285,,BAO_0000218
13208,,Renal clearance from the body,,,22224,,U,0,Autocuration,1,,CHEMBL627286,,BAO_0000218
13209,,Renal clearance from the body in rat,,,50597,,N,1,Intermediate,1,,CHEMBL875477,,BAO_0000218
13210,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627287,,BAO_0000218
13211,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,,50588,,N,1,Intermediate,1,,CHEMBL627288,,BAO_0000218
13212,,Total clearance from the body in rat,,,50597,,N,1,Intermediate,1,,CHEMBL627289,,BAO_0000218
13213,,Clearance into cortex from rat plasma or PBS,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627290,,BAO_0000218
13214,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,,22224,,U,0,Autocuration,1,,CHEMBL627291,,BAO_0000218
13215,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,,22224,,U,0,Autocuration,1,,CHEMBL627292,,BAO_0000218
13216,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,,22224,,U,0,Autocuration,1,,CHEMBL627293,,BAO_0000218
13217,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,,22224,,U,0,Autocuration,1,,CHEMBL627294,,BAO_0000218
13218,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,,22224,,U,0,Autocuration,1,,CHEMBL875478,,BAO_0000218
13219,,Clearance was determined,,,22224,,U,0,Autocuration,1,,CHEMBL627295,,BAO_0000218
13220,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,,50594,,N,1,Intermediate,1,,CHEMBL627296,,BAO_0000218
13221,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,,50592,,N,1,Intermediate,1,,CHEMBL626119,,BAO_0000218
13222,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,,50597,,N,1,Intermediate,1,,CHEMBL626120,,BAO_0000218
13223,,Clearance in rat after iv dose (100 ug/kg),,,50597,,N,1,Intermediate,1,,CHEMBL626121,,BAO_0000218
13224,,Clearance in guinea pig,,,22224,,U,0,Autocuration,1,,CHEMBL626122,,BAO_0000218
13225,,Compound was evaluated for clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL626123,,BAO_0000218
13226,,Compound was evaluated for the clearance in dog,,,50588,,N,1,Intermediate,1,,CHEMBL623456,,BAO_0000218
13227,,Compound was evaluated for the clearance in rat,,,50597,,N,1,Intermediate,1,,CHEMBL623457,,BAO_0000218
13228,,Compound was tested in vivo for clearance after iv administration in the rat,,,50597,,N,1,Intermediate,1,,CHEMBL623458,,BAO_0000218
13229,,IV clearance determined at an iv dose of 14 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL623459,,BAO_0000218
13230,,IV clearance determined at an iv dose of 15.2 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL875484,,BAO_0000218
13231,,IV clearance determined at an iv dose of 15 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL623460,,BAO_0000218
13232,,IV clearance determined at an peroral dose of 30 mg/kg.,,,22224,,U,0,Autocuration,1,,CHEMBL623461,,BAO_0000218
13233,,IV clearance determined at an peroral dose of 30.2 mg/kg.,,,22224,,U,0,Autocuration,1,,CHEMBL623462,,BAO_0000218
13234,,IV clearance determined at an peroral dose of 30.3 mg/kg.,,,22224,,U,0,Autocuration,1,,CHEMBL627386,,BAO_0000218
13235,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627387,,BAO_0000218
13236,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627388,,BAO_0000218
13237,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627389,,BAO_0000218
13238,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627390,,BAO_0000218
13239,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627391,,BAO_0000218
13240,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL627392,,BAO_0000218
13241,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL627393,,BAO_0000218
13242,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,3126.0,,50597,,N,1,Intermediate,1,,CHEMBL627394,,BAO_0000218
13243,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL627395,,BAO_0000218
13244,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL875485,,BAO_0000218
13245,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL627396,,BAO_0000218
13246,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL627397,,BAO_0000218
13247,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,948.0,,50597,,N,1,Intermediate,1,,CHEMBL627398,,BAO_0000218
13248,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL627399,,BAO_0000218
13249,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627400,,BAO_0000218
13250,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627401,,BAO_0000218
13251,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627402,,BAO_0000218
13252,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL627403,,BAO_0000218
13253,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL627404,,BAO_0000218
13254,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL623101,,BAO_0000218
13255,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL877480,,BAO_0000218
13256,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,3126.0,,50597,,N,1,Intermediate,1,,CHEMBL623102,,BAO_0000218
13257,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL623103,,BAO_0000218
13258,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL623104,,BAO_0000218
13259,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL623105,,BAO_0000218
13260,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL623106,,BAO_0000218
13261,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,948.0,,50597,,N,1,Intermediate,1,,CHEMBL623107,,BAO_0000218
13262,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,160.0,,50597,,N,1,Intermediate,1,,CHEMBL623108,,BAO_0000218
13263,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL623109,,BAO_0000218
13264,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL623110,,BAO_0000218
13265,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL623111,,BAO_0000218
13266,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL625060,,BAO_0000218
13267,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625061,,BAO_0000218
13268,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL625062,,BAO_0000218
13269,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625063,,BAO_0000218
13270,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,3126.0,,50597,,N,1,Intermediate,1,,CHEMBL625064,,BAO_0000218
13271,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,10000001.0,,50597,,N,1,Intermediate,1,,CHEMBL625065,,BAO_0000218
13272,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL625066,,BAO_0000218
13273,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL625067,,BAO_0000218
13274,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL625068,,BAO_0000218
13275,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,948.0,,50597,,N,1,Intermediate,1,,CHEMBL622159,,BAO_0000218
13276,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,160.0,,50597,,N,1,Intermediate,1,,CHEMBL622160,,BAO_0000218
13277,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL622161,,BAO_0000218
13278,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL622162,,BAO_0000218
13279,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL622163,,BAO_0000218
13280,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622313,,BAO_0000218
13281,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL622314,,BAO_0000218
13282,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622315,,BAO_0000218
13283,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,3126.0,,50597,,N,1,Intermediate,1,,CHEMBL622316,,BAO_0000218
13284,,Normal diffusion coefficient in water for Escherichia coli,,,50212,,N,1,Intermediate,1,,CHEMBL877486,,BAO_0000218
13285,,Average max percent decrease in RVR (renal vascular resistance) was determined,,,22224,,U,0,Autocuration,1,,CHEMBL622317,,BAO_0000019
13286,,Average max percent decrease in RVR (renal vascular resistance) was determined.,,,22224,,U,0,Autocuration,1,,CHEMBL622318,,BAO_0000019
13287,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,,22224,,U,0,Autocuration,1,,CHEMBL622319,,BAO_0000019
13288,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,,22224,,U,0,Autocuration,1,,CHEMBL622320,,BAO_0000019
13289,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,,22224,,U,0,Autocuration,1,,CHEMBL622321,,BAO_0000019
13290,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,,22224,,U,0,Autocuration,1,,CHEMBL622322,,BAO_0000019
13291,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,,22224,,U,0,Autocuration,1,,CHEMBL622323,,BAO_0000019
13292,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622324,,BAO_0000218
13293,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622325,,BAO_0000218
13294,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622326,,BAO_0000218
13295,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL877487,,BAO_0000218
13296,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622327,,BAO_0000218
13297,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622328,,BAO_0000218
13298,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622329,,BAO_0000218
13299,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622330,,BAO_0000218
13300,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622331,,BAO_0000218
13301,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622332,,BAO_0000218
13302,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622333,,BAO_0000218
13303,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL627658,,BAO_0000218
13304,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630428,,BAO_0000218
13305,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630429,,BAO_0000218
13306,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630430,,BAO_0000218
13307,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630431,,BAO_0000218
13308,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL630432,,BAO_0000218
13309,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL630433,,BAO_0000218
13310,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL630434,,BAO_0000218
13311,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629372,,BAO_0000218
13312,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629553,,BAO_0000218
13313,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629554,,BAO_0000218
13314,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL874447,,BAO_0000218
13315,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629555,,BAO_0000218
13316,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629556,,BAO_0000218
13317,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629557,,BAO_0000218
13318,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629558,,BAO_0000218
13319,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629559,,BAO_0000218
13320,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629560,,BAO_0000218
13321,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL629561,,BAO_0000218
13322,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL629562,,BAO_0000218
13323,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL629563,,BAO_0000218
13324,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL629564,,BAO_0000218
13325,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL629565,,BAO_0000218
13326,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL629566,,BAO_0000218
13327,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL629567,,BAO_0000218
13328,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL629568,,BAO_0000218
13329,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL629569,,BAO_0000218
13330,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL629570,,BAO_0000218
13331,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL629571,,BAO_0000218
13332,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,,22224,,U,0,Autocuration,1,,CHEMBL629572,,BAO_0000218
13333,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,,22224,,U,0,Autocuration,1,,CHEMBL629573,,BAO_0000218
13334,,Bioavailability (dose 20 mg/kg),,,22224,,U,0,Autocuration,1,,CHEMBL629574,,BAO_0000218
13335,,Bioavailability in dog,,,22224,,U,0,Autocuration,1,,CHEMBL629575,,BAO_0000218
13336,,Bioavailability in rat (Sprague-Dawley) (male),,,22224,,U,0,Autocuration,1,,CHEMBL874448,,BAO_0000218
13337,,Bioavailability in monkey (dose 10 mg/kg i.d.),,,22224,,U,0,Autocuration,1,,CHEMBL629576,,BAO_0000218
13338,,Bioavailability in rat,,,22224,,U,0,Autocuration,1,,CHEMBL629577,,BAO_0000218
13339,,Bioavailability in rat,,,22224,,U,0,Autocuration,1,,CHEMBL629578,,BAO_0000218
13340,,Bioavailability in dog (dose 3.0 mg/kg p.o.),,,22224,,U,0,Autocuration,1,,CHEMBL629579,,BAO_0000218
13341,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,,22224,,U,0,Autocuration,1,,CHEMBL882958,,BAO_0000218
13342,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,,50505,,N,1,Intermediate,1,,CHEMBL629580,,BAO_0000218
13343,,Bioavailability,,,22224,,U,0,Autocuration,1,,CHEMBL629581,,BAO_0000218
13344,,Bioavailability in squirrel monkey,,,22224,,U,0,Autocuration,1,,CHEMBL629582,,BAO_0000218
13345,,Bioavailability was evaluated in dog,,,50588,,N,1,Intermediate,1,,CHEMBL628522,,BAO_0000218
13346,,Bioavailability was evaluated in hamster,,,100712,,N,1,Intermediate,1,,CHEMBL625432,,BAO_0000218
13347,,Bioavailability in rat,,,22224,,U,0,Autocuration,1,,CHEMBL625433,,BAO_0000218
13348,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625434,,BAO_0000218
13349,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL625435,,BAO_0000218
13350,,Bioavailability in rat (dose 10 mg/kg p.o.),,,22224,,U,0,Autocuration,1,,CHEMBL625436,,BAO_0000218
13351,,Bioavailability was measured in cynomolgus monkeys.,,,100710,,N,1,Intermediate,1,,CHEMBL874588,,BAO_0000218
13352,,Bioavailability was measured in nude mice.,,,50594,,N,1,Intermediate,1,,CHEMBL625437,,BAO_0000218
13353,,Bioavailability in ferret (dose 10 mg/kg i.d.),,,22224,,U,0,Autocuration,1,,CHEMBL625438,,BAO_0000218
13354,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,,22224,,U,0,Autocuration,1,,CHEMBL625439,,BAO_0000218
13355,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,,22224,,U,0,Autocuration,1,,CHEMBL625440,,BAO_0000218
13356,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,,22224,,U,0,Autocuration,1,,CHEMBL625441,,BAO_0000218
13357,,Bioavailability in rat (dose 10 mg/kg i.d.),,,22224,,U,0,Autocuration,1,,CHEMBL625442,,BAO_0000218
13358,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,,50597,,N,1,Intermediate,1,,CHEMBL625443,,BAO_0000218
13359,,Bioavailability was determined; extremely poor,,,22224,,U,0,Autocuration,1,,CHEMBL625444,,BAO_0000218
13360,,% bioavailability in mice after oral administration of prodrug,,,50594,,N,1,Intermediate,1,,CHEMBL625445,,BAO_0000218
13361,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,,50588,,N,1,Intermediate,1,,CHEMBL625446,,BAO_0000218
13362,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,,50588,,N,1,Intermediate,1,,CHEMBL882960,,BAO_0000218
13363,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,,50588,,N,1,Intermediate,1,,CHEMBL625447,,BAO_0000218
13364,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,,50588,,N,1,Intermediate,1,,CHEMBL625448,,BAO_0000218
13365,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,,50588,,N,1,Intermediate,1,,CHEMBL625449,,BAO_0000218
13366,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,,50588,,N,1,Intermediate,1,,CHEMBL874589,,BAO_0000218
13367,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,,50588,,N,1,Intermediate,1,,CHEMBL625450,,BAO_0000218
13368,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,,50588,,N,1,Intermediate,1,,CHEMBL625451,,BAO_0000218
13369,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,,50588,,N,1,Intermediate,1,,CHEMBL626584,,BAO_0000218
13370,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,,50588,,N,1,Intermediate,1,,CHEMBL626585,,BAO_0000218
13371,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,,50588,,N,1,Intermediate,1,,CHEMBL626586,,BAO_0000218
13372,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,,50588,,N,1,Intermediate,1,,CHEMBL626587,,BAO_0000218
13373,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,,50588,,N,1,Intermediate,1,,CHEMBL626588,,BAO_0000218
13374,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,,50588,,N,1,Intermediate,1,,CHEMBL626589,,BAO_0000218
13375,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,,50588,,N,1,Intermediate,1,,CHEMBL626590,,BAO_0000218
13376,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,,50588,,N,1,Intermediate,1,,CHEMBL626591,,BAO_0000218
13377,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,,50588,,N,1,Intermediate,1,,CHEMBL627181,,BAO_0000218
13378,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,,50588,,N,1,Intermediate,1,,CHEMBL628083,,BAO_0000218
13379,,IV clearance determined at an peroral dose of 15 mg/kg.,,,22224,,U,0,Autocuration,1,,CHEMBL628084,,BAO_0000218
13380,,Mouse oral clearance was measured against Hymenolepiasis nana.,,,50064,,N,1,Expert,1,,CHEMBL628085,,BAO_0000218
13381,,Mouse oral clearance was measured against Nematospiroides dubius,,,50545,,N,1,Expert,1,,CHEMBL628086,,BAO_0000218
13382,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,,22224,,U,0,Autocuration,1,,CHEMBL628087,,BAO_0000218
13383,,Mouse oral clearance was measured against N. nana; NT is Not Tested,,,50594,,N,1,Intermediate,1,,CHEMBL628088,,BAO_0000218
13384,,Mouse oral clearance was measured against N. nana; NT is Not Tested,,,22224,,U,0,Autocuration,1,,CHEMBL628089,,BAO_0000218
13385,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,,22224,,U,0,Autocuration,1,,CHEMBL628090,,BAO_0000218
13386,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,,22224,,U,0,Autocuration,1,,CHEMBL628091,,BAO_0000218
13387,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,,22224,,U,0,Autocuration,1,,CHEMBL628092,,BAO_0000218
13388,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,,22224,,U,0,Autocuration,1,,CHEMBL628093,,BAO_0000218
13389,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,,22224,,U,0,Autocuration,1,,CHEMBL875607,,BAO_0000218
13390,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,,22224,,U,0,Autocuration,1,,CHEMBL625710,,BAO_0000218
13391,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,,22224,,U,0,Autocuration,1,,CHEMBL625711,,BAO_0000218
13392,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,,22224,,U,0,Autocuration,1,,CHEMBL625712,,BAO_0000218
13393,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,,22224,,U,0,Autocuration,1,,CHEMBL625713,,BAO_0000218
13394,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,,50588,,N,1,Intermediate,1,,CHEMBL625714,,BAO_0000218
13395,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,,50797,,N,1,Intermediate,1,,CHEMBL625715,,BAO_0000218
13396,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625716,,BAO_0000218
13397,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,,50597,,N,1,Intermediate,1,,CHEMBL625717,,BAO_0000218
13398,,Plasma clearance was determined for the compound in rats,,,50597,,N,1,Intermediate,1,,CHEMBL625718,,BAO_0000218
13399,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,,50597,,N,1,Intermediate,1,,CHEMBL625719,,BAO_0000218
13400,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,,50597,,N,1,Intermediate,1,,CHEMBL625720,,BAO_0000218
13401,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,,50597,,N,1,Intermediate,1,,CHEMBL625721,,BAO_0000218
13402,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,,50597,,N,1,Intermediate,1,,CHEMBL625722,,BAO_0000218
13403,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,,50597,,N,1,Intermediate,1,,CHEMBL625723,,BAO_0000218
13404,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,,50545,,N,1,Intermediate,1,,CHEMBL625724,,BAO_0000218
13405,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,,50545,,N,1,Intermediate,1,,CHEMBL625725,,BAO_0000218
13406,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,,50545,,N,1,Intermediate,1,,CHEMBL625726,,BAO_0000218
13407,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,,50545,,N,1,Intermediate,1,,CHEMBL875608,,BAO_0000218
13408,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,,50545,,N,1,Intermediate,1,,CHEMBL625727,,BAO_0000218
13409,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL625728,,BAO_0000218
13410,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,,22224,,U,0,Autocuration,1,,CHEMBL625729,,BAO_0000218
13411,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,,22224,,U,0,Autocuration,1,,CHEMBL625730,,BAO_0000218
13412,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL625731,,BAO_0000218
13413,,Urinary clearance was determined in rat at 25 mg/kg os dosage,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL626417,,BAO_0000218
13414,,Urinary clearance was determined at 100 mg/kg oral dosage in human,1088.0,,50587,,N,1,Intermediate,1,,CHEMBL626418,,BAO_0000218
13415,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL626419,,BAO_0000218
13416,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626592,,BAO_0000218
13417,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626593,,BAO_0000218
13418,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,,50597,,N,1,Intermediate,1,,CHEMBL626594,,BAO_0000218
13419,,Clearance rate in dogs,,,50588,,N,1,Intermediate,1,,CHEMBL625035,,BAO_0000218
13420,,Compound was measured for intrinsic clearance,,,22224,,U,0,Autocuration,1,,CHEMBL625036,,BAO_0000019
13421,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625037,,BAO_0000100
13422,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625038,,BAO_0000100
13423,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625039,,BAO_0000100
13424,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625040,,BAO_0000100
13425,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625041,,BAO_0000100
13426,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625042,,BAO_0000100
13427,,Partition coefficient of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL874411,,BAO_0000019
13428,,Permeability,,,22224,,U,0,Autocuration,1,,CHEMBL625043,,BAO_0000019
13429,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625044,,BAO_0000100
13430,,Partition coefficient (logD),,,22224,,U,0,Autocuration,1,,CHEMBL625045,,BAO_0000019
13431,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,22229,,U,0,Autocuration,1,,CHEMBL625046,,BAO_0000100
13432,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,22229,,U,0,Autocuration,1,,CHEMBL625047,,BAO_0000100
13433,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625048,,BAO_0000100
13434,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625049,,BAO_0000100
13435,,Calculated logarithm of partition coefficient (P) was determined,,,22229,,U,0,Autocuration,1,,CHEMBL625050,,BAO_0000100
13436,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625051,,BAO_0000100
13437,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL874412,,BAO_0000100
13438,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625052,,BAO_0000100
13439,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL625053,,BAO_0000100
13440,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,,22224,,U,0,Autocuration,1,,CHEMBL623250,,BAO_0000019
13441,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,,22224,,U,0,Autocuration,1,,CHEMBL623251,,BAO_0000019
13442,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,,22224,,U,0,Autocuration,1,,CHEMBL623252,,BAO_0000019
13443,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,,22224,,U,0,Autocuration,1,,CHEMBL623253,,BAO_0000019
13444,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,,22224,,U,0,Autocuration,1,,CHEMBL623254,,BAO_0000019
13445,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,,22224,,U,0,Autocuration,1,,CHEMBL623255,,BAO_0000019
13446,,Percent degradation of compound at a pH of 1 over a 18 hr period,,,22224,,U,0,Autocuration,1,,CHEMBL626831,,BAO_0000019
13447,,Percent degradation of compound at pH of 1 over an 18 hr period,,,22224,,U,0,Autocuration,1,,CHEMBL877494,,BAO_0000019
13448,,Delta Logarithm of Partition Coefficient value was determined.,,,22224,,U,0,Autocuration,1,,CHEMBL626832,,BAO_0000019
13449,,Delta logPoct-cyc,,,22224,,U,0,Autocuration,1,,CHEMBL626833,,BAO_0000019
13450,,Lipophilicity estimated on reversed phase TLC,,,22224,,U,0,Autocuration,1,,CHEMBL626834,,BAO_0000100
13451,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,,22224,,U,0,Autocuration,1,,CHEMBL626835,,BAO_0000019
13452,,Delta logPoct-cyc,,,22224,,U,0,Autocuration,1,,CHEMBL626836,,BAO_0000019
13453,,Change in logarithm of partition coefficient of the compound,,,22229,,U,0,Autocuration,1,,CHEMBL626837,,BAO_0000100
13454,,Delta logD (pH 6.5),,,22224,,U,0,Autocuration,1,,CHEMBL626838,,BAO_0000019
13455,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,,22224,,U,0,Autocuration,1,,CHEMBL626839,,BAO_0000100
13456,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,,22224,,U,0,Autocuration,1,,CHEMBL626840,,BAO_0000019
13457,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,,22224,,U,0,Autocuration,1,,CHEMBL626841,,BAO_0000019
13458,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,,22224,,U,0,Autocuration,1,,CHEMBL626842,,BAO_0000219
13459,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,,22224,,U,0,Autocuration,1,,CHEMBL626843,,BAO_0000219
13460,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,,50597,,N,1,Intermediate,1,,CHEMBL626844,,BAO_0000218
13461,,Amount of deuterium retained was reported after normal workup in rats,,,50597,,N,1,Intermediate,1,,CHEMBL877495,,BAO_0000218
13462,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,,50597,,N,1,Intermediate,1,,CHEMBL626845,,BAO_0000218
13463,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,,50597,,N,1,Intermediate,1,,CHEMBL626846,,BAO_0000218
13464,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,,50597,,N,1,Intermediate,1,,CHEMBL626847,,BAO_0000218
13465,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,,50597,,N,1,Intermediate,1,,CHEMBL628677,,BAO_0000218
13466,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,,50597,,N,1,Intermediate,1,,CHEMBL628678,,BAO_0000218
13467,,Compound was subjected to electrochemical oxidation,,,22224,,U,0,Autocuration,1,,CHEMBL628679,,BAO_0000019
13468,,Compound was subjected to photochemical oxidation,,,22224,,U,0,Autocuration,1,,CHEMBL628680,,BAO_0000019
13469,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,,22224,,U,0,Autocuration,1,,CHEMBL628681,,BAO_0000019
13470,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,,22224,,U,0,Autocuration,1,,CHEMBL628682,,BAO_0000019
13471,,Oxidation of compound by methemoglobin in presence of hydroperoxide,,,22224,,U,0,Autocuration,1,,CHEMBL628683,,BAO_0000019
13472,,Percent diffusion through fuzzy rat skin after 48 h of incubation,,,50597,,N,1,Intermediate,1,,CHEMBL628684,,BAO_0000218
13473,,Dissociation constant (pKa),,,22229,,U,0,Autocuration,1,,CHEMBL877501,,BAO_0000100
13474,,Dissociation constant value of the compound; ND means not determined.,,,22224,,U,0,Autocuration,1,,CHEMBL628685,,BAO_0000100
13475,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628686,,BAO_0000218
13476,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,178.0,,50597,,N,1,Intermediate,1,,CHEMBL628687,,BAO_0000218
13477,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,,50597,,N,1,Intermediate,1,,CHEMBL628688,,BAO_0000218
13478,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,50597,,N,1,Intermediate,1,,CHEMBL628689,,BAO_0000218
13479,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628690,,BAO_0000218
13480,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL629363,,BAO_0000218
13481,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL629364,,BAO_0000218
13482,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL629365,,BAO_0000218
13483,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,,50597,,N,1,Intermediate,1,,CHEMBL629366,,BAO_0000218
13484,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629367,,BAO_0000218
13485,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1988.0,,50597,,N,1,Intermediate,1,,CHEMBL629368,,BAO_0000218
13486,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL877502,,BAO_0000218
13487,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,2037.0,,50594,,N,1,Intermediate,1,,CHEMBL629369,,BAO_0000218
13488,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,955.0,,50594,,N,1,Intermediate,1,,CHEMBL629370,,BAO_0000218
13489,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL629371,,BAO_0000218
13490,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL626276,,BAO_0000218
13491,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL626277,,BAO_0000218
13492,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL631250,,BAO_0000218
13493,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631251,,BAO_0000218
13494,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631252,,BAO_0000218
13495,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631253,,BAO_0000218
13496,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631254,,BAO_0000218
13497,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631255,,BAO_0000218
13498,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631256,,BAO_0000218
13499,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631257,,BAO_0000218
13500,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628009,,BAO_0000218
13501,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628010,,BAO_0000218
13502,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628011,,BAO_0000218
13503,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628012,,BAO_0000218
13504,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628013,,BAO_0000218
13505,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628014,,BAO_0000218
13506,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL628015,,BAO_0000218
13507,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL628016,,BAO_0000218
13508,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL874461,,BAO_0000218
13509,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL628017,,BAO_0000218
13510,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL628018,,BAO_0000218
13511,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL628019,,BAO_0000218
13512,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL628020,,BAO_0000218
13513,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL628021,,BAO_0000218
13514,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL628022,,BAO_0000218
13515,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1088.0,,50588,,N,1,Intermediate,1,,CHEMBL628023,,BAO_0000218
13516,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL628024,,BAO_0000218
13517,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL628025,,BAO_0000218
13518,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL628026,,BAO_0000218
13519,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL628027,,BAO_0000218
13520,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",1088.0,,22224,,U,0,Autocuration,1,,CHEMBL628028,,BAO_0000218
13521,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628029,,BAO_0000218
13522,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628030,,BAO_0000218
13523,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628031,,BAO_0000218
13524,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628032,,BAO_0000218
13525,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628033,,BAO_0000218
13526,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628034,,BAO_0000218
13527,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628035,,BAO_0000218
13528,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628036,,BAO_0000218
13529,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL874462,,BAO_0000218
13530,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,,50588,,N,1,Intermediate,1,,CHEMBL628037,,BAO_0000218
13531,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,,50588,,N,1,Intermediate,1,,CHEMBL628123,,BAO_0000218
13532,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,,50588,,N,1,Intermediate,1,,CHEMBL628124,,BAO_0000218
13533,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,,50588,,N,1,Intermediate,1,,CHEMBL628125,,BAO_0000218
13534,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,,50588,,N,1,Intermediate,1,,CHEMBL628126,,BAO_0000218
13535,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,,50588,,N,1,Intermediate,1,,CHEMBL628127,,BAO_0000218
13536,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,,50588,,N,1,Intermediate,1,,CHEMBL628128,,BAO_0000218
13537,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,,50588,,N,1,Intermediate,1,,CHEMBL628129,,BAO_0000218
13538,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,,50588,,N,1,Intermediate,1,,CHEMBL628130,,BAO_0000218
13539,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,,50588,,N,1,Intermediate,1,,CHEMBL628131,,BAO_0000218
13540,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,,50588,,N,1,Intermediate,1,,CHEMBL628132,,BAO_0000218
13541,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,,50588,,N,1,Intermediate,1,,CHEMBL628133,,BAO_0000218
13542,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,,50588,,N,1,Intermediate,1,,CHEMBL628134,,BAO_0000218
13543,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,,50588,,N,1,Intermediate,1,,CHEMBL628135,,BAO_0000218
13544,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,,50588,,N,1,Intermediate,1,,CHEMBL628136,,BAO_0000218
13545,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,,50588,,N,1,Intermediate,1,,CHEMBL628137,,BAO_0000218
13546,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,,50588,,N,1,Intermediate,1,,CHEMBL628138,,BAO_0000218
13547,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,,50588,,N,1,Intermediate,1,,CHEMBL628139,,BAO_0000218
13548,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,,50588,,N,1,Intermediate,1,,CHEMBL628140,,BAO_0000218
13549,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,,50588,,N,1,Intermediate,1,,CHEMBL628141,,BAO_0000218
13550,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,,50588,,N,1,Intermediate,1,,CHEMBL628142,,BAO_0000218
13551,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,,50588,,N,1,Intermediate,1,,CHEMBL628143,,BAO_0000218
13552,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,,50588,,N,1,Intermediate,1,,CHEMBL628144,,BAO_0000218
13553,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,,50588,,N,1,Intermediate,1,,CHEMBL628145,,BAO_0000218
13554,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,,50588,,N,1,Intermediate,1,,CHEMBL628146,,BAO_0000218
13555,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,,50588,,N,1,Intermediate,1,,CHEMBL625355,,BAO_0000218
13556,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,,50588,,N,1,Intermediate,1,,CHEMBL625356,,BAO_0000218
13557,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,,50588,,N,1,Intermediate,1,,CHEMBL625357,,BAO_0000218
13558,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,,50588,,N,1,Intermediate,1,,CHEMBL625527,,BAO_0000218
13559,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,,50588,,N,1,Intermediate,1,,CHEMBL875473,,BAO_0000218
13560,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,,50588,,N,1,Intermediate,1,,CHEMBL625528,,BAO_0000218
13561,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,,50597,,N,1,Intermediate,1,,CHEMBL626304,,BAO_0000218
13562,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,1637.0,,50588,,N,1,Intermediate,1,,CHEMBL624138,,BAO_0000218
13563,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624139,,BAO_0000100
13564,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624140,,BAO_0000100
13565,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624141,,BAO_0000100
13566,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624142,,BAO_0000100
13567,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624143,,BAO_0000100
13568,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624144,,BAO_0000100
13569,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624145,,BAO_0000100
13570,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624146,,BAO_0000100
13571,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624147,,BAO_0000100
13572,,Calculated partition coefficient (clogP) (MacLogP),,,22229,,U,0,Autocuration,1,,CHEMBL883123,,BAO_0000100
13573,,Partition coefficient (logP),,,22224,,U,0,Autocuration,1,,CHEMBL624148,,BAO_0000019
13574,,Kinetic parameter was determined,,,22224,,U,0,Autocuration,1,,CHEMBL874416,,BAO_0000019
13575,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624149,,BAO_0000100
13576,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL624150,,BAO_0000100
13577,,Lipophilicity was determined,,,22224,,U,0,Autocuration,1,,CHEMBL624151,,BAO_0000100
13578,,Lipophilicity was determined,,,22224,,U,0,Autocuration,1,,CHEMBL624152,,BAO_0000100
13579,,Lipophilicity was determined,,,22224,,U,0,Autocuration,1,,CHEMBL622139,,BAO_0000100
13580,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL622140,,BAO_0000100
13581,,Lipophilicity was determined,,,22224,,U,0,Autocuration,1,,CHEMBL622141,,BAO_0000100
13582,,Lipophilicity in octanol-water,,,22224,,U,0,Autocuration,1,,CHEMBL622142,,BAO_0000100
13583,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL622143,,BAO_0000100
13584,,Octanol-water partition coefficient was determined,,,22229,,U,0,Autocuration,1,,CHEMBL622144,,BAO_0000100
13585,,Partition coefficient (logP),,,22224,,U,0,Autocuration,1,,CHEMBL877473,,BAO_0000019
13586,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL622145,,BAO_0000100
13587,,Partition coefficient was determined; ND means not determined,,,22224,,U,0,Autocuration,1,,CHEMBL622146,,BAO_0000019
13588,,Calculated partition coefficient (clogP),,,22229,,U,0,Autocuration,1,,CHEMBL622147,,BAO_0000100
13589,,Partition coefficient of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL622148,,BAO_0000019
13590,,Permeability was determined,,,22224,,U,0,Autocuration,1,,CHEMBL883124,,BAO_0000019
13591,,The compound was evaluated for the partition coefficient,,,22229,,U,0,Autocuration,1,,CHEMBL622149,,BAO_0000100
13592,,Partition coefficient (logP),,,22224,,U,0,Autocuration,1,,CHEMBL622150,,BAO_0000019
13593,,The lipophilicity was reported,,,22224,,U,0,Autocuration,1,,CHEMBL622151,,BAO_0000100
13594,,logarithm of the octanol-water partition coefficient for the compound,,,22229,,U,0,Autocuration,1,,CHEMBL622152,,BAO_0000100
13595,,Clogp value was determined,,,22224,,U,0,Autocuration,1,,CHEMBL622153,,BAO_0000019
13596,,Clp at a dose of 1.5 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL877474,,BAO_0000218
13597,,Clp at a dose of 2.0 mg/kg,,,22224,,U,0,Autocuration,1,,CHEMBL622154,,BAO_0000218
13598,,"Clp, plasma clearance at a dose of 10 mg/kg",1969.0,,22224,,U,0,Autocuration,1,,CHEMBL622155,,BAO_0000218
13599,,"Clp, plasma clearance at a dose of 50 mg/kg",1969.0,,22224,,U,0,Autocuration,1,,CHEMBL622156,,BAO_0000218
13600,,Compound was tested for plasma clearance in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622157,,BAO_0000218
13601,,Compound was tested for plasma clearance in rat; Not determined,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622158,,BAO_0000218
13602,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL622807,,BAO_0000218
13603,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,,50797,,N,1,Intermediate,1,,CHEMBL622808,,BAO_0000218
13604,,Plasma clearance by iv administration at a dose 0.003 ug/mL,,,22224,,U,0,Autocuration,1,,CHEMBL622809,,BAO_0000218
13605,,Plasma clearance determined,,,22224,,U,0,Autocuration,1,,CHEMBL622810,,BAO_0000218
13606,,Plasma clearance after iv administration at 3 mg/kg in hamster,,,100712,,N,1,Intermediate,1,,CHEMBL876653,,BAO_0000218
13607,,Plasma clearance after iv administration at 4 mg/kg in hamster,,,100712,,N,1,Intermediate,1,,CHEMBL622811,,BAO_0000218
13608,,Rate of clearance in rat was determined,,,50597,,N,1,Intermediate,1,,CHEMBL622986,,BAO_0000218
13609,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622987,,BAO_0000218
13610,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622988,,BAO_0000218
13611,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622989,,BAO_0000218
13612,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622990,,BAO_0000218
13613,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,1969.0,,22224,,U,0,Autocuration,1,,CHEMBL622991,,BAO_0000218
13614,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL622227,,BAO_0000218
13615,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL622228,,BAO_0000218
13616,,Clpl value in rat,,,50597,,N,1,Intermediate,1,,CHEMBL622229,,BAO_0000218
13617,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,,50512,,N,1,Intermediate,1,,CHEMBL622230,,BAO_0000218
13618,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,,50597,,N,1,Intermediate,1,,CHEMBL622231,,BAO_0000218
13619,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,,100710,,N,1,Intermediate,1,,CHEMBL622232,,BAO_0000218
13620,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,,22224,,U,0,Autocuration,1,,CHEMBL622233,,BAO_0000218
13621,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,,22224,,U,0,Autocuration,1,,CHEMBL622234,,BAO_0000218
13622,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,,22224,,U,0,Autocuration,1,,CHEMBL622235,,BAO_0000218
13623,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,,22224,,U,0,Autocuration,1,,CHEMBL622236,,BAO_0000218
13624,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,,22224,,U,0,Autocuration,1,,CHEMBL622237,,BAO_0000218
13625,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,,22224,,U,0,Autocuration,1,,CHEMBL877482,,BAO_0000218
13626,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,,22224,,U,0,Autocuration,1,,CHEMBL622238,,BAO_0000218
13627,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,,22224,,U,0,Autocuration,1,,CHEMBL622239,,BAO_0000218
13628,,Cmax was calculated as maximum concentration reached in the blood,178.0,,22224,,U,0,Autocuration,1,,CHEMBL622240,,BAO_0000218
13629,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,178.0,,22224,,U,0,Autocuration,1,,CHEMBL622241,,BAO_0000218
13630,,Cmax was determine after peroral administration at 10 mpk in Rat,,,50597,,N,1,Intermediate,1,,CHEMBL631013,,BAO_0000218
13631,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,,50797,,N,1,Intermediate,1,,CHEMBL631014,,BAO_0000218
13632,,Cmax was determine after peroral administration at 10 mpk in dog,,,50588,,N,1,Intermediate,1,,CHEMBL631015,,BAO_0000218
13633,,Cmax was determine after peroral administration at 160 mpk in Rat,,,50597,,N,1,Intermediate,1,,CHEMBL631016,,BAO_0000218
13634,,Cmax was determine after peroral administration at 20 mpk in Rat,,,50597,,N,1,Intermediate,1,,CHEMBL631017,,BAO_0000218
13635,,Cmax was determine after peroral administration at 50 mpk in Rat,,,50597,,N,1,Intermediate,1,,CHEMBL631018,,BAO_0000218
13636,,Cmax was determined,,,22224,,U,0,Autocuration,1,,CHEMBL631019,,BAO_0000218
13637,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,955.0,,50594,,N,1,Intermediate,1,,CHEMBL875761,,BAO_0000218
13638,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,955.0,,50594,,N,1,Intermediate,1,,CHEMBL631020,,BAO_0000218
13639,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,955.0,,50594,,N,1,Intermediate,1,,CHEMBL631669,,BAO_0000218
13640,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,955.0,,50594,,N,1,Intermediate,1,,CHEMBL631670,,BAO_0000218
13641,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,2435.0,,50594,,N,1,Intermediate,1,,CHEMBL631671,,BAO_0000218
13642,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631672,,BAO_0000218
13643,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631673,,BAO_0000218
13644,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631856,,BAO_0000218
13645,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631857,,BAO_0000218
13646,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631858,,BAO_0000218
13647,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631859,,BAO_0000218
13648,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631860,,BAO_0000218
13649,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631861,,BAO_0000218
13650,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631862,,BAO_0000218
13651,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631863,,BAO_0000218
13652,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631864,,BAO_0000218
13653,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631865,,BAO_0000218
13654,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631866,,BAO_0000218
13655,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629360,,BAO_0000218
13656,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629361,,BAO_0000218
13657,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,178.0,,50597,,N,1,Intermediate,1,,CHEMBL629362,,BAO_0000218
13658,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,178.0,,50597,,N,1,Intermediate,1,,CHEMBL630740,,BAO_0000218
13659,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,178.0,,50597,,N,1,Intermediate,1,,CHEMBL630741,,BAO_0000218
13660,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,178.0,,50597,,N,1,Intermediate,1,,CHEMBL630742,,BAO_0000218
13661,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,,50597,,N,1,Intermediate,1,,CHEMBL630743,,BAO_0000218
13662,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,,50597,,N,1,Intermediate,1,,CHEMBL630744,,BAO_0000218
13663,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,,50597,,N,1,Intermediate,1,,CHEMBL630745,,BAO_0000218
13664,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,,50597,,N,1,Intermediate,1,,CHEMBL630746,,BAO_0000218
13665,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,,50597,,N,1,Intermediate,1,,CHEMBL630747,,BAO_0000218
13666,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,,50597,,N,1,Intermediate,1,,CHEMBL630748,,BAO_0000218
13667,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,,50597,,N,1,Intermediate,1,,CHEMBL632056,,BAO_0000218
13668,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,,50597,,N,1,Intermediate,1,,CHEMBL632057,,BAO_0000218
13669,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,,50597,,N,1,Intermediate,1,,CHEMBL632058,,BAO_0000218
13670,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,,50597,,N,1,Intermediate,1,,CHEMBL632059,,BAO_0000218
13671,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,,50597,,N,1,Intermediate,1,,CHEMBL632060,,BAO_0000218
13672,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,,50597,,N,1,Intermediate,1,,CHEMBL632061,,BAO_0000218
13673,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,,50597,,N,1,Intermediate,1,,CHEMBL629207,,BAO_0000218
13674,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,,50597,,N,1,Intermediate,1,,CHEMBL629208,,BAO_0000218
13675,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,,50597,,N,1,Intermediate,1,,CHEMBL629209,,BAO_0000218
13676,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,,50597,,N,1,Intermediate,1,,CHEMBL629210,,BAO_0000218
13677,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,,50597,,N,1,Intermediate,1,,CHEMBL629211,,BAO_0000218
13678,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,,50597,,N,1,Intermediate,1,,CHEMBL629212,,BAO_0000218
13679,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,,50597,,N,1,Intermediate,1,,CHEMBL629213,,BAO_0000218
13680,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629214,,BAO_0000218
13681,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629215,,BAO_0000218
13682,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL635154,,BAO_0000218
13683,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL629216,,BAO_0000218
13684,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL629217,,BAO_0000218
13685,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL629218,,BAO_0000218
13686,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL629219,,BAO_0000218
13687,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL629220,,BAO_0000218
13688,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL629221,,BAO_0000218
13689,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631127,,BAO_0000218
13690,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL631128,,BAO_0000218
13691,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631129,,BAO_0000218
13692,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631130,,BAO_0000218
13693,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631131,,BAO_0000218
13694,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL631132,,BAO_0000218
13695,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631133,,BAO_0000218
13696,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL631134,,BAO_0000218
13697,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL875120,,BAO_0000218
13698,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631135,,BAO_0000218
13699,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631136,,BAO_0000218
13700,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL631137,,BAO_0000218
13701,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631138,,BAO_0000218
13702,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,,50597,,N,1,Intermediate,1,,CHEMBL631139,,BAO_0000218
13703,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631140,,BAO_0000218
13704,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631141,,BAO_0000218
13705,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631142,,BAO_0000218
13706,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,50597,,N,1,Intermediate,1,,CHEMBL631143,,BAO_0000218
13707,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,,N,1,Intermediate,1,,CHEMBL631144,,BAO_0000218
13708,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL631145,,BAO_0000218
13709,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631146,,BAO_0000218
13710,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL631147,,BAO_0000218
13711,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631148,,BAO_0000218
13712,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631149,,BAO_0000218
13713,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631150,,BAO_0000218
13714,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631151,,BAO_0000218
13715,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631152,,BAO_0000218
13716,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631443,,BAO_0000218
13717,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631444,,BAO_0000218
13718,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631445,,BAO_0000218
13719,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,50588,,N,1,Intermediate,1,,CHEMBL631446,,BAO_0000218
13720,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631447,,BAO_0000218
13721,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631448,,BAO_0000218
13722,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,,50588,,N,1,Intermediate,1,,CHEMBL631449,,BAO_0000218
13723,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL631450,,BAO_0000218
13724,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,50588,,N,1,Intermediate,1,,CHEMBL629724,,BAO_0000218
13725,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",14.0,,50594,,N,1,Intermediate,1,,CHEMBL629725,,BAO_0000218
13726,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",14.0,,50594,,N,1,Intermediate,1,,CHEMBL629726,,BAO_0000218
13727,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,,50594,,N,1,Intermediate,1,,CHEMBL629727,,BAO_0000218
13728,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,,50594,,N,1,Intermediate,1,,CHEMBL630404,,BAO_0000218
13729,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,,50594,,N,1,Intermediate,1,,CHEMBL630405,,BAO_0000218
13730,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,,50594,,N,1,Intermediate,1,,CHEMBL630406,,BAO_0000218
13731,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,,50594,,N,1,Intermediate,1,,CHEMBL630407,,BAO_0000218
13732,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,,50594,,N,1,Intermediate,1,,CHEMBL630573,,BAO_0000218
13733,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,,50594,,N,1,Intermediate,1,,CHEMBL630574,,BAO_0000218
13734,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,,50594,,N,1,Intermediate,1,,CHEMBL630575,,BAO_0000218
13735,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,,N,1,Intermediate,1,,CHEMBL630576,,BAO_0000218
13736,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,,N,1,Intermediate,1,,CHEMBL630577,,BAO_0000218
13737,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,,N,1,Intermediate,1,,CHEMBL630578,,BAO_0000218
13738,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,,N,1,Intermediate,1,,CHEMBL630579,,BAO_0000218
13739,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),2113.0,,50594,,N,1,Intermediate,1,,CHEMBL630580,,BAO_0000218
13740,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,2113.0,,50594,,N,1,Intermediate,1,,CHEMBL630581,,BAO_0000218
13741,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),2113.0,,50594,,N,1,Intermediate,1,,CHEMBL630582,,BAO_0000218
13742,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,,50594,,N,1,Intermediate,1,,CHEMBL630583,,BAO_0000218
13743,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,,50594,,N,1,Intermediate,1,,CHEMBL630584,,BAO_0000218
13744,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,,50594,,N,1,Intermediate,1,,CHEMBL630585,,BAO_0000218
13745,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,,50594,,N,1,Intermediate,1,,CHEMBL630586,,BAO_0000218
13746,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,,50594,,N,1,Intermediate,1,,CHEMBL630587,,BAO_0000218
13747,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,,50594,,N,1,Intermediate,1,,CHEMBL630588,,BAO_0000218
13748,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,,50594,,N,1,Intermediate,1,,CHEMBL630589,,BAO_0000218
13749,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,,50594,,N,1,Intermediate,1,,CHEMBL630590,,BAO_0000218
13750,,Removal of 238-Plutonium(IV) in feces at 24 h,1988.0,,22224,,U,0,Autocuration,1,,CHEMBL630591,,BAO_0000019
13751,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),1988.0,,22224,,U,0,Autocuration,1,,CHEMBL630592,,BAO_0000019
13752,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,,22224,,U,0,Autocuration,1,,CHEMBL630593,,BAO_0000019
13753,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,,22224,,U,0,Autocuration,1,,CHEMBL630594,,BAO_0000019
13754,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630595,,BAO_0000019
13755,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630596,,BAO_0000019
13756,,Removal of 238-Plutonium(IV) in urine after 0-24 h,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630597,,BAO_0000019
13757,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630598,,BAO_0000019
13758,,Removal of 238-Plutonium(IV) in urine after 0-4 h,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630599,,BAO_0000019
13759,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630600,,BAO_0000019
13760,,Removal of 238-Plutonium(IV) in urine after 4-24 h,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630601,,BAO_0000019
13761,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630602,,BAO_0000019
13762,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630603,,BAO_0000019
13763,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),1088.0,,22224,,U,0,Autocuration,1,,CHEMBL630604,,BAO_0000019
13764,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624869,,BAO_0000218
13765,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL624870,,BAO_0000218
13766,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,,50597,,N,1,Intermediate,1,,CHEMBL623189,,BAO_0000218
13767,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL623190,,BAO_0000218
13768,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL623191,,BAO_0000218
13769,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL623192,,BAO_0000218
13770,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL623193,,BAO_0000218
13771,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,,N,1,Intermediate,1,,CHEMBL623194,,BAO_0000218
13772,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL623195,,BAO_0000218
13773,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL623196,,BAO_0000218
13774,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL623197,,BAO_0000218
13775,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,,50597,,N,1,Intermediate,1,,CHEMBL623198,,BAO_0000218
13776,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL623199,,BAO_0000218
13777,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623200,,BAO_0000218
13778,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623201,,BAO_0000218
13779,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623202,,BAO_0000218
13780,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623203,,BAO_0000218
13781,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623204,,BAO_0000218
13782,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623205,,BAO_0000218
13783,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623206,,BAO_0000218
13784,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623207,,BAO_0000218
13785,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623208,,BAO_0000218
13786,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623209,,BAO_0000218
13787,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL623210,,BAO_0000218
13788,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,,50597,,N,1,Intermediate,1,,CHEMBL623211,,BAO_0000218
13789,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,995.0,,50597,,N,1,Intermediate,1,,CHEMBL623212,,BAO_0000218
13790,,Tested in vitro for intrinsic activity relative to quinpirole,,,22224,,U,0,Autocuration,1,,CHEMBL623213,,BAO_0000019
13791,,"Relative ion enhancement, determined in pulsed ultrafiltration",,,22224,,U,0,Autocuration,1,,CHEMBL623214,,BAO_0000019
13792,,% ionization at the pH 7.4 at 37 degree Centigrade,,,22224,,U,0,Autocuration,1,,CHEMBL623215,,BAO_0000019
13793,,Percentage ionization was measured,,,22224,,U,0,Autocuration,1,,CHEMBL623216,,BAO_0000019
13794,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,,50591,,N,1,Intermediate,1,,CHEMBL623217,,BAO_0000218
13795,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,,22224,,U,0,Autocuration,1,,CHEMBL623218,,BAO_0000019
13796,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,,22224,,U,0,Autocuration,1,,CHEMBL623913,,BAO_0000019
13797,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,,22224,,U,0,Autocuration,1,,CHEMBL623914,,BAO_0000019
13798,,Compound was evaluated for the partition coefficient in octanol/water,,,22229,,U,0,Autocuration,1,,CHEMBL623915,,BAO_0000100
13799,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,,22229,,U,0,Autocuration,1,,CHEMBL624080,,BAO_0000100
13800,,Equilibrium constant measured by the pulse radiolysis at pH 7,,,22224,,U,0,Autocuration,1,,CHEMBL624081,,BAO_0000019
13801,,In vitro hydrolytic rate constant determined in human blood,,,50587,,N,1,Intermediate,1,,CHEMBL624082,,BAO_0000218
13802,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,,50587,,N,1,Intermediate,1,,CHEMBL625054,,BAO_0000218
13803,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,,22224,,U,0,Autocuration,1,,CHEMBL877485,,BAO_0000019
13804,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,,50594,,N,1,Intermediate,1,,CHEMBL625055,,BAO_0000218
13805,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,,50594,,N,1,Intermediate,1,,CHEMBL625056,,BAO_0000218
13806,,In vitro oxidation of compound in presence of human plasma,,,50587,,N,1,Intermediate,1,,CHEMBL625057,,BAO_0000218
13807,,In vitro oxidation of compound in presence of hydrogen peroxide,,,22224,,U,0,Autocuration,1,,CHEMBL625058,,BAO_0000019
13808,,In vitro oxidation of compound in presence of mouse brain homogenate,,,50594,,N,1,Intermediate,1,,CHEMBL625059,,BAO_0000218
13809,,In vitro oxidation of compound in presence of mouse liver homogenate,,,50594,,N,1,Intermediate,1,,CHEMBL629536,,BAO_0000218
13810,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629537,,BAO_0000218
13811,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629538,,BAO_0000218
13812,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629539,,BAO_0000218
13813,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL874445,,BAO_0000218
13814,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629540,,BAO_0000218
13815,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629541,,BAO_0000218
13816,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629542,,BAO_0000218
13817,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL630243,,BAO_0000218
13818,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL630244,,BAO_0000218
13819,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL630245,,BAO_0000218
13820,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL630246,,BAO_0000218
13821,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL630247,,BAO_0000218
13822,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL630248,,BAO_0000218
13823,,Biodistribution in rat blood at 240 minutes after dose administration.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL630249,,BAO_0000218
13824,,Biodistribution in rat blood at 30 minutes after dose administration.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL630250,,BAO_0000218
13825,,Biodistribution in rat blood at 360 minutes after dose administration.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL630251,,BAO_0000218
13826,,Biodistribution in rat blood at 3 hr after dose administration.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL630252,,BAO_0000218
13827,,Biodistribution in rat blood at 60 minutes after dose administration.,178.0,,50597,,N,1,Intermediate,1,,CHEMBL630408,,BAO_0000218
13828,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL630409,,BAO_0000218
13829,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL874446,,BAO_0000218
13830,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL630410,,BAO_0000218
13831,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL630411,,BAO_0000218
13832,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL630412,,BAO_0000218
13833,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL630413,,BAO_0000218
13834,,Biodistribution in rat cerebellum at 3 hr after dose administration.,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL630414,,BAO_0000218
13835,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL630415,,BAO_0000218
13836,,Biodistribution in rat cortex at 120 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL630416,,BAO_0000218
13837,,Biodistribution in rat cortex at 1440 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL630417,,BAO_0000218
13838,,Biodistribution in rat cortex at 15 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL630418,,BAO_0000218
13839,,Biodistribution in rat cortex at 240 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL630419,,BAO_0000218
13840,,Biodistribution in rat cortex at 30 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL630420,,BAO_0000218
13841,,Biodistribution in rat cortex at 360 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL630421,,BAO_0000218
13842,,Biodistribution in rat cortex at 3 hr after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL630422,,BAO_0000218
13843,,Biodistribution in rat cortex at 60 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL630423,,BAO_0000218
13844,,Biodistribution in rat heart at 120 minutes after dose administration.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL630424,,BAO_0000218
13845,,Biodistribution in rat heart at 15 minutes after dose administration.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL630425,,BAO_0000218
13846,,Biodistribution in rat heart at 240 minutes after dose administration.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL629462,,BAO_0000218
13847,,Biodistribution in rat heart at 30 minutes after dose administration.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL630426,,BAO_0000218
13848,,Biodistribution in rat heart at 360 minutes after dose administration.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL630427,,BAO_0000218
13849,,Biodistribution in rat heart at 3 hr after dose administration.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625877,,BAO_0000218
13850,,Biodistribution in rat heart at 60 minutes after dose administration.,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625878,,BAO_0000218
13851,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL625879,,BAO_0000218
13852,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL625880,,BAO_0000218
13853,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL625881,,BAO_0000218
13854,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL625882,,BAO_0000218
13855,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL625883,,BAO_0000218
13856,,Biodistribution in rat kidney at 120 minutes after dose administration.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625884,,BAO_0000218
13857,,Biodistribution in rat kidney at 1440 minutes after dose administration.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625885,,BAO_0000218
13858,,Biodistribution in rat kidney at 15 minutes after dose administration.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL628649,,BAO_0000218
13859,,Biodistribution in rat kidney at 240 minutes after dose administration.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL628650,,BAO_0000218
13860,,Biodistribution in rat kidney at 30 minutes after dose administration.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL628651,,BAO_0000218
13861,,Biodistribution in rat kidney at 360 minutes after dose administration.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL628652,,BAO_0000218
13862,,Biodistribution in rat kidney at 60 minutes after dose administration.,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL628653,,BAO_0000218
13863,,Biodistribution in rat liver at 120 minutes after dose administration.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628654,,BAO_0000218
13864,,Biodistribution in rat liver at 1440 minutes after dose administration.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL628655,,BAO_0000218
13865,,Biodistribution in rat liver at 15 minutes after dose administration.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625238,,BAO_0000218
13866,,Biodistribution in rat liver at 240 minutes after dose administration.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625239,,BAO_0000218
13867,,Biodistribution in rat liver at 30 minutes after dose administration.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625240,,BAO_0000218
13868,,Biodistribution in rat liver at 360 minutes after dose administration.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625241,,BAO_0000218
13869,,Biodistribution in rat liver at 60 minutes after dose administration.,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625242,,BAO_0000218
13870,,Biodistribution in rat lung at 120 minutes after dose administration.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL874587,,BAO_0000218
13871,,Biodistribution in rat lung at 1440 minutes after dose administration.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625405,,BAO_0000218
13872,,Biodistribution in rat lung at 15 minutes after dose administration.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625406,,BAO_0000218
13873,,Biodistribution in rat lung at 240 minutes after dose administration.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625407,,BAO_0000218
13874,,Biodistribution in rat lung at 30 minutes after dose administration.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625408,,BAO_0000218
13875,,Biodistribution in rat lung at 360 minutes after dose administration.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625409,,BAO_0000218
13876,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,1515.0,,50597,,N,1,Intermediate,1,,CHEMBL625410,,BAO_0000218
13877,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,1515.0,,50597,,N,1,Intermediate,1,,CHEMBL625411,,BAO_0000218
13878,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,1515.0,,50597,,N,1,Intermediate,1,,CHEMBL625412,,BAO_0000218
13879,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,1515.0,,50597,,N,1,Intermediate,1,,CHEMBL625413,,BAO_0000218
13880,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,1515.0,,50597,,N,1,Intermediate,1,,CHEMBL625414,,BAO_0000218
13881,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,1515.0,,50597,,N,1,Intermediate,1,,CHEMBL625415,,BAO_0000218
13882,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,1515.0,,50597,,N,1,Intermediate,1,,CHEMBL625416,,BAO_0000218
13883,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625417,,BAO_0000218
13884,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,1988.0,,50597,,N,1,Intermediate,1,,CHEMBL625418,,BAO_0000218
13885,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625419,,BAO_0000218
13886,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL625420,,BAO_0000218
13887,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,,50597,,N,1,Intermediate,1,,CHEMBL626996,,BAO_0000218
13888,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",1988.0,,50597,,N,1,Intermediate,1,,CHEMBL626997,,BAO_0000218
13889,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626998,,BAO_0000218
13890,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,,50597,,N,1,Intermediate,1,,CHEMBL626999,,BAO_0000218
13891,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,,50594,,N,1,Intermediate,1,,CHEMBL627000,,BAO_0000218
13892,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,,50594,,N,1,Intermediate,1,,CHEMBL627001,,BAO_0000218
13893,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,,50594,,N,1,Intermediate,1,,CHEMBL627002,,BAO_0000218
13894,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,,50594,,N,1,Intermediate,1,,CHEMBL627003,,BAO_0000218
13895,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL627004,,BAO_0000218
13896,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL627005,,BAO_0000218
13897,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL874594,,BAO_0000218
13898,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL627006,,BAO_0000218
13899,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL627007,,BAO_0000218
13900,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL627884,,BAO_0000218
13901,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL627885,,BAO_0000218
13902,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL627886,,BAO_0000218
13903,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL627887,,BAO_0000218
13904,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL627888,,BAO_0000218
13905,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL628057,,BAO_0000218
13906,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL627405,,BAO_0000218
13907,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627406,,BAO_0000218
13908,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627407,,BAO_0000218
13909,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627408,,BAO_0000218
13910,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627409,,BAO_0000218
13911,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL875486,,BAO_0000218
13912,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627410,,BAO_0000218
13913,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627411,,BAO_0000218
13914,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627412,,BAO_0000218
13915,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627413,,BAO_0000218
13916,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627414,,BAO_0000218
13917,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627415,,BAO_0000218
13918,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627416,,BAO_0000218
13919,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627417,,BAO_0000218
13920,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627418,,BAO_0000218
13921,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627419,,BAO_0000218
13922,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627320,,BAO_0000218
13923,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627321,,BAO_0000218
13924,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627322,,BAO_0000218
13925,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627323,,BAO_0000218
13926,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627491,,BAO_0000218
13927,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627492,,BAO_0000218
13928,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL627493,,BAO_0000218
13929,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627494,,BAO_0000218
13930,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627495,,BAO_0000218
13931,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627496,,BAO_0000218
13932,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627497,,BAO_0000218
13933,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL627498,,BAO_0000218
13934,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627499,,BAO_0000218
13935,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627500,,BAO_0000218
13936,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627501,,BAO_0000218
13937,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625616,,BAO_0000218
13938,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625617,,BAO_0000218
13939,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL625618,,BAO_0000218
13940,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL625619,,BAO_0000218
13941,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2385.0,,50597,,N,1,Intermediate,1,,CHEMBL625620,,BAO_0000218
13942,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL625621,,BAO_0000218
13943,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL625622,,BAO_0000218
13944,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625788,,BAO_0000218
13945,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625789,,BAO_0000218
13946,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625790,,BAO_0000218
13947,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625791,,BAO_0000218
13948,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL622334,,BAO_0000218
13949,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622335,,BAO_0000218
13950,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622336,,BAO_0000218
13951,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622337,,BAO_0000218
13952,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622338,,BAO_0000218
13953,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL622339,,BAO_0000218
13954,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL624153,,BAO_0000218
13955,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL628430,,BAO_0000218
13956,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,,N,1,Intermediate,1,,CHEMBL628431,,BAO_0000218
13957,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL628432,,BAO_0000218
13958,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL628433,,BAO_0000218
13959,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL628434,,BAO_0000218
13960,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL626789,,BAO_0000218
13961,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL626790,,BAO_0000218
13962,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL626791,,BAO_0000218
13963,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL626792,,BAO_0000218
13964,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL626793,,BAO_0000218
13965,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627436,,BAO_0000218
13966,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627437,,BAO_0000218
13967,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627438,,BAO_0000218
13968,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627439,,BAO_0000218
13969,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627440,,BAO_0000218
13970,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627602,,BAO_0000218
13971,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627603,,BAO_0000218
13972,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627604,,BAO_0000218
13973,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627605,,BAO_0000218
13974,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627606,,BAO_0000218
13975,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627607,,BAO_0000218
13976,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627608,,BAO_0000218
13977,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627609,,BAO_0000218
13978,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627610,,BAO_0000218
13979,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627611,,BAO_0000218
13980,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL627612,,BAO_0000218
13981,,Octanol:water partition coefficient is evaluated,,,22229,,U,0,Autocuration,1,,CHEMBL627613,,BAO_0000100
13982,,Partition coefficient in 1-octanol/water system,,,22224,,U,0,Autocuration,1,,CHEMBL627614,,BAO_0000100
13983,,Partition coefficient in 1-octanol/water system measured using radio active compounds,,,22224,,U,0,Autocuration,1,,CHEMBL627615,,BAO_0000100
13984,,Partition coefficient in octanol/water system was determined,,,22224,,U,0,Autocuration,1,,CHEMBL627616,,BAO_0000100
13985,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,,22224,,U,0,Autocuration,1,,CHEMBL627617,,BAO_0000100
13986,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,,22224,,U,0,Autocuration,1,,CHEMBL627618,,BAO_0000019
13987,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,,22224,,U,0,Autocuration,1,,CHEMBL627619,,BAO_0000019
13988,,Pseudo-first-order rate constant of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL627620,,BAO_0000019
13989,,Pseudo-first-order rate constant with 1-min time point,,,22224,,U,0,Autocuration,1,,CHEMBL627621,,BAO_0000019
13990,,Pseudo-first-order rate constant without 1-min time point,,,22224,,U,0,Autocuration,1,,CHEMBL627622,,BAO_0000019
13991,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,,22224,,U,0,Autocuration,1,,CHEMBL627623,,BAO_0000019
13992,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,,22224,,U,0,Autocuration,1,,CHEMBL627624,,BAO_0000019
13993,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,,22224,,U,0,Autocuration,1,,CHEMBL627625,,BAO_0000019
13994,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,,22224,,U,0,Autocuration,1,,CHEMBL628523,,BAO_0000019
13995,,The alkaline hydrolysis second order rate constant(K OH) of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL628524,,BAO_0000019
13996,,The efflux rate constant of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL628525,,BAO_0000019
13997,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,22224,,U,0,Autocuration,1,,CHEMBL625732,,BAO_0000019
13998,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,22224,,U,0,Autocuration,1,,CHEMBL625733,,BAO_0000019
13999,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,22224,,U,0,Autocuration,1,,CHEMBL625734,,BAO_0000019
14000,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,,22224,,U,0,Autocuration,1,,CHEMBL625913,,BAO_0000019
14001,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,,22224,,U,0,Autocuration,1,,CHEMBL625914,,BAO_0000019
14002,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,,22224,,U,0,Autocuration,1,,CHEMBL625915,,BAO_0000019
14003,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,,22224,,U,0,Autocuration,1,,CHEMBL625916,,BAO_0000019
14004,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,,22224,,U,0,Autocuration,1,,CHEMBL625917,,BAO_0000019
14005,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL625918,,BAO_0000019
14006,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL625919,,BAO_0000019
14007,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL625920,,BAO_0000019
14008,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL874453,,BAO_0000019
14009,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL625921,,BAO_0000019
14010,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,,22224,,U,0,Autocuration,1,,CHEMBL625922,,BAO_0000019
14011,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL625923,,BAO_0000019
14012,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL625924,,BAO_0000019
14013,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL625925,,BAO_0000019
14014,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL625926,,BAO_0000019
14015,,Biodistribution in rat lung at 60 minutes after dose administration.,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL627704,,BAO_0000218
14016,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL627705,,BAO_0000218
14017,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL627706,,BAO_0000218
14018,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL627707,,BAO_0000218
14019,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL627708,,BAO_0000218
14020,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL628361,,BAO_0000218
14021,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,,50597,,N,1,Intermediate,1,,CHEMBL628362,,BAO_0000218
14022,,Biodistribution in rat striatum at 120 minutes after dose administration.,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL628363,,BAO_0000218
14023,,Biodistribution in rat striatum at 1440 minutes after dose administration.,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL628364,,BAO_0000218
14024,,Biodistribution in rat striatum at 15 minutes after dose administration.,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL628365,,BAO_0000218
14025,,Biodistribution in rat striatum at 240 minutes after dose administration.,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL874454,,BAO_0000218
14026,,Biodistribution in rat striatum at 30 minutes after dose administration.,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL628531,,BAO_0000218
14027,,Biodistribution in rat striatum at 360 minutes after dose administration.,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL628532,,BAO_0000218
14028,,Biodistribution in rat striatum at 3 hr after dose administration.,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL628533,,BAO_0000218
14029,,Biodistribution in rat striatum at 60 minutes after dose administration.,2435.0,,50597,,N,1,Intermediate,1,,CHEMBL628534,,BAO_0000218
14030,,Biodistribution in rat thyroid at 120 minutes after dose administration.,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL628535,,BAO_0000218
14031,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL628536,,BAO_0000218
14032,,Biodistribution in rat thyroid at 15 minutes after dose administration.,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL628537,,BAO_0000218
14033,,Biodistribution in rat thyroid at 240 minutes after dose administration.,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL628538,,BAO_0000218
14034,,Biodistribution in rat thyroid at 30 minutes after dose administration.,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL628539,,BAO_0000218
14035,,Biodistribution in rat thyroid at 360 minutes after dose administration.,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL630297,,BAO_0000218
14036,,Biodistribution in rat thyroid at 60 minutes after dose administration.,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL630298,,BAO_0000218
14037,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL630299,,BAO_0000218
14038,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL628094,,BAO_0000218
14039,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL628095,,BAO_0000218
14040,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL874648,,BAO_0000218
14041,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL628096,,BAO_0000218
14042,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL628097,,BAO_0000218
14043,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,955.0,,50597,,N,1,Intermediate,1,,CHEMBL628098,,BAO_0000218
14044,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,,22224,,U,0,Autocuration,1,,CHEMBL628099,,BAO_0000019
14045,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,22224,,U,0,Autocuration,1,,CHEMBL628100,,BAO_0000019
14046,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,,22224,,U,0,Autocuration,1,,CHEMBL628101,,BAO_0000019
14047,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,,22224,,U,0,Autocuration,1,,CHEMBL628102,,BAO_0000019
14048,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,,22224,,U,0,Autocuration,1,,CHEMBL628103,,BAO_0000019
14049,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,22224,,U,0,Autocuration,1,,CHEMBL628104,,BAO_0000019
14050,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,,22224,,U,0,Autocuration,1,,CHEMBL628105,,BAO_0000019
14051,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,,22224,,U,0,Autocuration,1,,CHEMBL628106,,BAO_0000019
14052,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628107,,BAO_0000218
14053,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL628108,,BAO_0000218
14054,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628109,,BAO_0000218
14055,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1088.0,,22224,,U,0,Autocuration,1,,CHEMBL625299,,BAO_0000218
14056,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625300,,BAO_0000218
14057,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625301,,BAO_0000218
14058,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625302,,BAO_0000218
14059,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL874649,,BAO_0000218
14060,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,,50597,,N,1,Intermediate,1,,CHEMBL625303,,BAO_0000218
14061,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL625463,,BAO_0000218
14062,,In vitro metabolism in human liver microsomes,2107.0,,50587,,N,1,Intermediate,1,,CHEMBL625464,,BAO_0000218
14063,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,,50587,,N,1,Intermediate,1,,CHEMBL625465,,BAO_0000218
14064,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625466,,BAO_0000218
14065,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625467,,BAO_0000218
14066,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625468,,BAO_0000218
14067,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625469,,BAO_0000218
14068,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625470,,BAO_0000218
14069,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL632418,,BAO_0000218
14070,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627250,,BAO_0000218
14071,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627251,,BAO_0000218
14072,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627252,,BAO_0000218
14073,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627253,,BAO_0000218
14074,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627254,,BAO_0000218
14075,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL875471,,BAO_0000218
14076,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627255,,BAO_0000218
14077,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627256,,BAO_0000218
14078,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627257,,BAO_0000218
14079,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627258,,BAO_0000218
14080,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627259,,BAO_0000218
14081,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627260,,BAO_0000218
14082,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623256,,BAO_0000218
14083,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL874413,,BAO_0000218
14084,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623257,,BAO_0000218
14085,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623258,,BAO_0000218
14086,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623259,,BAO_0000218
14087,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623260,,BAO_0000218
14088,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623261,,BAO_0000218
14089,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623262,,BAO_0000218
14090,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623263,,BAO_0000218
14091,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623264,,BAO_0000218
14092,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623265,,BAO_0000218
14093,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623266,,BAO_0000218
14094,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623267,,BAO_0000218
14095,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623268,,BAO_0000218
14096,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623269,,BAO_0000218
14097,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623270,,BAO_0000218
14098,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623271,,BAO_0000218
14099,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623272,,BAO_0000218
14100,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623273,,BAO_0000218
14101,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623274,,BAO_0000218
14102,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL874414,,BAO_0000218
14103,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623275,,BAO_0000218
14104,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629150,,BAO_0000218
14105,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623276,,BAO_0000218
14106,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623277,,BAO_0000218
14107,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623112,,BAO_0000218
14108,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623113,,BAO_0000218
14109,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623800,,BAO_0000218
14110,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623801,,BAO_0000218
14111,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,,50597,,N,1,Intermediate,1,,CHEMBL623802,,BAO_0000218
14112,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,995.0,,50597,,N,1,Intermediate,1,,CHEMBL623803,,BAO_0000218
14113,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,995.0,,50597,,N,1,Intermediate,1,,CHEMBL623970,,BAO_0000218
14114,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,995.0,,50597,,N,1,Intermediate,1,,CHEMBL623971,,BAO_0000218
14115,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),178.0,,50597,,N,1,Intermediate,1,,CHEMBL623972,,BAO_0000218
14116,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),178.0,,50597,,N,1,Intermediate,1,,CHEMBL623973,,BAO_0000218
14117,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),178.0,,50597,,N,1,Intermediate,1,,CHEMBL623974,,BAO_0000218
14118,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),178.0,,50597,,N,1,Intermediate,1,,CHEMBL623975,,BAO_0000218
14119,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),955.0,,50597,,N,1,Intermediate,1,,CHEMBL623976,,BAO_0000218
14120,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),955.0,,50597,,N,1,Intermediate,1,,CHEMBL623977,,BAO_0000218
14121,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),955.0,,50597,,N,1,Intermediate,1,,CHEMBL623978,,BAO_0000218
14122,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),955.0,,50597,,N,1,Intermediate,1,,CHEMBL623979,,BAO_0000218
14123,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,,50597,,N,1,Intermediate,1,,CHEMBL623980,,BAO_0000218
14124,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,,50597,,N,1,Intermediate,1,,CHEMBL623981,,BAO_0000218
14125,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,,50597,,N,1,Intermediate,1,,CHEMBL626278,,BAO_0000218
14126,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,,50597,,N,1,Intermediate,1,,CHEMBL626279,,BAO_0000218
14127,,Biodistribution in mice bladder plus excreted urine was determined,,,50594,,N,1,Intermediate,1,,CHEMBL626280,,BAO_0000218
14128,,"Percentage biodistribution in mouse blood, 10 minutes post injection",,,50594,,N,1,Intermediate,1,,CHEMBL626281,,BAO_0000218
14129,,"Percentage biodistribution in mouse blood, 30 minutes post injection",,,50594,,N,1,Intermediate,1,,CHEMBL626282,,BAO_0000218
14130,,"Percentage biodistribution in mouse blood, 5 minutes post injection",,,50594,,N,1,Intermediate,1,,CHEMBL626283,,BAO_0000218
14131,,"Percentage biodistribution in mouse blood, 60 minutes post injection",,,50594,,N,1,Intermediate,1,,CHEMBL626284,,BAO_0000218
14132,,"Percentage biodistribution in mouse brain, 10 minutes post injection",955.0,,50594,,N,1,Intermediate,1,,CHEMBL626285,,BAO_0000218
14133,,"Percentage biodistribution in mouse brain, 30 minutes post injection",955.0,,50594,,N,1,Intermediate,1,,CHEMBL626286,,BAO_0000218
14134,,"Percentage biodistribution in mouse brain, 5 minutes post injection",955.0,,50594,,N,1,Intermediate,1,,CHEMBL626287,,BAO_0000218
14135,,"Percentage biodistribution in mouse brain, 60 minutes post injection",955.0,,50594,,N,1,Intermediate,1,,CHEMBL626288,,BAO_0000218
14136,,"Percentage biodistribution in mouse heart, 10 minutes post injection",,,50594,,N,1,Intermediate,1,,CHEMBL626289,,BAO_0000218
14137,,"Percentage biodistribution in mouse heart, 30 minutes post injection",,,50594,,N,1,Intermediate,1,,CHEMBL626290,,BAO_0000218
14138,,"Percentage biodistribution in mouse heart, 5 minutes post injection",,,50594,,N,1,Intermediate,1,,CHEMBL626291,,BAO_0000218
14139,,"Percentage biodistribution in mouse heart, 60 minutes post injection",,,50594,,N,1,Intermediate,1,,CHEMBL839888,,BAO_0000218
14140,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",160.0,,50594,,N,1,Intermediate,1,,CHEMBL626292,,BAO_0000218
14141,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",160.0,,50594,,N,1,Intermediate,1,,CHEMBL626293,,BAO_0000218
14142,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",160.0,,50594,,N,1,Intermediate,1,,CHEMBL626294,,BAO_0000218
14143,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",160.0,,50594,,N,1,Intermediate,1,,CHEMBL626295,,BAO_0000218
14144,,"Percentage biodistribution in mouse liver, 10 minutes post injection",2107.0,,50594,,N,1,Intermediate,1,,CHEMBL627659,,BAO_0000218
14145,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",2107.0,,50594,,N,1,Intermediate,1,,CHEMBL627660,,BAO_0000218
14146,,"Percentage biodistribution in mouse liver, 5 minutes post injection",2107.0,,50594,,N,1,Intermediate,1,,CHEMBL627661,,BAO_0000218
14147,,Biodistribution in mice liver at 60 minutes of post injection,2107.0,,50594,,N,1,Intermediate,1,,CHEMBL627662,,BAO_0000218
14148,,Biodistribution in mice lungs at 10 min of post injection,2048.0,,50594,,N,1,Intermediate,1,,CHEMBL627663,,BAO_0000218
14149,,"Percentage biodistribution in mouse lung, 30 minutes post injection",,,50594,,N,1,Intermediate,1,,CHEMBL627664,,BAO_0000218
14150,,"Percentage biodistribution in mousee lung, 5 minutes post injection",,,50594,,N,1,Intermediate,1,,CHEMBL627665,,BAO_0000218
14151,,Biodistribution in mice lungs at 60 min of post injection,2048.0,,50594,,N,1,Intermediate,1,,CHEMBL627666,,BAO_0000218
14152,,Percentage biodistribution in mouse spleen,2106.0,,50594,,N,1,Intermediate,1,,CHEMBL627667,,BAO_0000218
14153,,Percentage biodistribution in mouse stomach,945.0,,50594,,N,1,Intermediate,1,,CHEMBL627668,,BAO_0000218
14154,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,1088.0,,50594,,N,1,Intermediate,1,,CHEMBL627669,,BAO_0000218
14155,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,1255.0,,22224,,U,0,Autocuration,1,,CHEMBL627670,,BAO_0000218
14156,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,178.0,,22224,,U,0,Autocuration,1,,CHEMBL627671,,BAO_0000218
14157,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,1474.0,,22224,,U,0,Autocuration,1,,CHEMBL627672,,BAO_0000218
14158,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,,22224,,U,0,Autocuration,1,,CHEMBL627673,,BAO_0000218
14159,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,2113.0,,22224,,U,0,Autocuration,1,,CHEMBL627674,,BAO_0000218
14160,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL627675,,BAO_0000218
14161,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,2048.0,,22224,,U,0,Autocuration,1,,CHEMBL627676,,BAO_0000218
14162,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL627677,,BAO_0000218
14163,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL627678,,BAO_0000019
14164,,Affinity for protein binding expressed as association constant in fresh rat serum,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL627679,,BAO_0000218
14165,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,22224,,U,0,Autocuration,1,,CHEMBL627680,,BAO_0000019
14166,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,22224,,U,0,Autocuration,1,,CHEMBL627681,,BAO_0000019
14167,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,22224,,U,0,Autocuration,1,,CHEMBL627682,,BAO_0000019
14168,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,22224,,U,0,Autocuration,1,,CHEMBL627683,,BAO_0000019
14169,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,,22224,,U,0,Autocuration,1,,CHEMBL627684,,BAO_0000019
14170,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,22224,,U,0,Autocuration,1,,CHEMBL874441,,BAO_0000019
14171,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,,22224,,U,0,Autocuration,1,,CHEMBL627685,,BAO_0000019
14172,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,22224,,U,0,Autocuration,1,,CHEMBL627686,,BAO_0000019
14173,,Apparent rate constant Koff for inactivation of dTMP synthase.,,,22224,,U,0,Autocuration,1,,CHEMBL627687,,BAO_0000019
14174,,The irreversible inhibitor activity by second order rate equation.,,,22224,,U,0,Autocuration,1,,CHEMBL627688,,BAO_0000019
14175,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL628038,,BAO_0000218
14176,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,,50597,,N,1,Intermediate,1,,CHEMBL628039,,BAO_0000218
14177,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,,50597,,N,1,Intermediate,1,,CHEMBL628040,,BAO_0000218
14178,,Dissociation rate calculated from the first-order equation using t1/2 value,,,22224,,U,0,Autocuration,1,,CHEMBL628041,,BAO_0000019
14179,,The compound was tested for Binding constant against DNA,,,22224,,U,0,Autocuration,1,,CHEMBL630226,,BAO_0000019
14180,,First order rate constant for cyclization of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL628042,,BAO_0000019
14181,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,22224,,U,0,Autocuration,1,,CHEMBL625232,,BAO_0000019
14182,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,22224,,U,0,Autocuration,1,,CHEMBL625233,,BAO_0000019
14183,,Hydrolysis rate constant was determined,,,22224,,U,0,Autocuration,1,,CHEMBL625979,,BAO_0000019
14184,,Observed first order rate constant,,,22224,,U,0,Autocuration,1,,CHEMBL625980,,BAO_0000019
14185,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,22224,,U,0,Autocuration,1,,CHEMBL625981,,BAO_0000019
14186,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,22224,,U,0,Autocuration,1,,CHEMBL625982,,BAO_0000019
14187,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,,22224,,U,0,Autocuration,1,,CHEMBL625983,,BAO_0000019
14188,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL625984,,BAO_0000019
14189,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL625985,,BAO_0000019
14190,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL625986,,BAO_0000019
14191,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL625987,,BAO_0000019
14192,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL625988,,BAO_0000019
14193,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL625989,,BAO_0000019
14194,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL625990,,BAO_0000019
14195,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL625991,,BAO_0000019
14196,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL625992,,BAO_0000019
14197,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL625993,,BAO_0000019
14198,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL631973,,BAO_0000019
14199,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL632143,,BAO_0000019
14200,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL632144,,BAO_0000019
14201,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL632145,,BAO_0000019
14202,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL632146,,BAO_0000019
14203,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL632147,,BAO_0000019
14204,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL632148,,BAO_0000019
14205,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL632149,,BAO_0000019
14206,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL632150,,BAO_0000019
14207,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL632151,,BAO_0000019
14208,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,,50587,,N,1,Intermediate,1,,CHEMBL632152,,BAO_0000218
14209,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,,50587,,N,1,Intermediate,1,,CHEMBL632153,,BAO_0000218
14210,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,,50587,,N,1,Intermediate,1,,CHEMBL632154,,BAO_0000218
14211,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,,50602,,N,1,Intermediate,1,,CHEMBL632155,,BAO_0000218
14212,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,,50602,,N,1,Intermediate,1,,CHEMBL632156,,BAO_0000218
14213,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,,50602,,N,1,Intermediate,1,,CHEMBL632157,,BAO_0000218
14214,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,,50602,,N,1,Intermediate,1,,CHEMBL632158,,BAO_0000218
14215,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,,50602,,N,1,Intermediate,1,,CHEMBL632159,,BAO_0000218
14216,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,,50602,,N,1,Intermediate,1,,CHEMBL626305,,BAO_0000218
14217,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,,50602,,N,1,Intermediate,1,,CHEMBL626306,,BAO_0000218
14218,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,,50602,,N,1,Intermediate,1,,CHEMBL626307,,BAO_0000218
14219,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,,50602,,N,1,Intermediate,1,,CHEMBL626308,,BAO_0000218
14220,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,,50602,,N,1,Intermediate,1,,CHEMBL626479,,BAO_0000218
14221,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,,50602,,N,1,Intermediate,1,,CHEMBL626480,,BAO_0000218
14222,,Calculated partition coefficient (clogP) (MlogP),,,22229,,U,0,Autocuration,1,,CHEMBL626481,,BAO_0000100
14223,,Equipotent potent ratio relative to carbachol (nicotinic activity),,,22224,,U,0,Autocuration,1,,CHEMBL626482,,BAO_0000019
14224,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,,50588,,N,1,Intermediate,1,,CHEMBL626483,,BAO_0000218
14225,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,,50588,,N,1,Intermediate,1,,CHEMBL626484,,BAO_0000218
14226,,Solubility at pH 7.4 in micro g/mL;NA denotes available,,,22229,,U,0,Autocuration,1,,CHEMBL626485,,BAO_0000100
14227,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,,22229,,U,0,Autocuration,1,,CHEMBL626486,,BAO_0000100
14228,,Solubility at pH 7.4 in ug/mL;NA denotes not available,,,22229,,U,0,Autocuration,1,,CHEMBL626487,,BAO_0000100
14229,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1969.0,,50588,,N,1,Intermediate,1,,CHEMBL626488,,BAO_0000218
14230,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,1977.0,,50597,,N,1,Intermediate,1,,CHEMBL626489,,BAO_0000218
14231,,Area under the MAP curve measured over 5 min; ND means Not determined,,,22224,,U,0,Autocuration,1,,CHEMBL626490,,BAO_0000019
14232,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,,22224,,U,0,Autocuration,1,,CHEMBL626491,,BAO_0000100
14233,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,,22229,,U,0,Autocuration,1,,CHEMBL626492,,BAO_0000100
14234,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,,22224,,U,0,Autocuration,1,,CHEMBL626493,,BAO_0000019
14235,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL626494,,BAO_0000218
14236,,Half life after oral tested,,,22224,,U,0,Autocuration,1,,CHEMBL626495,,BAO_0000218
14237,,Half life was determined in plasma of rat; NT indicates not tested,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626496,,BAO_0000218
14238,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,,50597,,N,1,Intermediate,1,,CHEMBL626497,,BAO_0000218
14239,,Oral bioavailability after oral tested,,,22224,,U,0,Autocuration,1,,CHEMBL626498,,BAO_0000218
14240,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,,50597,,N,1,Intermediate,1,,CHEMBL626499,,BAO_0000218
14241,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,,50597,,N,1,Intermediate,1,,CHEMBL626500,,BAO_0000218
14242,,half life was determined in plasma of rat; NT indicates not tested,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626501,,BAO_0000218
14243,,half life was determined in plasma of rat; NT means not tested,1969.0,,50597,,N,1,Intermediate,1,,CHEMBL626502,,BAO_0000218
14244,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,,50597,,N,1,Intermediate,1,,CHEMBL626503,,BAO_0000218
14245,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,,50597,,N,1,Intermediate,1,,CHEMBL626504,,BAO_0000218
14246,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,,50597,,N,1,Intermediate,1,,CHEMBL626505,,BAO_0000218
14247,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,,50597,,N,1,Intermediate,1,,CHEMBL626506,,BAO_0000218
14248,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,,50597,,N,1,Intermediate,1,,CHEMBL626507,,BAO_0000218
14249,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,,50597,,N,1,Intermediate,1,,CHEMBL626508,,BAO_0000218
14250,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,,50597,,N,1,Intermediate,1,,CHEMBL626509,,BAO_0000218
14251,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,,50597,,N,1,Intermediate,1,,CHEMBL875480,,BAO_0000218
14252,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,,50597,,N,1,Intermediate,1,,CHEMBL626510,,BAO_0000218
14253,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,,50597,,N,1,Intermediate,1,,CHEMBL626511,,BAO_0000218
14254,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,,50597,,N,1,Intermediate,1,,CHEMBL626512,,BAO_0000218
14255,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,,50597,,N,1,Intermediate,1,,CHEMBL628208,,BAO_0000218
14256,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,,50597,,N,1,Intermediate,1,,CHEMBL628209,,BAO_0000218
14257,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,,50597,,N,1,Intermediate,1,,CHEMBL628210,,BAO_0000218
14258,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,,50597,,N,1,Intermediate,1,,CHEMBL628211,,BAO_0000218
14259,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,,50597,,N,1,Intermediate,1,,CHEMBL628212,,BAO_0000218
14260,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,,50597,,N,1,Intermediate,1,,CHEMBL628213,,BAO_0000218
14261,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628214,,BAO_0000218
14262,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628215,,BAO_0000218
14263,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628216,,BAO_0000218
14264,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626595,,BAO_0000218
14265,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626596,,BAO_0000218
14266,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626597,,BAO_0000218
14267,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626598,,BAO_0000218
14268,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622242,,BAO_0000218
14269,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622243,,BAO_0000218
14270,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622244,,BAO_0000218
14271,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622245,,BAO_0000218
14272,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622246,,BAO_0000218
14273,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622247,,BAO_0000218
14274,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622248,,BAO_0000218
14275,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL877483,,BAO_0000218
14276,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL622249,,BAO_0000218
14277,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622250,,BAO_0000218
14278,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622251,,BAO_0000218
14279,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622252,,BAO_0000218
14280,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622253,,BAO_0000218
14281,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622254,,BAO_0000218
14282,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622255,,BAO_0000218
14283,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622256,,BAO_0000218
14284,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622257,,BAO_0000218
14285,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622258,,BAO_0000218
14286,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622259,,BAO_0000218
14287,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622927,,BAO_0000218
14288,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622928,,BAO_0000218
14289,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL622929,,BAO_0000218
14290,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL623182,,BAO_0000218
14291,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL623183,,BAO_0000218
14292,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623184,,BAO_0000218
14293,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623185,,BAO_0000218
14294,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL877484,,BAO_0000218
14295,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL627274,,BAO_0000218
14296,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623186,,BAO_0000218
14297,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623187,,BAO_0000218
14298,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL623188,,BAO_0000218
14299,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628055,,BAO_0000218
14300,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628056,,BAO_0000218
14301,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628200,,BAO_0000218
14302,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628201,,BAO_0000218
14303,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628202,,BAO_0000218
14304,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628203,,BAO_0000218
14305,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628204,,BAO_0000218
14306,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628205,,BAO_0000218
14307,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628206,,BAO_0000218
14308,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),2367.0,,22224,,U,0,Autocuration,1,,CHEMBL628207,,BAO_0000218
14309,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,2367.0,,22224,,U,0,Autocuration,1,,CHEMBL627220,,BAO_0000218
14310,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL627221,,BAO_0000218
14311,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),2367.0,,22224,,U,0,Autocuration,1,,CHEMBL627222,,BAO_0000218
14312,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,,22224,,U,0,Autocuration,1,,CHEMBL627223,,BAO_0000218
14313,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL632062,,BAO_0000218
14314,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,2106.0,,22224,,U,0,Autocuration,1,,CHEMBL632063,,BAO_0000218
14315,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,1255.0,,22224,,U,0,Autocuration,1,,CHEMBL632064,,BAO_0000218
14316,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,178.0,,22224,,U,0,Autocuration,1,,CHEMBL632065,,BAO_0000218
14317,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,1474.0,,22224,,U,0,Autocuration,1,,CHEMBL632066,,BAO_0000218
14318,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,,22224,,U,0,Autocuration,1,,CHEMBL632067,,BAO_0000218
14319,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,2113.0,,22224,,U,0,Autocuration,1,,CHEMBL629188,,BAO_0000218
14320,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL629189,,BAO_0000218
14321,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,2048.0,,22224,,U,0,Autocuration,1,,CHEMBL629190,,BAO_0000218
14322,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL629191,,BAO_0000218
14323,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),2367.0,,22224,,U,0,Autocuration,1,,CHEMBL629192,,BAO_0000218
14324,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL629193,,BAO_0000218
14325,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),2367.0,,22224,,U,0,Autocuration,1,,CHEMBL629194,,BAO_0000218
14326,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,,22224,,U,0,Autocuration,1,,CHEMBL629195,,BAO_0000218
14327,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL629373,,BAO_0000218
14328,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,2106.0,,22224,,U,0,Autocuration,1,,CHEMBL629374,,BAO_0000218
14329,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,2367.0,,22224,,U,0,Autocuration,1,,CHEMBL629375,,BAO_0000218
14330,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,1255.0,,22224,,U,0,Autocuration,1,,CHEMBL629376,,BAO_0000218
14331,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,178.0,,22224,,U,0,Autocuration,1,,CHEMBL629377,,BAO_0000218
14332,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,1474.0,,22224,,U,0,Autocuration,1,,CHEMBL629378,,BAO_0000218
14333,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,,22224,,U,0,Autocuration,1,,CHEMBL629379,,BAO_0000218
14334,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,2113.0,,22224,,U,0,Autocuration,1,,CHEMBL629151,,BAO_0000218
14335,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL629152,,BAO_0000218
14336,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,2048.0,,22224,,U,0,Autocuration,1,,CHEMBL629153,,BAO_0000218
14337,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL629154,,BAO_0000218
14338,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),2367.0,,22224,,U,0,Autocuration,1,,CHEMBL629155,,BAO_0000218
14339,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,2367.0,,22224,,U,0,Autocuration,1,,CHEMBL629156,,BAO_0000218
14340,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL629157,,BAO_0000218
14341,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),2367.0,,22224,,U,0,Autocuration,1,,CHEMBL629158,,BAO_0000218
14342,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,,22224,,U,0,Autocuration,1,,CHEMBL629159,,BAO_0000218
14343,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL629160,,BAO_0000218
14344,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,2106.0,,22224,,U,0,Autocuration,1,,CHEMBL629161,,BAO_0000218
14345,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,1255.0,,22224,,U,0,Autocuration,1,,CHEMBL629162,,BAO_0000218
14346,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,178.0,,22224,,U,0,Autocuration,1,,CHEMBL629163,,BAO_0000218
14347,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,1474.0,,22224,,U,0,Autocuration,1,,CHEMBL629164,,BAO_0000218
14348,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,,22224,,U,0,Autocuration,1,,CHEMBL629165,,BAO_0000218
14349,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL629166,,BAO_0000218
14350,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,2048.0,,22224,,U,0,Autocuration,1,,CHEMBL629167,,BAO_0000218
14351,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL629168,,BAO_0000218
14352,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,,22224,,U,0,Autocuration,1,,CHEMBL629169,,BAO_0000019
14353,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,,22224,,U,0,Autocuration,1,,CHEMBL629170,,BAO_0000019
14354,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,,22224,,U,0,Autocuration,1,,CHEMBL631153,,BAO_0000019
14355,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,,22224,,U,0,Autocuration,1,,CHEMBL875121,,BAO_0000019
14356,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,,22224,,U,0,Autocuration,1,,CHEMBL631154,,BAO_0000019
14357,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,,22224,,U,0,Autocuration,1,,CHEMBL631155,,BAO_0000019
14358,,Hydrolysis rate constant was determined,,,22224,,U,0,Autocuration,1,,CHEMBL631156,,BAO_0000019
14359,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,,22224,,U,0,Autocuration,1,,CHEMBL631157,,BAO_0000019
14360,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,22224,,U,0,Autocuration,1,,CHEMBL631158,,BAO_0000019
14361,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,22224,,U,0,Autocuration,1,,CHEMBL631159,,BAO_0000019
14362,,Observed second order rate constant,,,22224,,U,0,Autocuration,1,,CHEMBL631160,,BAO_0000019
14363,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,22224,,U,0,Autocuration,1,,CHEMBL631161,,BAO_0000019
14364,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,22224,,U,0,Autocuration,1,,CHEMBL631162,,BAO_0000019
14365,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,22224,,U,0,Autocuration,1,,CHEMBL630313,,BAO_0000019
14366,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,22224,,U,0,Autocuration,1,,CHEMBL630314,,BAO_0000019
14367,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,22224,,U,0,Autocuration,1,,CHEMBL630315,,BAO_0000019
14368,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL630316,,BAO_0000019
14369,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL630986,,BAO_0000019
14370,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL630987,,BAO_0000019
14371,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL630988,,BAO_0000019
14372,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL630989,,BAO_0000019
14373,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL630990,,BAO_0000019
14374,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL630991,,BAO_0000019
14375,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL630992,,BAO_0000019
14376,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL630993,,BAO_0000019
14377,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,,U,0,Autocuration,1,,CHEMBL630994,,BAO_0000019
14378,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,,50597,,N,1,Intermediate,1,,CHEMBL630995,,BAO_0000218
14379,,Association constant for compound at 31 degree C was determined,,,22224,,U,0,Autocuration,1,,CHEMBL629252,,BAO_0000019
14380,,Calculated antagonist equilibrium dissociation constant of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL629253,,BAO_0000019
14381,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,,22224,,U,0,Autocuration,1,,CHEMBL629944,,BAO_0000019
14382,,Dissociation constants vs LTE4 on guinea pig trachea,3126.0,,50512,,N,1,Intermediate,1,,CHEMBL629945,,BAO_0000218
14383,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,,22224,,U,0,Autocuration,1,,CHEMBL629946,,BAO_0000019
14384,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,,22224,,U,0,Autocuration,1,,CHEMBL629947,,BAO_0000019
14385,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,,22224,,U,0,Autocuration,1,,CHEMBL629948,,BAO_0000019
14386,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,,22224,,U,0,Autocuration,1,,CHEMBL856024,,BAO_0000019
14387,,Affinity constant KD value was derived from TMP,,,22224,,U,0,Autocuration,1,,CHEMBL629949,,BAO_0000019
14388,,Apparent dissociation (binding) rate constant was evaluated,,,22224,,U,0,Autocuration,1,,CHEMBL629950,,BAO_0000019
14389,,Dissociation constant (KD) of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL630127,,BAO_0000100
14390,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,,22224,,U,0,Autocuration,1,,CHEMBL630128,,BAO_0000100
14391,,Dissociation constant from ESR titration experiments,,,22224,,U,0,Autocuration,1,,CHEMBL630129,,BAO_0000100
14392,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,22224,,U,0,Autocuration,1,,CHEMBL630130,,BAO_0000019
14393,,Dissociation constant was evaluated.,,,22224,,U,0,Autocuration,1,,CHEMBL875234,,BAO_0000100
14394,,Dissociation constant was reported,,,22224,,U,0,Autocuration,1,,CHEMBL630131,,BAO_0000100
14395,,Dissociation constant was determined in rat pituitary cells.,,,50597,,N,1,Intermediate,1,,CHEMBL630132,,BAO_0000218
14396,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,,22224,,U,0,Autocuration,1,,CHEMBL630133,,BAO_0000019
14397,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,,22224,,U,0,Autocuration,1,,CHEMBL630134,,BAO_0000019
14398,,Equilibrium dissociation constant of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL630135,,BAO_0000019
14399,,Equilibrium dissociation constant was determined,,,22224,,U,0,Autocuration,1,,CHEMBL630136,,BAO_0000019
14400,,Kinetic constant KD was evaluated,,,22224,,U,0,Autocuration,1,,CHEMBL630137,,BAO_0000019
14401,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,,22224,,U,0,Autocuration,1,,CHEMBL630138,,BAO_0000019
14402,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,,22224,,U,0,Autocuration,1,,CHEMBL630139,,BAO_0000019
14403,,Rate constant for hydrolysis in aqueous acetone.,,,22224,,U,0,Autocuration,1,,CHEMBL630140,,BAO_0000019
14404,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,,22224,,U,0,Autocuration,1,,CHEMBL875235,,BAO_0000019
14405,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,,50597,,N,1,Intermediate,1,,CHEMBL876439,,BAO_0000218
14406,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,,50597,,N,1,Intermediate,1,,CHEMBL630605,,BAO_0000218
14407,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,,50597,,N,1,Intermediate,1,,CHEMBL630606,,BAO_0000218
14408,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,,50597,,N,1,Intermediate,1,,CHEMBL630607,,BAO_0000218
14409,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,,50597,,N,1,Intermediate,1,,CHEMBL630608,,BAO_0000218
14410,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,,50597,,N,1,Intermediate,1,,CHEMBL630609,,BAO_0000218
14411,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,,50597,,N,1,Intermediate,1,,CHEMBL630610,,BAO_0000218
14412,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,,50597,,N,1,Intermediate,1,,CHEMBL630611,,BAO_0000218
14413,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,,50597,,N,1,Intermediate,1,,CHEMBL629552,,BAO_0000218
14414,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629733,,BAO_0000218
14415,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629734,,BAO_0000218
14416,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629735,,BAO_0000218
14417,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629736,,BAO_0000218
14418,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629737,,BAO_0000218
14419,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629738,,BAO_0000218
14420,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629739,,BAO_0000218
14421,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,50597,,N,1,Intermediate,1,,CHEMBL629740,,BAO_0000218
14422,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629741,,BAO_0000218
14423,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629742,,BAO_0000218
14424,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629743,,BAO_0000218
14425,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629744,,BAO_0000218
14426,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629745,,BAO_0000218
14427,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629746,,BAO_0000218
14428,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629747,,BAO_0000218
14429,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629748,,BAO_0000218
14430,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629749,,BAO_0000218
14431,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629750,,BAO_0000218
14432,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629751,,BAO_0000218
14433,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629752,,BAO_0000218
14434,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629753,,BAO_0000218
14435,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629754,,BAO_0000218
14436,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629755,,BAO_0000218
14437,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629756,,BAO_0000218
14438,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629757,,BAO_0000218
14439,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629758,,BAO_0000218
14440,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629759,,BAO_0000218
14441,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL629760,,BAO_0000218
14442,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,50597,,N,1,Intermediate,1,,CHEMBL876443,,BAO_0000218
14443,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,,50588,,N,1,Intermediate,1,,CHEMBL629761,,BAO_0000218
14444,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,,50588,,N,1,Intermediate,1,,CHEMBL629762,,BAO_0000218
14445,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,50594,,N,1,Intermediate,1,,CHEMBL629763,,BAO_0000218
14446,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,50594,,N,1,Intermediate,1,,CHEMBL629764,,BAO_0000218
14447,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,50594,,N,1,Intermediate,1,,CHEMBL629765,,BAO_0000218
14448,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,,50594,,N,1,Intermediate,1,,CHEMBL629766,,BAO_0000218
14449,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,50594,,N,1,Intermediate,1,,CHEMBL629767,,BAO_0000218
14450,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,,50588,,N,1,Intermediate,1,,CHEMBL629768,,BAO_0000218
14451,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,,50594,,N,1,Intermediate,1,,CHEMBL629769,,BAO_0000218
14452,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,,50588,,N,1,Intermediate,1,,CHEMBL629770,,BAO_0000218
14453,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,,50588,,N,1,Intermediate,1,,CHEMBL629771,,BAO_0000218
14454,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,50594,,N,1,Intermediate,1,,CHEMBL629772,,BAO_0000218
14455,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,50594,,N,1,Intermediate,1,,CHEMBL629773,,BAO_0000218
14456,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,50594,,N,1,Intermediate,1,,CHEMBL625455,,BAO_0000218
14457,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,,50594,,N,1,Intermediate,1,,CHEMBL625456,,BAO_0000218
14458,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,,50594,,N,1,Intermediate,1,,CHEMBL625457,,BAO_0000218
14459,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625458,,BAO_0000218
14460,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625459,,BAO_0000218
14461,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL875483,,BAO_0000218
14462,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL634779,,BAO_0000218
14463,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625460,,BAO_0000218
14464,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626117,,BAO_0000218
14465,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626118,,BAO_0000218
14466,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628342,,BAO_0000218
14467,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628343,,BAO_0000218
14468,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628344,,BAO_0000218
14469,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628345,,BAO_0000218
14470,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628346,,BAO_0000218
14471,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628347,,BAO_0000218
14472,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628348,,BAO_0000218
14473,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628349,,BAO_0000218
14474,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL875611,,BAO_0000218
14475,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628350,,BAO_0000218
14476,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628351,,BAO_0000218
14477,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628352,,BAO_0000218
14478,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628353,,BAO_0000218
14479,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628354,,BAO_0000218
14480,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626667,,BAO_0000218
14481,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626668,,BAO_0000218
14482,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626669,,BAO_0000218
14483,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626670,,BAO_0000218
14484,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626671,,BAO_0000218
14485,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626672,,BAO_0000218
14486,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626673,,BAO_0000218
14487,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626674,,BAO_0000218
14488,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626675,,BAO_0000218
14489,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626676,,BAO_0000218
14490,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626677,,BAO_0000218
14491,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626678,,BAO_0000218
14492,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626679,,BAO_0000218
14493,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL875612,,BAO_0000218
14494,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626680,,BAO_0000218
14495,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626681,,BAO_0000218
14496,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626682,,BAO_0000218
14497,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626683,,BAO_0000218
14498,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626684,,BAO_0000218
14499,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626685,,BAO_0000218
14500,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626686,,BAO_0000218
14501,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626687,,BAO_0000218
14502,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624978,,BAO_0000218
14503,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624979,,BAO_0000218
14504,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624980,,BAO_0000218
14505,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL624981,,BAO_0000218
14506,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL624982,,BAO_0000218
14507,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),2367.0,,22224,,U,0,Autocuration,1,,CHEMBL627564,,BAO_0000218
14508,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),2367.0,,22224,,U,0,Autocuration,1,,CHEMBL627565,,BAO_0000218
14509,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,,22224,,U,0,Autocuration,1,,CHEMBL627566,,BAO_0000218
14510,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL627567,,BAO_0000218
14511,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,2106.0,,22224,,U,0,Autocuration,1,,CHEMBL627568,,BAO_0000218
14512,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,2113.0,,22224,,U,0,Autocuration,1,,CHEMBL627569,,BAO_0000218
14513,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,1255.0,,22224,,U,0,Autocuration,1,,CHEMBL627570,,BAO_0000218
14514,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,178.0,,22224,,U,0,Autocuration,1,,CHEMBL627571,,BAO_0000218
14515,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,1474.0,,22224,,U,0,Autocuration,1,,CHEMBL627572,,BAO_0000218
14516,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,,22224,,U,0,Autocuration,1,,CHEMBL627573,,BAO_0000218
14517,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,2113.0,,22224,,U,0,Autocuration,1,,CHEMBL627574,,BAO_0000218
14518,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,2107.0,,22224,,U,0,Autocuration,1,,CHEMBL627575,,BAO_0000218
14519,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,2048.0,,22224,,U,0,Autocuration,1,,CHEMBL627576,,BAO_0000218
14520,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL627577,,BAO_0000218
14521,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),2367.0,,22224,,U,0,Autocuration,1,,CHEMBL627578,,BAO_0000218
14522,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,2367.0,,22224,,U,0,Autocuration,1,,CHEMBL627579,,BAO_0000218
14523,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL627580,,BAO_0000218
14524,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),2367.0,,22224,,U,0,Autocuration,1,,CHEMBL627581,,BAO_0000218
14525,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,,22224,,U,0,Autocuration,1,,CHEMBL627582,,BAO_0000218
14526,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL627583,,BAO_0000218
14527,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,2106.0,,22224,,U,0,Autocuration,1,,CHEMBL627584,,BAO_0000218
14528,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,2367.0,,22224,,U,0,Autocuration,1,,CHEMBL627585,,BAO_0000218
14529,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,2385.0,,22224,,U,0,Autocuration,1,,CHEMBL627586,,BAO_0000218
14530,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,,50597,,N,1,Intermediate,1,,CHEMBL627587,,BAO_0000218
14531,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,,50597,,N,1,Intermediate,1,,CHEMBL627588,,BAO_0000218
14532,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,,50597,,N,1,Intermediate,1,,CHEMBL628250,,BAO_0000218
14533,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,,50597,,N,1,Intermediate,1,,CHEMBL628251,,BAO_0000218
14534,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL628252,,BAO_0000218
14535,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL628253,,BAO_0000218
14536,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,1898.0,,50597,,N,1,Intermediate,1,,CHEMBL628254,,BAO_0000218
14537,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1898.0,,50597,,N,1,Intermediate,1,,CHEMBL877493,,BAO_0000218
14538,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,,50597,,N,1,Intermediate,1,,CHEMBL628255,,BAO_0000218
14539,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,,50597,,N,1,Intermediate,1,,CHEMBL628256,,BAO_0000218
14540,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL628257,,BAO_0000218
14541,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1898.0,,50597,,N,1,Intermediate,1,,CHEMBL628258,,BAO_0000218
14542,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,,50597,,N,1,Intermediate,1,,CHEMBL628259,,BAO_0000218
14543,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,,50597,,N,1,Intermediate,1,,CHEMBL628429,,BAO_0000218
14544,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL626862,,BAO_0000218
14545,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,1898.0,,50597,,N,1,Intermediate,1,,CHEMBL626863,,BAO_0000218
14546,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL625886,,BAO_0000218
14547,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL625887,,BAO_0000218
14548,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,,50597,,N,1,Intermediate,1,,CHEMBL625888,,BAO_0000218
14549,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,,50597,,N,1,Intermediate,1,,CHEMBL625889,,BAO_0000218
14550,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL625890,,BAO_0000218
14551,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL625891,,BAO_0000218
14552,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,1898.0,,50597,,N,1,Intermediate,1,,CHEMBL625892,,BAO_0000218
14553,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,1898.0,,50597,,N,1,Intermediate,1,,CHEMBL625893,,BAO_0000218
14554,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,2037.0,,50597,,N,1,Intermediate,1,,CHEMBL625894,,BAO_0000218
14555,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,,50597,,N,1,Intermediate,1,,CHEMBL625895,,BAO_0000218
14556,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,22224,,U,0,Autocuration,1,,CHEMBL625896,,BAO_0000019
14557,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,,22224,,U,0,Autocuration,1,,CHEMBL625897,,BAO_0000019
14558,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,22224,,U,0,Autocuration,1,,CHEMBL625898,,BAO_0000019
14559,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,22224,,U,0,Autocuration,1,,CHEMBL625899,,BAO_0000019
14560,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,22224,,U,0,Autocuration,1,,CHEMBL626124,,BAO_0000019
14561,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,,50212,,N,1,Intermediate,1,,CHEMBL628500,,BAO_0000218
14562,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,,50597,,N,1,Intermediate,1,,CHEMBL857856,,BAO_0000218
14563,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,,50597,,N,1,Intermediate,1,,CHEMBL628501,,BAO_0000218
14564,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,,22224,,U,0,Autocuration,1,,CHEMBL628502,,BAO_0000019
14565,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,,22224,,U,0,Autocuration,1,,CHEMBL628503,,BAO_0000019
14566,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,,22224,,U,0,Autocuration,1,,CHEMBL628504,,BAO_0000019
14567,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,22224,,U,0,Autocuration,1,,CHEMBL628505,,BAO_0000019
14568,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,,22224,,U,0,Autocuration,1,,CHEMBL874452,,BAO_0000019
14569,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,,22224,,U,0,Autocuration,1,,CHEMBL628506,,BAO_0000019
14570,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,22224,,U,0,Autocuration,1,,CHEMBL628507,,BAO_0000019
14571,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,,22224,,U,0,Autocuration,1,,CHEMBL628508,,BAO_0000019
14572,,Michaelis constant (KM) was evaluated,,,22224,,U,0,Autocuration,1,,CHEMBL628509,,BAO_0000019
14573,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,22224,,U,0,Autocuration,1,,CHEMBL628510,,BAO_0000019
14574,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,,22224,,U,0,Autocuration,1,,CHEMBL628511,,BAO_0000019
14575,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,,22224,,U,0,Autocuration,1,,CHEMBL628512,,BAO_0000019
14576,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,,22224,,U,0,Autocuration,1,,CHEMBL628513,,BAO_0000019
14577,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,,22224,,U,0,Autocuration,1,,CHEMBL628514,,BAO_0000019
14578,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,,22224,,U,0,Autocuration,1,,CHEMBL628515,,BAO_0000019
14579,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,,22224,,U,0,Autocuration,1,,CHEMBL628516,,BAO_0000019
14580,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,22224,,U,0,Autocuration,1,,CHEMBL628517,,BAO_0000019
14581,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,22224,,U,0,Autocuration,1,,CHEMBL628518,,BAO_0000019
14582,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,,22224,,U,0,Autocuration,1,,CHEMBL628519,,BAO_0000019
14583,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,,22224,,U,0,Autocuration,1,,CHEMBL628520,,BAO_0000019
14584,,Binding constant was determined,,,22224,,U,0,Autocuration,1,,CHEMBL628521,,BAO_0000019
14585,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,,22224,,U,0,Autocuration,1,,CHEMBL630443,,BAO_0000019
14586,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,,22224,,U,0,Autocuration,1,,CHEMBL630444,,BAO_0000019
14587,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,,22224,,U,0,Autocuration,1,,CHEMBL857732,,BAO_0000019
14588,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,,22224,,U,0,Autocuration,1,,CHEMBL630445,,BAO_0000100
14589,,Catalytic rate constant of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL630446,,BAO_0000019
14590,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,,22224,,U,0,Autocuration,1,,CHEMBL630447,,BAO_0000019
14591,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,,22224,,U,0,Autocuration,1,,CHEMBL630448,,BAO_0000019
14592,,Catalytic rate constant against phospholipase A2 was determined,,,22224,,U,0,Autocuration,1,,CHEMBL630449,,BAO_0000019
14593,,"Compound was evaluated for catalytic constant, Kcat",,,22224,,U,0,Autocuration,1,,CHEMBL630450,,BAO_0000019
14594,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,,22224,,U,0,Autocuration,1,,CHEMBL630451,,BAO_0000019
14595,,Kcat calculated from 0.693/T1/2,,,22224,,U,0,Autocuration,1,,CHEMBL630452,,BAO_0000019
14596,,Kcat was determined,,,22224,,U,0,Autocuration,1,,CHEMBL630453,,BAO_0000019
14597,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,,22224,,U,0,Autocuration,1,,CHEMBL630454,,BAO_0000019
14598,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,,22224,,U,0,Autocuration,1,,CHEMBL630455,,BAO_0000019
14599,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,,22224,,U,0,Autocuration,1,,CHEMBL631487,,BAO_0000019
14600,,Kcat value was determined,,,22224,,U,0,Autocuration,1,,CHEMBL631488,,BAO_0000019
14601,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,,22224,,U,0,Autocuration,1,,CHEMBL876440,,BAO_0000019
14602,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,,22224,,U,0,Autocuration,1,,CHEMBL631489,,BAO_0000019
14603,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,22224,,U,0,Autocuration,1,,CHEMBL857742,,BAO_0000019
14604,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,22224,,U,0,Autocuration,1,,CHEMBL631490,,BAO_0000019
14605,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,,22224,,U,0,Autocuration,1,,CHEMBL631491,,BAO_0000019
14606,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,22224,,U,0,Autocuration,1,,CHEMBL631492,,BAO_0000019
14607,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,22224,,U,0,Autocuration,1,,CHEMBL631493,,BAO_0000019
14608,,Kinetic parameter for rate of conversion to PABA was determined,,,22224,,U,0,Autocuration,1,,CHEMBL631494,,BAO_0000019
14609,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,22224,,U,0,Autocuration,1,,CHEMBL631495,,BAO_0000019
14610,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1988.0,,50597,,N,1,Intermediate,1,,CHEMBL631496,,BAO_0000218
14611,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631497,,BAO_0000218
14612,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631498,,BAO_0000218
14613,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629776,,BAO_0000218
14614,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629777,,BAO_0000218
14615,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1088.0,,50597,,N,1,Intermediate,1,,CHEMBL629778,,BAO_0000218
14616,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630456,,BAO_0000218
14617,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630457,,BAO_0000218
14618,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630458,,BAO_0000218
14619,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630459,,BAO_0000218
14620,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630460,,BAO_0000218
14621,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL876550,,BAO_0000218
14622,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630461,,BAO_0000218
14623,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630462,,BAO_0000218
14624,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630463,,BAO_0000218
14625,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630464,,BAO_0000218
14626,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630465,,BAO_0000218
14627,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630466,,BAO_0000218
14628,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630467,,BAO_0000218
14629,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630633,,BAO_0000218
14630,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630634,,BAO_0000218
14631,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630635,,BAO_0000218
14632,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630636,,BAO_0000218
14633,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,,50597,,N,1,Intermediate,1,,CHEMBL630637,,BAO_0000218
14634,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL630638,,BAO_0000218
14635,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL630639,,BAO_0000218
14636,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL630640,,BAO_0000218
14637,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL876551,,BAO_0000218
14638,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL630641,,BAO_0000218
14639,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL630642,,BAO_0000218
14640,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL630643,,BAO_0000218
14641,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL630644,,BAO_0000218
14642,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL630645,,BAO_0000218
14643,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL625599,,BAO_0000218
14644,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL625600,,BAO_0000218
14645,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL625601,,BAO_0000218
14646,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1988.0,,50592,,N,1,Intermediate,1,,CHEMBL625602,,BAO_0000218
14647,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL627470,,BAO_0000218
14648,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL627471,,BAO_0000218
14649,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL627472,,BAO_0000218
14650,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL627473,,BAO_0000218
14651,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1088.0,,50592,,N,1,Intermediate,1,,CHEMBL627474,,BAO_0000218
14652,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627475,,BAO_0000218
14653,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,178.0,,50597,,N,1,Intermediate,1,,CHEMBL627476,,BAO_0000218
14654,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627477,,BAO_0000218
14655,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627478,,BAO_0000218
14656,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627479,,BAO_0000218
14657,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627480,,BAO_0000218
14658,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627481,,BAO_0000218
14659,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627482,,BAO_0000218
14660,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL627483,,BAO_0000218
14661,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL875636,,BAO_0000218
14662,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625764,,BAO_0000218
14663,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625765,,BAO_0000218
14664,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625766,,BAO_0000218
14665,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625767,,BAO_0000218
14666,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625768,,BAO_0000218
14667,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625769,,BAO_0000218
14668,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625770,,BAO_0000218
14669,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625771,,BAO_0000218
14670,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625772,,BAO_0000218
14671,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1088.0,,50588,,N,1,Intermediate,1,,CHEMBL625773,,BAO_0000218
14672,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625774,,BAO_0000218
14673,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625775,,BAO_0000218
14674,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625776,,BAO_0000218
14675,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625777,,BAO_0000218
14676,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625778,,BAO_0000218
14677,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625779,,BAO_0000218
14678,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625780,,BAO_0000218
14679,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL625781,,BAO_0000218
14680,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL875637,,BAO_0000218
14681,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626473,,BAO_0000218
14682,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626474,,BAO_0000218
14683,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626475,,BAO_0000218
14684,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626476,,BAO_0000218
14685,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL634397,,BAO_0000218
14686,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL626477,,BAO_0000218
14687,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631069,,BAO_0000218
14688,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631070,,BAO_0000218
14689,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631071,,BAO_0000218
14690,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631072,,BAO_0000218
14691,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631073,,BAO_0000218
14692,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631074,,BAO_0000218
14693,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631075,,BAO_0000218
14694,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631725,,BAO_0000218
14695,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631726,,BAO_0000218
14696,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631727,,BAO_0000218
14697,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631728,,BAO_0000218
14698,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631729,,BAO_0000218
14699,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631730,,BAO_0000218
14700,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631731,,BAO_0000218
14701,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631910,,BAO_0000218
14702,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,10000000.0,,50597,,N,1,Intermediate,1,,CHEMBL631911,,BAO_0000218
14703,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,1898.0,,50597,,N,1,Intermediate,1,,CHEMBL631912,,BAO_0000218
14704,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,1898.0,,50597,,N,1,Intermediate,1,,CHEMBL631913,,BAO_0000218
14705,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631914,,BAO_0000218
14706,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631915,,BAO_0000218
14707,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,,50597,,N,1,Intermediate,1,,CHEMBL875778,,BAO_0000218
14708,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631916,,BAO_0000218
14709,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631917,,BAO_0000218
14710,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631918,,BAO_0000218
14711,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631919,,BAO_0000218
14712,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,,50597,,N,1,Intermediate,1,,CHEMBL631920,,BAO_0000218
14713,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631921,,BAO_0000218
14714,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,,50597,,N,1,Intermediate,1,,CHEMBL631922,,BAO_0000218
14715,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,,50597,,N,1,Intermediate,1,,CHEMBL631923,,BAO_0000218
14716,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL631924,,BAO_0000218
14717,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL630234,,BAO_0000218
14718,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,,N,1,Intermediate,1,,CHEMBL630235,,BAO_0000218
14719,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL630236,,BAO_0000218
14720,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL630237,,BAO_0000218
14721,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL630238,,BAO_0000218
14722,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL630239,,BAO_0000218
14723,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,,N,1,Intermediate,1,,CHEMBL630303,,BAO_0000218
14724,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL630304,,BAO_0000218
14725,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,,N,1,Intermediate,1,,CHEMBL630305,,BAO_0000218
14726,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL630306,,BAO_0000218
14727,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL630307,,BAO_0000218
14728,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2113.0,,50597,,N,1,Intermediate,1,,CHEMBL630308,,BAO_0000218
14729,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL630309,,BAO_0000218
14730,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL629309,,BAO_0000218
14731,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL629993,,BAO_0000218
14732,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL629994,,BAO_0000218
14733,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2113.0,,50597,,N,1,Intermediate,1,,CHEMBL629995,,BAO_0000218
14734,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL631993,,BAO_0000218
14735,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL631994,,BAO_0000218
14736,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL631995,,BAO_0000218
14737,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631996,,BAO_0000218
14738,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631997,,BAO_0000218
14739,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631998,,BAO_0000218
14740,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631999,,BAO_0000218
14741,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,,50597,,N,1,Intermediate,1,,CHEMBL632000,,BAO_0000218
14742,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL632001,,BAO_0000218
14743,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL874424,,BAO_0000218
14744,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL632002,,BAO_0000218
14745,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL632003,,BAO_0000218
14746,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,22224,,U,0,Autocuration,1,,CHEMBL632004,,BAO_0000019
14747,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,,22224,,U,0,Autocuration,1,,CHEMBL632005,,BAO_0000019
14748,,Compound was tested for amidase rate in the presence of N62C screen enzyme,,,22224,,U,0,Autocuration,1,,CHEMBL632006,,BAO_0000019
14749,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,,22224,,U,0,Autocuration,1,,CHEMBL632007,,BAO_0000019
14750,,Compound was tested for amidase rate in the presence of S166C screen enzyme,,,22224,,U,0,Autocuration,1,,CHEMBL632008,,BAO_0000019
14751,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,,22224,,U,0,Autocuration,1,,CHEMBL632009,,BAO_0000019
14752,,Compound was tested for esterase rate in the presence of N62C screen enzyme,,,22224,,U,0,Autocuration,1,,CHEMBL632010,,BAO_0000019
14753,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,,22224,,U,0,Autocuration,1,,CHEMBL857750,,BAO_0000019
14754,,Compound was tested for esterase rate in the presence of S166C screen enzyme,,,22224,,U,0,Autocuration,1,,CHEMBL632011,,BAO_0000019
14755,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,22224,,U,0,Autocuration,1,,CHEMBL632012,,BAO_0000019
14756,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,22224,,U,0,Autocuration,1,,CHEMBL632013,,BAO_0000019
14757,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,,22224,,U,0,Autocuration,1,,CHEMBL632014,,BAO_0000019
14758,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,22224,,U,0,Autocuration,1,,CHEMBL629622,,BAO_0000019
14759,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,22224,,U,0,Autocuration,1,,CHEMBL629623,,BAO_0000019
14760,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,,22224,,U,0,Autocuration,1,,CHEMBL629624,,BAO_0000019
14761,,Ratio of Kcat to that of Km was determined,,,22224,,U,0,Autocuration,1,,CHEMBL629625,,BAO_0000019
14762,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,22224,,U,0,Autocuration,1,,CHEMBL629626,,BAO_0000019
14763,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,22224,,U,0,Autocuration,1,,CHEMBL629627,,BAO_0000019
14764,,"Compound was evaluated for constant, Kd",,,22224,,U,0,Autocuration,1,,CHEMBL629628,,BAO_0000019
14765,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,,22224,,U,0,Autocuration,1,,CHEMBL629629,,BAO_0000019
14766,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,,22224,,U,0,Autocuration,1,,CHEMBL629630,,BAO_0000019
14767,,Dissociation Constant of compound determined,,,22224,,U,0,Autocuration,1,,CHEMBL856030,,BAO_0000019
14768,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,,22224,,U,0,Autocuration,1,,CHEMBL629631,,BAO_0000019
14769,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,,22224,,U,0,Autocuration,1,,CHEMBL629632,,BAO_0000019
14770,,Dissociation constant of compound with Fructose was determined,,,22224,,U,0,Autocuration,1,,CHEMBL629633,,BAO_0000100
14771,,Dissociation constant of compound with Fructose was determined; Not determined,,,22224,,U,0,Autocuration,1,,CHEMBL629634,,BAO_0000100
14772,,Dissociation constant of compound with Lactulose was determined,,,22224,,U,0,Autocuration,1,,CHEMBL629635,,BAO_0000100
14773,,Dissociation constant of compound with Lactulose was determined; Not determined,,,22224,,U,0,Autocuration,1,,CHEMBL629636,,BAO_0000100
14774,,Dissociation constant of the Compound,,,22224,,U,0,Autocuration,1,,CHEMBL629637,,BAO_0000100
14775,,Dissociation constant by non-linear regression analysis,,,22224,,U,0,Autocuration,1,,CHEMBL629638,,BAO_0000100
14776,,Dissociation constant was determined,,,22224,,U,0,Autocuration,1,,CHEMBL629639,,BAO_0000100
14777,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,,22224,,U,0,Autocuration,1,,CHEMBL629640,,BAO_0000100
14778,,Dissociation constant was determined,,,22224,,U,0,Autocuration,1,,CHEMBL629641,,BAO_0000100
14779,,Dissociation constant was determined,,,22224,,U,0,Autocuration,1,,CHEMBL631344,,BAO_0000100
14780,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL631345,,BAO_0000218
14781,,The dissociation constant determined by fluorescence displacement assay,,,22224,,U,0,Autocuration,1,,CHEMBL631346,,BAO_0000019
14782,,kd value surface plasmon resonance (SPR) method,,,22224,,U,0,Autocuration,1,,CHEMBL631524,,BAO_0000019
14783,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL631525,,BAO_0000218
14784,,First dissociation constant of the binding of compound to V30M TTR,,,22224,,U,0,Autocuration,1,,CHEMBL631526,,BAO_0000019
14785,,Second dissociation constant of the binding of compound to V30M TTR,,,22224,,U,0,Autocuration,1,,CHEMBL631527,,BAO_0000019
14786,,"Compound was evaluated for equilibrium constant, Ke",,,22224,,U,0,Autocuration,1,,CHEMBL631528,,BAO_0000019
14787,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,1898.0,,22224,,U,0,Autocuration,1,,CHEMBL631529,,BAO_0000019
14788,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,1898.0,,22224,,U,0,Autocuration,1,,CHEMBL631530,,BAO_0000019
14789,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,,22224,,U,0,Autocuration,1,,CHEMBL631531,,BAO_0000019
14790,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,22224,,U,0,Autocuration,1,,CHEMBL631532,,BAO_0000019
14791,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,,22224,,U,0,Autocuration,1,,CHEMBL631533,,BAO_0000019
14792,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,50594,,N,1,Intermediate,1,,CHEMBL876552,,BAO_0000218
14793,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,,50594,,N,1,Intermediate,1,,CHEMBL631534,,BAO_0000218
14794,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,50594,,N,1,Intermediate,1,,CHEMBL631535,,BAO_0000218
14795,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,50594,,N,1,Intermediate,1,,CHEMBL631536,,BAO_0000218
14796,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,,50594,,N,1,Intermediate,1,,CHEMBL631537,,BAO_0000218
14797,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,,50594,,N,1,Intermediate,1,,CHEMBL631538,,BAO_0000218
14798,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,,50594,,N,1,Intermediate,1,,CHEMBL631539,,BAO_0000218
14799,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,50594,,N,1,Intermediate,1,,CHEMBL631540,,BAO_0000218
14800,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL625637,,BAO_0000218
14801,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,,N,1,Intermediate,1,,CHEMBL625638,,BAO_0000218
14802,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,,N,1,Intermediate,1,,CHEMBL625639,,BAO_0000218
14803,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625640,,BAO_0000218
14804,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625641,,BAO_0000218
14805,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625642,,BAO_0000218
14806,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625643,,BAO_0000218
14807,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625644,,BAO_0000218
14808,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2113.0,,50597,,N,1,Intermediate,1,,CHEMBL625645,,BAO_0000218
14809,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625646,,BAO_0000218
14810,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625647,,BAO_0000218
14811,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625648,,BAO_0000218
14812,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL625649,,BAO_0000218
14813,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL625650,,BAO_0000218
14814,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL625651,,BAO_0000218
14815,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,14.0,,50597,,N,1,Intermediate,1,,CHEMBL625652,,BAO_0000218
14816,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,14.0,,50597,,N,1,Intermediate,1,,CHEMBL625653,,BAO_0000218
14817,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625654,,BAO_0000218
14818,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL625655,,BAO_0000218
14819,,Biodistribution of Compound in rat blood after 15 minutes of administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625656,,BAO_0000218
14820,,Biodistribution of Compound in rat blood after 2 minutes of administration,178.0,,50597,,N,1,Intermediate,1,,CHEMBL625657,,BAO_0000218
14821,,Biodistribution of Compound in rat brain after 15 minutes of administration,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625658,,BAO_0000218
14822,,Biodistribution of Compound in rat brain after 2 minutes of administration,955.0,,50597,,N,1,Intermediate,1,,CHEMBL625659,,BAO_0000218
14823,,Biodistribution of Compound in rat heart after 15 minutes of administration,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625660,,BAO_0000218
14824,,Biodistribution of Compound in rat heart after 2 minutes of administration,948.0,,50597,,N,1,Intermediate,1,,CHEMBL625661,,BAO_0000218
14825,,Biodistribution of Compound in rat liver after 15 minutes of administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625662,,BAO_0000218
14826,,Biodistribution of Compound in rat liver after 2 minutes of administration,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL625663,,BAO_0000218
14827,,Biodistribution of Compound in rat lung after 15 minutes of administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL875621,,BAO_0000218
14828,,Biodistribution of Compound in rat lung after 2 minutes of administration,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL628382,,BAO_0000218
14829,,Biodistribution of Compound in rat muscle after 15 minutes of administration,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL628383,,BAO_0000218
14830,,Biodistribution of Compound in rat muscle after 2 minutes of administration,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL628384,,BAO_0000218
14831,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,,50597,,N,1,Intermediate,1,,CHEMBL628385,,BAO_0000218
14832,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,,50597,,N,1,Intermediate,1,,CHEMBL875753,,BAO_0000218
14833,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,,50597,,N,1,Intermediate,1,,CHEMBL628386,,BAO_0000218
14834,,Organ distribution in rat blood 2 minutes after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL628387,,BAO_0000218
14835,,Organ distribution in rat blood 2 hr after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL628388,,BAO_0000218
14836,,Organ distribution in rat blood 30 minutes after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL628389,,BAO_0000218
14837,,Organ distribution in rat blood 30 min after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL632756,,BAO_0000218
14838,,Organ distribution in rat brain 2 minutes after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL628390,,BAO_0000218
14839,,Organ distribution in rat brain 2 hr after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL631811,,BAO_0000218
14840,,Organ distribution in rat brain 30 minutes after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL631812,,BAO_0000218
14841,,Organ distribution in rat heart 2 minutes after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL631813,,BAO_0000218
14842,,Organ distribution in rat heart 2 hr after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL631814,,BAO_0000218
14843,,Organ distribution in rat heart 30 minutes after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL631815,,BAO_0000218
14844,,Organ distribution in rat kidney 2 minutes after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL631816,,BAO_0000218
14845,,Organ distribution in rat kidney 2 hr after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL875758,,BAO_0000218
14846,,Organ distribution in rat kidney 30 minutes after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL631817,,BAO_0000218
14847,,Organ distribution in rat liver 2 minutes after intravenous injection,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631818,,BAO_0000218
14848,,Organ distribution in rat liver 2 hr after intravenous injection,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631819,,BAO_0000218
14849,,Organ distribution in rat liver 30 minutes after intravenous injection,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL631820,,BAO_0000218
14850,,Organ distribution in rat lung 2 minutes after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL631821,,BAO_0000218
14851,,Organ distribution in rat lung 2 hr after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL631822,,BAO_0000218
14852,,Organ distribution in rat lung 30 minutes after intravenous injection,,,50597,,N,1,Intermediate,1,,CHEMBL631823,,BAO_0000218
14853,,Organ distribution in rat muscle 2 minutes after intravenous injection,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL631824,,BAO_0000218
14854,,Organ distribution in rat muscle 2 hr after intravenous injection,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL631825,,BAO_0000218
14855,,Organ distribution in rat muscle 30 minutes after intravenous injection,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL631826,,BAO_0000218
14856,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,,50594,,N,1,Intermediate,1,,CHEMBL631827,,BAO_0000218
14857,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,,50594,,N,1,Intermediate,1,,CHEMBL631828,,BAO_0000218
14858,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,,50594,,N,1,Intermediate,1,,CHEMBL631829,,BAO_0000218
14859,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL875759,,BAO_0000218
14860,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631830,,BAO_0000218
14861,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631831,,BAO_0000218
14862,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631832,,BAO_0000218
14863,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631833,,BAO_0000218
14864,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631834,,BAO_0000218
14865,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631835,,BAO_0000218
14866,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631836,,BAO_0000218
14867,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631837,,BAO_0000218
14868,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631838,,BAO_0000218
14869,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631839,,BAO_0000218
14870,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631840,,BAO_0000218
14871,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631841,,BAO_0000218
14872,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631842,,BAO_0000218
14873,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631843,,BAO_0000218
14874,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631844,,BAO_0000218
14875,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631845,,BAO_0000218
14876,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631846,,BAO_0000218
14877,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL875760,,BAO_0000218
14878,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL632199,,BAO_0000218
14879,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631847,,BAO_0000218
14880,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL631848,,BAO_0000218
14881,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628707,,BAO_0000218
14882,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628708,,BAO_0000218
14883,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628709,,BAO_0000218
14884,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628710,,BAO_0000218
14885,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628711,,BAO_0000218
14886,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628712,,BAO_0000218
14887,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628713,,BAO_0000218
14888,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1088.0,,50597,,N,1,Intermediate,1,,CHEMBL628714,,BAO_0000218
14889,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,,50597,,N,1,Intermediate,1,,CHEMBL628715,,BAO_0000218
14890,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,,22224,,U,0,Autocuration,1,,CHEMBL629179,,BAO_0000019
14891,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,,22224,,U,0,Autocuration,1,,CHEMBL629180,,BAO_0000019
14892,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,,22224,,U,0,Autocuration,1,,CHEMBL875108,,BAO_0000019
14893,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,1235.0,,22224,,U,0,Autocuration,1,,CHEMBL629181,,BAO_0000019
14894,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,1235.0,,22224,,U,0,Autocuration,1,,CHEMBL629182,,BAO_0000019
14895,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,,22224,,U,0,Autocuration,1,,CHEMBL629183,,BAO_0000019
14896,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,22224,,U,0,Autocuration,1,,CHEMBL629184,,BAO_0000019
14897,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,1235.0,,22224,,U,0,Autocuration,1,,CHEMBL629185,,BAO_0000019
14898,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,1235.0,,22224,,U,0,Autocuration,1,,CHEMBL629186,,BAO_0000019
14899,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,,22224,,U,0,Autocuration,1,,CHEMBL629187,,BAO_0000019
14900,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,,22224,,U,0,Autocuration,1,,CHEMBL629887,,BAO_0000019
14901,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,,22224,,U,0,Autocuration,1,,CHEMBL629888,,BAO_0000019
14902,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,,22224,,U,0,Autocuration,1,,CHEMBL629889,,BAO_0000019
14903,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,1235.0,,22224,,U,0,Autocuration,1,,CHEMBL629890,,BAO_0000019
14904,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,22224,,U,0,Autocuration,1,,CHEMBL629891,,BAO_0000019
14905,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,,22224,,U,0,Autocuration,1,,CHEMBL629892,,BAO_0000019
14906,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,1235.0,,22224,,U,0,Autocuration,1,,CHEMBL629893,,BAO_0000019
14907,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,,22224,,U,0,Autocuration,1,,CHEMBL629894,,BAO_0000019
14908,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,,22224,,U,0,Autocuration,1,,CHEMBL629895,,BAO_0000019
14909,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,,22224,,U,0,Autocuration,1,,CHEMBL875109,,BAO_0000218
14910,,Absolute bioavailability in male cynomolgus monkeys,,,22224,,U,0,Autocuration,1,,CHEMBL629896,,BAO_0000218
14911,,Absolute bioavailability in maleSprague-Dawley rats,,,22224,,U,0,Autocuration,1,,CHEMBL629897,,BAO_0000218
14912,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,,50597,,N,1,Intermediate,1,,CHEMBL629898,,BAO_0000218
14913,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL630057,,BAO_0000218
14914,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,,50597,,N,1,Intermediate,1,,CHEMBL630058,,BAO_0000218
14915,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630059,,BAO_0000218
14916,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630060,,BAO_0000218
14917,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630061,,BAO_0000218
14918,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630062,,BAO_0000218
14919,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630063,,BAO_0000218
14920,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630064,,BAO_0000218
14921,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630065,,BAO_0000218
14922,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630066,,BAO_0000218
14923,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630067,,BAO_0000218
14924,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,,50597,,N,1,Intermediate,1,,CHEMBL630068,,BAO_0000218
14925,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL631113,,BAO_0000218
14926,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL631114,,BAO_0000218
14927,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2385.0,,50597,,N,1,Intermediate,1,,CHEMBL631115,,BAO_0000218
14928,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL631116,,BAO_0000218
14929,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL630528,,BAO_0000218
14930,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL630529,,BAO_0000218
14931,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL630530,,BAO_0000218
14932,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2385.0,,50597,,N,1,Intermediate,1,,CHEMBL630531,,BAO_0000218
14933,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL630532,,BAO_0000218
14934,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,,50597,,N,1,Intermediate,1,,CHEMBL630533,,BAO_0000218
14935,,Biodistribution in normal mice blood after 120 hr,178.0,,50594,,N,1,Intermediate,1,,CHEMBL630534,,BAO_0000218
14936,,Biodistribution in normal mice blood after 24 hr,178.0,,50594,,N,1,Intermediate,1,,CHEMBL630535,,BAO_0000218
14937,,Biodistribution in normal mice blood after 4 hr,178.0,,50594,,N,1,Intermediate,1,,CHEMBL630536,,BAO_0000218
14938,,Biodistribution in normal mice bone after 120 hr,10000001.0,,50594,,N,1,Intermediate,1,,CHEMBL630537,,BAO_0000218
14939,,Biodistribution in normal mice bone after 24 hr,10000001.0,,50594,,N,1,Intermediate,1,,CHEMBL630538,,BAO_0000218
14940,,Biodistribution in normal mice bone after 4 hr,10000001.0,,50594,,N,1,Intermediate,1,,CHEMBL630539,,BAO_0000218
14941,,Biodistribution in normal mice heart after 120 hr,948.0,,50594,,N,1,Intermediate,1,,CHEMBL630540,,BAO_0000218
14942,,Biodistribution in normal mice heart after 24 hr,948.0,,50594,,N,1,Intermediate,1,,CHEMBL630541,,BAO_0000218
14943,,Biodistribution in normal mice heart after 4 hr,948.0,,50594,,N,1,Intermediate,1,,CHEMBL630542,,BAO_0000218
14944,,Biodistribution in normal mice kidney after 120 hr,2113.0,,50594,,N,1,Intermediate,1,,CHEMBL630543,,BAO_0000218
14945,,Biodistribution in normal mice kidney after 24 hr,2113.0,,50594,,N,1,Intermediate,1,,CHEMBL630544,,BAO_0000218
14946,,Biodistribution in normal mice kidney after 4 hr,2113.0,,50594,,N,1,Intermediate,1,,CHEMBL630545,,BAO_0000218
14947,,Biodistribution in normal mice liver after 120 hr,2107.0,,50594,,N,1,Intermediate,1,,CHEMBL630546,,BAO_0000218
14948,,Biodistribution in normal mice liver after 24 hr,2107.0,,50594,,N,1,Intermediate,1,,CHEMBL630547,,BAO_0000218
14949,,Biodistribution in normal mice liver after 4 hr,2107.0,,50594,,N,1,Intermediate,1,,CHEMBL630548,,BAO_0000218
14950,,Biodistribution in normal mice spleen after 120 hr,2106.0,,50594,,N,1,Intermediate,1,,CHEMBL630549,,BAO_0000218
14951,,Biodistribution in normal mice spleen after 24 hr,2106.0,,50594,,N,1,Intermediate,1,,CHEMBL630550,,BAO_0000218
14952,,Biodistribution in normal mice spleen after 4 hr,2106.0,,50594,,N,1,Intermediate,1,,CHEMBL876426,,BAO_0000218
14953,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630551,,BAO_0000218
14954,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630552,,BAO_0000218
14955,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630553,,BAO_0000218
14956,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630554,,BAO_0000218
14957,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630555,,BAO_0000218
14958,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630556,,BAO_0000218
14959,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630557,,BAO_0000218
14960,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630558,,BAO_0000218
14961,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630559,,BAO_0000218
14962,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,,50597,,N,1,Intermediate,1,,CHEMBL630560,,BAO_0000218
14963,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,,50597,,N,1,Intermediate,1,,CHEMBL876427,,BAO_0000218
14964,,The Kel values in female wistar rats.,,,50597,,N,1,Intermediate,1,,CHEMBL630561,,BAO_0000218
14965,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,,22224,,U,0,Autocuration,1,,CHEMBL630562,,BAO_0000019
14966,,Hydrolysis rate constant of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL630563,,BAO_0000019
14967,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,,22229,,U,0,Autocuration,1,,CHEMBL629673,,BAO_0000100
14968,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,,22224,,U,0,Autocuration,1,,CHEMBL629674,,BAO_0000019
14969,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,,22224,,U,0,Autocuration,1,,CHEMBL629675,,BAO_0000019
14970,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,,22224,,U,0,Autocuration,1,,CHEMBL629676,,BAO_0000019
14971,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,,22224,,U,0,Autocuration,1,,CHEMBL629677,,BAO_0000019
14972,,Apparent inactivation rate constant was evaluated,,,22224,,U,0,Autocuration,1,,CHEMBL629678,,BAO_0000019
14973,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,,22224,,U,0,Autocuration,1,,CHEMBL629679,,BAO_0000019
14974,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,,22224,,U,0,Autocuration,1,,CHEMBL629680,,BAO_0000019
14975,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,,22224,,U,0,Autocuration,1,,CHEMBL629681,,BAO_0000019
14976,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,,22224,,U,0,Autocuration,1,,CHEMBL629682,,BAO_0000019
14977,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,,22224,,U,0,Autocuration,1,,CHEMBL629683,,BAO_0000019
14978,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,,22224,,U,0,Autocuration,1,,CHEMBL629684,,BAO_0000019
14979,,Dissociation constant was determined,,,22224,,U,0,Autocuration,1,,CHEMBL629685,,BAO_0000100
14980,,Dissociation constant was determined,,,22224,,U,0,Autocuration,1,,CHEMBL629686,,BAO_0000100
14981,,Dissociation constant at pH 7.4,,,22224,,U,0,Autocuration,1,,CHEMBL872932,,BAO_0000100
14982,,Dissociation constant in presence of 1 mM dithiothreitol,,,22224,,U,0,Autocuration,1,,CHEMBL629687,,BAO_0000100
14983,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,22224,,U,0,Autocuration,1,,CHEMBL872931,,BAO_0000019
14984,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,22224,,U,0,Autocuration,1,,CHEMBL628151,,BAO_0000019
14985,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,22224,,U,0,Autocuration,1,,CHEMBL628152,,BAO_0000019
14986,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,22224,,U,0,Autocuration,1,,CHEMBL628153,,BAO_0000019
14987,,Kinetic constant for aromatization of androstenedione,,,22224,,U,0,Autocuration,1,,CHEMBL628154,,BAO_0000019
14988,,Kinetic constant for aromatization of testosterone,,,22224,,U,0,Autocuration,1,,CHEMBL628155,,BAO_0000019
14989,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,,22224,,U,0,Autocuration,1,,CHEMBL628156,,BAO_0000019
14990,,Local inhibition constant was determined,,,22224,,U,0,Autocuration,1,,CHEMBL628157,,BAO_0000019
14991,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,,50347,,N,1,Intermediate,1,,CHEMBL857533,,BAO_0000218
14992,,Dissociation constant value of the compound,,,22224,,U,0,Autocuration,1,,CHEMBL628158,,BAO_0000100
14993,,In vitro permeability through cornea without epithelium,964.0,,22224,,U,0,Autocuration,1,,CHEMBL628159,,BAO_0000019
14994,,In vitro permeability through intact cornea,964.0,,22224,,U,0,Autocuration,1,,CHEMBL875616,,BAO_0000019
14995,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,964.0,,50592,,N,1,Intermediate,1,,CHEMBL628160,,BAO_0000218
14996,,Rate of enzyme inactivation for the compound was determined,,,22224,,U,0,Autocuration,1,,CHEMBL628161,,BAO_0000019
14997,,In vitro permeability through cornea without epithelium,964.0,,22224,,U,0,Autocuration,1,,CHEMBL628162,,BAO_0000019
14998,,In vitro permeability through intact cornea,964.0,,22224,,U,0,Autocuration,1,,CHEMBL628163,,BAO_0000019
14999,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628164,,BAO_0000019
15000,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628165,,BAO_0000019
15001,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628166,,BAO_0000019
15002,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628167,,BAO_0000019
15003,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628168,,BAO_0000019
15004,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628169,,BAO_0000019
15005,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628170,,BAO_0000019
15006,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628171,,BAO_0000019
15007,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL627434,,BAO_0000019
15008,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL627435,,BAO_0000019
15009,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628110,,BAO_0000019
15010,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628111,,BAO_0000019
15011,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628112,,BAO_0000019
15012,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628260,,BAO_0000019
15013,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,,U,0,Autocuration,1,,CHEMBL628261,,BAO_0000019
15014,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,,50594,,N,1,Intermediate,1,,CHEMBL628262,,BAO_0000218
15015,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,,50587,,N,1,Intermediate,1,,CHEMBL628263,,BAO_0000218
15016,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,,50594,,N,1,Intermediate,1,,CHEMBL628264,,BAO_0000218
15017,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,,50594,,N,1,Intermediate,1,,CHEMBL628265,,BAO_0000218
15018,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,,50594,,N,1,Intermediate,1,,CHEMBL628266,,BAO_0000218
15019,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,,50594,,N,1,Intermediate,1,,CHEMBL628267,,BAO_0000218
15020,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,,50594,,N,1,Intermediate,1,,CHEMBL628268,,BAO_0000218
15021,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,,50594,,N,1,Intermediate,1,,CHEMBL628269,,BAO_0000218
15022,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,,50594,,N,1,Intermediate,1,,CHEMBL628270,,BAO_0000218
15023,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,,50594,,N,1,Intermediate,1,,CHEMBL628271,,BAO_0000218
15024,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,,50594,,N,1,Intermediate,1,,CHEMBL628272,,BAO_0000218
1,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,12052,,H,8,Autocuration,1,,CHEMBL615117,,BAO_0000019
2,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,22226,,U,0,Autocuration,1,,CHEMBL615118,,BAO_0000219
3,,,,,22226,,U,0,Autocuration,1,,CHEMBL615119,,BAO_0000019
4,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,,104729,,H,4,Autocuration,1,,CHEMBL615120,,BAO_0000249
5,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,80001,143B,N,1,Intermediate,1,,CHEMBL615121,163.0,BAO_0000219
6,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,80001,143B,N,1,Intermediate,1,,CHEMBL615122,163.0,BAO_0000219
7,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,,80001,143B,N,1,Intermediate,1,,CHEMBL615123,163.0,BAO_0000219
8,,In vitro cell cytotoxicity was determined against 143B cell line,,,80001,143B,N,1,Expert,1,,CHEMBL615124,163.0,BAO_0000219
9,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,,80001,143B,N,1,Intermediate,1,,CHEMBL615125,163.0,BAO_0000219
10,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,80001,143B,N,1,Intermediate,1,,CHEMBL615126,163.0,BAO_0000219
11,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,80001,143B,N,1,Intermediate,1,,CHEMBL615127,163.0,BAO_0000219
12,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,,80001,143B,N,1,Expert,1,,CHEMBL615128,163.0,BAO_0000219
13,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185,,N,1,Intermediate,1,,CHEMBL857900,,BAO_0000218
14,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185,,N,1,Intermediate,1,,CHEMBL615129,,BAO_0000218
15,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185,,N,1,Intermediate,1,,CHEMBL615130,,BAO_0000218
16,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185,,N,1,Intermediate,1,,CHEMBL615131,,BAO_0000218
17,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,,100122,,D,9,Expert,1,,CHEMBL884521,,BAO_0000357
18,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,12054,,H,8,Autocuration,1,,CHEMBL615132,,BAO_0000357
19,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,12054,,H,8,Autocuration,1,,CHEMBL615133,,BAO_0000019
20,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,12054,,H,8,Autocuration,1,,CHEMBL615134,,BAO_0000357
21,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,12054,,H,8,Autocuration,1,,CHEMBL615135,,BAO_0000357
22,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,12054,,H,8,Autocuration,1,,CHEMBL615136,,BAO_0000357
23,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,12054,,H,8,Autocuration,1,,CHEMBL615137,,BAO_0000357
24,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,12054,,H,8,Autocuration,1,,CHEMBL615138,,BAO_0000357
25,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,22226,,U,0,Autocuration,1,,CHEMBL836324,,BAO_0000219
26,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,,12054,,H,8,Autocuration,1,,CHEMBL615139,,BAO_0000357
27,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,,12054,,H,8,Autocuration,1,,CHEMBL615140,,BAO_0000357
28,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,12426,,H,8,Autocuration,1,,CHEMBL615141,,BAO_0000219
29,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,,12054,,H,8,Autocuration,1,,CHEMBL615142,,BAO_0000357
30,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,,12054,,H,8,Autocuration,1,,CHEMBL615143,,BAO_0000357
31,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,,12054,,H,8,Autocuration,1,,CHEMBL615144,,BAO_0000357
32,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,,12054,,H,8,Autocuration,1,,CHEMBL872867,,BAO_0000357
33,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,,12054,,H,8,Autocuration,1,,CHEMBL615145,,BAO_0000357
34,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,,12054,,H,8,Autocuration,1,,CHEMBL615146,,BAO_0000357
35,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,,12054,,H,8,Autocuration,1,,CHEMBL615147,,BAO_0000357
36,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,,22226,,U,0,Autocuration,1,,CHEMBL615148,,BAO_0000019
37,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,,22226,,U,0,Autocuration,1,,CHEMBL615149,,BAO_0000019
38,,Dissociation constant with dimeric 16S rRNA RNA construct B,,,22226,,U,0,Autocuration,1,,CHEMBL615150,,BAO_0000019
39,,Dissociation constant towards 16S rRNA construct A,,,22222,,M,3,Intermediate,1,,CHEMBL615151,,BAO_0000225
40,,Dissociation constant towards 16S rRNA construct B,,,22222,,M,3,Intermediate,1,,CHEMBL615152,,BAO_0000225
41,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,,100263,,M,3,Expert,1,,CHEMBL615153,,BAO_0000225
42,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,,100263,,M,3,Expert,1,,CHEMBL615154,,BAO_0000225
43,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,13053,,H,8,Autocuration,1,,CHEMBL615155,,BAO_0000019
44,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,13053,,H,8,Autocuration,1,,CHEMBL615156,,BAO_0000019
45,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,20001,,H,8,Autocuration,1,,CHEMBL615157,,BAO_0000019
46,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,20001,,H,8,Autocuration,1,,CHEMBL615158,,BAO_0000019
47,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,12971,,D,9,Expert,1,,CHEMBL615159,,BAO_0000019
48,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,12971,,D,9,Expert,1,,CHEMBL615172,,BAO_0000019
49,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,12971,,D,9,Expert,1,,CHEMBL615173,,BAO_0000019
50,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,12971,,D,9,Expert,1,,CHEMBL615174,,BAO_0000019
51,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,13053,,H,8,Autocuration,1,,CHEMBL884518,,BAO_0000019
52,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,11512,,H,8,Autocuration,1,,CHEMBL615175,,BAO_0000357
53,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,11512,,H,8,Autocuration,1,,CHEMBL615176,,BAO_0000357
54,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,11512,,H,8,Autocuration,1,,CHEMBL615177,,BAO_0000357
55,Membranes,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,,104740,,D,5,Autocuration,1,,CHEMBL615178,,BAO_0000249
56,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,,80002,1A9,N,1,Intermediate,1,,CHEMBL615179,506.0,BAO_0000219
57,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,,104835,Oocytes,D,7,Autocuration,1,,CHEMBL615180,,BAO_0000219
58,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,,104821,Oocytes,D,7,Autocuration,1,,CHEMBL615181,,BAO_0000219
59,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,,104848,Oocytes,D,7,Autocuration,1,,CHEMBL615182,,BAO_0000219
60,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,,80002,1A9,N,1,Expert,1,,CHEMBL615183,506.0,BAO_0000219
61,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,,80002,1A9,N,1,Intermediate,1,,CHEMBL615184,506.0,BAO_0000219
62,,Cytotoxic activity against human ovarian cancer (1A9) cell line,,,80002,1A9,N,1,Intermediate,1,,CHEMBL615185,506.0,BAO_0000219
63,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,,80002,1A9,N,1,Intermediate,1,,CHEMBL615186,506.0,BAO_0000219
64,,Effective dose of compound against replication of 1A9 cell line was evaluated,,,80002,1A9,N,1,Intermediate,1,,CHEMBL615187,506.0,BAO_0000219
65,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,,80002,1A9,N,1,Expert,1,,CHEMBL885343,506.0,BAO_0000219
66,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,,80002,1A9,N,1,Intermediate,1,,CHEMBL615188,506.0,BAO_0000219
67,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,,80002,1A9,N,1,Intermediate,1,,CHEMBL615189,506.0,BAO_0000219
68,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,,80002,1A9,N,1,Intermediate,1,,CHEMBL615190,506.0,BAO_0000219
69,,Inhibitory activity against Taxol resistant 1A9 cell lines,,,80002,1A9,N,1,Intermediate,1,,CHEMBL615191,506.0,BAO_0000219
70,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,,80002,1A9,N,1,Expert,1,,CHEMBL615192,506.0,BAO_0000219
71,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,,80002,1A9,N,1,Expert,1,,CHEMBL827083,506.0,BAO_0000219
72,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,,80002,1A9,N,1,Expert,1,,CHEMBL615193,506.0,BAO_0000219
73,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,,80002,1A9,N,1,Intermediate,1,,CHEMBL615194,506.0,BAO_0000219
74,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,,80002,1A9,N,1,Intermediate,1,,CHEMBL615195,506.0,BAO_0000219
75,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,,80002,1A9,N,1,Intermediate,1,,CHEMBL615196,506.0,BAO_0000219
76,,Inhibitory concentration against Jurkat cells,,,81072,Jurkat,N,1,Intermediate,1,,CHEMBL615197,503.0,BAO_0000219
77,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,22226,,U,0,Intermediate,1,,CHEMBL615198,,BAO_0000019
78,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,,100121,,D,9,Expert,1,,CHEMBL615199,,BAO_0000357
79,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,11231,,H,8,Expert,1,,CHEMBL615200,,BAO_0000357
80,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,11231,,H,8,Expert,1,,CHEMBL615201,,BAO_0000357
81,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,11231,,H,8,Expert,1,,CHEMBL615202,,BAO_0000357
82,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,,11231,,H,8,Autocuration,1,,CHEMBL615203,,BAO_0000251
83,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,,11231,,H,8,Autocuration,1,,CHEMBL615204,,BAO_0000251
84,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,,11231,,H,8,Autocuration,1,,CHEMBL615205,,BAO_0000251
85,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,,11231,,H,8,Autocuration,1,,CHEMBL615206,,BAO_0000251
86,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",2107.0,,12083,,H,8,Autocuration,1,,CHEMBL615207,,BAO_0000251
87,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,,11231,,H,8,Autocuration,1,,CHEMBL827084,,BAO_0000019
88,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,,11231,,H,8,Autocuration,1,,CHEMBL615208,,BAO_0000019
89,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,,11231,,H,8,Autocuration,1,,CHEMBL615209,,BAO_0000019
90,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",2107.0,,12083,,D,9,Autocuration,1,,CHEMBL615210,,BAO_0000251
91,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",2107.0,,12083,,D,9,Autocuration,1,,CHEMBL615211,,BAO_0000251
92,Microsomes,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",2107.0,,12083,,D,9,Autocuration,1,,CHEMBL615212,,BAO_0000251
93,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,11377,,H,8,Expert,1,,CHEMBL615213,,BAO_0000357
94,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,11377,,H,8,Expert,1,,CHEMBL615273,,BAO_0000357
95,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,81020,HepG2,N,1,Expert,1,,CHEMBL615274,726.0,BAO_0000219
96,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,,81020,HepG2,N,1,Intermediate,1,,CHEMBL615275,726.0,BAO_0000219
97,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,,81020,HepG2,N,1,Intermediate,1,,CHEMBL615276,726.0,BAO_0000219
98,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,,81020,HepG2,N,1,Intermediate,1,,CHEMBL615277,726.0,BAO_0000219
99,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,,81020,HepG2,N,1,Intermediate,1,,CHEMBL615326,726.0,BAO_0000219
100,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,50606,,N,1,Expert,1,,CHEMBL883130,,BAO_0000218
101,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,,81020,HepG2,N,1,Intermediate,1,,CHEMBL884519,726.0,BAO_0000219
102,,Concentration required to inhibit 50% of 2.2.15 cell line,,,81020,HepG2,N,1,Intermediate,1,,CHEMBL615327,726.0,BAO_0000219
103,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,,81020,HepG2,N,1,Intermediate,1,,CHEMBL615328,726.0,BAO_0000219
104,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,,50587,2.2.15,N,1,Intermediate,1,,CHEMBL615329,,BAO_0000218
105,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,,50587,2.2.15,N,1,Intermediate,1,,CHEMBL615330,,BAO_0000218
106,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,,50606,2.2.15,N,1,Expert,1,,CHEMBL615331,,BAO_0000218
107,,In vitro anti-HBV activity in 2.2.15 cells,,,50587,2.2.15,N,1,Intermediate,1,,CHEMBL615332,,BAO_0000218
108,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,,50587,2.2.15,N,1,Intermediate,1,,CHEMBL615333,,BAO_0000218
109,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,,50587,2.2.15,N,1,Intermediate,1,,CHEMBL615334,,BAO_0000218
110,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,,50587,2.2.15,N,1,Intermediate,1,,CHEMBL615335,,BAO_0000218
111,,Cytotoxicity in 2.2.15 cells,,,50587,2.2.15,N,1,Intermediate,1,,CHEMBL615336,,BAO_0000218
112,,Cytotoxicity in 2.2.15 cells; Not determined,,,50587,2.2.15,N,1,Intermediate,1,,CHEMBL615337,,BAO_0000218
113,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,,50587,2.2.15,N,1,Intermediate,1,,CHEMBL615338,,BAO_0000218
114,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,,50587,2.2.15,N,1,Intermediate,1,,CHEMBL615339,,BAO_0000218
115,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,,50587,2.2.15,N,1,Intermediate,1,,CHEMBL615340,,BAO_0000218
116,,Antiviral activity against HBV was determined in 2.215 cell line,,,81020,HepG2,N,1,Intermediate,1,,CHEMBL615341,726.0,BAO_0000219
117,Microsomes,Inhibition of 20-HETE synthesis in human renal microsomes,,,22226,,U,0,Autocuration,1,,CHEMBL615342,,BAO_0000251
118,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,22226,,U,0,Autocuration,1,,CHEMBL615343,,BAO_0000019
119,,Inhibitory concentration against 2008 (ovarian) cells,,,80612,2008,N,1,Intermediate,1,,CHEMBL615344,388.0,BAO_0000219
120,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,,80612,2008,N,1,Intermediate,1,,CHEMBL615345,388.0,BAO_0000219
121,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,,80612,2008,N,1,Intermediate,1,,CHEMBL615346,388.0,BAO_0000219
122,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,,80612,2008,N,1,Intermediate,1,,CHEMBL615347,388.0,BAO_0000219
123,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,,80612,2008,N,1,Intermediate,1,,CHEMBL615348,388.0,BAO_0000219
124,,In vitro inhibition of 2008/R ovarian cancer cell line,,,80613,2008/R,N,1,Intermediate,1,,CHEMBL827085,561.0,BAO_0000219
125,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,,80613,2008/R,N,1,Intermediate,1,,CHEMBL615349,561.0,BAO_0000219
126,,In vitro inhibition of 2008/S ovarian cancer cell line,,,80614,2008/S,N,1,Intermediate,1,,CHEMBL615350,389.0,BAO_0000219
127,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,,80614,2008/S,N,1,Intermediate,1,,CHEMBL615351,389.0,BAO_0000219
128,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,,100256,,S,2,Expert,1,,CHEMBL615352,,BAO_0000220
129,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,,100256,,S,2,Intermediate,1,,CHEMBL615353,,BAO_0000220
130,,Inhibition of chymotrypsin-like activity of 20S proteasome,,,100256,,S,2,Expert,1,,CHEMBL615354,,BAO_0000220
131,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,100256,,S,2,Expert,1,,CHEMBL615355,,BAO_0000220
132,,Inhibitory activity against 20S proteosome,,,100256,,S,2,Intermediate,1,,CHEMBL615356,,BAO_0000220
133,,Compound was tested for inhibitory activity against tryptase,,,22226,,U,0,Autocuration,1,,CHEMBL615357,,BAO_0000019
134,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,,81020,HepG2,N,1,Intermediate,1,,CHEMBL615358,726.0,BAO_0000219
135,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,,81020,HepG2,N,1,Intermediate,1,,CHEMBL827086,726.0,BAO_0000219
136,,Compound was tested for the inhibition of Alpha-glucosidase,,,22226,,U,0,Autocuration,1,,CHEMBL615359,,BAO_0000019
137,,Inhibitory concentration against human neutrophil elastase (HNE),,,235,,H,8,Autocuration,1,,CHEMBL615360,,BAO_0000357
138,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,948.0,,22226,,U,0,Autocuration,1,,CHEMBL615361,,BAO_0000218
139,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640,,H,8,Autocuration,1,,CHEMBL615362,,BAO_0000019
140,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640,,H,8,Expert,1,,CHEMBL615363,,BAO_0000019
141,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640,,H,8,Autocuration,1,,CHEMBL615364,,BAO_0000357
142,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640,,H,8,Expert,1,,CHEMBL615365,,BAO_0000019
143,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,,80360,P338,N,1,Intermediate,1,,CHEMBL615366,524.0,BAO_0000219
144,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,,80360,P338,N,1,Intermediate,1,,CHEMBL615367,524.0,BAO_0000219
145,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,,80384,PBL,N,1,Intermediate,1,,CHEMBL615368,554.0,BAO_0000219
146,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,,22226,,U,0,Autocuration,1,,CHEMBL615369,,BAO_0000019
147,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,,22226,,U,0,Autocuration,1,,CHEMBL615370,,BAO_0000019
148,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,191,,H,8,Autocuration,1,,CHEMBL615673,,BAO_0000357
149,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,,22226,,U,0,Autocuration,1,,CHEMBL615674,,BAO_0000019
150,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,,22226,,U,0,Autocuration,1,,CHEMBL615675,,BAO_0000019
151,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,,22226,CCRF-CEM,U,0,Autocuration,1,,CHEMBL615676,635.0,BAO_0000219
152,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,,22226,CCRF-CEM,U,0,Autocuration,1,,CHEMBL615677,635.0,BAO_0000219
153,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,,22226,CCRF-CEM,U,0,Autocuration,1,,CHEMBL615678,635.0,BAO_0000219
154,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,,22226,CCRF-CEM,U,0,Autocuration,1,,CHEMBL615679,635.0,BAO_0000219
155,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,,22226,,U,0,Autocuration,1,,CHEMBL615680,,BAO_0000019
156,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,,22226,,U,0,Autocuration,1,,CHEMBL615681,,BAO_0000019
157,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,104290,,H,6,Autocuration,1,,CHEMBL857972,,BAO_0000249
158,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,,50264,,N,1,Intermediate,1,,CHEMBL857899,,BAO_0000218
159,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,,50527,,N,1,Intermediate,1,,CHEMBL615371,,BAO_0000218
160,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,,50527,HEL,N,1,Expert,1,,CHEMBL615372,468.0,BAO_0000218
161,,Antiviral activity against 07/1 strain of VZV; ND: No data,,,50527,,N,1,Intermediate,1,,CHEMBL615373,,BAO_0000218
162,,Antiviral activity against 07/1 strain of VZV; ND=No data,,,50527,,N,1,Intermediate,1,,CHEMBL615374,,BAO_0000218
163,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,,50145,,N,1,Intermediate,1,,CHEMBL615375,,BAO_0000218
164,,Ratio of Ki at A2 to Ki at A1 receptors,,,22226,,U,0,Autocuration,1,,CHEMBL615376,,BAO_0000019
165,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,,11143,,H,8,Expert,1,,CHEMBL615377,,BAO_0000249
166,,"Inhibition of 1,3-beta-glucan synthase",,,18077,,H,8,Expert,1,,CHEMBL615378,,BAO_0000357
167,,Inhibition of growth of 1-87 human tumor cell line,,,80609,1-87 tumor cell line,N,1,Intermediate,1,,CHEMBL615379,832.0,BAO_0000219
168,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,,12166,,D,9,Expert,1,,CHEMBL615380,,BAO_0000219
169,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,,100171,,D,9,Autocuration,1,,CHEMBL615381,,BAO_0000357
170,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,,100171,,D,9,Autocuration,1,,CHEMBL615382,,BAO_0000357
171,,% inhibition against soybean 1-lipoxygenase (SLO),,,100171,,D,9,Autocuration,1,,CHEMBL615383,,BAO_0000357
172,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,,100171,,D,9,Autocuration,1,,CHEMBL615384,,BAO_0000357
173,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,,100171,,D,9,Autocuration,1,,CHEMBL615385,,BAO_0000357
174,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,,100171,,D,9,Autocuration,1,,CHEMBL615386,,BAO_0000357
175,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,,100171,,D,9,Autocuration,1,,CHEMBL615387,,BAO_0000357
176,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,,100171,,D,9,Autocuration,1,,CHEMBL615388,,BAO_0000357
177,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,,100171,,D,9,Autocuration,1,,CHEMBL615214,,BAO_0000357
178,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,,100171,,D,9,Autocuration,1,,CHEMBL827087,,BAO_0000357
179,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,,100171,,D,9,Autocuration,1,,CHEMBL615215,,BAO_0000357
180,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,,100171,,D,9,Autocuration,1,,CHEMBL615216,,BAO_0000357
181,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,,100171,,D,9,Autocuration,1,,CHEMBL615217,,BAO_0000357
182,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,,100171,,D,9,Autocuration,1,,CHEMBL615218,,BAO_0000357
183,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,,100171,,D,9,Autocuration,1,,CHEMBL615219,,BAO_0000357
184,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,,22226,,U,0,Autocuration,1,,CHEMBL615220,,BAO_0000019
185,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,,80049,C3H 10T1/2,N,1,Intermediate,1,,CHEMBL615221,294.0,BAO_0000219
186,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,22226,,U,0,Intermediate,1,,CHEMBL615222,,BAO_0000019
187,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,11489,,H,8,Autocuration,1,,CHEMBL615223,,BAO_0000357
188,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,11862,,H,8,Autocuration,1,,CHEMBL615224,,BAO_0000357
189,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,11862,,H,8,Autocuration,1,,CHEMBL615225,,BAO_0000357
190,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,11489,,H,8,Autocuration,1,,CHEMBL615226,,BAO_0000357
191,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,11862,,H,8,Autocuration,1,,CHEMBL615227,,BAO_0000357
192,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,,12347,,D,9,Expert,1,,CHEMBL615228,,BAO_0000019
193,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,,100120,,D,9,Expert,1,,CHEMBL615229,,BAO_0000357
194,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,2369.0,,100120,,D,9,Expert,1,,CHEMBL615230,,BAO_0000357
195,,Inhibition of rat adrenal 11-beta-hydroxylase,,,100120,,D,9,Expert,1,,CHEMBL615231,,BAO_0000357
196,,Inhibition of rat adrenal 11-beta-hydroxylase,,,100120,,D,9,Expert,1,,CHEMBL884520,,BAO_0000357
197,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,,100120,,D,9,Expert,1,,CHEMBL615232,,BAO_0000357
198,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,10328,,H,8,Autocuration,1,,CHEMBL615233,,BAO_0000019
199,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,11490,,H,8,Autocuration,1,,CHEMBL827088,,BAO_0000357
200,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,11490,,H,8,Autocuration,1,,CHEMBL615234,,BAO_0000357
201,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,11134,,H,8,Autocuration,1,,CHEMBL615235,,BAO_0000019
202,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,12052,,H,8,Autocuration,1,,CHEMBL615236,,BAO_0000019
203,,Compound was tested in vitro for inhibition of 12-LO human platelet,,,11134,,H,8,Autocuration,1,,CHEMBL615237,,BAO_0000019
204,,Inhibitory concentration against human platelet 12-lipoxygenase,,,11134,,H,8,Autocuration,1,,CHEMBL615238,,BAO_0000019
205,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,11134,,H,8,Autocuration,1,,CHEMBL615239,,BAO_0000019
206,,Inhibitory concentration against human platelet 12-lipoxygenase,,,11134,,D,9,Autocuration,1,,CHEMBL615240,,BAO_0000019
207,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,11835,,H,8,Expert,1,,CHEMBL615241,,BAO_0000019
208,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,11601,,H,8,Expert,1,,CHEMBL615242,,BAO_0000357
209,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,11134,,H,8,Autocuration,1,,CHEMBL615243,,BAO_0000019
210,,Inhibitory activity against human platelet 12-lipoxygenase,,,11134,,H,8,Autocuration,1,,CHEMBL615244,,BAO_0000019
211,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,11134,,H,8,Autocuration,1,,CHEMBL615245,,BAO_0000019
212,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,11134,,H,8,Autocuration,1,,CHEMBL615246,,BAO_0000019
213,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,11134,,H,8,Autocuration,1,,CHEMBL615247,,BAO_0000019
214,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,11134,,H,8,Autocuration,1,,CHEMBL615248,,BAO_0000019
215,,Inhibitory activity towards porcine 12-lipoxygenase,,,11601,,H,8,Autocuration,1,,CHEMBL615249,,BAO_0000357
216,,Tested for inhibition against porcine 12-LO,,,11601,,H,8,Autocuration,1,,CHEMBL615250,,BAO_0000357
217,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,12052,,H,8,Autocuration,1,,CHEMBL615251,,BAO_0000019
218,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,12052,,H,8,Autocuration,1,,CHEMBL615252,,BAO_0000019
219,,In vitro inhibition of rat platelet 12-lipoxygenase,,,12052,,H,8,Expert,1,,CHEMBL828340,,BAO_0000019
220,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,12052,,H,8,Autocuration,1,,CHEMBL615253,,BAO_0000019
221,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,12052,,H,8,Autocuration,1,,CHEMBL615254,,BAO_0000019
222,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,12052,,H,8,Autocuration,1,,CHEMBL615255,,BAO_0000019
223,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,12052,,H,8,Autocuration,1,,CHEMBL615256,,BAO_0000019
224,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,12052,,H,8,Autocuration,1,,CHEMBL615257,,BAO_0000019
225,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,12052,,H,8,Autocuration,1,,CHEMBL615258,,BAO_0000019
226,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,,80007,41M,N,1,Intermediate,1,,CHEMBL615259,621.0,BAO_0000219
227,,In vitro antitumor activity against 41M cell line.,,,80007,41M,N,1,Expert,1,,CHEMBL615260,621.0,BAO_0000219
228,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,,80007,41M,N,1,Intermediate,1,,CHEMBL615261,621.0,BAO_0000219
229,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,,80007,41M,N,1,Intermediate,1,,CHEMBL615262,621.0,BAO_0000219
230,,In vitro antitumor activity against 41McisR cell line.,,,80007,41M,N,1,Expert,1,,CHEMBL615263,621.0,BAO_0000219
231,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,,80007,41M,N,1,Expert,1,,CHEMBL838393,621.0,BAO_0000219
232,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,,80007,41M,N,1,Intermediate,1,,CHEMBL615264,621.0,BAO_0000219
233,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,,84,,D,9,Expert,1,,CHEMBL615265,,BAO_0000357
234,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,68,,D,9,Expert,1,,CHEMBL615266,,BAO_0000357
235,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,68,,H,8,Expert,1,,CHEMBL615267,,BAO_0000357
236,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,10201,,H,8,Expert,1,,CHEMBL615268,,BAO_0000357
237,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,10201,,H,8,Expert,1,,CHEMBL615269,,BAO_0000357
238,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,10201,,H,8,Expert,1,,CHEMBL615270,,BAO_0000357
239,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,12220,,H,8,Autocuration,1,,CHEMBL615271,,BAO_0000357
240,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,11303,,H,8,Autocuration,1,,CHEMBL615272,,BAO_0000357
241,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,11303,,H,8,Autocuration,1,,CHEMBL615103,,BAO_0000357
242,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,,11303,,H,8,Autocuration,1,,CHEMBL615104,,BAO_0000357
243,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,12220,,H,8,Autocuration,1,,CHEMBL615105,,BAO_0000357
244,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,12220,,H,8,Autocuration,1,,CHEMBL872866,,BAO_0000357
245,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,11303,,H,8,Autocuration,1,,CHEMBL615106,,BAO_0000357
246,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,,11303,,H,8,Autocuration,1,,CHEMBL615107,,BAO_0000019
247,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,,11303,,H,8,Autocuration,1,,CHEMBL615108,,BAO_0000357
248,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,,11303,,H,8,Autocuration,1,,CHEMBL615109,,BAO_0000357
249,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,11303,,H,8,Autocuration,1,,CHEMBL615110,,BAO_0000357
250,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,11303,,H,8,Autocuration,1,,CHEMBL840105,,BAO_0000019
251,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,,11303,,H,8,Autocuration,1,,CHEMBL615111,,BAO_0000019
252,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,,11303,,H,8,Autocuration,1,,CHEMBL615112,,BAO_0000019
253,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,,11303,,H,8,Autocuration,1,,CHEMBL615113,,BAO_0000019
254,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,,11303,,H,8,Autocuration,1,,CHEMBL615114,,BAO_0000019
255,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,11303,,H,8,Autocuration,1,,CHEMBL615115,,BAO_0000357
256,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,11303,,H,8,Autocuration,1,,CHEMBL615116,,BAO_0000019
257,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,11303,,H,8,Autocuration,1,,CHEMBL615698,,BAO_0000357
258,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,,22226,,U,0,Autocuration,1,,CHEMBL615699,,BAO_0000019
259,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,,22226,,U,0,Autocuration,1,,CHEMBL615700,,BAO_0000019
260,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,,100249,,H,8,Expert,1,,CHEMBL615701,,BAO_0000357
261,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,22226,,U,0,Autocuration,1,,CHEMBL615702,,BAO_0000019
262,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,22226,,U,0,Autocuration,1,,CHEMBL615703,,BAO_0000019
263,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,,22226,,U,0,Autocuration,1,,CHEMBL615704,,BAO_0000019
264,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,104698,,H,6,Autocuration,1,,CHEMBL615705,,BAO_0000019
265,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,104698,,H,6,Autocuration,1,,CHEMBL615706,,BAO_0000019
266,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL615707,,BAO_0000221
267,,Stimulatory activity of intragastric pressure was tested in the rat,,,10623,,H,8,Expert,1,,CHEMBL615708,,BAO_0000019
268,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,121,,H,8,Autocuration,1,,CHEMBL615709,,BAO_0000357
269,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,,22226,,U,0,Autocuration,1,,CHEMBL615710,,BAO_0000218
270,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,12688,,H,8,Autocuration,1,,CHEMBL615711,,BAO_0000019
271,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,,121,,D,9,Expert,1,,CHEMBL615712,,BAO_0000357
272,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,,121,,D,9,Expert,1,,CHEMBL836325,,BAO_0000357
273,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,12198,,H,8,Autocuration,1,,CHEMBL615713,,BAO_0000019
274,,Inhibition constant of high-affinity 5-HT uptake,,,12198,,H,8,Autocuration,1,,CHEMBL615714,,BAO_0000357
275,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,12198,,H,8,Autocuration,1,,CHEMBL615715,,BAO_0000019
276,,Maximum rate was determined for high affinity transport of 5-HT,,,12198,,H,8,Autocuration,1,,CHEMBL615716,,BAO_0000019
277,,Compound was tested for agonistic activity against 5-HT uptake,,,104714,,H,4,Autocuration,1,,CHEMBL615717,,BAO_0000019
278,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,10577,,H,8,Expert,1,,CHEMBL881818,,BAO_0000019
279,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,,105,,H,8,Expert,1,,CHEMBL884540,,BAO_0000357
280,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,104744,,D,5,Autocuration,1,,CHEMBL615718,,BAO_0000224
281,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,104744,,H,4,Autocuration,1,,CHEMBL615719,,BAO_0000224
282,Membranes,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,104744,,H,4,Autocuration,1,,CHEMBL615720,,BAO_0000249
283,Membranes,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,104744,,H,4,Autocuration,1,,CHEMBL615721,,BAO_0000249
284,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744,,H,4,Autocuration,1,,CHEMBL615722,,BAO_0000019
285,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,51,,H,8,Autocuration,1,,CHEMBL615723,,BAO_0000019
286,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615724,,BAO_0000221
287,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615725,,BAO_0000221
288,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615726,,BAO_0000221
289,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,,10576,,H,8,Autocuration,1,,CHEMBL615727,,BAO_0000218
290,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,,105570,,D,9,Intermediate,1,,CHEMBL615728,,BAO_0000019
291,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,279,CHO,H,8,Autocuration,1,,CHEMBL857971,449.0,BAO_0000219
292,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL615729,,BAO_0000357
293,,Efficacy against 5-hydroxytryptamine 2A receptor,,,12687,,D,9,Expert,1,,CHEMBL615730,,BAO_0000019
294,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,12687,,H,8,Expert,1,,CHEMBL615731,,BAO_0000019
295,,Relative potency towards 5-HT2A receptor of rat tail artery,,,12687,,H,8,Expert,1,,CHEMBL615732,,BAO_0000019
296,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,12687,,H,8,Expert,1,,CHEMBL615733,,BAO_0000019
297,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,12687,,H,8,Expert,1,,CHEMBL615734,,BAO_0000019
298,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,12687,,H,8,Autocuration,1,,CHEMBL615735,,BAO_0000019
299,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,12687,,H,8,Expert,1,,CHEMBL615736,,BAO_0000019
300,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL615737,,BAO_0000221
301,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),2116.0,,20033,,D,9,Intermediate,1,,CHEMBL615738,,BAO_0000221
302,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL615739,,BAO_0000221
303,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,10623,,H,8,Autocuration,1,,CHEMBL615278,,BAO_0000357
304,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,10623,,D,9,Expert,1,,CHEMBL615279,,BAO_0000019
305,,Binding affinity against 5-hydroxytryptamine 4 receptor,,,168,,H,8,Expert,1,,CHEMBL615280,,BAO_0000357
306,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,,22226,,U,0,Autocuration,1,,CHEMBL615281,,BAO_0000019
307,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,,22226,,U,0,Autocuration,1,,CHEMBL615282,,BAO_0000019
308,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,22226,,U,0,Autocuration,1,,CHEMBL615283,,BAO_0000019
309,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,,80156,HL-60,N,1,Autocuration,1,,CHEMBL615284,649.0,BAO_0000219
310,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,,22226,,U,0,Autocuration,1,,CHEMBL615285,,BAO_0000019
311,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,22226,,U,0,Autocuration,1,,CHEMBL615286,,BAO_0000019
312,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,,104703,Oocytes,D,7,Autocuration,1,,CHEMBL615287,,BAO_0000219
313,,Chymotryptic inhibitory activity against 26S proteasome,,,100256,,S,2,Intermediate,1,,CHEMBL615288,,BAO_0000220
314,,Inhibitory activity against 26S proteasome degradation of IkB,,,100256,,S,2,Intermediate,1,,CHEMBL615289,,BAO_0000220
315,,In vitro inhibition of 2780/DOX ovarian cancer cell line,,,81034,A2780,N,1,Intermediate,1,,CHEMBL615290,478.0,BAO_0000219
316,,In vitro inhibition of 2780/S ovarian cancer cell line,,,81034,A2780,N,1,Intermediate,1,,CHEMBL884522,478.0,BAO_0000219
317,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,,22226,,U,0,Autocuration,1,,CHEMBL615291,,BAO_0000019
318,,Association constant for binding to AATT 28-mer AATT hairpin,,,22222,,M,3,Intermediate,1,,CHEMBL615292,,BAO_0000225
319,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,22222,,M,3,Intermediate,1,,CHEMBL615293,,BAO_0000225
320,,Reaction Rate Parameter for 28-mer AATT hairpin,,,22222,,M,3,Intermediate,1,,CHEMBL615294,,BAO_0000225
321,,Reaction Rate Parameter for 28-mer AATT hairpin,,,22222,,M,3,Intermediate,1,,CHEMBL615295,,BAO_0000225
322,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,,22226,,U,0,Autocuration,1,,CHEMBL825021,,BAO_0000019
323,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,,22226,,U,0,Autocuration,1,,CHEMBL615296,,BAO_0000019
324,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,,22226,,U,0,Autocuration,1,,CHEMBL615297,,BAO_0000019
325,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,,22226,,U,0,Autocuration,1,,CHEMBL615298,,BAO_0000019
326,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,,22226,,U,0,Autocuration,1,,CHEMBL615299,,BAO_0000019
327,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,,22226,,U,0,Autocuration,1,,CHEMBL615300,,BAO_0000019
328,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,241,,H,8,Autocuration,1,,CHEMBL615301,,BAO_0000357
329,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,,241,,D,9,Expert,1,,CHEMBL615302,,BAO_0000357
330,,Selectivity ratio of ID50 in liver and heart,,,22226,,U,0,Autocuration,1,,CHEMBL615303,,BAO_0000019
331,,"Selectivity, ratio of relative ID50 in liver and heart",,,12132,,H,8,Autocuration,1,,CHEMBL615304,,BAO_0000019
332,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,12132,,H,8,Autocuration,1,,CHEMBL615305,,BAO_0000019
333,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132,,H,8,Autocuration,1,,CHEMBL615306,,BAO_0000218
334,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132,,H,8,Autocuration,1,,CHEMBL615307,,BAO_0000218
335,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132,,H,8,Autocuration,1,,CHEMBL615308,,BAO_0000218
336,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132,,H,8,Autocuration,1,,CHEMBL615309,,BAO_0000218
337,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,22226,,U,0,Autocuration,1,,CHEMBL615310,,BAO_0000019
338,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,12132,,H,8,Autocuration,1,,CHEMBL615311,,BAO_0000019
339,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,,22226,,U,0,Autocuration,1,,CHEMBL615312,,BAO_0000019
340,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,12132,,H,8,Autocuration,1,,CHEMBL615313,,BAO_0000019
341,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,12132,,H,8,Autocuration,1,,CHEMBL615314,,BAO_0000019
342,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,12132,,H,8,Autocuration,1,,CHEMBL615315,,BAO_0000019
343,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,,22226,,U,0,Autocuration,1,,CHEMBL615316,,BAO_0000218
344,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,,12132,,H,8,Autocuration,1,,CHEMBL615317,,BAO_0000218
345,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132,,H,8,Autocuration,1,,CHEMBL615318,,BAO_0000218
346,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,,22226,,U,0,Autocuration,1,,CHEMBL615319,,BAO_0000218
347,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,12132,,H,8,Autocuration,1,,CHEMBL615320,,BAO_0000019
348,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,12132,,H,8,Autocuration,1,,CHEMBL615321,,BAO_0000019
349,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,,22226,,U,0,Autocuration,1,,CHEMBL615322,,BAO_0000019
350,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,19690,,H,8,Autocuration,1,,CHEMBL615323,,BAO_0000357
351,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,19690,,H,8,Autocuration,1,,CHEMBL615407,,BAO_0000357
352,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,19690,,H,8,Autocuration,1,,CHEMBL857267,,BAO_0000357
353,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,19690,,H,8,Autocuration,1,,CHEMBL615408,,BAO_0000357
354,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,19690,,H,8,Autocuration,1,,CHEMBL615409,,BAO_0000357
355,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,19690,,H,8,Autocuration,1,,CHEMBL615410,,BAO_0000357
356,,Inhibition constant against 3-dehydroquinate synthase,,,19690,,H,8,Autocuration,1,,CHEMBL615411,,BAO_0000357
357,,Association rate constant against 3-dehydroquinate synthase,,,19690,,H,8,Autocuration,1,,CHEMBL615412,,BAO_0000357
358,,Rate constant against 3-dehydroquinate synthase,,,19690,,H,8,Autocuration,1,,CHEMBL615413,,BAO_0000357
359,,Inhibitory activity against fuc-TVII,,,22226,,U,0,Autocuration,1,,CHEMBL615414,,BAO_0000019
360,Microsomes,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,,12236,,D,9,Autocuration,1,,CHEMBL615415,,BAO_0000251
361,Microsomes,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,,12236,,D,9,Autocuration,1,,CHEMBL615416,,BAO_0000251
362,Microsomes,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,,12236,,D,9,Autocuration,1,,CHEMBL615417,,BAO_0000251
363,Microsomes,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,,12236,,D,9,Autocuration,1,,CHEMBL615418,,BAO_0000251
364,Microsomes,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,,12236,,D,9,Autocuration,1,,CHEMBL615419,,BAO_0000251
365,Microsomes,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,2107.0,,12236,,D,9,Autocuration,1,,CHEMBL615420,,BAO_0000251
366,Microsomes,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,2107.0,,12236,,D,9,Autocuration,1,,CHEMBL615421,,BAO_0000251
367,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,2107.0,,12236,,D,9,Autocuration,1,,CHEMBL615422,,BAO_0000251
368,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,2107.0,,12236,,D,9,Autocuration,1,,CHEMBL615423,,BAO_0000251
369,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,2107.0,,12236,,D,9,Autocuration,1,,CHEMBL872868,,BAO_0000251
370,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,2107.0,,12236,,D,9,Autocuration,1,,CHEMBL615424,,BAO_0000251
371,,Inhibitory activity against 3-phosphoglycerate kinase.,,,104832,,H,4,Autocuration,1,,CHEMBL825022,,BAO_0000224
372,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,104832,,H,4,Autocuration,1,,CHEMBL615425,,BAO_0000224
373,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,104832,,H,4,Autocuration,1,,CHEMBL615426,,BAO_0000224
374,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,,10612,,D,9,Expert,1,,CHEMBL615427,,BAO_0000357
375,,Cytotoxicity on 3677 melanoma cells,,,80616,3677 melanoma cell line,N,1,Intermediate,1,,CHEMBL615428,844.0,BAO_0000219
376,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,,80616,3677 melanoma cell line,N,1,Intermediate,1,,CHEMBL615429,844.0,BAO_0000219
377,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,,80617,MC-38,N,1,Intermediate,1,,CHEMBL615430,700.0,BAO_0000219
378,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,,22226,,U,0,Intermediate,1,,CHEMBL615431,,BAO_0000019
379,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,,22226,B16,U,0,Autocuration,1,,CHEMBL615432,798.0,BAO_0000218
380,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,,22226,B16,U,0,Autocuration,1,,CHEMBL615433,798.0,BAO_0000218
381,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,,12464,,D,9,Expert,1,,CHEMBL615434,,BAO_0000019
382,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,,50085,,N,1,Intermediate,1,,CHEMBL615435,,BAO_0000218
383,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,,50679,,N,1,Intermediate,1,,CHEMBL615436,,BAO_0000218
384,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,,50679,,N,1,Intermediate,1,,CHEMBL615437,,BAO_0000218
385,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,12464,,D,9,Expert,1,,CHEMBL615438,,BAO_0000019
386,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,12464,,D,9,Expert,1,,CHEMBL615439,,BAO_0000019
387,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,12464,,D,9,Expert,1,,CHEMBL615440,,BAO_0000019
388,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,,12464,,D,9,Expert,1,,CHEMBL615441,,BAO_0000019
389,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,,50665,,N,1,Intermediate,1,,CHEMBL615641,,BAO_0000218
390,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,,50665,,N,1,Intermediate,1,,CHEMBL872065,,BAO_0000218
391,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,,50665,,N,1,Intermediate,1,,CHEMBL825023,,BAO_0000218
392,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,,50665,,N,1,Intermediate,1,,CHEMBL615642,,BAO_0000218
393,,Inhibition of human rhinovirus 3C protease,,,12464,,H,8,Expert,1,,CHEMBL615643,,BAO_0000357
394,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,,22226,,U,0,Autocuration,1,,CHEMBL615644,,BAO_0000019
395,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,,80619,3EM 37,N,1,Intermediate,1,,CHEMBL615645,833.0,BAO_0000218
396,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,,80619,3EM 37,N,1,Intermediate,1,,CHEMBL615646,833.0,BAO_0000218
397,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,,80619,3EM 37,N,1,Intermediate,1,,CHEMBL615647,833.0,BAO_0000218
398,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,,80619,3EM 37,N,1,Intermediate,1,,CHEMBL615648,833.0,BAO_0000218
399,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,,80619,3EM 37,N,1,Intermediate,1,,CHEMBL615649,833.0,BAO_0000218
400,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,,80619,3EM 37,N,1,Intermediate,1,,CHEMBL615650,833.0,BAO_0000218
401,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615651,847.0,BAO_0000218
402,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615652,847.0,BAO_0000218
403,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,,80620,3LL cell line,N,1,Expert,1,,CHEMBL615653,847.0,BAO_0000218
404,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615654,847.0,BAO_0000219
405,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615655,847.0,BAO_0000219
406,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL825024,847.0,BAO_0000219
407,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615656,847.0,BAO_0000219
408,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615657,847.0,BAO_0000219
409,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615658,847.0,BAO_0000219
410,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615659,847.0,BAO_0000219
411,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615660,847.0,BAO_0000219
412,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615661,847.0,BAO_0000219
413,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615662,847.0,BAO_0000219
414,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615663,847.0,BAO_0000219
415,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615664,847.0,BAO_0000219
416,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615665,847.0,BAO_0000219
417,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615666,847.0,BAO_0000219
418,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615667,847.0,BAO_0000219
419,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615668,847.0,BAO_0000219
420,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615669,847.0,BAO_0000219
421,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615670,847.0,BAO_0000219
422,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL836739,847.0,BAO_0000219
423,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615671,847.0,BAO_0000219
424,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615672,847.0,BAO_0000219
425,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615791,847.0,BAO_0000219
426,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615792,847.0,BAO_0000219
427,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615793,847.0,BAO_0000219
428,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615794,847.0,BAO_0000219
429,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,,80620,3LL cell line,N,1,Intermediate,1,,CHEMBL615795,847.0,BAO_0000219
430,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,,80621,3LLD122,N,1,Intermediate,1,,CHEMBL615590,971.0,BAO_0000219
431,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,22226,,U,0,Autocuration,1,,CHEMBL615591,,BAO_0000218
432,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,22226,,U,0,Autocuration,1,,CHEMBL615592,,BAO_0000218
433,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,22226,,U,0,Autocuration,1,,CHEMBL615593,,BAO_0000218
434,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,22226,,U,0,Autocuration,1,,CHEMBL615594,,BAO_0000218
435,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615595,723.0,BAO_0000219
436,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615596,723.0,BAO_0000219
437,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,,11169,NIH3T3,H,8,Expert,1,,CHEMBL615597,723.0,BAO_0000219
438,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615598,723.0,BAO_0000219
439,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615599,723.0,BAO_0000219
440,,Effective dose against murine 3T3 fibroblasts cells,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615600,723.0,BAO_0000219
441,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615601,723.0,BAO_0000219
442,,Cytotoxic effect on 3T3 cells,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615602,723.0,BAO_0000219
443,,Cytotoxic effect on 3T3 cells,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615603,723.0,BAO_0000219
444,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615604,723.0,BAO_0000219
445,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615605,723.0,BAO_0000219
446,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615606,723.0,BAO_0000219
447,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL884526,723.0,BAO_0000219
448,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615607,723.0,BAO_0000219
449,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615608,723.0,BAO_0000219
450,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615609,723.0,BAO_0000219
451,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615682,723.0,BAO_0000219
452,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615683,723.0,BAO_0000219
453,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615684,723.0,BAO_0000218
454,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,,104860,,D,7,Autocuration,1,,CHEMBL615685,,BAO_0000219
455,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615686,723.0,BAO_0000219
456,,Inhibitory activity against 3T3 cell line,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615687,723.0,BAO_0000219
457,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL884523,723.0,BAO_0000219
458,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,11169,,H,8,Expert,1,,CHEMBL615688,,BAO_0000019
459,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615689,723.0,BAO_0000219
460,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615690,723.0,BAO_0000219
461,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,11169,,H,8,Expert,1,,CHEMBL615691,,BAO_0000019
462,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,11169,,H,8,Expert,1,,CHEMBL615692,,BAO_0000019
463,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615693,723.0,BAO_0000219
464,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615324,723.0,BAO_0000219
465,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,,9,NIH3T3,D,9,Expert,1,,CHEMBL615325,723.0,BAO_0000219
466,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,,9,NIH3T3,D,9,Expert,1,,CHEMBL615490,723.0,BAO_0000219
467,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,,188,NIH3T3,D,9,Expert,1,,CHEMBL615491,723.0,BAO_0000219
468,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,,188,NIH3T3,D,9,Expert,1,,CHEMBL615492,723.0,BAO_0000219
469,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615493,723.0,BAO_0000219
470,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615494,723.0,BAO_0000219
471,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615495,723.0,BAO_0000219
472,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615496,723.0,BAO_0000219
473,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615497,723.0,BAO_0000219
474,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615498,723.0,BAO_0000219
475,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615499,723.0,BAO_0000219
476,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL835522,723.0,BAO_0000219
477,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615500,723.0,BAO_0000219
478,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615501,723.0,BAO_0000219
479,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615502,723.0,BAO_0000219
480,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615503,723.0,BAO_0000219
481,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615504,723.0,BAO_0000219
482,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615505,723.0,BAO_0000219
483,,Inhibition of swiss 3T3 mouse fibroblast proliferation,,,80951,NIH3T3,N,1,Expert,1,,CHEMBL615506,723.0,BAO_0000219
484,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,,80951,NIH3T3,N,1,Intermediate,1,,CHEMBL615507,723.0,BAO_0000219
485,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615508,620.0,BAO_0000218
486,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615509,620.0,BAO_0000219
487,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615510,620.0,BAO_0000219
488,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615511,620.0,BAO_0000219
489,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615512,620.0,BAO_0000219
490,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615513,620.0,BAO_0000218
491,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615514,620.0,BAO_0000218
492,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615515,620.0,BAO_0000219
493,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615516,620.0,BAO_0000219
494,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615517,620.0,BAO_0000219
495,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615518,620.0,BAO_0000219
496,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615519,620.0,BAO_0000219
497,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615520,620.0,BAO_0000218
498,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615521,620.0,BAO_0000218
499,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615522,620.0,BAO_0000218
500,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615523,620.0,BAO_0000218
501,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615524,620.0,BAO_0000218
502,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615525,620.0,BAO_0000218
503,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615526,620.0,BAO_0000218
504,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615527,620.0,BAO_0000218
505,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615528,620.0,BAO_0000218
506,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615529,620.0,BAO_0000218
507,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615530,620.0,BAO_0000218
508,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615531,620.0,BAO_0000218
509,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615532,620.0,BAO_0000219
510,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615533,620.0,BAO_0000219
511,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615534,620.0,BAO_0000219
512,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615535,620.0,BAO_0000218
513,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615536,620.0,BAO_0000218
514,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615537,620.0,BAO_0000218
515,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615538,620.0,BAO_0000218
516,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL836166,620.0,BAO_0000218
517,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,,11214,3T3-L1,H,8,Expert,1,,CHEMBL615539,620.0,BAO_0000219
518,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615540,620.0,BAO_0000219
519,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,,11214,3T3-L1,H,8,Expert,1,,CHEMBL615541,620.0,BAO_0000219
520,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615542,620.0,BAO_0000219
521,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,,80006,3T3-L1,N,1,Intermediate,1,,CHEMBL615543,620.0,BAO_0000219
522,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615544,620.0,BAO_0000219
523,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615545,620.0,BAO_0000219
524,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615546,620.0,BAO_0000219
525,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615547,620.0,BAO_0000219
526,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615548,620.0,BAO_0000219
527,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615549,620.0,BAO_0000219
528,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,,80006,3T3-L1,N,1,Expert,1,,CHEMBL615550,620.0,BAO_0000219
529,,Inhibitory activity against rat fibroblast (3Y1) cell line,,,80622,3Y1 cell line,N,1,Intermediate,1,,CHEMBL615551,1118.0,BAO_0000219
530,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,,80622,3Y1 cell line,N,1,Expert,1,,CHEMBL615552,1118.0,BAO_0000219
531,,Cytotoxicity in 3Y1 cells.,,,80622,3Y1 cell line,N,1,Expert,1,,CHEMBL615553,1118.0,BAO_0000219
532,,Cytostatic effect in 3Y1 cells.,,,80622,3Y1 cell line,N,1,Expert,1,,CHEMBL615554,1118.0,BAO_0000219
533,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,,80622,3Y1 cell line,N,1,Intermediate,1,,CHEMBL615555,1118.0,BAO_0000219
534,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,,80622,3Y1 cell line,N,1,Expert,1,,CHEMBL615556,1118.0,BAO_0000219
535,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,22226,,U,0,Autocuration,1,,CHEMBL615557,,BAO_0000019
536,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,22226,,U,0,Autocuration,1,,CHEMBL615558,,BAO_0000019
537,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,22226,,U,0,Autocuration,1,,CHEMBL872066,,BAO_0000019
538,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,,11607,,D,9,Expert,1,,CHEMBL615559,,BAO_0000019
539,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,11607,,H,8,Autocuration,1,,CHEMBL615560,,BAO_0000019
540,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,11607,,H,8,Autocuration,1,,CHEMBL615561,,BAO_0000019
541,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,11607,,H,8,Expert,1,,CHEMBL857062,,BAO_0000019
542,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,11607,,H,8,Expert,1,,CHEMBL615562,,BAO_0000019
543,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,11607,,H,8,Autocuration,1,,CHEMBL615563,,BAO_0000019
544,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,11607,,H,8,Autocuration,1,,CHEMBL615564,,BAO_0000357
545,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,11607,,H,8,Autocuration,1,,CHEMBL615565,,BAO_0000019
546,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,11607,,H,8,Autocuration,1,,CHEMBL615566,,BAO_0000019
547,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,,11607,,D,9,Expert,1,,CHEMBL615567,,BAO_0000019
548,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,11607,,H,8,Autocuration,1,,CHEMBL615568,,BAO_0000019
549,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,11607,,H,8,Autocuration,1,,CHEMBL615569,,BAO_0000357
550,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,11607,,H,8,Autocuration,1,,CHEMBL615570,,BAO_0000019
551,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,11607,,H,8,Autocuration,1,,CHEMBL615571,,BAO_0000019
552,,Binding affinity against melatonin (MT1) receptor (pC1),,,104733,,H,4,Autocuration,1,,CHEMBL615572,,BAO_0000224
553,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,22226,,U,0,Autocuration,1,,CHEMBL615573,,BAO_0000019
554,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,22226,,U,0,Autocuration,1,,CHEMBL615574,,BAO_0000019
555,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,22226,,U,0,Autocuration,1,,CHEMBL615575,,BAO_0000019
556,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,10619,,H,8,Autocuration,1,,CHEMBL615576,,BAO_0000357
557,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,10619,,H,8,Autocuration,1,,CHEMBL615577,,BAO_0000357
558,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615578,,BAO_0000221
559,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Expert,1,,CHEMBL615579,,BAO_0000357
560,,Binding affinity for 5-hydroxytryptamine 1A receptor,,,51,,H,8,Expert,1,,CHEMBL615580,,BAO_0000357
561,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,51,,H,8,Expert,1,,CHEMBL615581,,BAO_0000019
562,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615582,,BAO_0000221
563,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615583,,BAO_0000221
564,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615584,,BAO_0000221
565,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL833691,,BAO_0000221
566,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615585,,BAO_0000221
567,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615586,,BAO_0000221
568,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL884524,,BAO_0000221
569,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615587,,BAO_0000221
570,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615588,,BAO_0000221
571,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,,10576,,D,9,Expert,1,,CHEMBL615589,,BAO_0000249
572,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,10000000.0,,51,,H,8,Expert,1,,CHEMBL615442,,BAO_0000221
573,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615443,,BAO_0000221
574,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615444,,BAO_0000221
575,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,10000000.0,,51,,H,8,Expert,1,,CHEMBL615445,,BAO_0000221
576,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615446,,BAO_0000221
577,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL615447,449.0,BAO_0000219
578,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,,51,,H,8,Expert,1,,CHEMBL615448,,BAO_0000221
579,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,,51,,H,8,Expert,1,,CHEMBL615449,,BAO_0000221
580,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL615450,449.0,BAO_0000219
581,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",10000000.0,,51,,H,8,Expert,1,,CHEMBL615451,,BAO_0000221
582,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,51,,H,8,Autocuration,1,,CHEMBL615452,,BAO_0000357
583,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615453,,BAO_0000221
584,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615454,,BAO_0000221
585,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615455,,BAO_0000221
586,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615456,,BAO_0000221
587,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615457,,BAO_0000221
588,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,10000000.0,,51,,H,8,Expert,1,,CHEMBL615458,,BAO_0000218
589,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Expert,1,,CHEMBL615459,,BAO_0000221
590,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,,51,CHO,D,9,Expert,1,,CHEMBL615460,449.0,BAO_0000219
591,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,,51,,H,8,Autocuration,1,,CHEMBL615461,,BAO_0000019
592,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,,51,,H,8,Autocuration,1,,CHEMBL615462,,BAO_0000019
593,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL615463,,BAO_0000221
594,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,2116.0,,51,,H,8,Autocuration,1,,CHEMBL615464,,BAO_0000221
595,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,2116.0,,51,,H,8,Autocuration,1,,CHEMBL615465,,BAO_0000221
596,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,2116.0,,51,,H,8,Autocuration,1,,CHEMBL615466,,BAO_0000221
597,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,2116.0,,51,,H,8,Autocuration,1,,CHEMBL615467,,BAO_0000221
598,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,2116.0,,51,,H,8,Autocuration,1,,CHEMBL615468,,BAO_0000221
599,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,2116.0,,51,,H,8,Autocuration,1,,CHEMBL615469,,BAO_0000221
600,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615470,,BAO_0000357
601,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615471,,BAO_0000357
602,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615472,,BAO_0000357
603,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10000000.0,,106,,H,8,Autocuration,1,,CHEMBL883242,,BAO_0000221
604,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10000000.0,,106,,H,8,Autocuration,1,,CHEMBL615473,,BAO_0000221
605,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,11863,CHO,H,8,Autocuration,1,,CHEMBL615474,449.0,BAO_0000218
606,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615475,,BAO_0000357
607,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,,51,HeLa,H,8,Autocuration,1,,CHEMBL615476,308.0,BAO_0000219
608,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,,51,HeLa,H,8,Autocuration,1,,CHEMBL615477,308.0,BAO_0000219
609,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615478,,BAO_0000019
610,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,51,CHO,H,8,Autocuration,1,,CHEMBL615160,449.0,BAO_0000219
611,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,51,CHO,H,8,Expert,1,,CHEMBL615161,449.0,BAO_0000219
612,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,,51,CHO,H,8,Autocuration,1,,CHEMBL615162,449.0,BAO_0000219
613,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,,51,CHO,H,8,Autocuration,1,,CHEMBL615163,449.0,BAO_0000219
614,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,51,CHO,H,8,Expert,1,,CHEMBL615164,449.0,BAO_0000219
615,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,51,CHO,H,8,Expert,1,,CHEMBL615165,449.0,BAO_0000219
616,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,,51,CHO,H,8,Autocuration,1,,CHEMBL615166,449.0,BAO_0000219
617,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,51,,H,8,Autocuration,1,,CHEMBL615167,,BAO_0000219
618,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,51,HeLa,D,9,Expert,1,,CHEMBL615168,308.0,BAO_0000219
619,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,,51,HeLa,D,9,Expert,1,,CHEMBL615169,308.0,BAO_0000219
620,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,,51,CHO,D,9,Expert,1,,CHEMBL615170,449.0,BAO_0000219
621,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,51,CHO,D,9,Expert,1,,CHEMBL615171,449.0,BAO_0000219
622,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615694,,BAO_0000019
623,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615695,,BAO_0000019
624,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,51,,H,8,Autocuration,1,,CHEMBL615696,,BAO_0000019
625,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,51,CHO,H,8,Autocuration,1,,CHEMBL615697,449.0,BAO_0000219
626,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,51,CHO,D,9,Expert,1,,CHEMBL859410,449.0,BAO_0000219
627,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,51,CHO,H,8,Autocuration,1,,CHEMBL615841,449.0,BAO_0000219
628,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,51,CHO,D,9,Expert,1,,CHEMBL615842,449.0,BAO_0000219
629,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,51,CHO,H,8,Autocuration,1,,CHEMBL835003,449.0,BAO_0000219
630,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,,51,CHO,H,8,Autocuration,1,,CHEMBL615843,449.0,BAO_0000219
631,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,51,CHO,D,9,Expert,1,,CHEMBL615979,449.0,BAO_0000219
632,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,51,CHO,H,8,Autocuration,1,,CHEMBL615980,449.0,BAO_0000219
633,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,51,CHO,D,9,Expert,1,,CHEMBL615981,449.0,BAO_0000219
634,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,,51,,D,9,Expert,1,,CHEMBL615982,,BAO_0000019
635,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,51,,D,9,Expert,1,,CHEMBL615983,,BAO_0000019
636,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,,51,,D,9,Expert,1,,CHEMBL615984,,BAO_0000019
637,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,,51,,D,9,Expert,1,,CHEMBL615985,,BAO_0000019
638,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL615986,449.0,BAO_0000219
639,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL615987,449.0,BAO_0000219
640,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,51,CHO,H,8,Autocuration,1,,CHEMBL615988,449.0,BAO_0000219
641,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,51,CHO,H,8,Expert,1,,CHEMBL615989,449.0,BAO_0000219
642,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,51,CHO,H,8,Autocuration,1,,CHEMBL615990,449.0,BAO_0000219
643,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,,51,CHO,H,8,Autocuration,1,,CHEMBL615991,449.0,BAO_0000219
644,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,51,CHO,H,8,Autocuration,1,,CHEMBL615992,449.0,BAO_0000219
645,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,51,CHO,H,8,Autocuration,1,,CHEMBL615993,449.0,BAO_0000219
646,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,51,CHO,H,8,Expert,1,,CHEMBL615994,449.0,BAO_0000219
647,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,,51,CHO,H,8,Autocuration,1,,CHEMBL615995,449.0,BAO_0000219
648,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,51,CHO,H,8,Autocuration,1,,CHEMBL615996,449.0,BAO_0000219
649,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,51,CHO,H,8,Autocuration,1,,CHEMBL615997,449.0,BAO_0000219
650,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51,,H,8,Autocuration,1,,CHEMBL615998,,BAO_0000019
651,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51,,H,8,Autocuration,1,,CHEMBL615999,,BAO_0000019
652,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,51,,H,8,Autocuration,1,,CHEMBL616000,,BAO_0000019
653,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616001,722.0,BAO_0000219
654,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,,51,,D,9,Expert,1,,CHEMBL616002,,BAO_0000019
655,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,51,,H,8,Expert,1,,CHEMBL616003,,BAO_0000019
656,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,,51,,D,9,Expert,1,,CHEMBL616004,,BAO_0000019
657,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,,51,,D,9,Expert,1,,CHEMBL616005,,BAO_0000019
658,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,51,,H,8,Autocuration,1,,CHEMBL616006,,BAO_0000019
659,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,51,,H,8,Expert,1,,CHEMBL616007,,BAO_0000019
660,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,51,,H,8,Autocuration,1,,CHEMBL616008,,BAO_0000019
661,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,51,,H,8,Autocuration,1,,CHEMBL616009,,BAO_0000019
662,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,51,,H,8,Expert,1,,CHEMBL616010,,BAO_0000019
663,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,,51,,D,9,Expert,1,,CHEMBL616011,,BAO_0000019
664,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,,51,,D,9,Expert,1,,CHEMBL615740,,BAO_0000019
665,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,51,,H,8,Autocuration,1,,CHEMBL615741,,BAO_0000019
666,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,51,,H,8,Expert,1,,CHEMBL615742,,BAO_0000019
667,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,51,,H,8,Autocuration,1,,CHEMBL615743,,BAO_0000019
668,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,,51,CHO,H,8,Autocuration,1,,CHEMBL615744,449.0,BAO_0000219
669,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,,51,CHO,H,8,Expert,1,,CHEMBL615745,449.0,BAO_0000219
670,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,51,,H,8,Autocuration,1,,CHEMBL615746,,BAO_0000357
671,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,51,,H,8,Autocuration,1,,CHEMBL615747,,BAO_0000357
672,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51,,H,8,Autocuration,1,,CHEMBL615748,,BAO_0000019
673,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,51,,H,8,Autocuration,1,,CHEMBL615749,,BAO_0000019
674,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,51,,H,8,Autocuration,1,,CHEMBL615750,,BAO_0000019
675,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,,51,,D,9,Expert,1,,CHEMBL616259,,BAO_0000019
676,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51,,H,8,Autocuration,1,,CHEMBL616260,,BAO_0000019
677,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,,51,,D,9,Expert,1,,CHEMBL616261,,BAO_0000019
678,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,51,,D,9,Expert,1,,CHEMBL616262,,BAO_0000019
679,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,51,,D,9,Expert,1,,CHEMBL616263,,BAO_0000019
680,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,,51,,D,9,Expert,1,,CHEMBL616264,,BAO_0000019
681,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,,51,,D,9,Expert,1,,CHEMBL616265,,BAO_0000019
682,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,51,,D,9,Expert,1,,CHEMBL616266,,BAO_0000019
683,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,51,,D,9,Expert,1,,CHEMBL616267,,BAO_0000019
684,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,,51,,D,9,Expert,1,,CHEMBL616268,,BAO_0000019
685,,Inhibition of human 5-hydroxytryptamine 1A receptor,,,51,,D,9,Expert,1,,CHEMBL616269,,BAO_0000357
686,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL884528,449.0,BAO_0000219
687,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,,105,HEK293,D,9,Expert,1,,CHEMBL616270,722.0,BAO_0000219
688,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL616271,449.0,BAO_0000219
689,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,51,CHO,H,8,Autocuration,1,,CHEMBL616272,449.0,BAO_0000219
690,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,51,,H,8,Expert,1,,CHEMBL616273,,BAO_0000357
691,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,51,,D,9,Expert,1,,CHEMBL616274,,BAO_0000357
692,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL616275,449.0,BAO_0000219
693,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL616276,449.0,BAO_0000219
694,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,22226,,U,0,Autocuration,1,,CHEMBL616277,,BAO_0000218
695,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,,22226,,U,0,Autocuration,1,,CHEMBL616278,,BAO_0000218
696,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,,22226,,U,0,Autocuration,1,,CHEMBL616279,,BAO_0000218
697,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,22226,,U,0,Autocuration,1,,CHEMBL616280,,BAO_0000218
698,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,,22226,,U,0,Autocuration,1,,CHEMBL616281,,BAO_0000218
699,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,22226,,U,0,Autocuration,1,,CHEMBL616282,,BAO_0000218
700,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,,22226,,U,0,Autocuration,1,,CHEMBL616283,,BAO_0000218
701,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,,22226,,U,0,Autocuration,1,,CHEMBL616284,,BAO_0000218
702,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,,22226,,U,0,Autocuration,1,,CHEMBL616285,,BAO_0000218
703,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,,22226,,U,0,Autocuration,1,,CHEMBL616286,,BAO_0000218
704,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,,22226,,U,0,Autocuration,1,,CHEMBL616287,,BAO_0000218
705,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,,22226,,U,0,Autocuration,1,,CHEMBL616288,,BAO_0000218
706,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,,22226,,U,0,Autocuration,1,,CHEMBL616289,,BAO_0000218
707,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,,22226,,U,0,Autocuration,1,,CHEMBL615610,,BAO_0000218
708,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,,22226,,U,0,Autocuration,1,,CHEMBL615611,,BAO_0000218
709,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,,22226,,U,0,Autocuration,1,,CHEMBL615612,,BAO_0000218
710,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,,22226,,U,0,Autocuration,1,,CHEMBL615613,,BAO_0000218
711,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,,22226,,U,0,Autocuration,1,,CHEMBL615614,,BAO_0000218
712,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,22226,,U,0,Autocuration,1,,CHEMBL615615,,BAO_0000218
713,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,105093,,H,4,Autocuration,1,,CHEMBL615616,,BAO_0000019
714,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,1898.0,,11923,,H,8,Autocuration,1,,CHEMBL615617,,BAO_0000249
715,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,10577,,H,8,Autocuration,1,,CHEMBL615618,,BAO_0000019
716,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,10577,,H,8,Autocuration,1,,CHEMBL615619,,BAO_0000019
717,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,10577,,H,8,Expert,1,,CHEMBL615620,,BAO_0000019
718,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,55,,H,8,Autocuration,1,,CHEMBL615621,,BAO_0000357
719,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,55,,H,8,Autocuration,1,,CHEMBL615622,,BAO_0000357
720,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,12166,,H,8,Autocuration,1,,CHEMBL615623,,BAO_0000019
721,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,12166,,H,8,Autocuration,1,,CHEMBL615624,,BAO_0000019
722,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,12166,,H,8,Autocuration,1,,CHEMBL615625,,BAO_0000019
723,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,12166,,H,8,Autocuration,1,,CHEMBL767045,,BAO_0000019
724,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,,55,,H,8,Autocuration,1,,CHEMBL615626,,BAO_0000019
725,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,,55,,H,8,Autocuration,1,,CHEMBL615627,,BAO_0000019
726,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,,55,,H,8,Autocuration,1,,CHEMBL615628,,BAO_0000019
727,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,55,,H,8,Autocuration,1,,CHEMBL615629,,BAO_0000357
728,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,,55,,D,9,Expert,1,,CHEMBL615630,,BAO_0000357
729,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,55,,H,8,Autocuration,1,,CHEMBL615631,,BAO_0000219
730,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,17087,,H,8,Autocuration,1,,CHEMBL615632,,BAO_0000218
731,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,17087,,H,8,Autocuration,1,,CHEMBL615633,,BAO_0000357
732,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,17087,,H,8,Autocuration,1,,CHEMBL615634,,BAO_0000218
733,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,55,,H,8,Expert,1,,CHEMBL615635,,BAO_0000019
734,,In vitro inhibition of rat 5-Lipoxygenase,,,12166,,H,8,Expert,1,,CHEMBL615636,,BAO_0000357
735,,Inhibitory activity against 5-Lipoxygenase,,,12166,,D,9,Expert,1,,CHEMBL615637,,BAO_0000357
736,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,,12166,RBL-1,H,8,Expert,1,,CHEMBL615638,702.0,BAO_0000219
737,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,12166,RBL-1,H,8,Autocuration,1,,CHEMBL615639,702.0,BAO_0000219
738,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,,12166,RBL-1,H,8,Autocuration,1,,CHEMBL615640,702.0,BAO_0000219
739,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,12166,,H,8,Autocuration,1,,CHEMBL615796,,BAO_0000019
740,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,12166,,H,8,Autocuration,1,,CHEMBL615845,,BAO_0000219
741,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,12166,,H,8,Autocuration,1,,CHEMBL615846,,BAO_0000357
742,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,12166,RBL-1,H,8,Autocuration,1,,CHEMBL615847,702.0,BAO_0000219
743,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,12166,,H,8,Autocuration,1,,CHEMBL615848,,BAO_0000357
744,,Ratio of IC50 against 5-LO and COX,,,22226,,U,0,Autocuration,1,,CHEMBL615849,,BAO_0000019
745,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,12166,,H,8,Autocuration,1,,CHEMBL615850,,BAO_0000357
746,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,12166,,H,8,Autocuration,1,,CHEMBL615851,,BAO_0000357
747,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,12166,,H,8,Autocuration,1,,CHEMBL615852,,BAO_0000219
748,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,12166,,H,8,Autocuration,1,,CHEMBL615853,,BAO_0000019
749,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,2367.0,,120,,H,8,Autocuration,1,,CHEMBL884527,,BAO_0000357
750,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,,22226,,U,0,Autocuration,1,,CHEMBL872871,,BAO_0000019
751,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,,22226,,U,0,Autocuration,1,,CHEMBL615854,,BAO_0000019
752,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,,22226,,U,0,Autocuration,1,,CHEMBL767046,,BAO_0000019
753,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,10732,,H,8,Autocuration,1,,CHEMBL615855,,BAO_0000357
754,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,,12198,,D,9,Expert,1,,CHEMBL615856,,BAO_0000019
755,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,12198,,D,9,Expert,1,,CHEMBL615857,,BAO_0000019
756,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,12198,,D,9,Expert,1,,CHEMBL615858,,BAO_0000019
757,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10000000.0,,10576,,H,8,Expert,1,,CHEMBL615859,,BAO_0000221
758,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,51,,H,8,Autocuration,1,,CHEMBL615860,,BAO_0000357
759,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,22226,,U,0,Autocuration,1,,CHEMBL615861,,BAO_0000019
760,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,22226,,U,0,Autocuration,1,,CHEMBL615862,,BAO_0000019
761,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,,22226,,U,0,Autocuration,1,,CHEMBL615863,,BAO_0000019
762,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,22226,,U,0,Autocuration,1,,CHEMBL615864,,BAO_0000019
763,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10000000.0,,104744,,H,4,Autocuration,1,,CHEMBL615865,,BAO_0000221
764,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10000000.0,,104744,,H,4,Autocuration,1,,CHEMBL615866,,BAO_0000221
765,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10000000.0,,104744,,H,4,Autocuration,1,,CHEMBL615867,,BAO_0000221
766,Membranes,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,104744,,H,4,Autocuration,1,,CHEMBL615868,,BAO_0000249
767,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,,104744,,D,5,Autocuration,1,,CHEMBL615869,,BAO_0000249
768,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,,104744,,D,5,Autocuration,1,,CHEMBL615870,,BAO_0000019
769,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,,104744,,D,5,Autocuration,1,,CHEMBL615871,,BAO_0000019
770,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,104744,,H,4,Autocuration,1,,CHEMBL615872,,BAO_0000224
771,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,10000000.0,,104744,,H,4,Autocuration,1,,CHEMBL833492,,BAO_0000221
772,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,10000000.0,,104744,,H,4,Autocuration,1,,CHEMBL615873,,BAO_0000221
773,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,104744,,H,4,Autocuration,1,,CHEMBL615479,,BAO_0000224
774,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,104744,,H,4,Autocuration,1,,CHEMBL615480,,BAO_0000019
775,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,,104744,,D,5,Autocuration,1,,CHEMBL615481,,BAO_0000249
776,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744,,H,4,Autocuration,1,,CHEMBL872869,,BAO_0000019
777,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744,,H,4,Autocuration,1,,CHEMBL615482,,BAO_0000019
778,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,955.0,,104744,,H,4,Autocuration,1,,CHEMBL615483,,BAO_0000221
779,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,955.0,,104744,,H,4,Autocuration,1,,CHEMBL615484,,BAO_0000221
780,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,104744,,H,4,Autocuration,1,,CHEMBL615485,,BAO_0000019
781,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,,104744,,D,5,Autocuration,1,,CHEMBL615486,,BAO_0000224
782,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,104744,,H,4,Autocuration,1,,CHEMBL615487,,BAO_0000224
783,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,104744,,H,4,Autocuration,1,,CHEMBL615488,,BAO_0000224
784,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,104744,,H,4,Autocuration,1,,CHEMBL615489,,BAO_0000224
785,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,104744,,H,4,Autocuration,1,,CHEMBL615389,,BAO_0000224
786,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,104744,,H,4,Autocuration,1,,CHEMBL615390,,BAO_0000019
787,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,104744,,H,4,Autocuration,1,,CHEMBL615391,,BAO_0000019
788,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,104744,,H,4,Autocuration,1,,CHEMBL615392,,BAO_0000224
789,,Affinity for 5-hydroxytryptamine 1 receptor,,,22226,,U,0,Autocuration,1,,CHEMBL615393,,BAO_0000019
790,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,955.0,,104744,,H,4,Autocuration,1,,CHEMBL615394,,BAO_0000221
791,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,955.0,,104744,,H,4,Autocuration,1,,CHEMBL615395,,BAO_0000221
792,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,104744,,H,4,Autocuration,1,,CHEMBL615396,,BAO_0000224
793,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,955.0,,104744,,H,4,Autocuration,1,,CHEMBL615397,,BAO_0000221
794,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744,,H,4,Autocuration,1,,CHEMBL615398,,BAO_0000019
795,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,,22226,,U,0,Autocuration,1,,CHEMBL615399,,BAO_0000019
796,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,104744,,H,4,Autocuration,1,,CHEMBL615400,,BAO_0000019
797,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,,104744,,D,5,Autocuration,1,,CHEMBL615401,,BAO_0000019
798,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,,22226,,U,0,Autocuration,1,,CHEMBL615402,,BAO_0000019
799,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,104744,,H,4,Autocuration,1,,CHEMBL615403,,BAO_0000019
800,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,955.0,,104744,,H,4,Autocuration,1,,CHEMBL615404,,BAO_0000221
801,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,104744,,H,4,Autocuration,1,,CHEMBL615781,,BAO_0000019
802,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,955.0,,104744,,H,4,Autocuration,1,,CHEMBL615782,,BAO_0000220
803,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,955.0,,104744,,H,4,Autocuration,1,,CHEMBL615783,,BAO_0000221
804,,Compound was tested for binding affinity against 5-HT1 receptor,,,22226,,U,0,Autocuration,1,,CHEMBL873481,,BAO_0000019
805,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,22226,,U,0,Autocuration,1,,CHEMBL615784,,BAO_0000019
806,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,10576,,H,8,Expert,1,,CHEMBL615785,,BAO_0000357
807,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,10576,,H,8,Autocuration,1,,CHEMBL615786,,BAO_0000249
808,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,10576,,H,8,Autocuration,1,,CHEMBL615787,,BAO_0000218
809,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,10576,,H,8,Autocuration,1,,CHEMBL615788,,BAO_0000218
810,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL767044,,BAO_0000019
811,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,10576,,H,8,Autocuration,1,,CHEMBL615789,,BAO_0000218
812,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,10576,,H,8,Autocuration,1,,CHEMBL615790,,BAO_0000218
813,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,10576,,H,8,Autocuration,1,,CHEMBL615813,,BAO_0000019
814,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,10576,,H,8,Autocuration,1,,CHEMBL615814,,BAO_0000219
815,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,51,,H,8,Expert,1,,CHEMBL615815,,BAO_0000219
816,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,10576,,H,8,Autocuration,1,,CHEMBL615816,,BAO_0000219
817,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,10576,,H,8,Expert,1,,CHEMBL615817,,BAO_0000249
818,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615818,,BAO_0000221
819,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615819,,BAO_0000221
820,Membranes,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,10576,,H,8,Expert,1,,CHEMBL615820,,BAO_0000249
821,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10000000.0,,10576,,D,9,Expert,1,,CHEMBL615821,,BAO_0000221
822,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10000000.0,,10576,,D,9,Expert,1,,CHEMBL615822,,BAO_0000221
823,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10000000.0,,10576,,H,8,Expert,1,,CHEMBL615823,,BAO_0000221
824,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10000000.0,,10576,,D,9,Expert,1,,CHEMBL615824,,BAO_0000221
825,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10000000.0,,10576,,D,9,Expert,1,,CHEMBL615825,,BAO_0000221
826,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,10576,,H,8,Expert,1,,CHEMBL615826,,BAO_0000357
827,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,10576,,H,8,Expert,1,,CHEMBL615827,,BAO_0000249
828,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,10000000.0,,10576,,H,8,Expert,1,,CHEMBL615828,,BAO_0000249
829,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Expert,1,,CHEMBL615829,,BAO_0000221
830,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615830,,BAO_0000221
831,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,10000000.0,,10576,,H,8,Expert,1,,CHEMBL615831,,BAO_0000221
832,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL615832,,BAO_0000357
833,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,10576,,H,8,Autocuration,1,,CHEMBL615833,,BAO_0000019
834,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615834,,BAO_0000221
835,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,10576,,H,8,Intermediate,1,,CHEMBL615835,,BAO_0000249
836,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615836,,BAO_0000249
837,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,,10576,,D,9,Expert,1,,CHEMBL615837,,BAO_0000019
838,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,,10576,,D,9,Expert,1,,CHEMBL615838,,BAO_0000019
839,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,10576,,H,8,Expert,1,,CHEMBL615839,,BAO_0000249
840,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,10576,,H,8,Autocuration,1,,CHEMBL884525,,BAO_0000019
841,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,10576,,H,8,Autocuration,1,,CHEMBL615840,,BAO_0000249
842,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Expert,1,,CHEMBL615405,,BAO_0000221
843,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,10576,,H,8,Expert,1,,CHEMBL615406,,BAO_0000019
844,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10000000.0,,10576,,H,8,Expert,1,,CHEMBL615900,,BAO_0000221
845,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,10000000.0,,10576,,H,8,Expert,1,,CHEMBL615901,,BAO_0000221
846,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,10576,,H,8,Expert,1,,CHEMBL615902,,BAO_0000357
847,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615903,,BAO_0000221
848,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,10576,,H,8,Autocuration,1,,CHEMBL615904,,BAO_0000357
849,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,10576,,H,8,Expert,1,,CHEMBL615905,,BAO_0000357
850,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,10576,,H,8,Autocuration,1,,CHEMBL615906,,BAO_0000019
851,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,10576,,H,8,Autocuration,1,,CHEMBL615907,,BAO_0000019
852,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,10576,,H,8,Expert,1,,CHEMBL615908,,BAO_0000019
853,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615909,,BAO_0000221
854,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,10576,,H,8,Autocuration,1,,CHEMBL615910,,BAO_0000019
855,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,10576,,H,8,Autocuration,1,,CHEMBL615911,,BAO_0000019
856,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,10576,,H,8,Autocuration,1,,CHEMBL615912,,BAO_0000019
857,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,10576,,H,8,Expert,1,,CHEMBL615913,,BAO_0000019
858,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,10576,,H,8,Expert,1,,CHEMBL615914,,BAO_0000357
859,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615915,,BAO_0000221
860,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,10576,,H,8,Autocuration,1,,CHEMBL615916,,BAO_0000357
861,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,10576,,H,8,Expert,1,,CHEMBL615917,,BAO_0000357
862,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Expert,1,,CHEMBL615918,,BAO_0000357
863,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,10000000.0,,10576,,H,8,Expert,1,,CHEMBL615919,,BAO_0000249
864,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10000000.0,,10576,,D,9,Expert,1,,CHEMBL615920,,BAO_0000221
865,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL615921,,BAO_0000357
866,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,10576,,H,8,Expert,1,,CHEMBL615922,,BAO_0000357
867,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,10576,,D,9,Expert,1,,CHEMBL881290,,BAO_0000249
868,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615923,,BAO_0000221
869,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615924,,BAO_0000221
870,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615925,,BAO_0000221
871,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,,10576,,D,9,Expert,1,,CHEMBL615926,,BAO_0000357
872,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,,10576,,D,9,Expert,1,,CHEMBL615927,,BAO_0000019
873,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615928,,BAO_0000221
874,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,,10576,,D,9,Expert,1,,CHEMBL615929,,BAO_0000357
875,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615930,,BAO_0000221
876,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL615931,449.0,BAO_0000219
877,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,51,CHO,H,8,Autocuration,1,,CHEMBL615932,449.0,BAO_0000219
878,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,51,CHO,H,8,Autocuration,1,,CHEMBL615933,449.0,BAO_0000219
879,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615934,,BAO_0000357
880,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,51,,H,8,Autocuration,1,,CHEMBL615935,,BAO_0000357
881,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51,,H,8,Autocuration,1,,CHEMBL615936,,BAO_0000019
882,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,,51,CHO,H,8,Autocuration,1,,CHEMBL615937,449.0,BAO_0000219
883,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615938,,BAO_0000357
884,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,51,,H,8,Autocuration,1,,CHEMBL615797,,BAO_0000357
885,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL615798,,BAO_0000357
886,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,51,,H,8,Autocuration,1,,CHEMBL872870,,BAO_0000357
887,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,51,,H,8,Autocuration,1,,CHEMBL615799,,BAO_0000357
888,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615800,,BAO_0000357
889,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,51,HEK293,H,8,Autocuration,1,,CHEMBL615801,722.0,BAO_0000219
890,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,51,,H,8,Autocuration,1,,CHEMBL615802,,BAO_0000019
891,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,51,,H,8,Autocuration,1,,CHEMBL615803,,BAO_0000357
892,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,51,,H,8,Expert,1,,CHEMBL835002,,BAO_0000019
893,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,51,,H,8,Autocuration,1,,CHEMBL615804,,BAO_0000019
894,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,,51,HeLa,H,8,Expert,1,,CHEMBL615805,308.0,BAO_0000219
895,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,,51,CHO,H,8,Autocuration,1,,CHEMBL615806,449.0,BAO_0000219
896,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,,51,,D,9,Expert,1,,CHEMBL615807,,BAO_0000357
897,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL615808,,BAO_0000357
898,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,51,,D,9,Expert,1,,CHEMBL615809,,BAO_0000357
899,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,,51,HeLa,H,8,Autocuration,1,,CHEMBL615810,308.0,BAO_0000219
900,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL615811,,BAO_0000357
901,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL615812,449.0,BAO_0000219
902,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL615751,449.0,BAO_0000219
903,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615752,,BAO_0000357
904,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,,51,CHO,H,8,Expert,1,,CHEMBL615753,449.0,BAO_0000219
905,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,,51,CHO,H,8,Autocuration,1,,CHEMBL615754,449.0,BAO_0000219
906,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615755,,BAO_0000357
907,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,51,CHO,D,9,Expert,1,,CHEMBL615756,449.0,BAO_0000219
908,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL615757,,BAO_0000019
909,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,51,,H,8,Autocuration,1,,CHEMBL615758,,BAO_0000357
910,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,51,,H,8,Expert,1,,CHEMBL615759,,BAO_0000357
911,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615760,,BAO_0000357
912,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,,51,HeLa,H,8,Expert,1,,CHEMBL615761,308.0,BAO_0000219
913,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL872104,,BAO_0000357
914,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL615762,,BAO_0000357
915,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL615763,,BAO_0000357
916,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,51,,H,8,Autocuration,1,,CHEMBL615764,,BAO_0000357
917,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,,51,Cell line,H,8,Autocuration,1,,CHEMBL615765,1167.0,BAO_0000219
918,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,51,,H,8,Autocuration,1,,CHEMBL615766,,BAO_0000019
919,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL615767,,BAO_0000357
920,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Expert,1,,CHEMBL615768,,BAO_0000357
921,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL615769,,BAO_0000357
922,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,51,,H,8,Expert,1,,CHEMBL615770,,BAO_0000357
923,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL615771,,BAO_0000357
924,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,51,,H,8,Expert,1,,CHEMBL615772,,BAO_0000357
925,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL615773,,BAO_0000357
926,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Expert,1,,CHEMBL615774,,BAO_0000357
927,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL615775,,BAO_0000357
928,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,51,,H,8,Autocuration,1,,CHEMBL615776,,BAO_0000357
929,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Expert,1,,CHEMBL615777,,BAO_0000357
930,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,51,,H,8,Autocuration,1,,CHEMBL615778,,BAO_0000219
931,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,51,,D,9,Expert,1,,CHEMBL615779,,BAO_0000357
932,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,51,,H,8,Autocuration,1,,CHEMBL615780,,BAO_0000357
933,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616298,,BAO_0000357
934,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616299,,BAO_0000357
935,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,,51,CHO-K1,H,8,Autocuration,1,,CHEMBL616300,485.0,BAO_0000219
936,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,,51,CHO-K1,H,8,Expert,1,,CHEMBL616301,485.0,BAO_0000219
937,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616302,,BAO_0000019
938,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,51,,H,8,Autocuration,1,,CHEMBL616117,,BAO_0000019
939,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,51,,H,8,Autocuration,1,,CHEMBL616118,,BAO_0000019
940,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,51,,H,8,Autocuration,1,,CHEMBL616119,,BAO_0000019
941,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,51,HeLa,D,9,Expert,1,,CHEMBL616120,308.0,BAO_0000219
942,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616121,,BAO_0000357
943,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,51,,H,8,Autocuration,1,,CHEMBL616122,,BAO_0000357
944,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616123,,BAO_0000357
945,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,,51,,D,9,Expert,1,,CHEMBL616124,,BAO_0000357
946,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,51,,H,8,Expert,1,,CHEMBL616125,,BAO_0000357
947,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,,51,,H,8,Expert,1,,CHEMBL616126,,BAO_0000357
948,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,,51,CHO,H,8,Autocuration,1,,CHEMBL616127,449.0,BAO_0000219
949,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Expert,1,,CHEMBL616128,,BAO_0000019
950,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,51,,H,8,Autocuration,1,,CHEMBL616129,,BAO_0000357
951,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Expert,1,,CHEMBL616130,,BAO_0000357
952,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,51,,H,8,Autocuration,1,,CHEMBL616131,,BAO_0000357
953,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,,51,HeLa,H,8,Autocuration,1,,CHEMBL616132,308.0,BAO_0000219
954,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,,51,HeLa,D,9,Expert,1,,CHEMBL616133,308.0,BAO_0000219
955,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL616134,,BAO_0000357
956,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,51,,H,8,Autocuration,1,,CHEMBL616135,,BAO_0000357
957,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,,51,,D,9,Expert,1,,CHEMBL616136,,BAO_0000357
958,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,51,,H,8,Autocuration,1,,CHEMBL616137,,BAO_0000019
959,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,51,,H,8,Autocuration,1,,CHEMBL872105,,BAO_0000019
960,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,51,,H,8,Autocuration,1,,CHEMBL616138,,BAO_0000357
961,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,51,,D,9,Expert,1,,CHEMBL616139,,BAO_0000357
962,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,51,,H,8,Autocuration,1,,CHEMBL616140,,BAO_0000019
963,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,51,,H,8,Expert,1,,CHEMBL616141,,BAO_0000019
964,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL616142,,BAO_0000357
965,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,51,,H,8,Autocuration,1,,CHEMBL616143,,BAO_0000357
966,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,51,HeLa,H,8,Autocuration,1,,CHEMBL616144,308.0,BAO_0000219
967,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,,51,HeLa,H,8,Autocuration,1,,CHEMBL616145,308.0,BAO_0000219
968,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,51,HeLa,H,8,Autocuration,1,,CHEMBL616012,308.0,BAO_0000219
969,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,51,HeLa,H,8,Autocuration,1,,CHEMBL616013,308.0,BAO_0000219
970,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,51,,H,8,Autocuration,1,,CHEMBL616014,,BAO_0000019
971,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,51,,H,8,Autocuration,1,,CHEMBL616015,,BAO_0000019
972,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,51,,H,8,Autocuration,1,,CHEMBL616016,,BAO_0000019
973,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,,51,,H,8,Autocuration,1,,CHEMBL616017,,BAO_0000218
974,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,51,,H,8,Autocuration,1,,CHEMBL616018,,BAO_0000019
975,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,51,,H,8,Autocuration,1,,CHEMBL616019,,BAO_0000019
976,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,51,,H,8,Autocuration,1,,CHEMBL616020,,BAO_0000019
977,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL858018,,BAO_0000357
978,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616021,722.0,BAO_0000219
979,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,51,,H,8,Expert,1,,CHEMBL616022,,BAO_0000019
980,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,51,,H,8,Autocuration,1,,CHEMBL616023,,BAO_0000019
981,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,51,,H,8,Autocuration,1,,CHEMBL616024,,BAO_0000019
982,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,51,,H,8,Autocuration,1,,CHEMBL616025,,BAO_0000019
983,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,51,CHO,H,8,Autocuration,1,,CHEMBL616026,449.0,BAO_0000219
984,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,51,,H,8,Autocuration,1,,CHEMBL616027,,BAO_0000019
985,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,,51,,D,9,Expert,1,,CHEMBL616028,,BAO_0000019
986,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,,51,,D,9,Expert,1,,CHEMBL616029,,BAO_0000019
987,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,,51,CHO,H,8,Expert,1,,CHEMBL616030,449.0,BAO_0000219
988,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,51,,H,8,Expert,1,,CHEMBL616031,,BAO_0000019
989,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,51,,D,9,Expert,1,,CHEMBL616032,,BAO_0000019
990,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,51,,D,9,Expert,1,,CHEMBL616033,,BAO_0000019
991,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51,,H,8,Autocuration,1,,CHEMBL616034,,BAO_0000019
992,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51,,H,8,Autocuration,1,,CHEMBL616035,,BAO_0000019
993,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616036,,BAO_0000019
994,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51,,H,8,Autocuration,1,,CHEMBL616037,,BAO_0000019
995,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51,,H,8,Autocuration,1,,CHEMBL616038,,BAO_0000019
996,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51,,H,8,Autocuration,1,,CHEMBL616039,,BAO_0000019
997,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616040,,BAO_0000019
998,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,51,HeLa,D,9,Expert,1,,CHEMBL616041,308.0,BAO_0000219
999,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,51,HeLa,D,9,Expert,1,,CHEMBL616042,308.0,BAO_0000219
1000,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,51,HeLa,D,9,Expert,1,,CHEMBL616043,308.0,BAO_0000219
1001,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,51,,H,8,Autocuration,1,,CHEMBL616044,,BAO_0000019
1002,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,51,,H,8,Autocuration,1,,CHEMBL616045,,BAO_0000019
1003,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616046,722.0,BAO_0000219
1004,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,51,CHO,H,8,Autocuration,1,,CHEMBL616047,449.0,BAO_0000219
1005,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL616048,449.0,BAO_0000219
1006,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,,51,CHO,D,9,Expert,1,,CHEMBL616049,449.0,BAO_0000219
1007,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,51,CHO,H,8,Autocuration,1,,CHEMBL616050,449.0,BAO_0000219
1008,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,51,,H,8,Expert,1,,CHEMBL616051,,BAO_0000219
1009,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,51,,H,8,Autocuration,1,,CHEMBL616212,,BAO_0000219
1010,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,51,,H,8,Autocuration,1,,CHEMBL616213,,BAO_0000019
1011,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,,51,,H,8,Expert,1,,CHEMBL616214,,BAO_0000219
1012,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,,51,,H,8,Expert,1,,CHEMBL616215,,BAO_0000219
1013,,Binding activity radioligand.,,,51,,H,8,Autocuration,1,,CHEMBL616216,,BAO_0000357
1014,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,51,,H,8,Autocuration,1,,CHEMBL616217,,BAO_0000019
1015,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616218,,BAO_0000357
1016,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616219,,BAO_0000357
1017,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616220,,BAO_0000357
1018,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,,51,,D,9,Expert,1,,CHEMBL833493,,BAO_0000357
1019,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616221,,BAO_0000357
1020,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,51,CHO,D,9,Expert,1,,CHEMBL616222,449.0,BAO_0000219
1021,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616223,,BAO_0000019
1022,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,51,,H,8,Autocuration,1,,CHEMBL616224,,BAO_0000019
1023,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,51,,H,8,Expert,1,,CHEMBL616225,,BAO_0000019
1024,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,,51,HEK293,D,9,Expert,1,,CHEMBL616226,722.0,BAO_0000219
1025,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616227,722.0,BAO_0000219
1026,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616228,722.0,BAO_0000219
1027,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616229,722.0,BAO_0000219
1028,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616230,722.0,BAO_0000219
1029,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616231,722.0,BAO_0000219
1030,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL616232,,BAO_0000357
1031,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616233,722.0,BAO_0000219
1032,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,,51,HEK293,H,8,Autocuration,1,,CHEMBL857973,722.0,BAO_0000219
1033,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,51,,H,8,Autocuration,1,,CHEMBL616234,,BAO_0000219
1034,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616235,,BAO_0000357
1035,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,51,HeLa,H,8,Expert,1,,CHEMBL616236,308.0,BAO_0000219
1036,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,51,,H,8,Expert,1,,CHEMBL616237,,BAO_0000019
1037,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616238,722.0,BAO_0000219
1038,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616239,722.0,BAO_0000219
1039,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,51,,H,8,Autocuration,1,,CHEMBL616240,,BAO_0000219
1040,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,,51,HeLa,D,9,Expert,1,,CHEMBL616241,308.0,BAO_0000219
1041,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,,51,HEK293,H,8,Autocuration,1,,CHEMBL616242,722.0,BAO_0000219
1042,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,,51,HEK293,H,8,Autocuration,1,,CHEMBL616243,722.0,BAO_0000219
1043,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,51,,D,9,Expert,1,,CHEMBL616244,,BAO_0000357
1044,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,,51,,D,9,Autocuration,1,,CHEMBL616245,,BAO_0000357
1045,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,106,,H,8,Autocuration,1,,CHEMBL616246,,BAO_0000357
1046,,Binding affinity against 5-HT1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616247,,BAO_0000357
1047,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,105,,H,8,Autocuration,1,,CHEMBL616248,,BAO_0000357
1048,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,107,,H,8,Autocuration,1,,CHEMBL616249,,BAO_0000357
1049,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,10576,,H,8,Autocuration,1,,CHEMBL616250,,BAO_0000357
1050,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616251,,BAO_0000357
1051,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,,11863,,H,8,Autocuration,1,,CHEMBL616252,,BAO_0000218
1052,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,,11863,,H,8,Autocuration,1,,CHEMBL616253,,BAO_0000218
1053,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,,11863,,H,8,Autocuration,1,,CHEMBL616254,,BAO_0000218
1054,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,,11863,,D,9,Expert,1,,CHEMBL616255,,BAO_0000218
1055,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,,11863,,D,9,Expert,1,,CHEMBL832872,,BAO_0000218
1056,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,,11863,,D,9,Expert,1,,CHEMBL616256,,BAO_0000218
1057,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,,11863,,D,9,Expert,1,,CHEMBL616257,,BAO_0000218
1058,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,,11863,,D,9,Expert,1,,CHEMBL616258,,BAO_0000218
1059,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,,11863,,D,9,Expert,1,,CHEMBL616384,,BAO_0000218
1060,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10000000.0,,11863,,H,8,Autocuration,1,,CHEMBL616385,,BAO_0000221
1061,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,11863,,H,8,Expert,1,,CHEMBL616386,,BAO_0000357
1062,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10000000.0,,11863,,D,9,Expert,1,,CHEMBL616387,,BAO_0000221
1063,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,10000000.0,,11863,,H,8,Autocuration,1,,CHEMBL616388,,BAO_0000221
1064,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10000000.0,,11863,,D,9,Expert,1,,CHEMBL616389,,BAO_0000221
1065,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,10000000.0,,11863,,H,8,Autocuration,1,,CHEMBL616390,,BAO_0000221
1066,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,11863,,H,8,Autocuration,1,,CHEMBL616391,,BAO_0000357
1067,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10000000.0,,11863,,D,9,Expert,1,,CHEMBL616392,,BAO_0000221
1068,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616393,,BAO_0000357
1069,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,,51,,H,8,Autocuration,1,,CHEMBL616394,,BAO_0000357
1070,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,,51,,H,8,Autocuration,1,,CHEMBL616395,,BAO_0000019
1071,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616396,,BAO_0000357
1072,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,51,,H,8,Autocuration,1,,CHEMBL872907,,BAO_0000019
1073,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,51,,H,8,Autocuration,1,,CHEMBL616397,,BAO_0000019
1074,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,,51,,H,8,Autocuration,1,,CHEMBL616398,,BAO_0000019
1075,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,,51,,H,8,Expert,1,,CHEMBL616399,,BAO_0000357
1076,,Binding activity radioligand.,,,51,,H,8,Autocuration,1,,CHEMBL857065,,BAO_0000357
1077,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,51,,H,8,Expert,1,,CHEMBL616400,,BAO_0000019
1078,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,51,,H,8,Autocuration,1,,CHEMBL616401,,BAO_0000019
1079,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,10624,,H,8,Expert,1,,CHEMBL616402,,BAO_0000019
1080,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,,51,,H,8,Expert,1,,CHEMBL616403,,BAO_0000019
1081,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL616404,,BAO_0000221
1082,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,,51,,H,8,Autocuration,1,,CHEMBL616405,,BAO_0000249
1083,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,,51,,H,8,Autocuration,1,,CHEMBL616406,,BAO_0000019
1084,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,,51,,H,8,Expert,1,,CHEMBL616407,,BAO_0000019
1085,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,,51,,H,8,Autocuration,1,,CHEMBL616408,,BAO_0000019
1086,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,,10576,,D,9,Expert,1,,CHEMBL616409,,BAO_0000249
1087,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10000000.0,,10576,,D,9,Expert,1,,CHEMBL616410,,BAO_0000221
1088,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,10576,,H,8,Autocuration,1,,CHEMBL616411,,BAO_0000357
1089,Membranes,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,10576,,D,9,Expert,1,,CHEMBL616412,,BAO_0000249
1090,Membranes,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10000000.0,,10576,,D,9,Expert,1,,CHEMBL616413,,BAO_0000249
1091,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616414,,BAO_0000221
1092,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616415,,BAO_0000221
1093,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,10576,,H,8,Autocuration,1,,CHEMBL616416,,BAO_0000019
1094,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,10576,,H,8,Expert,1,,CHEMBL616417,,BAO_0000357
1095,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,10576,,H,8,Autocuration,1,,CHEMBL616418,,BAO_0000357
1096,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,10576,,H,8,Autocuration,1,,CHEMBL616419,,BAO_0000219
1097,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,10576,,H,8,Autocuration,1,,CHEMBL616420,,BAO_0000357
1098,Membranes,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,10576,,H,8,Autocuration,1,,CHEMBL616421,,BAO_0000249
1099,Membranes,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,10576,,H,8,Autocuration,1,,CHEMBL616422,,BAO_0000249
1100,Membranes,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,10576,,H,8,Expert,1,,CHEMBL616423,,BAO_0000249
1101,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,,10576,,D,9,Expert,1,,CHEMBL616424,,BAO_0000357
1102,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Expert,1,,CHEMBL616425,,BAO_0000357
1103,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,10576,,H,8,Expert,1,,CHEMBL616426,,BAO_0000357
1104,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616427,,BAO_0000221
1105,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616428,,BAO_0000221
1106,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616290,,BAO_0000221
1107,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,,10576,,D,9,Expert,1,,CHEMBL616052,,BAO_0000357
1108,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616053,,BAO_0000357
1109,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,10576,,H,8,Autocuration,1,,CHEMBL616054,,BAO_0000249
1110,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616055,,BAO_0000357
1111,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,10576,,H,8,Autocuration,1,,CHEMBL616056,,BAO_0000357
1112,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,10576,,H,8,Expert,1,,CHEMBL616057,,BAO_0000019
1113,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,955.0,,10576,,D,9,Expert,1,,CHEMBL616058,,BAO_0000221
1114,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,955.0,,10576,,H,8,Autocuration,1,,CHEMBL616059,,BAO_0000221
1115,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,10576,,H,8,Autocuration,1,,CHEMBL616060,,BAO_0000249
1116,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616061,,BAO_0000221
1117,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616062,,BAO_0000221
1118,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,10576,,H,8,Autocuration,1,,CHEMBL616063,,BAO_0000249
1119,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",2435.0,,10576,,H,8,Autocuration,1,,CHEMBL616064,,BAO_0000249
1120,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,,10576,,D,9,Expert,1,,CHEMBL616065,,BAO_0000249
1121,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,,10576,,D,9,Expert,1,,CHEMBL616066,,BAO_0000249
1122,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616067,,BAO_0000221
1123,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616068,,BAO_0000221
1124,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,10000000.0,,10576,,H,8,Intermediate,1,,CHEMBL616069,,BAO_0000221
1125,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,10576,,H,8,Expert,1,,CHEMBL616070,,BAO_0000249
1126,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616071,,BAO_0000221
1127,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616072,,BAO_0000221
1128,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616073,,BAO_0000221
1129,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616074,,BAO_0000221
1130,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,10576,,H,8,Expert,1,,CHEMBL616075,,BAO_0000019
1131,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616076,,BAO_0000357
1132,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,,10576,,D,9,Expert,1,,CHEMBL616077,,BAO_0000019
1133,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,,10576,,D,9,Expert,1,,CHEMBL616078,,BAO_0000019
1134,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,,10576,,D,9,Expert,1,,CHEMBL616079,,BAO_0000019
1135,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,10576,CHO-K1,D,9,Expert,1,,CHEMBL616080,485.0,BAO_0000219
1136,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616081,,BAO_0000357
1137,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616082,,BAO_0000221
1138,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616083,,BAO_0000221
1139,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,10576,,H,8,Autocuration,1,,CHEMBL616084,,BAO_0000019
1140,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,10576,,H,8,Expert,1,,CHEMBL616085,,BAO_0000019
1141,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,10576,,H,8,Autocuration,1,,CHEMBL616086,,BAO_0000019
1142,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616087,,BAO_0000221
1143,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,10576,,H,8,Expert,1,,CHEMBL616088,,BAO_0000357
1144,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,10576,,H,8,Autocuration,1,,CHEMBL616089,,BAO_0000019
1145,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,,10576,,D,9,Expert,1,,CHEMBL616090,,BAO_0000357
1146,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,10576,,H,8,Autocuration,1,,CHEMBL616091,,BAO_0000357
1147,Membranes,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",2435.0,,10576,,H,8,Autocuration,1,,CHEMBL616092,,BAO_0000249
1148,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,10576,,H,8,Autocuration,1,,CHEMBL616093,,BAO_0000357
1149,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,,10576,,H,8,Autocuration,1,,CHEMBL616094,,BAO_0000218
1150,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,955.0,,10576,,H,8,Autocuration,1,,CHEMBL616095,,BAO_0000221
1151,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,10576,,D,9,Expert,1,,CHEMBL616096,,BAO_0000357
1152,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,10576,,H,8,Expert,1,,CHEMBL616097,,BAO_0000249
1153,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,,10576,,D,9,Expert,1,,CHEMBL616098,,BAO_0000249
1154,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616099,,BAO_0000221
1155,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616100,,BAO_0000221
1156,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Expert,1,,CHEMBL616101,,BAO_0000357
1157,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,10576,,H,8,Expert,1,,CHEMBL616102,,BAO_0000249
1158,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616103,,BAO_0000357
1159,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,10576,,H,8,Expert,1,,CHEMBL616104,,BAO_0000019
1160,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,10576,,H,8,Expert,1,,CHEMBL616105,,BAO_0000019
1161,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,,10576,,D,9,Expert,1,,CHEMBL616106,,BAO_0000019
1162,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,10576,,H,8,Autocuration,1,,CHEMBL616107,,BAO_0000019
1163,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,10576,,H,8,Expert,1,,CHEMBL616108,,BAO_0000357
1164,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616109,,BAO_0000221
1165,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,10576,,H,8,Autocuration,1,,CHEMBL616110,,BAO_0000357
1166,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,,10576,CHO,H,8,Expert,1,,CHEMBL616111,449.0,BAO_0000219
1167,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,10576,,H,8,Expert,1,,CHEMBL616112,,BAO_0000019
1168,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616113,,BAO_0000221
1169,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616114,,BAO_0000019
1170,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616115,,BAO_0000019
1171,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616116,,BAO_0000357
1172,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,955.0,,10576,,H,8,Expert,1,,CHEMBL615844,,BAO_0000221
1173,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,,10576,,H,8,Expert,1,,CHEMBL615939,,BAO_0000221
1174,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,10576,,H,8,Expert,1,,CHEMBL615940,,BAO_0000019
1175,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,10000000.0,,10576,,H,8,Expert,1,,CHEMBL615941,,BAO_0000221
1176,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615942,,BAO_0000221
1177,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615943,,BAO_0000221
1178,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615944,,BAO_0000221
1179,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615945,,BAO_0000221
1180,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615946,,BAO_0000221
1181,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615947,,BAO_0000221
1182,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615948,,BAO_0000221
1183,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615949,,BAO_0000221
1184,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615950,,BAO_0000221
1185,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615951,,BAO_0000221
1186,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615952,,BAO_0000221
1187,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615953,,BAO_0000221
1188,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615954,,BAO_0000221
1189,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10000000.0,,10576,,D,9,Expert,1,,CHEMBL615955,,BAO_0000221
1190,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615956,,BAO_0000221
1191,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL615957,,BAO_0000221
1192,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,10576,,H,8,Expert,1,,CHEMBL615958,,BAO_0000019
1193,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,10576,,H,8,Expert,1,,CHEMBL615959,,BAO_0000019
1194,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,10576,,H,8,Autocuration,1,,CHEMBL615960,,BAO_0000019
1195,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,10576,,H,8,Autocuration,1,,CHEMBL615961,,BAO_0000019
1196,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,955.0,,10576,,H,8,Expert,1,,CHEMBL615962,,BAO_0000221
1197,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,10576,,H,8,Expert,1,,CHEMBL615963,,BAO_0000019
1198,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,10576,,H,8,Autocuration,1,,CHEMBL615964,,BAO_0000019
1199,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,10576,,H,8,Autocuration,1,,CHEMBL615965,,BAO_0000019
1200,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,,10576,CHO,H,8,Expert,1,,CHEMBL615966,449.0,BAO_0000219
1201,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,10576,,H,8,Expert,1,,CHEMBL615967,,BAO_0000249
1202,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,10576,,H,8,Expert,1,,CHEMBL615968,,BAO_0000019
1203,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,10576,CHO,H,8,Autocuration,1,,CHEMBL615969,449.0,BAO_0000218
1204,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,10576,,H,8,Autocuration,1,,CHEMBL615970,,BAO_0000218
1205,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,,10576,,D,9,Expert,1,,CHEMBL615971,,BAO_0000357
1206,Membranes,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,10576,,H,8,Expert,1,,CHEMBL615972,,BAO_0000249
1207,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,10576,,H,8,Autocuration,1,,CHEMBL615973,,BAO_0000249
1208,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,10576,,H,8,Autocuration,1,,CHEMBL615974,,BAO_0000249
1209,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,51,CHO,D,9,Expert,1,,CHEMBL615975,449.0,BAO_0000219
1210,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,10576,,H,8,Expert,1,,CHEMBL615976,,BAO_0000249
1211,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10000000.0,,10576,,D,9,Expert,1,,CHEMBL872106,,BAO_0000221
1212,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,10576,,H,8,Autocuration,1,,CHEMBL615977,,BAO_0000357
1213,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,10576,,H,8,Autocuration,1,,CHEMBL615978,,BAO_0000357
1214,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,10576,,H,8,Autocuration,1,,CHEMBL616166,,BAO_0000357
1215,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,10576,,H,8,Autocuration,1,,CHEMBL616167,,BAO_0000357
1216,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,10576,,H,8,Autocuration,1,,CHEMBL616168,,BAO_0000357
1217,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,10576,,H,8,Autocuration,1,,CHEMBL616169,,BAO_0000357
1218,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,10576,,H,8,Autocuration,1,,CHEMBL616170,,BAO_0000357
1219,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,10576,,H,8,Autocuration,1,,CHEMBL616171,,BAO_0000357
1220,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,10576,,H,8,Autocuration,1,,CHEMBL616172,,BAO_0000357
1221,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,10576,,H,8,Autocuration,1,,CHEMBL616173,,BAO_0000357
1222,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,10576,,H,8,Autocuration,1,,CHEMBL616174,,BAO_0000357
1223,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,10576,,H,8,Autocuration,1,,CHEMBL616175,,BAO_0000357
1224,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,10576,,H,8,Autocuration,1,,CHEMBL616176,,BAO_0000357
1225,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,10576,,H,8,Autocuration,1,,CHEMBL616177,,BAO_0000357
1226,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,10576,,H,8,Autocuration,1,,CHEMBL616178,,BAO_0000357
1227,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,10576,,H,8,Autocuration,1,,CHEMBL616179,,BAO_0000019
1228,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616180,,BAO_0000357
1229,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,10576,,H,8,Autocuration,1,,CHEMBL616181,,BAO_0000357
1230,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,10576,,H,8,Autocuration,1,,CHEMBL616182,,BAO_0000019
1231,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616183,,BAO_0000221
1232,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,10576,,H,8,Expert,1,,CHEMBL615874,,BAO_0000019
1233,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,10576,CHO-K1,D,9,Expert,1,,CHEMBL615875,485.0,BAO_0000219
1234,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,10576,,H,8,Autocuration,1,,CHEMBL615876,,BAO_0000019
1235,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,10576,,H,8,Autocuration,1,,CHEMBL615877,,BAO_0000019
1236,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,10576,,H,8,Autocuration,1,,CHEMBL615878,,BAO_0000357
1237,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,10576,,H,8,Expert,1,,CHEMBL615879,,BAO_0000357
1238,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,10576,,H,8,Expert,1,,CHEMBL615880,,BAO_0000357
1239,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,10576,,H,8,Autocuration,1,,CHEMBL615881,,BAO_0000019
1240,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,10576,,D,9,Expert,1,,CHEMBL615882,,BAO_0000019
1241,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,,10576,,H,8,Autocuration,1,,CHEMBL615883,,BAO_0000218
1242,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,,10576,,H,8,Autocuration,1,,CHEMBL615884,,BAO_0000218
1243,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,,10576,,H,8,Autocuration,1,,CHEMBL615885,,BAO_0000218
1244,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,,10576,,H,8,Autocuration,1,,CHEMBL615886,,BAO_0000218
1245,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,,10576,,H,8,Autocuration,1,,CHEMBL615887,,BAO_0000218
1246,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,,10576,,H,8,Autocuration,1,,CHEMBL615888,,BAO_0000218
1247,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,,10576,,H,8,Autocuration,1,,CHEMBL615889,,BAO_0000218
1248,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,,10576,,H,8,Autocuration,1,,CHEMBL615890,,BAO_0000218
1249,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,,10576,,H,8,Autocuration,1,,CHEMBL615891,,BAO_0000218
1250,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,,10576,,H,8,Autocuration,1,,CHEMBL615892,,BAO_0000218
1251,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,,10576,,H,8,Autocuration,1,,CHEMBL615893,,BAO_0000218
1252,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,,10576,,H,8,Autocuration,1,,CHEMBL615894,,BAO_0000218
1253,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,,10576,,H,8,Autocuration,1,,CHEMBL615895,,BAO_0000218
1254,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,,10576,,H,8,Autocuration,1,,CHEMBL615896,,BAO_0000218
1255,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,,10576,,H,8,Autocuration,1,,CHEMBL615897,,BAO_0000218
1256,Membranes,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,10576,,D,9,Expert,1,,CHEMBL615898,,BAO_0000249
1257,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,10576,,H,8,Autocuration,1,,CHEMBL615899,,BAO_0000019
1258,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,10576,,H,8,Autocuration,1,,CHEMBL616291,,BAO_0000019
1259,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,10576,,H,8,Autocuration,1,,CHEMBL616292,,BAO_0000357
1260,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,10576,,H,8,Autocuration,1,,CHEMBL616293,,BAO_0000249
1261,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616294,,BAO_0000221
1262,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616295,,BAO_0000249
1263,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,955.0,,10576,,H,8,Autocuration,1,,CHEMBL616296,,BAO_0000221
1264,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL616297,,BAO_0000019
1265,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL616605,,BAO_0000019
1266,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL616606,,BAO_0000019
1267,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,10576,,H,8,Autocuration,1,,CHEMBL616607,,BAO_0000019
1268,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,10576,,H,8,Expert,1,,CHEMBL616608,,BAO_0000019
1269,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL616609,,BAO_0000019
1270,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,,10576,,D,9,Expert,1,,CHEMBL616610,,BAO_0000019
1271,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL616611,,BAO_0000019
1272,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,10576,,H,8,Expert,1,,CHEMBL616612,,BAO_0000019
1273,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL616613,,BAO_0000019
1274,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,10576,,H,8,Expert,1,,CHEMBL616614,,BAO_0000019
1275,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL616615,,BAO_0000019
1276,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,10576,,H,8,Expert,1,,CHEMBL616616,,BAO_0000019
1277,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL616617,,BAO_0000019
1278,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL616618,,BAO_0000019
1279,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL616619,,BAO_0000019
1280,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,10576,,H,8,Expert,1,,CHEMBL616620,,BAO_0000019
1281,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,10576,,H,8,Expert,1,,CHEMBL616621,,BAO_0000019
1282,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,10576,,H,8,Autocuration,1,,CHEMBL616622,,BAO_0000019
1283,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,10576,,H,8,Expert,1,,CHEMBL616146,,BAO_0000019
1284,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL832873,,BAO_0000019
1285,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,10576,,H,8,Autocuration,1,,CHEMBL616147,,BAO_0000019
1286,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL872872,,BAO_0000019
1287,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,10576,,H,8,Autocuration,1,,CHEMBL616148,,BAO_0000019
1288,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616149,,BAO_0000221
1289,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616150,,BAO_0000221
1290,Membranes,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,,10576,,D,9,Expert,1,,CHEMBL616151,,BAO_0000249
1291,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,10000000.0,,10576,,H,8,Expert,1,,CHEMBL872873,,BAO_0000221
1292,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616670,,BAO_0000221
1293,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616671,,BAO_0000221
1294,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,10576,,D,9,Expert,1,,CHEMBL884861,,BAO_0000249
1295,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616672,,BAO_0000357
1296,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,10576,,H,8,Autocuration,1,,CHEMBL616673,,BAO_0000019
1297,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,10576,,H,8,Expert,1,,CHEMBL616674,,BAO_0000019
1298,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,10576,,H,8,Autocuration,1,,CHEMBL616675,,BAO_0000357
1299,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616676,,BAO_0000221
1300,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616677,,BAO_0000221
1301,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616678,,BAO_0000221
1302,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,10576,,D,9,Expert,1,,CHEMBL616679,,BAO_0000357
1303,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616680,,BAO_0000221
1304,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616681,,BAO_0000221
1305,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616682,,BAO_0000221
1306,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616683,,BAO_0000221
1307,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616684,,BAO_0000221
1308,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616685,,BAO_0000221
1309,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,955.0,,10576,,H,8,Autocuration,1,,CHEMBL616686,,BAO_0000221
1310,,Affinity for 5-hydroxytryptamine 1A receptor site,,,10576,,H,8,Autocuration,1,,CHEMBL616687,,BAO_0000357
1311,,Affinity for 5-hydroxytryptamine 1A receptor site,,,10576,,H,8,Autocuration,1,,CHEMBL616688,,BAO_0000357
1312,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616689,,BAO_0000221
1313,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,10576,,H,8,Autocuration,1,,CHEMBL616690,,BAO_0000357
1314,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,10576,,H,8,Expert,1,,CHEMBL616691,,BAO_0000357
1315,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616692,,BAO_0000221
1316,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,10576,,H,8,Expert,1,,CHEMBL616693,,BAO_0000249
1317,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,10576,,D,9,Expert,1,,CHEMBL616694,,BAO_0000019
1318,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616695,,BAO_0000221
1319,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,10576,,H,8,Autocuration,1,,CHEMBL616696,,BAO_0000357
1320,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,10576,,H,8,Autocuration,1,,CHEMBL616697,,BAO_0000357
1321,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616698,,BAO_0000357
1322,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,,10576,,D,9,Expert,1,,CHEMBL616949,,BAO_0000019
1323,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616950,,BAO_0000221
1324,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,10576,,H,8,Autocuration,1,,CHEMBL832875,,BAO_0000357
1325,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,955.0,,10576,,H,8,Expert,1,,CHEMBL616951,,BAO_0000221
1326,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,955.0,,10576,,H,8,Expert,1,,CHEMBL616952,,BAO_0000221
1327,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,10576,,H,8,Expert,1,,CHEMBL616953,,BAO_0000357
1328,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,10576,,H,8,Autocuration,1,,CHEMBL616954,,BAO_0000357
1329,,GTPgammaS radioligand binding assay,,,106,,H,8,Autocuration,1,,CHEMBL616955,,BAO_0000357
1330,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,106,,H,8,Autocuration,1,,CHEMBL616956,,BAO_0000357
1331,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,106,,H,8,Autocuration,1,,CHEMBL616957,,BAO_0000019
1332,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,106,,H,8,Autocuration,1,,CHEMBL616958,,BAO_0000019
1333,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,106,,H,8,Autocuration,1,,CHEMBL616959,,BAO_0000357
1334,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,106,,H,8,Autocuration,1,,CHEMBL616960,,BAO_0000357
1335,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,106,,H,8,Autocuration,1,,CHEMBL616961,,BAO_0000019
1336,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,,106,HeLa,H,8,Expert,1,,CHEMBL616962,308.0,BAO_0000219
1337,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,,106,HeLa,H,8,Autocuration,1,,CHEMBL616963,308.0,BAO_0000219
1338,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,,106,,D,9,Expert,1,,CHEMBL616524,,BAO_0000357
1339,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,106,CHO,H,8,Autocuration,1,,CHEMBL616525,449.0,BAO_0000219
1340,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,106,,H,8,Autocuration,1,,CHEMBL872908,,BAO_0000019
1341,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,106,,H,8,Autocuration,1,,CHEMBL616526,,BAO_0000019
1342,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,,106,,D,9,Expert,1,,CHEMBL616527,,BAO_0000357
1343,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,106,,H,8,Expert,1,,CHEMBL616528,,BAO_0000219
1344,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,106,,H,8,Autocuration,1,,CHEMBL616529,,BAO_0000357
1345,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,106,,H,8,Autocuration,1,,CHEMBL616530,,BAO_0000357
1346,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,106,,H,8,Expert,1,,CHEMBL616531,,BAO_0000357
1347,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,106,,H,8,Autocuration,1,,CHEMBL616532,,BAO_0000357
1348,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,106,,H,8,Autocuration,1,,CHEMBL616533,,BAO_0000357
1349,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,106,,H,8,Expert,1,,CHEMBL616534,,BAO_0000357
1350,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,106,,H,8,Expert,1,,CHEMBL616535,,BAO_0000357
1351,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,106,,H,8,Autocuration,1,,CHEMBL616536,,BAO_0000357
1352,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,106,,H,8,Autocuration,1,,CHEMBL616537,,BAO_0000357
1353,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,,106,CHO-K1,H,8,Expert,1,,CHEMBL616538,485.0,BAO_0000219
1354,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,106,,H,8,Expert,1,,CHEMBL616539,,BAO_0000019
1355,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,106,,H,8,Expert,1,,CHEMBL616540,,BAO_0000019
1356,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,106,,H,8,Autocuration,1,,CHEMBL616429,,BAO_0000357
1357,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,106,,H,8,Expert,1,,CHEMBL616430,,BAO_0000357
1358,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,,106,,D,9,Expert,1,,CHEMBL616431,,BAO_0000219
1359,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,106,,D,9,Expert,1,,CHEMBL616432,,BAO_0000357
1360,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,,106,,D,9,Expert,1,,CHEMBL616433,,BAO_0000357
1361,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,106,,D,9,Expert,1,,CHEMBL616434,,BAO_0000357
1362,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,,106,CHO,H,8,Autocuration,1,,CHEMBL616435,449.0,BAO_0000219
1363,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,106,,H,8,Expert,1,,CHEMBL616436,,BAO_0000019
1364,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,106,HeLa,H,8,Autocuration,1,,CHEMBL616437,308.0,BAO_0000219
1365,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,,106,HeLa,H,8,Autocuration,1,,CHEMBL616438,308.0,BAO_0000219
1366,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,106,HeLa,H,8,Autocuration,1,,CHEMBL616439,308.0,BAO_0000219
1367,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,,106,,D,9,Expert,1,,CHEMBL616440,,BAO_0000357
1368,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,,106,CHO-K1,H,8,Autocuration,1,,CHEMBL616441,485.0,BAO_0000219
1369,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,106,,H,8,Expert,1,,CHEMBL616442,,BAO_0000357
1370,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,106,,H,8,Autocuration,1,,CHEMBL616443,,BAO_0000357
1371,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,,106,CHO-K1,H,8,Expert,1,,CHEMBL616444,485.0,BAO_0000219
1372,,Binding activity against human 5-hydroxytryptamine 1B receptor,,,106,,D,9,Expert,1,,CHEMBL616445,,BAO_0000357
1373,,Binding activity against human 5-hydroxytryptamine 1B receptor,,,106,,D,9,Expert,1,,CHEMBL616446,,BAO_0000357
1374,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,106,CHO,D,9,Expert,1,,CHEMBL616447,449.0,BAO_0000219
1375,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,106,,H,8,Autocuration,1,,CHEMBL616448,,BAO_0000357
1376,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,,106,CHO,H,8,Autocuration,1,,CHEMBL616449,449.0,BAO_0000219
1377,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,,106,CHO,H,8,Autocuration,1,,CHEMBL616450,449.0,BAO_0000219
1378,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,,106,CHO,H,8,Autocuration,1,,CHEMBL857974,449.0,BAO_0000219
1379,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,106,CHO,H,8,Autocuration,1,,CHEMBL616451,449.0,BAO_0000219
1380,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,106,CHO,H,8,Autocuration,1,,CHEMBL616452,449.0,BAO_0000219
1381,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,106,CHO,H,8,Autocuration,1,,CHEMBL616453,449.0,BAO_0000219
1382,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,,106,CHO,H,8,Autocuration,1,,CHEMBL616454,449.0,BAO_0000219
1383,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,106,,D,9,Expert,1,,CHEMBL616455,,BAO_0000357
1384,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,106,CHO,H,8,Autocuration,1,,CHEMBL616456,449.0,BAO_0000219
1385,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,106,,H,8,Autocuration,1,,CHEMBL616457,,BAO_0000357
1386,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,106,CHO,H,8,Autocuration,1,,CHEMBL616458,449.0,BAO_0000219
1387,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,,106,CHO,H,8,Autocuration,1,,CHEMBL616459,449.0,BAO_0000219
1388,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,106,,H,8,Expert,1,,CHEMBL616460,,BAO_0000019
1389,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,106,,H,8,Expert,1,,CHEMBL616461,,BAO_0000019
1390,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,106,CHO,H,8,Autocuration,1,,CHEMBL616462,449.0,BAO_0000219
1391,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,106,CHO,H,8,Autocuration,1,,CHEMBL616463,449.0,BAO_0000219
1392,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,105,,H,8,Autocuration,1,,CHEMBL616464,,BAO_0000019
1393,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,,105,CHO,H,8,Autocuration,1,,CHEMBL616465,449.0,BAO_0000219
1394,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,17105,,H,8,Autocuration,1,,CHEMBL832874,,BAO_0000357
1395,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,,106,,H,8,Autocuration,1,,CHEMBL616184,,BAO_0000019
1396,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,,106,,H,8,Autocuration,1,,CHEMBL616185,,BAO_0000019
1397,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,,106,,H,8,Intermediate,1,,CHEMBL616186,,BAO_0000019
1398,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,,106,,H,8,Autocuration,1,,CHEMBL616187,,BAO_0000019
1399,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,10577,,H,8,Expert,1,,CHEMBL616188,,BAO_0000357
1400,,Binding affinity for 5-hydroxytryptamine 1B receptor,,,10577,,D,9,Intermediate,1,,CHEMBL873475,,BAO_0000357
1401,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,2435.0,,10577,,D,9,Expert,1,,CHEMBL616189,,BAO_0000019
1402,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,10577,,H,8,Expert,1,,CHEMBL616190,,BAO_0000357
1403,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,10576,,H,8,Autocuration,1,,CHEMBL616191,,BAO_0000357
1404,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,10576,,H,8,Autocuration,1,,CHEMBL616192,,BAO_0000357
1405,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,10576,,H,8,Autocuration,1,,CHEMBL616193,,BAO_0000357
1406,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,10576,,H,8,Autocuration,1,,CHEMBL616194,,BAO_0000357
1407,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,10576,,H,8,Autocuration,1,,CHEMBL616195,,BAO_0000357
1408,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,10576,,H,8,Autocuration,1,,CHEMBL616196,,BAO_0000357
1409,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616197,,BAO_0000249
1410,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,10576,,H,8,Intermediate,1,,CHEMBL616198,,BAO_0000019
1411,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616199,,BAO_0000221
1412,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616200,,BAO_0000221
1413,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616201,,BAO_0000221
1414,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616202,,BAO_0000221
1415,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616203,,BAO_0000221
1416,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616204,,BAO_0000221
1417,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616205,,BAO_0000221
1418,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616206,,BAO_0000221
1419,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,10576,,H,8,Expert,1,,CHEMBL616207,,BAO_0000249
1420,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,10576,,H,8,Autocuration,1,,CHEMBL616208,,BAO_0000249
1421,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,10576,,H,8,Autocuration,1,,CHEMBL616209,,BAO_0000249
1422,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,10576,,H,8,Expert,1,,CHEMBL616210,,BAO_0000357
1423,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616211,,BAO_0000221
1424,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616504,,BAO_0000221
1425,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616505,,BAO_0000221
1426,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616506,,BAO_0000019
1427,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL872107,,BAO_0000221
1428,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616507,,BAO_0000221
1429,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,10576,,H,8,Autocuration,1,,CHEMBL616303,,BAO_0000249
1430,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616304,,BAO_0000221
1431,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616305,,BAO_0000221
1432,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,10000000.0,,10576,,H,8,Intermediate,1,,CHEMBL616306,,BAO_0000221
1433,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616307,,BAO_0000357
1434,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10000000.0,,10576,,D,9,Expert,1,,CHEMBL881829,,BAO_0000221
1435,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,10576,,H,8,Expert,1,,CHEMBL616308,,BAO_0000357
1436,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,10576,,H,8,Autocuration,1,,CHEMBL616309,,BAO_0000019
1437,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,10576,,H,8,Expert,1,,CHEMBL616310,,BAO_0000019
1438,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,,10576,CHO,H,8,Autocuration,1,,CHEMBL616311,449.0,BAO_0000219
1439,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,10576,,H,8,Expert,1,,CHEMBL616312,,BAO_0000357
1440,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,10576,,H,8,Autocuration,1,,CHEMBL616313,,BAO_0000357
1441,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616314,,BAO_0000221
1442,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616315,,BAO_0000221
1443,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616567,,BAO_0000221
1444,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616568,,BAO_0000221
1445,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,10576,,H,8,Intermediate,1,,CHEMBL616569,,BAO_0000019
1446,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,10576,,H,8,Expert,1,,CHEMBL616570,,BAO_0000357
1447,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,10576,,H,8,Autocuration,1,,CHEMBL616571,,BAO_0000357
1448,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616572,,BAO_0000221
1449,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,10576,,H,8,Expert,1,,CHEMBL616573,,BAO_0000249
1450,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,,10576,,D,9,Expert,1,,CHEMBL616574,,BAO_0000357
1451,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616575,,BAO_0000221
1452,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL872108,,BAO_0000221
1453,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,10576,,H,8,Autocuration,1,,CHEMBL616576,,BAO_0000357
1454,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,10576,,H,8,Autocuration,1,,CHEMBL616577,,BAO_0000249
1455,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,10576,,H,8,Autocuration,1,,CHEMBL616578,,BAO_0000249
1456,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,10576,,H,8,Expert,1,,CHEMBL616579,,BAO_0000357
1457,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,,10576,,D,9,Expert,1,,CHEMBL616580,,BAO_0000019
1458,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,10576,,H,8,Autocuration,1,,CHEMBL616581,,BAO_0000019
1459,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616582,,BAO_0000221
1460,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616583,,BAO_0000221
1461,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616584,,BAO_0000221
1462,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Expert,1,,CHEMBL616585,,BAO_0000357
1463,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616586,,BAO_0000221
1464,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616587,,BAO_0000221
1465,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616588,,BAO_0000221
1466,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616589,,BAO_0000221
1467,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616590,,BAO_0000221
1468,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,,10576,CHO,H,8,Expert,1,,CHEMBL616591,449.0,BAO_0000219
1469,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Expert,1,,CHEMBL616592,,BAO_0000357
1470,,The inhibition activity of 5-HT1A at 1 uM,,,10576,,H,8,Autocuration,1,,CHEMBL616593,,BAO_0000357
1471,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,,10576,CHO-K1,H,8,Expert,1,,CHEMBL616594,485.0,BAO_0000219
1472,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,10576,,H,8,Expert,1,,CHEMBL616595,,BAO_0000249
1473,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,10576,,H,8,Autocuration,1,,CHEMBL616596,,BAO_0000357
1474,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616597,,BAO_0000221
1475,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10000000.0,,10576,,H,8,Expert,1,,CHEMBL616598,,BAO_0000221
1476,Membranes,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,,10576,,D,9,Expert,1,,CHEMBL616599,,BAO_0000249
1477,Membranes,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10000000.0,,10576,,D,9,Expert,1,,CHEMBL616600,,BAO_0000249
1478,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,10576,,H,8,Autocuration,1,,CHEMBL616601,,BAO_0000019
1479,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,10576,,H,8,Autocuration,1,,CHEMBL616602,,BAO_0000019
1480,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,10576,,H,8,Autocuration,1,,CHEMBL616603,,BAO_0000019
1481,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,10576,,H,8,Autocuration,1,,CHEMBL616604,,BAO_0000019
1482,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,10576,,H,8,Autocuration,1,,CHEMBL616316,,BAO_0000249
1483,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,10576,,H,8,Autocuration,1,,CHEMBL616317,,BAO_0000249
1484,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,,10576,,D,9,Expert,1,,CHEMBL616318,,BAO_0000019
1485,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616319,,BAO_0000221
1486,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616320,,BAO_0000221
1487,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616321,,BAO_0000221
1488,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,10576,,H,8,Autocuration,1,,CHEMBL616322,,BAO_0000019
1489,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,10576,,H,8,Autocuration,1,,CHEMBL616323,,BAO_0000019
1490,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616324,,BAO_0000357
1491,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616325,,BAO_0000221
1492,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616326,,BAO_0000221
1493,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616327,,BAO_0000221
1494,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Autocuration,1,,CHEMBL616328,,BAO_0000357
1495,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,10576,,H,8,Autocuration,1,,CHEMBL858110,,BAO_0000249
1496,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,10576,,H,8,Autocuration,1,,CHEMBL616329,,BAO_0000249
1497,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,10576,,H,8,Autocuration,1,,CHEMBL616330,,BAO_0000249
1498,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,10576,,H,8,Autocuration,1,,CHEMBL616331,,BAO_0000249
1499,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,10576,,H,8,Autocuration,1,,CHEMBL616332,,BAO_0000249
1500,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,,10576,,H,8,Autocuration,1,,CHEMBL857063,,BAO_0000249
1501,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,10576,,H,8,Autocuration,1,,CHEMBL616333,,BAO_0000019
1502,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,10576,,H,8,Expert,1,,CHEMBL616334,,BAO_0000019
1503,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616335,,BAO_0000221
1504,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,10576,,H,8,Autocuration,1,,CHEMBL616336,,BAO_0000019
1505,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,10576,,H,8,Expert,1,,CHEMBL616337,,BAO_0000249
1506,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,10576,,H,8,Autocuration,1,,CHEMBL616338,,BAO_0000019
1507,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616339,,BAO_0000221
1508,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616340,,BAO_0000221
1509,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,10576,,H,8,Autocuration,1,,CHEMBL616341,,BAO_0000357
1510,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,10576,,D,9,Expert,1,,CHEMBL616342,,BAO_0000357
1511,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,,10576,,D,9,Expert,1,,CHEMBL616343,,BAO_0000019
1512,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,10576,,H,8,Expert,1,,CHEMBL616344,,BAO_0000019
1513,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,10576,,H,8,Expert,1,,CHEMBL616345,,BAO_0000357
1514,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,10576,,H,8,Expert,1,,CHEMBL616346,,BAO_0000019
1515,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616347,,BAO_0000221
1516,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,10576,,H,8,Expert,1,,CHEMBL616348,,BAO_0000019
1517,,Binding affinity at 5-hydroxytryptamine 1A receptor,,,10576,,H,8,Expert,1,,CHEMBL616349,,BAO_0000357
1518,Membranes,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,,10576,,D,9,Expert,1,,CHEMBL616152,,BAO_0000249
1519,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,10576,,H,8,Autocuration,1,,CHEMBL616153,,BAO_0000249
1520,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,10576,,H,8,Expert,1,,CHEMBL616154,,BAO_0000019
1521,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,10576,,H,8,Autocuration,1,,CHEMBL616155,,BAO_0000019
1522,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616156,,BAO_0000221
1523,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10000000.0,,10576,,D,9,Expert,1,,CHEMBL616157,,BAO_0000221
1524,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL616158,,BAO_0000221
1525,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,10576,,H,8,Autocuration,1,,CHEMBL616159,,BAO_0000357
1526,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,10576,,H,8,Expert,1,,CHEMBL616160,,BAO_0000357
1527,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,10576,,H,8,Autocuration,1,,CHEMBL616161,,BAO_0000019
1528,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,10576,,H,8,Autocuration,1,,CHEMBL616162,,BAO_0000019
1529,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,12687,,D,9,Expert,1,,CHEMBL616163,,BAO_0000357
1530,Membranes,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,10626,,H,8,Expert,1,,CHEMBL616164,,BAO_0000249
1531,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,955.0,,10576,,H,8,Autocuration,1,,CHEMBL616165,,BAO_0000221
1532,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,,51,,H,8,Autocuration,1,,CHEMBL616355,,BAO_0000019
1533,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,10576,,H,8,Autocuration,1,,CHEMBL616356,,BAO_0000019
1534,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,955.0,,10576,,H,8,Autocuration,1,,CHEMBL616357,,BAO_0000221
1535,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,10576,,H,8,Autocuration,1,,CHEMBL616358,,BAO_0000019
1536,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616359,,BAO_0000357
1537,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,51,,H,8,Expert,1,,CHEMBL616360,,BAO_0000357
1538,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,51,,H,8,Expert,1,,CHEMBL616361,,BAO_0000357
1539,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616362,,BAO_0000357
1540,Brain membranes,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,51,,H,8,Autocuration,1,,CHEMBL616363,,BAO_0000249
1541,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,51,,H,8,Autocuration,1,,CHEMBL616364,,BAO_0000357
1542,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616365,,BAO_0000357
1543,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Expert,1,,CHEMBL616366,,BAO_0000357
1544,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,51,,H,8,Expert,1,,CHEMBL872906,,BAO_0000357
1545,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,51,,H,8,Autocuration,1,,CHEMBL616367,,BAO_0000357
1546,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616368,,BAO_0000357
1547,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,51,,H,8,Autocuration,1,,CHEMBL616369,,BAO_0000357
1548,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,,51,,D,9,Expert,1,,CHEMBL616370,,BAO_0000357
1549,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,,51,,D,9,Expert,1,,CHEMBL616371,,BAO_0000357
1550,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,51,CHO,H,8,Autocuration,1,,CHEMBL616372,449.0,BAO_0000219
1551,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,51,,H,8,Expert,1,,CHEMBL616373,,BAO_0000219
1552,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,,H,8,Autocuration,1,,CHEMBL616374,,BAO_0000218
1553,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,51,,H,8,Autocuration,1,,CHEMBL616375,,BAO_0000221
1554,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,51,,H,8,Autocuration,1,,CHEMBL616376,,BAO_0000357
1555,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,51,,H,8,Expert,1,,CHEMBL857064,,BAO_0000357
1556,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,51,,H,8,Autocuration,1,,CHEMBL616377,,BAO_0000357
1557,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,51,,H,8,Autocuration,1,,CHEMBL616378,,BAO_0000357
1558,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL616379,,BAO_0000357
1559,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,11863,,H,8,Autocuration,1,,CHEMBL616380,,BAO_0000357
1560,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,11863,,H,8,Autocuration,1,,CHEMBL616381,,BAO_0000357
1561,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,11863,,H,8,Autocuration,1,,CHEMBL616382,,BAO_0000357
1562,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,11863,,H,8,Autocuration,1,,CHEMBL616383,,BAO_0000357
1563,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,,11863,CHO,D,9,Expert,1,,CHEMBL616350,449.0,BAO_0000219
1564,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,11863,,H,8,Autocuration,1,,CHEMBL616351,,BAO_0000357
1565,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,11863,,H,8,Autocuration,1,,CHEMBL616352,,BAO_0000357
1566,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,11863,,H,8,Autocuration,1,,CHEMBL616353,,BAO_0000357
1567,,Binding affinity against serotonergic 5-HT1a receptor,,,11863,,H,8,Autocuration,1,,CHEMBL616354,,BAO_0000357
1568,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,11863,,H,8,Autocuration,1,,CHEMBL616508,,BAO_0000357
1569,,Binding affinity for 5-hydroxytryptamine 1A receptor,,,11863,,D,9,Expert,1,,CHEMBL616559,,BAO_0000357
1570,,Binding affinity at 5-hydroxytryptamine 1A receptor,,,11863,,H,8,Autocuration,1,,CHEMBL616560,,BAO_0000357
1571,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,11863,,H,8,Autocuration,1,,CHEMBL616561,,BAO_0000357
1572,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,11863,CHO,H,8,Autocuration,1,,CHEMBL616562,449.0,BAO_0000219
1573,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,11863,CHO,H,8,Autocuration,1,,CHEMBL616563,449.0,BAO_0000219
1574,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,11863,,H,8,Autocuration,1,,CHEMBL616564,,BAO_0000357
1575,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,11863,,H,8,Autocuration,1,,CHEMBL616565,,BAO_0000357
1576,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,11863,,H,8,Autocuration,1,,CHEMBL616566,,BAO_0000218
1577,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,11863,,H,8,Autocuration,1,,CHEMBL616989,,BAO_0000357
1578,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,11863,,H,8,Autocuration,1,,CHEMBL857975,,BAO_0000357
1579,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,11863,,D,9,Expert,1,,CHEMBL616990,,BAO_0000357
1580,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,11863,,H,8,Autocuration,1,,CHEMBL616991,,BAO_0000357
1581,,Tested against 5-hydroxytryptamine 1A receptor,,,11863,,H,8,Autocuration,1,,CHEMBL616992,,BAO_0000357
1582,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,11863,,H,8,Autocuration,1,,CHEMBL616993,,BAO_0000357
1583,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,,106,,H,8,Expert,1,,CHEMBL616994,,BAO_0000019
1584,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,,106,,H,8,Autocuration,1,,CHEMBL616995,,BAO_0000019
1585,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,105571,HEK293,D,9,Intermediate,1,,CHEMBL616996,722.0,BAO_0000219
1586,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,106,,H,8,Autocuration,1,,CHEMBL616997,,BAO_0000218
1587,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,106,,H,8,Autocuration,1,,CHEMBL616998,,BAO_0000218
1588,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,,106,,H,8,Autocuration,1,,CHEMBL616999,,BAO_0000019
1589,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,,106,,H,8,Autocuration,1,,CHEMBL617000,,BAO_0000019
1590,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,,106,,H,8,Autocuration,1,,CHEMBL617001,,BAO_0000019
1591,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,,106,,H,8,Autocuration,1,,CHEMBL858111,,BAO_0000019
1592,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,106,,H,8,Autocuration,1,,CHEMBL617002,,BAO_0000019
1593,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,106,,H,8,Autocuration,1,,CHEMBL617003,,BAO_0000019
1594,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,106,,H,8,Autocuration,1,,CHEMBL617004,,BAO_0000019
1595,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,,106,,D,9,Expert,1,,CHEMBL617005,,BAO_0000019
1596,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,,106,CHO-K1,D,9,Expert,1,,CHEMBL616623,485.0,BAO_0000219
1597,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,,106,CHO,H,8,Autocuration,1,,CHEMBL616624,449.0,BAO_0000219
1598,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,106,,H,8,Autocuration,1,,CHEMBL883243,,BAO_0000357
1599,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,106,,H,8,Autocuration,1,,CHEMBL616625,,BAO_0000019
1600,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,,106,CHO,H,8,Expert,1,,CHEMBL616626,449.0,BAO_0000219
1601,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,,106,CHO,H,8,Autocuration,1,,CHEMBL616627,449.0,BAO_0000219
1602,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,,106,CHO,H,8,Autocuration,1,,CHEMBL616628,449.0,BAO_0000219
1603,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,,106,CHO,H,8,Autocuration,1,,CHEMBL616629,449.0,BAO_0000219
1604,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,,106,CHO,H,8,Autocuration,1,,CHEMBL616630,449.0,BAO_0000219
1605,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,106,,H,8,Expert,1,,CHEMBL616631,,BAO_0000019
1606,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,106,,H,8,Autocuration,1,,CHEMBL616632,,BAO_0000019
1607,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,,106,,D,9,Expert,1,,CHEMBL616633,,BAO_0000357
1608,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,,106,CHO,H,8,Expert,1,,CHEMBL616634,449.0,BAO_0000219
1609,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,106,,H,8,Autocuration,1,,CHEMBL616635,,BAO_0000357
1610,,Binding affinity against 5-hydroxytryptamine 1B receptor,,,106,,D,9,Expert,1,,CHEMBL885358,,BAO_0000357
1611,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,106,CHO,D,9,Expert,1,,CHEMBL616636,449.0,BAO_0000219
1612,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,,106,CHO,H,8,Expert,1,,CHEMBL616637,449.0,BAO_0000219
1613,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,106,,H,8,Autocuration,1,,CHEMBL616638,,BAO_0000357
1614,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,106,CHO,H,8,Expert,1,,CHEMBL616639,449.0,BAO_0000219
1615,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,106,CHO,H,8,Expert,1,,CHEMBL616640,449.0,BAO_0000219
1616,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,106,CHO,H,8,Expert,1,,CHEMBL616641,449.0,BAO_0000219
1617,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,,106,CHO,H,8,Expert,1,,CHEMBL616642,449.0,BAO_0000219
1618,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,106,CHO,H,8,Expert,1,,CHEMBL616643,449.0,BAO_0000219
1619,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,106,,H,8,Autocuration,1,,CHEMBL616644,,BAO_0000357
1620,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,106,,H,8,Autocuration,1,,CHEMBL616645,,BAO_0000357
1621,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,105,,H,8,Autocuration,1,,CHEMBL616646,,BAO_0000019
1622,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,105,,H,8,Expert,1,,CHEMBL616647,,BAO_0000019
1623,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,105,,H,8,Autocuration,1,,CHEMBL616509,,BAO_0000357
1624,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,105,,H,8,Autocuration,1,,CHEMBL616510,,BAO_0000357
1625,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616511,,BAO_0000357
1626,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,,105,,H,8,Expert,1,,CHEMBL616512,,BAO_0000357
1627,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,,105,,H,8,Autocuration,1,,CHEMBL616513,,BAO_0000357
1628,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,2435.0,,105,,H,8,Autocuration,1,,CHEMBL616514,,BAO_0000019
1629,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,,105,,H,8,Expert,1,,CHEMBL616515,,BAO_0000357
1630,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,,105,,H,8,Autocuration,1,,CHEMBL616516,,BAO_0000019
1631,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616517,,BAO_0000357
1632,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616518,,BAO_0000357
1633,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616519,,BAO_0000357
1634,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616520,,BAO_0000357
1635,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616521,,BAO_0000357
1636,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,,105,,H,8,Autocuration,1,,CHEMBL616522,,BAO_0000357
1637,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,105,,H,8,Autocuration,1,,CHEMBL884531,,BAO_0000357
1638,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616523,,BAO_0000357
1639,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,2435.0,,105,,H,8,Autocuration,1,,CHEMBL616731,,BAO_0000019
1640,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,,105,,H,8,Autocuration,1,,CHEMBL616732,,BAO_0000019
1641,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,,105,,H,8,Autocuration,1,,CHEMBL616733,,BAO_0000357
1642,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,105,,H,8,Autocuration,1,,CHEMBL616734,,BAO_0000357
1643,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,,105,,H,8,Autocuration,1,,CHEMBL616735,,BAO_0000249
1644,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,,105,,H,8,Autocuration,1,,CHEMBL616736,,BAO_0000249
1645,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105,,H,8,Expert,1,,CHEMBL616737,,BAO_0000019
1646,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,,105,,H,8,Autocuration,1,,CHEMBL616738,,BAO_0000019
1647,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105,,H,8,Expert,1,,CHEMBL616739,,BAO_0000019
1648,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105,,H,8,Expert,1,,CHEMBL616740,,BAO_0000019
1649,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105,,H,8,Expert,1,,CHEMBL616741,,BAO_0000019
1650,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,105,HEK293,H,8,Autocuration,1,,CHEMBL616742,722.0,BAO_0000219
1651,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,,105570,,D,9,Intermediate,1,,CHEMBL616743,,BAO_0000019
1652,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,,105570,,D,9,Intermediate,1,,CHEMBL616744,,BAO_0000019
1653,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,,105570,,D,9,Intermediate,1,,CHEMBL616745,,BAO_0000019
1654,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570,,D,9,Intermediate,1,,CHEMBL616746,,BAO_0000019
1655,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,,105570,,D,9,Intermediate,1,,CHEMBL616747,,BAO_0000019
1656,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,,105570,,D,9,Intermediate,1,,CHEMBL616748,,BAO_0000019
1657,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,,105570,,D,9,Intermediate,1,,CHEMBL616648,,BAO_0000019
1658,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,105570,,D,9,Intermediate,1,,CHEMBL616649,,BAO_0000357
1659,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,,105570,,D,9,Intermediate,1,,CHEMBL616650,,BAO_0000357
1660,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570,,D,9,Intermediate,1,,CHEMBL616651,,BAO_0000218
1661,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570,,D,9,Intermediate,1,,CHEMBL616652,,BAO_0000218
1662,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570,,D,9,Intermediate,1,,CHEMBL616653,,BAO_0000218
1663,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,,105570,,D,9,Intermediate,1,,CHEMBL616654,,BAO_0000218
1664,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,,105570,,D,9,Intermediate,1,,CHEMBL616655,,BAO_0000019
1665,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,,105570,,D,9,Intermediate,1,,CHEMBL616656,,BAO_0000357
1666,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,,105,,H,8,Autocuration,1,,CHEMBL616657,,BAO_0000019
1667,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,2435.0,,105570,,D,9,Intermediate,1,,CHEMBL616658,,BAO_0000357
1668,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,,105570,,D,9,Intermediate,1,,CHEMBL616659,,BAO_0000357
1669,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,51,,H,8,Autocuration,1,,CHEMBL616660,,BAO_0000357
1670,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,106,,H,8,Autocuration,1,,CHEMBL616661,,BAO_0000357
1671,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,105,,H,8,Expert,1,,CHEMBL616662,,BAO_0000019
1672,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616663,,BAO_0000019
1673,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616664,,BAO_0000019
1674,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,,105,CHO,D,9,Expert,1,,CHEMBL881820,449.0,BAO_0000219
1675,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,,105,CHO,H,8,Autocuration,1,,CHEMBL616665,449.0,BAO_0000219
1676,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,105,CHO,H,8,Expert,1,,CHEMBL616666,449.0,BAO_0000219
1677,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,,105,CHO,H,8,Autocuration,1,,CHEMBL616667,449.0,BAO_0000219
1678,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,105,CHO,H,8,Expert,1,,CHEMBL616668,449.0,BAO_0000219
1679,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,105,CHO,D,9,Expert,1,,CHEMBL616669,449.0,BAO_0000219
1680,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,,105,CHO,H,8,Expert,1,,CHEMBL617040,449.0,BAO_0000219
1681,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,,105,CHO,H,8,Autocuration,1,,CHEMBL617041,449.0,BAO_0000219
1682,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,,105,CHO,H,8,Expert,1,,CHEMBL617042,449.0,BAO_0000219
1683,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,,105,CHO,H,8,Expert,1,,CHEMBL617043,449.0,BAO_0000219
1684,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL617044,,BAO_0000019
1685,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,105,CHO,H,8,Expert,1,,CHEMBL617045,449.0,BAO_0000219
1686,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,105,CHO,D,9,Expert,1,,CHEMBL617046,449.0,BAO_0000219
1687,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,105,CHO,D,9,Expert,1,,CHEMBL617047,449.0,BAO_0000219
1688,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,105,,H,8,Expert,1,,CHEMBL617048,,BAO_0000019
1689,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,105,,H,8,Autocuration,1,,CHEMBL616897,,BAO_0000019
1690,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,,105,,D,9,Expert,1,,CHEMBL616898,,BAO_0000019
1691,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,,105,CHO,D,9,Expert,1,,CHEMBL858201,449.0,BAO_0000219
1692,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616899,,BAO_0000019
1693,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,,105,,H,8,Autocuration,1,,CHEMBL616900,,BAO_0000219
1694,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,,105,CHO,H,8,Expert,1,,CHEMBL616901,449.0,BAO_0000219
1695,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,105,,H,8,Autocuration,1,,CHEMBL616902,,BAO_0000357
1696,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,105,CHO,D,9,Expert,1,,CHEMBL616903,449.0,BAO_0000219
1697,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,,105,CHO,H,8,Expert,1,,CHEMBL616904,449.0,BAO_0000219
1698,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616905,,BAO_0000357
1699,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,105,CHO,H,8,Expert,1,,CHEMBL616906,449.0,BAO_0000219
1700,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,105,CHO,H,8,Expert,1,,CHEMBL616907,449.0,BAO_0000219
1701,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,105,CHO,H,8,Expert,1,,CHEMBL616908,449.0,BAO_0000219
1702,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,105,CHO,D,9,Expert,1,,CHEMBL616909,449.0,BAO_0000219
1703,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,105,CHO,D,9,Expert,1,,CHEMBL616910,449.0,BAO_0000219
1704,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,105,CHO,H,8,Expert,1,,CHEMBL616911,449.0,BAO_0000219
1705,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,105,CHO,H,8,Expert,1,,CHEMBL616912,449.0,BAO_0000219
1706,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,105,,H,8,Autocuration,1,,CHEMBL616913,,BAO_0000357
1707,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,,105,CHO,D,9,Expert,1,,CHEMBL616914,449.0,BAO_0000219
1708,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,105,CHO,H,8,Autocuration,1,,CHEMBL616915,449.0,BAO_0000219
1709,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616916,,BAO_0000019
1710,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,,105,,D,9,Expert,1,,CHEMBL616917,,BAO_0000357
1711,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,105,,H,8,Autocuration,1,,CHEMBL616918,,BAO_0000357
1712,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,105,,H,8,Expert,1,,CHEMBL616919,,BAO_0000219
1713,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616920,,BAO_0000357
1714,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,105,,H,8,Autocuration,1,,CHEMBL872914,,BAO_0000357
1715,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616921,,BAO_0000357
1716,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,105,,H,8,Expert,1,,CHEMBL616922,,BAO_0000357
1717,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616923,,BAO_0000357
1718,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,105,,H,8,Expert,1,,CHEMBL616924,,BAO_0000357
1719,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,105,,H,8,Expert,1,,CHEMBL875909,,BAO_0000357
1720,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,105,,H,8,Autocuration,1,,CHEMBL616925,,BAO_0000357
1721,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,105,,H,8,Autocuration,1,,CHEMBL616926,,BAO_0000357
1722,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616927,,BAO_0000357
1723,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,,105,CHO-K1,H,8,Expert,1,,CHEMBL616928,485.0,BAO_0000219
1724,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,,105,,D,9,Expert,1,,CHEMBL616929,,BAO_0000219
1725,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,,105,,D,9,Expert,1,,CHEMBL616930,,BAO_0000357
1726,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,105,,H,8,Expert,1,,CHEMBL616931,,BAO_0000019
1727,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616932,,BAO_0000357
1728,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,105,,H,8,Expert,1,,CHEMBL616933,,BAO_0000357
1729,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,,105,,D,9,Expert,1,,CHEMBL616934,,BAO_0000219
1730,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,105,,D,9,Expert,1,,CHEMBL616935,,BAO_0000357
1731,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,105,,H,8,Autocuration,1,,CHEMBL616936,,BAO_0000357
1732,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,,105,,D,9,Expert,1,,CHEMBL616937,,BAO_0000357
1733,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,105,,D,9,Expert,1,,CHEMBL616938,,BAO_0000357
1734,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616939,,BAO_0000019
1735,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,105,,H,8,Expert,1,,CHEMBL616940,,BAO_0000019
1736,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,,105,,D,9,Expert,1,,CHEMBL616941,,BAO_0000357
1737,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,,105,CHO-K1,H,8,Autocuration,1,,CHEMBL616942,485.0,BAO_0000219
1738,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,,105,CHO-K1,H,8,Autocuration,1,,CHEMBL616943,485.0,BAO_0000219
1739,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,,104802,CHO,H,4,Autocuration,1,,CHEMBL616944,449.0,BAO_0000219
1740,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,105,,H,8,Autocuration,1,,CHEMBL616945,,BAO_0000019
1741,,Binding activity radioligand.,,,105,,H,8,Autocuration,1,,CHEMBL616946,,BAO_0000357
1742,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,105,,H,8,Autocuration,1,,CHEMBL616947,,BAO_0000019
1743,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,,105,CHO-K1,H,8,Expert,1,,CHEMBL616948,485.0,BAO_0000219
1744,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616851,,BAO_0000357
1745,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616852,,BAO_0000357
1746,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616853,,BAO_0000357
1747,,Binding activity against human 5-hydroxytryptamine 1D receptor,,,105,,D,9,Expert,1,,CHEMBL616854,,BAO_0000357
1748,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,105,CHO,D,9,Expert,1,,CHEMBL616855,449.0,BAO_0000219
1749,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,,105,CHO,H,8,Autocuration,1,,CHEMBL616856,449.0,BAO_0000219
1750,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,105,CHO,H,8,Autocuration,1,,CHEMBL616857,449.0,BAO_0000219
1751,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL616858,,BAO_0000357
1752,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,,105,CHO,H,8,Autocuration,1,,CHEMBL616859,449.0,BAO_0000219
1753,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,,105,CHO,H,8,Autocuration,1,,CHEMBL616860,449.0,BAO_0000219
1754,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,105,HEK293,H,8,Autocuration,1,,CHEMBL616861,722.0,BAO_0000219
1755,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,105,HEK293,H,8,Autocuration,1,,CHEMBL616541,722.0,BAO_0000219
1756,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,,105,HEK293,H,8,Autocuration,1,,CHEMBL616542,722.0,BAO_0000219
1757,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,,105,CHO,H,8,Autocuration,1,,CHEMBL616543,449.0,BAO_0000219
1758,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,105,,D,9,Expert,1,,CHEMBL616544,,BAO_0000357
1759,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,,105,CHO,H,8,Autocuration,1,,CHEMBL616545,449.0,BAO_0000219
1760,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616546,,BAO_0000357
1761,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,,105,CHO,H,8,Autocuration,1,,CHEMBL616547,449.0,BAO_0000219
1762,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,,105,CHO,H,8,Autocuration,1,,CHEMBL616548,449.0,BAO_0000219
1763,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,105,,H,8,Expert,1,,CHEMBL616549,,BAO_0000019
1764,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,105,,H,8,Expert,1,,CHEMBL616550,,BAO_0000019
1765,,Binding affinity against 5-HT2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL857066,,BAO_0000357
1766,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,108,,H,8,Autocuration,1,,CHEMBL616551,,BAO_0000357
1767,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,10577,,H,8,Autocuration,1,,CHEMBL616552,,BAO_0000357
1768,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,10577,,H,8,Autocuration,1,,CHEMBL832876,,BAO_0000019
1769,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,10577,,H,8,Expert,1,,CHEMBL616553,,BAO_0000019
1770,,Binding affinity towards 5-HT1B was determined,,,10577,,H,8,Autocuration,1,,CHEMBL616554,,BAO_0000357
1771,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,10577,,H,8,Expert,1,,CHEMBL616555,,BAO_0000019
1772,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,10577,,H,8,Expert,1,,CHEMBL616556,,BAO_0000019
1773,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,10577,,H,8,Autocuration,1,,CHEMBL616557,,BAO_0000019
1774,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,10577,,H,8,Expert,1,,CHEMBL616558,,BAO_0000019
1775,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,,10577,,D,9,Expert,1,,CHEMBL616749,,BAO_0000019
1776,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,10577,,H,8,Autocuration,1,,CHEMBL616750,,BAO_0000357
1777,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,10577,,H,8,Autocuration,1,,CHEMBL616751,,BAO_0000357
1778,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,10577,,H,8,Autocuration,1,,CHEMBL616752,,BAO_0000249
1779,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,2435.0,,10577,,H,8,Autocuration,1,,CHEMBL616753,,BAO_0000019
1780,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,,10577,,D,9,Expert,1,,CHEMBL616754,,BAO_0000357
1781,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,10577,,H,8,Autocuration,1,,CHEMBL616755,,BAO_0000019
1782,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,2435.0,,10577,,H,8,Autocuration,1,,CHEMBL616756,,BAO_0000019
1783,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,2435.0,,10577,,H,8,Autocuration,1,,CHEMBL616757,,BAO_0000019
1784,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,2435.0,,10577,,H,8,Autocuration,1,,CHEMBL616758,,BAO_0000357
1785,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,10577,,H,8,Autocuration,1,,CHEMBL616759,,BAO_0000249
1786,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,10577,,H,8,Autocuration,1,,CHEMBL616760,,BAO_0000357
1787,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,2435.0,,10577,,H,8,Autocuration,1,,CHEMBL616761,,BAO_0000019
1788,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,2435.0,,10577,,H,8,Autocuration,1,,CHEMBL616762,,BAO_0000019
1789,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,10577,,H,8,Autocuration,1,,CHEMBL616763,,BAO_0000019
1790,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,10577,,H,8,Expert,1,,CHEMBL872909,,BAO_0000357
1791,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,10577,,H,8,Autocuration,1,,CHEMBL616764,,BAO_0000357
1792,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,,10577,,D,9,Expert,1,,CHEMBL616765,,BAO_0000357
1793,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,2435.0,,10577,,H,8,Autocuration,1,,CHEMBL616766,,BAO_0000357
1794,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,2435.0,,10577,,H,8,Autocuration,1,,CHEMBL616767,,BAO_0000357
1795,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,10577,,H,8,Autocuration,1,,CHEMBL616768,,BAO_0000357
1796,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,10577,,H,8,Autocuration,1,,CHEMBL616769,,BAO_0000357
1797,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,10577,,H,8,Autocuration,1,,CHEMBL616770,,BAO_0000019
1798,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,10577,,H,8,Autocuration,1,,CHEMBL616771,,BAO_0000019
1799,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,2435.0,,10577,,H,8,Autocuration,1,,CHEMBL616772,,BAO_0000019
1800,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,10577,,H,8,Expert,1,,CHEMBL616773,,BAO_0000019
1801,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,10577,,H,8,Autocuration,1,,CHEMBL616774,,BAO_0000019
1802,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,10577,,H,8,Autocuration,1,,CHEMBL616775,,BAO_0000357
1803,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,10577,,H,8,Autocuration,1,,CHEMBL616776,,BAO_0000249
1804,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,10577,,H,8,Autocuration,1,,CHEMBL616777,,BAO_0000357
1805,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,10577,,H,8,Autocuration,1,,CHEMBL616778,,BAO_0000357
1806,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,,10577,,D,9,Expert,1,,CHEMBL616779,,BAO_0000249
1807,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,10577,,D,9,Expert,1,,CHEMBL616780,,BAO_0000357
1808,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,10577,,H,8,Autocuration,1,,CHEMBL616781,,BAO_0000019
1809,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,10577,,H,8,Autocuration,1,,CHEMBL616782,,BAO_0000357
1810,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,10577,,H,8,Autocuration,1,,CHEMBL616783,,BAO_0000357
1811,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,2435.0,,10577,,H,8,Expert,1,,CHEMBL616784,,BAO_0000019
1812,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,10577,,H,8,Autocuration,1,,CHEMBL616785,,BAO_0000357
1813,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,,10577,,H,8,Autocuration,1,,CHEMBL857067,,BAO_0000249
1814,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,10577,,H,8,Autocuration,1,,CHEMBL616786,,BAO_0000019
1815,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,,10577,,H,8,Autocuration,1,,CHEMBL616787,,BAO_0000249
1816,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,10577,,H,8,Autocuration,1,,CHEMBL616788,,BAO_0000357
1817,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,10577,,H,8,Autocuration,1,,CHEMBL616789,,BAO_0000357
1818,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,,10577,,D,9,Expert,1,,CHEMBL616790,,BAO_0000019
1819,,Binding affinity at 5-hydroxytryptamine 1B receptor,,,10577,,H,8,Expert,1,,CHEMBL616791,,BAO_0000357
1820,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,10577,,H,8,Autocuration,1,,CHEMBL616792,,BAO_0000019
1821,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,,10577,,D,9,Expert,1,,CHEMBL616793,,BAO_0000249
1822,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,10577,,H,8,Autocuration,1,,CHEMBL616794,,BAO_0000357
1823,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,10577,,H,8,Autocuration,1,,CHEMBL616795,,BAO_0000357
1824,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,104686,,H,4,Autocuration,1,,CHEMBL616796,,BAO_0000019
1825,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,106,,H,8,Autocuration,1,,CHEMBL616797,,BAO_0000357
1826,Brain membranes,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,106,,H,8,Autocuration,1,,CHEMBL616798,,BAO_0000249
1827,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,106,,H,8,Autocuration,1,,CHEMBL616799,,BAO_0000357
1828,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,106,,H,8,Autocuration,1,,CHEMBL616800,,BAO_0000357
1829,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,106,,H,8,Autocuration,1,,CHEMBL616801,,BAO_0000357
1830,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,106,,H,8,Autocuration,1,,CHEMBL616802,,BAO_0000357
1831,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,106,,H,8,Autocuration,1,,CHEMBL616803,,BAO_0000357
1832,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,106,,H,8,Expert,1,,CHEMBL857068,,BAO_0000357
1833,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,106,,H,8,Autocuration,1,,CHEMBL616804,,BAO_0000357
1834,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,106,,H,8,Autocuration,1,,CHEMBL616805,,BAO_0000357
1835,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,106,,H,8,Autocuration,1,,CHEMBL616806,,BAO_0000357
1836,,Binding affinity against 5-hydroxytryptamine 1B receptor,,,106,,H,8,Autocuration,1,,CHEMBL616807,,BAO_0000357
1837,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,106,,H,8,Autocuration,1,,CHEMBL616808,,BAO_0000357
1838,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,106,,H,8,Autocuration,1,,CHEMBL616809,,BAO_0000357
1839,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,106,,H,8,Autocuration,1,,CHEMBL616810,,BAO_0000357
1840,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,104802,,H,4,Autocuration,1,,CHEMBL616811,,BAO_0000224
1841,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,,108,,H,8,Autocuration,1,,CHEMBL616812,,BAO_0000357
1842,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL616813,,BAO_0000357
1843,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL616814,,BAO_0000357
1844,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,108,,H,8,Autocuration,1,,CHEMBL616815,,BAO_0000357
1845,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,108,,H,8,Autocuration,1,,CHEMBL616816,,BAO_0000357
1846,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,,108,,H,8,Autocuration,1,,CHEMBL616817,,BAO_0000357
1847,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,,108,,H,8,Autocuration,1,,CHEMBL616818,,BAO_0000357
1848,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,,108,,H,8,Expert,1,,CHEMBL616819,,BAO_0000357
1849,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,,108,,H,8,Expert,1,,CHEMBL616820,,BAO_0000357
1850,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,,108,,H,8,Expert,1,,CHEMBL616821,,BAO_0000019
1851,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,,108,,H,8,Autocuration,1,,CHEMBL616822,,BAO_0000357
1852,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,108,,H,8,Autocuration,1,,CHEMBL616823,,BAO_0000019
1853,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,,12689,,D,9,Autocuration,1,,CHEMBL616824,,BAO_0000357
1854,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,12689,,D,9,Autocuration,1,,CHEMBL616825,,BAO_0000357
1855,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,12689,,D,9,Autocuration,1,,CHEMBL616826,,BAO_0000357
1856,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,,12689,,D,9,Expert,1,,CHEMBL616827,,BAO_0000019
1857,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,,12689,,D,9,Autocuration,1,,CHEMBL616828,,BAO_0000357
1858,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,12689,,D,9,Autocuration,1,,CHEMBL616829,,BAO_0000357
1859,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,,12689,,D,9,Autocuration,1,,CHEMBL616830,,BAO_0000019
1860,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,12689,,D,9,Expert,1,,CHEMBL616831,,BAO_0000357
1861,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689,,D,9,Autocuration,1,,CHEMBL616832,,BAO_0000019
1862,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689,,D,9,Autocuration,1,,CHEMBL616833,,BAO_0000019
1863,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689,,D,9,Expert,1,,CHEMBL616834,,BAO_0000019
1864,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689,,D,9,Autocuration,1,,CHEMBL829595,,BAO_0000019
1865,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,,12689,,D,9,Autocuration,1,,CHEMBL616835,,BAO_0000357
1866,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,,12689,,D,9,Autocuration,1,,CHEMBL872910,,BAO_0000249
1867,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,12689,,H,8,Expert,1,,CHEMBL616836,,BAO_0000357
1868,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,,12689,,D,9,Autocuration,1,,CHEMBL616837,,BAO_0000357
1869,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,,12689,,D,9,Autocuration,1,,CHEMBL616466,,BAO_0000019
1870,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,,12689,HEK293,D,9,Autocuration,1,,CHEMBL616467,722.0,BAO_0000219
1871,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,108,,H,8,Autocuration,1,,CHEMBL616468,,BAO_0000357
1872,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL616469,,BAO_0000357
1873,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL616470,,BAO_0000357
1874,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL616471,,BAO_0000357
1875,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL616472,,BAO_0000357
1876,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL616473,,BAO_0000357
1877,,Binding affinity against serotonergic 5-HT1c receptor,,,12689,,H,8,Autocuration,1,,CHEMBL616474,,BAO_0000357
1878,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,12689,,H,8,Autocuration,1,,CHEMBL616475,,BAO_0000357
1879,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,12689,,H,8,Autocuration,1,,CHEMBL616476,,BAO_0000357
1880,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,105,,H,8,Autocuration,1,,CHEMBL616477,,BAO_0000019
1881,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL616478,,BAO_0000224
1882,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL616479,,BAO_0000224
1883,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,104686,,H,4,Autocuration,1,,CHEMBL616480,,BAO_0000019
1884,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,,104686,,D,5,Autocuration,1,,CHEMBL616481,,BAO_0000019
1885,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,,104686,,D,5,Autocuration,1,,CHEMBL616482,,BAO_0000249
1886,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,955.0,,104686,,D,5,Autocuration,1,,CHEMBL884713,,BAO_0000221
1887,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,104686,,H,4,Autocuration,1,,CHEMBL616483,,BAO_0000224
1888,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,104686,,H,4,Autocuration,1,,CHEMBL616484,,BAO_0000224
1889,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,104686,,H,4,Autocuration,1,,CHEMBL616485,,BAO_0000019
1890,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,104686,,H,4,Autocuration,1,,CHEMBL616486,,BAO_0000224
1891,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,104686,,H,4,Autocuration,1,,CHEMBL616487,,BAO_0000224
1892,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,104686,,H,4,Autocuration,1,,CHEMBL616488,,BAO_0000224
1893,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL616489,,BAO_0000019
1894,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL616490,,BAO_0000019
1895,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,104686,,H,4,Autocuration,1,,CHEMBL616491,,BAO_0000019
1896,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,104686,,H,4,Autocuration,1,,CHEMBL616492,,BAO_0000019
1897,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL616493,,BAO_0000019
1898,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL616494,,BAO_0000019
1899,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL616495,,BAO_0000019
1900,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,104686,,H,4,Autocuration,1,,CHEMBL616496,,BAO_0000019
1901,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL616497,,BAO_0000019
1902,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL616498,,BAO_0000019
1903,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL616499,,BAO_0000019
1904,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,104686,,H,4,Autocuration,1,,CHEMBL616500,,BAO_0000019
1905,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,955.0,,104686,,D,5,Autocuration,1,,CHEMBL616501,,BAO_0000221
1906,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,955.0,,104686,,H,4,Autocuration,1,,CHEMBL616502,,BAO_0000221
1907,Membranes,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,104686,,H,4,Autocuration,1,,CHEMBL884529,,BAO_0000249
1908,Membranes,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,104686,,H,4,Autocuration,1,,CHEMBL616503,,BAO_0000249
1909,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL616964,,BAO_0000224
1910,Membranes,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,104686,,H,4,Autocuration,1,,CHEMBL616965,,BAO_0000249
1911,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,104686,,H,4,Autocuration,1,,CHEMBL616966,,BAO_0000224
1912,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,104686,,H,4,Autocuration,1,,CHEMBL616967,,BAO_0000224
1913,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,,104686,,D,5,Autocuration,1,,CHEMBL616968,,BAO_0000224
1914,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,104686,,H,4,Autocuration,1,,CHEMBL616969,,BAO_0000224
1915,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,104686,,H,4,Autocuration,1,,CHEMBL884530,,BAO_0000019
1916,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL616970,,BAO_0000224
1917,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,104686,,H,4,Autocuration,1,,CHEMBL616971,,BAO_0000224
1918,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,104686,,H,4,Autocuration,1,,CHEMBL616972,,BAO_0000224
1919,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,104686,,H,4,Autocuration,1,,CHEMBL616973,,BAO_0000224
1920,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,104686,,H,4,Autocuration,1,,CHEMBL616974,,BAO_0000224
1921,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,104686,,H,4,Autocuration,1,,CHEMBL616975,,BAO_0000019
1922,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,104686,,H,4,Autocuration,1,,CHEMBL616976,,BAO_0000019
1923,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL616977,,BAO_0000224
1924,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,104686,,H,4,Autocuration,1,,CHEMBL616978,,BAO_0000224
1925,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,104686,,H,4,Autocuration,1,,CHEMBL616979,,BAO_0000224
1926,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL616980,,BAO_0000224
1927,Membranes,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,104686,,H,4,Autocuration,1,,CHEMBL616981,,BAO_0000249
1928,Membranes,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,104686,,H,4,Autocuration,1,,CHEMBL616982,,BAO_0000249
1929,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,104686,,H,4,Autocuration,1,,CHEMBL616983,,BAO_0000224
1930,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,104686,,H,4,Autocuration,1,,CHEMBL616984,,BAO_0000019
1931,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,,104686,,D,5,Autocuration,1,,CHEMBL616985,,BAO_0000224
1932,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,104686,,H,4,Autocuration,1,,CHEMBL616986,,BAO_0000224
1933,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,104686,,H,4,Autocuration,1,,CHEMBL616987,,BAO_0000224
1934,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,104686,,H,4,Autocuration,1,,CHEMBL616988,,BAO_0000019
1935,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,104686,,H,4,Autocuration,1,,CHEMBL617243,,BAO_0000019
1936,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,104686,,H,4,Autocuration,1,,CHEMBL617244,,BAO_0000019
1937,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,104686,CHO-K1,D,5,Autocuration,1,,CHEMBL617245,485.0,BAO_0000219
1938,Membranes,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,104686,,H,4,Autocuration,1,,CHEMBL617246,,BAO_0000249
1939,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,104686,,H,4,Autocuration,1,,CHEMBL617546,,BAO_0000224
1940,Brain membranes,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,104686,,H,4,Autocuration,1,,CHEMBL617547,,BAO_0000249
1941,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,104686,,H,4,Autocuration,1,,CHEMBL617548,,BAO_0000219
1942,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617549,,BAO_0000224
1943,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,104686,,H,4,Autocuration,1,,CHEMBL617550,,BAO_0000224
1944,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,104686,,H,4,Autocuration,1,,CHEMBL617551,,BAO_0000224
1945,Membranes,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,104686,,H,4,Autocuration,1,,CHEMBL617552,,BAO_0000249
1946,Membranes,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,104686,,H,4,Autocuration,1,,CHEMBL617553,,BAO_0000249
1947,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,1515.0,,104686,,H,4,Autocuration,1,,CHEMBL617554,,BAO_0000019
1948,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617555,,BAO_0000019
1949,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,104686,,H,4,Autocuration,1,,CHEMBL617556,,BAO_0000224
1950,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,10624,,H,8,Autocuration,1,,CHEMBL617557,,BAO_0000357
1951,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,10624,,H,8,Autocuration,1,,CHEMBL617558,,BAO_0000357
1952,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,17106,,H,8,Expert,1,,CHEMBL617559,,BAO_0000357
1953,,Binding affinity for 5-hydroxytryptamine 1D receptor,,,17106,,D,9,Expert,1,,CHEMBL617560,,BAO_0000357
1954,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,17106,,H,8,Autocuration,1,,CHEMBL617561,,BAO_0000249
1955,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,17106,,H,8,Autocuration,1,,CHEMBL617562,,BAO_0000249
1956,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,2435.0,,17106,,H,8,Autocuration,1,,CHEMBL617563,,BAO_0000357
1957,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,17106,,H,8,Autocuration,1,,CHEMBL617564,,BAO_0000019
1958,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,17106,,H,8,Expert,1,,CHEMBL617565,,BAO_0000019
1959,,Binding activity radioligand.,,,17106,,H,8,Autocuration,1,,CHEMBL856076,,BAO_0000357
1960,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,17106,,H,8,Autocuration,1,,CHEMBL617566,,BAO_0000019
1961,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,17106,,H,8,Expert,1,,CHEMBL875911,,BAO_0000019
1962,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,17106,,H,8,Autocuration,1,,CHEMBL617567,,BAO_0000019
1963,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,17106,,H,8,Autocuration,1,,CHEMBL617568,,BAO_0000249
1964,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,17106,,H,8,Expert,1,,CHEMBL617569,,BAO_0000019
1965,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,17106,,H,8,Expert,1,,CHEMBL617570,,BAO_0000249
1966,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,17106,,H,8,Autocuration,1,,CHEMBL617571,,BAO_0000357
1967,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,,105,,H,8,Autocuration,1,,CHEMBL617572,,BAO_0000357
1968,,The compound was tested for intrinsic activity against 5-HT1D receptor,,,105,,H,8,Expert,1,,CHEMBL617573,,BAO_0000357
1969,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,105,,H,8,Autocuration,1,,CHEMBL617574,,BAO_0000019
1970,,The compound was tested for binding affinity against 5-HT1D receptor,,,105,,H,8,Expert,1,,CHEMBL617575,,BAO_0000357
1971,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,10578,,H,8,Autocuration,1,,CHEMBL617576,,BAO_0000357
1972,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,10578,,H,8,Autocuration,1,,CHEMBL617577,,BAO_0000019
1973,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,10578,,H,8,Autocuration,1,,CHEMBL617578,,BAO_0000019
1974,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,10578,,H,8,Autocuration,1,,CHEMBL617579,,BAO_0000357
1975,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,10578,,H,8,Expert,1,,CHEMBL617580,,BAO_0000019
1976,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,10578,,H,8,Autocuration,1,,CHEMBL617581,,BAO_0000249
1977,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,10578,,H,8,Autocuration,1,,CHEMBL617582,,BAO_0000357
1978,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,10578,,H,8,Expert,1,,CHEMBL617583,,BAO_0000019
1979,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,105,,H,8,Autocuration,1,,CHEMBL617584,,BAO_0000357
1980,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL617585,,BAO_0000357
1981,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL875912,,BAO_0000357
1982,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL617586,,BAO_0000357
1983,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,105,,H,8,Autocuration,1,,CHEMBL617587,,BAO_0000357
1984,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,105,,H,8,Autocuration,1,,CHEMBL617588,,BAO_0000357
1985,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL857980,,BAO_0000357
1986,,Tested against 5-hydroxytryptamine 1D receptor,,,105,,H,8,Autocuration,1,,CHEMBL617589,,BAO_0000357
1987,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL617590,,BAO_0000357
1988,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,105,HEK293,H,8,Autocuration,1,,CHEMBL617591,722.0,BAO_0000219
1989,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,,105,,D,9,Expert,1,,CHEMBL617592,,BAO_0000357
1990,,,,,105,,H,8,Autocuration,1,,CHEMBL617593,,BAO_0000357
1991,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,106,CHO-K1,H,8,Autocuration,1,,CHEMBL617594,485.0,BAO_0000219
1992,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,105,CHO-K1,H,8,Autocuration,1,,CHEMBL617595,485.0,BAO_0000219
1993,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,,105,HEK293,H,8,Autocuration,1,,CHEMBL617596,722.0,BAO_0000219
1994,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,105,HEK293,H,8,Autocuration,1,,CHEMBL617597,722.0,BAO_0000219
1995,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,105,,H,8,Autocuration,1,,CHEMBL617598,,BAO_0000019
1996,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,105,,H,8,Autocuration,1,,CHEMBL872916,,BAO_0000357
1997,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,105,,H,8,Expert,1,,CHEMBL617599,,BAO_0000357
1998,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,105,,H,8,Autocuration,1,,CHEMBL617091,,BAO_0000357
1999,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,,105,CHO-K1,H,8,Expert,1,,CHEMBL617092,485.0,BAO_0000219
2000,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,105,CHO-K1,H,8,Autocuration,1,,CHEMBL617093,485.0,BAO_0000219
2001,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,105,,H,8,Autocuration,1,,CHEMBL617094,,BAO_0000019
2002,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,105,,H,8,Autocuration,1,,CHEMBL617095,,BAO_0000019
2003,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,105,,H,8,Autocuration,1,,CHEMBL617096,,BAO_0000019
2004,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,105,,H,8,Autocuration,1,,CHEMBL617097,,BAO_0000019
2005,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,105,,H,8,Autocuration,1,,CHEMBL617098,,BAO_0000019
2006,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL617301,,BAO_0000357
2007,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL617302,,BAO_0000357
2008,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,105,,H,8,Autocuration,1,,CHEMBL617303,,BAO_0000357
2009,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,105,,H,8,Expert,1,,CHEMBL617304,,BAO_0000357
2010,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,,105,CHO,H,8,Expert,1,,CHEMBL617305,449.0,BAO_0000219
2011,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,,105,,D,9,Autocuration,1,,CHEMBL617306,,BAO_0000219
2012,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,17106,,H,8,Autocuration,1,,CHEMBL617307,,BAO_0000357
2013,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,105,,H,8,Autocuration,1,,CHEMBL617308,,BAO_0000019
2014,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,105,,H,8,Autocuration,1,,CHEMBL617309,,BAO_0000357
2015,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,105,,H,8,Autocuration,1,,CHEMBL617310,,BAO_0000357
2016,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,105,,H,8,Autocuration,1,,CHEMBL617311,,BAO_0000357
2017,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL617312,,BAO_0000357
2018,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,105,,H,8,Autocuration,1,,CHEMBL617313,,BAO_0000357
2019,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,105,,H,8,Expert,1,,CHEMBL617314,,BAO_0000357
2020,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,106,,H,8,Autocuration,1,,CHEMBL617315,,BAO_0000019
2021,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,,106,HEK293,H,8,Autocuration,1,,CHEMBL617316,722.0,BAO_0000219
2022,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,106,HEK293,H,8,Autocuration,1,,CHEMBL617317,722.0,BAO_0000219
2023,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,106,CHO,H,8,Autocuration,1,,CHEMBL617318,449.0,BAO_0000219
2024,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,106,,H,8,Autocuration,1,,CHEMBL617319,,BAO_0000019
2025,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,106,,D,9,Expert,1,,CHEMBL617320,,BAO_0000357
2026,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,106,,D,9,Expert,1,,CHEMBL617321,,BAO_0000357
2027,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,106,,D,9,Expert,1,,CHEMBL617322,,BAO_0000357
2028,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,106,,H,8,Autocuration,1,,CHEMBL616862,,BAO_0000357
2029,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,106,,H,8,Autocuration,1,,CHEMBL616863,,BAO_0000357
2030,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,,106,CHO,H,8,Autocuration,1,,CHEMBL616864,449.0,BAO_0000219
2031,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,,106,CHO-K1,H,8,Autocuration,1,,CHEMBL616865,485.0,BAO_0000219
2032,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,,106,CHO-K1,H,8,Autocuration,1,,CHEMBL616866,485.0,BAO_0000219
2033,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,106,,H,8,Autocuration,1,,CHEMBL616867,,BAO_0000019
2034,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,,106,CHO-K1,H,8,Expert,1,,CHEMBL616868,485.0,BAO_0000219
2035,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,105,,H,8,Expert,1,,CHEMBL616869,,BAO_0000357
2036,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,106,CHO,H,8,Expert,1,,CHEMBL616870,449.0,BAO_0000219
2037,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,,105,CHO-K1,H,8,Autocuration,1,,CHEMBL616871,485.0,BAO_0000219
2038,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,,105,CHO-K1,H,8,Autocuration,1,,CHEMBL616872,485.0,BAO_0000219
2039,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,,105,CHO-K1,H,8,Autocuration,1,,CHEMBL616873,485.0,BAO_0000219
2040,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,,105,CHO-K1,H,8,Autocuration,1,,CHEMBL616838,485.0,BAO_0000219
2041,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,105,,H,8,Autocuration,1,,CHEMBL616839,,BAO_0000357
2042,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,,106,,H,8,Autocuration,1,,CHEMBL616840,,BAO_0000019
2043,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616841,,BAO_0000357
2044,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,105,,H,8,Autocuration,1,,CHEMBL616842,,BAO_0000357
2045,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,105,,H,8,Expert,1,,CHEMBL857976,,BAO_0000357
2046,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,,10618,CHO,H,8,Autocuration,1,,CHEMBL616843,449.0,BAO_0000219
2047,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,,10618,,D,9,Expert,1,,CHEMBL616844,,BAO_0000357
2048,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,10618,,H,8,Autocuration,1,,CHEMBL616845,,BAO_0000357
2049,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,,10618,,D,9,Expert,1,,CHEMBL616846,,BAO_0000357
2050,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,10618,,H,8,Autocuration,1,,CHEMBL616847,,BAO_0000357
2051,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,10618,,H,8,Autocuration,1,,CHEMBL616848,,BAO_0000019
2052,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,10618,,H,8,Autocuration,1,,CHEMBL616849,,BAO_0000357
2053,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,10618,,H,8,Autocuration,1,,CHEMBL872911,,BAO_0000357
2054,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,10618,,H,8,Autocuration,1,,CHEMBL616850,,BAO_0000019
2055,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,,10618,CHO,D,9,Expert,1,,CHEMBL616699,449.0,BAO_0000219
2056,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,10618,,H,8,Autocuration,1,,CHEMBL616700,,BAO_0000357
2057,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,10618,CHO,H,8,Autocuration,1,,CHEMBL616701,449.0,BAO_0000219
2058,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,,10618,CHO,H,8,Autocuration,1,,CHEMBL616702,449.0,BAO_0000219
2059,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,10618,CHO,H,8,Autocuration,1,,CHEMBL616703,449.0,BAO_0000219
2060,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,10618,,H,8,Autocuration,1,,CHEMBL616704,,BAO_0000357
2061,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,,10618,CHO,H,8,Autocuration,1,,CHEMBL616705,449.0,BAO_0000219
2062,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,10618,,H,8,Autocuration,1,,CHEMBL616706,,BAO_0000357
2063,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,,10618,CHO,H,8,Autocuration,1,,CHEMBL616707,449.0,BAO_0000219
2064,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,10618,,H,8,Autocuration,1,,CHEMBL616708,,BAO_0000357
2065,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,10618,,H,8,Autocuration,1,,CHEMBL616709,,BAO_0000357
2066,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,,10618,CHO,H,8,Autocuration,1,,CHEMBL616710,449.0,BAO_0000219
2067,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,,10618,CHO,H,8,Autocuration,1,,CHEMBL616711,449.0,BAO_0000219
2068,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,,10618,CHO,H,8,Autocuration,1,,CHEMBL616712,449.0,BAO_0000219
2069,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,10618,,H,8,Autocuration,1,,CHEMBL616713,,BAO_0000357
2070,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,10618,,H,8,Autocuration,1,,CHEMBL616714,,BAO_0000357
2071,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,10618,,H,8,Autocuration,1,,CHEMBL616715,,BAO_0000357
2072,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,10618,,H,8,Autocuration,1,,CHEMBL616716,,BAO_0000357
2073,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,279,,H,8,Autocuration,1,,CHEMBL616717,,BAO_0000019
2074,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,279,,H,8,Expert,1,,CHEMBL616718,,BAO_0000019
2075,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,279,,H,8,Autocuration,1,,CHEMBL875905,,BAO_0000019
2076,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,279,,H,8,Autocuration,1,,CHEMBL616719,,BAO_0000019
2077,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,279,,H,8,Expert,1,,CHEMBL616720,,BAO_0000019
2078,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,279,,H,8,Autocuration,1,,CHEMBL616721,,BAO_0000357
2079,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,,279,CHO,H,8,Autocuration,1,,CHEMBL616722,449.0,BAO_0000219
2080,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,279,,H,8,Autocuration,1,,CHEMBL616723,,BAO_0000357
2081,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,,279,CHO,H,8,Autocuration,1,,CHEMBL616724,449.0,BAO_0000219
2082,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,279,,H,8,Autocuration,1,,CHEMBL616725,,BAO_0000357
2083,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,279,,H,8,Autocuration,1,,CHEMBL616726,,BAO_0000357
2084,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,279,,H,8,Autocuration,1,,CHEMBL616727,,BAO_0000357
2085,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,279,,H,8,Autocuration,1,,CHEMBL616728,,BAO_0000357
2086,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,279,,H,8,Autocuration,1,,CHEMBL616729,,BAO_0000357
2087,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,279,,H,8,Expert,1,,CHEMBL616730,,BAO_0000019
2088,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,279,,H,8,Autocuration,1,,CHEMBL617125,,BAO_0000357
2089,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,279,,H,8,Autocuration,1,,CHEMBL857977,,BAO_0000357
2090,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,279,CHO,H,8,Autocuration,1,,CHEMBL617126,449.0,BAO_0000219
2091,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,,279,CHO,H,8,Autocuration,1,,CHEMBL617127,449.0,BAO_0000219
2092,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,279,,H,8,Autocuration,1,,CHEMBL617128,,BAO_0000357
2093,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,,279,CHO,H,8,Autocuration,1,,CHEMBL617129,449.0,BAO_0000219
2094,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,279,,H,8,Autocuration,1,,CHEMBL617130,,BAO_0000357
2095,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,,279,CHO,H,8,Autocuration,1,,CHEMBL617131,449.0,BAO_0000219
2096,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,279,CHO,H,8,Autocuration,1,,CHEMBL617132,449.0,BAO_0000219
2097,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,279,CHO,H,8,Autocuration,1,,CHEMBL617133,449.0,BAO_0000219
2098,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,279,,H,8,Autocuration,1,,CHEMBL617134,,BAO_0000357
2099,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,279,,H,8,Autocuration,1,,CHEMBL617135,,BAO_0000357
2100,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,279,,H,8,Autocuration,1,,CHEMBL617136,,BAO_0000357
2101,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,104686,,H,4,Autocuration,1,,CHEMBL617137,,BAO_0000019
2102,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,104686,,H,4,Autocuration,1,,CHEMBL617138,,BAO_0000019
2103,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,104686,,H,4,Autocuration,1,,CHEMBL617139,,BAO_0000019
2104,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617140,,BAO_0000019
2105,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,,104686,,H,4,Autocuration,1,,CHEMBL617141,,BAO_0000218
2106,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686,,H,4,Autocuration,1,,CHEMBL858112,,BAO_0000019
2107,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,17005,,H,8,Intermediate,1,,CHEMBL617142,,BAO_0000019
2108,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,,22226,,U,0,Autocuration,1,,CHEMBL617143,,BAO_0000019
2109,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,,22226,,U,0,Autocuration,1,,CHEMBL617144,,BAO_0000019
2110,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,,22226,,U,0,Autocuration,1,,CHEMBL617145,,BAO_0000019
2111,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,22226,,U,0,Autocuration,1,,CHEMBL617146,,BAO_0000019
2112,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,,104784,,H,4,Autocuration,1,,CHEMBL617147,,BAO_0000019
2113,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,,104784,,H,4,Autocuration,1,,CHEMBL617148,,BAO_0000019
2114,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,,104784,,H,4,Autocuration,1,,CHEMBL617149,,BAO_0000019
2115,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,104784,,H,4,Autocuration,1,,CHEMBL617150,,BAO_0000224
2116,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,104784,,H,4,Autocuration,1,,CHEMBL617151,,BAO_0000224
2117,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,104784,,H,4,Autocuration,1,,CHEMBL617201,,BAO_0000224
2118,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,10209,,H,8,Autocuration,1,,CHEMBL617202,,BAO_0000357
2119,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,104826,,H,4,Autocuration,1,,CHEMBL617203,,BAO_0000218
2120,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,104826,,H,4,Autocuration,1,,CHEMBL617204,,BAO_0000019
2121,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,104826,,H,4,Autocuration,1,,CHEMBL617205,,BAO_0000224
2122,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,,104826,,D,5,Autocuration,1,,CHEMBL617206,,BAO_0000019
2123,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,104826,,H,4,Autocuration,1,,CHEMBL617207,,BAO_0000218
2124,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,,104826,,D,5,Autocuration,1,,CHEMBL617208,,BAO_0000019
2125,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,104826,,H,4,Autocuration,1,,CHEMBL617209,,BAO_0000224
2126,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,104826,,H,4,Autocuration,1,,CHEMBL617210,,BAO_0000224
2127,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,104826,,H,4,Autocuration,1,,CHEMBL617211,,BAO_0000224
2128,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,104826,,D,5,Autocuration,1,,CHEMBL617212,,BAO_0000019
2129,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,,104784,,H,4,Autocuration,1,,CHEMBL617213,,BAO_0000224
2130,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,,104784,,H,4,Autocuration,1,,CHEMBL617214,,BAO_0000224
2131,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,22226,,U,0,Autocuration,1,,CHEMBL617215,,BAO_0000221
2132,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,22226,,U,0,Autocuration,1,,CHEMBL617216,,BAO_0000221
2133,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,,17005,,H,8,Autocuration,1,,CHEMBL617217,,BAO_0000357
2134,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617218,,BAO_0000019
2135,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL872913,,BAO_0000019
2136,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,104826,,H,4,Autocuration,1,,CHEMBL617219,,BAO_0000019
2137,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL873482,,BAO_0000224
2138,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,,104686,,D,5,Autocuration,1,,CHEMBL617220,,BAO_0000019
2139,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,104686,,H,4,Autocuration,1,,CHEMBL617221,,BAO_0000019
2140,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,104686,,H,4,Autocuration,1,,CHEMBL617222,,BAO_0000019
2141,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,104686,,H,4,Autocuration,1,,CHEMBL875906,,BAO_0000019
2142,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,104686,,H,4,Autocuration,1,,CHEMBL617223,,BAO_0000019
2143,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617224,,BAO_0000224
2144,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,104686,,D,5,Autocuration,1,,CHEMBL617225,,BAO_0000224
2145,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,104686,,H,4,Autocuration,1,,CHEMBL617226,,BAO_0000224
2146,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL617227,,BAO_0000224
2147,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL617228,,BAO_0000224
2148,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,104686,,H,4,Autocuration,1,,CHEMBL617229,,BAO_0000224
2149,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,104686,,H,4,Autocuration,1,,CHEMBL617230,,BAO_0000224
2150,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,104686,,H,4,Autocuration,1,,CHEMBL617231,,BAO_0000224
2151,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617232,,BAO_0000224
2152,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617233,,BAO_0000224
2153,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,104686,,H,4,Autocuration,1,,CHEMBL617234,,BAO_0000224
2154,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,104686,,H,4,Autocuration,1,,CHEMBL617235,,BAO_0000019
2155,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,104686,,H,4,Autocuration,1,,CHEMBL617236,,BAO_0000019
2156,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,10000000.0,,104686,,H,4,Autocuration,1,,CHEMBL617237,,BAO_0000221
2157,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,10000000.0,,104686,,H,4,Autocuration,1,,CHEMBL617238,,BAO_0000221
2158,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,955.0,,104686,,D,5,Autocuration,1,,CHEMBL617239,,BAO_0000221
2159,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,104686,,H,4,Autocuration,1,,CHEMBL617240,,BAO_0000019
2160,Membranes,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,104686,,H,4,Autocuration,1,,CHEMBL617241,,BAO_0000249
2161,Membranes,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,104686,,H,4,Autocuration,1,,CHEMBL875907,,BAO_0000249
2162,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,104686,,H,4,Autocuration,1,,CHEMBL617242,,BAO_0000019
2163,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,104686,,H,4,Autocuration,1,,CHEMBL617152,,BAO_0000019
2164,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,955.0,,104686,,D,5,Autocuration,1,,CHEMBL617153,,BAO_0000221
2165,Membranes,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,,104686,,D,5,Autocuration,1,,CHEMBL617154,,BAO_0000249
2166,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,955.0,,104686,,H,4,Autocuration,1,,CHEMBL617155,,BAO_0000221
2167,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,104686,,H,4,Autocuration,1,,CHEMBL617156,,BAO_0000019
2168,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,104686,,H,4,Autocuration,1,,CHEMBL617157,,BAO_0000019
2169,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686,,H,4,Autocuration,1,,CHEMBL617158,,BAO_0000019
2170,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,104686,,H,4,Autocuration,1,,CHEMBL617159,,BAO_0000019
2171,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,104686,,H,4,Autocuration,1,,CHEMBL617160,,BAO_0000019
2172,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686,,H,4,Autocuration,1,,CHEMBL858113,,BAO_0000019
2173,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,955.0,,104686,,H,4,Autocuration,1,,CHEMBL617247,,BAO_0000220
2174,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617248,,BAO_0000019
2175,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,,104686,,H,4,Autocuration,1,,CHEMBL617249,,BAO_0000249
2176,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,104686,,H,4,Autocuration,1,,CHEMBL617250,,BAO_0000019
2177,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617251,,BAO_0000019
2178,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,,104686,,D,5,Autocuration,1,,CHEMBL617252,,BAO_0000019
2179,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,104686,,H,4,Autocuration,1,,CHEMBL617006,,BAO_0000019
2180,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,104686,,H,4,Autocuration,1,,CHEMBL617007,,BAO_0000019
2181,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,104686,,H,4,Autocuration,1,,CHEMBL617008,,BAO_0000019
2182,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,104686,,H,4,Autocuration,1,,CHEMBL617009,,BAO_0000019
2183,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,,104686,,D,5,Autocuration,1,,CHEMBL617010,,BAO_0000224
2184,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,104686,,D,5,Autocuration,1,,CHEMBL857978,,BAO_0000019
2185,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,104686,,D,5,Autocuration,1,,CHEMBL617011,,BAO_0000019
2186,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,,104686,,D,5,Autocuration,1,,CHEMBL617012,,BAO_0000019
2187,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL617013,,BAO_0000224
2188,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,104686,,H,4,Autocuration,1,,CHEMBL617014,,BAO_0000249
2189,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617015,,BAO_0000019
2190,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617016,,BAO_0000019
2191,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,104686,,H,4,Autocuration,1,,CHEMBL617017,,BAO_0000224
2192,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,955.0,,104686,,H,4,Autocuration,1,,CHEMBL617018,,BAO_0000221
2193,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,104686,,H,4,Autocuration,1,,CHEMBL617019,,BAO_0000019
2194,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,,H,4,Autocuration,1,,CHEMBL617020,,BAO_0000019
2195,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,,H,4,Autocuration,1,,CHEMBL617021,,BAO_0000019
2196,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,,H,4,Autocuration,1,,CHEMBL617022,,BAO_0000019
2197,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,,H,4,Autocuration,1,,CHEMBL617023,,BAO_0000019
2198,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,,H,4,Autocuration,1,,CHEMBL617024,,BAO_0000019
2199,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,,H,4,Autocuration,1,,CHEMBL617025,,BAO_0000019
2200,,Hill coefficient of compound was determined,,,105075,,H,4,Autocuration,1,,CHEMBL617026,,BAO_0000224
2201,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,22226,,U,0,Autocuration,1,,CHEMBL617027,,BAO_0000019
2202,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,,104686,,D,5,Autocuration,1,,CHEMBL617028,,BAO_0000019
2203,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,12687,,H,8,Expert,1,,CHEMBL617029,,BAO_0000019
2204,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,12687,,H,8,Expert,1,,CHEMBL875908,,BAO_0000019
2205,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,12687,,H,8,Autocuration,1,,CHEMBL617030,,BAO_0000357
2206,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,12687,,H,8,Autocuration,1,,CHEMBL617031,,BAO_0000019
2207,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL617032,,BAO_0000019
2208,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,,104686,,D,5,Autocuration,1,,CHEMBL617033,,BAO_0000224
2209,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,104686,,H,4,Autocuration,1,,CHEMBL617034,,BAO_0000224
2210,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617035,,BAO_0000224
2211,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,104686,,H,4,Autocuration,1,,CHEMBL617036,,BAO_0000019
2212,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,104784,,H,4,Autocuration,1,,CHEMBL617037,,BAO_0000224
2213,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,22226,,U,0,Autocuration,1,,CHEMBL617038,,BAO_0000219
2214,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,104784,,H,4,Autocuration,1,,CHEMBL617039,,BAO_0000219
2215,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,104784,,H,4,Autocuration,1,,CHEMBL617161,,BAO_0000224
2216,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,104784,,H,4,Autocuration,1,,CHEMBL617162,,BAO_0000224
2217,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,104784,,H,4,Autocuration,1,,CHEMBL617163,,BAO_0000224
2218,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,104784,,H,4,Autocuration,1,,CHEMBL617164,,BAO_0000224
2219,Brain membranes,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,104784,,H,4,Autocuration,1,,CHEMBL617165,,BAO_0000249
2220,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,104784,,H,4,Autocuration,1,,CHEMBL617166,,BAO_0000224
2221,,Binding affinity towards 5-HT2 receptor,,,104784,,H,4,Autocuration,1,,CHEMBL617167,,BAO_0000224
2222,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,104784,,H,4,Autocuration,1,,CHEMBL872912,,BAO_0000224
2223,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,104784,,H,4,Autocuration,1,,CHEMBL617168,,BAO_0000224
2224,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,104686,,H,4,Autocuration,1,,CHEMBL617169,,BAO_0000224
2225,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,104784,,H,4,Autocuration,1,,CHEMBL617170,,BAO_0000224
2226,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,104784,,H,4,Autocuration,1,,CHEMBL617171,,BAO_0000224
2227,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,104784,,H,4,Autocuration,1,,CHEMBL617172,,BAO_0000224
2228,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,104784,,H,4,Autocuration,1,,CHEMBL617173,,BAO_0000224
2229,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,22226,,U,0,Autocuration,1,,CHEMBL617174,,BAO_0000019
2230,,5-hydroxytryptamine 2 receptor binding affinity,,,104784,,H,4,Autocuration,1,,CHEMBL617175,,BAO_0000224
2231,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,17005,,H,8,Autocuration,1,,CHEMBL617176,,BAO_0000357
2232,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,17005,,H,8,Autocuration,1,,CHEMBL617177,,BAO_0000357
2233,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,104784,,H,4,Autocuration,1,,CHEMBL617178,,BAO_0000224
2234,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,104784,,H,4,Autocuration,1,,CHEMBL617179,,BAO_0000224
2235,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,104784,,H,4,Autocuration,1,,CHEMBL617180,,BAO_0000224
2236,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,17005,,H,8,Autocuration,1,,CHEMBL617181,,BAO_0000357
2237,,Binding affinity against 5-hydroxytryptamine 2 receptor,,,17005,,H,8,Autocuration,1,,CHEMBL617182,,BAO_0000357
2238,,Binding affinity against 5-hydroxytryptamine 2 receptor,,,17005,,H,8,Autocuration,1,,CHEMBL617183,,BAO_0000357
2239,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,17005,,H,8,Autocuration,1,,CHEMBL617184,,BAO_0000357
2240,,Binding affinity against serotonergic 5-HT2 receptor,,,17005,,H,8,Autocuration,1,,CHEMBL617185,,BAO_0000357
2241,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,17005,,H,8,Autocuration,1,,CHEMBL617186,,BAO_0000357
2242,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,17005,,H,8,Autocuration,1,,CHEMBL617187,,BAO_0000357
2243,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,17005,,H,8,Autocuration,1,,CHEMBL617188,,BAO_0000357
2244,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,17005,,H,8,Autocuration,1,,CHEMBL617189,,BAO_0000218
2245,,Inhibitory activity against cloned human 5-HT2 receptor,,,104784,,D,5,Autocuration,1,,CHEMBL617190,,BAO_0000224
2246,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,,104784,CHO,D,5,Autocuration,1,,CHEMBL617191,449.0,BAO_0000219
2247,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,,104784,CHO,D,5,Autocuration,1,,CHEMBL617192,449.0,BAO_0000219
2248,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,,104784,CHO,D,5,Autocuration,1,,CHEMBL617193,449.0,BAO_0000219
2249,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,,104784,CHO,D,5,Autocuration,1,,CHEMBL617194,449.0,BAO_0000219
2250,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104784,,H,4,Autocuration,1,,CHEMBL617195,,BAO_0000224
2251,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,104784,,H,4,Autocuration,1,,CHEMBL881830,,BAO_0000224
2252,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,17005,,H,8,Autocuration,1,,CHEMBL617196,,BAO_0000357
2253,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,104686,,H,4,Autocuration,1,,CHEMBL617197,,BAO_0000224
2254,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,17005,,H,8,Expert,1,,CHEMBL617198,,BAO_0000357
2255,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,17005,,H,8,Expert,1,,CHEMBL873476,,BAO_0000357
2256,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,17005,,H,8,Expert,1,,CHEMBL617199,,BAO_0000019
2257,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617200,,BAO_0000357
2258,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,51,,H,8,Autocuration,1,,CHEMBL617484,,BAO_0000357
2259,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617485,,BAO_0000357
2260,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,51,,H,8,Autocuration,1,,CHEMBL617486,,BAO_0000357
2261,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,107,,H,8,Autocuration,1,,CHEMBL858022,,BAO_0000357
2262,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,107,CHO,H,8,Autocuration,1,,CHEMBL617049,449.0,BAO_0000219
2263,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,,107,CHO,D,9,Expert,1,,CHEMBL617050,449.0,BAO_0000219
2264,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,107,,H,8,Autocuration,1,,CHEMBL617051,,BAO_0000219
2265,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,107,,H,8,Autocuration,1,,CHEMBL617052,,BAO_0000219
2266,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,107,,H,8,Autocuration,1,,CHEMBL617053,,BAO_0000219
2267,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,,107,CHO,H,8,Autocuration,1,,CHEMBL617054,449.0,BAO_0000219
2268,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,,107,CHO,H,8,Autocuration,1,,CHEMBL617055,449.0,BAO_0000219
2269,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,107,,H,8,Autocuration,1,,CHEMBL882924,,BAO_0000357
2270,,Inhibition of human 5-hydroxytryptamine 2A receptor,,,107,,D,9,Expert,1,,CHEMBL617056,,BAO_0000357
2271,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,107,CHO,H,8,Autocuration,1,,CHEMBL617057,449.0,BAO_0000219
2272,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,107,,H,8,Expert,1,,CHEMBL617058,,BAO_0000219
2273,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,107,,H,8,Autocuration,1,,CHEMBL617059,,BAO_0000357
2274,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,,107,CHO,H,8,Autocuration,1,,CHEMBL617060,449.0,BAO_0000219
2275,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,,107,CHO,H,8,Expert,1,,CHEMBL617061,449.0,BAO_0000219
2276,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,,107,L929,H,8,Expert,1,,CHEMBL617062,307.0,BAO_0000219
2277,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,107,CHO,H,8,Expert,1,,CHEMBL617063,449.0,BAO_0000219
2278,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617064,,BAO_0000019
2279,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617065,,BAO_0000019
2280,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,107,CHO,H,8,Autocuration,1,,CHEMBL617066,449.0,BAO_0000219
2281,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,,107,CHO,H,8,Autocuration,1,,CHEMBL617067,449.0,BAO_0000219
2282,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617068,,BAO_0000019
2283,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,107,,H,8,Autocuration,1,,CHEMBL617069,,BAO_0000019
2284,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617070,,BAO_0000019
2285,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617071,,BAO_0000357
2286,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,107,,H,8,Autocuration,1,,CHEMBL872915,,BAO_0000357
2287,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,107,,H,8,Autocuration,1,,CHEMBL617072,,BAO_0000357
2288,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,107,,H,8,Autocuration,1,,CHEMBL617073,,BAO_0000357
2289,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617074,,BAO_0000357
2290,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,107,CHO,H,8,Expert,1,,CHEMBL617075,449.0,BAO_0000219
2291,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617076,,BAO_0000357
2292,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,,107,,D,9,Expert,1,,CHEMBL617077,,BAO_0000019
2293,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,107,,H,8,Expert,1,,CHEMBL617078,,BAO_0000357
2294,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,,107,,D,9,Expert,1,,CHEMBL617079,,BAO_0000357
2295,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,107,,H,8,Autocuration,1,,CHEMBL617080,,BAO_0000357
2296,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,,107,CHO,H,8,Expert,1,,CHEMBL617081,449.0,BAO_0000219
2297,,Binding affinity towards human 5-HT2A receptor in BEK cells,,,107,,H,8,Expert,1,,CHEMBL617082,,BAO_0000219
2298,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617083,,BAO_0000357
2299,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,107,,H,8,Autocuration,1,,CHEMBL617084,,BAO_0000357
2300,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,107,,D,9,Expert,1,,CHEMBL617085,,BAO_0000357
2301,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617086,,BAO_0000357
2302,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,107,,H,8,Autocuration,1,,CHEMBL617087,,BAO_0000219
2303,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617088,,BAO_0000357
2304,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617089,,BAO_0000357
2305,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,107,,H,8,Expert,1,,CHEMBL617090,,BAO_0000019
2306,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617513,,BAO_0000357
2307,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,,107,HEK293,H,8,Autocuration,1,,CHEMBL617514,722.0,BAO_0000219
2308,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617515,,BAO_0000019
2309,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617516,,BAO_0000357
2310,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,107,,D,9,Expert,1,,CHEMBL617517,,BAO_0000357
2311,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,,107,CHO,D,9,Expert,1,,CHEMBL617518,449.0,BAO_0000219
2312,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617519,,BAO_0000357
2313,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,,107,,D,9,Expert,1,,CHEMBL617520,,BAO_0000357
2314,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,107,,H,8,Autocuration,1,,CHEMBL617521,,BAO_0000357
2315,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,,107,,D,9,Expert,1,,CHEMBL617522,,BAO_0000357
2316,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617523,,BAO_0000357
2317,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,107,,H,8,Autocuration,1,,CHEMBL617524,,BAO_0000357
2318,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,104686,,H,4,Autocuration,1,,CHEMBL617525,,BAO_0000019
2319,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,,104686,,D,5,Autocuration,1,,CHEMBL617526,,BAO_0000019
2320,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,104686,,H,4,Autocuration,1,,CHEMBL617527,,BAO_0000224
2321,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,104686,,H,4,Autocuration,1,,CHEMBL617528,,BAO_0000019
2322,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,104686,,H,4,Autocuration,1,,CHEMBL617529,,BAO_0000019
2323,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,104686,,H,4,Autocuration,1,,CHEMBL617530,,BAO_0000224
2324,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617531,,BAO_0000019
2325,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617532,,BAO_0000019
2326,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617533,,BAO_0000019
2327,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617534,,BAO_0000019
2328,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617535,,BAO_0000224
2329,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,104686,,H,4,Autocuration,1,,CHEMBL617536,,BAO_0000224
2330,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617537,,BAO_0000224
2331,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617538,,BAO_0000224
2332,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,104686,,H,4,Autocuration,1,,CHEMBL617539,,BAO_0000219
2333,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,104686,,D,5,Autocuration,1,,CHEMBL617540,,BAO_0000224
2334,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,,104686,,D,5,Autocuration,1,,CHEMBL617541,,BAO_0000224
2335,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617542,,BAO_0000224
2336,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,104686,,H,4,Autocuration,1,,CHEMBL617543,,BAO_0000224
2337,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,104686,CHO-K1,D,5,Autocuration,1,,CHEMBL617544,485.0,BAO_0000219
2338,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,104686,CHO-K1,D,5,Autocuration,1,,CHEMBL617545,485.0,BAO_0000219
2339,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,,104686,,D,5,Autocuration,1,,CHEMBL617413,,BAO_0000019
2340,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL617414,,BAO_0000019
2341,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,,104686,,D,5,Autocuration,1,,CHEMBL617415,,BAO_0000019
2342,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617416,,BAO_0000224
2343,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,104686,,H,4,Autocuration,1,,CHEMBL617417,,BAO_0000224
2344,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,104686,,H,4,Autocuration,1,,CHEMBL617418,,BAO_0000019
2345,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,104686,,H,4,Autocuration,1,,CHEMBL617419,,BAO_0000019
2346,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,104686,,H,4,Autocuration,1,,CHEMBL617420,,BAO_0000224
2347,,Affinity for 5-hydroxytryptamine 2 receptor,,,104686,,D,5,Autocuration,1,,CHEMBL617421,,BAO_0000224
2348,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,104686,,H,4,Autocuration,1,,CHEMBL617422,,BAO_0000224
2349,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,104686,,H,4,Autocuration,1,,CHEMBL617423,,BAO_0000019
2350,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,104686,,H,4,Autocuration,1,,CHEMBL617424,,BAO_0000019
2351,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,104686,,H,4,Autocuration,1,,CHEMBL617425,,BAO_0000019
2352,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,104686,,H,4,Autocuration,1,,CHEMBL617426,,BAO_0000224
2353,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,,104686,,H,4,Autocuration,1,,CHEMBL617427,,BAO_0000218
2354,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,955.0,,104686,,H,4,Autocuration,1,,CHEMBL617428,,BAO_0000221
2355,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,104686,,H,4,Autocuration,1,,CHEMBL617429,,BAO_0000224
2356,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617430,,BAO_0000019
2357,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617431,,BAO_0000019
2358,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,1870.0,,104686,,H,4,Autocuration,1,,CHEMBL617432,,BAO_0000019
2359,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617433,,BAO_0000224
2360,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617434,,BAO_0000224
2361,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,,104686,,D,5,Autocuration,1,,CHEMBL617435,,BAO_0000224
2362,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,104686,,H,4,Autocuration,1,,CHEMBL617436,,BAO_0000019
2363,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,2435.0,,104686,,D,5,Autocuration,1,,CHEMBL617437,,BAO_0000019
2364,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,104686,,H,4,Autocuration,1,,CHEMBL617438,,BAO_0000019
2365,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,104686,,H,4,Autocuration,1,,CHEMBL617439,,BAO_0000019
2366,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617440,,BAO_0000224
2367,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617441,,BAO_0000224
2368,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,,104686,,D,5,Autocuration,1,,CHEMBL872918,,BAO_0000019
2369,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,,104686,,D,5,Autocuration,1,,CHEMBL617442,,BAO_0000019
2370,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,104686,,H,4,Autocuration,1,,CHEMBL617443,,BAO_0000019
2371,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617444,,BAO_0000019
2372,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,104686,,H,4,Autocuration,1,,CHEMBL617445,,BAO_0000019
2373,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL617446,,BAO_0000019
2374,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,104686,,H,4,Autocuration,1,,CHEMBL617447,,BAO_0000249
2375,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,104686,,H,4,Autocuration,1,,CHEMBL617448,,BAO_0000019
2376,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,104686,,H,4,Autocuration,1,,CHEMBL617449,,BAO_0000019
2377,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,104686,,H,4,Autocuration,1,,CHEMBL617450,,BAO_0000019
2378,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,104686,,H,4,Autocuration,1,,CHEMBL617451,,BAO_0000019
2379,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,104686,,H,4,Autocuration,1,,CHEMBL617452,,BAO_0000019
2380,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,104686,,H,4,Autocuration,1,,CHEMBL617453,,BAO_0000019
2381,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,104686,,H,4,Autocuration,1,,CHEMBL617660,,BAO_0000019
2382,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,104686,,H,4,Autocuration,1,,CHEMBL617661,,BAO_0000019
2383,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,104686,,H,4,Autocuration,1,,CHEMBL617662,,BAO_0000019
2384,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,104686,,H,4,Autocuration,1,,CHEMBL872919,,BAO_0000019
2385,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,104686,,H,4,Autocuration,1,,CHEMBL617663,,BAO_0000019
2386,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,104686,,H,4,Autocuration,1,,CHEMBL617664,,BAO_0000019
2387,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,104686,,H,4,Autocuration,1,,CHEMBL617665,,BAO_0000019
2388,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,104686,,H,4,Autocuration,1,,CHEMBL617666,,BAO_0000019
2389,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,104686,,H,4,Autocuration,1,,CHEMBL617667,,BAO_0000019
2390,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,104686,,H,4,Autocuration,1,,CHEMBL617668,,BAO_0000249
2391,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617669,,BAO_0000249
2392,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617670,,BAO_0000224
2393,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,,104686,,D,5,Autocuration,1,,CHEMBL617671,,BAO_0000224
2394,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617672,,BAO_0000224
2395,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,104686,,H,4,Autocuration,1,,CHEMBL617673,,BAO_0000019
2396,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617674,,BAO_0000224
2397,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,104686,,H,4,Autocuration,1,,CHEMBL617675,,BAO_0000019
2398,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,104686,,H,4,Autocuration,1,,CHEMBL617676,,BAO_0000019
2399,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,104686,,H,4,Autocuration,1,,CHEMBL617677,,BAO_0000019
2400,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,104686,,D,5,Autocuration,1,,CHEMBL617678,,BAO_0000019
2401,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,104686,,H,4,Autocuration,1,,CHEMBL617679,,BAO_0000224
2402,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,104686,,H,4,Autocuration,1,,CHEMBL617680,,BAO_0000224
2403,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,104686,,H,4,Autocuration,1,,CHEMBL617681,,BAO_0000019
2404,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,955.0,,104686,,H,4,Autocuration,1,,CHEMBL617682,,BAO_0000221
2405,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,104686,,H,4,Autocuration,1,,CHEMBL617683,,BAO_0000224
2406,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,104686,,H,4,Autocuration,1,,CHEMBL617684,,BAO_0000224
2407,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104686,,D,5,Autocuration,1,,CHEMBL617685,,BAO_0000224
2408,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,104686,,H,4,Autocuration,1,,CHEMBL617686,,BAO_0000019
2409,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,104686,,H,4,Autocuration,1,,CHEMBL617687,,BAO_0000224
2410,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,104686,,H,4,Autocuration,1,,CHEMBL617688,,BAO_0000224
2411,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686,,H,4,Autocuration,1,,CHEMBL617689,,BAO_0000019
2412,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686,,H,4,Autocuration,1,,CHEMBL617690,,BAO_0000019
2413,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,104686,,H,4,Autocuration,1,,CHEMBL617691,,BAO_0000218
2414,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,104686,,H,4,Autocuration,1,,CHEMBL617692,,BAO_0000218
2415,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,104686,,H,4,Autocuration,1,,CHEMBL617693,,BAO_0000218
2416,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,104686,,H,4,Autocuration,1,,CHEMBL617694,,BAO_0000218
2417,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,955.0,,12687,,H,8,Expert,1,,CHEMBL857985,,BAO_0000221
2418,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,12687,,D,9,Expert,1,,CHEMBL617695,,BAO_0000019
2419,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,12687,,H,8,Autocuration,1,,CHEMBL617696,,BAO_0000019
2420,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,12687,,H,8,Autocuration,1,,CHEMBL617697,,BAO_0000357
2421,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,,12687,,D,9,Expert,1,,CHEMBL617257,,BAO_0000019
2422,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,12687,,D,9,Expert,1,,CHEMBL617258,,BAO_0000357
2423,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,12687,,H,8,Expert,1,,CHEMBL617259,,BAO_0000019
2424,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617260,,BAO_0000357
2425,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,,12687,,D,9,Expert,1,,CHEMBL617261,,BAO_0000357
2426,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL617262,,BAO_0000019
2427,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,12687,,H,8,Expert,1,,CHEMBL617263,,BAO_0000019
2428,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,12687,,H,8,Autocuration,1,,CHEMBL617264,,BAO_0000019
2429,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,,12687,,D,9,Expert,1,,CHEMBL617265,,BAO_0000019
2430,Membranes,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617266,,BAO_0000249
2431,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,12687,,H,8,Autocuration,1,,CHEMBL617267,,BAO_0000019
2432,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,12687,,H,8,Expert,1,,CHEMBL617268,,BAO_0000019
2433,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,12687,CHO,H,8,Autocuration,1,,CHEMBL617269,449.0,BAO_0000219
2434,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,12687,,H,8,Expert,1,,CHEMBL617323,,BAO_0000357
2435,,Serotonergic activity of the compound.,,,12687,,H,8,Autocuration,1,,CHEMBL617324,,BAO_0000357
2436,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,12687,,H,8,Autocuration,1,,CHEMBL617325,,BAO_0000249
2437,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,,12687,,D,9,Expert,1,,CHEMBL617326,,BAO_0000019
2438,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,12687,,H,8,Expert,1,,CHEMBL617327,,BAO_0000249
2439,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687,,D,9,Expert,1,,CHEMBL617328,,BAO_0000019
2440,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687,,D,9,Expert,1,,CHEMBL617329,,BAO_0000019
2441,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687,,D,9,Expert,1,,CHEMBL617330,,BAO_0000019
2442,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL617331,,BAO_0000357
2443,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,12687,,H,8,Autocuration,1,,CHEMBL617332,,BAO_0000357
2444,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,107,,H,8,Expert,1,,CHEMBL617333,,BAO_0000357
2445,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,107,,H,8,Autocuration,1,,CHEMBL617334,,BAO_0000357
2446,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,107,,H,8,Autocuration,1,,CHEMBL617335,,BAO_0000357
2447,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,107,,H,8,Autocuration,1,,CHEMBL617336,,BAO_0000357
2448,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,107,,H,8,Autocuration,1,,CHEMBL617337,,BAO_0000357
2449,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,,107,,D,9,Expert,1,,CHEMBL617338,,BAO_0000357
2450,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617339,,BAO_0000357
2451,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,107,,H,8,Expert,1,,CHEMBL617340,,BAO_0000357
2452,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,107,,H,8,Autocuration,1,,CHEMBL617341,,BAO_0000357
2453,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,107,,H,8,Expert,1,,CHEMBL617342,,BAO_0000357
2454,,Affinity for 5-hydroxytryptamine 2A receptor,,,107,,H,8,Expert,1,,CHEMBL617343,,BAO_0000357
2455,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,,107,NIH3T3,H,8,Expert,1,,CHEMBL617344,723.0,BAO_0000219
2456,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,107,,H,8,Expert,1,,CHEMBL617345,,BAO_0000357
2457,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,107,,H,8,Expert,1,,CHEMBL617346,,BAO_0000357
2458,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617347,,BAO_0000357
2459,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,107,,H,8,Autocuration,1,,CHEMBL617348,,BAO_0000357
2460,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,107,,H,8,Autocuration,1,,CHEMBL617349,,BAO_0000357
2461,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617350,,BAO_0000019
2462,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,107,,H,8,Expert,1,,CHEMBL872339,,BAO_0000357
2463,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,107,,H,8,Autocuration,1,,CHEMBL617351,,BAO_0000357
2464,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,107,,H,8,Expert,1,,CHEMBL617352,,BAO_0000357
2465,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617353,,BAO_0000357
2466,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617354,,BAO_0000357
2467,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617355,,BAO_0000357
2468,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,,107,CHO,H,8,Expert,1,,CHEMBL617356,449.0,BAO_0000219
2469,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617357,,BAO_0000357
2470,,Binding affinity at 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617358,,BAO_0000357
2471,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,107,,H,8,Expert,1,,CHEMBL617359,,BAO_0000357
2472,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,107,,H,8,Autocuration,1,,CHEMBL617360,,BAO_0000357
2473,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,107,,H,8,Autocuration,1,,CHEMBL875913,,BAO_0000357
2474,,Affinity against 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617361,,BAO_0000357
2475,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,,107,,D,9,Expert,1,,CHEMBL617362,,BAO_0000357
2476,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,107,,H,8,Autocuration,1,,CHEMBL617363,,BAO_0000357
2477,,Tested against 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617364,,BAO_0000357
2478,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,105075,,H,4,Autocuration,1,,CHEMBL617365,,BAO_0000224
2479,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,105075,,H,4,Autocuration,1,,CHEMBL617366,,BAO_0000224
2480,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,105075,,H,4,Autocuration,1,,CHEMBL617367,,BAO_0000224
2481,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,105075,,H,4,Autocuration,1,,CHEMBL617368,,BAO_0000224
2482,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,107,,H,8,Autocuration,1,,CHEMBL617369,,BAO_0000357
2483,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,,227,HEK293,D,9,Expert,1,,CHEMBL617370,722.0,BAO_0000219
2484,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,,227,CHO,D,9,Expert,1,,CHEMBL617371,449.0,BAO_0000219
2485,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,227,,H,8,Autocuration,1,,CHEMBL617372,,BAO_0000357
2486,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,,227,,D,9,Expert,1,,CHEMBL617373,,BAO_0000357
2487,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,227,,H,8,Autocuration,1,,CHEMBL617374,,BAO_0000019
2488,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,227,,H,8,Autocuration,1,,CHEMBL617375,,BAO_0000019
2489,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,227,,H,8,Autocuration,1,,CHEMBL617376,,BAO_0000019
2490,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,227,,H,8,Autocuration,1,,CHEMBL617377,,BAO_0000019
2491,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,227,,H,8,Autocuration,1,,CHEMBL617378,,BAO_0000019
2492,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,227,,H,8,Autocuration,1,,CHEMBL617379,,BAO_0000019
2493,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,227,,H,8,Autocuration,1,,CHEMBL617380,,BAO_0000357
2494,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,227,,H,8,Autocuration,1,,CHEMBL617381,,BAO_0000357
2495,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,227,,H,8,Autocuration,1,,CHEMBL617382,,BAO_0000357
2496,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617383,,BAO_0000357
2497,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,107,,H,8,Expert,1,,CHEMBL617384,,BAO_0000357
2498,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,107,,H,8,Expert,1,,CHEMBL617385,,BAO_0000357
2499,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,107,,H,8,Autocuration,1,,CHEMBL617386,,BAO_0000019
2500,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,107,,H,8,Autocuration,1,,CHEMBL617387,,BAO_0000019
2501,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,107,NIH3T3,H,8,Autocuration,1,,CHEMBL617388,723.0,BAO_0000219
2502,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,107,CHO,H,8,Autocuration,1,,CHEMBL617389,449.0,BAO_0000219
2503,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,107,CHO,D,9,Expert,1,,CHEMBL617390,449.0,BAO_0000219
2504,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,104817,,H,4,Autocuration,1,,CHEMBL617391,,BAO_0000224
2505,,Binding activity radioligand.,,,107,,H,8,Autocuration,1,,CHEMBL617392,,BAO_0000357
2506,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,107,,H,8,Autocuration,1,,CHEMBL617393,,BAO_0000019
2507,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,107,L929,H,8,Autocuration,1,,CHEMBL617394,307.0,BAO_0000219
2508,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,107,L929,H,8,Expert,1,,CHEMBL617395,307.0,BAO_0000219
2509,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,,107,L929,H,8,Expert,1,,CHEMBL617396,307.0,BAO_0000219
2510,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,,107,L929,H,8,Autocuration,1,,CHEMBL617397,307.0,BAO_0000219
2511,,Binding affinity against 5-HT2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617398,,BAO_0000357
2512,,Binding affinity against 5-hydroxytryptamine 2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL617399,,BAO_0000357
2513,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,107,HEK293,H,8,Autocuration,1,,CHEMBL617400,722.0,BAO_0000219
2514,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,107,HEK293,H,8,Autocuration,1,,CHEMBL617401,722.0,BAO_0000219
2515,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,,107,HEK293,D,9,Expert,1,,CHEMBL617402,722.0,BAO_0000219
2516,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,107,HEK293,D,9,Expert,1,,CHEMBL617403,722.0,BAO_0000219
2517,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,107,,H,8,Expert,1,,CHEMBL617404,,BAO_0000357
2518,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,107,HEK293,D,9,Expert,1,,CHEMBL857981,722.0,BAO_0000219
2519,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,107,HEK293,D,9,Expert,1,,CHEMBL617405,722.0,BAO_0000219
2520,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,,107,HEK293,D,9,Expert,1,,CHEMBL617253,722.0,BAO_0000219
2521,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,107,,H,8,Expert,1,,CHEMBL617254,,BAO_0000357
2522,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,107,HEK293,H,8,Autocuration,1,,CHEMBL617255,722.0,BAO_0000219
2523,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,107,HEK293,H,8,Autocuration,1,,CHEMBL617256,722.0,BAO_0000219
2524,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,,107,HEK293,H,8,Autocuration,1,,CHEMBL616874,722.0,BAO_0000219
2525,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,,107,HEK293,D,9,Expert,1,,CHEMBL616875,722.0,BAO_0000219
2526,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,,107,HEK293,H,8,Expert,1,,CHEMBL616876,722.0,BAO_0000219
2527,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,,107,HEK293,H,8,Expert,1,,CHEMBL616877,722.0,BAO_0000219
2528,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,,107,HEK293,D,9,Expert,1,,CHEMBL616878,722.0,BAO_0000219
2529,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,,107,HEK293,H,8,Expert,1,,CHEMBL616879,722.0,BAO_0000219
2530,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,,107,HEK293,H,8,Expert,1,,CHEMBL616880,722.0,BAO_0000219
2531,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,107,HEK293,D,9,Expert,1,,CHEMBL616881,722.0,BAO_0000219
2532,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,107,NIH3T3,H,8,Autocuration,1,,CHEMBL616882,723.0,BAO_0000219
2533,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,107,NIH3T3,H,8,Autocuration,1,,CHEMBL616883,723.0,BAO_0000219
2534,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,107,NIH3T3,H,8,Autocuration,1,,CHEMBL616884,723.0,BAO_0000219
2535,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,,107,HEK293,H,8,Autocuration,1,,CHEMBL616885,722.0,BAO_0000219
2536,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,,107,CHO-K1,H,8,Autocuration,1,,CHEMBL616886,485.0,BAO_0000219
2537,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,,107,CHO-K1,H,8,Expert,1,,CHEMBL616887,485.0,BAO_0000219
2538,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,107,,D,9,Expert,1,,CHEMBL616888,,BAO_0000357
2539,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,,107,HEK293,H,8,Autocuration,1,,CHEMBL616889,722.0,BAO_0000219
2540,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,,107,HEK293,H,8,Autocuration,1,,CHEMBL616890,722.0,BAO_0000219
2541,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,107,CHO,D,9,Expert,1,,CHEMBL616891,449.0,BAO_0000219
2542,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,,107,HEK293,H,8,Autocuration,1,,CHEMBL616892,722.0,BAO_0000219
2543,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,,107,HEK293,H,8,Autocuration,1,,CHEMBL616893,722.0,BAO_0000219
2544,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,,10620,NIH3T3,H,8,Autocuration,1,,CHEMBL616894,723.0,BAO_0000219
2545,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,,107,NIH3T3,H,8,Expert,1,,CHEMBL616895,723.0,BAO_0000219
2546,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,10620,,H,8,Autocuration,1,,CHEMBL616896,,BAO_0000019
2547,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,10621,,H,8,Autocuration,1,,CHEMBL617099,,BAO_0000357
2548,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,10621,,H,8,Autocuration,1,,CHEMBL617100,,BAO_0000357
2549,,Binding affinity against rabbit aorta 5-HT2A receptor,,,107,,H,8,Autocuration,1,,CHEMBL884532,,BAO_0000357
2550,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,,107,,H,8,Expert,1,,CHEMBL617101,,BAO_0000357
2551,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,,107,,H,8,Expert,1,,CHEMBL617102,,BAO_0000357
2552,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,107,,H,8,Autocuration,1,,CHEMBL617103,,BAO_0000019
2553,,The compound was tested for binding affinity against 5-HT2A receptor,,,107,,H,8,Expert,1,,CHEMBL617104,,BAO_0000357
2554,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,,10576,CHO-K1,H,8,Autocuration,1,,CHEMBL857979,485.0,BAO_0000219
2555,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,12687,,H,8,Autocuration,1,,CHEMBL857502,,BAO_0000019
2556,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,12687,,H,8,Autocuration,1,,CHEMBL617105,,BAO_0000019
2557,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,945.0,,12687,,H,8,Autocuration,1,,CHEMBL858021,,BAO_0000019
2558,,Binding affinity for 5-HT 2A in rat stomach fundus,945.0,,12687,,D,9,Expert,1,,CHEMBL875910,,BAO_0000019
2559,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,12687,,H,8,Autocuration,1,,CHEMBL617106,,BAO_0000019
2560,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,,12687,NIH3T3,H,8,Expert,1,,CHEMBL617107,723.0,BAO_0000219
2561,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617108,,BAO_0000019
2562,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617109,,BAO_0000019
2563,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617110,,BAO_0000357
2564,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,12687,,H,8,Autocuration,1,,CHEMBL617111,,BAO_0000357
2565,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,,12687,,D,9,Expert,1,,CHEMBL617112,,BAO_0000019
2566,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617113,,BAO_0000357
2567,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617114,,BAO_0000357
2568,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617115,,BAO_0000357
2569,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,12687,,H,8,Autocuration,1,,CHEMBL617116,,BAO_0000219
2570,,Efficacy at 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617117,,BAO_0000019
2571,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,12687,,H,8,Autocuration,1,,CHEMBL617118,,BAO_0000357
2572,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,12687,,D,9,Expert,1,,CHEMBL617119,,BAO_0000357
2573,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,,12687,,D,9,Expert,1,,CHEMBL617120,,BAO_0000357
2574,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,12687,,D,9,Expert,1,,CHEMBL617121,,BAO_0000219
2575,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,12687,,H,8,Autocuration,1,,CHEMBL617122,,BAO_0000219
2576,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617123,,BAO_0000019
2577,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,12687,,H,8,Expert,1,,CHEMBL617124,,BAO_0000019
2578,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,12687,,H,8,Expert,1,,CHEMBL617600,,BAO_0000249
2579,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,12687,,H,8,Expert,1,,CHEMBL617601,,BAO_0000357
2580,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,12687,,H,8,Expert,1,,CHEMBL882923,,BAO_0000019
2581,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617602,,BAO_0000357
2582,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,12687,,H,8,Autocuration,1,,CHEMBL617603,,BAO_0000019
2583,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617604,,BAO_0000357
2584,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,12687,,H,8,Expert,1,,CHEMBL617605,,BAO_0000019
2585,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,12687,,H,8,Expert,1,,CHEMBL617606,,BAO_0000019
2586,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,,12687,,D,9,Expert,1,,CHEMBL617607,,BAO_0000019
2587,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,,H,8,Autocuration,1,,CHEMBL617455,,BAO_0000249
2588,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,12687,,D,9,Expert,1,,CHEMBL617456,,BAO_0000019
2589,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,12687,,H,8,Expert,1,,CHEMBL617457,,BAO_0000357
2590,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,,12687,,D,9,Expert,1,,CHEMBL617458,,BAO_0000357
2591,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,,12687,,D,9,Expert,1,,CHEMBL617459,,BAO_0000019
2592,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,12687,,H,8,Expert,1,,CHEMBL617460,,BAO_0000357
2593,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,12687,,H,8,Expert,1,,CHEMBL617461,,BAO_0000357
2594,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,,12687,,D,9,Expert,1,,CHEMBL617462,,BAO_0000019
2595,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,12687,,H,8,Autocuration,1,,CHEMBL617463,,BAO_0000357
2596,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,12687,,H,8,Autocuration,1,,CHEMBL617464,,BAO_0000019
2597,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,12687,,H,8,Autocuration,1,,CHEMBL617465,,BAO_0000019
2598,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,12687,,H,8,Expert,1,,CHEMBL617466,,BAO_0000019
2599,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,12687,,H,8,Autocuration,1,,CHEMBL617467,,BAO_0000019
2600,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,12687,,H,8,Expert,1,,CHEMBL617468,,BAO_0000019
2601,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,12687,,H,8,Autocuration,1,,CHEMBL617469,,BAO_0000019
2602,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617470,,BAO_0000019
2603,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,12687,,H,8,Autocuration,1,,CHEMBL617471,,BAO_0000019
2604,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,,12687,NIH3T3,H,8,Expert,1,,CHEMBL617472,723.0,BAO_0000219
2605,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,12687,,H,8,Expert,1,,CHEMBL617473,,BAO_0000357
2606,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,12687,,D,9,Expert,1,,CHEMBL617474,,BAO_0000019
2607,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,12687,,D,9,Expert,1,,CHEMBL617475,,BAO_0000019
2608,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,955.0,,12687,,H,8,Autocuration,1,,CHEMBL617476,,BAO_0000221
2609,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Expert,1,,CHEMBL617477,,BAO_0000357
2610,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,,12687,NIH3T3,H,8,Expert,1,,CHEMBL617478,723.0,BAO_0000219
2611,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,12687,,H,8,Autocuration,1,,CHEMBL617479,,BAO_0000221
2612,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL617480,,BAO_0000357
2613,,Binding affinity against 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Expert,1,,CHEMBL617481,,BAO_0000357
2614,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,12687,,H,8,Expert,1,,CHEMBL617482,,BAO_0000019
2615,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL617483,,BAO_0000019
2616,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL621528,,BAO_0000357
2617,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,,12687,NIH3T3,D,9,Expert,1,,CHEMBL621529,723.0,BAO_0000219
2618,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,12687,,H,8,Expert,1,,CHEMBL621530,,BAO_0000357
2619,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687,,H,8,Expert,1,,CHEMBL621531,,BAO_0000357
2620,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,,12687,,D,9,Expert,1,,CHEMBL621532,,BAO_0000019
2621,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,12687,,H,8,Expert,1,,CHEMBL621533,,BAO_0000357
2622,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,12687,CHO,H,8,Expert,1,,CHEMBL621534,449.0,BAO_0000219
2623,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,12687,,H,8,Autocuration,1,,CHEMBL621535,,BAO_0000019
2624,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,12687,,H,8,Autocuration,1,,CHEMBL621536,,BAO_0000357
2625,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL621537,,BAO_0000357
2626,,Binding affinity for 5-hydroxytryptamine 2A receptor,,,12687,,D,9,Expert,1,,CHEMBL621538,,BAO_0000357
2627,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,12687,,H,8,Autocuration,1,,CHEMBL621539,,BAO_0000019
2628,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,12687,,H,8,Autocuration,1,,CHEMBL621540,,BAO_0000019
2629,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,12687,,H,8,Autocuration,1,,CHEMBL621541,,BAO_0000019
2630,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL621542,,BAO_0000019
2631,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,12687,,H,8,Expert,1,,CHEMBL621543,,BAO_0000357
2632,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,12687,,H,8,Expert,1,,CHEMBL621544,,BAO_0000357
2633,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,,12687,,D,9,Expert,1,,CHEMBL621545,,BAO_0000357
2634,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL621546,,BAO_0000357
2635,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,12687,,H,8,Autocuration,1,,CHEMBL621547,,BAO_0000357
2636,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,,12687,NIH3T3,H,8,Expert,1,,CHEMBL618692,723.0,BAO_0000219
2637,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL618693,,BAO_0000357
2638,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL872922,,BAO_0000357
2639,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL618694,,BAO_0000357
2640,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,,12687,,D,9,Expert,1,,CHEMBL618695,,BAO_0000357
2641,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,12687,,H,8,Autocuration,1,,CHEMBL618696,,BAO_0000357
2642,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,12687,,H,8,Expert,1,,CHEMBL618697,,BAO_0000357
2643,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL618892,,BAO_0000357
2644,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL618893,,BAO_0000357
2645,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL618894,,BAO_0000357
2646,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,,12687,NIH3T3,H,8,Expert,1,,CHEMBL618895,723.0,BAO_0000219
2647,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,12687,,D,9,Expert,1,,CHEMBL618896,,BAO_0000357
2648,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,5383.0,,12687,,H,8,Autocuration,1,,CHEMBL618897,,BAO_0000019
2649,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL618898,,BAO_0000357
2650,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,12687,,H,8,Autocuration,1,,CHEMBL618899,,BAO_0000357
2651,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,12687,,H,8,Autocuration,1,,CHEMBL618900,,BAO_0000357
2652,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,12687,,H,8,Autocuration,1,,CHEMBL618901,,BAO_0000019
2653,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL618902,,BAO_0000357
2654,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,10000000.0,,12687,,D,9,Expert,1,,CHEMBL618903,,BAO_0000221
2655,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL618904,,BAO_0000357
2656,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,12687,,H,8,Autocuration,1,,CHEMBL618905,,BAO_0000357
2657,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,12687,,H,8,Autocuration,1,,CHEMBL618906,,BAO_0000357
2658,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,,12687,NIH3T3,H,8,Expert,1,,CHEMBL618907,723.0,BAO_0000219
2659,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,12687,,H,8,Autocuration,1,,CHEMBL618908,,BAO_0000019
2660,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617909,,BAO_0000357
2661,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,12687,,H,8,Expert,1,,CHEMBL617910,,BAO_0000019
2662,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,955.0,,12687,,H,8,Autocuration,1,,CHEMBL617911,,BAO_0000221
2663,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,,H,8,Autocuration,1,,CHEMBL872923,,BAO_0000249
2664,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,,H,8,Autocuration,1,,CHEMBL617912,,BAO_0000249
2665,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,,12687,,D,9,Expert,1,,CHEMBL617913,,BAO_0000019
2666,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,,H,8,Expert,1,,CHEMBL617914,,BAO_0000249
2667,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,,H,8,Autocuration,1,,CHEMBL617915,,BAO_0000249
2668,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,,H,8,Autocuration,1,,CHEMBL617916,,BAO_0000249
2669,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,,12687,,D,9,Expert,1,,CHEMBL617917,,BAO_0000019
2670,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,12687,,H,8,Expert,1,,CHEMBL617918,,BAO_0000019
2671,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,12687,,H,8,Autocuration,1,,CHEMBL617919,,BAO_0000019
2672,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,12687,,D,9,Expert,1,,CHEMBL617920,,BAO_0000019
2673,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,,12687,,D,9,Expert,1,,CHEMBL617921,,BAO_0000019
2674,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,,105102,,D,5,Expert,1,,CHEMBL617922,,BAO_0000224
2675,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL617923,,BAO_0000357
2676,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL617924,,BAO_0000357
2677,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,12687,,H,8,Autocuration,1,,CHEMBL617925,,BAO_0000357
2678,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,,12687,,D,9,Expert,1,,CHEMBL617926,,BAO_0000357
2679,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,12687,,H,8,Autocuration,1,,CHEMBL617927,,BAO_0000357
2680,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,12687,,H,8,Autocuration,1,,CHEMBL617928,,BAO_0000357
2681,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687,,D,9,Expert,1,,CHEMBL617929,,BAO_0000019
2682,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,12687,,H,8,Expert,1,,CHEMBL617930,,BAO_0000019
2683,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,12687,,H,8,Autocuration,1,,CHEMBL617931,,BAO_0000019
2684,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,12687,,H,8,Autocuration,1,,CHEMBL617932,,BAO_0000019
2685,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,,12687,CHO,H,8,Autocuration,1,,CHEMBL617933,449.0,BAO_0000219
2686,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,12687,,H,8,Autocuration,1,,CHEMBL617934,,BAO_0000019
2687,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,12687,,H,8,Autocuration,1,,CHEMBL617935,,BAO_0000019
2688,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,12687,,H,8,Autocuration,1,,CHEMBL617936,,BAO_0000357
2689,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,12687,,H,8,Autocuration,1,,CHEMBL617937,,BAO_0000019
2690,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,12687,,H,8,Autocuration,1,,CHEMBL617938,,BAO_0000019
2691,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,12687,,H,8,Autocuration,1,,CHEMBL617939,,BAO_0000218
2692,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,12687,,H,8,Autocuration,1,,CHEMBL617940,,BAO_0000218
2693,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,12687,,H,8,Autocuration,1,,CHEMBL617941,,BAO_0000218
2694,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,12687,,H,8,Expert,1,,CHEMBL617942,,BAO_0000357
2695,,Ratio of pKi of 5-HT2A to that of D2 receptor,,,12687,,H,8,Expert,1,,CHEMBL617943,,BAO_0000357
2696,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,105093,,H,4,Expert,1,,CHEMBL617944,,BAO_0000224
2697,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,105093,,H,4,Expert,1,,CHEMBL617945,,BAO_0000224
2698,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,105075,,H,4,Expert,1,,CHEMBL617946,,BAO_0000224
2699,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,12687,,H,8,Autocuration,1,,CHEMBL617947,,BAO_0000357
2700,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,12687,,H,8,Expert,1,,CHEMBL617948,,BAO_0000357
2701,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,12687,,H,8,Autocuration,1,,CHEMBL858116,,BAO_0000019
2702,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,12687,,H,8,Autocuration,1,,CHEMBL617949,,BAO_0000019
2703,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,12687,,H,8,Autocuration,1,,CHEMBL617950,,BAO_0000019
2704,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,1515.0,,12687,,H,8,Expert,1,,CHEMBL617951,,BAO_0000019
2705,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,1515.0,,12687,,H,8,Expert,1,,CHEMBL617952,,BAO_0000019
2706,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,1515.0,,12687,,H,8,Autocuration,1,,CHEMBL617953,,BAO_0000019
2707,,Binding activity radioligand.,,,12687,,H,8,Autocuration,1,,CHEMBL617954,,BAO_0000357
2708,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,12687,,H,8,Expert,1,,CHEMBL617955,,BAO_0000019
2709,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,12687,,H,8,Autocuration,1,,CHEMBL857071,,BAO_0000019
2710,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,12687,,H,8,Expert,1,,CHEMBL617270,,BAO_0000019
2711,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,,12687,N1E-115,H,8,Autocuration,1,,CHEMBL617271,339.0,BAO_0000219
2712,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,,12687,N1E-115,H,8,Autocuration,1,,CHEMBL617272,339.0,BAO_0000219
2713,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,12687,,H,8,Autocuration,1,,CHEMBL617273,,BAO_0000019
2714,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,,12687,,D,9,Expert,1,,CHEMBL617274,,BAO_0000019
2715,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617275,,BAO_0000357
2716,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617276,,BAO_0000357
2717,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617277,,BAO_0000357
2718,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,108,,H,8,Expert,1,,CHEMBL617278,,BAO_0000019
2719,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,108,,H,8,Expert,1,,CHEMBL617279,,BAO_0000019
2720,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,108,,H,8,Expert,1,,CHEMBL617280,,BAO_0000019
2721,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617281,,BAO_0000357
2722,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617282,,BAO_0000357
2723,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,108,,H,8,Expert,1,,CHEMBL617283,,BAO_0000019
2724,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,108,,H,8,Expert,1,,CHEMBL617284,,BAO_0000019
2725,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,,108,HEK293,H,8,Autocuration,1,,CHEMBL617285,722.0,BAO_0000219
2726,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617286,,BAO_0000019
2727,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,,108,,D,9,Expert,1,,CHEMBL617287,,BAO_0000357
2728,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,108,,H,8,Expert,1,,CHEMBL617288,,BAO_0000357
2729,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL617289,,BAO_0000357
2730,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL872917,,BAO_0000357
2731,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL617290,,BAO_0000357
2732,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,108,CHO,H,8,Autocuration,1,,CHEMBL617291,449.0,BAO_0000219
2733,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,,108,CHO,H,8,Autocuration,1,,CHEMBL617292,449.0,BAO_0000219
2734,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,108,NIH3T3,H,8,Autocuration,1,,CHEMBL617293,723.0,BAO_0000219
2735,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,108,CHO,D,9,Expert,1,,CHEMBL617294,449.0,BAO_0000219
2736,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,108,,H,8,Expert,1,,CHEMBL617295,,BAO_0000019
2737,,Binding activity radioligand.,,,108,,H,8,Autocuration,1,,CHEMBL617296,,BAO_0000357
2738,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,108,,H,8,Autocuration,1,,CHEMBL617297,,BAO_0000019
2739,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,,108,CHO,H,8,Expert,1,,CHEMBL617298,449.0,BAO_0000219
2740,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,,108,CHO,H,8,Expert,1,,CHEMBL617299,449.0,BAO_0000219
2741,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,,108,CHO,H,8,Autocuration,1,,CHEMBL617300,449.0,BAO_0000219
2742,,Binding affinity against 5-HT2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617454,,BAO_0000357
2743,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,108,HEK293,H,8,Autocuration,1,,CHEMBL617505,722.0,BAO_0000219
2744,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,,108,HEK293,D,9,Expert,1,,CHEMBL617506,722.0,BAO_0000219
2745,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,108,HEK293,D,9,Expert,1,,CHEMBL617507,722.0,BAO_0000219
2746,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,108,,H,8,Expert,1,,CHEMBL617508,,BAO_0000357
2747,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,108,HEK293,D,9,Expert,1,,CHEMBL857982,722.0,BAO_0000219
2748,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,,108,HEK293,D,9,Expert,1,,CHEMBL617509,722.0,BAO_0000219
2749,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,,108,HEK293,D,9,Expert,1,,CHEMBL617510,722.0,BAO_0000219
2750,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,108,,H,8,Autocuration,1,,CHEMBL617511,,BAO_0000357
2751,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,,108,HEK293,H,8,Autocuration,1,,CHEMBL617512,722.0,BAO_0000219
2752,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,,108,HEK293,H,8,Autocuration,1,,CHEMBL617749,722.0,BAO_0000219
2753,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,108,HEK293,H,8,Autocuration,1,,CHEMBL617750,722.0,BAO_0000219
2754,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,108,HEK293,H,8,Autocuration,1,,CHEMBL617751,722.0,BAO_0000219
2755,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,,108,HEK293,H,8,Expert,1,,CHEMBL617752,722.0,BAO_0000219
2756,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,,108,HEK293,H,8,Autocuration,1,,CHEMBL617753,722.0,BAO_0000219
2757,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,,108,HEK293,H,8,Expert,1,,CHEMBL617754,722.0,BAO_0000219
2758,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,,108,HEK293,D,9,Expert,1,,CHEMBL617755,722.0,BAO_0000219
2759,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,,108,HEK293,H,8,Autocuration,1,,CHEMBL617756,722.0,BAO_0000219
2760,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,,108,HEK293,H,8,Expert,1,,CHEMBL617757,722.0,BAO_0000219
2761,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,,108,HEK293,H,8,Expert,1,,CHEMBL617758,722.0,BAO_0000219
2762,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,108,NIH3T3,H,8,Autocuration,1,,CHEMBL617759,723.0,BAO_0000219
2763,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,,108,HEK293,H,8,Autocuration,1,,CHEMBL617760,722.0,BAO_0000219
2764,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,,108,CHO-K1,H,8,Expert,1,,CHEMBL617761,485.0,BAO_0000219
2765,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,108,,D,9,Expert,1,,CHEMBL617762,,BAO_0000357
2766,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617763,,BAO_0000357
2767,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,,108,HEK293,H,8,Autocuration,1,,CHEMBL857983,722.0,BAO_0000219
2768,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,,108,HEK293,H,8,Autocuration,1,,CHEMBL617764,722.0,BAO_0000219
2769,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,,108,HeLa,H,8,Autocuration,1,,CHEMBL617765,308.0,BAO_0000219
2770,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,108,,H,8,Autocuration,1,,CHEMBL617766,,BAO_0000019
2771,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,10000000.0,,108,,H,8,Autocuration,1,,CHEMBL617767,,BAO_0000221
2772,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,,108,HEK293,H,8,Autocuration,1,,CHEMBL617768,722.0,BAO_0000219
2773,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,,108,HEK293,H,8,Autocuration,1,,CHEMBL617769,722.0,BAO_0000219
2774,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,11864,,H,8,Autocuration,1,,CHEMBL858023,,BAO_0000357
2775,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,945.0,,11864,,H,8,Autocuration,1,,CHEMBL617770,,BAO_0000019
2776,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,945.0,,11864,,H,8,Autocuration,1,,CHEMBL617771,,BAO_0000019
2777,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,,11864,A9,H,8,Autocuration,1,,CHEMBL617772,625.0,BAO_0000219
2778,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,11864,NIH3T3,H,8,Autocuration,1,,CHEMBL617773,723.0,BAO_0000219
2779,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,,11864,NIH3T3,H,8,Autocuration,1,,CHEMBL617850,723.0,BAO_0000219
2780,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,11864,NIH3T3,H,8,Autocuration,1,,CHEMBL617851,723.0,BAO_0000219
2781,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,11864,,H,8,Autocuration,1,,CHEMBL617852,,BAO_0000019
2782,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,945.0,,12689,,H,8,Autocuration,1,,CHEMBL858024,,BAO_0000019
2783,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,945.0,,12689,,D,9,Expert,1,,CHEMBL617853,,BAO_0000019
2784,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,108,,H,8,Expert,1,,CHEMBL617854,,BAO_0000357
2785,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,108,,H,8,Expert,1,,CHEMBL873477,,BAO_0000357
2786,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,108,,H,8,Expert,1,,CHEMBL617855,,BAO_0000357
2787,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,108,,H,8,Expert,1,,CHEMBL617856,,BAO_0000019
2788,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,108,,H,8,Autocuration,1,,CHEMBL617857,,BAO_0000019
2789,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,108,,H,8,Autocuration,1,,CHEMBL617858,,BAO_0000249
2790,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617859,,BAO_0000357
2791,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617860,,BAO_0000357
2792,,Binding activity radioligand.,,,108,,H,8,Autocuration,1,,CHEMBL617861,,BAO_0000357
2793,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,108,,H,8,Expert,1,,CHEMBL617862,,BAO_0000019
2794,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,108,,H,8,Autocuration,1,,CHEMBL617863,,BAO_0000019
2795,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,108,,H,8,Autocuration,1,,CHEMBL617864,,BAO_0000249
2796,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,108,,H,8,Autocuration,1,,CHEMBL617649,,BAO_0000249
2797,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,108,,H,8,Expert,1,,CHEMBL617650,,BAO_0000019
2798,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,108,,H,8,Expert,1,,CHEMBL617651,,BAO_0000019
2799,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,,108,,H,8,Autocuration,1,,CHEMBL617652,,BAO_0000357
2800,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,,108,,H,8,Autocuration,1,,CHEMBL857072,,BAO_0000019
2801,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617653,,BAO_0000357
2802,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,12687,,H,8,Autocuration,1,,CHEMBL617654,,BAO_0000019
2803,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL617655,,BAO_0000019
2804,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,12689,,H,8,Expert,1,,CHEMBL617656,,BAO_0000357
2805,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,12689,,H,8,Autocuration,1,,CHEMBL617657,,BAO_0000357
2806,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,12689,,H,8,Autocuration,1,,CHEMBL617658,,BAO_0000357
2807,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,,12689,,D,9,Expert,1,,CHEMBL617659,,BAO_0000357
2808,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,,12689,,D,9,Expert,1,,CHEMBL617838,,BAO_0000357
2809,Brain membranes,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,,12689,,D,9,Expert,1,,CHEMBL617839,,BAO_0000249
2810,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,12689,,H,8,Autocuration,1,,CHEMBL617840,,BAO_0000357
2811,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,12689,,H,8,Autocuration,1,,CHEMBL617841,,BAO_0000019
2812,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL875915,,BAO_0000019
2813,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,,12689,,H,8,Expert,1,,CHEMBL617842,,BAO_0000219
2814,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,,12689,NIH3T3,H,8,Expert,1,,CHEMBL617843,723.0,BAO_0000219
2815,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,12689,,H,8,Expert,1,,CHEMBL617844,,BAO_0000357
2816,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,12689,,H,8,Expert,1,,CHEMBL617845,,BAO_0000357
2817,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,,12689,NIH3T3,H,8,Expert,1,,CHEMBL617846,723.0,BAO_0000219
2818,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,12689,,H,8,Autocuration,1,,CHEMBL617847,,BAO_0000357
2819,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,12689,,H,8,Expert,1,,CHEMBL617848,,BAO_0000357
2820,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,12689,,H,8,Autocuration,1,,CHEMBL617849,,BAO_0000357
2821,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,12689,,H,8,Expert,1,,CHEMBL621507,,BAO_0000357
2822,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,12689,,H,8,Expert,1,,CHEMBL621508,,BAO_0000357
2823,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,12689,,H,8,Autocuration,1,,CHEMBL621509,,BAO_0000019
2824,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,12689,,H,8,Autocuration,1,,CHEMBL621510,,BAO_0000019
2825,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,12689,,H,8,Autocuration,1,,CHEMBL621511,,BAO_0000019
2826,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,,12689,A9,H,8,Expert,1,,CHEMBL621512,625.0,BAO_0000219
2827,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,12689,,H,8,Autocuration,1,,CHEMBL621513,,BAO_0000357
2828,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,12689,,H,8,Expert,1,,CHEMBL621514,,BAO_0000357
2829,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,,12689,,H,8,Expert,1,,CHEMBL621515,,BAO_0000219
2830,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,12689,,H,8,Autocuration,1,,CHEMBL621516,,BAO_0000219
2831,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,5383.0,,12689,,H,8,Autocuration,1,,CHEMBL621517,,BAO_0000019
2832,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,12689,,H,8,Autocuration,1,,CHEMBL621518,,BAO_0000357
2833,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,12689,,H,8,Autocuration,1,,CHEMBL621519,,BAO_0000019
2834,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL621520,,BAO_0000357
2835,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL621521,,BAO_0000357
2836,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL621522,,BAO_0000357
2837,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,12689,,H,8,Expert,1,,CHEMBL621523,,BAO_0000219
2838,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL621524,,BAO_0000357
2839,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,,12689,,D,9,Expert,1,,CHEMBL621525,,BAO_0000357
2840,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,12689,,H,8,Autocuration,1,,CHEMBL872921,,BAO_0000357
2841,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL621526,,BAO_0000357
2842,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,12689,,H,8,Expert,1,,CHEMBL621527,,BAO_0000219
2843,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,,12689,,D,9,Expert,1,,CHEMBL617865,,BAO_0000019
2844,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL617866,,BAO_0000357
2845,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,12689,,H,8,Autocuration,1,,CHEMBL617867,,BAO_0000019
2846,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,12689,,H,8,Autocuration,1,,CHEMBL617487,,BAO_0000357
2847,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,12689,,H,8,Expert,1,,CHEMBL617488,,BAO_0000357
2848,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,12689,,H,8,Autocuration,1,,CHEMBL617489,,BAO_0000357
2849,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,12689,,H,8,Autocuration,1,,CHEMBL617490,,BAO_0000019
2850,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,12689,,H,8,Autocuration,1,,CHEMBL617491,,BAO_0000019
2851,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,12689,,H,8,Autocuration,1,,CHEMBL617492,,BAO_0000019
2852,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,12689,,H,8,Autocuration,1,,CHEMBL617493,,BAO_0000019
2853,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,12689,,H,8,Autocuration,1,,CHEMBL617494,,BAO_0000357
2854,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,,12689,,D,9,Expert,1,,CHEMBL617495,,BAO_0000019
2855,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,12689,,H,8,Autocuration,1,,CHEMBL617496,,BAO_0000357
2856,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,,12689,CHO-K1,H,8,Autocuration,1,,CHEMBL617497,485.0,BAO_0000219
2857,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,12689,,H,8,Autocuration,1,,CHEMBL617498,,BAO_0000357
2858,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,12689,,H,8,Autocuration,1,,CHEMBL617499,,BAO_0000357
2859,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,12689,,H,8,Autocuration,1,,CHEMBL617500,,BAO_0000019
2860,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617501,,BAO_0000357
2861,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,108,,H,8,Expert,1,,CHEMBL617502,,BAO_0000357
2862,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,227,,H,8,Autocuration,1,,CHEMBL617503,,BAO_0000357
2863,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,227,,H,8,Autocuration,1,,CHEMBL617504,,BAO_0000357
2864,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,227,,H,8,Autocuration,1,,CHEMBL617406,,BAO_0000357
2865,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,,227,,D,9,Expert,1,,CHEMBL617407,,BAO_0000019
2866,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,227,,H,8,Autocuration,1,,CHEMBL617408,,BAO_0000357
2867,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,227,,H,8,Autocuration,1,,CHEMBL617409,,BAO_0000357
2868,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,227,,H,8,Autocuration,1,,CHEMBL617410,,BAO_0000357
2869,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,227,,H,8,Autocuration,1,,CHEMBL617411,,BAO_0000357
2870,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,227,,H,8,Autocuration,1,,CHEMBL617412,,BAO_0000019
2871,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,,227,,D,9,Expert,1,,CHEMBL617774,,BAO_0000357
2872,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,227,HEK293,D,9,Expert,1,,CHEMBL617775,722.0,BAO_0000219
2873,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,227,HEK293,D,9,Expert,1,,CHEMBL617776,722.0,BAO_0000219
2874,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,227,CHO,D,9,Expert,1,,CHEMBL617777,449.0,BAO_0000219
2875,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,227,CHO,D,9,Expert,1,,CHEMBL617778,449.0,BAO_0000219
2876,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,227,HEK293,H,8,Autocuration,1,,CHEMBL617779,722.0,BAO_0000219
2877,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,,227,HEK293,H,8,Expert,1,,CHEMBL617780,722.0,BAO_0000219
2878,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,,227,HEK293,H,8,Autocuration,1,,CHEMBL617781,722.0,BAO_0000219
2879,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,,227,HEK293,D,9,Expert,1,,CHEMBL617782,722.0,BAO_0000219
2880,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,,227,HEK293,D,9,Expert,1,,CHEMBL617783,722.0,BAO_0000219
2881,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,227,,H,8,Autocuration,1,,CHEMBL617784,,BAO_0000357
2882,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,,227,HEK293,H,8,Autocuration,1,,CHEMBL617785,722.0,BAO_0000219
2883,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,,227,HEK293,H,8,Expert,1,,CHEMBL857984,722.0,BAO_0000219
2884,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,,227,HEK293,H,8,Expert,1,,CHEMBL617786,722.0,BAO_0000219
2885,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,,227,HEK293,H,8,Expert,1,,CHEMBL617787,722.0,BAO_0000219
2886,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,,227,HEK293,D,9,Expert,1,,CHEMBL617788,722.0,BAO_0000219
2887,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,,227,HEK293,D,9,Expert,1,,CHEMBL617789,722.0,BAO_0000219
2888,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,,227,HEK293,H,8,Autocuration,1,,CHEMBL617790,722.0,BAO_0000219
2889,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,,227,CHO-K1,H,8,Expert,1,,CHEMBL617791,485.0,BAO_0000219
2890,,Binding affinity against 5-hydroxytryptamine 2B receptor,,,227,,H,8,Expert,1,,CHEMBL617608,,BAO_0000357
2891,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,,227,HEK293,H,8,Autocuration,1,,CHEMBL617609,722.0,BAO_0000219
2892,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,,227,HEK293,H,8,Autocuration,1,,CHEMBL617610,722.0,BAO_0000219
2893,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,,227,HEK293,H,8,Autocuration,1,,CHEMBL617611,722.0,BAO_0000219
2894,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,227,HEK293,H,8,Autocuration,1,,CHEMBL617612,722.0,BAO_0000219
2895,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,227,HEK293,H,8,Autocuration,1,,CHEMBL617613,722.0,BAO_0000219
2896,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,,227,,H,8,Autocuration,1,,CHEMBL617614,,BAO_0000019
2897,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,945.0,,12688,,H,8,Expert,1,,CHEMBL617615,,BAO_0000019
2898,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,945.0,,12688,,H,8,Expert,1,,CHEMBL858114,,BAO_0000357
2899,,Affinity against serotonergic receptor in the isolated rat stomach fundus,945.0,,12688,,H,8,Autocuration,1,,CHEMBL617616,,BAO_0000357
2900,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,945.0,,12688,,D,9,Expert,1,,CHEMBL617617,,BAO_0000019
2901,,Antagonistic against 5-hydroxytryptamine 2B receptor,,,12688,,D,9,Expert,1,,CHEMBL875914,,BAO_0000019
2902,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,945.0,,12688,,H,8,Autocuration,1,,CHEMBL617618,,BAO_0000019
2903,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,945.0,,12688,,D,9,Expert,1,,CHEMBL617619,,BAO_0000357
2904,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,12688,,H,8,Autocuration,1,,CHEMBL617620,,BAO_0000019
2905,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,12688,,H,8,Autocuration,1,,CHEMBL617621,,BAO_0000019
2906,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,12688,,H,8,Autocuration,1,,CHEMBL617622,,BAO_0000019
2907,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,,12688,,D,9,Expert,1,,CHEMBL617623,,BAO_0000357
2908,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,,12688,,D,9,Expert,1,,CHEMBL617624,,BAO_0000357
2909,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,,12688,,D,9,Expert,1,,CHEMBL617625,,BAO_0000357
2910,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,,12688,,D,9,Expert,1,,CHEMBL617626,,BAO_0000357
2911,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,945.0,,12688,,H,8,Autocuration,1,,CHEMBL617627,,BAO_0000019
2912,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,945.0,,12688,,H,8,Expert,1,,CHEMBL617628,,BAO_0000019
2913,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,945.0,,12688,,H,8,Autocuration,1,,CHEMBL617629,,BAO_0000019
2914,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,945.0,,12688,,H,8,Autocuration,1,,CHEMBL858115,,BAO_0000019
2915,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,945.0,,12688,,D,9,Expert,1,,CHEMBL617630,,BAO_0000019
2916,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,1515.0,,12688,,H,8,Autocuration,1,,CHEMBL617631,,BAO_0000019
2917,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,12688,,H,8,Autocuration,1,,CHEMBL617632,,BAO_0000357
2918,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,12688,,H,8,Expert,1,,CHEMBL617633,,BAO_0000357
2919,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,12688,,H,8,Autocuration,1,,CHEMBL617634,,BAO_0000357
2920,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,12688,,H,8,Autocuration,1,,CHEMBL617635,,BAO_0000357
2922,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,945.0,,12688,,D,9,Autocuration,1,,CHEMBL617637,,BAO_0000019
2923,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,227,,H,8,Autocuration,1,,CHEMBL617638,,BAO_0000357
2924,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,227,,H,8,Autocuration,1,,CHEMBL617639,,BAO_0000357
2925,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,227,,H,8,Autocuration,1,,CHEMBL617640,,BAO_0000357
2926,,Evaluated for the binding affinity to 5-HT 2B receptor,,,227,,H,8,Autocuration,1,,CHEMBL617641,,BAO_0000357
2927,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,227,,H,8,Autocuration,1,,CHEMBL617642,,BAO_0000357
2928,,Binding affinities against 5-hydroxytryptamine 2B receptor,,,227,,H,8,Autocuration,1,,CHEMBL617643,,BAO_0000357
2929,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,227,,H,8,Autocuration,1,,CHEMBL617644,,BAO_0000357
2930,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,227,,H,8,Autocuration,1,,CHEMBL617645,,BAO_0000357
2931,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,108,,H,8,Expert,1,,CHEMBL617646,,BAO_0000357
2932,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,108,,H,8,Autocuration,1,,CHEMBL617647,,BAO_0000357
2933,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,,108,,H,8,Autocuration,1,,CHEMBL617648,,BAO_0000357
2934,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,,108,,H,8,Autocuration,1,,CHEMBL617875,,BAO_0000357
2935,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,,108,,H,8,Autocuration,1,,CHEMBL617876,,BAO_0000357
2936,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,,108,,H,8,Expert,1,,CHEMBL617877,,BAO_0000357
2937,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,108,,H,8,Expert,1,,CHEMBL617878,,BAO_0000357
2938,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,108,,H,8,Autocuration,1,,CHEMBL617879,,BAO_0000357
2939,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,,108,,H,8,Autocuration,1,,CHEMBL617880,,BAO_0000019
2940,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL617881,,BAO_0000357
2941,,Binding affinity against 5-HT1A receptor,,,51,,H,8,Autocuration,1,,CHEMBL857073,,BAO_0000357
2942,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,,108,CHO,H,8,Expert,1,,CHEMBL617882,449.0,BAO_0000219
2943,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,,108,CHO,D,9,Expert,1,,CHEMBL617883,449.0,BAO_0000219
2944,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,108,,H,8,Autocuration,1,,CHEMBL617884,,BAO_0000219
2945,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,,108,CHO,H,8,Autocuration,1,,CHEMBL617885,449.0,BAO_0000219
2946,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,,108,CHO,H,8,Autocuration,1,,CHEMBL617886,449.0,BAO_0000219
2947,,Inhibition of human 5-hydroxytryptamine 2C receptor,,,108,,D,9,Expert,1,,CHEMBL617887,,BAO_0000357
2948,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,108,,H,8,Autocuration,1,,CHEMBL617888,,BAO_0000357
2949,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,108,,H,8,Autocuration,1,,CHEMBL617889,,BAO_0000019
2950,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL617890,,BAO_0000357
2951,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,108,,H,8,Autocuration,1,,CHEMBL617891,,BAO_0000357
2952,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,108,,H,8,Autocuration,1,,CHEMBL617892,,BAO_0000357
2953,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,,108,CHO,H,8,Expert,1,,CHEMBL617893,449.0,BAO_0000219
2954,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,,108,CHO,H,8,Expert,1,,CHEMBL617894,449.0,BAO_0000219
2955,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,108,CHO,H,8,Expert,1,,CHEMBL617895,449.0,BAO_0000219
2956,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,,108,CHO,H,8,Autocuration,1,,CHEMBL617896,449.0,BAO_0000219
2957,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,,108,,D,9,Expert,1,,CHEMBL617897,,BAO_0000357
2958,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,108,,H,8,Autocuration,1,,CHEMBL617898,,BAO_0000019
2959,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL617899,,BAO_0000019
2960,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,,108,CHO,H,8,Expert,1,,CHEMBL617900,449.0,BAO_0000219
2961,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,108,,H,8,Autocuration,1,,CHEMBL617901,,BAO_0000019
2962,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,108,,H,8,Autocuration,1,,CHEMBL617902,,BAO_0000019
2963,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL617903,,BAO_0000019
2964,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL617904,,BAO_0000357
2965,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL617905,,BAO_0000357
2966,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,108,,H,8,Autocuration,1,,CHEMBL617906,,BAO_0000357
2967,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,108,,H,8,Autocuration,1,,CHEMBL617907,,BAO_0000357
2968,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,108,,H,8,Autocuration,1,,CHEMBL617908,,BAO_0000357
2969,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,108,CHO,H,8,Expert,1,,CHEMBL620617,449.0,BAO_0000219
2970,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,,108,,D,9,Expert,1,,CHEMBL620618,,BAO_0000019
2971,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,108,,H,8,Expert,1,,CHEMBL620619,,BAO_0000357
2972,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,,108,,D,9,Expert,1,,CHEMBL620620,,BAO_0000357
2973,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL620621,,BAO_0000357
2974,Membranes,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,,104698,,D,7,Autocuration,1,,CHEMBL872920,,BAO_0000249
2975,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,104698,,H,6,Autocuration,1,,CHEMBL620622,,BAO_0000223
2976,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,,104698,,D,7,Autocuration,1,,CHEMBL620623,,BAO_0000019
2977,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,104698,,H,6,Autocuration,1,,CHEMBL620624,,BAO_0000019
2978,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,104698,,H,6,Autocuration,1,,CHEMBL620625,,BAO_0000019
2979,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,104698,,H,6,Autocuration,1,,CHEMBL620626,,BAO_0000219
2980,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,104698,,H,6,Autocuration,1,,CHEMBL621307,,BAO_0000019
2981,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,104698,,H,6,Autocuration,1,,CHEMBL621308,,BAO_0000019
2982,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,104698,,H,6,Autocuration,1,,CHEMBL621309,,BAO_0000223
2983,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,104698,,H,6,Autocuration,1,,CHEMBL621310,,BAO_0000223
2984,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,104698,,H,6,Autocuration,1,,CHEMBL621311,,BAO_0000223
2985,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,104698,,H,6,Autocuration,1,,CHEMBL621502,,BAO_0000249
2986,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,104698,,H,6,Autocuration,1,,CHEMBL621503,,BAO_0000249
2987,Membranes,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,104698,,H,6,Autocuration,1,,CHEMBL621504,,BAO_0000249
2988,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,104698,,H,6,Autocuration,1,,CHEMBL621505,,BAO_0000223
2989,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,104698,,H,6,Autocuration,1,,CHEMBL621506,,BAO_0000019
2990,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,104698,,H,6,Autocuration,1,,CHEMBL619781,,BAO_0000223
2991,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,104698,,H,6,Autocuration,1,,CHEMBL619782,,BAO_0000223
2992,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,104698,,H,6,Autocuration,1,,CHEMBL619783,,BAO_0000019
2993,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL619784,,BAO_0000019
2994,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,104698,,H,6,Autocuration,1,,CHEMBL619785,,BAO_0000249
2995,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,104698,,H,6,Autocuration,1,,CHEMBL619786,,BAO_0000223
2996,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,104698,,H,6,Autocuration,1,,CHEMBL619787,,BAO_0000019
2997,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,104698,,H,6,Autocuration,1,,CHEMBL872925,,BAO_0000019
2998,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,104698,,H,6,Autocuration,1,,CHEMBL619788,,BAO_0000019
2999,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,104698,,H,6,Autocuration,1,,CHEMBL619789,,BAO_0000249
3000,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,104698,,H,6,Autocuration,1,,CHEMBL619790,,BAO_0000249
3001,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,104698,,H,6,Autocuration,1,,CHEMBL619791,,BAO_0000019
3002,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,104698,,H,6,Autocuration,1,,CHEMBL619792,,BAO_0000019
3003,Membranes,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,104698,,H,6,Autocuration,1,,CHEMBL619793,,BAO_0000249
3004,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL619794,,BAO_0000223
3005,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,955.0,,104698,,H,6,Autocuration,1,,CHEMBL619795,,BAO_0000221
3006,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,104698,,H,6,Autocuration,1,,CHEMBL619796,,BAO_0000019
3007,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,104698,,H,6,Autocuration,1,,CHEMBL620448,,BAO_0000223
3008,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,104698,,H,6,Autocuration,1,,CHEMBL620449,,BAO_0000223
3009,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,104698,,H,6,Autocuration,1,,CHEMBL620450,,BAO_0000223
3010,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,104698,,H,6,Autocuration,1,,CHEMBL620451,,BAO_0000223
3011,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,104698,,H,6,Autocuration,1,,CHEMBL620631,,BAO_0000223
3012,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,104698,,H,6,Autocuration,1,,CHEMBL620632,,BAO_0000019
3013,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,104698,,H,6,Autocuration,1,,CHEMBL620633,,BAO_0000019
3014,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,104698,,H,6,Autocuration,1,,CHEMBL620634,,BAO_0000223
3015,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,104698,,H,6,Autocuration,1,,CHEMBL620635,,BAO_0000019
3016,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620636,,BAO_0000218
3017,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620637,,BAO_0000218
3018,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620638,,BAO_0000218
3019,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620639,,BAO_0000218
3020,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620640,,BAO_0000218
3021,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620641,,BAO_0000218
3022,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620642,,BAO_0000218
3023,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620643,,BAO_0000218
3024,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620644,,BAO_0000218
3025,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620645,,BAO_0000218
3026,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620646,,BAO_0000218
3027,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620647,,BAO_0000218
3028,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620648,,BAO_0000218
3029,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620649,,BAO_0000218
3030,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620650,,BAO_0000218
3031,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620651,,BAO_0000218
3032,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL872875,,BAO_0000218
3033,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL620652,,BAO_0000218
3034,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,104698,,H,6,Autocuration,1,,CHEMBL620653,,BAO_0000019
3035,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,104698,,H,6,Autocuration,1,,CHEMBL857076,,BAO_0000019
3036,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL620654,,BAO_0000019
3037,,Binding activity radioligand.,,,104698,,H,6,Autocuration,1,,CHEMBL620655,,BAO_0000223
3038,Brain membranes,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,104698,,H,6,Autocuration,1,,CHEMBL620656,,BAO_0000249
3039,Brain membranes,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,104698,,H,6,Autocuration,1,,CHEMBL620657,,BAO_0000249
3040,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,108,,H,8,Autocuration,1,,CHEMBL620658,,BAO_0000357
3041,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,108,,H,8,Autocuration,1,,CHEMBL620659,,BAO_0000357
3042,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,108,,H,8,Autocuration,1,,CHEMBL620660,,BAO_0000357
3043,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL620661,,BAO_0000357
3044,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL620662,,BAO_0000357
3045,,Affinity for 5-hydroxytryptamine 2C receptor,,,108,,H,8,Expert,1,,CHEMBL620663,,BAO_0000357
3046,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,108,,H,8,Autocuration,1,,CHEMBL620664,,BAO_0000357
3047,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,108,,H,8,Expert,1,,CHEMBL620665,,BAO_0000357
3048,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,108,,H,8,Autocuration,1,,CHEMBL620666,,BAO_0000357
3049,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,108,,H,8,Autocuration,1,,CHEMBL620667,,BAO_0000357
3050,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,108,,H,8,Expert,1,,CHEMBL620668,,BAO_0000357
3051,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,108,,H,8,Autocuration,1,,CHEMBL620669,,BAO_0000357
3052,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,108,,H,8,Expert,1,,CHEMBL620670,,BAO_0000357
3053,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL620671,,BAO_0000357
3054,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,108,,H,8,Autocuration,1,,CHEMBL620672,,BAO_0000357
3055,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,108,,H,8,Autocuration,1,,CHEMBL620673,,BAO_0000357
3056,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL620674,,BAO_0000357
3057,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL620675,,BAO_0000357
3058,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,108,,H,8,Autocuration,1,,CHEMBL620676,,BAO_0000357
3059,,Affinity against 5-hydroxytryptamine 2C receptor,,,108,,H,8,Autocuration,1,,CHEMBL621382,,BAO_0000357
3060,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,108,,D,9,Expert,1,,CHEMBL621383,,BAO_0000357
3061,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,108,,H,8,Autocuration,1,,CHEMBL621384,,BAO_0000357
3062,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,,144,,H,8,Autocuration,1,,CHEMBL621385,,BAO_0000357
3063,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,,144,,H,8,Autocuration,1,,CHEMBL617989,,BAO_0000357
3064,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,,104714,,H,4,Expert,1,,CHEMBL617990,,BAO_0000019
3065,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL875085,,BAO_0000221
3066,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,,104714,,H,4,Autocuration,1,,CHEMBL617991,,BAO_0000019
3067,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,,104714,,H,4,Autocuration,1,,CHEMBL617992,,BAO_0000019
3068,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617993,,BAO_0000221
3069,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617994,,BAO_0000221
3070,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,,104714,,H,4,Autocuration,1,,CHEMBL617995,,BAO_0000019
3071,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,,104714,,H,4,Autocuration,1,,CHEMBL617996,,BAO_0000019
3072,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,,104714,,H,4,Autocuration,1,,CHEMBL617997,,BAO_0000019
3073,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,,104714,,H,4,Autocuration,1,,CHEMBL617998,,BAO_0000019
3074,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,,104714,,H,4,Autocuration,1,,CHEMBL617999,,BAO_0000019
3075,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,,104714,,H,4,Autocuration,1,,CHEMBL618000,,BAO_0000019
3076,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617815,,BAO_0000221
3077,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617816,,BAO_0000221
3078,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617817,,BAO_0000221
3079,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617818,,BAO_0000221
3080,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617819,,BAO_0000221
3081,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,,104714,,H,4,Autocuration,1,,CHEMBL617820,,BAO_0000223
3082,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617821,,BAO_0000221
3083,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617822,,BAO_0000221
3084,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617823,,BAO_0000221
3085,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617824,,BAO_0000221
3086,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617825,,BAO_0000221
3087,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617826,,BAO_0000221
3088,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617827,,BAO_0000221
3089,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617828,,BAO_0000221
3090,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617829,,BAO_0000221
3091,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617830,,BAO_0000221
3092,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617831,,BAO_0000221
3093,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617832,,BAO_0000221
3094,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,22226,,U,0,Autocuration,1,,CHEMBL617833,,BAO_0000019
3095,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,51,,H,8,Autocuration,1,,CHEMBL617834,,BAO_0000357
3096,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,,104714,,D,5,Expert,1,,CHEMBL617835,,BAO_0000223
3097,,Binding affinity towards 5-HT3 receptor,,,104714,,H,4,Autocuration,1,,CHEMBL617836,,BAO_0000223
3098,,Binding activity radioligand.,,,104714,,H,4,Autocuration,1,,CHEMBL617837,,BAO_0000223
3099,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,104714,,H,4,Autocuration,1,,CHEMBL620392,,BAO_0000019
3100,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,104714,,H,4,Autocuration,1,,CHEMBL620393,,BAO_0000223
3101,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,104714,,H,4,Autocuration,1,,CHEMBL620394,,BAO_0000223
3102,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,104714,,H,4,Autocuration,1,,CHEMBL620395,,BAO_0000223
3103,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,22226,,U,0,Autocuration,1,,CHEMBL620396,,BAO_0000019
3104,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,,105030,NG108-15,H,4,Expert,1,,CHEMBL620582,433.0,BAO_0000219
3105,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,,105030,,H,4,Autocuration,1,,CHEMBL620583,,BAO_0000218
3106,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,105030,,H,4,Autocuration,1,,CHEMBL620584,,BAO_0000019
3107,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,105030,,H,4,Autocuration,1,,CHEMBL620585,,BAO_0000224
3108,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,105030,,H,4,Autocuration,1,,CHEMBL620586,,BAO_0000224
3109,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,105030,,H,4,Autocuration,1,,CHEMBL620587,,BAO_0000019
3110,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,105030,,H,4,Autocuration,1,,CHEMBL620588,,BAO_0000019
3111,,5-hydroxytryptamine 3 receptor agonism in mouse,,,105030,,H,4,Autocuration,1,,CHEMBL620589,,BAO_0000218
3112,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,105030,,H,4,Autocuration,1,,CHEMBL620590,,BAO_0000219
3113,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,105030,,H,4,Autocuration,1,,CHEMBL617956,,BAO_0000019
3114,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,105030,,H,4,Autocuration,1,,CHEMBL617957,,BAO_0000019
3115,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,105030,,H,4,Autocuration,1,,CHEMBL617958,,BAO_0000224
3116,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,105030,,H,4,Autocuration,1,,CHEMBL617959,,BAO_0000219
3117,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,105030,,H,4,Autocuration,1,,CHEMBL617960,,BAO_0000219
3118,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,105030,,H,4,Autocuration,1,,CHEMBL617961,,BAO_0000224
3119,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,,105030,,H,4,Autocuration,1,,CHEMBL617962,,BAO_0000219
3120,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,,105030,N1E-115,H,4,Autocuration,1,,CHEMBL617963,339.0,BAO_0000219
3121,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,11765,,H,8,Autocuration,1,,CHEMBL617964,,BAO_0000019
3122,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,11765,,H,8,Autocuration,1,,CHEMBL617965,,BAO_0000219
3123,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,,10630,,D,9,Autocuration,1,,CHEMBL617966,,BAO_0000357
3124,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,17106,,H,8,Autocuration,1,,CHEMBL857074,,BAO_0000019
3125,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,,144,,H,8,Autocuration,1,,CHEMBL617967,,BAO_0000357
3126,,Binding activity radioligand.,,,144,,H,8,Autocuration,1,,CHEMBL617968,,BAO_0000357
3127,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,,104714,,H,4,Autocuration,1,,CHEMBL617969,,BAO_0000223
3128,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,104714,,H,4,Autocuration,1,,CHEMBL617970,,BAO_0000223
3129,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,,104714,,H,4,Autocuration,1,,CHEMBL617971,,BAO_0000223
3130,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,104714,,H,4,Autocuration,1,,CHEMBL617972,,BAO_0000019
3131,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,104714,,H,4,Autocuration,1,,CHEMBL617973,,BAO_0000019
3132,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,104714,,H,4,Autocuration,1,,CHEMBL617974,,BAO_0000019
3133,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),2116.0,,104714,,H,4,Autocuration,1,,CHEMBL617975,,BAO_0000221
3134,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,104714,,H,4,Autocuration,1,,CHEMBL617976,,BAO_0000019
3135,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,104714,,H,4,Autocuration,1,,CHEMBL617977,,BAO_0000019
3136,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,104714,,H,4,Autocuration,1,,CHEMBL617978,,BAO_0000019
3137,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,104714,,H,4,Autocuration,1,,CHEMBL617979,,BAO_0000019
3138,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,,104714,CHO,H,4,Autocuration,1,,CHEMBL617980,449.0,BAO_0000219
3139,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL617981,,BAO_0000019
3140,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,12020,,H,8,Autocuration,1,,CHEMBL617982,,BAO_0000019
3141,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,12020,,H,8,Autocuration,1,,CHEMBL617983,,BAO_0000357
3142,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,,104698,,D,7,Autocuration,1,,CHEMBL617984,,BAO_0000019
3143,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,104698,,H,6,Autocuration,1,,CHEMBL617985,,BAO_0000019
3144,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",948.0,,104698,,H,6,Autocuration,1,,CHEMBL617986,,BAO_0000218
3145,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",948.0,,104698,,H,6,Autocuration,1,,CHEMBL617987,,BAO_0000019
3146,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",948.0,,104698,,H,6,Autocuration,1,,CHEMBL617988,,BAO_0000019
3147,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",948.0,,104698,,H,6,Autocuration,1,,CHEMBL617792,,BAO_0000019
3148,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",948.0,,104698,,H,6,Autocuration,1,,CHEMBL617793,,BAO_0000019
3149,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,104698,,H,6,Autocuration,1,,CHEMBL617794,,BAO_0000019
3150,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,104698,,H,6,Autocuration,1,,CHEMBL617795,,BAO_0000019
3151,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,104698,,H,6,Autocuration,1,,CHEMBL617796,,BAO_0000019
3152,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,104698,,H,6,Autocuration,1,,CHEMBL617797,,BAO_0000019
3153,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,,104698,,D,7,Autocuration,1,,CHEMBL617798,,BAO_0000218
3154,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,,104698,,H,6,Autocuration,1,,CHEMBL617799,,BAO_0000218
3155,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,,D,7,Autocuration,1,,CHEMBL617800,,BAO_0000218
3156,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,,104698,,D,7,Autocuration,1,,CHEMBL617801,,BAO_0000019
3157,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,,104698,,D,7,Autocuration,1,,CHEMBL617802,,BAO_0000218
3158,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,,104698,,D,7,Autocuration,1,,CHEMBL617803,,BAO_0000019
3159,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,104698,,H,6,Autocuration,1,,CHEMBL617804,,BAO_0000019
3160,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL617805,,BAO_0000019
3161,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,104698,,H,6,Autocuration,1,,CHEMBL617806,,BAO_0000223
3162,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,104698,,H,6,Autocuration,1,,CHEMBL617807,,BAO_0000019
3163,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,104698,,H,6,Autocuration,1,,CHEMBL617808,,BAO_0000019
3164,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,104698,,H,6,Autocuration,1,,CHEMBL617809,,BAO_0000249
3165,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,104698,,H,6,Autocuration,1,,CHEMBL617810,,BAO_0000019
3166,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,955.0,,104698,,H,6,Autocuration,1,,CHEMBL617811,,BAO_0000249
3167,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,955.0,,104698,,H,6,Autocuration,1,,CHEMBL617812,,BAO_0000221
3168,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,104698,,H,6,Autocuration,1,,CHEMBL617813,,BAO_0000249
3169,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,104698,,H,6,Autocuration,1,,CHEMBL617814,,BAO_0000249
3170,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,104698,,H,6,Autocuration,1,,CHEMBL617698,,BAO_0000019
3171,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,,104698,,D,7,Autocuration,1,,CHEMBL617699,,BAO_0000019
3172,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,,104698,,D,7,Autocuration,1,,CHEMBL617700,,BAO_0000019
3173,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL617701,,BAO_0000223
3174,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,104698,,H,6,Autocuration,1,,CHEMBL617702,,BAO_0000019
3175,Membranes,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,104698,,H,6,Autocuration,1,,CHEMBL617703,,BAO_0000249
3176,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL617704,,BAO_0000019
3177,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,104698,,H,6,Autocuration,1,,CHEMBL617705,,BAO_0000223
3178,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL617706,,BAO_0000223
3179,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,,104698,NG108-15,H,6,Autocuration,1,,CHEMBL617707,433.0,BAO_0000219
3180,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,,104698,NG108-15,H,6,Autocuration,1,,CHEMBL617708,433.0,BAO_0000219
3181,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,104698,,H,6,Autocuration,1,,CHEMBL617709,,BAO_0000019
3182,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,104698,,H,6,Autocuration,1,,CHEMBL617710,,BAO_0000019
3183,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,104698,,H,6,Autocuration,1,,CHEMBL882925,,BAO_0000019
3184,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,104698,,H,6,Autocuration,1,,CHEMBL617711,,BAO_0000019
3185,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,104698,,H,6,Autocuration,1,,CHEMBL617712,,BAO_0000019
3186,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,,104698,,D,7,Autocuration,1,,CHEMBL617713,,BAO_0000019
3187,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,104698,,H,6,Autocuration,1,,CHEMBL617714,,BAO_0000019
3188,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,104698,,H,6,Autocuration,1,,CHEMBL617715,,BAO_0000218
3189,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,,104698,,H,6,Autocuration,1,,CHEMBL617716,,BAO_0000218
3190,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,104698,,H,6,Autocuration,1,,CHEMBL617717,,BAO_0000218
3191,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617718,,BAO_0000218
3192,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617719,,BAO_0000218
3193,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,,104698,,H,6,Autocuration,1,,CHEMBL617720,,BAO_0000218
3194,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,,104698,,D,7,Autocuration,1,,CHEMBL617721,,BAO_0000218
3195,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617722,,BAO_0000218
3196,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617723,,BAO_0000218
3197,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617724,,BAO_0000218
3198,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617725,,BAO_0000218
3199,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617726,,BAO_0000218
3200,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617727,,BAO_0000218
3201,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617728,,BAO_0000218
3202,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617729,,BAO_0000218
3203,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617730,,BAO_0000218
3204,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617731,,BAO_0000218
3205,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617732,,BAO_0000218
3206,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617733,,BAO_0000218
3207,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617734,,BAO_0000218
3208,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,,104698,,H,6,Autocuration,1,,CHEMBL872874,,BAO_0000218
3209,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,,104698,,H,6,Autocuration,1,,CHEMBL617735,,BAO_0000218
3210,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,,104698,,H,6,Autocuration,1,,CHEMBL617736,,BAO_0000218
3211,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,,104698,,H,6,Autocuration,1,,CHEMBL617737,,BAO_0000218
3212,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,,104698,,H,6,Autocuration,1,,CHEMBL617738,,BAO_0000218
3213,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617739,,BAO_0000218
3214,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617740,,BAO_0000218
3215,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617741,,BAO_0000218
3216,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617742,,BAO_0000218
3217,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617743,,BAO_0000218
3218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617744,,BAO_0000218
3219,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,,104698,,H,6,Autocuration,1,,CHEMBL617745,,BAO_0000218
3220,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,104698,,H,6,Autocuration,1,,CHEMBL617746,,BAO_0000218
3221,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,104698,,H,6,Autocuration,1,,CHEMBL617747,,BAO_0000218
3222,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,,104698,,H,6,Autocuration,1,,CHEMBL617748,,BAO_0000218
3223,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,,104698,,H,6,Autocuration,1,,CHEMBL618909,,BAO_0000218
3224,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,,104698,,H,6,Autocuration,1,,CHEMBL618910,,BAO_0000218
3225,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,,104698,,H,6,Autocuration,1,,CHEMBL618911,,BAO_0000218
3226,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,,104698,,H,6,Autocuration,1,,CHEMBL618912,,BAO_0000218
3227,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,,104698,,H,6,Autocuration,1,,CHEMBL618913,,BAO_0000218
3228,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,104698,,H,6,Autocuration,1,,CHEMBL618914,,BAO_0000019
3229,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,104698,,H,6,Autocuration,1,,CHEMBL618915,,BAO_0000019
3230,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL618916,,BAO_0000223
3231,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,104698,,H,6,Autocuration,1,,CHEMBL618917,,BAO_0000019
3232,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,10000000.0,,104698,,D,7,Intermediate,1,,CHEMBL618918,,BAO_0000221
3233,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,,104698,,D,7,Autocuration,1,,CHEMBL618919,,BAO_0000019
3234,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL618920,,BAO_0000019
3235,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,104698,,H,6,Autocuration,1,,CHEMBL618921,,BAO_0000223
3236,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,104698,,H,6,Autocuration,1,,CHEMBL618922,,BAO_0000019
3237,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,104698,,H,6,Autocuration,1,,CHEMBL618923,,BAO_0000019
3238,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,104698,,H,6,Autocuration,1,,CHEMBL618924,,BAO_0000019
3239,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,104698,,H,6,Autocuration,1,,CHEMBL618925,,BAO_0000019
3240,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,104698,,H,6,Autocuration,1,,CHEMBL618926,,BAO_0000019
3241,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL618927,,BAO_0000221
3242,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL618928,,BAO_0000221
3243,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",2116.0,,20033,,D,9,Intermediate,1,,CHEMBL618929,,BAO_0000221
3244,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",2116.0,,20033,,D,9,Intermediate,1,,CHEMBL618930,,BAO_0000221
3245,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",2116.0,,20033,,D,9,Intermediate,1,,CHEMBL618931,,BAO_0000221
3246,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619594,,BAO_0000221
3247,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619595,,BAO_0000221
3248,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619596,,BAO_0000221
3249,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619755,,BAO_0000221
3250,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619756,,BAO_0000221
3251,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619757,,BAO_0000221
3252,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619758,,BAO_0000221
3253,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619759,,BAO_0000221
3254,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619760,,BAO_0000221
3255,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619761,,BAO_0000221
3256,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619762,,BAO_0000221
3257,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619763,,BAO_0000221
3258,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",2116.0,,20033,,D,9,Intermediate,1,,CHEMBL617868,,BAO_0000221
3259,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,20033,,D,9,Intermediate,1,,CHEMBL617869,,BAO_0000357
3260,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL882926,,BAO_0000249
3261,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL617870,,BAO_0000249
3262,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL617871,,BAO_0000357
3263,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL617872,,BAO_0000357
3264,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL617873,,BAO_0000357
3265,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL617874,,BAO_0000357
3266,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619067,,BAO_0000221
3267,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619068,,BAO_0000221
3268,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619069,,BAO_0000221
3269,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,,20033,,D,9,Intermediate,1,,CHEMBL619070,,BAO_0000357
3270,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,,20033,,D,9,Intermediate,1,,CHEMBL619071,,BAO_0000357
3271,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,,20033,,D,9,Intermediate,1,,CHEMBL619072,,BAO_0000019
3272,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,,20033,,D,9,Intermediate,1,,CHEMBL619073,,BAO_0000019
3273,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,,20033,,D,9,Intermediate,1,,CHEMBL619074,,BAO_0000019
3274,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,,20033,,D,9,Intermediate,1,,CHEMBL619075,,BAO_0000357
3275,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL619076,,BAO_0000357
3276,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL619077,,BAO_0000357
3277,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL619078,,BAO_0000249
3278,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL619079,,BAO_0000249
3279,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619080,,BAO_0000221
3280,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,,20033,,D,9,Expert,1,,CHEMBL619081,,BAO_0000357
3281,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,20033,,D,9,Intermediate,1,,CHEMBL619082,,BAO_0000357
3282,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,,20033,,D,9,Intermediate,1,,CHEMBL619083,,BAO_0000357
3283,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,20033,,D,9,Intermediate,1,,CHEMBL619084,,BAO_0000357
3284,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL859397,,BAO_0000221
3285,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619085,,BAO_0000221
3286,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619086,,BAO_0000221
3287,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619087,,BAO_0000221
3288,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619088,,BAO_0000221
3289,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,,20033,,D,9,Intermediate,1,,CHEMBL619089,,BAO_0000357
3290,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,,168,,H,8,Autocuration,1,,CHEMBL619090,,BAO_0000357
3291,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,,20033,,D,9,Intermediate,1,,CHEMBL619091,,BAO_0000019
3292,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,,20033,,D,9,Intermediate,1,,CHEMBL619092,,BAO_0000357
3293,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,,20033,,D,9,Intermediate,1,,CHEMBL619093,,BAO_0000019
3294,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,,168,HEK293,H,8,Autocuration,1,,CHEMBL619094,722.0,BAO_0000219
3295,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,,20033,,D,9,Intermediate,1,,CHEMBL619095,,BAO_0000019
3296,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,,20033,,D,9,Intermediate,1,,CHEMBL857988,,BAO_0000357
3297,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,,20033,,D,9,Intermediate,1,,CHEMBL619096,,BAO_0000357
3298,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,2435.0,,20033,,D,9,Intermediate,1,,CHEMBL619097,,BAO_0000357
3299,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,10000000.0,,20033,,D,9,Intermediate,1,,CHEMBL619098,,BAO_0000221
3300,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,,20033,,D,9,Intermediate,1,,CHEMBL619751,,BAO_0000357
3301,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,,20033,,D,9,Intermediate,1,,CHEMBL619752,,BAO_0000357
3302,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL875096,,BAO_0000221
3303,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,108,,H,8,Autocuration,1,,CHEMBL619004,,BAO_0000357
3304,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,168,,H,8,Autocuration,1,,CHEMBL619005,,BAO_0000357
3305,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,168,,H,8,Autocuration,1,,CHEMBL619006,,BAO_0000019
3306,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,,168,HeLa,H,8,Autocuration,1,,CHEMBL619007,308.0,BAO_0000219
3307,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,168,,H,8,Autocuration,1,,CHEMBL619008,,BAO_0000357
3308,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,168,,H,8,Autocuration,1,,CHEMBL619009,,BAO_0000357
3309,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,,168,HeLa,H,8,Autocuration,1,,CHEMBL619010,308.0,BAO_0000219
3310,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,10622,,H,8,Autocuration,1,,CHEMBL619011,,BAO_0000357
3311,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,10622,,H,8,Autocuration,1,,CHEMBL619012,,BAO_0000357
3312,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,10622,,H,8,Autocuration,1,,CHEMBL619013,,BAO_0000219
3313,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,10622,,H,8,Autocuration,1,,CHEMBL619014,,BAO_0000357
3314,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,2081.0,,11249,,H,8,Autocuration,1,,CHEMBL857503,,BAO_0000019
3315,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,2081.0,,11249,,H,8,Autocuration,1,,CHEMBL619015,,BAO_0000019
3316,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,11249,,H,8,Autocuration,1,,CHEMBL619016,,BAO_0000357
3317,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,10000000.0,,11249,,H,8,Autocuration,1,,CHEMBL619017,,BAO_0000221
3318,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,10000000.0,,168,,H,8,Autocuration,1,,CHEMBL619018,,BAO_0000221
3319,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,,168,,H,8,Autocuration,1,,CHEMBL619019,,BAO_0000019
3320,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,,10623,,D,9,Expert,1,,CHEMBL619020,,BAO_0000357
3321,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,10623,,H,8,Autocuration,1,,CHEMBL619021,,BAO_0000019
3322,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,10623,,H,8,Autocuration,1,,CHEMBL619022,,BAO_0000357
3323,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,10623,,H,8,Autocuration,1,,CHEMBL619023,,BAO_0000357
3324,,lntrinsic activity relative to 5-HT receptor,,,10623,,H,8,Autocuration,1,,CHEMBL619024,,BAO_0000019
3325,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,10623,,H,8,Autocuration,1,,CHEMBL619025,,BAO_0000019
3326,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,10623,,H,8,Expert,1,,CHEMBL619026,,BAO_0000019
3327,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,10623,,H,8,Autocuration,1,,CHEMBL619027,,BAO_0000019
3328,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,10623,,H,8,Autocuration,1,,CHEMBL619028,,BAO_0000019
3329,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,10623,,H,8,Autocuration,1,,CHEMBL619029,,BAO_0000019
3330,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,10623,,H,8,Autocuration,1,,CHEMBL619030,,BAO_0000019
3331,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,10623,,H,8,Expert,1,,CHEMBL619031,,BAO_0000357
3332,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,10623,,H,8,Autocuration,1,,CHEMBL619032,,BAO_0000019
3333,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,,10623,,D,9,Expert,1,,CHEMBL619033,,BAO_0000357
3334,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,10623,,H,8,Autocuration,1,,CHEMBL619034,,BAO_0000357
3335,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,10623,,H,8,Autocuration,1,,CHEMBL619035,,BAO_0000357
3336,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,10623,,H,8,Autocuration,1,,CHEMBL619036,,BAO_0000357
3337,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,,10623,,D,9,Expert,1,,CHEMBL619037,,BAO_0000019
3338,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,2435.0,,10623,,H,8,Autocuration,1,,CHEMBL619038,,BAO_0000249
3339,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,10623,,H,8,Autocuration,1,,CHEMBL619039,,BAO_0000249
3340,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,10623,,H,8,Expert,1,,CHEMBL619040,,BAO_0000249
3341,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,2435.0,,10623,,D,9,Expert,1,,CHEMBL619041,,BAO_0000019
3342,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,2435.0,,10623,,H,8,Autocuration,1,,CHEMBL619042,,BAO_0000019
3343,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,2435.0,,10623,,H,8,Expert,1,,CHEMBL619043,,BAO_0000249
3344,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,2435.0,,10623,,H,8,Expert,1,,CHEMBL619044,,BAO_0000019
3345,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,2435.0,,10623,,H,8,Expert,1,,CHEMBL619045,,BAO_0000249
3346,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,2435.0,,10623,,H,8,Expert,1,,CHEMBL619046,,BAO_0000249
3347,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,10623,,H,8,Expert,1,,CHEMBL619047,,BAO_0000249
3348,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,955.0,,10623,,H,8,Autocuration,1,,CHEMBL619048,,BAO_0000221
3349,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,10623,,H,8,Autocuration,1,,CHEMBL859398,,BAO_0000019
3350,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,10623,,H,8,Autocuration,1,,CHEMBL619049,,BAO_0000019
3351,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,10623,,H,8,Autocuration,1,,CHEMBL857886,,BAO_0000019
3352,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,10623,,H,8,Autocuration,1,,CHEMBL619050,,BAO_0000019
3353,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,10623,,H,8,Autocuration,1,,CHEMBL620591,,BAO_0000019
3354,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,,10623,,D,9,Expert,1,,CHEMBL620592,,BAO_0000357
3355,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,2435.0,,10623,,H,8,Expert,1,,CHEMBL620593,,BAO_0000249
3356,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,,10623,,D,9,Expert,1,,CHEMBL620594,,BAO_0000019
3357,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,10623,,H,8,Expert,1,,CHEMBL875079,,BAO_0000019
3358,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,10623,,H,8,Expert,1,,CHEMBL620595,,BAO_0000019
3359,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,,10623,,D,9,Expert,1,,CHEMBL620596,,BAO_0000019
3360,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,10623,,H,8,Autocuration,1,,CHEMBL620597,,BAO_0000019
3361,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,10623,,H,8,Expert,1,,CHEMBL620598,,BAO_0000019
3362,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,10623,,H,8,Expert,1,,CHEMBL620599,,BAO_0000218
3363,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,10623,,H,8,Autocuration,1,,CHEMBL620600,,BAO_0000019
3364,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,,168,,H,8,Autocuration,1,,CHEMBL620601,,BAO_0000019
3365,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,168,,H,8,Autocuration,1,,CHEMBL620602,,BAO_0000019
3366,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,168,,H,8,Autocuration,1,,CHEMBL620603,,BAO_0000357
3367,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,168,,H,8,Autocuration,1,,CHEMBL620604,,BAO_0000357
3368,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,168,,H,8,Autocuration,1,,CHEMBL620605,,BAO_0000357
3369,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,168,,H,8,Autocuration,1,,CHEMBL620606,,BAO_0000357
3370,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,168,,H,8,Autocuration,1,,CHEMBL620607,,BAO_0000019
3371,,In vitro binding affinity towards 5-HT4 receptor was determined,,,168,,H,8,Autocuration,1,,CHEMBL620608,,BAO_0000357
3372,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,168,,H,8,Autocuration,1,,CHEMBL620609,,BAO_0000019
3373,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,168,,H,8,Autocuration,1,,CHEMBL620610,,BAO_0000019
3374,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,168,,H,8,Autocuration,1,,CHEMBL620611,,BAO_0000357
3375,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,168,,H,8,Autocuration,1,,CHEMBL620612,,BAO_0000357
3376,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,168,,H,8,Autocuration,1,,CHEMBL620613,,BAO_0000357
3377,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,168,,H,8,Autocuration,1,,CHEMBL620614,,BAO_0000357
3378,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,168,,H,8,Expert,1,,CHEMBL620615,,BAO_0000357
3379,Brain membranes,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,104698,,H,6,Autocuration,1,,CHEMBL857075,,BAO_0000249
3380,Brain membranes,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,104698,,H,6,Autocuration,1,,CHEMBL620616,,BAO_0000249
3381,Brain membranes,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,104698,,H,6,Autocuration,1,,CHEMBL619411,,BAO_0000249
3382,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,104698,,H,6,Autocuration,1,,CHEMBL619412,,BAO_0000019
3383,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL619413,,BAO_0000019
3384,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,10000000.0,,104698,,H,6,Autocuration,1,,CHEMBL619414,,BAO_0000221
3385,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,104698,,H,6,Autocuration,1,,CHEMBL619415,,BAO_0000019
3386,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,104698,,H,6,Autocuration,1,,CHEMBL619416,,BAO_0000019
3387,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,104698,,H,6,Autocuration,1,,CHEMBL619417,,BAO_0000019
3388,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL619418,,BAO_0000223
3389,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL619419,,BAO_0000223
3390,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,104698,,H,6,Autocuration,1,,CHEMBL619420,,BAO_0000019
3391,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,104698,,H,6,Autocuration,1,,CHEMBL619421,,BAO_0000249
3392,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,,104698,,D,7,Autocuration,1,,CHEMBL619422,,BAO_0000019
3393,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,104698,,H,6,Autocuration,1,,CHEMBL619423,,BAO_0000019
3394,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,104698,,H,6,Autocuration,1,,CHEMBL875080,,BAO_0000019
3395,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,104698,,H,6,Autocuration,1,,CHEMBL619424,,BAO_0000019
3396,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,104698,,H,6,Autocuration,1,,CHEMBL619425,,BAO_0000249
3397,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,104698,,H,6,Autocuration,1,,CHEMBL619426,,BAO_0000223
3398,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,104698,,H,6,Autocuration,1,,CHEMBL619427,,BAO_0000223
3399,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,,104698,,D,7,Autocuration,1,,CHEMBL619645,,BAO_0000223
3400,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,10576,,D,9,Expert,1,,CHEMBL619646,,BAO_0000249
3401,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,955.0,,12020,,H,8,Autocuration,1,,CHEMBL619647,,BAO_0000221
3402,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,12020,,H,8,Autocuration,1,,CHEMBL619648,,BAO_0000019
3403,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,12020,,H,8,Autocuration,1,,CHEMBL619165,,BAO_0000019
3404,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,,12020,,H,8,Autocuration,1,,CHEMBL620719,,BAO_0000218
3405,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,12020,,H,8,Autocuration,1,,CHEMBL872924,,BAO_0000019
3406,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,12020,,H,8,Autocuration,1,,CHEMBL620720,,BAO_0000357
3407,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,12020,,H,8,Autocuration,1,,CHEMBL620721,,BAO_0000019
3408,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,12020,,H,8,Autocuration,1,,CHEMBL620722,,BAO_0000019
3409,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,104698,,H,6,Autocuration,1,,CHEMBL620723,,BAO_0000019
3410,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,12020,,H,8,Autocuration,1,,CHEMBL620724,,BAO_0000019
3411,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,104698,,H,6,Autocuration,1,,CHEMBL620725,,BAO_0000249
3412,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,,12020,,D,9,Autocuration,1,,CHEMBL620726,,BAO_0000019
3413,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,144,,H,8,Expert,1,,CHEMBL620727,,BAO_0000357
3414,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,104714,,H,4,Autocuration,1,,CHEMBL620728,,BAO_0000223
3415,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,22226,,U,0,Autocuration,1,,CHEMBL620729,,BAO_0000019
3416,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,104714,,H,4,Autocuration,1,,CHEMBL858288,,BAO_0000019
3417,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714,,H,4,Autocuration,1,,CHEMBL620730,,BAO_0000223
3418,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714,,H,4,Autocuration,1,,CHEMBL620731,,BAO_0000223
3419,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,,104714,,H,4,Autocuration,1,,CHEMBL620732,,BAO_0000019
3420,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,104714,,H,4,Autocuration,1,,CHEMBL618042,,BAO_0000019
3421,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,,104714,,H,4,Autocuration,1,,CHEMBL618043,,BAO_0000019
3422,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,104714,,H,4,Autocuration,1,,CHEMBL618044,,BAO_0000223
3423,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,104714,,H,4,Autocuration,1,,CHEMBL618045,,BAO_0000019
3424,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,104714,,H,4,Autocuration,1,,CHEMBL618046,,BAO_0000223
3425,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,104714,,H,4,Autocuration,1,,CHEMBL618047,,BAO_0000019
3426,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,104714,,H,4,Autocuration,1,,CHEMBL875084,,BAO_0000019
3427,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,104714,,H,4,Autocuration,1,,CHEMBL618048,,BAO_0000019
3428,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,104714,,H,4,Autocuration,1,,CHEMBL618049,,BAO_0000223
3429,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,104714,,H,4,Autocuration,1,,CHEMBL619764,,BAO_0000019
3430,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,104714,,H,4,Autocuration,1,,CHEMBL619765,,BAO_0000019
3431,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,104714,,H,4,Autocuration,1,,CHEMBL619766,,BAO_0000019
3432,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,104714,,H,4,Autocuration,1,,CHEMBL619767,,BAO_0000223
3433,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,104714,,H,4,Autocuration,1,,CHEMBL619768,,BAO_0000223
3434,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,104714,,H,4,Autocuration,1,,CHEMBL619769,,BAO_0000019
3435,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,104714,,H,4,Autocuration,1,,CHEMBL619770,,BAO_0000223
3436,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714,,H,4,Autocuration,1,,CHEMBL619771,,BAO_0000223
3437,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,104714,,H,4,Autocuration,1,,CHEMBL619772,,BAO_0000219
3438,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,104714,,H,4,Autocuration,1,,CHEMBL619773,,BAO_0000223
3439,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,,104714,NG108-15,H,4,Autocuration,1,,CHEMBL619774,433.0,BAO_0000219
3440,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,104714,,H,4,Autocuration,1,,CHEMBL875083,,BAO_0000019
3441,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,,104714,NG108-15,H,4,Autocuration,1,,CHEMBL620718,433.0,BAO_0000219
3442,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,104714,,H,4,Autocuration,1,,CHEMBL618127,,BAO_0000223
3443,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,104714,,H,4,Autocuration,1,,CHEMBL618128,,BAO_0000223
3444,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,,104714,,H,4,Autocuration,1,,CHEMBL618129,,BAO_0000219
3445,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,104714,,H,4,Autocuration,1,,CHEMBL618130,,BAO_0000223
3446,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,104714,,H,4,Autocuration,1,,CHEMBL618131,,BAO_0000019
3447,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,,104714,,H,4,Autocuration,1,,CHEMBL618132,,BAO_0000019
3448,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,,104714,,H,4,Autocuration,1,,CHEMBL618133,,BAO_0000019
3449,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,,104714,,H,4,Autocuration,1,,CHEMBL618134,,BAO_0000019
3450,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,104714,,H,4,Autocuration,1,,CHEMBL618135,,BAO_0000019
3451,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,104714,,H,4,Autocuration,1,,CHEMBL618136,,BAO_0000223
3452,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714,,H,4,Autocuration,1,,CHEMBL618137,,BAO_0000223
3453,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,104714,,H,4,Autocuration,1,,CHEMBL618138,,BAO_0000223
3454,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,104714,,H,4,Autocuration,1,,CHEMBL618139,,BAO_0000223
3455,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,104714,,H,4,Autocuration,1,,CHEMBL618140,,BAO_0000223
3456,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,104714,,H,4,Autocuration,1,,CHEMBL618141,,BAO_0000223
3457,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,108,,H,8,Expert,1,,CHEMBL873478,,BAO_0000357
3458,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104698,,H,6,Autocuration,1,,CHEMBL618142,,BAO_0000223
3459,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,144,,H,8,Autocuration,1,,CHEMBL618143,,BAO_0000357
3460,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,144,,H,8,Autocuration,1,,CHEMBL618144,,BAO_0000357
3461,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,144,,H,8,Autocuration,1,,CHEMBL618145,,BAO_0000357
3462,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,104714,,H,4,Autocuration,1,,CHEMBL618146,,BAO_0000223
3463,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,104714,,H,4,Autocuration,1,,CHEMBL618147,,BAO_0000223
3464,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,104714,,H,4,Autocuration,1,,CHEMBL618148,,BAO_0000223
3465,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,144,,H,8,Autocuration,1,,CHEMBL618149,,BAO_0000019
3466,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,144,,H,8,Autocuration,1,,CHEMBL872927,,BAO_0000357
3467,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,144,,H,8,Autocuration,1,,CHEMBL618150,,BAO_0000357
3468,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,144,,H,8,Autocuration,1,,CHEMBL618151,,BAO_0000357
3469,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,144,,H,8,Autocuration,1,,CHEMBL875094,,BAO_0000357
3470,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,144,,H,8,Autocuration,1,,CHEMBL618152,,BAO_0000019
3471,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,144,,H,8,Autocuration,1,,CHEMBL618153,,BAO_0000357
3472,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,144,,H,8,Autocuration,1,,CHEMBL618888,,BAO_0000357
3473,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,144,,H,8,Autocuration,1,,CHEMBL618889,,BAO_0000019
3474,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,144,,H,8,Autocuration,1,,CHEMBL618890,,BAO_0000357
3475,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,144,,H,8,Autocuration,1,,CHEMBL618891,,BAO_0000019
3476,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,144,,H,8,Autocuration,1,,CHEMBL619054,,BAO_0000019
3477,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,104714,,H,4,Autocuration,1,,CHEMBL619055,,BAO_0000223
3478,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,144,,H,8,Autocuration,1,,CHEMBL619056,,BAO_0000357
3479,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,144,,H,8,Autocuration,1,,CHEMBL619057,,BAO_0000019
3480,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,144,,H,8,Autocuration,1,,CHEMBL619058,,BAO_0000357
3481,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,,12020,Oocytes,D,9,Expert,1,,CHEMBL619059,,BAO_0000219
3482,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,,12020,Oocytes,D,9,Expert,1,,CHEMBL619060,,BAO_0000219
3483,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,,12020,Oocytes,D,9,Expert,1,,CHEMBL875095,,BAO_0000219
3484,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619061,,BAO_0000221
3485,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619062,,BAO_0000221
3486,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,,20033,,D,9,Intermediate,1,,CHEMBL619063,,BAO_0000019
3487,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619064,,BAO_0000221
3488,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,,20033,,D,9,Intermediate,1,,CHEMBL619065,,BAO_0000357
3489,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,2116.0,,20033,,D,9,Intermediate,1,,CHEMBL619066,,BAO_0000221
3490,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,2116.0,,10209,,H,8,Autocuration,1,,CHEMBL619775,,BAO_0000221
3491,,Affinity against 5-hydroxytryptamine 7 receptor,,,10209,,H,8,Autocuration,1,,CHEMBL619776,,BAO_0000357
3492,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,104841,,H,4,Autocuration,1,,CHEMBL619777,,BAO_0000224
3493,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,104841,,H,4,Autocuration,1,,CHEMBL619778,,BAO_0000224
3494,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,2116.0,,104841,,H,4,Autocuration,1,,CHEMBL619779,,BAO_0000221
3495,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,104841,,H,4,Autocuration,1,,CHEMBL619780,,BAO_0000224
3496,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,104841,,H,4,Autocuration,1,,CHEMBL619166,,BAO_0000224
3497,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,104841,,H,4,Autocuration,1,,CHEMBL619167,,BAO_0000019
3498,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,104841,,H,4,Autocuration,1,,CHEMBL619168,,BAO_0000019
3499,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,2081.0,,168,,D,9,Expert,1,,CHEMBL619169,,BAO_0000219
3500,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,2081.0,,168,,D,9,Expert,1,,CHEMBL619170,,BAO_0000219
3501,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,,104841,,D,5,Autocuration,1,,CHEMBL619171,,BAO_0000019
3502,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",2081.0,,168,,D,9,Expert,1,,CHEMBL619172,,BAO_0000219
3503,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,,22226,,U,0,Autocuration,1,,CHEMBL619173,,BAO_0000019
3504,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,,22226,,U,0,Autocuration,1,,CHEMBL619174,,BAO_0000019
3505,,5-hydroxytryptamine receptor binding affinity was determined in rats,,,104705,,H,4,Autocuration,1,,CHEMBL619175,,BAO_0000019
3506,,Binding affinity at rat 5-hydroxytryptamine receptor.,,,104705,,H,4,Autocuration,1,,CHEMBL619176,,BAO_0000224
3507,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,104705,,H,4,Autocuration,1,,CHEMBL619177,,BAO_0000019
3508,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,104705,,H,4,Autocuration,1,,CHEMBL619178,,BAO_0000224
3509,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,104705,,H,4,Autocuration,1,,CHEMBL619179,,BAO_0000224
3510,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,945.0,,104705,,H,4,Autocuration,1,,CHEMBL619180,,BAO_0000019
3511,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,945.0,,104705,,H,4,Autocuration,1,,CHEMBL619181,,BAO_0000019
3512,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,104705,,H,4,Autocuration,1,,CHEMBL619182,,BAO_0000019
3513,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,104705,,H,4,Autocuration,1,,CHEMBL619183,,BAO_0000224
3514,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,104705,,H,4,Autocuration,1,,CHEMBL619184,,BAO_0000224
3515,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10000000.0,,10576,,H,8,Autocuration,1,,CHEMBL619185,,BAO_0000221
3516,,Binding affinity for rat 5-hydroxytryptamine transporter.,,,12198,,H,8,Expert,1,,CHEMBL619186,,BAO_0000357
3517,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,104705,,H,4,Autocuration,1,,CHEMBL619187,,BAO_0000019
3518,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,,104705,,D,5,Autocuration,1,,CHEMBL619188,,BAO_0000019
3519,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,,104705,,D,5,Autocuration,1,,CHEMBL619189,,BAO_0000224
3520,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,955.0,,12198,,D,9,Expert,1,,CHEMBL619190,,BAO_0000019
3521,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,2037.0,,12198,,D,9,Expert,1,,CHEMBL619191,,BAO_0000221
3522,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,,104705,,D,5,Autocuration,1,,CHEMBL619192,,BAO_0000019
3523,,Percent binding affinity against 5-hydroxytryptamine receptor,,,104705,,D,5,Autocuration,1,,CHEMBL619193,,BAO_0000224
3524,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,22226,,U,0,Autocuration,1,,CHEMBL619194,,BAO_0000019
3525,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,,104705,,D,5,Autocuration,1,,CHEMBL619195,,BAO_0000224
3526,,Affinity against 5-hydroxytryptamine receptor was determined,,,104705,,D,5,Autocuration,1,,CHEMBL619196,,BAO_0000224
3527,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,945.0,,104705,,D,5,Autocuration,1,,CHEMBL619197,,BAO_0000019
3528,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,121,,D,9,Expert,1,,CHEMBL619198,,BAO_0000219
3529,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,121,,D,9,Expert,1,,CHEMBL875081,,BAO_0000219
3530,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,18065,,H,8,Autocuration,1,,CHEMBL884712,,BAO_0000357
3531,,Inhibition of 5-hydroxytryptamine reuptake,,,121,,H,8,Expert,1,,CHEMBL884710,,BAO_0000357
3532,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,18065,,H,8,Autocuration,1,,CHEMBL619199,,BAO_0000019
3533,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,18065,,H,8,Autocuration,1,,CHEMBL619200,,BAO_0000019
3534,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,18065,,H,8,Autocuration,1,,CHEMBL619201,,BAO_0000019
3535,,Tested for 5-hydroxytryptamine receptor uptake,,,18065,,H,8,Autocuration,1,,CHEMBL619202,,BAO_0000019
3536,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,51,CHO,D,9,Expert,1,,CHEMBL619203,449.0,BAO_0000219
3537,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,,51,,D,9,Expert,1,,CHEMBL619204,,BAO_0000019
3538,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,,10576,,H,8,Autocuration,1,,CHEMBL619205,,BAO_0000249
3539,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,10576,,H,8,Autocuration,1,,CHEMBL619206,,BAO_0000357
3540,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,10576,,H,8,Expert,1,,CHEMBL619207,,BAO_0000249
3541,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,2435.0,,10825,,H,8,Autocuration,1,,CHEMBL619208,,BAO_0000019
3542,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,2435.0,,10825,,H,8,Autocuration,1,,CHEMBL619209,,BAO_0000019
3543,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,2435.0,,10825,,H,8,Autocuration,1,,CHEMBL619210,,BAO_0000019
3544,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,2435.0,,10825,,H,8,Autocuration,1,,CHEMBL619211,,BAO_0000019
3545,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,2435.0,,10825,,H,8,Autocuration,1,,CHEMBL619212,,BAO_0000019
3546,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,2435.0,,10825,,H,8,Autocuration,1,,CHEMBL620681,,BAO_0000019
3547,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,2435.0,,10825,,H,8,Autocuration,1,,CHEMBL620682,,BAO_0000019
3548,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,2435.0,,10825,,H,8,Autocuration,1,,CHEMBL620683,,BAO_0000019
3549,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,2435.0,,10825,,H,8,Autocuration,1,,CHEMBL620684,,BAO_0000019
3550,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,2435.0,,10825,,H,8,Autocuration,1,,CHEMBL620685,,BAO_0000019
3551,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,2435.0,,10825,,H,8,Autocuration,1,,CHEMBL620686,,BAO_0000019
3552,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,349.0,,10825,,H,8,Autocuration,1,,CHEMBL620687,,BAO_0000019
3553,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,349.0,,10825,,H,8,Autocuration,1,,CHEMBL620688,,BAO_0000019
3554,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,349.0,,10825,,H,8,Autocuration,1,,CHEMBL620689,,BAO_0000019
3555,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,349.0,,10825,,H,8,Autocuration,1,,CHEMBL620690,,BAO_0000019
3556,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,349.0,,10825,,H,8,Autocuration,1,,CHEMBL620691,,BAO_0000019
3557,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,349.0,,10825,,H,8,Autocuration,1,,CHEMBL620692,,BAO_0000019
3558,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,349.0,,10825,,H,8,Autocuration,1,,CHEMBL620693,,BAO_0000019
3559,,Binding affinity against 5-hydroxytryptamine 4 receptor,,,168,,H,8,Expert,1,,CHEMBL620694,,BAO_0000357
3560,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,168,,H,8,Autocuration,1,,CHEMBL857986,,BAO_0000019
3561,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,168,,H,8,Autocuration,1,,CHEMBL620695,,BAO_0000357
3562,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,168,,H,8,Expert,1,,CHEMBL620696,,BAO_0000357
3563,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,168,,H,8,Autocuration,1,,CHEMBL620697,,BAO_0000357
3564,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,168,,H,8,Autocuration,1,,CHEMBL620698,,BAO_0000357
3565,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,168,,H,8,Autocuration,1,,CHEMBL620699,,BAO_0000357
3566,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,168,,H,8,Autocuration,1,,CHEMBL620700,,BAO_0000357
3567,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,,168,COS-7,H,8,Autocuration,1,,CHEMBL620701,643.0,BAO_0000219
3568,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,,168,COS-7,H,8,Autocuration,1,,CHEMBL875082,643.0,BAO_0000219
3569,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,,168,COS-7,H,8,Autocuration,1,,CHEMBL620702,643.0,BAO_0000219
3570,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,,168,COS-7,H,8,Autocuration,1,,CHEMBL620703,643.0,BAO_0000219
3571,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,168,C6,H,8,Autocuration,1,,CHEMBL620704,673.0,BAO_0000219
3572,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,168,C6,H,8,Expert,1,,CHEMBL620705,673.0,BAO_0000219
3573,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,,168,C6,H,8,Expert,1,,CHEMBL620706,673.0,BAO_0000219
3574,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,,168,C6,H,8,Expert,1,,CHEMBL620707,673.0,BAO_0000219
3575,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,10624,,H,8,Expert,1,,CHEMBL620708,,BAO_0000357
3576,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,105,,H,8,Autocuration,1,,CHEMBL620709,,BAO_0000357
3577,,Binding affinity against 5-hydroxytryptamine 5A receptor,,,10624,,D,9,Expert,1,,CHEMBL620710,,BAO_0000357
3578,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,,10624,CHO,H,8,Autocuration,1,,CHEMBL620711,449.0,BAO_0000219
3579,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,,10624,,D,9,Expert,1,,CHEMBL620712,,BAO_0000357
3580,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,,10624,,D,9,Expert,1,,CHEMBL620713,,BAO_0000357
3581,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,,10624,,D,9,Expert,1,,CHEMBL620714,,BAO_0000357
3582,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,,10624,,D,9,Expert,1,,CHEMBL620715,,BAO_0000357
3583,,Binding affinity towards 5-HT5A receptor,,,10624,,H,8,Autocuration,1,,CHEMBL620716,,BAO_0000357
3584,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,10624,,H,8,Expert,1,,CHEMBL620717,,BAO_0000357
3585,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,10624,,H,8,Autocuration,1,,CHEMBL618072,,BAO_0000357
3586,,Binding affinity towards cloned human 5-HT5A receptor was determined,,,10624,,H,8,Autocuration,1,,CHEMBL857987,,BAO_0000357
3587,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,10624,HEK293,H,8,Autocuration,1,,CHEMBL618073,722.0,BAO_0000219
3588,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,10624,HEK293,H,8,Autocuration,1,,CHEMBL618074,722.0,BAO_0000219
3589,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,,10624,HEK293,H,8,Autocuration,1,,CHEMBL618075,722.0,BAO_0000219
3590,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,,10625,,D,9,Expert,1,,CHEMBL618076,,BAO_0000357
3591,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,10625,,D,9,Expert,1,,CHEMBL618077,,BAO_0000357
3592,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,,10625,,D,9,Expert,1,,CHEMBL618078,,BAO_0000357
3593,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,,10625,,D,9,Expert,1,,CHEMBL881821,,BAO_0000357
3594,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,,10625,,D,9,Expert,1,,CHEMBL618079,,BAO_0000357
3595,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,10625,,H,8,Expert,1,,CHEMBL618080,,BAO_0000357
3596,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,10576,HEK293,H,8,Autocuration,1,,CHEMBL618081,722.0,BAO_0000219
3597,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,10626,HEK293,H,8,Autocuration,1,,CHEMBL618082,722.0,BAO_0000219
3598,,Binding affinity towards 5-HT5a receptor,,,10624,,H,8,Expert,1,,CHEMBL618083,,BAO_0000357
3599,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,,10624,,D,9,Expert,1,,CHEMBL618084,,BAO_0000357
3600,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,10624,,H,8,Expert,1,,CHEMBL618085,,BAO_0000357
3601,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,10624,,H,8,Expert,1,,CHEMBL618086,,BAO_0000357
3602,,Binding affinities against 5-hydroxytryptamine 5A receptor,,,10624,,H,8,Autocuration,1,,CHEMBL875092,,BAO_0000357
3603,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,10624,,H,8,Autocuration,1,,CHEMBL618087,,BAO_0000357
3604,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,10624,,H,8,Autocuration,1,,CHEMBL872926,,BAO_0000357
3605,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,,104714,,H,4,Autocuration,1,,CHEMBL618088,,BAO_0000019
3606,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,104714,,H,4,Autocuration,1,,CHEMBL618089,,BAO_0000223
3607,,Inhibition of human 5-hydroxytryptamine 6 receptor,,,10627,,D,9,Expert,1,,CHEMBL618090,,BAO_0000357
3608,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,,10627,,D,9,Expert,1,,CHEMBL618091,,BAO_0000357
3609,,Inhibition against human 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL618092,,BAO_0000357
3610,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,,10627,,D,9,Expert,1,,CHEMBL618093,,BAO_0000357
3611,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,,10627,HeLa,H,8,Expert,1,,CHEMBL618094,308.0,BAO_0000219
3612,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,,10627,,D,9,Expert,1,,CHEMBL618095,,BAO_0000357
3613,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,,D,9,Expert,1,,CHEMBL875093,,BAO_0000357
3614,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,10627,,D,9,Expert,1,,CHEMBL618096,,BAO_0000357
3615,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,,10627,,D,9,Expert,1,,CHEMBL618118,,BAO_0000357
3616,,Binding affinity against 5-hydroxytryptamine 6 receptor,,,10627,,D,9,Expert,1,,CHEMBL618119,,BAO_0000357
3617,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Expert,1,,CHEMBL618120,,BAO_0000357
3618,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL618121,,BAO_0000357
3619,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,,10627,HEK293,H,8,Expert,1,,CHEMBL618122,722.0,BAO_0000219
3620,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,10627,,H,8,Autocuration,1,,CHEMBL618123,,BAO_0000357
3621,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,,10627,HEK293,H,8,Expert,1,,CHEMBL618124,722.0,BAO_0000219
3622,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL618125,,BAO_0000357
3623,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,10627,HEK293,D,9,Expert,1,,CHEMBL618126,722.0,BAO_0000219
3624,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,10627,,H,8,Expert,1,,CHEMBL618236,,BAO_0000019
3625,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,10627,,H,8,Expert,1,,CHEMBL618237,,BAO_0000019
3626,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,,10627,COS-7,H,8,Expert,1,,CHEMBL618238,643.0,BAO_0000219
3627,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,,10627,,D,9,Expert,1,,CHEMBL618239,,BAO_0000357
3628,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL618240,,BAO_0000019
3629,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,10627,,H,8,Autocuration,1,,CHEMBL618241,,BAO_0000357
3630,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,10627,HEK293,H,8,Autocuration,1,,CHEMBL859399,722.0,BAO_0000219
3631,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,10627,,H,8,Autocuration,1,,CHEMBL618242,,BAO_0000019
3632,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL857991,,BAO_0000357
3633,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Expert,1,,CHEMBL619951,,BAO_0000357
3634,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,,10627,HeLa,D,9,Expert,1,,CHEMBL619952,308.0,BAO_0000219
3635,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,,10627,HeLa,D,9,Expert,1,,CHEMBL619953,308.0,BAO_0000219
3636,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,,10627,HeLa,H,8,Autocuration,1,,CHEMBL619954,308.0,BAO_0000219
3637,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,10627,HeLa,H,8,Autocuration,1,,CHEMBL619955,308.0,BAO_0000219
3638,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,10627,HeLa,H,8,Autocuration,1,,CHEMBL619956,308.0,BAO_0000219
3639,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,10627,CHO,H,8,Autocuration,1,,CHEMBL619957,449.0,BAO_0000219
3640,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,10627,HEK293,H,8,Autocuration,1,,CHEMBL619958,722.0,BAO_0000219
3641,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,,10627,HEK293,H,8,Autocuration,1,,CHEMBL620627,722.0,BAO_0000219
3642,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,10627,HEK293,H,8,Autocuration,1,,CHEMBL620628,722.0,BAO_0000219
3643,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,,10627,HeLa,H,8,Autocuration,1,,CHEMBL620629,308.0,BAO_0000219
3644,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL620630,,BAO_0000357
3645,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,,10627,HeLa,H,8,Autocuration,1,,CHEMBL620782,308.0,BAO_0000219
3646,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL620783,,BAO_0000357
3647,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Expert,1,,CHEMBL620784,,BAO_0000357
3648,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,,10627,HeLa,H,8,Expert,1,,CHEMBL620785,308.0,BAO_0000219
3649,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,10627,,H,8,Autocuration,1,,CHEMBL857992,,BAO_0000357
3650,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,10627,,H,8,Autocuration,1,,CHEMBL620786,,BAO_0000219
3651,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,,10627,HeLa,H,8,Autocuration,1,,CHEMBL620787,308.0,BAO_0000219
3652,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,,10627,HeLa,H,8,Autocuration,1,,CHEMBL620788,308.0,BAO_0000219
3653,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,,10627,HeLa,H,8,Autocuration,1,,CHEMBL620789,308.0,BAO_0000219
3654,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,,10627,HeLa,H,8,Autocuration,1,,CHEMBL620790,308.0,BAO_0000219
3655,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,,10628,CHO,H,8,Autocuration,1,,CHEMBL620791,449.0,BAO_0000219
3656,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,10628,,H,8,Autocuration,1,,CHEMBL620792,,BAO_0000019
3657,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,10628,,H,8,Autocuration,1,,CHEMBL620793,,BAO_0000357
3658,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,10628,,H,8,Autocuration,1,,CHEMBL620794,,BAO_0000357
3659,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,,10627,HeLa,D,9,Autocuration,1,,CHEMBL620795,308.0,BAO_0000219
3660,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Expert,1,,CHEMBL620796,,BAO_0000357
3661,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,10627,,H,8,Autocuration,1,,CHEMBL620797,,BAO_0000357
3662,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,10627,,D,9,Expert,1,,CHEMBL620798,,BAO_0000019
3663,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,10627,,H,8,Autocuration,1,,CHEMBL620799,,BAO_0000357
3664,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Expert,1,,CHEMBL620800,,BAO_0000357
3665,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,10627,,H,8,Autocuration,1,,CHEMBL620801,,BAO_0000357
3666,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL875100,,BAO_0000357
3667,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,10627,,H,8,Autocuration,1,,CHEMBL620802,,BAO_0000357
3668,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Expert,1,,CHEMBL620803,,BAO_0000019
3669,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,10627,,H,8,Expert,1,,CHEMBL620804,,BAO_0000019
3670,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,10627,,H,8,Autocuration,1,,CHEMBL620805,,BAO_0000357
3671,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL620806,,BAO_0000357
3672,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,10627,,H,8,Autocuration,1,,CHEMBL620807,,BAO_0000357
3673,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,10627,,H,8,Autocuration,1,,CHEMBL620808,,BAO_0000357
3674,,Binding affinities against 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL620809,,BAO_0000357
3675,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL620810,,BAO_0000357
3676,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,,10627,,D,9,Expert,1,,CHEMBL620811,,BAO_0000357
3677,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,10627,,H,8,Autocuration,1,,CHEMBL620812,,BAO_0000357
3678,,Affinity against 5-hydroxytryptamine 6 receptor,,,10627,,H,8,Autocuration,1,,CHEMBL620813,,BAO_0000357
3679,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,10627,,H,8,Autocuration,1,,CHEMBL620814,,BAO_0000357
3680,,Inhibition of human 5-hydroxytryptamine 7 receptor,,,10209,,D,9,Expert,1,,CHEMBL620815,,BAO_0000357
3681,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,,10209,HEK293,H,8,Autocuration,1,,CHEMBL620816,722.0,BAO_0000219
3682,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,10209,,H,8,Autocuration,1,,CHEMBL620817,,BAO_0000357
3683,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,10209,,H,8,Autocuration,1,,CHEMBL620818,,BAO_0000357
3684,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,,10209,HEK293,H,8,Expert,1,,CHEMBL620819,722.0,BAO_0000219
3685,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,,10209,,D,9,Expert,1,,CHEMBL620820,,BAO_0000357
3686,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,,10209,CHO,H,8,Autocuration,1,,CHEMBL620821,449.0,BAO_0000219
3687,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,10209,,D,9,Expert,1,,CHEMBL620822,,BAO_0000357
3688,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,,10209,,D,9,Expert,1,,CHEMBL620823,,BAO_0000357
3689,,Binding affinity against 5-hydroxytryptamine 7 receptor,,,10209,,D,9,Expert,1,,CHEMBL620824,,BAO_0000357
3690,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,,10209,CHO,H,8,Expert,1,,CHEMBL620825,449.0,BAO_0000219
3691,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,10209,,H,8,Autocuration,1,,CHEMBL872930,,BAO_0000357
3692,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,10209,,H,8,Autocuration,1,,CHEMBL620826,,BAO_0000357
3693,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,10209,,H,8,Autocuration,1,,CHEMBL620827,,BAO_0000357
3694,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,10209,,H,8,Autocuration,1,,CHEMBL620828,,BAO_0000357
3695,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,10209,,H,8,Autocuration,1,,CHEMBL620829,,BAO_0000357
3696,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,,10209,HEK293,H,8,Expert,1,,CHEMBL620830,722.0,BAO_0000219
3697,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,10209,,H,8,Expert,1,,CHEMBL620831,,BAO_0000019
3698,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,10209,,H,8,Expert,1,,CHEMBL620832,,BAO_0000019
3699,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,,10209,,D,9,Expert,1,,CHEMBL621548,,BAO_0000357
3700,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,10209,,H,8,Autocuration,1,,CHEMBL621549,,BAO_0000019
3701,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,10209,,H,8,Autocuration,1,,CHEMBL621550,,BAO_0000357
3702,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,,10209,CHO,H,8,Autocuration,1,,CHEMBL621551,449.0,BAO_0000219
3703,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,10209,,H,8,Autocuration,1,,CHEMBL621552,,BAO_0000019
3704,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,10209,,H,8,Autocuration,1,,CHEMBL857077,,BAO_0000357
3705,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,10209,,H,8,Autocuration,1,,CHEMBL618158,,BAO_0000357
3706,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,10209,COS-7,D,9,Expert,1,,CHEMBL618159,643.0,BAO_0000219
3707,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,10209,COS-7,H,8,Autocuration,1,,CHEMBL875101,643.0,BAO_0000219
3708,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,,10209,HEK293,D,9,Expert,1,,CHEMBL618160,722.0,BAO_0000219
3709,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,10209,,H,8,Expert,1,,CHEMBL618161,,BAO_0000357
3710,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,,10209,HEK293,H,8,Expert,1,,CHEMBL618162,722.0,BAO_0000219
3711,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,10209,,H,8,Expert,1,,CHEMBL618163,,BAO_0000357
3712,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,10209,,H,8,Autocuration,1,,CHEMBL618164,,BAO_0000357
3713,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,10209,,H,8,Expert,1,,CHEMBL618165,,BAO_0000219
3714,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,,10209,HEK293,H,8,Autocuration,1,,CHEMBL618166,722.0,BAO_0000219
3715,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,10209,HEK293,H,8,Autocuration,1,,CHEMBL857989,722.0,BAO_0000219
3716,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,10209,HEK293,H,8,Autocuration,1,,CHEMBL619888,722.0,BAO_0000219
3717,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,10209,HEK293,H,8,Autocuration,1,,CHEMBL619889,722.0,BAO_0000219
3718,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,,10209,HEK293,H,8,Autocuration,1,,CHEMBL619890,722.0,BAO_0000219
3719,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,,10209,CHO,H,8,Autocuration,1,,CHEMBL619891,449.0,BAO_0000219
3720,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,,10209,HEK293,H,8,Autocuration,1,,CHEMBL619892,722.0,BAO_0000219
3721,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,,10209,HEK293,D,9,Expert,1,,CHEMBL619893,722.0,BAO_0000219
3722,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,,10209,HEK293,H,8,Autocuration,1,,CHEMBL619894,722.0,BAO_0000219
3723,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,,10209,HEK293,D,9,Intermediate,1,,CHEMBL619895,722.0,BAO_0000219
3724,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,10209,,D,9,Intermediate,1,,CHEMBL619896,,BAO_0000357
3725,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,,10209,COS-7,H,8,Autocuration,1,,CHEMBL619897,643.0,BAO_0000219
3726,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,,10209,HEK293,H,8,Autocuration,1,,CHEMBL619898,722.0,BAO_0000219
3727,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,,10209,HEK293,H,8,Expert,1,,CHEMBL619899,722.0,BAO_0000219
3728,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,,10209,HEK293,H,8,Autocuration,1,,CHEMBL619900,722.0,BAO_0000219
3729,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,,10209,HEK293,D,9,Expert,1,,CHEMBL619901,722.0,BAO_0000219
3730,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,,10209,HEK293,H,8,Autocuration,1,,CHEMBL620580,722.0,BAO_0000219
3731,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,,10209,HEK293,H,8,Autocuration,1,,CHEMBL620581,722.0,BAO_0000219
3732,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,,10209,HEK293,H,8,Autocuration,1,,CHEMBL620733,722.0,BAO_0000219
3733,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,,10209,,D,9,Autocuration,1,,CHEMBL620734,,BAO_0000357
3734,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,10022,,D,9,Expert,1,,CHEMBL620735,,BAO_0000357
3735,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,,10209,,H,8,Autocuration,1,,CHEMBL620736,,BAO_0000019
3736,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620737,449.0,BAO_0000219
3737,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620738,449.0,BAO_0000219
3738,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620739,449.0,BAO_0000219
3739,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620740,449.0,BAO_0000219
3740,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620741,449.0,BAO_0000219
3741,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620742,449.0,BAO_0000219
3742,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620743,449.0,BAO_0000219
3743,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620744,449.0,BAO_0000219
3744,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620745,449.0,BAO_0000219
3745,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620746,449.0,BAO_0000219
3746,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620747,449.0,BAO_0000219
3747,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620748,449.0,BAO_0000219
3748,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,,11923,CHO,H,8,Autocuration,1,,CHEMBL620749,449.0,BAO_0000219
3749,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,11923,,H,8,Expert,1,,CHEMBL620750,,BAO_0000357
3750,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,11923,,D,9,Expert,1,,CHEMBL620751,,BAO_0000357
3751,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,11923,,H,8,Expert,1,,CHEMBL620752,,BAO_0000357
